molecular_profile_id,molecular_profile_name,molecular_profile_score,description,summary,aliases,evidence_items,evidence_sources,source_ids,sources,variant_ids
1,BCR::ABL1 Fusion,353.5,"The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.","The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.","['T(9;22)(Q34;Q11)', 'BCR-ABL1', 'BCR-ABL']","[259, 260, 344, 220, 261, 11223, 11224, 11235, 11287, 11288, 12213, 12046, 12047, 12048, 12088, 12089, 12090, 12087, 4706, 4436, 213, 232, 7838]","{<CIViC source 4604>, <CIViC source 5062>, <CIViC source 5063>, <CIViC source 5064>, <CIViC source 4858>, <CIViC source 4606>, <CIViC source 5016>, <CIViC source 1621>, <CIViC source 164>, <CIViC source 4615>, <CIViC source 151>, <CIViC source 4641>, <CIViC source 5017>, <CIViC source 4640>, <CIViC source 5140>, <CIViC source 156>, <CIViC source 5018>, <CIViC source 2096>}","[156, 1747]","[<CIViC source 156>, <CIViC source 1747>]",[1]
2,ABL1 T315I,0.0,"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","['THR334ILE', 'RS121913459']","[11225, 11226, 6195, 6284]","{<CIViC source 1622>, <CIViC source 4608>, <CIViC source 4607>}",[],[],[2]
3,ABL1 E255K,0.0,"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","['E274K', 'RS121913448']","[7032, 6283]","{<CIViC source 1622>, <CIViC source 1998>}",[],[],[3]
4,AKT1 E17K,33.5,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.","AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.","['GLU17LYS', 'RS34409589']","[12181, 3039, 9007, 709, 231, 707, 4029]","{<CIViC source 1745>, <CIViC source 163>, <CIViC source 466>, <CIViC source 4994>, <CIViC source 465>, <CIViC source 1941>, <CIViC source 3796>}",[],[],[4]
5,EML4::ALK Fusion,48.0,"The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.","The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.",['EML4-ALK'],"[262, 1207, 9228, 7482, 1121, 1188, 1203, 1206, 1332]","{<CIViC source 819>, <CIViC source 166>, <CIViC source 820>, <CIViC source 776>, <CIViC source 3949>, <CIViC source 2971>, <CIViC source 826>, <CIViC source 832>, <CIViC source 919>}",[],[],[5]
8,ALK F1174L,33.5,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.","ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.","['PHE1174LEU', 'RS863225281']","[2344, 2345, 1271, 4041, 142, 1329, 32, 33, 37, 38, 125, 1327]","{<CIViC source 859>, <CIViC source 79>, <CIViC source 1574>, <CIViC source 73>, <CIViC source 78>, <CIViC source 119>, <CIViC source 917>, <CIViC source 77>, <CIViC source 919>, <CIViC source 2040>}",[],[],[8]
9,ALK R1275Q,23.0,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.","ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.","['ARG1275GLN', 'RS113994087']","[2341, 2342, 7571, 1269, 1270, 1331, 48, 143, 39]","{<CIViC source 859>, <CIViC source 79>, <CIViC source 1574>, <CIViC source 119>, <CIViC source 1236>, <CIViC source 919>}",[],[],[9]
10,ARAF S214C,14.0,"ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.","ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.","['SER214CYS', 'RS1057519786']","[17, 40, 41, 11147]","{<CIViC source 2536>, <CIViC source 6>}",[],[],[10]
11,BRAF V600D,47.0,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","['RS121913377', 'VAL600ASP']","[94, 7616, 7629, 4489, 4488]","{<CIViC source 104>, <CIViC source 3026>, <CIViC source 351>, <CIViC source 1952>}",[],[],[11]
12,BRAF V600E,1433.5,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.","BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.","['RS113488022', 'VAL600GLU', 'V640E', 'VAL640GLU']","[1409, 9851, 3017, 10785, 11244, 12161, 12162, 11312, 11313, 2120, 2126, 2138, 2140, 2141, 2145, 2146, 2504, 3736, 3763, 3764, 3765, 3782, 80, 95, 102, 103, 656, 1398, 6178, 6938, 7612, 11436, 816, 1127, 1405, 1421, 1749, 1902, 1940, 2135, 2137, 3739, 3750, 3758, 5958, 6123, 6940, 6975, 7156, 7157, 7191, 7583, 9018, 9170, 11303, 79, 104, 105, 106, 107, 126, 463, 1406, 1410, 1413, 1552, 1591, 2115, 2116, 2117, 2118, 2121, 2503, 3755, 3757, 5959, 6045, 6124, 7260, 7264, 7453, 7454, 7485, 7761, 7762, 8646, 11315, 11427, 11672, 11770, 82, 994, 1579, 2119, 3737, 3740, 3742, 3749, 3754, 3766, 3767, 3768, 3769, 3770, 3771, 3772, 3773, 3774, 3778, 3779, 3780, 3781, 3783, 3786, 3788, 3789, 1414, 1430, 1698, 3738, 3743, 3744, 3777, 3787, 3827, 5902, 5903, 5904, 5906, 5961, 5962, 757, 1589, 1699, 2362, 5960, 11309, 11311, 3790, 11310, 2122, 2123, 2124, 2125, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2136, 2139, 2142, 2143, 2144, 3741, 3745, 3746, 3747, 3748, 3751, 3752, 3753, 3756, 3759, 3760, 3761, 3762, 3775, 3776, 3784, 3785, 8033, 86, 89, 96, 98, 1141, 1408, 1428, 2894, 7077, 8040, 8506, 8507, 8952, 10328, 10329, 97, 99, 1005]","{<CIViC source 2973>, <CIViC source 1982>, <CIViC source 969>, <CIViC source 93>, <CIViC source 3807>, <CIViC source 1920>, <CIViC source 688>, <CIViC source 1985>, <CIViC source 112>, <CIViC source 1949>, <CIViC source 694>, <CIViC source 1953>, <CIViC source 2475>, <CIViC source 1948>, <CIViC source 107>, <CIViC source 1210>, <CIViC source 1496>, <CIViC source 1945>, <CIViC source 1296>, <CIViC source 106>, <CIViC source 1955>, <CIViC source 1966>, <CIViC source 2860>, <CIViC source 4204>, <CIViC source 108>, <CIViC source 1952>, <CIViC source 1498>, <CIViC source 1957>, <CIViC source 2671>, <CIViC source 953>, <CIViC source 1481>, <CIViC source 278>, <CIViC source 1495>, <CIViC source 1971>, <CIViC source 1367>, <CIViC source 105>, <CIViC source 2954>, <CIViC source 947>, <CIViC source 1499>, <CIViC source 1977>, <CIViC source 958>, <CIViC source 1986>, <CIViC source 1040>, <CIViC source 1970>, <CIViC source 1984>, <CIViC source 413>, <CIViC source 963>, <CIViC source 1492>, <CIViC source 3012>, <CIViC source 1981>, <CIViC source 954>, <CIViC source 1052>, <CIViC source 96>, <CIViC source 1954>, <CIViC source 1487>, <CIViC source 1050>, <CIViC source 351>, <CIViC source 100>, <CIViC source 1494>, <CIViC source 341>, <CIViC source 1964>, <CIViC source 4902>, <CIViC source 1946>, <CIViC source 2686>, <CIViC source 1962>, <CIViC source 1959>, <CIViC source 1968>, <CIViC source 60>, <CIViC source 3096>, <CIViC source 1947>, <CIViC source 1493>, <CIViC source 2414>, <CIViC source 109>, <CIViC source 111>, <CIViC source 1965>, <CIViC source 2380>, <CIViC source 353>, <CIViC source 3893>, <CIViC source 1931>, <CIViC source 1980>, <CIViC source 1961>, <CIViC source 1482>, <CIViC source 1491>, <CIViC source 2783>, <CIViC source 1500>, <CIViC source 1497>, <CIViC source 1479>, <CIViC source 4650>, <CIViC source 4834>, <CIViC source 4652>, <CIViC source 352>, <CIViC source 2816>, <CIViC source 345>, <CIViC source 780>, <CIViC source 1978>, <CIViC source 500>, <CIViC source 110>, <CIViC source 2382>, <CIViC source 957>, <CIViC source 94>, <CIViC source 1027>, <CIViC source 76>, <CIViC source 1973>, <CIViC source 1489>, <CIViC source 790>, <CIViC source 354>, <CIViC source 1147>, <CIViC source 1972>, <CIViC source 2381>, <CIViC source 967>, <CIViC source 1974>, <CIViC source 2858>, <CIViC source 1963>, <CIViC source 2379>, <CIViC source 1983>, <CIViC source 4534>, <CIViC source 4405>, <CIViC source 1976>, <CIViC source 5119>, <CIViC source 3025>, <CIViC source 2468>, <CIViC source 1484>, <CIViC source 1969>, <CIViC source 1485>, <CIViC source 344>, <CIViC source 1967>, <CIViC source 1975>, <CIViC source 1475>, <CIViC source 3501>, <CIViC source 2752>, <CIViC source 1488>, <CIViC source 1043>, <CIViC source 4648>, <CIViC source 1956>, <CIViC source 1960>, <CIViC source 4651>, <CIViC source 103>, <CIViC source 1951>, <CIViC source 74>, <CIViC source 1979>, <CIViC source 3168>, <CIViC source 348>, <CIViC source 1958>, <CIViC source 98>, <CIViC source 1336>, <CIViC source 5118>, <CIViC source 1480>, <CIViC source 548>}",[],[],[12]
16,BRAF V600R,0.0,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",['RS121913227'],"[7615, 7628, 8948, 4170, 4172, 8949, 4171]","{<CIViC source 351>, <CIViC source 3026>, <CIViC source 356>, <CIViC source 1951>}",[],[],[16]
17,BRAF V600,460.0,"BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.","BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.",['VAL600'],"[1411, 6044, 7287, 11237, 11238, 6180, 6937, 30, 1407, 1422, 5905, 6046, 11302, 88, 93, 1574, 1575, 1576, 1750, 6047, 6966, 7355, 8034, 1415, 1431, 1598, 1000]","{<CIViC source 99>, <CIViC source 2442>, <CIViC source 1040>, <CIViC source 3124>, <CIViC source 963>, <CIViC source 345>, <CIViC source 2475>, <CIViC source 959>, <CIViC source 4617>, <CIViC source 1210>, <CIViC source 2688>, <CIViC source 2441>, <CIViC source 103>, <CIViC source 2874>, <CIViC source 4616>, <CIViC source 353>, <CIViC source 2671>, <CIViC source 2905>, <CIViC source 71>, <CIViC source 690>}",[],[],[17]
18,CCND1 Amplification,47.0,CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.,CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.,[],"[7405, 354, 858, 1495, 7789, 1599, 1560, 1562]","{<CIViC source 3116>, <CIViC source 1031>, <CIViC source 210>, <CIViC source 212>, <CIViC source 1002>, <CIViC source 2924>, <CIViC source 933>, <CIViC source 574>}",[],[],[18]
19,CCND1 Expression,30.0,"CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.","CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.",[],"[342, 355]",{<CIViC source 210>},[],[],[19]
20,CCND1 Overexpression,116.0,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",[],"[221, 356, 357, 358, 856, 1536, 8115, 7788, 7790, 1563]","{<CIViC source 573>, <CIViC source 3123>, <CIViC source 3117>, <CIViC source 1023>, <CIViC source 218>, <CIViC source 157>, <CIViC source 1032>, <CIViC source 3115>, <CIViC source 219>}",[],[],[20]
21,CCND2 OVEREXPRESSION,16.0,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",[],"[359, 360, 361, 362]",{<CIViC source 220>},[],[],[21]
22,CCND2 PROMOTER DEMETHYLATION,3.0,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.","Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.",[],[219],{<CIViC source 155>},[],[],[22]
23,CCND3 Loss,3.0,"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.","Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.",[],[263],{<CIViC source 177>},[],[],[23]
24,CCNE1 Overexpression,42.0,"Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.","Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.",[],"[363, 364, 365, 7792, 10182, 10183, 1734]","{<CIViC source 222>, <CIViC source 3119>, <CIViC source 4261>, <CIViC source 1177>, <CIViC source 221>}",[],[],[24]
25,CDK4 EXPRESSION,10.0,"CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.","CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",[],"[345, 264, 4872, 7798]","{<CIViC source 2168>, <CIViC source 212>, <CIViC source 178>, <CIViC source 3123>}",[],[],[25]
26,CDK6 EXPRESSION,0.0,"CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.","CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.",[],[],set(),[],[],[26]
27,CDKN2A Promoter Hypermethylation,30.0,"CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.","CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.",[],"[367, 368]",{<CIViC source 18>},[],[],[27]
28,CEBPA N-TERMINAL FRAME SHIFT,18.0,"CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.","CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.",[],"[169, 1103]","{<CIViC source 761>, <CIViC source 133>}",[1326],[<CIViC source 1326>],[28]
29,CEBPA Mutation,163.0,"CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.","CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.",[],"[167, 467, 468, 12173, 12174, 12231, 122, 166, 168, 12172, 12175, 12200]","{<CIViC source 281>, <CIViC source 5128>, <CIViC source 5129>, <CIViC source 5127>, <CIViC source 118>, <CIViC source 5126>, <CIViC source 133>, <CIViC source 137>, <CIViC source 282>}",[],[],[29]
30,MEF2D::CSF1R Fusion,10.5,"MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.","MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.",['MEF2D-CSF1R'],"[9360, 403, 9359]","{<CIViC source 237>, <CIViC source 3622>, <CIViC source 3879>}",[],[],[30]
31,DNAJB1::PRKACA Fusion,75.0,"This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.","This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.",['DNAJB1-PRKACA'],"[532, 405, 754, 1643]","{<CIViC source 499>, <CIViC source 260>, <CIViC source 1089>, <CIViC source 22>}",[],[],[31]
32,DNMT3A R882,510.0,"DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.","DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.","['R693', 'ARG882', 'ARG693']","[62, 64, 65, 112, 11, 18, 24, 25, 51, 66, 67, 68, 157, 187, 4, 31, 49, 50, 61, 63, 110, 114, 115, 170, 186, 189, 3, 113]","{<CIViC source 53>, <CIViC source 68>, <CIViC source 72>, <CIViC source 81>, <CIViC source 54>, <CIViC source 86>}",[],[],[32]
33,EGFR L858R,379.0,"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.","EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.","['LEU858ARG', 'RS121434568', 'L813R', 'LEU813ARG']","[2994, 2997, 4860, 275, 879, 982, 2621, 229, 347, 883, 885, 1665, 2634, 12203, 4290, 6183, 2623, 2630, 8053, 4288, 2632, 2624, 276, 2626, 2627, 2628, 2631, 3811, 4265, 4286, 4292, 4295, 5922, 968, 2629, 4284, 4285, 4291, 4293, 4294, 2633, 4287]","{<CIViC source 4919>, <CIViC source 1510>, <CIViC source 2478>, <CIViC source 1525>, <CIViC source 2081>, <CIViC source 213>, <CIViC source 1991>, <CIViC source 507>, <CIViC source 2158>, <CIViC source 1501>, <CIViC source 1508>, <CIViC source 669>, <CIViC source 1513>, <CIViC source 2086>, <CIViC source 182>, <CIViC source 1526>, <CIViC source 594>, <CIViC source 162>, <CIViC source 1509>, <CIViC source 1993>, <CIViC source 1515>, <CIViC source 1127>, <CIViC source 595>, <CIViC source 1230>, <CIViC source 1724>, <CIViC source 181>, <CIViC source 2070>, <CIViC source 1725>, <CIViC source 665>, <CIViC source 3253>, <CIViC source 1608>, <CIViC source 679>, <CIViC source 592>, <CIViC source 1528>, <CIViC source 2067>}",[],[],[33]
34,EGFR T790M,406.25,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.","EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.","['THR790MET', 'RS121434569']","[238, 1592, 1867, 2166, 240, 369, 370, 646, 965, 1863, 5709, 239, 966, 1391, 1667, 2159, 10358, 3806, 3807, 2158, 12066, 277, 2157, 6006, 1397, 3801, 3808, 3809, 642, 2160, 4836, 762, 963, 2161, 3810, 6318, 967, 2162, 2163, 2164, 2165, 3812, 278]","{<CIViC source 943>, <CIViC source 2322>, <CIViC source 1282>, <CIViC source 1525>, <CIViC source 1991>, <CIViC source 183>, <CIViC source 669>, <CIViC source 946>, <CIViC source 405>, <CIViC source 667>, <CIViC source 1516>, <CIViC source 1526>, <CIViC source 1053>, <CIViC source 1331>, <CIViC source 184>, <CIViC source 1128>, <CIViC source 1520>, <CIViC source 1993>, <CIViC source 169>, <CIViC source 224>, <CIViC source 1515>, <CIViC source 4314>, <CIViC source 1527>, <CIViC source 167>, <CIViC source 2142>, <CIViC source 505>, <CIViC source 2492>, <CIViC source 5034>, <CIViC source 408>, <CIViC source 1992>, <CIViC source 665>, <CIViC source 668>, <CIViC source 225>, <CIViC source 1524>, <CIViC source 168>, <CIViC source 1528>, <CIViC source 1994>, <CIViC source 1286>, <CIViC source 2359>}","[1053, 1054]","[<CIViC source 1053>, <CIViC source 1054>]",[34]
35,ERBB2 D769H,4.0,"ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['ASP769HIS', 'D739H', 'D754H', 'ASP739HIS', 'ASP754HIS', 'D769H', 'RS121913468']","[11499, 279, 10024]","{<CIViC source 170>, <CIViC source 1143>}",[170],[<CIViC source 170>],[35]
36,ERBB2 D769Y,11.5,"ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['D739Y', 'D754Y', 'RS121913468', 'ASP769TYR', 'D769Y', 'ASP754TYR', 'ASP739TYR']","[11688, 11689, 280]","{<CIViC source 4837>, <CIViC source 170>}",[170],[<CIViC source 170>],[36]
37,ERBB2 L755_T759del,5.0,"ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['RS1131692241', 'LEU755_THR759DEL']","[281, 10021, 10026]",{<CIViC source 170>},[170],[<CIViC source 170>],[37]
38,ERBB2 G309A,5.0,"ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['GLY309ALA', 'GLY279ALA', 'GLY294ALA', 'G294A', 'G279A', 'RS1057519787']","[282, 11490, 11491, 10028]","{<CIViC source 1160>, <CIViC source 170>}",[170],[<CIViC source 170>],[38]
39,ERBB2 L755S,23.5,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.","ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.","['LEU755SER', 'L725S', 'L740S']","[12233, 4955, 8015, 8055, 4519, 241, 283, 1176, 10022, 11557, 3004]","{<CIViC source 1164>, <CIViC source 811>, <CIViC source 4879>, <CIViC source 170>, <CIViC source 1396>, <CIViC source 4746>, <CIViC source 3245>}",[170],[<CIViC source 170>],[39]
40,ERBB2 L755W,5.0,"ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['LEU755TRP', 'L725W', 'L740W', 'RS121913470']","[12234, 284]","{<CIViC source 4879>, <CIViC source 170>}",[170],[<CIViC source 170>],[40]
42,ERBB2 R678Q,5.0,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.","ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.","['ARG678GLN', 'R648Q', 'R663Q', 'RS1057519862']","[286, 10027, 11551, 11469, 11470]","{<CIViC source 170>, <CIViC source 4746>, <CIViC source 3074>}",[170],[<CIViC source 170>],[42]
43,ERBB2 R896C,5.0,"ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['ARG896CYS', 'R866C', 'R881C', 'RS758222990']",[287],{<CIViC source 170>},[170],[<CIViC source 170>],[43]
44,ERBB2 V777L,11.0,"ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['V747L', 'V762L', 'VAL777LEU', 'RS121913471']","[12106, 5817, 11690, 4452, 288, 12103, 1177, 10023, 11559, 11569, 12101, 12102, 12105, 9697, 12104]","{<CIViC source 4645>, <CIViC source 5075>, <CIViC source 811>, <CIViC source 5074>, <CIViC source 170>, <CIViC source 1396>, <CIViC source 2354>, <CIViC source 4746>, <CIViC source 4837>, <CIViC source 5073>}",[170],[<CIViC source 170>],[44]
45,ERBB2 V842I,9.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","['VAL842ILE', 'V812I', 'V827I', 'VAL812ILE', 'VAL827ILE', 'RS1057519738']","[11501, 4520, 289, 1174, 10025, 11561]","{<CIViC source 170>, <CIViC source 1143>, <CIViC source 4746>, <CIViC source 811>}",[170],[<CIViC source 170>],[45]
46,ESR1 L536Q,8.0,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",['LEU536GLN'],"[12229, 290, 242]","{<CIViC source 30>, <CIViC source 171>, <CIViC source 4727>}",[],[],[46]
47,ESR1 D538G,18.0,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",['ASP538GLY'],"[12219, 4814, 4813, 291, 243, 10018]","{<CIViC source 4727>, <CIViC source 171>, <CIViC source 2136>, <CIViC source 2135>, <CIViC source 30>}",[],[],[47]
48,ESR1 Y537C,8.0,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",['GLY537CYS'],"[12222, 4812, 292, 244]","{<CIViC source 30>, <CIViC source 2135>, <CIViC source 171>, <CIViC source 4727>}",[],[],[48]
49,ESR1 Y537N,8.0,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",['GLY537ASN'],"[12221, 4817, 4816, 293, 245]","{<CIViC source 4727>, <CIViC source 171>, <CIViC source 2136>, <CIViC source 2135>, <CIViC source 30>}",[],[],[49]
50,ESR1 Y537S,8.0,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",['GLY537SER'],"[12220, 4819, 4818, 294, 246, 10019]","{<CIViC source 4727>, <CIViC source 171>, <CIViC source 2136>, <CIViC source 2135>, <CIViC source 30>}",[],[],[50]
51,FGFR2 P235R,0.0,,,[],[],set(),[],[],[51]
52,FGFR2::OGA Fusion,5.0,"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",['FGFR2-MGEA5'],[295],{<CIViC source 186>},[33],[<CIViC source 33>],[52]
53,FGFR3::BAIAP2L1 Fusion,3.0,"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",['FGFR3-BAIAP2L1'],[144],{<CIViC source 33>},[33],[<CIViC source 33>],[53]
54,FGFR2::TACC3 Fusion,7.5,"In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.",['FGFR2-TACC3'],[296],{<CIViC source 186>},[33],[<CIViC source 33>],[54]
55,FLT3 ITD,448.5,"FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.","FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.",[],"[190, 69, 1515, 7061, 9070, 52, 128, 158, 191, 192, 193, 195, 297, 298, 372, 1112, 8658, 9069, 9259, 127, 129, 198, 222, 371, 1109, 9217, 159, 1040, 1137, 1555, 7369, 7372, 7373, 299, 7374, 7382, 8924, 130, 131, 8923, 11084]","{<CIViC source 3831>, <CIViC source 767>, <CIViC source 226>, <CIViC source 121>, <CIViC source 188>, <CIViC source 3480>, <CIViC source 1028>, <CIViC source 3830>, <CIViC source 2913>, <CIViC source 68>, <CIViC source 118>, <CIViC source 152>, <CIViC source 173>, <CIViC source 187>, <CIViC source 113>, <CIViC source 787>, <CIViC source 2740>, <CIViC source 1009>, <CIViC source 765>, <CIViC source 3336>, <CIViC source 145>, <CIViC source 54>, <CIViC source 3332>, <CIViC source 3936>, <CIViC source 3642>, <CIViC source 134>, <CIViC source 4167>, <CIViC source 116>, <CIViC source 172>, <CIViC source 141>}",[],[],[55]
56,FLT3 TKD MUTATION,120.0,"FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.","FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.",[],"[248, 373, 171, 214, 322, 1295, 9246]","{<CIViC source 1009>, <CIViC source 138>, <CIViC source 227>, <CIViC source 152>, <CIViC source 890>, <CIViC source 173>}",[],[],[56]
57,GATA2 EXPRESSION,4.0,"GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.","GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.",[],[301],{<CIViC source 35>},[],[],[57]
58,IDH1 R132,199.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.","IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",['ARG132'],"[10886, 11194, 3718, 480, 481, 374, 160, 348, 349, 4031, 4032, 7448, 11198, 223, 323, 2020, 2330, 11197, 7637, 6439]","{<CIViC source 3421>, <CIViC source 135>, <CIViC source 201>, <CIViC source 2949>, <CIViC source 3029>, <CIViC source 214>, <CIViC source 4589>, <CIViC source 228>, <CIViC source 1433>, <CIViC source 215>, <CIViC source 158>, <CIViC source 38>, <CIViC source 1361>, <CIViC source 4591>}",[],[],[58]
59,IDH1 R132C,56.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.","IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.","['RS121913499', 'ARG132CYS']","[2326, 2328, 224, 324, 2327, 2331, 732, 2332, 10144, 2329]","{<CIViC source 480>, <CIViC source 1424>, <CIViC source 1434>, <CIViC source 1425>, <CIViC source 1432>, <CIViC source 1570>, <CIViC source 159>, <CIViC source 678>, <CIViC source 1683>}",[],[],[59]
62,IDH2 R140,60.0,"IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.","IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.",['ARG140'],"[330, 350, 327, 329, 1542, 10292]","{<CIViC source 1363>, <CIViC source 202>, <CIViC source 205>, <CIViC source 204>, <CIViC source 216>}",[],[],[62]
63,IDH2 R172K,35.0,"IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.","IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.","['ARG172LYS', 'R120K', 'RS121913503']","[375, 331, 332]","{<CIViC source 202>, <CIViC source 204>, <CIViC source 216>}",[],[],[63]
64,JAK2 V617F,103.0,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.","JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.","['VAL617PHE', 'RS77375493']","[1, 5, 6, 7, 19, 20]","{<CIViC source 65>, <CIViC source 64>, <CIViC source 51>, <CIViC source 55>}",[2166],[<CIViC source 2166>],[64]
65,KIT D816V,67.0,KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.,KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.,"['ASP816VAL', 'RS121913507']","[11274, 26, 1725, 1726, 11160, 4159, 7465, 4160, 4161, 4162, 4163, 8360, 8361, 8362, 11369, 2451, 6956]","{<CIViC source 2049>, <CIViC source 1170>, <CIViC source 4632>, <CIViC source 2054>, <CIViC source 2059>, <CIViC source 4567>, <CIViC source 69>, <CIViC source 2060>, <CIViC source 1598>, <CIViC source 412>, <CIViC source 1171>, <CIViC source 1994>, <CIViC source 2681>}",[],[],[65]
66,KIT Exon 11 Mutation,197.5,"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.","c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.",[],"[654, 653, 2471, 53, 58, 333, 376, 4072, 6377, 225, 334, 4599, 4629, 4686, 1224, 7071]","{<CIViC source 82>, <CIViC source 847>, <CIViC source 2045>, <CIViC source 965>, <CIViC source 206>, <CIViC source 160>, <CIViC source 85>, <CIViC source 207>, <CIViC source 2056>, <CIViC source 2044>, <CIViC source 2046>, <CIViC source 1586>, <CIViC source 412>}",[],[],[66]
67,KIT Internal Duplication,7.5,"c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.",[],[302],{<CIViC source 190>},[],[],[67]
69,KIT Exon 14 Mutation,15.0,"c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.","c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.",[],[70],{<CIViC source 82>},[],[],[69]
70,KIT EXON 17 MUTATIONS,0.0,"c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.","c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.",[],[],set(),[],[],[70]
72,KIT L576P,16.0,"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.","KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.","['RS121913513', 'LEU576PRO']","[4137, 4136, 2479, 34, 42, 303, 4141]","{<CIViC source 1589>, <CIViC source 2054>, <CIViC source 965>, <CIViC source 74>, <CIViC source 191>, <CIViC source 2043>}",[],[],[72]
73,KIT V654A,18.0,"KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.","KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.","['RS121913523', 'VAL654ALA']","[304, 4148, 4149, 4150, 249]","{<CIViC source 62>, <CIViC source 192>, <CIViC source 1994>, <CIViC source 2042>}",[],[],[73]
74,KRAS EXON 2 Mutations,0.0,A study by Livre et al in 2006 showed that colorectal cancer patients with KRAS exon 1 mutations had low cetuximab response rates.,A study by Livre et al in 2006 showed that colorectal cancer patients with KRAS exon 1 mutations had low cetuximab response rates.,[],[11053],{<CIViC source 2783>},[],[],[74]
75,KRAS Exon 2 Mutation,168.0,Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.,Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.,[],"[993, 1219, 250, 916, 917, 1208, 2361, 4052, 87, 1326, 8367]","{<CIViC source 623>, <CIViC source 97>, <CIViC source 916>, <CIViC source 833>, <CIViC source 687>, <CIViC source 174>, <CIViC source 1475>, <CIViC source 842>, <CIViC source 1474>, <CIViC source 108>}",[],[],[75]
76,KRAS G12,115.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.","While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",['GLY12'],"[336, 487, 8, 215, 337, 377, 378, 2938, 7183]","{<CIViC source 230>, <CIViC source 208>, <CIViC source 229>, <CIViC source 56>, <CIViC source 209>, <CIViC source 1416>, <CIViC source 2810>, <CIViC source 153>}",[],[],[76]
77,KRAS G12/G13,191.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.","While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",[],"[622, 35, 134, 990, 2004, 2231, 6292, 6293, 6294, 6295, 6296, 6363, 135, 194]","{<CIViC source 385>, <CIViC source 122>, <CIViC source 75>, <CIViC source 76>, <CIViC source 1479>, <CIViC source 1412>, <CIViC source 176>}",[],[],[77]
78,KRAS G12C,256.5,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.","While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.","['GLY12CYS', 'RS121913530']","[9431, 12063, 12264, 2259, 2260, 8068, 11652, 1216, 1217, 3967, 7387, 7455, 10110, 11680, 227, 1142, 2257, 2258, 2254, 2255, 2256, 3962, 3963, 3964, 3965, 3966, 3968, 3969, 3970, 3971, 3972, 3976, 3977, 3980, 3981, 3982, 3983, 9959, 2253, 2262, 3974, 3975, 9958, 5927, 9963, 1173, 7572, 8039, 9146, 9960, 9962, 9964, 9965, 11521, 2212, 2261, 2263, 3973, 9961]","{<CIViC source 1935>, <CIViC source 1937>, <CIViC source 4080>, <CIViC source 1419>, <CIViC source 1421>, <CIViC source 1940>, <CIViC source 3174>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 507>, <CIViC source 5166>, <CIViC source 1936>, <CIViC source 810>, <CIViC source 3008>, <CIViC source 2916>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 3771>, <CIViC source 2955>, <CIViC source 1414>, <CIViC source 2022>, <CIViC source 1417>, <CIViC source 1415>, <CIViC source 5031>, <CIViC source 839>, <CIViC source 1413>, <CIViC source 1925>, <CIViC source 161>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 1924>, <CIViC source 174>, <CIViC source 4818>, <CIViC source 1422>, <CIViC source 1406>, <CIViC source 1926>, <CIViC source 1418>, <CIViC source 1931>, <CIViC source 122>, <CIViC source 1420>, <CIViC source 2026>, <CIViC source 840>, <CIViC source 791>, <CIViC source 1934>, <CIViC source 2399>, <CIViC source 1416>, <CIViC source 4226>, <CIViC source 1412>, <CIViC source 4772>, <CIViC source 4507>, <CIViC source 3272>}",[],[],[78]
79,KRAS G12D,162.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.","While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.","['GLY12ASP', 'RS121913529']","[2241, 2243, 2244, 2245, 2248, 2249, 3938, 3951, 3952, 3953, 3954, 1300, 8031, 228, 1215, 1311, 1732, 2207, 12137, 2240, 2247, 2236, 2237, 2238, 2239, 2246, 3933, 3934, 3935, 3936, 3937, 3940, 3941, 3942, 3943, 3944, 3945, 3947, 3949, 3955, 3960, 3961, 1898, 2193, 91, 937, 1580, 6316, 10797, 2251, 3948, 3959, 305, 7171, 12136, 2218, 3958, 6962, 2250, 2252, 3957, 7181, 3946]","{<CIViC source 1935>, <CIViC source 1419>, <CIViC source 1421>, <CIViC source 838>, <CIViC source 1940>, <CIViC source 641>, <CIViC source 1548>, <CIViC source 1479>, <CIViC source 1549>, <CIViC source 4406>, <CIViC source 2024>, <CIViC source 2685>, <CIViC source 1546>, <CIViC source 176>, <CIViC source 1936>, <CIViC source 1550>, <CIViC source 5097>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 1414>, <CIViC source 1407>, <CIViC source 1417>, <CIViC source 1415>, <CIViC source 193>, <CIViC source 1941>, <CIViC source 902>, <CIViC source 1043>, <CIViC source 1413>, <CIViC source 1925>, <CIViC source 161>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 1924>, <CIViC source 174>, <CIViC source 2808>, <CIViC source 2025>, <CIViC source 1422>, <CIViC source 1406>, <CIViC source 1926>, <CIViC source 1418>, <CIViC source 1931>, <CIViC source 122>, <CIViC source 1420>, <CIViC source 1634>, <CIViC source 2020>, <CIViC source 1330>, <CIViC source 893>, <CIViC source 101>, <CIViC source 1934>, <CIViC source 1416>, <CIViC source 1937>, <CIViC source 1412>, <CIViC source 2019>, <CIViC source 2796>, <CIViC source 2023>}",[],[],[79]
80,KRAS G13,20.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.","While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",['GLY13'],[488],{<CIViC source 229>},[],[],[80]
81,KRAS G13D,108.5,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.","While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.","['GLY13ASP', 'RS112445441']","[3879, 3882, 3884, 306, 1181, 6974, 1180, 3881, 11054, 806, 3873, 3874, 3875, 3876, 3877, 3880, 3883, 3885, 3886, 3887, 3888, 3892, 3893, 3896, 2178, 6320, 6322, 3878, 3890, 3891, 3897, 145, 2041, 7076, 2183, 3889]","{<CIViC source 1935>, <CIViC source 1937>, <CIViC source 1940>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 1920>, <CIViC source 176>, <CIViC source 1936>, <CIViC source 2784>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 2022>, <CIViC source 813>, <CIViC source 2008>, <CIViC source 2752>, <CIViC source 123>, <CIViC source 2694>, <CIViC source 1925>, <CIViC source 1435>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 1973>, <CIViC source 540>, <CIViC source 174>, <CIViC source 1406>, <CIViC source 1926>, <CIViC source 1931>, <CIViC source 122>, <CIViC source 2020>, <CIViC source 2021>, <CIViC source 1934>, <CIViC source 814>, <CIViC source 2019>}",[813],[<CIViC source 813>],[81]
82,MAP2K1 P124S,3.0,"MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.","MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.",['PRO124SER'],"[7660, 12]","{<CIViC source 58>, <CIViC source 3044>}",[],[],[82]
83,MAP2K1 Q56P,3.0,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,"['GLN56PRO', 'RS1057519729']","[4727, 13]","{<CIViC source 60>, <CIViC source 58>}",[],[],[83]
85,MGMT Promoter Methylation,136.0,"MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.","MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.",[],"[307, 7303, 491, 172, 308, 490, 309]","{<CIViC source 194>, <CIViC source 139>, <CIViC source 298>, <CIViC source 2883>}",[],[],[85]
86,NPM1 EXON 11 MUTATION,454.0,"NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.","NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.",['EXON 12 MUTATION'],"[116, 176, 111, 118, 173, 181, 184, 1102, 108, 119, 120, 137, 174, 175, 177, 180, 182, 183, 185, 199, 1369, 117, 146, 147, 148, 179, 196, 149, 150, 151]","{<CIViC source 760>, <CIViC source 39>, <CIViC source 127>, <CIViC source 130>, <CIViC source 128>, <CIViC source 118>, <CIViC source 114>, <CIViC source 113>, <CIViC source 930>, <CIViC source 143>, <CIViC source 19>, <CIViC source 140>, <CIViC source 117>, <CIViC source 129>, <CIViC source 142>, <CIViC source 146>, <CIViC source 116>, <CIViC source 137>, <CIViC source 144>, <CIViC source 141>, <CIViC source 147>}",[],[],[86]
87,NPM1 W288FS,13.75,"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","['NPM1-A', 'RS587776806', 'TRP288FS']","[1510, 109, 121, 152, 153]","{<CIViC source 68>, <CIViC source 128>, <CIViC source 1009>, <CIViC source 130>}",[],[],[87]
88,NRAS EXON 2-3 MUTATION,0.0,NRAS exon 2 and 3 mutations were studied by Jakob et al in 2012 and were shown to be correlated with poorer overall survival relative to wild-type NRAS in melanoma patients.,NRAS exon 2 and 3 mutations were studied by Jakob et al in 2012 and were shown to be correlated with poorer overall survival relative to wild-type NRAS in melanoma patients.,[],[],set(),[],[],[88]
89,NRAS EXON 2 MUTATIONS,0.0,"NRAS exon 2 mutations have been shown to be correlated with poorer overall survival in melanoma patients and colorectal cancer patients, however no prognostic impact was seen in acute myeloid leukemia patients.","NRAS exon 2 mutations have been shown to be correlated with poorer overall survival in melanoma patients and colorectal cancer patients, however no prognostic impact was seen in acute myeloid leukemia patients.",[],[],set(),[],[],[89]
90,NRAS EXON 3 MUTATIONS,0.0,"In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.","In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.",[],[],set(),[],[],[90]
91,NRAS EXON 4 MUTATIONS,0.0,"In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.","In a multi-gene prognostic survey, Therkildsen et al 2014 found NRAS exon 3 and 4 mutations were correlated with poorer overall survival.",[],[],set(),[],[],[91]
92,NRAS G12,15.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.","While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",[],[57],{<CIViC source 84>},[],[],[92]
93,NRAS G13D,5.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.","While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.","['GLY13ASP', 'RS121434596']","[21, 3840]","{<CIViC source 66>, <CIViC source 1919>}",[],[],[93]
94,NRAS Q61,100.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.","NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",['GLN61'],"[14, 10, 124, 497, 36, 1226, 6959, 7104, 1473]","{<CIViC source 76>, <CIViC source 60>, <CIViC source 987>, <CIViC source 57>, <CIViC source 303>, <CIViC source 2683>, <CIViC source 849>}",[],[],[94]
95,NRAS Q61L,12.5,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.","NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.","['GLN61LEU', 'RS11554290']","[2179, 2182, 3825, 2181, 22, 2177, 2180, 3826, 3018]","{<CIViC source 67>, <CIViC source 1670>, <CIViC source 1482>, <CIViC source 76>, <CIViC source 1407>, <CIViC source 1941>, <CIViC source 1406>}",[],[],[95]
96,NRAS Q61R,10.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.","NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.","['GLN61ARG', 'RS11554290']","[2185, 2188, 3829, 23, 2184, 2186, 3828, 3830, 3831, 3019]","{<CIViC source 67>, <CIViC source 1670>, <CIViC source 76>, <CIViC source 1407>, <CIViC source 2003>, <CIViC source 1941>, <CIViC source 2004>, <CIViC source 1406>}",[],[],[96]
97,PDGFRA V536E,0.0,,,[],[],set(),[],[],[97]
98,PDGFRA D842I,4.0,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",['ASP842ILE'],[43],{<CIViC source 80>},[],[],[98]
99,PDGFRA D842V,100.5,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","['ASP842VAL', 'RS121908585']","[11545, 15, 16, 738, 7479, 2, 4058, 4597, 2478, 4057, 4059, 44, 651, 2463, 4060, 5346, 7514]","{<CIViC source 80>, <CIViC source 62>, <CIViC source 486>, <CIViC source 52>, <CIViC source 61>, <CIViC source 965>, <CIViC source 846>, <CIViC source 411>, <CIViC source 412>, <CIViC source 192>, <CIViC source 1580>, <CIViC source 2968>, <CIViC source 2041>, <CIViC source 1994>}",[],[],[99]
100,PDGFRA D842Y,4.0,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","['ASP842TYR', 'RS121913265']",[45],{<CIViC source 80>},[],[],[100]
101,PDGFRA I843DEL,5.0,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",['DELI843'],"[46, 1309]","{<CIViC source 412>, <CIViC source 80>}",[],[],[101]
102,PDGFRA D842_I843delinsVM,4.0,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",[],[47],{<CIViC source 80>},[],[],[102]
103,PIK3CA E542K,75.5,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.","PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.","['GLU542LYS', 'RS121913273']","[7315, 12184, 2032, 2033, 83, 256, 385, 2024, 3719, 4424, 1549, 2027, 310, 311, 1626, 2022, 2026, 2058, 8007, 8013, 8016]","{<CIViC source 1076>, <CIViC source 195>, <CIViC source 1463>, <CIViC source 1435>, <CIViC source 1447>, <CIViC source 76>, <CIViC source 4994>, <CIViC source 1479>, <CIViC source 176>, <CIViC source 2888>, <CIViC source 1464>, <CIViC source 1452>, <CIViC source 196>, <CIViC source 1026>, <CIViC source 4081>}",[],[],[103]
104,PIK3CA E545K,77.5,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.","PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.","['GLU545LYS', 'RS104886003']","[12188, 2039, 3720, 2106, 3721, 387, 2217, 1670, 2037, 1550, 2062, 710, 2036, 2984, 2985, 6207, 6209, 6211, 6213, 8112, 1171, 1453, 2034, 2040, 3722, 6212, 8180, 8181, 8547, 8008, 8017, 8018]","{<CIViC source 1026>, <CIViC source 1128>, <CIViC source 1435>, <CIViC source 76>, <CIViC source 1708>, <CIViC source 163>, <CIViC source 1479>, <CIViC source 4994>, <CIViC source 1452>, <CIViC source 1464>, <CIViC source 2486>, <CIViC source 981>, <CIViC source 1475>, <CIViC source 1941>, <CIViC source 808>, <CIViC source 176>, <CIViC source 1468>}",[],[],[104]
105,PIK3CA Exon 21 Mutation,45.0,"PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.","PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",['EXON 20 MUTATION'],"[6198, 138, 3729]","{<CIViC source 76>, <CIViC source 232>, <CIViC source 2483>}",[],[],[105]
106,PIK3CA Exon 10 Mutation,45.0,"PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.","PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",['EXON 9 MUTATION'],"[6199, 123, 384]","{<CIViC source 76>, <CIViC source 232>, <CIViC source 2483>}",[],[],[106]
107,PIK3CA H1047R,96.5,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.","PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.","['HIS1047ARG', 'RS121913279']","[12196, 2101, 2108, 2109, 3731, 258, 2097, 2100, 3728, 3841, 9484, 388, 1623, 7219, 314, 2096, 6202, 6203, 6204, 6205, 6206, 1447, 1505, 1506, 1625, 2103, 3733, 8364, 1362, 1363, 1465, 2102, 2110, 8182, 8548, 1361, 1401, 8010]","{<CIViC source 1463>, <CIViC source 1446>, <CIViC source 1479>, <CIViC source 1005>, <CIViC source 1464>, <CIViC source 1445>, <CIViC source 176>, <CIViC source 1468>, <CIViC source 927>, <CIViC source 2834>, <CIViC source 4994>, <CIViC source 1475>, <CIViC source 193>, <CIViC source 195>, <CIViC source 1435>, <CIViC source 76>, <CIViC source 3929>, <CIViC source 984>, <CIViC source 1452>, <CIViC source 1444>, <CIViC source 2486>, <CIViC source 1075>, <CIViC source 108>, <CIViC source 1076>, <CIViC source 949>, <CIViC source 926>}",[],[],[107]
108,PML::RARA Fusion,192.5,"The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.","The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.",['PML-RARA'],"[1090, 1091, 316, 12333, 12334, 8300, 12288, 12289, 12292, 1519]","{<CIViC source 197>, <CIViC source 5194>, <CIViC source 749>, <CIViC source 5178>, <CIViC source 5170>, <CIViC source 1012>, <CIViC source 5171>, <CIViC source 3436>, <CIViC source 5195>, <CIViC source 750>}",[1156],[<CIViC source 1156>],[108]
110,PTEN R233*,19.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.","PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.","['R233X', 'ARG233TER', 'RS121909219']","[343, 317]","{<CIViC source 211>, <CIViC source 198>}",[],[],[110]
112,RET C634W,3.0,"RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.","RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.",['CYS634TRP'],"[3694, 3695, 75]","{<CIViC source 1922>, <CIViC source 90>, <CIViC source 1921>}",[],[],[112]
113,RET M918T,86.0,"RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.","RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.","['MET918THR', 'RS74799832']","[74, 78, 7710, 1365, 11306, 3696, 11723, 11867, 76, 77, 11876]","{<CIViC source 4870>, <CIViC source 4954>, <CIViC source 1921>, <CIViC source 2677>, <CIViC source 3061>, <CIViC source 91>, <CIViC source 90>, <CIViC source 44>, <CIViC source 928>, <CIViC source 92>}",[],[],[113]
114,SF3B1 K666N,2.0,"SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.","SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.","['LYS666ASN', 'RS377023736']",[1418],{<CIViC source 960>},[],[],[114]
115,SF3B1 K700E,0.0,"SF3B1 K700E is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients. Additionally, these mutations are the most common SF3B1 mutation observed in MDS and highly associated with subtypes of MDS that are defined by ringed sideroblasts.","SF3B1 K700E is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients. Additionally, these mutations are the most common SF3B1 mutation observed in MDS and highly associated with subtypes of MDS that are defined by ringed sideroblasts.",[],[],set(),[],[],[115]
116,TP53 R175H,25.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).","While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).","['ARG175HIS', 'RS28934578', 'R43H', 'R136H']","[389, 2310, 4880, 7119, 7432, 7526, 10074, 10075, 10076, 319, 7106, 7112, 10527, 7429]","{<CIViC source 199>, <CIViC source 4356>, <CIViC source 2992>, <CIViC source 1696>, <CIViC source 1557>, <CIViC source 2933>, <CIViC source 2931>, <CIViC source 2757>, <CIViC source 2758>, <CIViC source 233>}",[],[],[116]
117,TP53 R248Q,46.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.","While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.","['ARG248GLN', 'RS11540652']","[390, 391, 3042, 7161, 7175, 7525, 7529, 7109, 7115, 7162, 7442, 10535]","{<CIViC source 234>, <CIViC source 2944>, <CIViC source 4356>, <CIViC source 2787>, <CIViC source 2992>, <CIViC source 2800>, <CIViC source 2788>, <CIViC source 2757>, <CIViC source 1696>, <CIViC source 233>}",[],[],[117]
118,TP53 R248W,22.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.","While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.","['ARG248TRP', 'RS121912651']","[392, 4879, 7120, 10261]","{<CIViC source 4271>, <CIViC source 2758>, <CIViC source 1696>, <CIViC source 233>}",[],[],[118]
119,TP53 R249,30.0,"This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",['ARG249'],"[393, 399, 7340]","{<CIViC source 234>, <CIViC source 2904>}",[],[],[119]
120,TP53 R249W,0.0,"This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",[],[],set(),[],[],[120]
121,TP53 R273C,44.5,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","['ARG273CYS', 'RS121913343']","[395, 396, 2292, 4881, 10072, 10073, 7443, 10256, 10537, 9464]","{<CIViC source 4271>, <CIViC source 2944>, <CIViC source 234>, <CIViC source 4356>, <CIViC source 4058>, <CIViC source 1557>, <CIViC source 1696>, <CIViC source 233>}",[],[],[121]
122,TP53 R273H,41.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","['ARG273HIS', 'RS28934576']","[397, 398, 2289, 4882, 7121, 7433, 7530, 7111, 7117, 7430, 7980, 10536, 9465]","{<CIViC source 234>, <CIViC source 4356>, <CIViC source 1555>, <CIViC source 4058>, <CIViC source 2992>, <CIViC source 3203>, <CIViC source 1696>, <CIViC source 2933>, <CIViC source 2932>, <CIViC source 2757>, <CIViC source 2758>, <CIViC source 233>}",[],[],[122]
123,TP53 r249,0.0,"While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.","While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",[],[],set(),[],[],[123]
124,TSC1 Frameshift Truncation,18.0,"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.",[],"[320, 154]","{<CIViC source 131>, <CIViC source 132>}",[],[],[124]
125,TSC1 Loss-of-function,15.0,"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.",[],"[7280, 155, 5837, 6053]","{<CIViC source 132>, <CIViC source 2107>, <CIViC source 2869>, <CIViC source 2363>}",[],[],[125]
127,U2AF1 Q157P/R,50.0,"U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.","U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",[],"[217, 400, 338, 339]","{<CIViC source 235>, <CIViC source 154>}",[],[],[127]
128,U2AF1 S34Y/F,25.0,"U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.","U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",[],"[218, 401, 340]","{<CIViC source 235>, <CIViC source 154>}",[],[],[128]
129,WT1 Exon 7 Mutation,130.0,"WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.","WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.",[],"[163, 139, 162, 203, 204, 205, 206, 201, 202]","{<CIViC source 124>, <CIViC source 149>, <CIViC source 148>, <CIViC source 136>}",[],[],[129]
130,WT1 Exon 9 Mutation,35.0,"WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.","WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.",[],"[165, 210]","{<CIViC source 149>, <CIViC source 136>}",[],[],[130]
131,BRCA1 Loss-of-function,254.0,BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,[],"[7384, 11201, 11216, 5815, 211, 4838, 1523, 4876, 6075, 845, 1924]","{<CIViC source 2143>, <CIViC source 1016>, <CIViC source 150>, <CIViC source 409>, <CIViC source 4541>, <CIViC source 2914>, <CIViC source 2329>, <CIViC source 2388>, <CIViC source 1346>}",[],[],[131]
132,BRCA2 Loss-of-function,261.0,BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.,[],"[7385, 11202, 11217, 212, 650, 4839, 1524, 4875, 5816, 6076, 1925, 8979, 8980, 8981, 8982, 1308]","{<CIViC source 3786>, <CIViC source 2143>, <CIViC source 1016>, <CIViC source 409>, <CIViC source 150>, <CIViC source 4541>, <CIViC source 900>, <CIViC source 2914>, <CIViC source 2329>, <CIViC source 2388>, <CIViC source 1346>}",[],[],[132]
133,EGFR Exon 19 Deletion,318.0,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.","Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.",[],"[2995, 2996, 413, 880, 981, 983, 7586, 7587, 882, 884, 1666, 2519, 4859, 6184, 12202, 4766, 273, 12205, 881, 969]","{<CIViC source 4919>, <CIViC source 680>, <CIViC source 2478>, <CIViC source 2158>, <CIViC source 669>, <CIViC source 1513>, <CIViC source 594>, <CIViC source 1990>, <CIViC source 1127>, <CIViC source 595>, <CIViC source 1724>, <CIViC source 1725>, <CIViC source 593>, <CIViC source 243>, <CIViC source 5135>, <CIViC source 679>, <CIViC source 3014>, <CIViC source 592>, <CIViC source 180>}",[],[],[133]
134,EGFR G719S,23.0,"While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.","While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.","['GLY719SER', 'RS28929495']","[1736, 4192, 6040, 2617, 4190, 4191, 274, 787, 9643, 9660, 9651]","{<CIViC source 2064>, <CIViC source 2065>, <CIViC source 1180>, <CIViC source 4099>, <CIViC source 523>, <CIViC source 181>, <CIViC source 1528>}",[],[],[134]
135,NOTCH1 D1642H,20.0,"Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.","Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.",['ASP1642HIS'],[380],{<CIViC source 231>},[],[],[135]
136,NOTCH1 R2327W,20.0,"Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.","Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.",['ARG2327TRP'],[381],{<CIViC source 231>},[],[],[136]
137,NOTCH1 V2444FS,20.0,"Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.","Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.",['VAL2444FS'],[383],{<CIViC source 231>},[],[],[137]
138,NOTCH1 S2275FS,20.0,"Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.","Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.",[],[382],{<CIViC source 231>},[],[],[138]
139,DDR2 L63V,4.0,"Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.",['LEU63VAL'],[271],{<CIViC source 179>},[],[],[139]
140,DDR2 L239R,4.0,"Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.",['LEU239ARG'],[270],{<CIViC source 179>},[],[],[140]
141,DDR2 G253C,4.0,"Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.",['GLY253CYS'],[266],{<CIViC source 179>},[],[],[141]
142,DDR2 G505S,4.0,"Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.","['GLY505SER', 'RS115169993']",[267],{<CIViC source 179>},[],[],[142]
143,DDR2 I638F,4.0,"DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.","DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.","['ILE638PHE', 'RS1057519789']",[269],{<CIViC source 179>},[],[],[143]
144,DDR2 G774V,4.0,"Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.",['GLY774VAL'],[268],{<CIViC source 179>},[],[],[144]
145,DDR2 S768R,7.5,"Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.","Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.",['SER768ARG'],[272],{<CIViC source 179>},[],[],[145]
147,KRAS G12V,0.0,"KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.","KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",[],[12180],{<CIViC source 5133>},[],[],[147]
148,KRAS G12A,63.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.","KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.","['GLY12ALA', 'RS121913529']","[2010, 2011, 251, 4429, 2008, 2009, 2005, 2006, 2007, 3699, 3700, 3701, 3702, 3703, 3705, 3706, 3707, 3708, 3709, 3712, 3714, 3716, 3717, 6319, 6325, 3711, 2012, 2013, 2014, 3710]","{<CIViC source 1935>, <CIViC source 1419>, <CIViC source 1421>, <CIViC source 1940>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 176>, <CIViC source 1936>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 1414>, <CIViC source 1415>, <CIViC source 1417>, <CIViC source 1413>, <CIViC source 1925>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 174>, <CIViC source 1939>, <CIViC source 1422>, <CIViC source 1926>, <CIViC source 1418>, <CIViC source 1931>, <CIViC source 175>, <CIViC source 122>, <CIViC source 1420>, <CIViC source 1934>, <CIViC source 1416>, <CIViC source 1937>}",[],[],[148]
151,BCL2 reg_e@[IGH]::BCL2,20.0,"The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.","The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.","['RECIPROCAL T(14;18)(Q32;Q21)', 'IGH-BCL2']","[11808, 407]","{<CIViC source 239>, <CIViC source 4936>}",[],[],[151]
152,BCL2 Overexpression,20.0,,,[],"[423, 424, 9313]","{<CIViC source 3994>, <CIViC source 251>}",[],[],[152]
153,FOXP1 AMPLIFICATION,15.0,Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.,Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.,[],[408],{<CIViC source 240>},[],[],[153]
154,REL AMPLIFICATION,20.0,,,[],[409],{<CIViC source 239>},[],[],[154]
155,RUNX1 Mutation,110.0,"RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.","RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.",[],"[411, 429, 430, 509, 6944, 508, 1558]","{<CIViC source 241>, <CIViC source 1029>, <CIViC source 283>, <CIViC source 2675>, <CIViC source 313>}",[],[],[155]
156,IGF2 Overexpression,6.0,,,[],"[7000, 412, 414, 6972]","{<CIViC source 2691>, <CIViC source 2696>, <CIViC source 242>}",[],[],[156]
157,TET2 Mutation,120.0,"TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving ""CN AML"" and ""de novo AML"" however have been unable to elucidate a clinical impact.","TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving ""CN AML"" and ""de novo AML"" however have been unable to elucidate a clinical impact.",[],"[415, 417, 419, 421, 426, 427, 11992]","{<CIViC source 250>, <CIViC source 247>, <CIViC source 253>, <CIViC source 4965>, <CIViC source 142>}","[2197, 2198]","[<CIViC source 2198>, <CIViC source 2197>]",[157]
158,AURKA EXPRESSION,30.0,,,[],"[416, 1653, 1959]","{<CIViC source 246>, <CIViC source 1117>, <CIViC source 1378>}",[],[],[158]
159,VHL Loss-of-function,15.0,,,[],"[428, 4828]","{<CIViC source 719>, <CIViC source 254>}",[],[],[159]
160,VHL Mutation,85.0,,,[],"[418, 4830, 4831, 4832, 5323, 422, 1672]","{<CIViC source 248>, <CIViC source 1132>, <CIViC source 249>, <CIViC source 2139>, <CIViC source 2227>}",[],[],[160]
161,PBRM1 Mutation,30.0,,,[],"[7247, 420, 499, 5996]","{<CIViC source 2234>, <CIViC source 2855>, <CIViC source 305>, <CIViC source 249>}",[],[],[161]
162,REL EXPRESSION,0.0,,,[],[],set(),[],[],[162]
163,EZH2 Mutation,35.0,,,[],"[1015, 425, 6945]","{<CIViC source 703>, <CIViC source 2675>, <CIViC source 252>}",[],[],[163]
164,EWSR1::FLI1 e7::e6,20.0,"Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.","Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.","['EWSR1-FLI1 TYPE 1', 'EWSR1-FLI1 E7-E6']",[431],{<CIViC source 255>},[1099],[<CIViC source 1099>],[164]
165,EZH2 Y646,45.0,"Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).","Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).","['Y641', 'TYR646']","[432, 433, 5677, 9412, 1494]","{<CIViC source 4040>, <CIViC source 2307>, <CIViC source 256>, <CIViC source 1001>}",[256],[<CIViC source 256>],[165]
166,BCL2 LOSS-OF-FUNCTION,0.0,,,[],[],set(),[],[],[166]
167,KMT2D Loss-of-function,15.0,,,[],[435],{<CIViC source 258>},[],[],[167]
168,BTK C481S,40.0,,,"['CYS481SER', 'RS1057519826']","[436, 1770]","{<CIViC source 259>, <CIViC source 1237>}",[],[],[168]
169,AKT1 Q79K,16.0,,,"['Q17K', 'GLN79LYS', 'RS1057519804']","[6260, 439, 4498]","{<CIViC source 1941>, <CIViC source 261>}",[],[],[169]
171,ALK G1202R,0.0,"ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.","ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.",['RS1057519783'],[],set(),[],[],[171]
172,ALK S1206Y,0.0,,,['RS1057519782'],[],set(),[],[],[172]
174,APC Mutation,7.0,,,[],"[8038, 446, 445]","{<CIViC source 3259>, <CIViC source 263>, <CIViC source 264>}",[],[],[174]
175,AR F877L,4.0,,,['PHE877LEU'],[447],{<CIViC source 265>},[],[],[175]
176,AR W742,4.0,,,['TRP742'],[448],{<CIViC source 266>},[],[],[176]
177,ASXL1 Mutation,100.0,ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.,ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.,[],"[1513, 451, 450, 1378, 1508, 6942, 449]","{<CIViC source 1007>, <CIViC source 267>, <CIViC source 1009>, <CIViC source 268>, <CIViC source 2675>, <CIViC source 935>}",[],[],[177]
178,ATM Mutation,130.5,,,[],"[1539, 8505, 2927, 7458, 7472, 11736, 1960, 455, 2222, 452, 453, 1907, 11908]","{<CIViC source 1335>, <CIViC source 409>, <CIViC source 1541>, <CIViC source 3554>, <CIViC source 1006>, <CIViC source 269>, <CIViC source 1680>, <CIViC source 4965>, <CIViC source 4881>, <CIViC source 271>, <CIViC source 2956>, <CIViC source 2961>}",[],[],[178]
179,ATM Underexpression,39.0,,,[],"[7708, 1564, 1292, 5215, 454, 878]","{<CIViC source 2209>, <CIViC source 3059>, <CIViC source 1033>, <CIViC source 888>, <CIViC source 591>, <CIViC source 270>}",[],[],[179]
180,AURKA Amplification,0.75,,,[],[456],{<CIViC source 272>},[],[],[180]
181,AURKA Overexpression,38.0,,,[],"[871, 1650, 9627, 457]","{<CIViC source 272>, <CIViC source 585>, <CIViC source 273>, <CIViC source 1114>}",[],[],[181]
182,BAP1 EXPRESSION,15.0,,,[],[458],{<CIViC source 274>},[],[],[182]
183,BAP1 Mutation,98.5,"BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of ""atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC"".","BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and -amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of ""atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC"".",[],"[459, 460, 461, 5339, 11740, 11741, 12008, 1234, 1235]","{<CIViC source 276>, <CIViC source 4884>, <CIViC source 2234>, <CIViC source 335>, <CIViC source 4887>, <CIViC source 854>, <CIViC source 275>}",[2200],[<CIViC source 2200>],[183]
184,AKAP9::BRAF Fusion,20.0,,,['AKAP9-BRAF'],"[462, 7759]","{<CIViC source 3095>, <CIViC source 277>}",[],[],[184]
185,BRCA1 Mutation,455.0,,,[],"[7274, 7277, 11136, 11138, 11203, 11734, 7275, 1370, 5830, 5915, 6333, 7470, 464, 1529, 1531, 1675, 1677, 1684, 1772, 1775, 1897, 5914, 5932, 5934, 6341, 7459, 9019, 9291, 7435]","{<CIViC source 2406>, <CIViC source 3983>, <CIViC source 1137>, <CIViC source 2357>, <CIViC source 4560>, <CIViC source 1328>, <CIViC source 4881>, <CIViC source 2956>, <CIViC source 2405>, <CIViC source 2389>, <CIViC source 1020>, <CIViC source 279>, <CIViC source 359>, <CIViC source 3808>, <CIViC source 1133>, <CIViC source 3554>, <CIViC source 2867>, <CIViC source 2510>, <CIViC source 2934>, <CIViC source 1134>, <CIViC source 1239>, <CIViC source 2388>, <CIViC source 2961>}",[],[],[185]
186,BRCA2 Mutation,462.5,,,[],"[7276, 8842, 11137, 11139, 11733, 1371, 5831, 5913, 5916, 6334, 7471, 11425, 465, 1530, 1532, 1676, 1678, 1685, 1773, 1776, 5933, 5935, 6343, 7436, 7457, 9292, 11426, 2868, 5936, 7434, 9293]","{<CIViC source 2406>, <CIViC source 3983>, <CIViC source 1137>, <CIViC source 2357>, <CIViC source 4560>, <CIViC source 4716>, <CIViC source 1328>, <CIViC source 4881>, <CIViC source 2956>, <CIViC source 2407>, <CIViC source 2405>, <CIViC source 2389>, <CIViC source 1020>, <CIViC source 279>, <CIViC source 359>, <CIViC source 1133>, <CIViC source 3554>, <CIViC source 4541>, <CIViC source 2867>, <CIViC source 2510>, <CIViC source 2934>, <CIViC source 1134>, <CIViC source 1239>, <CIViC source 2388>, <CIViC source 2961>}",[],[],[186]
187,CCNE1 Amplification,27.0,,,[],"[466, 7437, 1735, 1629, 10181, 7799, 7791]","{<CIViC source 280>, <CIViC source 1078>, <CIViC source 1178>, <CIViC source 3150>, <CIViC source 3119>, <CIViC source 4260>, <CIViC source 3118>}",[],[],[187]
188,CEBPA Mutation,0.0,,,[],[],set(),[],[],[188]
189,DNMT3A Mutation,115.0,"DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.","DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.",[],"[469, 1585, 1586, 188, 1238, 1587, 2926]","{<CIViC source 1679>, <CIViC source 1048>, <CIViC source 785>, <CIViC source 1009>, <CIViC source 1049>, <CIViC source 283>, <CIViC source 54>}",[1060],[<CIViC source 1060>],[189]
190,EGFR Amplification,173.0,,,[],"[473, 691, 948, 5924, 5925, 7802, 470, 471, 854, 911, 6927, 977, 7785, 3015, 9674]","{<CIViC source 618>, <CIViC source 2395>, <CIViC source 3112>, <CIViC source 450>, <CIViC source 285>, <CIViC source 571>, <CIViC source 284>, <CIViC source 2660>, <CIViC source 287>, <CIViC source 676>, <CIViC source 2083>, <CIViC source 650>, <CIViC source 2134>, <CIViC source 1733>}",[],[],[190]
191,EGFR Copy Number Variation,20.0,,,[],[472],{<CIViC source 286>},[],[],[191]
192,EGFR INCREASED COPY NUMBER,0.0,,,[],[],set(),[],[],[192]
193,EGFR Overexpression,145.0,,,[],"[692, 693, 10894, 474, 737, 782, 783, 784, 833, 834, 849, 954, 5827, 3797, 7803]","{<CIViC source 2173>, <CIViC source 568>, <CIViC source 452>, <CIViC source 1938>, <CIViC source 522>, <CIViC source 451>, <CIViC source 656>, <CIViC source 288>, <CIViC source 521>, <CIViC source 3126>, <CIViC source 485>, <CIViC source 4427>}",[],[],[193]
195,TMPRSS2::ERG Fusion,15.0,"TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.","TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.",['TMPRSS2-ERG'],[476],{<CIViC source 290>},[],[],[195]
198,FOXL2 C134W,70.0,"The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.","The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.",[],"[6034, 479, 10718]","{<CIViC source 292>, <CIViC source 2237>, <CIViC source 3558>}",[],[],[198]
199,IDH2 R172,105.0,"IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation ""catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate"" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).","IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation ""catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate"" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).",['ARG172'],"[482, 483, 628, 1511, 627]","{<CIViC source 390>, <CIViC source 391>, <CIViC source 1009>, <CIViC source 38>}",[2199],[<CIViC source 2199>],[199]
200,IKZF1 Deletion,240.0,"IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for ""normal hematopoiesis"". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease. Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.","IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for ""normal hematopoiesis"". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease. Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.",[],"[7365, 7404, 484, 629, 7366, 7391, 7532, 7542, 7543, 7544, 624, 625, 626, 7403, 7541, 9238]","{<CIViC source 2996>, <CIViC source 2993>, <CIViC source 392>, <CIViC source 388>, <CIViC source 2911>, <CIViC source 2994>, <CIViC source 2995>, <CIViC source 2997>, <CIViC source 2923>, <CIViC source 3849>, <CIViC source 2918>, <CIViC source 387>, <CIViC source 294>, <CIViC source 2922>, <CIViC source 389>}",[2205],[<CIViC source 2205>],[200]
201,KIT M541L,25.5,,,"['MET541LEU', 'RS3822214']","[485, 9698, 1423, 7195]","{<CIViC source 4137>, <CIViC source 964>, <CIViC source 295>, <CIViC source 2817>}",[],[],[201]
202,KIT V560DEL,12.5,V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.,V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.,"['VAL560DEL', 'V559DEL', 'V555DEL', 'V556DEL']","[4117, 4118, 486, 7359, 2461]","{<CIViC source 296>, <CIViC source 965>, <CIViC source 2043>, <CIViC source 1589>}",[2250],[<CIViC source 2250>],[202]
203,KRAS Q61,40.0,,,['GLN61'],"[489, 3917]","{<CIViC source 229>, <CIViC source 76>}",[],[],[203]
204,NCOA3 AMPLIFICATION,15.0,,,[],[492],{<CIViC source 300>},[],[],[204]
205,NCOA3 OVEREXPRESSION,15.0,,,[],[493],{<CIViC source 300>},[],[],[205]
206,NOTCH1 Mutation,100.0,,,[],"[1538, 1486, 494, 1479, 2692, 2693, 11895, 11900, 11970]","{<CIViC source 997>, <CIViC source 1006>, <CIViC source 3409>, <CIViC source 301>, <CIViC source 1630>, <CIViC source 992>, <CIViC source 4949>}",[],[],[206]
207,NOTCH1 P2514FS,35.0,"This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.","This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.",['PRO2514ARGFS'],"[1014, 495]","{<CIViC source 702>, <CIViC source 302>}",[],[],[207]
208,NRAS Mutation,213.0,,,[],"[5344, 2937, 496, 27, 56, 71, 2931, 7452, 11674, 1225, 1227, 1472, 2210, 6263, 996, 1429, 1230, 1509, 1703, 1476]","{<CIViC source 2236>, <CIViC source 1682>, <CIViC source 989>, <CIViC source 688>, <CIViC source 1008>, <CIViC source 229>, <CIViC source 4836>, <CIViC source 1686>, <CIViC source 1941>, <CIViC source 849>, <CIViC source 70>, <CIViC source 83>, <CIViC source 848>, <CIViC source 76>, <CIViC source 850>, <CIViC source 87>, <CIViC source 968>, <CIViC source 2953>, <CIViC source 851>, <CIViC source 1138>}",[],[],[208]
209,PAX8::PPARG Fusion,15.0,PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.,PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.,"['T(2;3)(Q13;P25)', 'PAX8-PPARG']",[498],{<CIViC source 304>},[1110],[<CIViC source 1110>],[209]
210,PGR Expression,60.0,,,[],"[502, 503, 500, 501]","{<CIViC source 308>, <CIViC source 306>, <CIViC source 307>}",[],[],[210]
211,PGR LOW EXPRESSION,0.0,,,[],[],set(),[],[],[211]
212,PIK3CA Amplification,45.0,,,[],"[504, 7186, 756, 1403, 6275, 8267, 8268, 8269, 8270, 8271, 8272, 8273, 1464]","{<CIViC source 2812>, <CIViC source 950>, <CIViC source 984>, <CIViC source 309>, <CIViC source 500>, <CIViC source 1941>, <CIViC source 2486>}",[],[],[212]
213,PTEN Deletion,55.0,,,[],"[505, 643, 1741, 1231]","{<CIViC source 310>, <CIViC source 1190>, <CIViC source 852>}",[],[],[213]
214,PTEN Loss,272.0,,,[],"[644, 1297, 8675, 10876, 506, 893, 1385, 1386, 5840, 6315, 8706, 864, 1493, 2035, 2043, 5957, 645, 6361, 714, 12145, 938, 507, 716, 6271, 8275, 1455, 1502, 1611, 1614, 2045, 708, 711, 1383, 1492, 2074, 8274, 8276, 8277, 8278, 8279, 8280, 8283, 11064, 1500, 8012, 8021, 8022]","{<CIViC source 471>, <CIViC source 5104>, <CIViC source 407>, <CIViC source 641>, <CIViC source 406>, <CIViC source 999>, <CIViC source 2413>, <CIViC source 1005>, <CIViC source 311>, <CIViC source 176>, <CIViC source 312>, <CIViC source 1468>, <CIViC source 602>, <CIViC source 1004>, <CIViC source 938>, <CIViC source 465>, <CIViC source 469>, <CIViC source 1000>, <CIViC source 4440>, <CIViC source 1941>, <CIViC source 2364>, <CIViC source 983>, <CIViC source 1067>, <CIViC source 1435>, <CIViC source 467>, <CIViC source 2486>, <CIViC source 1447>, <CIViC source 939>, <CIViC source 1066>, <CIViC source 3651>, <CIViC source 891>, <CIViC source 579>}",[],[],[214]
215,SF3B1 Mutation,130.0,,,[],"[1540, 1487, 510, 1480, 352, 5931, 7135]","{<CIViC source 997>, <CIViC source 2769>, <CIViC source 1006>, <CIViC source 46>, <CIViC source 314>, <CIViC source 2404>, <CIViC source 992>}",[],[],[215]
216,SMAD4 Mutation,25.0,,,[],"[511, 6451, 719]","{<CIViC source 315>, <CIViC source 2558>, <CIViC source 473>}",[],[],[216]
217,SMARCA4 Mutation,25.0,,,[],"[512, 11985, 11828]","{<CIViC source 4965>, <CIViC source 316>, <CIViC source 4938>}",[],[],[217]
218,SMARCA4 INACTIVATING MUTATION,20.75,,,[],"[513, 8065, 5928]","{<CIViC source 316>, <CIViC source 2400>, <CIViC source 1656>}",[],[],[218]
219,TERT Amplification,15.0,,,[],[514],{<CIViC source 317>},[],[],[219]
220,TERT Promoter Mutation,105.0,"TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.","TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.","['-124C>T', '-146C>T']","[516, 7968, 515, 657, 658, 976, 6933, 6961, 7188]","{<CIViC source 2816>, <CIViC source 675>, <CIViC source 319>, <CIViC source 2670>, <CIViC source 318>, <CIViC source 2666>, <CIViC source 2684>, <CIViC source 414>}",[2206],[<CIViC source 2206>],[220]
221,TP53 Deleterious Mutation,78.0,Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.,Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.,[],"[1147, 517, 2966, 1148, 1170, 2967, 2968]","{<CIViC source 1695>, <CIViC source 793>, <CIViC source 1697>, <CIViC source 807>, <CIViC source 320>, <CIViC source 1696>}","[1696, 1695, 1697]","[<CIViC source 1695>, <CIViC source 1696>, <CIViC source 1697>]",[221]
222,TP53 Mutation,457.0,,,[],"[1507, 1452, 1485, 2999, 8346, 8347, 519, 520, 521, 522, 523, 524, 640, 1018, 1451, 6943, 7963, 7964, 8345, 12029, 518, 850, 1450, 1478, 6031, 6032, 7540, 7976, 7978, 11709, 12033, 1028, 1481, 6074, 8282, 12076, 8348, 2784, 2820, 851, 12010, 12011, 1145, 11825, 11894, 11913, 11893]","{<CIViC source 3294>, <CIViC source 322>, <CIViC source 569>, <CIViC source 3193>, <CIViC source 258>, <CIViC source 993>, <CIViC source 991>, <CIViC source 4856>, <CIViC source 2432>, <CIViC source 4949>, <CIViC source 3479>, <CIViC source 723>, <CIViC source 294>, <CIViC source 495>, <CIViC source 2675>, <CIViC source 997>, <CIViC source 325>, <CIViC source 199>, <CIViC source 3194>, <CIViC source 5008>, <CIViC source 324>, <CIViC source 494>, <CIViC source 321>, <CIViC source 1557>, <CIViC source 4986>, <CIViC source 4938>, <CIViC source 3000>, <CIViC source 792>, <CIViC source 403>, <CIViC source 1727>, <CIViC source 978>, <CIViC source 1006>, <CIViC source 2434>, <CIViC source 1555>, <CIViC source 3203>, <CIViC source 705>, <CIViC source 980>, <CIViC source 3478>, <CIViC source 5003>, <CIViC source 979>, <CIViC source 323>, <CIViC source 2232>}",[],[],[222]
223,TP53 Truncating Mutation,40.0,,,[],"[525, 526]",{<CIViC source 326>},[],[],[223]
224,TTF1 AMPLIFICATION,15.0,,,[],[527],{<CIViC source 327>},[],[],[224]
227,CHEK2 Loss-of-function,25.0,,,[],[531],{<CIViC source 331>},[],[],[230]
228,ERBB2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[232]
229,KRAS EXON 1 MUTATIONS,0.0,,,[],[],set(),[],[],[233]
230,AR F876L,0.0,,,[],[],set(),[],[],[234]
231,AR W741,0.0,,,[],[],set(),[],[],[235]
232,CDK12 Loss-of-function,4.0,,,[],[623],{<CIViC source 386>},[],[],[236]
233,AKT1 Gain-of-function,0.0,,,[],[],set(),[],[],[237]
234,NT5C2 R367Q,21.0,,,['ARG367GLN'],"[634, 7812, 630, 633, 7815, 7862]","{<CIViC source 399>, <CIViC source 3131>}",[],[],[238]
235,NT5C2 K359Q,28.0,,,['LYS359GLN'],"[667, 631, 636]",{<CIViC source 399>},[],[],[239]
236,NT5C2 D407A,8.0,,,['ASP407ALA'],"[632, 635]",{<CIViC source 399>},[],[],[240]
238,TP53 DNA Binding Domain Mutation,35.0,,,[],"[641, 2783]","{<CIViC source 1555>, <CIViC source 404>}",[],[],[242]
239,ATM S2289*,7.5,A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.,A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.,['V2288FS*1'],[647],{<CIViC source 409>},[],[],[243]
240,ATM N2875H,7.5,A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain,A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain,"['ASN2875HIS', 'RS1057519869']",[648],{<CIViC source 409>},[],[],[244]
241,NF2 Y177fs,7.5,,,['TYR177FS'],[649],{<CIViC source 410>},[],[],[245]
243,PDGFRA V561A,3.0,,,"['VAL561ALA', 'RS121908586']",[652],{<CIViC source 411>},[],[],[247]
244,TERT C228T,40.0,"Two TERT promotor mutations -124 (C228T, most common) and -146 (C250T) occur in up to 83% of primary glioblastomas,   71% of melanomas, 66% of urothelial carcinomas of the bladder, 47% of hapatocellular carcinomas, 21% of medulloblastomas and up to 40% of thyroid cancers. These promoter mutations reactivate TERT expression by recruitment of the GABP transcription factor.","Two TERT promotor mutations -124 (C228T, most common) and -146 (C250T) occur in up to 83% of primary glioblastomas,   71% of melanomas, 66% of urothelial carcinomas of the bladder, 47% of hapatocellular carcinomas, 21% of medulloblastomas and up to 40% of thyroid cancers. These promoter mutations reactivate TERT expression by recruitment of the GABP transcription factor.",['-124C>T'],"[655, 1646, 6934, 6935]","{<CIViC source 2667>, <CIViC source 1092>, <CIViC source 413>}","[2666, 2668, 2669]","[<CIViC source 2666>, <CIViC source 2668>, <CIViC source 2669>]",[248]
245,XRCC1 R194W,20.0,,,"['RS1799782', 'ARG194TRP']",[659],{<CIViC source 416>},[],[],[249]
246,GSTP1 Deletion,4.0,,,[],[660],{<CIViC source 417>},[],[],[250]
247,BIRC7 Amplification,4.0,,,[],"[661, 8314]","{<CIViC source 3450>, <CIViC source 418>}",[],[],[251]
248,EGFR Exon 4 Deletion,4.0,,,[],[662],{<CIViC source 419>},[],[],[252]
249,EGFR 3' UTR MUTATION,0.0,,,[],[663],{<CIViC source 420>},[],[],[253]
250,KRAS RS61764370,30.0,Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.,Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.,[],"[664, 872]","{<CIViC source 586>, <CIViC source 420>}",[],[],[254]
251,ERCC5 RS751402,15.0,,,[],[665],{<CIViC source 421>},[],[],[255]
252,KIT rs17084733,15.0,,,"[""3' UTR MUTATION""]",[666],{<CIViC source 422>},[],[],[256]
253,EZH2 Intron 6 Mutation,20.0,,,['RS3757441'],[668],{<CIViC source 423>},[],[],[257]
254,MTHFR A222V,55.0,,,"['RS1801133', 'C677T', 'ALA222VAL']","[1756, 1757, 669]","{<CIViC source 1218>, <CIViC source 1221>, <CIViC source 424>}","[424, 1218]","[<CIViC source 424>, <CIViC source 1218>]",[258]
255,GSTP1 I105V,20.0,,,['ILE105VAL'],[670],{<CIViC source 425>},[],[],[259]
256,ABCG2 Q141K,15.0,,,"['GLN141LYS', 'RS2231142']",[671],{<CIViC source 426>},[],[],[260]
257,XRCC1 Q399R,40.0,XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.,XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.,"['GLN399ARG', 'RS25487']","[672, 673]","{<CIViC source 427>, <CIViC source 907>}",[],[],[261]
258,ABCB1 S893T,15.0,,,"['A893S', 'SER893THR', 'RS2032582']",[674],{<CIViC source 428>},[],[],[262]
259,ABCB1 I1145I,25.0,"ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.","ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.","['T3435C', 'RS1045642', '3435C-T', 'ILE1145=']","[1076, 675]","{<CIViC source 429>, <CIViC source 744>}",[],[],[263]
260,ERCC2 K751Q,35.0,,,['LYS751GLN'],"[676, 677]","{<CIViC source 431>, <CIViC source 430>}",[],[],[264]
261,TYMS 5' TANDEM REPEAT,15.0,,,[],[678],{<CIViC source 432>},[],[],[265]
262,LRP1B EXON 12-22 DELETION,3.0,,,[],[679],{<CIViC source 433>},[],[],[266]
263,FGFR1 Amplification,185.5,"FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).","FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).",[],"[682, 685, 687, 683, 1908, 7488, 684, 1604, 1909, 3027, 7811, 1911, 1991, 7246, 680, 686, 1105, 1247, 1767, 7954]","{<CIViC source 1342>, <CIViC source 439>, <CIViC source 763>, <CIViC source 1397>, <CIViC source 3130>, <CIViC source 3184>, <CIViC source 441>, <CIViC source 438>, <CIViC source 1233>, <CIViC source 437>, <CIViC source 1064>, <CIViC source 2854>, <CIViC source 1337>, <CIViC source 434>, <CIViC source 440>, <CIViC source 446>, <CIViC source 436>, <CIViC source 2974>}","[434, 1220]","[<CIViC source 434>, <CIViC source 1220>]",[267]
264,FGFR1 Expression,46.0,"FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).","FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (Gke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).",[],"[793, 798, 970, 681, 799, 2915, 800, 801, 802, 896]","{<CIViC source 435>, <CIViC source 535>, <CIViC source 604>, <CIViC source 1678>, <CIViC source 534>, <CIViC source 536>, <CIViC source 532>, <CIViC source 533>, <CIViC source 527>, <CIViC source 670>}","[435, 533, 535, 1219]","[<CIViC source 1219>, <CIViC source 535>, <CIViC source 435>, <CIViC source 533>]",[268]
266,MET Amplification,81.5,,,[],"[7729, 7502, 7639, 8849, 11452, 11454, 1588, 689, 735, 1565, 1692, 1714, 11383, 836, 890, 1392, 1713, 733, 1566, 1971, 1979, 7873]","{<CIViC source 943>, <CIViC source 1141>, <CIViC source 481>, <CIViC source 1386>, <CIViC source 448>, <CIViC source 3163>, <CIViC source 600>, <CIViC source 1050>, <CIViC source 3690>, <CIViC source 2984>, <CIViC source 1158>, <CIViC source 3031>, <CIViC source 3082>, <CIViC source 564>, <CIViC source 4734>, <CIViC source 483>, <CIViC source 2124>, <CIViC source 1157>, <CIViC source 1035>, <CIViC source 1034>}",[],[],[270]
267,ATR I774FS,20.0,"Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.","Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.",[],[690],{<CIViC source 449>},[],[],[271]
268,CDKN2A p16 Expression,180.0,"CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.","CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.",[],"[758, 695, 697, 759, 694, 696, 753, 804, 1155, 1314, 4873]","{<CIViC source 453>, <CIViC source 501>, <CIViC source 454>, <CIViC source 904>, <CIViC source 456>, <CIViC source 502>, <CIViC source 795>, <CIViC source 455>, <CIViC source 2168>, <CIViC source 538>}",[537],[<CIViC source 537>],[272]
269,KIF5B::RET Fusion,10.0,"In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)","In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)",['KIF5B-RET'],"[7067, 6948, 698, 1622, 11265]","{<CIViC source 1074>, <CIViC source 378>, <CIViC source 2677>, <CIViC source 4628>, <CIViC source 2745>}",[1359],[<CIViC source 1359>],[273]
270,HRAS G13D,7.5,,,"['GLY13ASP', 'RS104894226']","[3851, 699, 3852]","{<CIViC source 1924>, <CIViC source 457>}",[],[],[274]
271,HRAS Mutation,23.0,,,[],"[9632, 9633, 700]","{<CIViC source 4125>, <CIViC source 458>, <CIViC source 4124>}",[],[],[275]
272,CD274 Expression,330.0,,,[],"[11484, 701, 704, 743, 1167, 1172, 3000, 5507, 5811, 702, 703, 1274, 1275, 1615, 1733, 4855, 4857, 9009, 975, 1517, 1578, 4844, 4856, 9886, 9008, 9010]","{<CIViC source 2154>, <CIViC source 2148>, <CIViC source 4756>, <CIViC source 3803>, <CIViC source 461>, <CIViC source 1176>, <CIViC source 2155>, <CIViC source 804>, <CIViC source 2256>, <CIViC source 3802>, <CIViC source 880>, <CIViC source 674>, <CIViC source 460>, <CIViC source 2156>, <CIViC source 3804>, <CIViC source 1068>, <CIViC source 881>, <CIViC source 1042>, <CIViC source 462>, <CIViC source 1728>, <CIViC source 459>, <CIViC source 1010>, <CIViC source 4207>, <CIViC source 2351>, <CIViC source 809>}",[],[],[276]
273,MTOR Mutation,22.5,,,[],"[712, 705]","{<CIViC source 468>, <CIViC source 463>}",[],[],[277]
274,AKT2 EXPRESSION,15.0,,,[],[706],{<CIViC source 464>},[],[],[278]
275,NF2 K159fs,7.5,,,['LYS159FS*16'],[715],{<CIViC source 470>},[],[],[279]
276,EGFR S249R,0.0,,,[],[],set(),[],[],[280]
277,FBXW7 Mutation,20.0,,,[],"[718, 1631]","{<CIViC source 473>, <CIViC source 1079>}",[],[],[281]
278,SMAD4 Underexpression,3.0,,,[],"[6437, 6440, 6445, 6462, 720]","{<CIViC source 474>, <CIViC source 2547>, <CIViC source 2545>, <CIViC source 2552>, <CIViC source 2569>}",[],[],[282]
279,MTOR H1968Y,3.0,,,['HIS1968TYR'],"[713, 721]",{<CIViC source 468>},[],[],[283]
280,MTOR P2213S,3.0,,,['PRO2213SER'],[722],{<CIViC source 468>},[],[],[284]
281,AGK::BRAF Fusion,7.0,,,['AGK-BRAF'],"[723, 724]",{<CIViC source 475>},[],[],[285]
282,PAPSS1::BRAF Fusion,6.0,,,"['T(4;7)(Q24;Q34)', 'PAPSS1-BRAF']","[725, 726]",{<CIViC source 476>},[476],[<CIViC source 476>],[286]
283,TRIM24::BRAF Fusion,6.0,,,['TRIM24-BRAF'],"[727, 1416]",{<CIViC source 476>},[],[],[287]
284,BRAF L597R,12.0,,,"['LEU597ARG', 'RS121913366']","[728, 1458]","{<CIViC source 338>, <CIViC source 477>}",[],[],[288]
285,ERBB3 Overexpression,37.0,,,[],"[729, 7427, 3053, 8707, 1153, 3050, 1152, 7804]","{<CIViC source 2930>, <CIViC source 478>, <CIViC source 1742>, <CIViC source 3127>, <CIViC source 686>, <CIViC source 1755>, <CIViC source 1468>}",[],[],[289]
286,NT5E Overexpression,15.0,,,[],[730],{<CIViC source 478>},[],[],[290]
287,EZH2 Overexpression,20.0,,,[],"[731, 8006, 9115]","{<CIViC source 3853>, <CIViC source 479>, <CIViC source 3244>}",[],[],[291]
288,MYD88 Overexpression,2.0,,,[],[734],{<CIViC source 482>},[],[],[292]
290,PIK3CA P471L,7.5,,,"['PRO471LEU', 'RS1057519872']",[739],{<CIViC source 487>},[],[],[294]
291,RET EXPRESSION,0.0,,,[],[],set(),[],[],[295]
292,RIT1 OVEREXPRESSION,15.0,,,[],[741],{<CIViC source 489>},[],[],[296]
293,RIT1 Mutation,3.0,,,[],[742],{<CIViC source 490>},[],[],[297]
294,MYCN Amplification,46.0,,,[],"[1328, 6017, 744, 5325, 5327, 6018, 6019, 6020]","{<CIViC source 2430>, <CIViC source 918>, <CIViC source 2228>, <CIViC source 2427>, <CIViC source 494>, <CIViC source 2428>, <CIViC source 491>, <CIViC source 2429>}",[],[],[298]
295,SMO D473H,13.5,,,['ASP473HIS'],"[745, 4427, 755, 1099]","{<CIViC source 2100>, <CIViC source 492>, <CIViC source 493>, <CIViC source 758>}",[],[],[299]
296,SMO Mutation,44.0,,,[],"[746, 1477, 5979, 747]","{<CIViC source 493>, <CIViC source 990>, <CIViC source 2414>}",[],[],[300]
297,PTCH1 Mutation,25.0,,,[],"[748, 5978]","{<CIViC source 494>, <CIViC source 2414>}",[],[],[301]
298,PTCH1 LOH,10.0,,,[],[749],{<CIViC source 495>},[],[],[302]
299,STK11 EXON 1-2 MUTATION,20.0,,,[],[750],{<CIViC source 496>},[],[],[303]
300,STK11 Underexpression,2.0,,,[],[751],{<CIViC source 497>},[],[],[304]
301,SYK OVEREXPRESSION,3.0,,,[],[752],{<CIViC source 498>},[],[],[305]
302,ERBB2 Amplification,891.0,"Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy. These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors. Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC. Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC. The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases. In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely. Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy. Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.","Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy. These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors. Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC. Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC. The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases. In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely. Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy. Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.",['OVEREXPRESSION'],"[11249, 11250, 11256, 1113, 1122, 1499, 8047, 8048, 8049, 11247, 11248, 11251, 11252, 11253, 11254, 528, 529, 1077, 1007, 1008, 1009, 1012, 1022, 1096, 1132, 1133, 1159, 1160, 1437, 1439, 1686, 1687, 1689, 1764, 5981, 7648, 11321, 11322, 11485, 761, 961, 1010, 1011, 1013, 1023, 1042, 1432, 1891, 1993, 5982, 7302, 7585, 7647, 7856, 8050, 11668, 12025, 887, 1041, 1098, 1688, 5983, 5984, 5985, 5986, 7810, 895, 9778, 1044, 1097, 7638, 1693, 1393, 1050, 1448, 760, 1006, 1380, 1382, 2071, 6929, 7807, 7808, 8072, 11563, 886, 962, 1381, 1561, 1613, 8073, 8023]","{<CIViC source 943>, <CIViC source 695>, <CIViC source 597>, <CIViC source 757>, <CIViC source 1229>, <CIViC source 4163>, <CIViC source 3265>, <CIViC source 4746>, <CIViC source 328>, <CIViC source 3264>, <CIViC source 4831>, <CIViC source 4625>, <CIViC source 4623>, <CIViC source 3274>, <CIViC source 970>, <CIViC source 663>, <CIViC source 708>, <CIViC source 4626>, <CIViC source 3984>, <CIViC source 4757>, <CIViC source 972>, <CIViC source 2881>, <CIViC source 3273>, <CIViC source 725>, <CIViC source 696>, <CIViC source 4624>, <CIViC source 1140>, <CIViC source 768>, <CIViC source 3266>, <CIViC source 1142>, <CIViC source 756>, <CIViC source 727>, <CIViC source 799>, <CIViC source 1139>, <CIViC source 664>, <CIViC source 724>, <CIViC source 596>, <CIViC source 699>, <CIViC source 755>, <CIViC source 701>, <CIViC source 503>, <CIViC source 603>, <CIViC source 2661>, <CIViC source 1435>, <CIViC source 697>, <CIViC source 1399>, <CIViC source 1031>, <CIViC source 3267>, <CIViC source 3128>, <CIViC source 698>, <CIViC source 2414>, <CIViC source 4998>, <CIViC source 783>, <CIViC source 1138>, <CIViC source 784>, <CIViC source 3036>, <CIViC source 700>, <CIViC source 4627>, <CIViC source 504>, <CIViC source 3035>, <CIViC source 729>, <CIViC source 977>, <CIViC source 329>, <CIViC source 777>, <CIViC source 709>, <CIViC source 3013>, <CIViC source 971>, <CIViC source 3030>, <CIViC source 937>, <CIViC source 798>, <CIViC source 730>, <CIViC source 2915>, <CIViC source 1208>, <CIViC source 1066>, <CIViC source 745>}",[],[],[306]
303,ALK L1152R,0.0,,,"['RS1057519785', 'LEU1152ARG']",[],set(),[],[],[307]
304,ALK G1269A,0.0,,,['RS1057519781'],[],set(),[],[],[308]
305,EGFR AUTOCRINE ACTIVATION,0.0,,,[],"[769, 768]","{<CIViC source 506>, <CIViC source 508>}",[],[],[309]
306,ERBB4 Mutation,4.0,"ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.","ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.",[],[770],{<CIViC source 509>},[513],[<CIViC source 513>],[310]
307,PIK3CA Mutation,446.5,"PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer, colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.","PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer, colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.",[],"[7313, 7317, 915, 1296, 3040, 892, 2025, 2087, 2098, 2105, 2355, 6188, 6189, 6297, 6298, 6299, 6300, 6301, 6362, 6375, 7072, 7185, 7187, 7400, 8536, 8705, 11678, 1384, 3732, 2076, 11679, 1402, 1600, 771, 1360, 1490, 1501, 1503, 1607, 1610, 1616, 1358, 1364, 1504, 1705]","{<CIViC source 178>, <CIViC source 1745>, <CIViC source 1463>, <CIViC source 4839>, <CIViC source 950>, <CIViC source 1446>, <CIViC source 1479>, <CIViC source 1005>, <CIViC source 2888>, <CIViC source 176>, <CIViC source 1468>, <CIViC source 927>, <CIViC source 602>, <CIViC source 622>, <CIViC source 1004>, <CIViC source 938>, <CIViC source 4840>, <CIViC source 2751>, <CIViC source 1474>, <CIViC source 2812>, <CIViC source 1067>, <CIViC source 76>, <CIViC source 984>, <CIViC source 2920>, <CIViC source 1444>, <CIViC source 1138>, <CIViC source 1470>, <CIViC source 1447>, <CIViC source 510>, <CIViC source 1066>, <CIViC source 926>, <CIViC source 891>}",[2238],[<CIViC source 2238>],[311]
308,EGFR VIII,69.0,"The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)","The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)",[],"[772, 971, 1128, 848, 8191, 4500, 8192, 1017]","{<CIViC source 568>, <CIViC source 704>, <CIViC source 3377>, <CIViC source 671>, <CIViC source 1608>, <CIViC source 514>}",[513],[<CIViC source 513>],[312]
309,PTEN Expression,54.5,,,[],"[774, 955, 1129, 1624, 775]","{<CIViC source 516>, <CIViC source 657>, <CIViC source 1075>, <CIViC source 514>}",[],[],[313]
310,NRG1 Expression,37.0,,,[],"[813, 7653, 7654, 776, 777, 778, 779, 861, 1967]","{<CIViC source 545>, <CIViC source 518>, <CIViC source 1382>, <CIViC source 520>, <CIViC source 3041>, <CIViC source 577>, <CIViC source 517>, <CIViC source 519>}",[],[],[314]
311,AREG Expression,58.0,,,[],"[1020, 788, 847, 781, 846, 780]","{<CIViC source 568>, <CIViC source 707>, <CIViC source 506>, <CIViC source 524>, <CIViC source 508>}",[],[],[315]
312,TGFA EXPRESSION,15.0,,,[],[785],{<CIViC source 521>},[],[],[316]
313,EGFR G724S,4.0,,,"['GLY724SER', 'RS1051753269']","[786, 9644, 9652, 10039]","{<CIViC source 1388>, <CIViC source 523>, <CIViC source 4099>}",[],[],[317]
314,EREG EXPRESSION,35.5,,,[],"[1021, 789, 1055]","{<CIViC source 707>, <CIViC source 524>, <CIViC source 733>}",[],[],[318]
315,EFNA2 EXPRESSION,0.0,,,[],[790],{<CIViC source 524>},[],[],[319]
316,MAPK1 E322K,10.0,,,['GLU322LYS'],"[791, 4797]","{<CIViC source 2132>, <CIViC source 525>}",[],[],[320]
317,MAPK1 Amplification,4.0,,,[],[792],{<CIViC source 526>},[],[],[321]
318,KRAS A146V,8.0,,,"['ALA146VAL', 'RS1057519725']","[794, 2209, 12069]","{<CIViC source 1406>, <CIViC source 528>, <CIViC source 5036>}",[],[],[322]
319,MET Mutation,15.0,,,[],[796],{<CIViC source 530>},[],[],[323]
320,MET Exon 14 Skipping Mutation,108.5,"Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).","Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).",[],"[8847, 8848, 11766, 11377, 11416, 7272, 7640, 11378, 11379, 11380, 7642, 11465, 797, 1185, 1186, 7795, 7796, 11384, 11395, 11398, 11410, 11415, 11417, 11459, 11474, 11476, 11487, 1651, 7643, 11391, 11399, 11400, 11401, 11409, 11411, 11464, 11477, 4786, 736, 7797]","{<CIViC source 1115>, <CIViC source 4689>, <CIViC source 4698>, <CIViC source 4683>, <CIViC source 2446>, <CIViC source 818>, <CIViC source 4704>, <CIViC source 4739>, <CIViC source 3690>, <CIViC source 4751>, <CIViC source 2865>, <CIViC source 4705>, <CIViC source 754>, <CIViC source 4759>, <CIViC source 4743>, <CIViC source 2127>, <CIViC source 3031>, <CIViC source 4706>, <CIViC source 3033>, <CIViC source 4699>, <CIViC source 4687>, <CIViC source 4748>, <CIViC source 4744>, <CIViC source 4518>, <CIViC source 484>, <CIViC source 531>, <CIViC source 4895>, <CIViC source 2124>, <CIViC source 4697>, <CIViC source 4750>, <CIViC source 3691>}","[531, 754]","[<CIViC source 531>, <CIViC source 754>]",[324]
321,FGFR3 Overexpression,6.0,,,[],"[10363, 10364, 803, 10352, 12294]","{<CIViC source 535>, <CIViC source 3456>, <CIViC source 5176>}",[],[],[325]
322,CBLC EXPRESSION,2.0,,,[],[805],{<CIViC source 539>},[],[],[326]
323,PTPRD Mutation,3.0,,,[],[807],{<CIViC source 541>},[],[],[327]
324,DEFA1 EXPRESSION,10.0,,,[],[808],{<CIViC source 542>},[],[],[328]
325,ERCC1 Expression,30.0,,,[],"[809, 9234, 6438, 810]","{<CIViC source 2546>, <CIViC source 543>, <CIViC source 3955>}",[],[],[329]
326,NOTCH1 Amplification,12.0,,,[],"[812, 811]",{<CIViC source 544>},[],[],[330]
327,WEE1 RS3910384,15.0,,,['INTRON POLYMORPHISM'],[814],{<CIViC source 546>},[],[],[331]
328,FNTB RS11623866,10.0,,,[],[815],{<CIViC source 547>},[],[],[332]
329,PTPRT Promoter Hypermethylation,2.0,,,[],[817],{<CIViC source 549>},[],[],[333]
330,VEGFA Decreased Peri-therapeutic Expression,10.0,,,[],[818],{<CIViC source 550>},[],[],[334]
331,DNMT1 EXPRESSION,18.0,,,[],"[946, 819]","{<CIViC source 648>, <CIViC source 551>}",[],[],[335]
332,KRAS Mutation,545.5,,,[],"[2998, 5345, 999, 1139, 1700, 3704, 4867, 4868, 4996, 4997, 8301, 997, 1218, 1596, 2385, 3715, 3895, 4842, 4862, 4863, 4866, 6464, 8773, 894, 998, 1220, 1642, 2242, 3713, 6264, 7150, 8932, 1001, 935, 988, 991, 1003, 4869, 820, 947, 1004, 1140, 1183, 1702, 4865, 7166, 943, 989, 992, 1182, 11960, 4864]","{<CIViC source 2236>, <CIViC source 2146>, <CIViC source 2163>, <CIViC source 910>, <CIViC source 1726>, <CIViC source 685>, <CIViC source 640>, <CIViC source 1058>, <CIViC source 688>, <CIViC source 649>, <CIViC source 1501>, <CIViC source 2164>, <CIViC source 2165>, <CIViC source 789>, <CIViC source 602>, <CIViC source 1938>, <CIViC source 1088>, <CIViC source 3442>, <CIViC source 692>, <CIViC source 551>, <CIViC source 693>, <CIViC source 3672>, <CIViC source 1547>, <CIViC source 2022>, <CIViC source 816>, <CIViC source 1941>, <CIViC source 2159>, <CIViC source 2160>, <CIViC source 2008>, <CIViC source 2162>, <CIViC source 689>, <CIViC source 257>, <CIViC source 1148>, <CIViC source 864>, <CIViC source 76>, <CIViC source 3764>, <CIViC source 790>, <CIViC source 2189>, <CIViC source 1138>, <CIViC source 815>, <CIViC source 1470>, <CIViC source 843>, <CIViC source 1410>, <CIViC source 645>, <CIViC source 2161>, <CIViC source 686>, <CIViC source 690>}",[],[],[336]
333,PDCD4 EXPRESSION,20.0,"A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.","A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.",[],[821],{<CIViC source 552>},[],[],[337]
334,MGMT RS16906252,15.0,,,[],[822],{<CIViC source 553>},[],[],[338]
335,TFF3 EXPRESSION,15.0,,,[],[823],{<CIViC source 554>},[],[],[339]
336,DKK1 NUCLEAR EXPRESSION,15.0,,,[],[824],{<CIViC source 555>},[],[],[340]
337,CD44 CD44s Expression,3.0,,,[],[825],{<CIViC source 556>},[],[],[341]
338,EGF EXPRESSION,3.0,,,[],[826],{<CIViC source 557>},[],[],[342]
339,MDM2 EXPRESSION,20.0,,,[],"[828, 827, 9852]","{<CIViC source 4193>, <CIViC source 558>}",[],[],[343]
340,HMOX1 EXPRESSION,15.0,,,[],[829],{<CIViC source 559>},[],[],[344]
341,SPHK1 OVEREXPRESSION,10.0,,,[],[830],{<CIViC source 560>},[],[],[345]
342,CASP8 Overexpression,3.0,,,[],[831],{<CIViC source 561>},[],[],[346]
343,TYMS Overexpression,40.0,,,[],"[832, 922, 929]","{<CIViC source 562>, <CIViC source 628>, <CIViC source 635>}",[],[],[347]
344,PBK OVEREXPRESSION,3.0,,,[],[835],{<CIViC source 563>},[],[],[348]
345,SMARCA4 Underexpression,30.0,,,[],"[837, 838, 6373]","{<CIViC source 2517>, <CIViC source 565>}",[],[],[349]
346,SETBP1 Exon 4 Mutation,15.0,,,[],[839],{<CIViC source 566>},[],[],[350]
347,SETBP1 G870S,3.0,,,"['GLY870SER', 'RS267607040']",[840],{<CIViC source 566>},[],[],[351]
349,BRCA1 LOSS,0.0,,,[],[],set(),[],[],[353]
350,EGFR Expression,60.0,,,[],"[1572, 4877, 1708, 1984, 8299, 1709, 4213, 7445]","{<CIViC source 1038>, <CIViC source 1938>, <CIViC source 1394>, <CIViC source 2946>, <CIViC source 2170>, <CIViC source 1151>, <CIViC source 3435>, <CIViC source 1152>}",[],[],[354]
351,CDKN1A EXPRESSION,15.0,,,[],[852],{<CIViC source 570>},[],[],[355]
352,ALCAM EXPRESSION,15.0,,,[],[853],{<CIViC source 570>},[],[],[356]
353,STMN1 EXPRESSION,15.0,,,[],[855],{<CIViC source 572>},[],[],[357]
354,RSF1 Amplification,10.0,,,[],[857],{<CIViC source 574>},[],[],[358]
355,AR OVEREXPRESSION,3.0,,,[],"[6953, 859]","{<CIViC source 2678>, <CIViC source 575>}",[],[],[359]
356,CDKN1B CYTOPLASMIC MISLOCALIZATION,3.0,,,[],[860],{<CIViC source 576>},[],[],[360]
357,ERBB3 EXPRESSION,6.0,,,[],"[862, 865, 3051]","{<CIViC source 580>, <CIViC source 577>, <CIViC source 1754>}",[],[],[361]
358,AR V7 EXPRESSION,15.0,,,[],"[9547, 9552, 9553, 9554, 9555, 9576, 863, 9548, 9549, 6954]","{<CIViC source 4084>, <CIViC source 4082>, <CIViC source 2679>, <CIViC source 4085>, <CIViC source 4093>, <CIViC source 578>, <CIViC source 4088>, <CIViC source 4083>, <CIViC source 4087>, <CIViC source 4086>}",[],[],[362]
359,UGT1A EXPRESSION,3.0,,,[],[866],{<CIViC source 581>},[],[],[363]
360,ERBB4 NUCLEAR TRANSLOCATION,2.0,,,[],[867],{<CIViC source 582>},[],[],[364]
361,ERBB4 EXPRESSION,5.0,,,[],"[1961, 869, 868]","{<CIViC source 583>, <CIViC source 582>}",[],[],[365]
362,SLFN11 EXPRESSION,2.0,,,[],"[5883, 5884, 870]","{<CIViC source 584>, <CIViC source 2378>, <CIViC source 2377>}",[],[],[366]
363,RAC1 P29S,4.0,,,['PRO29SER'],"[7669, 873, 8056]","{<CIViC source 587>, <CIViC source 3268>, <CIViC source 3044>}",[],[],[367]
364,BIRC5 NUCLEAR EXPRESSION,15.0,,,[],[874],{<CIViC source 588>},[],[],[368]
365,TP53 Wildtype,68.0,,,[],"[875, 906, 1149, 2965, 2963, 2964]","{<CIViC source 1695>, <CIViC source 793>, <CIViC source 1697>, <CIViC source 589>, <CIViC source 613>, <CIViC source 1696>}",[],[],[369]
366,MRE11 Loss,2.0,,,[],"[877, 876]","{<CIViC source 409>, <CIViC source 590>}",[],[],[370]
367,TOP1 Amplification,5.0,,,[],"[12143, 888]","{<CIViC source 4857>, <CIViC source 598>}",[],[],[371]
368,CDKN1B EXPRESSION,10.0,,,[],[889],{<CIViC source 599>},[],[],[372]
369,AGR2 EXPRESSION,5.0,,,[],[891],{<CIViC source 601>},[],[],[373]
370,NAPRT Promoter Hypermethylation,3.0,,,[],[897],{<CIViC source 605>},[],[],[374]
371,EGFR Exon 18 Overexpression,10.0,,,[],[898],{<CIViC source 606>},[],[],[375]
372,ZEB1 Expression,5.0,,,[],"[8086, 900, 899]","{<CIViC source 607>, <CIViC source 3308>}",[],[],[376]
373,TIMP1 Overexpression,12.0,,,[],"[927, 901]","{<CIViC source 633>, <CIViC source 608>}",[],[],[377]
374,PTP4A3 OVEREXPRESSION,3.0,,,[],[902],{<CIViC source 609>},[],[],[378]
375,TYMS Amplification,15.0,,,[],"[903, 12097, 12098]","{<CIViC source 5071>, <CIViC source 5070>, <CIViC source 610>}",[],[],[379]
376,IGF1R EXPRESSION,2.0,,,[],[904],{<CIViC source 611>},[],[],[380]
377,EPHB4 EXPRESSION,10.0,,,[],[905],{<CIViC source 612>},[],[],[381]
378,TYMS Underexpression,20.0,,,[],"[907, 908]","{<CIViC source 615>, <CIViC source 614>}",[],[],[382]
379,TOP2A EXPRESSION,10.0,,,[],[909],{<CIViC source 616>},[],[],[383]
380,TOP1 EXPRESSION,25.0,,,[],"[912, 910]","{<CIViC source 617>, <CIViC source 619>}",[],[],[384]
381,PRKAA2 T172 PHOSPHORYLATION,0.5,,,[],[913],{<CIViC source 620>},[],[],[385]
382,HSPA5 EXPRESSION,20.0,,,[],[914],{<CIViC source 621>},[],[],[386]
383,EIF4EBP1 PHOSPHORYLATION,4.0,,,[],"[918, 932]","{<CIViC source 638>, <CIViC source 624>}",[],[],[387]
384,KIT Mutation,17.0,,,[],"[11282, 11283, 11284, 11285, 1222, 8576, 7145, 5573, 919]","{<CIViC source 4637>, <CIViC source 3603>, <CIViC source 4638>, <CIViC source 2383>, <CIViC source 2281>, <CIViC source 625>, <CIViC source 2044>, <CIViC source 845>, <CIViC source 4639>}",[],[],[388]
385,TUBB3 EXPRESSION,12.0,,,[],"[921, 920]","{<CIViC source 627>, <CIViC source 626>}",[],[],[389]
386,EGFR Y1092 PHOSPHORYLATION,15.0,"Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).","Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).",['Y1039 PHOSPHORYLATION'],[923],{<CIViC source 629>},[],[],[390]
387,IGF1R NUCLEAR EXPRESSION,10.0,,,[],[924],{<CIViC source 630>},[],[],[391]
388,CFLAR EXPRESSION,3.0,,,[],[925],{<CIViC source 631>},[],[],[392]
389,PROM1 EXPRESSION,10.0,,,[],[926],{<CIViC source 632>},[],[],[393]
390,FOXP3 EXPRESSION,20.0,,,[],[928],{<CIViC source 634>},[],[],[394]
391,RPS6 PHOSPHORYLATION,2.0,,,[],[930],{<CIViC source 636>},[],[],[395]
392,JAK1 OVEREXPRESSION,11.5,,,[],"[7852, 931]","{<CIViC source 637>, <CIViC source 3141>}",[],[],[396]
393,BRCA1 Expression,2.0,,,[],[933],{<CIViC source 639>},[],[],[397]
394,DUSP6 EXPRESSION,3.0,,,[],[934],{<CIViC source 640>},[],[],[398]
395,BRAF Mutation,166.0,,,[],"[7158, 7159, 1404, 2187, 6302, 6303, 6304, 6305, 6306, 6307, 936, 1704, 11937]","{<CIViC source 257>, <CIViC source 2784>, <CIViC source 76>, <CIViC source 1479>, <CIViC source 640>, <CIViC source 951>, <CIViC source 2785>, <CIViC source 1138>}",[],[],[399]
396,HSPB1 EXPRESSION,2.0,,,[],[939],{<CIViC source 642>},[],[],[400]
397,NQO1 EXPRESSION,2.0,,,[],[940],{<CIViC source 643>},[],[],[401]
398,NQO1 P187S,2.0,,,['PRO187SER'],[941],{<CIViC source 643>},[],[],[402]
399,BRCA1 Underexpression,15.0,,,[],[942],{<CIViC source 644>},[],[],[403]
400,ABCB1 EXPRESSION,0.0,,,[],[],set(),[],[],[404]
401,CXCR4 EXPRESSION,10.0,,,[],"[949, 2912]","{<CIViC source 1674>, <CIViC source 651>}",[],[],[405]
402,MAGEH1 EXPRESSION,2.0,,,[],[950],{<CIViC source 652>},[],[],[406]
403,ABCC3 Amplification,3.0,,,[],[951],{<CIViC source 653>},[],[],[407]
404,ABCC10 Overexpression,3.0,,,[],[952],{<CIViC source 654>},[],[],[408]
405,ASNS Amplification,2.0,,,[],[953],{<CIViC source 655>},[],[],[409]
406,CDX2 EXPRESSION,20.0,,,[],"[956, 1130]","{<CIViC source 781>, <CIViC source 658>}",[],[],[410]
407,STAT3 SH2 DOMAIN MUTATION,20.0,,,[],[957],{<CIViC source 659>},[],[],[411]
408,POU5F1 EXPRESSION,2.0,,,[],[958],{<CIViC source 660>},[],[],[412]
409,ERBB2 Kinase Domain Mutation,17.5,,,[],"[1043, 959]","{<CIViC source 726>, <CIViC source 661>}",[],[],[413]
410,ERBB2 Y772_A775DUP,42.0,"Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.","Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.","['A775INSYVMA', 'P.A775_G776INSYVMA', 'P.E770_A771INSAYVM', 'TYR772_ALA775DUP', 'A775_G776INSYVMA', 'M774INSAYVM']","[11764, 1893, 1045, 1049, 1125, 1888, 4428, 1046, 1047, 960]","{<CIViC source 779>, <CIViC source 661>, <CIViC source 4879>, <CIViC source 729>, <CIViC source 2101>, <CIViC source 728>, <CIViC source 662>}",[662],[<CIViC source 662>],[414]
411,EGFR C797S,17.5,,,"['CYS797SER', 'RS1057519861']","[964, 1396, 4837, 8028, 8057, 8070, 8076, 8080]","{<CIViC source 946>, <CIViC source 2142>, <CIViC source 666>, <CIViC source 3253>}",[],[],[415]
412,ERBB2 SERUM LEVELS,35.0,,,[],"[972, 973]",{<CIViC source 672>},[],[],[416]
413,THBS2 UNDEREXPRESSION,15.0,,,[],[974],{<CIViC source 673>},[],[],[417]
414,TERT MUTATION,0.0,,,[],[],set(),[],[],[418]
415,v::NTRK1 Fusion,135.0,,,['NTRK1 Fusion'],"[11124, 6567, 2948, 6569, 7293, 2947, 7649, 2953, 2956, 6051, 6052, 1019]","{<CIViC source 1691>, <CIViC source 2445>, <CIViC source 2878>, <CIViC source 1690>, <CIViC source 1288>, <CIViC source 706>, <CIViC source 3037>, <CIViC source 1689>, <CIViC source 4345>, <CIViC source 2467>}",[],[],[419]
416,IDH1 R132H,9.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.","IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.","['ARG132HIS', 'RS121913500']","[8629, 2323, 6125, 2019, 5987, 2324, 2325, 979]","{<CIViC source 1360>, <CIViC source 1425>, <CIViC source 1432>, <CIViC source 1569>, <CIViC source 2469>, <CIViC source 678>, <CIViC source 3625>}",[],[],[420]
417,TERT RS2736100,10.0,,,[],[980],{<CIViC source 675>},[],[],[421]
418,STAG2 Underexpression,14.0,,,[],"[984, 7207, 1659]","{<CIViC source 681>, <CIViC source 2825>, <CIViC source 1123>}",[],[],[422]
419,HLA-DRA EXPRESSION,15.0,,,[],[985],{<CIViC source 682>},[],[],[423]
420,MYD88 L265P,31.0,,,"['LEU265PRO', 'L273P', 'LEU273PRO', 'RS387907272']","[986, 9376, 1489, 1641]","{<CIViC source 997>, <CIViC source 1086>, <CIViC source 683>, <CIViC source 4021>}",[],[],[424]
421,KRAS G12V,67.5,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,"['GLY12VAL', 'RS121913529']","[3916, 3919, 987, 2219, 1143, 2232, 2233, 2234, 2235, 3911, 3912, 3913, 3914, 3915, 3918, 3920, 3921, 3922, 3923, 3927, 3928, 3931, 3824, 8891, 1715, 2268, 6313, 6323, 3925, 3926, 3932, 136, 2001, 3924, 795]","{<CIViC source 1935>, <CIViC source 1940>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 507>, <CIViC source 529>, <CIViC source 176>, <CIViC source 1936>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 1414>, <CIViC source 2022>, <CIViC source 1415>, <CIViC source 684>, <CIViC source 1158>, <CIViC source 123>, <CIViC source 1413>, <CIViC source 1925>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 1973>, <CIViC source 174>, <CIViC source 1406>, <CIViC source 1926>, <CIViC source 1931>, <CIViC source 122>, <CIViC source 2021>, <CIViC source 791>, <CIViC source 1934>, <CIViC source 1416>, <CIViC source 1937>, <CIViC source 1412>, <CIViC source 2019>}",[2254],[<CIViC source 2254>],[425]
422,BRAF Wildtype,10.0,,,[],"[11657, 11663, 11664, 995]","{<CIViC source 688>, <CIViC source 4826>}",[],[],[426]
423,NRAS Q61K,24.5,,,"['GLN61LYS', 'RS121913254']","[2194, 3833, 7678, 2190, 2195, 3835, 2191, 2189, 8933, 2196, 3834, 3836, 3837, 3838, 3839, 7169, 7172, 1002, 2192, 2908, 1474, 1475, 2907]","{<CIViC source 1670>, <CIViC source 691>, <CIViC source 76>, <CIViC source 1491>, <CIViC source 2003>, <CIViC source 2797>, <CIViC source 3765>, <CIViC source 2005>, <CIViC source 1407>, <CIViC source 3045>, <CIViC source 988>, <CIViC source 1941>, <CIViC source 2794>, <CIViC source 2006>, <CIViC source 1406>}",[],[],[427]
424,MRE11 Frameshift,10.0,,,[],[1016],{<CIViC source 409>},[],[],[428]
425,KIT EXPRESSION,35.0,,,[],"[2488, 10180, 2480, 1024, 1025, 7758]","{<CIViC source 82>, <CIViC source 711>, <CIViC source 4259>, <CIViC source 710>, <CIViC source 2056>, <CIViC source 1586>}",[],[],[429]
427,CBFB::MYH11 Fusion,35.0,"CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.","CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.","['INV(16)(P13.1;Q22)', 'T(16;16)(P13.1;Q22)', 'CBFB-MYH11']","[11788, 11791, 11792, 1026, 1027, 11793]","{<CIViC source 4920>, <CIViC source 4922>, <CIViC source 4921>, <CIViC source 4914>, <CIViC source 712>}",[712],[<CIViC source 712>],[431]
428,KMT2A::MLLT3 Fusion,40.0,,,"['T(9;11)(P22;Q23)', 'MLL-MLLT3', 'KMT2A-MLLT3', 'MLL::MLLT3', 'T(9;11)(P21.3;Q23.3)']","[1029, 8500]","{<CIViC source 966>, <CIViC source 19>}",[19],[<CIViC source 19>],[432]
429,HIF1A 3' UTR Polymorphism,10.0,,,[],[1031],{<CIViC source 716>},[],[],[433]
430,HIF1A OVEREXPRESSION,25.0,,,[],"[1032, 1034]","{<CIViC source 718>, <CIViC source 717>}",[],[],[434]
431,EPAS1 Overexpression,25.0,,,[],"[1033, 1673]","{<CIViC source 1132>, <CIViC source 717>}",[],[],[435]
432,VHL Loss,3.0,,,[],"[4829, 1035]","{<CIViC source 719>, <CIViC source 1132>}",[],[],[436]
433,FLT3 D835,46.0,,,['ASP835'],"[8330, 1038, 1039, 8333, 4024, 4025, 1036, 1037, 4026]","{<CIViC source 2033>, <CIViC source 2031>, <CIViC source 722>, <CIViC source 172>, <CIViC source 721>, <CIViC source 2030>, <CIViC source 3462>, <CIViC source 720>, <CIViC source 2871>}",[],[],[437]
434,PSMB8 NUCLEAR EXPRESSION,10.0,,,[],[1051],{<CIViC source 731>},[],[],[438]
435,PBK NUCLEAR EXPRESSION,10.0,,,[],[1052],{<CIViC source 731>},[],[],[439]
436,PTTG1 OVEREXPRESSION,10.0,,,[],[1053],{<CIViC source 732>},[],[],[440]
437,LEPR UNDEREXPRESSION,10.0,,,[],[1054],{<CIViC source 732>},[],[],[441]
438,EGFR Mutation,260.0,,,[],"[1937, 2148, 1701, 1728, 2053, 2153, 5923, 7024, 2559, 3016, 3792, 3794, 7650, 12074, 2939, 3864, 10359, 4201, 6187, 1056, 6465]","{<CIViC source 1358>, <CIViC source 1510>, <CIViC source 2478>, <CIViC source 2081>, <CIViC source 4315>, <CIViC source 1172>, <CIViC source 1501>, <CIViC source 1938>, <CIViC source 746>, <CIViC source 5051>, <CIViC source 1547>, <CIViC source 2723>, <CIViC source 1509>, <CIViC source 1148>, <CIViC source 3038>, <CIViC source 1470>, <CIViC source 1502>, <CIViC source 1416>, <CIViC source 2571>}",[],[],[442]
439,EGFR G465R,20.0,,,['GLY465ARG'],"[7083, 1057, 1058]","{<CIViC source 2672>, <CIViC source 746>}",[],[],[443]
440,NEDD9 EXPRESSION,15.0,,,[],[1059],{<CIViC source 734>},[],[],[444]
441,ETS2 RS461155,10.0,,,"['P341P', 'P481P', 'PRO341=']",[1060],{<CIViC source 735>},[],[],[445]
442,KRT18 UNDEREXPRESSION,2.0,,,[],[1061],{<CIViC source 736>},[],[],[446]
443,FGF13 CYTOPLASMIC EXPRESSION,15.0,,,[],[1062],{<CIViC source 737>},[],[],[447]
444,SS18::SSX1 Fusion,145.0,,,"['T(X;18)(P11.23;Q11)', 'SS18-SSX1', 'SYT-SSX', 'SYT-SSX1', 'SS18-SSX']","[1063, 1069, 1070, 1072, 12122, 1065, 1068, 1071]","{<CIViC source 738>, <CIViC source 739>, <CIViC source 741>, <CIViC source 740>, <CIViC source 5087>, <CIViC source 742>}",[740],[<CIViC source 740>],[448]
445,SS18::SSX2 Fusion,85.0,,,"['T(X;18)(P11.21;Q11)', 'SS18-SSX2']","[1064, 1066, 1067, 1073]","{<CIViC source 738>, <CIViC source 739>, <CIViC source 742>}",[740],[<CIViC source 740>],[449]
446,SS18::SSX4 Fusion,5.0,,,['SS18-SSX4'],[1074],{<CIViC source 743>},[],[],[450]
447,ABCB1 S893A/T,15.0,"Refer to 
https://www.pharmgkb.org/rsid/rs2032582 
for more information.","Refer to 
https://www.pharmgkb.org/rsid/rs2032582 
for more information.",['RS2032582'],[1075],{<CIViC source 744>},[],[],[451]
448,EGFR S2492R,0.0,,,[],[],set(),[],[],[452]
449,EGFR S492R,23.0,,,"['SER492ARG', 'RS1057519860']","[7092, 717, 1078, 1079, 1080, 9639, 9647, 9656, 9657]","{<CIViC source 4099>, <CIViC source 2672>, <CIViC source 746>, <CIViC source 472>}",[],[],[453]
450,EGFR R451C,2.0,,,"['ARG451CYS', 'RS377567759']",[1081],{<CIViC source 746>},[],[],[454]
451,EGFR K467T,6.0,,,['LYS467THR'],"[7087, 1082, 1083]","{<CIViC source 2672>, <CIViC source 746>}",[],[],[455]
452,FCGR2A H167R,35.0,,,"['RS1801274', 'H131R', 'H166R', 'HIS167ARG']","[1088, 1084]","{<CIViC source 744>, <CIViC source 747>}",[],[],[456]
453,FCGR3A F212V,35.0,,,"['RS396991', 'V158F', 'PHE176VAL']","[1087, 1085]","{<CIViC source 744>, <CIViC source 747>}",[744],[<CIViC source 744>],[457]
454,FCGR2B I232T,20.0,,,"['RS1050501', 'ILE232THR']",[1086],{<CIViC source 747>},[747],[<CIViC source 747>],[458]
455,FCGR2A R131H,0.0,,,[],[],set(),[],[],[459]
456,EGFR P753S,7.5,,,"['PRO753SER', 'RS121913231']",[1089],{<CIViC source 748>},[],[],[460]
457,PML B2 DOMAIN MUTATION,20.0,The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.,The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.,[],[1092],{<CIViC source 751>},[],[],[461]
458,PML A216V,30.0,A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,[],[],set(),[],[],[462]
459,PML L218P,7.5,L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,['LEU218PRO'],[],set(),[],[],[463]
463,KDR A1065T,3.0,,,"['ALA1065THR', 'RS56302315']",[1106],{<CIViC source 764>},[],[],[467]
464,KDR D717V,3.0,,,['ASP717VAL'],[1107],{<CIViC source 764>},[],[],[468]
465,TSC2 Q1178*,12.5,,,"['Q1178X', 'GLN1178TER', 'RS45517297']",[1108],{<CIViC source 372>},[],[],[469]
466,MTOR F2108L,16.5,,,['PHE2108LEU'],"[1110, 1543]","{<CIViC source 1025>, <CIViC source 372>}",[],[],[470]
467,RAD51D R186*,5.0,,,"['R186X', 'ARG186TER', 'RS387906843']",[1111],{<CIViC source 766>},[],[],[471]
468,ALDH1A2 Overexpression,30.0,,,[],"[1114, 1116]","{<CIViC source 769>, <CIViC source 770>}",[],[],[472]
469,ALDH1A2 Underexpression,2.0,,,[],[1115],{<CIViC source 769>},[],[],[473]
470,CIP2A EXPRESSION,15.0,,,[],[1117],{<CIViC source 774>},[],[],[474]
471,CIP2A Underexpression,3.0,,,[],[1118],{<CIViC source 774>},[],[],[475]
472,MIR218-1 EXPRESSION,30.0,,,[],"[1119, 1120]",{<CIViC source 775>},[],[],[476]
473,BRCA1 P968FS,20.0,,,"['3021INSTC', 'PRO968LEUFS', 'RS398122670']","[1123, 1124]",{<CIViC source 778>},[],[],[477]
474,AR SPLICE VARIANT 7,0.0,,,[],[1126],{<CIViC source 578>},[],[],[478]
475,KRAS Q22*,5.0,,,"['Q22X', 'GLN22TER']",[1131],{<CIViC source 782>},[],[],[479]
476,DNMT3A P904L,0.0,,,[],[1134],{<CIViC source 785>},[],[],[480]
477,DDX43 Overexpression,4.0,,,[],[1135],{<CIViC source 786>},[],[],[481]
478,KIT RS3733542,5.0,,,['LEU862='],[1136],{<CIViC source 787>},[],[],[482]
479,TBK1 Overexpression,2.0,,,[],[1138],{<CIViC source 788>},[],[],[483]
481,STK11 Loss,23.0,,,[],"[1737, 1144, 1620, 1618, 1619]","{<CIViC source 1072>, <CIViC source 1181>, <CIViC source 1071>, <CIViC source 1070>, <CIViC source 792>}",[],[],[485]
482,HAVCR2 Overexpression,10.5,,,[],"[1150, 1151]",{<CIViC source 794>},[],[],[486]
483,MMP2 SERUM LEVELS,25.0,,,[],"[1156, 1158]","{<CIViC source 796>, <CIViC source 797>}",[],[],[487]
484,MMP9 SERUM LEVELS,15.0,,,[],[1157],{<CIViC source 796>},[],[],[488]
485,FST SERUM LEVELS,0.0,,,[],[],set(),[],[],[489]
486,HSPH1 NUCLEAR EXPRESSION,11.0,,,[],"[1162, 1163]",{<CIViC source 801>},[],[],[490]
487,HSPH1 T17 DELETION,10.0,,,[],[1164],{<CIViC source 802>},[],[],[491]
488,ECSCR EXPRESSION,5.0,,,[],[1165],{<CIViC source 803>},[],[],[492]
489,ROBO4 EXPRESSION,5.0,,,[],[1166],{<CIViC source 803>},[],[],[493]
490,PIM1 NUCLEAR EXPRESSION,10.0,,,[],[1168],{<CIViC source 805>},[],[],[494]
491,MDM2 SNP309,10.0,,,[],[1169],{<CIViC source 806>},[],[],[495]
492,ERBB2 L866M,4.0,This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.,This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.,['LEU866MET'],"[4673, 1178]",{<CIViC source 811>},[],[],[496]
493,ERBB2 S310F/Y,4.0,"ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",[],"[4518, 1179]",{<CIViC source 811>},[1160],[<CIViC source 1160>],[497]
494,MIR218-1 UNDEREXPRESSION,3.0,,,[],[1184],{<CIViC source 817>},[],[],[498]
495,v::ALK Fusion,798.0,"Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets. ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC. ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC. Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.","Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets. ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC. ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC. Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.","['REARRANGEMENT', 'ALK Fusion']","[1187, 1198, 1199, 1282, 7284, 7285, 7533, 7872, 8657, 11121, 12012, 11190, 11191, 11218, 11122, 4858, 1175, 1200, 1201, 1279, 1323, 4835, 7286, 7535, 7590, 11192, 945, 1243, 1272, 1419, 1577, 2952, 7053, 7361, 7362, 11290, 11291, 11404, 1240, 1783, 11294, 1242, 1273, 1691, 5954, 7546, 7547, 10324, 1202, 1264, 6042, 6043, 7144, 1334, 1335]","{<CIViC source 647>, <CIViC source 3640>, <CIViC source 830>, <CIViC source 1141>, <CIViC source 812>, <CIViC source 860>, <CIViC source 879>, <CIViC source 4290>, <CIViC source 961>, <CIViC source 4557>, <CIViC source 884>, <CIViC source 874>, <CIViC source 886>, <CIViC source 1041>, <CIViC source 3794>, <CIViC source 920>, <CIViC source 2775>, <CIViC source 819>, <CIViC source 2410>, <CIViC source 2440>, <CIViC source 2728>, <CIViC source 1689>, <CIViC source 878>, <CIViC source 4644>, <CIViC source 912>, <CIViC source 829>, <CIViC source 3648>, <CIViC source 856>, <CIViC source 2872>, <CIViC source 858>, <CIViC source 1245>, <CIViC source 4584>, <CIViC source 831>, <CIViC source 828>, <CIViC source 2439>, <CIViC source 2908>, <CIViC source 1197>, <CIViC source 4987>, <CIViC source 2141>, <CIViC source 859>, <CIViC source 4587>, <CIViC source 2873>, <CIViC source 3162>, <CIViC source 827>, <CIViC source 2157>}",[],[],[499]
496,EML4::ALK e20::e20,16.5,"EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.","EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.",['EML4-ALK E20-E20'],"[1189, 1196, 1204]","{<CIViC source 819>, <CIViC source 826>}",[],[],[500]
497,EML4::ALK e2::e20,1.75,,,['EML4-ALK E2-E20'],"[1190, 1266]","{<CIViC source 876>, <CIViC source 821>}",[],[],[501]
498,KDR R961W,2.5,,,"['ARG961TRP', 'RS530419081']",[1191],{<CIViC source 822>},[],[],[502]
499,EML4::ALK e6::e20,25.0,"The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.","The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.",['EML4-ALK E6-E20'],"[1193, 1245, 1192, 1340, 1194, 1195, 1197, 1205]","{<CIViC source 825>, <CIViC source 819>, <CIViC source 823>, <CIViC source 824>, <CIViC source 924>, <CIViC source 826>, <CIViC source 862>}",[],[],[503]
500,TP53 P47S,0.5,,,"['PRO47SER', 'RS1800371']",[1209],{<CIViC source 834>},[834],[<CIViC source 834>],[504]
501,GNAQ Mutation,26.0,,,[],"[1229, 5068, 1953, 1210]","{<CIViC source 835>, <CIViC source 1374>, <CIViC source 1753>, <CIViC source 850>}",[],[],[505]
502,GNA11 Mutation,24.0,,,[],"[3049, 1228, 1952, 1211]","{<CIViC source 835>, <CIViC source 1374>, <CIViC source 1753>, <CIViC source 850>}",[],[],[506]
503,GNAQ Q209,20.0,,,['GLN209'],"[1213, 1233]","{<CIViC source 836>, <CIViC source 690>}",[],[],[507]
504,PMS2 K706FS*19,10.0,,,"['RS587782704', 'LYS706SERFS']",[1214],{<CIViC source 837>},[],[],[508]
505,KIT Exon 9 Mutation,122.5,"In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.","In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.",[],"[1221, 1223, 1424, 2466, 4603, 2477, 4139, 4628, 4104]","{<CIViC source 2045>, <CIViC source 965>, <CIViC source 1586>, <CIViC source 846>, <CIViC source 2044>, <CIViC source 2046>, <CIViC source 844>, <CIViC source 412>, <CIViC source 2043>}",[],[],[509]
506,PTEN Mutation,31.0,,,[],"[8176, 1232, 7074, 9751, 1931, 1467, 1491, 1522, 1359, 11832]","{<CIViC source 998>, <CIViC source 4063>, <CIViC source 1352>, <CIViC source 984>, <CIViC source 1015>, <CIViC source 3364>, <CIViC source 853>, <CIViC source 926>, <CIViC source 2751>, <CIViC source 4938>}",[],[],[510]
507,FGFR2 Mutation,28.0,,,[],"[5912, 6457, 6444, 10375, 10398, 1912, 1236]","{<CIViC source 2551>, <CIViC source 855>, <CIViC source 4325>, <CIViC source 1337>, <CIViC source 2384>, <CIViC source 2564>}",[],[],[511]
508,ALK Mutation,20.0,,,[],"[11286, 1237]","{<CIViC source 856>, <CIViC source 2873>}",[],[],[512]
509,NPM1::ALK Fusion,27.0,,,"['T(2;5)(P23;Q35)', 'NPM-ALK', 'NPM1-ALK']","[1241, 1239, 1268, 1356]","{<CIViC source 859>, <CIViC source 925>, <CIViC source 857>, <CIViC source 826>}","[859, 925]","[<CIViC source 859>, <CIViC source 925>]",[513]
510,RANBP2::ALK Fusion,10.0,,,['RANBP2-ALK'],[1244],{<CIViC source 861>},[],[],[514]
511,FGFR1 N546K,8.0,,,"['ASN546LYS', 'RS779707422']","[10325, 11023, 11649, 1246]","{<CIViC source 446>, <CIViC source 4291>, <CIViC source 4771>, <CIViC source 4503>}",[],[],[515]
512,ROS1 L2026M,9.0,"The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.","The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.",['LEU2026MET'],[],set(),[],[],[516]
513,ROS1 L2155S,3.0,,,"['L2149S', 'LEU2155SER', 'LEU2149SER']",[],set(),[],[],[517]
514,ROS1 G2101A,4.0,,,"['GLY2101ALA', 'GLY2095ALA', 'G2095A']",[],set(),[],[],[518]
515,FLT3 Mutation,85.0,,,[],"[7728, 5261, 7283, 8266, 5575, 156, 8888, 5574]","{<CIViC source 3724>, <CIViC source 3417>, <CIViC source 2281>, <CIViC source 3080>, <CIViC source 133>, <CIViC source 2224>, <CIViC source 2871>}",[],[],[519]
516,CLTC::ALK Fusion,19.0,"The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).","The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).","['T(2;17)(P23;Q23)', 'CLTC-ALK']","[1263, 1265, 1261]","{<CIViC source 871>, <CIViC source 873>, <CIViC source 875>}",[871],[<CIViC source 871>],[520]
517,U2AF1 MUTATION,20.0,,,[],[1262],{<CIViC source 872>},[],[],[521]
518,BRAF DEL 485-490,3.0,,,[],[1267],{<CIViC source 877>},[],[],[522]
520,DUX4::v Fusion,11.5,,,['DUX4 Fusion'],"[1277, 1276]",{<CIViC source 882>},[],[],[524]
521,B4GALT1 Overexpression,15.0,,,[],[1278],{<CIViC source 883>},[],[],[525]
522,BCL2L11 Deletion Polymorphism,40.0,,,[],"[1280, 1281, 9701]","{<CIViC source 885>, <CIViC source 4140>}",[],[],[526]
523,ALK I1171,42.5,Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.,Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.,['ILE1171'],"[4610, 1283, 1284, 1368, 1367, 4611, 4612, 1344, 1285, 1287]","{<CIViC source 2111>, <CIViC source 929>, <CIViC source 2112>, <CIViC source 924>, <CIViC source 887>}",[],[],[527]
524,ALK V1180L,0.0,"The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.","The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.",[],[],set(),[],[],[528]
525,SIRT1 Overexpression,16.0,,,[],"[1293, 1294]",{<CIViC source 889>},[],[],[529]
526,KRAS G12R,32.5,,,"['GLY12ARG', 'RS121913530']","[1298, 1299, 2264, 2265, 2266, 2267, 3984, 3985, 3986, 3988, 3990, 3993, 3995, 3998, 3987, 7310, 3992, 3997, 3999, 3989, 3991]","{<CIViC source 1935>, <CIViC source 1940>, <CIViC source 892>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 2886>, <CIViC source 1936>, <CIViC source 2027>, <CIViC source 1933>, <CIViC source 687>, <CIViC source 1414>, <CIViC source 1415>, <CIViC source 2008>, <CIViC source 1413>, <CIViC source 76>, <CIViC source 2004>, <CIViC source 1926>, <CIViC source 122>, <CIViC source 1937>, <CIViC source 1412>}",[],[],[530]
527,TP53 P72R,45.0,"This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.","This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.","['PRO72ARG', 'P33R', 'RS1042522']","[1303, 1304, 6932]","{<CIViC source 2665>, <CIViC source 896>, <CIViC source 897>}",[],[],[531]
528,PALB2 Biallelic Inactivation,17.5,,,[],"[1305, 1963]","{<CIViC source 898>, <CIViC source 409>}",[],[],[532]
529,SMAD4 Expression,15.0,,,[],"[1306, 7179]","{<CIViC source 899>, <CIViC source 2803>}",[],[],[533]
530,FANCC Loss-of-function,3.0,,,[],[1307],{<CIViC source 900>},[],[],[534]
531,EBF1::PDGFRB Fusion,32.5,EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.,EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.,['EBF1-PDGFRB'],"[1310, 6976, 8260, 11625, 7028, 7127, 7128]","{<CIViC source 2693>, <CIViC source 3392>, <CIViC source 2495>, <CIViC source 1087>, <CIViC source 901>}",[1087],[<CIViC source 1087>],[535]
532,SULT1E1 SNP,0.0,,,[],[1312],{<CIViC source 903>},[],[],[536]
533,RB1 EXPRESSION,10.0,,,[],[1313],{<CIViC source 904>},[],[],[537]
534,MLH1 METHYLATION,10.0,,,[],[1315],{<CIViC source 905>},[],[],[538]
535,PTPN11 Overexpression,10.0,,,[],[1316],{<CIViC source 906>},[],[],[539]
536,FLT3 T227M,15.0,"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.","FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.","['RS1933437', 'THR227MET']",[1317],{<CIViC source 914>},[914],[<CIViC source 914>],[540]
537,PALB2 L531FS*30,15.0,,,['LEU531FS*30'],[1318],{<CIViC source 909>},[],[],[541]
538,MTOR S2215Y,2.0,,,['SER2215TYR'],[1319],{<CIViC source 911>},[],[],[542]
539,MTOR C1483Y,2.0,,,['CYS1483TYR'],[1320],{<CIViC source 911>},[],[],[543]
540,MTOR E1799K,2.0,,,"['GLU1799LYS', 'RS863225264']","[9489, 9486, 1321]","{<CIViC source 4067>, <CIViC source 4059>, <CIViC source 911>}",[],[],[544]
541,FGFR2 N550K,3.0,,,"['ASN550LYS', 'N549K', 'RS121913476']",[1322],{<CIViC source 952>},[],[],[545]
542,ACTA1 EXPRESSION,10.0,,,[],[1161],{<CIViC source 800>},[],[],[546]
543,RB1 Overexpression,2.0,,,[],[1324],{<CIViC source 913>},[],[],[547]
544,PPP1R15A RS557806,5.0,,,"['ARG251PRO', 'R251P']",[1325],{<CIViC source 915>},[],[],[548]
545,ALK F1245C,10.5,,,"['PHE1245CYS', 'RS863225283']","[1333, 1330]","{<CIViC source 859>, <CIViC source 919>}",[],[],[549]
546,ALK Exon 4-11 Deletion,3.0,,,[],[1336],{<CIViC source 921>},[],[],[550]
549,CDK4 Amplification,30.0,,,[],"[1366, 4841]","{<CIViC source 2145>, <CIViC source 360>}",[],[],[553]
550,CDKN2A Loss,52.5,,,[],"[7679, 7986, 7444, 1765, 1373, 1375, 1377, 1372, 1559, 1879, 1881]","{<CIViC source 2945>, <CIViC source 1305>, <CIViC source 1030>, <CIViC source 931>, <CIViC source 1306>, <CIViC source 3204>, <CIViC source 212>, <CIViC source 1231>, <CIViC source 932>, <CIViC source 933>, <CIViC source 1941>}",[],[],[554]
551,CDKN2B Loss,5.0,,,[],"[1374, 1880]","{<CIViC source 212>, <CIViC source 1305>}",[],[],[555]
552,CDK4 R24C,1.0,,,"['ARG24CYS', 'RS11547328']",[1376],{<CIViC source 932>},[],[],[556]
553,ASXL1 EXON 12 MUTATION,20.0,,,[],[1379],{<CIViC source 936>},[],[],[557]
554,GNA11 Q209,15.0,,,[],[1212],{<CIViC source 836>},[],[],[558]
555,CALR EXON 9 FRAMESHIFT,80.0,"Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.","Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.",[],"[1387, 1482, 1649, 6386, 6387, 6388, 6389]","{<CIViC source 2524>, <CIViC source 2527>, <CIViC source 940>, <CIViC source 2526>, <CIViC source 994>, <CIViC source 1113>}","[1112, 940, 966]","[<CIViC source 1112>, <CIViC source 940>, <CIViC source 966>]",[559]
556,CSF3R Mutation,30.0,,,[],"[1388, 1389]",{<CIViC source 941>},[],[],[560]
558,EGFR S768I,20.5,,,"['SER768ILE', 'RS121913465']","[2614, 2615, 7859, 4273, 1394, 1395, 2906, 2616, 4185, 4274]","{<CIViC source 1614>, <CIViC source 945>, <CIViC source 944>, <CIViC source 1991>, <CIViC source 2079>, <CIViC source 1613>, <CIViC source 1669>, <CIViC source 1528>, <CIViC source 3144>, <CIViC source 1615>}",[],[],[562]
559,BRAF V600K,107.5,,,"['VAL600LYS', 'RS121913227']","[2505, 2507, 4177, 6939, 1399, 6179, 6941, 6965, 4180, 4181, 2506, 4174, 4175, 4176, 4179, 1400, 4173, 4178]","{<CIViC source 2061>, <CIViC source 1488>, <CIViC source 2062>, <CIViC source 1957>, <CIViC source 1953>, <CIViC source 2475>, <CIViC source 2671>, <CIViC source 1482>, <CIViC source 60>, <CIViC source 1491>, <CIViC source 103>, <CIViC source 1951>, <CIViC source 353>, <CIViC source 354>, <CIViC source 1210>, <CIViC source 948>, <CIViC source 947>, <CIViC source 963>}",[],[],[563]
560,SMAD4 LOSS,15.0,,,[],"[6452, 1412]","{<CIViC source 2559>, <CIViC source 956>}",[],[],[564]
561,SF3B1 K700E,5.0,,,"['LYS700GLU', 'RS559063155']","[10139, 1417]","{<CIViC source 4228>, <CIViC source 960>}",[],[],[565]
562,MAP2K7 E116K,25.0,,,['GLU116LYS'],[1420],{<CIViC source 962>},[],[],[566]
563,v::PDGFRA Fusion,100.0,,,"['PDGFRA Fusion', 'PDGFRA Rearrangement']","[1425, 1433]",{<CIViC source 966>},[],[],[567]
564,v::PDGFRB Fusion,140.0,,,['PDGFRB Fusion'],"[1426, 1434, 1498, 7022, 11272]","{<CIViC source 966>, <CIViC source 2495>, <CIViC source 1003>, <CIViC source 4630>}",[],[],[568]
565,v::FGFR1 Fusion,103.0,,,['FGFR1 Fusion'],"[1427, 1435, 7375, 7376]","{<CIViC source 2913>, <CIViC source 966>}",[],[],[569]
566,IDH2 Mutation,101.5,,,[],"[5069, 7279, 7726, 328, 1640, 8857, 4833, 2932]","{<CIViC source 203>, <CIViC source 1085>, <CIViC source 3072>, <CIViC source 1363>, <CIViC source 3698>, <CIViC source 1683>, <CIViC source 2194>}",[],[],[570]
567,PCM1::JAK2 Fusion,57.5,,,"['T(8;9)(P22;P24.1)', 'PCM1-JAK2']","[1436, 7704]","{<CIViC source 966>, <CIViC source 2498>}",[966],[<CIViC source 966>],[571]
568,MTOR E2014K,0.0,,,[],[],set(),[],[],[572]
569,RICTOR Amplification,12.5,,,[],"[7449, 1440, 1915, 1916]","{<CIViC source 1340>, <CIViC source 2950>, <CIViC source 973>, <CIViC source 1339>}",[],[],[573]
570,FIP1L1::PDGFRA Fusion,63.5,"Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).","Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).",['FIP1L1-PDGFRA'],"[11273, 1445, 1441, 1774, 1777, 7377, 7378, 7381]","{<CIViC source 1240>, <CIViC source 2913>, <CIViC source 376>, <CIViC source 4631>, <CIViC source 974>, <CIViC source 1241>}",[1073],[<CIViC source 1073>],[574]
572,TFG::ROS1 Fusion,7.5,,,['TFG-ROS1'],"[1444, 11860, 11862]","{<CIViC source 4951>, <CIViC source 976>}",[],[],[576]
573,PDGFRA T674I,15.5,A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.,A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.,"['THR674ILE', 'RS121908587']",[],set(),[],[],[577]
574,BIRC5 Overexpression,20.0,,,[],[1449],{<CIViC source 977>},[],[],[578]
575,BRAF D594A,0.75,,,"['ASP594ALA', 'RS121913338']",[1454],{<CIViC source 982>},[],[],[579]
576,BRAF D594V,0.75,,,"['ASP594VAL', 'RS121913338']",[1456],{<CIViC source 982>},[],[],[580]
577,BRAF K483M,0.75,The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.,The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.,['LYS483MET'],[1457],{<CIViC source 982>},[1161],[<CIViC source 1161>],[581]
578,BRAF L597S,9.5,,,['LEU597SER'],"[1460, 1459]",{<CIViC source 338>},[],[],[582]
579,BRAF L597Q,14.5,,,"['LEU597GLN', 'RS121913366']","[4905, 5971, 1461]","{<CIViC source 2178>, <CIViC source 338>, <CIViC source 2414>}",[],[],[583]
580,BRAF K601E,3.0,,,"['LYS601GLU', 'RS121913364']","[2812, 7622, 5963, 1462]","{<CIViC source 1488>, <CIViC source 3026>, <CIViC source 338>, <CIViC source 2414>}",[],[],[584]
581,BRAF L597V,7.5,,,"['LEU597VAL', 'RS121913369']",[1463],{<CIViC source 850>},[],[],[585]
582,KIT Amplification,15.0,,,[],"[1466, 5907]","{<CIViC source 2383>, <CIViC source 85>}",[],[],[586]
583,NF1 Mutation,62.0,,,[],"[11176, 1958, 7266, 7426, 7487, 1470, 12272, 1469, 6054, 1468, 1471]","{<CIViC source 2929>, <CIViC source 2973>, <CIViC source 985>, <CIViC source 4822>, <CIViC source 5168>, <CIViC source 2421>, <CIViC source 986>, <CIViC source 1377>, <CIViC source 2862>}",[],[],[587]
584,ALK I1171N,0.0,,,['RS1057519698'],[],set(),[],[],[588]
585,ALK I1171S,0.0,,,['ILE1171SER'],[],set(),[],[],[589]
586,BIRC3 TRUNCATING MUTATION,10.0,,,[],[1488],{<CIViC source 997>},[],[],[590]
587,RAF1 Amplification,10.0,,,[],"[1496, 11767, 9113]","{<CIViC source 4896>, <CIViC source 1002>, <CIViC source 3851>}",[],[],[591]
588,KRAS Amplification,27.0,,,[],"[2928, 5836, 7105, 1497, 9116, 9086, 6317]","{<CIViC source 2362>, <CIViC source 2756>, <CIViC source 1681>, <CIViC source 1002>, <CIViC source 3837>, <CIViC source 1941>, <CIViC source 3854>}",[],[],[592]
590,CEBPA BIALLELIC INACTIVATION,25.0,,,[],[1512],{<CIViC source 1009>},[],[],[594]
591,SRSF2 MUTATION,25.0,,,[],[1514],{<CIViC source 1009>},[],[],[595]
592,NRAS G12/G13,20.0,,,[],[1516],{<CIViC source 1009>},[],[],[596]
593,RET Overexpression,24.5,,,[],"[7056, 1518, 2992, 740]","{<CIViC source 1011>, <CIViC source 488>, <CIViC source 2733>}",[],[],[597]
595,CTLA4::CD28 Fusion,5.0,"A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).","A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).",['CTLA4-CD28'],[1520],{<CIViC source 1013>},[1125],[<CIViC source 1125>],[599]
596,AR Mutation,20.0,,,[],[1521],{<CIViC source 1014>},[],[],[600]
597,NOTCH1 Loss-of-function,2.0,,,[],[1525],{<CIViC source 1017>},[],[],[601]
598,CDK6 Overexpression,24.0,,,[],"[1526, 11200, 8113, 1527, 7800]","{<CIViC source 3125>, <CIViC source 1018>, <CIViC source 2898>, <CIViC source 3123>}",[],[],[602]
599,FLT3 Overexpression,7.5,,,[],[1528],{<CIViC source 1019>},[],[],[603]
600,GNAQ Q209P,8.0,,,"['GLN209PRO', 'RS121913492']","[1533, 1537]",{<CIViC source 1021>},[],[],[604]
601,PTEN V317FS,3.0,,,['VAL317FS'],[1534],{<CIViC source 1021>},[],[],[605]
602,RB1 Loss-of-function,6.0,,,[],"[12032, 1535, 1595, 12329, 12330, 12331]","{<CIViC source 5007>, <CIViC source 3449>, <CIViC source 1057>, <CIViC source 1022>}",[],[],[606]
603,ESR1 Overexpression,20.0,,,[],[1541],{<CIViC source 1024>},[],[],[607]
605,MTOR M2327I,7.0,,,['MET2327ILE'],"[1544, 1546, 10082, 1545]",{<CIViC source 1025>},[],[],[609]
606,MTOR A2034V,8.0,,,['ALA2034VAL'],"[1547, 1548]",{<CIViC source 1025>},[],[],[610]
607,BRAF D594G,43.5,This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.,This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.,"['ASP594GLY', 'RS121913338']","[1553, 1551, 2201, 4472, 1554, 6001, 6002, 7556, 7760]","{<CIViC source 1027>, <CIViC source 3005>, <CIViC source 337>, <CIViC source 76>, <CIViC source 1946>}",[337],[<CIViC source 337>],[611]
608,FLT3 D835H,9.5,,,"['ASP835HIS', 'RS121913488']","[4027, 1556, 4028, 8517]","{<CIViC source 3336>, <CIViC source 2031>, <CIViC source 1028>, <CIViC source 2030>}",[],[],[612]
609,FLT3 D835H/Y,1.0,,,"['ASP835HIS', 'ASP835TYR']",[1557],{<CIViC source 1028>},[],[],[613]
610,JAK1 Q503*,10.0,,,"['Q503X', 'GLN503TER']",[1567],{<CIViC source 1036>},[],[],[614]
611,JAK2 c.1641+1dup,10.0,,,[],[1568],{<CIViC source 1036>},[],[],[615]
612,B2M S14FS,7.5,,,[],[1569],{<CIViC source 1036>},[],[],[616]
613,PPFIBP2::BRAF Fusion,5.0,,,['PPFIBP2-BRAF'],[1570],{<CIViC source 1037>},[],[],[617]
614,KIAA1549::BRAF Fusion,109.5,,,['KIAA1549-BRAF'],"[7148, 7193, 7200, 7319, 7486, 1664, 7312, 1571, 7204, 7197, 7337, 8944, 9694, 7199, 7402, 8943]","{<CIViC source 2820>, <CIViC source 1126>, <CIViC source 2816>, <CIViC source 2973>, <CIViC source 864>, <CIViC source 2822>, <CIViC source 2921>, <CIViC source 2890>, <CIViC source 1198>, <CIViC source 1037>, <CIViC source 2819>}",[],[],[618]
615,PTGS2 Overexpression,0.0,,,[],[1573],{<CIViC source 1039>},[],[],[619]
617,MET Overexpression,64.0,,,[],"[5835, 1581, 11371, 1584, 3037, 3038, 7932, 1583, 1582]","{<CIViC source 1046>, <CIViC source 1045>, <CIViC source 1044>, <CIViC source 1742>, <CIViC source 4514>, <CIViC source 2361>, <CIViC source 3173>, <CIViC source 1047>}",[],[],[621]
619,POT1 MUTATION,15.0,,,[],[1590],{<CIViC source 1051>},[],[],[623]
620,MKI67 EXPRESSION,35.0,,,[],"[1593, 1594]","{<CIViC source 1056>, <CIViC source 1055>}",[],[],[624]
621,RAD23B EXPRESSION,2.0,,,[],[1597],{<CIViC source 1059>},[],[],[625]
622,CCDC6::RET Fusion,12.5,,,['CCDC6-RET'],"[7480, 11263, 1601]","{<CIViC source 2969>, <CIViC source 4628>, <CIViC source 1061>}",[],[],[626]
623,MAP2K1 C121S,10.0,,,['CYS121SER'],"[1602, 1903]","{<CIViC source 1336>, <CIViC source 1062>}",[],[],[627]
624,FGFR3 S249C,21.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['SER249CYS', 'RS121913483']","[7306, 6404, 7834, 11635, 1603, 8316, 4871, 8853, 10386, 7941, 8060, 8642, 8668, 8811, 8854, 8855, 8859, 9088, 10512]","{<CIViC source 3695>, <CIViC source 3644>, <CIViC source 2534>, <CIViC source 2167>, <CIViC source 3696>, <CIViC source 3136>, <CIViC source 1233>, <CIViC source 3678>, <CIViC source 3701>, <CIViC source 3137>, <CIViC source 1063>, <CIViC source 2859>, <CIViC source 3456>, <CIViC source 3631>, <CIViC source 4353>, <CIViC source 3694>, <CIViC source 4823>, <CIViC source 3447>}",[],[],[628]
625,FGFR2 Amplification,25.0,,,[],"[6458, 1990, 1605, 11648, 11637, 8062, 7953]","{<CIViC source 1397>, <CIViC source 3184>, <CIViC source 2565>, <CIViC source 1233>, <CIViC source 1064>, <CIViC source 4823>}",[],[],[629]
626,FGF3 Amplification,10.0,,,[],"[1606, 1966]","{<CIViC source 1064>, <CIViC source 1106>}",[],[],[630]
627,VHL R200W (c.598C>T),10.0,,,"['ARG200TRP', 'C.598C>T', 'RS28940298']","[8250, 1608, 5763, 8238, 8463, 8544, 9436, 5539, 5569, 5855, 6470, 6481, 6482, 6650, 8232, 5532]","{<CIViC source 2584>, <CIViC source 3396>, <CIViC source 1368>, <CIViC source 2279>, <CIViC source 1065>, <CIViC source 3531>, <CIViC source 3673>, <CIViC source 2583>, <CIViC source 2620>, <CIViC source 2264>, <CIViC source 3391>, <CIViC source 2268>, <CIViC source 2366>, <CIViC source 2575>, <CIViC source 3580>, <CIViC source 3399>}",[],[],[631]
628,RB1 PHOSPHORYLATION,15.0,,,[],[1609],{<CIViC source 178>},[],[],[632]
629,PIK3R1 Mutation,2.0,,,[],"[7073, 1612]","{<CIViC source 1066>, <CIViC source 2751>}",[],[],[633]
630,STK11 D194E,5.0,,,"['ASP194GLU', 'RS786202134']",[1617],{<CIViC source 1069>},[],[],[634]
631,AKT2 Amplification,2.5,,,[],[1621],{<CIViC source 1074>},[],[],[635]
632,PTEN R130*,2.0,,,"['R130X', 'ARG130TER', 'RS121909224']",[1627],{<CIViC source 1076>},[],[],[636]
633,FBXW7 Loss-of-function,4.5,,,[],"[1632, 1628]","{<CIViC source 1077>, <CIViC source 1080>}",[],[],[637]
634,RB1 M695FS*26,2.0,,,[],[1630],{<CIViC source 1078>},[],[],[638]
635,JUN Overexpression,5.0,,,[],[1633],{<CIViC source 1081>},[],[],[639]
636,FOS Overexpression,5.0,,,[],[1634],{<CIViC source 1081>},[],[],[640]
637,CDKN2A RS3814960,15.0,,,[],[1635],{<CIViC source 1082>},[],[],[641]
638,MDM2 RS34886328,10.0,,,[],[1636],{<CIViC source 1082>},[],[],[642]
639,CBLB RS2305035,10.0,,,['D424D'],[1637],{<CIViC source 1083>},[],[],[643]
640,PRDM1 MUTATION,20.0,,,[],"[1638, 1717]",{<CIViC source 1084>},[],[],[644]
641,IDH1 Mutation,90.5,,,[],"[10313, 7278, 7725, 1639, 7447, 8856, 2933]","{<CIViC source 1085>, <CIViC source 3072>, <CIViC source 2948>, <CIViC source 4286>, <CIViC source 3698>, <CIViC source 2868>, <CIViC source 1683>}",[],[],[645]
642,SMAD4 Deletion,15.0,,,[],[1644],{<CIViC source 1090>},[],[],[646]
643,LRP1B DELETION,20.0,,,[],[1645],{<CIViC source 1091>},[],[],[647]
644,ATRX Underexpression,39.0,,,['UNDEREXPRESSION'],"[7190, 1647, 1648, 5832]","{<CIViC source 2358>, <CIViC source 2816>, <CIViC source 1093>, <CIViC source 1094>}",[],[],[648]
645,MET D1228N,5.0,,,"['D1246N', 'ASP1246ASN', 'ASP1228ASN']",[1652],{<CIViC source 1116>},[],[],[649]
646,CASP8 D302H,15.0,,,"['RS1045485', 'D285H', 'ASP302HIS']",[1654],{<CIViC source 1118>},[1118],[<CIViC source 1118>],[650]
647,AXL EXPRESSION,20.0,,,[],[1655],{<CIViC source 1119>},[],[],[651]
648,GAS6 EXPRESSION,23.0,,,[],"[1657, 1656]","{<CIViC source 1120>, <CIViC source 1121>}",[],[],[652]
649,ETV4 Overexpression,15.0,,,[],"[1658, 5119, 5121]","{<CIViC source 1122>, <CIViC source 2207>}",[],[],[653]
650,STAG3 Underexpression,4.0,,,[],[1660],{<CIViC source 1123>},[],[],[654]
651,MAP2K1 Q56_V60del,10.0,,,[],[1661],{<CIViC source 1124>},[],[],[655]
652,BRAF::CUL1 Fusion,5.0,,,['BRAF-CUL1'],[1662],{<CIViC source 1124>},[],[],[656]
653,ZKSCAN1::BRAF Fusion,7.5,,,['ZKSCAN1-BRAF'],[1663],{<CIViC source 1126>},[],[],[657]
654,BRAF L505H,19.0,,,['LEU505HIS'],"[1669, 1668]","{<CIViC source 1129>, <CIViC source 1130>}",[],[],[658]
655,NF2 Mutation,0.0,,,[],[1671],{<CIViC source 1131>},[],[],[659]
656,HIF1A EXPRESSION,10.0,,,[],[1674],{<CIViC source 1132>},[],[],[660]
657,BRCA2 D3095E,7.5,,,"['ASP3095GLU', 'RS80359198']","[1679, 9939]","{<CIViC source 1135>, <CIViC source 4202>}",[],[],[661]
658,MLH1 EXPRESSION,15.0,,,[],[1680],{<CIViC source 1136>},[],[],[662]
659,BCOR Mutation,15.0,,,[],"[7450, 1681]","{<CIViC source 2951>, <CIViC source 1136>}",[],[],[663]
660,CDH1 MUTATION,0.5,,,[],[1682],{<CIViC source 1136>},[],[],[664]
661,RHOA MUTATION,0.5,,,[],"[11981, 11830, 1683]","{<CIViC source 4973>, <CIViC source 4938>, <CIViC source 1136>}",[],[],[665]
662,ERBB2 Mutation,37.5,,,[],"[11731, 5338, 5980, 1694]","{<CIViC source 4879>, <CIViC source 2414>, <CIViC source 1143>, <CIViC source 2233>}",[],[],[666]
663,MEN1 FRAMESHIFT TRUNCATION,5.0,,,[],[1695],{<CIViC source 1144>},[],[],[667]
664,KMT2C Mutation,15.0,,,[],"[1696, 11959]","{<CIViC source 4964>, <CIViC source 1145>}",[],[],[668]
665,STAG2 MUTATION,30.0,,,[],"[1697, 6947, 7451]","{<CIViC source 2676>, <CIViC source 2952>, <CIViC source 1146>}",[],[],[669]
666,MYCL EXPRESSION,1.0,,,[],[1706],{<CIViC source 1149>},[],[],[670]
667,HGF EXPRESSION,2.0,,,[],[1707],{<CIViC source 1150>},[],[],[671]
668,SOX10 Loss,4.0,,,[],[1710],{<CIViC source 1153>},[],[],[672]
669,FGF2 EXPRESSION,4.0,,,[],[1711],{<CIViC source 1154>},[],[],[673]
670,EIF1AX MUTATION,10.0,,,[],[1712],{<CIViC source 1155>},[],[],[674]
671,PAX8 Expression,40.0,,,[],[1716],{<CIViC source 1159>},[],[],[683]
672,ERRFI1 E384*,5.0,,,"['E384X', 'GLU384TER']","[5869, 1724]",{<CIViC source 186>},[],[],[691]
673,ESR1 S463P,2.0,,,"['SER463PRO', 'RS1057519714']","[12230, 4815, 1727]","{<CIViC source 2135>, <CIViC source 171>, <CIViC source 4727>}",[],[],[692]
674,SGK1 Overexpression,24.0,,,[],"[1730, 1729, 1731]",{<CIViC source 1174>},[],[],[693]
675,BRAF G596C,2.0,,,"['GLY596CYS', 'RS121913361']","[9514, 1738]",{<CIViC source 3009>},[],[],[694]
676,SMARCB1 Underexpression,2.0,,,[],"[6374, 1739]","{<CIViC source 1185>, <CIViC source 2517>}",[],[],[695]
677,SMARCB1 Deletion,3.0,,,[],"[9992, 11179, 1740, 1964]","{<CIViC source 4576>, <CIViC source 1380>, <CIViC source 4215>, <CIViC source 1186>}",[],[],[696]
678,NF2 Loss,4.0,,,[],[1742],{<CIViC source 1191>},[],[],[697]
679,NF1 Loss,3.0,,,[],"[7727, 7265, 1743, 1956, 1957]","{<CIViC source 3149>, <CIViC source 2861>, <CIViC source 985>, <CIViC source 1192>, <CIViC source 1376>}",[],[],[698]
680,SH2B3 RS3184504,10.0,,,"['ARG262TRP', 'R262W', 'TRP262ARG']",[1744],{<CIViC source 1193>},[],[],[699]
681,KIF23 EXPRESSION,15.0,,,[],[1745],{<CIViC source 1203>},[],[],[700]
682,ERBB3 V104M,15.0,,,['VAL104MET'],"[1746, 9668, 9669, 9670]","{<CIViC source 1208>, <CIViC source 1644>}",[],[],[701]
683,ERBB3 R103G,15.0,,,['ARG103GLY'],[1747],{<CIViC source 1208>},[],[],[702]
684,ERBB3 G284R,15.0,,,['GLY284ARG'],"[1748, 7244, 9682, 9683, 9684]","{<CIViC source 1208>, <CIViC source 2852>, <CIViC source 1644>}",[],[],[703]
685,BRAF V600E+V600K,0.0,,,[],[],set(),[],[],[704]
686,GADD45A rs681673,15.0,,,['1506T>C'],[1751],{<CIViC source 1211>},[],[],[705]
687,EWSR1::FLI1 Fusion,90.0,"In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.","In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.","['EWS-FLI', 'T(11;22)(Q24;Q12)', 'EWSR1-FLI1']","[478, 1752, 1754, 10337, 1753]","{<CIViC source 1216>, <CIViC source 1215>, <CIViC source 1212>, <CIViC source 289>, <CIViC source 4815>}","[1213, 1214, 1287]","[<CIViC source 1287>, <CIViC source 1214>, <CIViC source 1213>]",[706]
689,BRCA2 TRUNCATING MUTATION,2.5,,,[],[1758],{<CIViC source 1222>},[],[],[708]
690,BRCA1 Alu insertion,7.5,,,[],[1759],{<CIViC source 1222>},[],[],[709]
691,HOXB1 G84E,0.0,,,['RS138213197'],[],set(),[1224],[<CIViC source 1224>],[710]
692,KLLN PROMOTER METHYLATION,30.0,,,[],"[1761, 1762]",{<CIViC source 1225>},[],[],[711]
693,EGFR D761Y,7.5,,,"['ASP761TYR', 'RS121913418']",[1763],{<CIViC source 1331>},[],[],[712]
694,CRBN Mutation,7.5,,,[],[1766],{<CIViC source 1232>},[],[],[713]
695,TSC1 R1062W,8.0,,,['ARG1062TRP'],"[1768, 1921]","{<CIViC source 1234>, <CIViC source 1343>}",[],[],[714]
696,STK11 Mutation,40.0,,,[],"[1769, 6441, 12338]","{<CIViC source 2548>, <CIViC source 5199>, <CIViC source 1235>}",[],[],[715]
697,PDGFRA Amplification,3.0,,,[],"[1771, 7989]","{<CIViC source 1238>, <CIViC source 3212>}",[],[],[716]
698,EWSR1::DDIT3 Fusion,7.5,,,"['T(12;22)(Q13;Q12)', 'EWS-CHOP', 'EWSR1-DDIT3']","[7982, 1778, 11520]","{<CIViC source 1243>, <CIViC source 1175>}",[1243],[<CIViC source 1243>],[717]
699,EGFR G719,25.0,"This is a ""bucket"" variant for evidence that refers generically to missense variants happening at this position such as: G719A, G719D, G719S.","This is a ""bucket"" variant for evidence that refers generically to missense variants happening at this position such as: G719A, G719D, G719S.","['GLY719', 'G719X']","[11242, 7857, 4189, 1780]","{<CIViC source 1503>, <CIViC source 3144>, <CIViC source 594>, <CIViC source 1244>}",[],[],[718]
701,EGFR S720,7.5,,,['SER720'],[1782],{<CIViC source 1244>},[],[],[720]
702,CYP2D6 Loss-of-function,20.0,,,[],[1784],{<CIViC source 1248>},[],[],[721]
703,FUS::DDIT3 Fusion,70.0,,,['FUS-DDIT3'],"[7981, 1785, 5920]","{<CIViC source 2393>, <CIViC source 1175>, <CIViC source 1249>}",[],[],[722]
704,EGFR K757R,7.5,,,"['LYS757ARG', 'RS397517102']",[1786],{<CIViC source 1244>},[],[],[723]
705,EGFR E746G,2.5,,,['GLU746GLY'],[1787],{<CIViC source 1244>},[],[],[724]
706,MLH1 E13fs,2.5,,,"['GLU13ARGFS', 'RS63750081', 'E13FS*3']",[1788],{<CIViC source 1251>},[],[],[725]
707,EGFR Exon 20 Insertion,105.0,,,[],"[11227, 11228, 12014, 1809, 7273, 7610, 9222, 4650, 1789, 4646]","{<CIViC source 4989>, <CIViC source 2866>, <CIViC source 3913>, <CIViC source 1257>, <CIViC source 4610>, <CIViC source 2079>, <CIViC source 4611>, <CIViC source 1244>, <CIViC source 3023>}",[],[],[726]
708,MSH2 R383*,2.5,,,"['R383X', 'ARG383TER', 'RS63749849']",[1790],{<CIViC source 1251>},[],[],[727]
709,MLH1 V534R,2.5,,,['VAL534ARG'],[1791],{<CIViC source 1251>},[],[],[728]
710,UGT1A1 UGT1A1*28,50.0,,,['RS8175347'],[1792],{<CIViC source 1252>},[1252],[<CIViC source 1252>],[729]
711,MLH1 G606FS*2,2.5,,,['GLY606FS'],[1793],{<CIViC source 1251>},[],[],[730]
712,MLH1 c.790+1G>A,2.5,,,['RS267607789'],[1794],{<CIViC source 1251>},[],[],[731]
713,UGT1A1 UGT1A1*60,20.0,,,[],[1795],{<CIViC source 1252>},[],[],[732]
714,MLH1 K618DEL,2.5,,,"['RS63751247', 'LYS618DEL']",[1796],{<CIViC source 1251>},[],[],[733]
715,MLH1 P138T,2.5,,,[],[1797],{<CIViC source 1251>},[],[],[734]
716,MLH1 R687FS,2.5,,,"['ARG687GLYFS', 'RS863225381']",[1798],{<CIViC source 1251>},[],[],[735]
717,EGFR V769_D770insASV,7.5,,,"['VAL769_ASP770INSALASERVAL, V769_770INSASV']","[1799, 5943, 4649]","{<CIViC source 2079>, <CIViC source 1230>, <CIViC source 1244>}",[],[],[736]
718,DPYD DPYD*2A HOMOZYGOSITY,50.0,,,"['RS3918290', 'DPYD*2A', 'DPYD:IVS14 + 1G>A', 'C.1905+1G>A']",[1800],{<CIViC source 1253>},[],[],[737]
719,DPYD DPYD*13 HOMOZYGOSITY,50.0,,,"['RS55886062', 'ILE560SER', 'I560S']",[1801],{<CIViC source 1253>},[1253],[<CIViC source 1253>],[738]
720,FOS::v Fusion,7.5,,,['FOS Truncating Fusion'],[1802],{<CIViC source 1254>},[],[],[739]
721,DPYD RS67376798 HOMOZYGOSITY,50.0,,,"['C.2846A>T', 'P.ASP949VAL', 'N949V']",[1803],{<CIViC source 1253>},[],[],[740]
722,MLH1 R100*,2.5,,,"['ARG100TER', 'R100X', 'RS63751221']",[1804],{<CIViC source 1251>},[],[],[741]
723,WWTR1::CAMTA1 Fusion,40.0,,,"['T(1;3)(P36.3;Q25)', 'WWTR1-CAMTA1']","[1805, 12017, 12018, 12019]","{<CIViC source 4992>, <CIViC source 4993>, <CIViC source 1255>}",[1255],[<CIViC source 1255>],[742]
724,MLH1 T117M,2.5,,,"['THR117MET', 'RS63750781']",[1806],{<CIViC source 1251>},[],[],[743]
725,MLH1 Q426FS,2.5,,,['GLN426FS'],[1807],{<CIViC source 1251>},[],[],[744]
726,MLH1 V49A,2.5,,,['VAL49ALA'],[1808],{<CIViC source 1251>},[],[],[745]
727,MLH1 D667FS,2.5,,,['ASP667FS'],[1810],{<CIViC source 1251>},[],[],[746]
728,MLH1 M1L,2.5,,,['MET1LEU'],[1811],{<CIViC source 1251>},[],[],[747]
729,MLH1 *757L,2.5,,,['X757L'],[1812],{<CIViC source 1251>},[],[],[748]
730,MLH1 R265G,2.5,,,['ARG265GLY'],[1813],{<CIViC source 1251>},[],[],[749]
731,MLH1 V213FS,2.5,,,['VAL213FS'],[1814],{<CIViC source 1251>},[],[],[750]
732,MLH1 N551T,2.5,,,"['ASN551THR', 'RS63750271']",[1815],{<CIViC source 1251>},[],[],[751]
733,MLH1 A424T,2.5,,,"['ALA424THR', 'RS377433038']",[1816],{<CIViC source 1251>},[],[],[752]
734,MLH1 Q149*,2.5,,,"['Q149X', 'GLN149TER', 'RS63751302']",[1817],{<CIViC source 1251>},[],[],[753]
735,MLH1 R226*,2.5,,,"['R226X', 'ARG226TER', 'R128*', 'RS63751615']",[1818],{<CIViC source 1251>},[],[],[754]
736,MSH6 I972F,0.0,,,['ILE972PHE'],[1819],{<CIViC source 1251>},[],[],[755]
737,MLH1 P536FS,2.5,,,['PRO536FS'],[1820],{<CIViC source 1251>},[],[],[756]
738,MLH1 G67R,2.5,,,"['GLY67ARG', 'RS63750206']",[1821],{<CIViC source 1251>},[],[],[757]
739,MLH1 I68S,2.5,,,['ILE68SER'],[1822],{<CIViC source 1251>},[],[],[758]
740,MLH1 G65D,2.5,,,"['GLY65ASP', 'RS63751465']",[1823],{<CIViC source 1251>},[],[],[759]
741,MLH1 A681V,2.5,,,"['ALA681VAL', 'A440V', 'RS63750864']",[1824],{<CIViC source 1251>},[],[],[760]
742,MSH6 P138T,2.5,,,['PRO138THR'],[1825],{<CIViC source 1251>},[],[],[761]
743,MSH2 V273FS,2.5,,,[],[1826],{<CIViC source 1251>},[],[],[762]
744,MSH2 E28FS,2.5,,,[],[1827],{<CIViC source 1251>},[],[],[763]
745,VHL E55FS (c.163_164delGA),2.5,,,"['C.163_164DELGA', 'GLU55FS']",[1828],{<CIViC source 1258>},[],[],[764]
746,MSH6 I891FS,2.5,,,['ILE891FS'],[1829],{<CIViC source 1251>},[],[],[765]
747,VHL E55RfsTer11 (c.163delG),7.5,,,"['C.163DELG', 'GLU55ARGFS']",[1830],{<CIViC source 1259>},[],[],[766]
748,MSH6 R1242H,2.5,,,"['ARG1242HIS', 'RS63750119']",[1831],{<CIViC source 1251>},[],[],[767]
749,PMS2 R315*,2.5,,,"['ARG315TER', 'RS200640585', 'R315X']",[1832],{<CIViC source 1251>},[],[],[768]
750,MLH1 M490T,2.5,,,['MET490THR'],[1833],{<CIViC source 1251>},[],[],[769]
751,MSH2 K172*,2.5,,,"['K172X', 'LYS172TER']",[1834],{<CIViC source 1251>},[],[],[770]
752,VHL A56FS (c.164_165insG),7.5,,,"['164INSG', 'C.164_165INSG', '377_378INSG']","[1855, 1835]",{<CIViC source 1264>},[],[],[771]
753,HOXB13 G84E,40.0,,,"['RS138213197', 'GLY84GLU']","[1760, 1836]","{<CIViC source 1265>, <CIViC source 1224>}",[1265],[<CIViC source 1265>],[772]
754,MSH2 E483G,2.5,,,['GLU483GLY'],[1837],{<CIViC source 1251>},[],[],[773]
755,TNKS2::PDGFRA Fusion,7.5,,,['TNKS2-PDGFRA'],[1838],{<CIViC source 1266>},[],[],[774]
756,MSH6 V352I,2.5,,,"['VAL352ILE', 'RS730881787']",[1839],{<CIViC source 1251>},[],[],[775]
757,MSH6 R1242C,2.5,,,"['ARG1242CYS', 'RS587779285']",[1840],{<CIViC source 1251>},[],[],[776]
758,SLCO1B1 RS4149056,15.0,,,"['VAL174ALA', 'V174A']",[1841],{<CIViC source 1268>},[],[],[777]
759,SLCO1B1 N130D,15.0,,,"['ASN130ASP', 'RS2306283']",[1842],{<CIViC source 1268>},[],[],[778]
760,TYMS RS34743033,15.0,,,[],[1843],{<CIViC source 1268>},[],[],[779]
761,ACTB::GLI1 Fusion,15.0,"Fusion of the hedgehog pathway component gene GLI1 to the -actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.","Fusion of the hedgehog pathway component gene GLI1 to the -actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.","['T(7;12)(P21-22;Q13-15)', 'ACTB-GLI1']",[1844],{<CIViC source 1269>},"[368, 1269]","[<CIViC source 368>, <CIViC source 1269>]",[780]
762,ERBB3 V855A,2.0,,,['VAL855ALA'],"[10060, 1845]",{<CIViC source 1267>},[],[],[781]
763,FGFR2::BICC1 Fusion,38.0,,,['FGFR2-BICC1'],"[1846, 11610, 1917, 1920, 11629, 1851]","{<CIViC source 4823>, <CIViC source 1270>, <CIViC source 1341>, <CIViC source 4821>}",[],[],[782]
764,FGFR2::AHCYL1 Fusion,23.0,,,['FGFR2-AHCYL1'],"[1847, 1853]",{<CIViC source 1270>},[],[],[783]
765,CDKN2B METHYLATION,20.0,,,[],[1848],{<CIViC source 1271>},[],[],[784]
766,CHEK2 1100DELC,15.0,,,"['THR367METFS', 'RS555607708']","[7235, 1849, 1850]","{<CIViC source 2846>, <CIViC source 1272>}",[],[],[785]
768,CHEK2 I157T,15.0,,,"['ILE157THR', 'I200T', 'RS17879961']",[1852],{<CIViC source 1272>},[],[],[787]
769,CHEK2 IVS2+1G>A,10.0,,,[],[1854],{<CIViC source 1272>},[],[],[788]
770,PTPRD V253I,10.0,,,['VAL253ILE'],[1856],{<CIViC source 1276>},[],[],[792]
771,VHL A56fs (c.164_165insA),5.0,,,"['165INSA', 'C.164_165INSA']",[1857],{<CIViC source 1329>},[],[],[793]
772,VHL E55= (c.165G>A),5.0,,,"['GLU55GLU', 'C.165G>A', 'RS1553619391', 'GLU55=', 'E55E (C.165G>A)']",[1858],{<CIViC source 1278>},[],[],[794]
773,RRM1 Overexpression,2.0,,,[],[1859],{<CIViC source 1279>},[],[],[795]
774,RRM2 OVEREXPRESSION,2.0,,,[],[1860],{<CIViC source 1279>},[],[],[796]
775,POLE Mutation,15.0,,,[],"[1861, 1862, 7469]","{<CIViC source 1281>, <CIViC source 1280>, <CIViC source 2960>}",[],[],[797]
776,MET D1228V,20.0,,,"['ASP1228VAL', 'D1246V', 'ASP1246VAL']","[1864, 1865]",{<CIViC source 1283>},[],[],[798]
777,RB1 Mutation,10.0,,,[],"[1866, 6097, 11899, 11980]","{<CIViC source 1285>, <CIViC source 4963>, <CIViC source 2466>, <CIViC source 4965>}",[],[],[799]
778,SQSTM1::NTRK1 Fusion,45.0,,,['SQSTM1-NTRK1'],"[1868, 2950, 6103, 8865, 11574, 11575]","{<CIViC source 2925>, <CIViC source 4801>, <CIViC source 1288>, <CIViC source 1689>, <CIViC source 2467>, <CIViC source 4802>}",[],[],[800]
779,ETV6::NTRK3 Fusion,314.0,,,['ETV6-NTRK3'],"[6099, 8332, 7496, 6474, 10503, 10841, 10842, 11276, 11277, 11279, 11343, 11344, 11345, 11280, 8917, 10840, 1869, 6395, 6475, 7060, 7418, 7993, 10502, 10692, 10717, 10931, 11848, 11857, 1870, 6473, 11853, 11858, 10421, 10422, 12295, 6930, 8931, 7994, 8930, 10504, 11087]","{<CIViC source 2925>, <CIViC source 4422>, <CIViC source 2495>, <CIViC source 4592>, <CIViC source 3423>, <CIViC source 2579>, <CIViC source 4951>, <CIViC source 3217>, <CIViC source 3419>, <CIViC source 2577>, <CIViC source 4341>, <CIViC source 4670>, <CIViC source 4634>, <CIViC source 4343>, <CIViC source 1289>, <CIViC source 2530>, <CIViC source 3463>, <CIViC source 2978>, <CIViC source 4423>, <CIViC source 4351>, <CIViC source 3742>, <CIViC source 4471>, <CIViC source 4636>, <CIViC source 4633>, <CIViC source 2498>, <CIViC source 2467>, <CIViC source 3218>, <CIViC source 2578>, <CIViC source 2662>, <CIViC source 4372>}",[],[],[801]
780,RUNX1 K83E,10.0,,,"['LYS83GLU', 'K110E', 'RS121912498']",[1871],{<CIViC source 1290>},[],[],[802]
781,RUNX1 Y260*,7.5,,,"['Y260X', 'TYR260TER', 'RS121912499']",[1872],{<CIViC source 1290>},[1290],[<CIViC source 1290>],[803]
782,RUNX1 R135FSX177,10.0,,,[],[1873],{<CIViC source 1290>},[],[],[804]
784,RUNX1 D198Y,7.5,"D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease.","D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease.",['ASP198TYR'],[1875],{<CIViC source 1292>},[2201],[<CIViC source 2201>],[806]
785,RUNX1 A107P,12.5,,,"['A134P', 'ALA134PRO', 'RS74315451']",[1876],{<CIViC source 1294>},[],[],[807]
786,MSH2 Loss,7.5,,,[],[1877],{<CIViC source 1304>},[],[],[808]
787,MSH6 LOSS,7.5,,,[],[1878],{<CIViC source 1304>},[],[],[809]
788,RUNX1 T148HFSX9,5.0,,,"['C.442_449DEL', 'THR148HISFSX9', 'RS587776811']",[1882],{<CIViC source 1310>},[1310],[<CIViC source 1310>],[810]
789,ETV6 R399C,0.0,,,"['ARG399CYS', 'RS724159945']",[1883],{<CIViC source 1315>},[],[],[811]
790,ETV6 R369Q,0.0,,,"['ARG369GLN', 'RS724159946']",[1884],{<CIViC source 1315>},[],[],[812]
791,ETV6 P214L,0.0,,,[],"[1886, 1885, 10048]","{<CIViC source 1316>, <CIViC source 1315>}",[],[],[813]
792,DDX41 R164W,7.5,,,[],[1887],{<CIViC source 1323>},[],[],[814]
793,ERBB2 Y772_A775DUP,0.0,,,"['TYR772_ALA775DUP', 'A775_G776INSYVMA']",[],set(),[],[],[815]
794,ERBB2 G776L,7.5,,,['GLY776LEU'],[1889],{<CIViC source 661>},[],[],[816]
796,ERBB2 M774DELINSWLV,7.5,,,[],[1894],{<CIViC source 729>},[],[],[818]
797,PTPRB Loss-of-function,18.0,,,[],"[10079, 1895]",{<CIViC source 1324>},[],[],[819]
798,VHL A149S (c.445G>T),17.5,,,"['ALA149SER', 'C.445G>T', 'RS587780077']","[1896, 5679, 8437, 9189]","{<CIViC source 1327>, <CIViC source 3522>, <CIViC source 3870>, <CIViC source 2309>}",[],[],[820]
799,HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY,7.5,,,[],[1899],{<CIViC source 1330>},[],[],[821]
800,JAK1 S703I,4.0,,,['SER703ILE'],"[1900, 10051]",{<CIViC source 1332>},[],[],[822]
801,EPCAM 3' Exon Deletion,20.0,,,[],[1901],{<CIViC source 1295>},[],[],[823]
802,MAP2K1 K57T,0.0,,,['LYS57THR'],"[2971, 1904]","{<CIViC source 1336>, <CIViC source 1700>}",[],[],[824]
803,ARAF S490T,2.5,,,['SER490THR'],[1905],{<CIViC source 1336>},[],[],[825]
804,GNAS R201C,5.0,,,"['ARG201CYS', 'R202C', 'RS11554273']",[1906],{<CIViC source 1336>},[],[],[826]
805,FGFR3 Mutation,70.0,,,[],"[7263, 7422, 1910, 7566, 9258, 10397]","{<CIViC source 3970>, <CIViC source 4325>, <CIViC source 3007>, <CIViC source 2859>, <CIViC source 1337>, <CIViC source 2927>}",[],[],[827]
807,VHL M54IFS (c.162_166delGGAGG),2.5,,,"['C.162_166DELGGAGG', 'MET54ILEFS']",[1914],{<CIViC source 1338>},[],[],[829]
808,FGFR3::TACC3 Fusion,22.5,,,['FGFR3-TACC3'],"[1919, 2962, 6409, 9227, 9241, 9242, 11638]","{<CIViC source 2534>, <CIViC source 1341>, <CIViC source 1694>, <CIViC source 4823>, <CIViC source 3447>}",[],[],[830]
809,AKT3 UPREGULATION,0.0,,,[],[],set(),[],[],[835]
810,AKT3 DEPLETION,0.0,,,[],[],set(),[],[],[836]
811,SMO W535L,0.0,,,"['RS121918347', 'TRP535LEU']","[3735, 1928, 1929, 3734, 1926, 1927]","{<CIViC source 1350>, <CIViC source 1942>, <CIViC source 493>, <CIViC source 1348>, <CIViC source 1347>, <CIViC source 1349>}",[],[],[837]
812,PTEN R173C,13.0,,,"['ARG173CYS', 'RS121913293']","[1932, 1935, 1933, 1934, 1930]","{<CIViC source 1354>, <CIViC source 1353>, <CIViC source 1351>, <CIViC source 1356>, <CIViC source 1355>}",[],[],[838]
813,ALK Alternative Transcript (ATI),20.0,A novel ALK transcript (alternative isoform) that initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19 produces three protein products with slight variation in size and all containing the tyrosine kinase domain. ALK(ATI) products have been shown to stimulate oncogenic pathways and promote tumourigenesis in vivo. ALK(ATI) expression was found in 11% of melanomas examined and rarely in other cancer types.,A novel ALK transcript (alternative isoform) that initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19 produces three protein products with slight variation in size and all containing the tyrosine kinase domain. ALK(ATI) products have been shown to stimulate oncogenic pathways and promote tumourigenesis in vivo. ALK(ATI) expression was found in 11% of melanomas examined and rarely in other cancer types.,"['ALK(ATI)', 'ALK INTRON 19 ATI ISOFORM', 'ALK ALTERNATIVE ISOFORM']","[1936, 7421, 7646, 7484]","{<CIViC source 2926>, <CIViC source 1357>}",[],[],[839]
814,BRAF G469R,0.0,,,"['GLY469ARG', 'RS121913357']",[1938],{<CIViC source 1365>},[],[],[840]
815,BRAF G469V,0.0,,,"['GLY469VAL', 'RS121913355']","[1939, 9513]","{<CIViC source 1366>, <CIViC source 3009>}",[],[],[841]
816,BRAF APC,0.0,,,[],[1941],{<CIViC source 1367>},[],[],[842]
817,VHL Exon 1-3 Deletion,17.5,,,[],"[1942, 6426, 6628, 6765, 6788, 6849, 6887, 8120, 8390, 8635, 8746, 8938, 9111, 9401, 10104, 10789, 10994, 5227, 6532]","{<CIViC source 1368>, <CIViC source 3845>, <CIViC source 4222>, <CIViC source 3351>, <CIViC source 2649>, <CIViC source 2192>, <CIViC source 1373>, <CIViC source 4482>, <CIViC source 4404>, <CIViC source 3666>, <CIViC source 2174>, <CIViC source 2610>, <CIViC source 3714>, <CIViC source 3489>, <CIViC source 2650>, <CIViC source 2655>, <CIViC source 2645>, <CIViC source 4029>, <CIViC source 2585>}",[],[],[843]
818,VHL Exon 1 Deletion,20.0,,,[],"[6420, 1943, 6358, 6418, 6419, 6421, 6624, 6692, 6702, 6716, 6759, 6787, 6847, 8124, 8125, 8126, 8127, 8382, 8489, 8744, 8876, 8958, 9039, 9281, 9402, 10103, 10107, 10298, 10970, 5222, 5249, 6422, 6472, 6483, 6668, 8198, 10008]","{<CIViC source 2311>, <CIViC source 1368>, <CIViC source 2627>, <CIViC source 4222>, <CIViC source 3351>, <CIViC source 2649>, <CIViC source 2192>, <CIViC source 3666>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 3777>, <CIViC source 2610>, <CIViC source 4473>, <CIViC source 3714>, <CIViC source 1372>, <CIViC source 2631>, <CIViC source 3489>, <CIViC source 3973>, <CIViC source 2634>, <CIViC source 2650>, <CIViC source 3817>, <CIViC source 3543>, <CIViC source 2215>, <CIViC source 2645>, <CIViC source 2625>, <CIViC source 3429>, <CIViC source 2576>, <CIViC source 4029>, <CIViC source 3383>, <CIViC source 2585>}",[],[],[844]
819,VHL Exon 1-2 Deletion,7.5,,,[],"[1944, 6355, 6424, 6848, 6884, 8121, 8448, 8637, 8743, 8961, 9043, 9117, 10102, 10880, 10972, 5225, 5277, 6515, 6669]","{<CIViC source 4442>, <CIViC source 1368>, <CIViC source 2216>, <CIViC source 4222>, <CIViC source 3351>, <CIViC source 2192>, <CIViC source 3525>, <CIViC source 1373>, <CIViC source 3666>, <CIViC source 3778>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 4473>, <CIViC source 3820>, <CIViC source 3855>, <CIViC source 2650>, <CIViC source 2655>, <CIViC source 2625>, <CIViC source 2585>}",[],[],[845]
820,VHL M1FS (c.1_17del17),2.5,,,"['C.1_17DEL17', 'MET1FS']",[1945],{<CIViC source 1369>},[],[],[846]
821,VHL M1? (c.1-1_20del21),2.5,,,"['MET1 LOSS', 'START LOSS', 'NO INITIATION', 'C.1-1_20DEL21']",[1946],{<CIViC source 1369>},[],[],[847]
822,VHL M1? (c.3G>A),2.5,,,"['MET1 LOSS', 'START LOSS', 'NO INITIATION', 'C.3G>A', 'RS578091032']","[7717, 1947]","{<CIViC source 1370>, <CIViC source 3066>}",[],[],[848]
823,VHL N7D (c.19A>G),2.5,,,"['ASN7ASP', 'C.19A>G', 'RS1311403806']",[1948],{<CIViC source 1371>},[],[],[849]
824,VHL P25L (c.74C>T),7.5,,,"['PRO25LEU', 'C.74C>T', 'RS35460768']","[1949, 4892, 4899, 6732, 7711, 7719, 8385, 8692, 9033, 9497, 9533, 9616, 10748, 4893, 4900, 6647, 6726, 2989]","{<CIViC source 3815>, <CIViC source 2182>, <CIViC source 2639>, <CIViC source 3062>, <CIViC source 4383>, <CIViC source 3533>, <CIViC source 2620>, <CIViC source 2174>, <CIViC source 3067>, <CIViC source 3489>, <CIViC source 2176>, <CIViC source 1710>, <CIViC source 3972>, <CIViC source 2175>, <CIViC source 2181>, <CIViC source 1372>, <CIViC source 2320>, <CIViC source 2640>}",[],[],[850]
825,VHL P59fs (c.173_174insC),7.5,,,"['PRO59FS', 'C.173_174INSC']","[1950, 5173, 10195]","{<CIViC source 2655>, <CIViC source 1373>}",[1373],[<CIViC source 1373>],[851]
826,VHL Y98FS (c.291_310del20),2.5,,,"['C.291_310DEL20', 'TYR98FS']",[1951],{<CIViC source 1369>},[],[],[852]
827,NBN Loss,0.0,,,[],[1954],{<CIViC source 1375>},[],[],[853]
828,HRAS Q61L,0.0,,,"['GLN61LEU', 'RS121913233']","[3848, 1955]","{<CIViC source 458>, <CIViC source 1924>}",[],[],[854]
829,KIT D419del,0.0,,,['ASP419DEL'],"[9295, 1962]",{<CIViC source 1379>},[],[],[855]
830,CREBBP Deletion,0.0,,,[],[1965],{<CIViC source 1381>},[],[],[856]
831,NTRK3 EXPRESSION,0.0,,,[],[1968],{<CIViC source 1383>},[],[],[857]
832,CSF1 Overexpression,0.0,,,[],[1969],{<CIViC source 1384>},[],[],[858]
833,ROS1 Overexpression,0.0,,,[],[1970],{<CIViC source 1385>},[],[],[859]
834,NTRK1 Overexpression,20.0,,,[],[1972],{<CIViC source 1387>},[],[],[860]
835,EGFR T725M,0.0,,,"['THR725MET', 'RS767505234']","[1973, 10037]",{<CIViC source 1388>},[],[],[861]
836,PDGFRA P577S,3.0,,,"['PRO577SER', 'RS1057519811']",[1974],{<CIViC source 1389>},[],[],[862]
837,PDGFRA R841K,3.0,,,"['ARG841LYS', 'RS1057519813']",[1975],{<CIViC source 1389>},[],[],[863]
838,PDGFRA H845Y,3.0,,,"['HIS845TYR', 'RS1057519814']",[1976],{<CIViC source 1389>},[],[],[864]
839,PDGFRA G853D,3.0,,,"['GLY853ASP', 'RS763576329']",[1977],{<CIViC source 1389>},[],[],[865]
840,MITF Overexpression,0.0,,,[],[1978],{<CIViC source 1390>},[],[],[866]
841,MTAP Underexpression,1.0,,,[],[1980],{<CIViC source 1391>},[],[],[867]
842,VPS37A Underexpression,3.0,,,[],[1981],{<CIViC source 1392>},[],[],[868]
843,YAP1 Overexpression,0.0,,,[],"[1982, 1983, 9329]",{<CIViC source 1393>},[],[],[869]
844,BTK T316A,10.0,,,['THR316ALA'],[1985],{<CIViC source 1395>},[],[],[870]
845,ERBB2 T862A,3.0,,,['THR862ALA'],[1986],{<CIViC source 1396>},[],[],[871]
846,ERBB2 V773A,1.0,,,['VAL773ALA'],[1987],{<CIViC source 1396>},[],[],[872]
847,ERBB2 N857S,1.0,,,"['ASN857SER', 'N827S', 'N842S', 'RS28933370']",[1988],{<CIViC source 1396>},[],[],[873]
848,ERBB2 H878Y,1.0,,,['HIS878TYR'],[1989],{<CIViC source 1396>},[],[],[874]
849,ERBB2 Overexpression,77.5,,,[],"[12013, 11444, 4840, 5955, 5956, 7014, 7015, 7078, 7386, 7062, 7063, 7064, 6171, 1992, 6170, 7805, 7806]","{<CIViC source 2470>, <CIViC source 4988>, <CIViC source 4728>, <CIViC source 2144>, <CIViC source 2412>, <CIViC source 2712>, <CIViC source 2741>, <CIViC source 2471>, <CIViC source 2411>, <CIViC source 2713>, <CIViC source 1398>, <CIViC source 3128>, <CIViC source 2915>, <CIViC source 2753>, <CIViC source 2743>}",[],[],[875]
850,GNAS R201,15.0,,,[],[1994],{<CIViC source 1400>},[],[],[876]
851,GNAS c.393T>C,165.0,,,"['I131=', 'RS7121', 'L131=']","[1997, 2892, 2893, 2895, 2896, 2897, 2898, 1996, 1995]","{<CIViC source 1653>, <CIViC source 1652>, <CIViC source 1658>, <CIViC source 1404>, <CIViC source 1659>, <CIViC source 1401>, <CIViC source 1660>, <CIViC source 1405>, <CIViC source 1661>}",[],[],[877]
852,NRAS G12D,7.5,,,"['RS121913237', 'GLY12ASP']","[3693, 2000, 2003, 2002, 1998, 3691, 3692]","{<CIViC source 1919>, <CIViC source 76>, <CIViC source 1407>, <CIViC source 1920>, <CIViC source 1406>}",[],[],[878]
853,TP53 G245S,10.0,,,['RS28934575'],"[4883, 7108, 7114, 10253, 10532, 9456]","{<CIViC source 4356>, <CIViC source 4058>, <CIViC source 2757>, <CIViC source 1696>, <CIViC source 4271>}",[],[],[879]
854,IDH1 R132L,0.0,,,"['RS121913500', 'ARG132LEU']","[2017, 2018, 2021]","{<CIViC source 1425>, <CIViC source 1424>, <CIViC source 1434>}",[],[],[880]
855,PIK3CA E545Q,7.5,,,"['RS104886003', 'GLU545GLN']","[12187, 2213, 2046]","{<CIViC source 1452>, <CIViC source 76>, <CIViC source 4994>}",[],[],[881]
856,PIK3CA E545A,0.0,,,"['RS121913274', 'GLU545ALA']","[12185, 2052]","{<CIViC source 1452>, <CIViC source 4994>}",[],[],[882]
857,PIK3CA E545G,2.0,,,"['RS121913274', 'GLU545GLY']","[12189, 2069, 2070, 2060, 3723, 2063, 3724]","{<CIViC source 1463>, <CIViC source 1447>, <CIViC source 1479>, <CIViC source 4994>, <CIViC source 1452>, <CIViC source 1464>, <CIViC source 1941>}",[],[],[883]
858,PIK3CA E545V,0.0,,,"['RS121913274', 'GLU545VAL']","[2073, 3725, 2072, 3726]","{<CIViC source 1447>, <CIViC source 176>, <CIViC source 1479>}",[],[],[884]
859,PIK3CA Q546K,5.0,,,"['RS121913286', 'GLN546LYS']","[12191, 3727, 2198, 2079]","{<CIViC source 1452>, <CIViC source 76>, <CIViC source 1479>, <CIViC source 4994>}",[],[],[885]
860,PIK3CA Q546E,0.0,,,"['RS121913286', 'GLN546GLU']","[12190, 2090]","{<CIViC source 1452>, <CIViC source 4994>}",[],[],[886]
861,PIK3CA Q546P,0.0,,,['GLN546PRO'],"[12192, 7695]","{<CIViC source 1471>, <CIViC source 4994>}",[],[],[887]
862,PIK3CA Q546R,0.0,,,[],"[7723, 10810]",{<CIViC source 3070>},[],[],[888]
863,PIK3CA Q546L,0.0,,,[],[],set(),[],[],[889]
864,EGFR L747_S752del,0.0,,,"['L747_S752DELLREATS', 'LEU747_SER752DEL']","[2149, 2150, 2151, 2154, 3796, 3798, 2152]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1509>, <CIViC source 1989>, <CIViC source 1988>, <CIViC source 592>, <CIViC source 665>}",[],[],[890]
865,EGFR S752_I759delSPKANKEI,0.0,,,[],[3804],{<CIViC source 1988>},[],[],[891]
867,NRAS Q61H,5.0,,,"['RS121913255', 'GLN61HIS']","[7333, 2172, 2173, 2175, 2176, 3823, 3690, 2171, 2174, 7332]","{<CIViC source 76>, <CIViC source 2899>, <CIViC source 1407>, <CIViC source 1406>, <CIViC source 2900>}",[],[],[893]
868,NRAS G60E,0.0,,,[],[],set(),[],[],[894]
869,NRAS G13C,0.0,,,"['RS121434595', 'GLY13CYS']","[2199, 2202, 2197, 2200]","{<CIViC source 1406>, <CIViC source 1407>}",[],[],[895]
870,NRAS G13R,5.0,,,"['RS121434595', 'GLY13ARG']","[2205, 2208, 3843, 3844, 2204, 3842, 2203]","{<CIViC source 76>, <CIViC source 1951>, <CIViC source 1407>, <CIViC source 1941>, <CIViC source 1406>}",[],[],[896]
871,NRAS G12C,7.5,,,"['RS121913250', 'GLY12CYS']","[2211, 2214, 3845, 3846]","{<CIViC source 76>, <CIViC source 1919>, <CIViC source 1407>}",[],[],[897]
872,NRAS G12S,0.0,,,"['RS121913250', 'GLY12SER']","[2216, 2220, 2215]","{<CIViC source 1406>, <CIViC source 1407>}",[],[],[898]
873,PTEN R130Q,0.0,,,[],[7693],{<CIViC source 1351>},[],[],[899]
874,PTEN G165R,0.0,,,[],[],set(),[],[],[900]
875,ATM T2666A,3.0,,,[],[2221],{<CIViC source 1541>},[],[],[901]
876,ATM L2890V,0.0,,,"['LEU2890VAL', 'RS587779874']",[],set(),[],[],[902]
877,ATM R3008C,3.0,,,[],[2223],{<CIViC source 1541>},[],[],[903]
878,ATM R3008H,0.0,,,[],[],set(),[],[],[904]
879,KRAS A146P,7.5,,,"['RS121913527', 'ALA146PRO']","[3856, 2225, 12068, 12168]","{<CIViC source 5036>, <CIViC source 4031>, <CIViC source 1480>}",[],[],[905]
880,KRAS A146T,21.0,,,"['RS121913527', 'ALA146THR']","[2226, 3858, 3857, 3859, 7165, 2206, 2943, 2944, 7176, 12070, 7167]","{<CIViC source 1632>, <CIViC source 1480>, <CIViC source 5036>, <CIViC source 1920>, <CIViC source 2791>, <CIViC source 1406>, <CIViC source 2792>, <CIViC source 1946>, <CIViC source 2008>}",[],[],[906]
881,KRAS Q61H,10.5,,,"['RS17851045', 'GLN61HIS']","[2227, 3860, 3862, 3863, 2970, 3861, 3865, 7936]","{<CIViC source 1960>, <CIViC source 76>, <CIViC source 1480>, <CIViC source 1700>, <CIViC source 1544>, <CIViC source 1946>, <CIViC source 2008>}",[],[],[907]
882,KRAS Q61L,7.5,,,"['RS121913240', 'GLN61LEU']","[2228, 3866, 3868, 3867]","{<CIViC source 76>, <CIViC source 1480>, <CIViC source 1946>}",[],[],[908]
883,KRAS Q61R,7.5,,,"['RS121913240', 'GLN61ARG']","[2229, 3869, 3870]","{<CIViC source 76>, <CIViC source 1480>}",[],[],[909]
884,KRAS Q61K,7.5,,,"['RS121913238', 'GLN61LYS']","[2230, 3871, 3872]","{<CIViC source 76>, <CIViC source 1480>}",[],[],[910]
885,KRAS G13C,0.0,,,"['RS121913535', 'GLY13CYS']","[3898, 3899, 3900, 3901, 3902]","{<CIViC source 122>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 1937>, <CIViC source 1926>}",[],[],[911]
886,KRAS G12FS,0.0,,,[],[],set(),[],[],[912]
887,KRAS G12S,38.0,,,"['RS121913530', 'GLY12SER']","[2275, 2276, 4005, 4006, 7168, 2273, 2274, 2269, 2270, 2271, 2272, 4000, 4001, 4002, 4003, 4004, 4007, 4008, 4009, 4010, 4011, 4013, 4017, 6314, 6324, 4014, 4018, 4019, 4020, 7178, 2277, 2278, 2279, 4012, 7050]","{<CIViC source 1935>, <CIViC source 1419>, <CIViC source 1421>, <CIViC source 1479>, <CIViC source 1546>, <CIViC source 176>, <CIViC source 1936>, <CIViC source 2028>, <CIViC source 687>, <CIViC source 1414>, <CIViC source 1415>, <CIViC source 1417>, <CIViC source 2802>, <CIViC source 1413>, <CIViC source 1925>, <CIViC source 1960>, <CIViC source 76>, <CIViC source 1932>, <CIViC source 179>, <CIViC source 174>, <CIViC source 1452>, <CIViC source 1422>, <CIViC source 1926>, <CIViC source 1418>, <CIViC source 1931>, <CIViC source 122>, <CIViC source 1420>, <CIViC source 2020>, <CIViC source 1934>, <CIViC source 1416>, <CIViC source 1937>, <CIViC source 1412>, <CIViC source 2019>, <CIViC source 2793>}",[],[],[913]
888,TP53 R306X,0.0,,,[],[],set(),[],[],[914]
889,TP53 E286K,2.0,,,[],[10270],{<CIViC source 4271>},[],[],[915]
890,TP53 R282W,3.0,,,[],"[7531, 10580]","{<CIViC source 2992>, <CIViC source 4356>}",[],[],[916]
891,TP53 C275Y,0.0,,,[],[10578],{<CIViC source 4356>},[],[],[917]
892,TP53 R273L,0.0,,,"['RS28934576', 'ARG273LEU']","[2286, 10538]","{<CIViC source 4356>, <CIViC source 1423>}",[],[],[918]
893,TP53 V272M,0.0,,,[],[],set(),[],[],[919]
894,TP53 R248L,0.0,,,[],[9459],{<CIViC source 4058>},[],[],[920]
895,TP53 R248FS,0.0,,,[],[],set(),[],[],[921]
896,TP53 Y220C,15.5,,,"['RS121912666', 'TYR220CYS']","[2306, 6172, 12297, 4884, 7527, 7107, 7113, 10571, 12296, 9506]","{<CIViC source 2472>, <CIViC source 5181>, <CIViC source 4356>, <CIViC source 4058>, <CIViC source 2992>, <CIViC source 1557>, <CIViC source 2757>, <CIViC source 1696>}",[],[],[922]
897,TP53 R213X,0.0,,,[],[],set(),[],[],[923]
898,TP53 C135W,3.0,,,"['CYS135TRP', 'C3W', 'C96W']",[10557],{<CIViC source 4356>},[],[],[924]
899,STK11 Loss,0.0,,,[],"[2314, 2315, 2316, 2317, 2319, 2320, 2321, 2322, 2313, 2318]","{<CIViC source 1559>, <CIViC source 1560>, <CIViC source 1561>, <CIViC source 1563>, <CIViC source 1562>}",[],[],[925]
900,IDH1 R132FS,0.0,,,[],[],set(),[],[],[926]
901,IDH1 R132G,0.0,,,"['RS121913499', 'ARG132GLY']","[2333, 2334, 2335]","{<CIViC source 1425>, <CIViC source 1432>, <CIViC source 1424>}",[],[],[927]
902,IDH1 R132S,0.0,,,"['RS121913499', 'ARG132SER']","[2336, 2337, 2338, 2340, 4033, 2339]","{<CIViC source 1424>, <CIViC source 1434>, <CIViC source 1425>, <CIViC source 1432>, <CIViC source 1433>}",[],[],[928]
903,PIK3CA R88Q,7.5,,,"['RS121913287', 'ARG88GLN']","[12034, 3832]","{<CIViC source 76>, <CIViC source 4994>}",[],[],[929]
904,PIK3CA N345K,2.5,,,"['RS121913284', 'ASN345LYS']","[12182, 4047]","{<CIViC source 76>, <CIViC source 4994>}",[],[],[930]
905,PIK3CA C420R,15.5,,,"['RS121913272', 'CYS420ARG']","[11275, 12183, 1999, 2078, 2346, 8549]","{<CIViC source 1435>, <CIViC source 76>, <CIViC source 4994>, <CIViC source 2888>, <CIViC source 1468>}",[],[],[931]
906,PIK3CA P539R,0.0,,,[],[],set(),[],[],[932]
907,PIK3CA E542Q,0.0,,,"['RS121913273', 'GLU542GLN']",[2347],{<CIViC source 1452>},[],[],[933]
908,PIK3CA E545D,0.0,,,"['RS121913275', 'GLU545ASP']","[12186, 2353, 4048, 4049, 2354]","{<CIViC source 1452>, <CIViC source 1479>, <CIViC source 176>, <CIViC source 4994>}",[],[],[934]
909,PIK3CA Y1021C,0.0,,,"['RS121913288', 'TYR1021CYS']",[2364],{<CIViC source 1452>},[],[],[935]
910,PIK3CA M1043V,0.0,,,[],[12193],{<CIViC source 4994>},[],[],[936]
911,PIK3CA M1043I,0.0,,,"['RS121913283', 'MET1043ILE']","[12194, 2370]","{<CIViC source 1452>, <CIViC source 4994>}",[],[],[937]
912,PIK3CA H1047Y,0.0,,,"['RS121913281', 'HIS1047TYR']","[12195, 2376]","{<CIViC source 1452>, <CIViC source 4994>}",[],[],[938]
913,PIK3CA G1049S,0.0,,,"['RS121913277', 'GLY1049SER']",[2382],{<CIViC source 1452>},[],[],[939]
914,PIK3CA G1049R,7.5,,,"['RS121913277', 'GLY1049ARG']","[12198, 4054, 3847, 2388]","{<CIViC source 1452>, <CIViC source 76>, <CIViC source 1479>, <CIViC source 4994>}",[],[],[940]
915,PDGFRA V561D,8.5,,,['RS121908586'],"[2474, 2454, 4056, 5347]","{<CIViC source 412>, <CIViC source 965>, <CIViC source 1586>}",[],[],[941]
916,PDGFRA R748G,0.0,,,[],[],set(),[],[],[942]
917,PDGFRA D842_H845DELDIMH,2.0,,,[],[2460],{<CIViC source 412>},[],[],[943]
918,PDGFRA Y849S,0.0,,,[],[],set(),[],[],[944]
919,KIT D496V,0.0,,,[],[],set(),[],[],[945]
920,KIT Y503_F504insAY,2.0,,,[],"[2394, 2484]","{<CIViC source 412>, <CIViC source 844>}",[],[],[946]
921,KIT N512D,0.0,,,[],[],set(),[],[],[947]
922,KIT K550_W557del,2.0,,,[],"[2395, 4583]","{<CIViC source 2042>, <CIViC source 1589>}",[],[],[948]
923,KIT K550_K558del,5.0,,,"['RS121913234', 'KPMYEVQWK550-558DEL']","[4063, 4062, 2398]","{<CIViC source 965>, <CIViC source 2043>, <CIViC source 1589>}",[],[],[949]
924,KIT P551L,0.0,,,['PRO551LEU'],[2401],{<CIViC source 1589>},[],[],[950]
925,KIT M552_W557DEL,0.0,,,[],[2404],{<CIViC source 1589>},[],[],[951]
926,KIT Y553D,0.0,,,['TYR553ASP'],[2407],{<CIViC source 1589>},[],[],[952]
927,KIT Y553_K558DEL,0.0,,,[],"[4067, 4068, 2410]","{<CIViC source 965>, <CIViC source 2043>, <CIViC source 1589>}",[],[],[953]
928,KIT DEL 554-558,0.0,,,['E554_K558DEL'],"[4073, 2413]","{<CIViC source 2043>, <CIViC source 1589>}",[],[],[954]
929,KIT E554D,0.0,,,['GLU554ASP'],[2416],{<CIViC source 1589>},[],[],[955]
930,KIT V555_Q556DEL,0.0,,,[],[2419],{<CIViC source 1589>},[],[],[956]
931,KIT V555_P573DEL,0.0,,,[],[2422],{<CIViC source 1589>},[],[],[957]
932,KIT W557R,0.0,,,"['RS121913235', 'TRP557ARG']",[2426],{<CIViC source 1589>},[],[],[958]
933,KIT W557G,0.0,,,"['RS121913235', 'TRP557GLY']","[4078, 2428]","{<CIViC source 2043>, <CIViC source 1589>}",[],[],[959]
934,KIT W557T,0.0,,,['TRP557THR'],[2431],{<CIViC source 1589>},[],[],[960]
935,KIT W557_K558del,14.5,,,[],"[4085, 4082, 2434, 4083, 4084, 2481, 4087]","{<CIViC source 1589>, <CIViC source 965>, <CIViC source 192>, <CIViC source 2042>, <CIViC source 412>, <CIViC source 2043>}",[],[],[961]
936,KIT W557_E561del,0.0,,,[],"[4090, 4091, 2437]","{<CIViC source 965>, <CIViC source 2043>, <CIViC source 1589>}",[],[],[962]
937,KIT K558Q,0.0,,,"['LYS558GLN', 'RS1057520031']",[2440],{<CIViC source 1589>},[],[],[963]
938,KIT K558_V559del,5.0,,,[],"[4096, 4095, 2443]","{<CIViC source 965>, <CIViC source 2043>, <CIViC source 1589>}",[],[],[964]
939,KIT K558R,0.0,,,['LYS558ARG'],[2446],{<CIViC source 1589>},[],[],[965]
940,KIT V559DEL,0.0,,,"['VAL559DEL', 'RS121913685']","[4101, 2449]","{<CIViC source 2043>, <CIViC source 1589>}",[],[],[966]
941,KIT V559_V560DEL,0.0,,,['VAL559_VAL560DEL'],"[4105, 2452, 4106]","{<CIViC source 2048>, <CIViC source 2049>, <CIViC source 1589>}",[],[],[967]
942,KIT V559D,11.5,,,"['RS121913517', 'VAL559ASP']","[4108, 4110, 3028, 4107, 4109, 4114, 4592, 3033, 7870, 3029, 4459]","{<CIViC source 1739>, <CIViC source 2049>, <CIViC source 1734>, <CIViC source 2919>, <CIViC source 965>, <CIViC source 1735>, <CIViC source 2042>, <CIViC source 191>, <CIViC source 2043>}",[],[],[968]
943,KIT V559A,0.0,,,"['RS121913517', 'VAL559ALA']",[2455],{<CIViC source 1589>},[],[],[969]
944,KIT V559G,0.0,,,"['RS121913517', 'VAL559GLY']","[4116, 7357, 2458]","{<CIViC source 2050>, <CIViC source 1589>}",[],[],[970]
945,KIT V560D,14.5,,,"['VAL560ASP', 'RS121913521']","[4123, 4124, 4122, 2464, 4127, 4077, 5348]","{<CIViC source 1589>, <CIViC source 965>, <CIViC source 2048>, <CIViC source 2042>, <CIViC source 2051>}",[],[],[971]
946,KIT V560G,5.0,,,"['RS121913521', 'VAL560GLY']","[4129, 4130, 2467, 2470, 4134, 4135, 7394, 7395, 2469, 7396]","{<CIViC source 1589>, <CIViC source 965>, <CIViC source 2042>, <CIViC source 412>, <CIViC source 1994>, <CIViC source 2043>}",[],[],[972]
947,KIT V560FS,0.0,,,[],[],set(),[],[],[973]
948,KIT T574A,0.0,,,['THR574ALA'],[2473],{<CIViC source 1589>},[],[],[974]
949,KIT Q575L,0.0,,,['GLN575LEU'],[2476],{<CIViC source 1589>},[],[],[975]
950,KIT P577L,0.0,,,['PRO577LEU'],[2482],{<CIViC source 1589>},[],[],[976]
951,KIT D579del,5.0,,,"['ASP579DEL', 'RS1060502543']","[4143, 7252, 4142, 2485]","{<CIViC source 965>, <CIViC source 1589>, <CIViC source 2043>, <CIViC source 2856>}",[],[],[977]
952,KIT K642E,10.0,,,"['RS121913512', 'LYS642GLU']","[4147, 2889, 4145, 4146, 7397, 7398, 2472]","{<CIViC source 192>, <CIViC source 2056>, <CIViC source 1922>, <CIViC source 2042>, <CIViC source 412>, <CIViC source 1649>}",[],[],[978]
953,KIT T661I,0.0,,,['THR661ILE'],"[2491, 2492, 2489, 2490]","{<CIViC source 1601>, <CIViC source 1602>, <CIViC source 1587>, <CIViC source 1603>}",[],[],[979]
954,KIT S692L,0.0,,,"['SER692LEU', 'RS757733297']","[2493, 2496, 2497, 2494, 2495]","{<CIViC source 82>, <CIViC source 1602>, <CIViC source 1603>, <CIViC source 1601>, <CIViC source 1587>}",[],[],[980]
955,KIT Q694K,0.0,,,['GLN694LYS'],"[2498, 2501, 2502, 2499, 2500]","{<CIViC source 82>, <CIViC source 1602>, <CIViC source 1603>, <CIViC source 1601>, <CIViC source 1587>}",[],[],[981]
956,KIT H697Y,0.0,,,[],[],set(),[],[],[982]
957,KIT D816H,7.5,,,"['ASP816HIS', 'RS121913506']","[2923, 4151, 4152, 4153, 4154, 7409, 6957]","{<CIViC source 2049>, <CIViC source 62>, <CIViC source 2682>, <CIViC source 2042>, <CIViC source 1994>}",[],[],[983]
958,KIT D816Y,0.0,,,"['RS121913506', 'ASP816TYR']","[4155, 4156]","{<CIViC source 2049>, <CIViC source 2042>}",[],[],[984]
959,KIT D816FS,0.0,,,[],[],set(),[],[],[985]
960,KIT D820Y,14.5,,,"['ASP820TYR', 'RS1057519710']","[2886, 2887, 4589, 2888]","{<CIViC source 2045>, <CIViC source 1593>, <CIViC source 1647>, <CIViC source 1648>}",[],[],[986]
961,KIT N822H,2.0,,,[],[2445],{<CIViC source 412>},[],[],[987]
962,KIT N822K,0.0,,,[],[],set(),[],[],[988]
963,KIT Y823D,7.5,,,"['TYR823ASP', 'RS1057519761']",[2919],{<CIViC source 62>},[],[],[989]
964,KIT A829P,8.0,,,"['RS1057519713', 'ALA829PRO']","[7413, 7415, 5862]",{<CIViC source 2042>},[],[],[990]
966,BRAF G469A,5.0,,,"['RS121913355', 'GLY469ALA']","[4182, 5965, 4183, 4184, 10514, 10515]","{<CIViC source 1953>, <CIViC source 4354>, <CIViC source 2414>, <CIViC source 2006>, <CIViC source 1946>}",[],[],[992]
967,BRAF G469E,6.0,The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.,The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.,['RS121913355'],"[7861, 6003, 6004]","{<CIViC source 337>, <CIViC source 3143>}",[337],[<CIViC source 337>],[993]
968,EGFR R108K,3.0,,,['ARG108LYS'],[4186],{<CIViC source 1608>},[],[],[994]
969,EGFR T263P,3.0,,,['THR263PRO'],"[10068, 4187]",{<CIViC source 1608>},[],[],[995]
970,EGFR A289V,3.0,,,"['RS149840192', 'ALA289VAL']","[10069, 4188]",{<CIViC source 1608>},[],[],[996]
971,EGFR G598V,3.0,,,['RS139236063'],"[10067, 8235, 10066, 8234, 8236, 8261, 8284]","{<CIViC source 3377>, <CIViC source 1608>}",[],[],[997]
972,EGFR G719C,0.0,,,['RS28929495'],[],set(),[],[],[998]
973,EGFR G719A,5.0,,,"['RS121913428', 'GLY719ALA']","[4195, 2508, 4196, 4194, 4193, 6181]","{<CIViC source 1501>, <CIViC source 1987>, <CIViC source 1503>, <CIViC source 2473>, <CIViC source 2067>}",[],[],[999]
974,EGFR G729R,0.0,,,[],[],set(),[],[],[1000]
975,EGFR V742A,0.0,,,['RS121913466'],"[4214, 4197, 5819]","{<CIViC source 1503>, <CIViC source 1528>}",[],[],[1001]
976,EGFR E746_A750del,19.5,,,"['RS121913421', 'E746_A750DELELREA']","[2510, 2511, 2515, 2516, 4205, 4206, 4207, 4215, 4198, 2513, 2514, 2518, 4199, 4202, 4203, 4204, 4208, 4216, 4642, 5945, 5946, 2625]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1509>, <CIViC source 2071>, <CIViC source 1510>, <CIViC source 665>, <CIViC source 1991>, <CIViC source 1230>, <CIViC source 592>, <CIViC source 1988>, <CIViC source 2074>, <CIViC source 2070>, <CIViC source 1331>, <CIViC source 1992>, <CIViC source 2067>}",[],[],[1002]
977,EGFR E746_T751>I,5.0,,,[],"[2522, 2523, 2527, 2528, 4211, 4209, 2526]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1509>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 1988>, <CIViC source 665>}",[],[],[1003]
978,EGFR E746_T751delinsA,0.0,,,"['E746_T751>A', 'RS121913425', 'GLU746_THR751DELINSALA']","[2531, 2532, 2533, 4221, 4222]","{<CIViC source 1519>, <CIViC source 1988>, <CIViC source 1612>, <CIViC source 1331>, <CIViC source 1521>}",[],[],[1004]
979,EGFR E746V,0.0,,,[],"[2535, 2536, 2540, 2541, 2539]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1005]
980,EGFR L747_A750delinsP,0.0,,,['L747_A750>P'],"[2545, 2546, 2550, 2551, 2549]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1006]
981,EGFR L747_T751delLREAT,0.0,,,[],"[2554, 2588, 2589, 2590, 2603]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1007]
982,EGFR L747_T751delinsQ,0.0,,,['L747_T751>Q'],"[2556, 2557, 2561, 2562, 2560]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1008]
983,EGFR E746_S752delinsD,0.0,,,"['RS121913423', 'E746_S752>D']","[2566, 2567, 2571, 2572, 2570]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1009]
984,EGFR L747_T751delinsP,0.0,,,['L747_T751>P'],"[2576, 2577, 2578, 2581, 2582, 2580]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 1502>, <CIViC source 592>, <CIViC source 665>}",[],[],[1010]
985,EGFR L747_P753>Q,0.0,,,[],"[2594, 2595, 2599, 2600, 2598]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 592>, <CIViC source 665>}",[],[],[1011]
986,EGFR L747_P753delinsS,7.5,,,['RS121913438'],"[2605, 2606, 2610, 2611, 4270, 6005, 2609, 4266, 4267, 5944]","{<CIViC source 1358>, <CIViC source 1508>, <CIViC source 1510>, <CIViC source 2359>, <CIViC source 1230>, <CIViC source 592>, <CIViC source 1528>, <CIViC source 665>, <CIViC source 2067>}",[],[],[1012]
987,EGFR D761N,0.0,,,['RS121913418'],"[5821, 5820]",{<CIViC source 1528>},[],[],[1013]
988,EGFR V774L,0.0,,,[],[],set(),[],[],[1014]
989,EGFR R776H,0.0,,,[],[],set(),[],[],[1015]
990,EGFR G810S,0.0,,,['RS121913230'],"[5824, 5825]",{<CIViC source 1528>},[],[],[1016]
991,EGFR R831H,3.0,,,"['RS150036236', 'ARG831HIS']","[2618, 2619, 2620, 4279]","{<CIViC source 1519>, <CIViC source 2081>, <CIViC source 1612>, <CIViC source 1521>}",[],[],[1017]
992,EGFR L838V,2.0,,,['LEU838VAL'],[4280],{<CIViC source 1528>},[],[],[1018]
993,EGFR K860E,0.0,,,[],[],set(),[],[],[1019]
994,EGFR L861Q,10.5,,,['RS121913444'],"[7858, 4514, 3802, 9679, 10070, 4299, 5826]","{<CIViC source 1608>, <CIViC source 1503>, <CIViC source 2134>, <CIViC source 1528>, <CIViC source 3144>}",[],[],[1020]
997,ABL1 G250E,0.0,,,"['RS121913453', 'GLY250GLU']",[],set(),[],[],[1023]
1002,ABL1 F317L,0.0,,,"['RS121913451', 'F336L', 'PHE317LEU', 'RS1057519773']",[],set(),[],[],[1028]
1003,ABL1 M351T,0.0,,,"['RS121913457', 'M370T', 'MET351THR', 'MET370THR']",[],set(),[],[],[1029]
1005,NOTCH1 L1600P,0.0,,,['LEU1600PRO'],[2690],{<CIViC source 1630>},[],[],[1031]
1006,NOTCH1 L1574P,0.0,,,['LEU1574PRO'],[2691],{<CIViC source 1630>},[],[],[1032]
1007,NOTCH1 R1598P,0.0,,,[],[],set(),[],[],[1033]
1008,NOTCH1 L1678P,0.0,,,['LEU1678PRO'],[5921],{<CIViC source 2394>},[],[],[1034]
1009,TP53 V272L,0.0,,,[],[9495],{<CIViC source 4058>},[],[],[1035]
1010,TP53 G245D,3.0,,,[],"[10254, 10533]","{<CIViC source 4356>, <CIViC source 4271>}",[],[],[1036]
1011,PTEN R130G,0.0,,,[],[9760],{<CIViC source 3875>},[],[],[1037]
1012,PTEN R130L,0.0,,,[],[],set(),[],[],[1038]
1013,PTEN R173H,0.0,,,[],[],set(),[],[],[1039]
1014,TP53 R342X,0.0,,,[],[],set(),[],[],[1040]
1015,TP53 E298X,0.0,,,[],[],set(),[],[],[1041]
1016,TP53 E286V,0.0,,,[],[],set(),[],[],[1042]
1017,TP53 E285K,0.0,,,[],[9496],{<CIViC source 4058>},[],[],[1043]
1018,TP53 D281E,3.0,,,[],"[10260, 9466]","{<CIViC source 4058>, <CIViC source 4271>}",[],[],[1044]
1019,TP53 D281G,0.0,,,[],[7122],{<CIViC source 2758>},[],[],[1045]
1020,TP53 D281H,0.0,,,[],[],set(),[],[],[1046]
1021,TP53 R280S,0.0,,,[],[],set(),[],[],[1047]
1022,TP53 R280I,0.0,,,[],[],set(),[],[],[1048]
1023,TP53 P278S,3.0,,,[],"[4419, 10233]","{<CIViC source 1924>, <CIViC source 4271>}",[],[],[1049]
1024,TP53 A276V,3.0,,,['ALA276VAL'],[10232],{<CIViC source 4271>},[],[],[1050]
1025,TP53 C275G,0.0,,,[],[],set(),[],[],[1051]
1026,TP53 R273G,0.0,,,[],[],set(),[],[],[1052]
1027,TP53 F270S,3.0,,,[],[10576],{<CIViC source 4356>},[],[],[1053]
1028,TP53 R267P,0.0,,,[],[],set(),[],[],[1054]
1029,TP53 G266R,3.0,,,[],"[10230, 10573, 9463]","{<CIViC source 4058>, <CIViC source 4356>, <CIViC source 4271>}",[],[],[1055]
1030,TP53 D259Y,0.0,,,[],[],set(),[],[],[1056]
1031,TP53 I255S,0.0,,,[],[],set(),[],[],[1057]
1032,TP53 T253P,0.0,,,[],[],set(),[],[],[1058]
1033,TP53 G245V,0.0,,,[],[],set(),[],[],[1059]
1034,TP53 G244S,3.0,,,[],"[7336, 10252]","{<CIViC source 2903>, <CIViC source 4271>}",[],[],[1060]
1035,TP53 M243V,0.0,,,[],[],set(),[],[],[1061]
1036,TP53 C242F,0.0,,,['RS121912655'],[9451],{<CIViC source 4058>},[],[],[1062]
1037,TP53 C242S,0.0,,,[],[9452],{<CIViC source 4058>},[],[],[1063]
1038,TP53 C242Y,3.0,,,['RS121912655'],"[10251, 9453]","{<CIViC source 4058>, <CIViC source 4271>}",[],[],[1064]
1039,TP53 S241C,0.0,,,[],[9439],{<CIViC source 4058>},[],[],[1065]
1040,TP53 M237I,7.0,,,['MET237ILE'],"[8064, 7528, 4885, 7979, 9507]","{<CIViC source 3269>, <CIViC source 4058>, <CIViC source 2992>, <CIViC source 3203>, <CIViC source 1696>}",[],[],[1066]
1041,TP53 Y236C,0.0,,,"['TYR236CYS', 'Y104C', 'Y197C']",[],set(),[],[],[1067]
1042,TP53 Y234C,0.0,,,"['TYR234CYS', 'Y102C', 'Y195C', 'RS587780073']",[2745],{<CIViC source 1423>},[],[],[1068]
1043,TP53 Y234S,0.0,,,[],[],set(),[],[],[1069]
1044,TP53 V216L,0.0,,,[],[],set(),[],[],[1070]
1045,TP53 V216M,0.0,,,[],[],set(),[],[],[1071]
1046,TP53 R213L,0.0,,,[],[],set(),[],[],[1072]
1047,TP53 V203L,0.0,,,[],[],set(),[],[],[1073]
1048,TP53 L201F,0.0,,,[],[],set(),[],[],[1074]
1049,TP53 E198*,0.0,,,"['E198X', 'GLU198TER']",[],set(),[],[],[1075]
1050,TP53 R196X,0.0,,,[],[],set(),[],[],[1076]
1051,TP53 I195N,0.0,,,[],[],set(),[],[],[1077]
1052,TP53 L194P,0.0,,,[],[9505],{<CIViC source 4058>},[],[],[1078]
1053,TP53 H193R,0.0,,,[],[],set(),[],[],[1079]
1054,TP53 P190L,0.0,,,[],[9504],{<CIViC source 4058>},[],[],[1080]
1055,TP53 H179Q,0.0,,,[],[],set(),[],[],[1081]
1056,TP53 H179R,3.0,,,[],"[10530, 9444]","{<CIViC source 4058>, <CIViC source 4356>}",[],[],[1082]
1057,TP53 H179Y,3.0,,,[],[10247],{<CIViC source 4271>},[],[],[1083]
1058,TP53 H179D,0.0,,,[],[],set(),[],[],[1084]
1059,TP53 R174W,0.0,,,[],[9494],{<CIViC source 4058>},[],[],[1085]
1060,TP53 V173L,0.0,,,[],[9442],{<CIViC source 4058>},[],[],[1086]
1061,TP53 Y163C,0.0,,,[],[10563],{<CIViC source 4356>},[],[],[1087]
1062,TP53 M160K,0.0,,,[],[],set(),[],[],[1088]
1063,TP53 A159V,0.0,,,['ALA159VAL'],[],set(),[],[],[1089]
1064,TP53 A159S,0.0,,,['ALA159SER'],[],set(),[],[],[1090]
1065,TP53 R158P,0.0,,,[],[],set(),[],[],[1091]
1066,TP53 V157F,4.0,,,"['RS121912654', 'VAL157PHE']",[4887],{<CIViC source 1696>},[],[],[1092]
1067,TP53 P151H,3.0,,,[],"[10222, 9493]","{<CIViC source 4058>, <CIViC source 4271>}",[],[],[1093]
1068,TP53 C141W,0.0,,,[],[9500],{<CIViC source 4058>},[],[],[1094]
1069,TP53 K132R,0.0,,,[],[],set(),[],[],[1095]
1070,TP53 K132T,0.0,,,[],[],set(),[],[],[1096]
1071,TP53 K132E,0.0,,,[],[],set(),[],[],[1097]
1072,TP53 K132Q,0.0,,,[],[],set(),[],[],[1098]
1073,TP53 L130V,0.0,,,[],[9499],{<CIViC source 4058>},[],[],[1099]
1074,TP53 Y103X,0.0,,,[],[],set(),[],[],[1100]
1075,TP53 V73L,0.0,,,[],[],set(),[],[],[1101]
1076,TP53 D42Y,0.0,,,[],[],set(),[],[],[1102]
1077,KRAS Q61P,0.0,,,"['RS121913240', 'GLN61PRO']","[2806, 2805, 7160, 4421, 7177]","{<CIViC source 1632>, <CIViC source 2801>, <CIViC source 1480>, <CIViC source 2786>}",[],[],[1103]
1078,KRAS Q61E,0.0,,,"['RS121913238', 'GLN61GLU']","[2808, 2807, 4422]","{<CIViC source 1632>, <CIViC source 1480>}",[],[],[1104]
1079,KRAS Q61FS,0.0,,,[],"[2809, 2810, 4423]","{<CIViC source 1632>, <CIViC source 1480>}",[],[],[1105]
1080,BRAF G464V,5.0,,,"['RS121913348', 'GLY464VAL']","[5964, 2811]","{<CIViC source 1635>, <CIViC source 2414>}",[],[],[1106]
1081,BRAF D594N,0.0,,,"['ASP594ASN', 'RS397516896']","[2813, 2814, 2815, 2816, 2817, 7557, 8820]","{<CIViC source 1488>, <CIViC source 352>, <CIViC source 1485>, <CIViC source 3009>, <CIViC source 3005>, <CIViC source 1491>, <CIViC source 1492>}",[],[],[1107]
1082,TP53 R282L,0.0,,,"['ARG282LEU', 'R150L', 'R243L', 'RS730882008']",[2818],{<CIViC source 1557>},[],[],[1108]
1083,TP53 R213P,0.0,,,"['ARG213PRO', 'R174P', 'R81P', 'RS587778720']",[2819],{<CIViC source 1557>},[],[],[1109]
1084,TP53 H178D,0.0,,,['RS68130327'],[],set(),[],[],[1110]
1085,TP53 C135Y,0.0,,,[],[9441],{<CIViC source 4058>},[],[],[1111]
1086,TP53 R337L,0.0,,,[],[9544],{<CIViC source 4078>},[],[],[1112]
1087,TP53 K132N,0.0,,,[],[],set(),[],[],[1113]
1088,TP53 A161T,3.0,,,[],[9286],{<CIViC source 3976>},[],[],[1114]
1089,TP53 Y126N,0.0,,,[],[],set(),[],[],[1115]
1090,TP53 C176Y,0.0,,,[],[10566],{<CIViC source 4356>},[],[],[1116]
1091,TP53 Q331X,0.0,,,[],[],set(),[],[],[1117]
1092,TP53 E180X,0.0,,,[],[],set(),[],[],[1118]
1093,KRAS L19F,0.0,,,[],[],set(),[],[],[1119]
1094,KRAS K117N,0.0,,,"['LYS117ASN', 'RS770248150']",[4425],{<CIViC source 2098>},[],[],[1120]
1095,BRAF F595L,0.0,,,"['F203L', 'F23L', 'RS121913341', 'PHE595LEU']",[4426],{<CIViC source 2099>},[],[],[1121]
1096,CSF1R Y571D,0.0,,,[],[],set(),[],[],[1122]
1097,DNMT3A W893S,0.0,,,[],[],set(),[],[],[1123]
1098,DNMT3A R882P,0.0,,,[],[7228],{<CIViC source 68>},[],[],[1124]
1099,DNMT3A R882H,0.0,,,[],[7232],{<CIViC source 2844>},[],[],[1125]
1100,DNMT3A R882C,0.0,,,[],[],set(),[],[],[1126]
1101,NOTCH1 F1592S,0.0,,,['PHE1592SER'],[2821],{<CIViC source 1630>},[],[],[1127]
1102,DNMT3A K577X,0.0,,,[],[],set(),[],[],[1128]
1103,KIT P834L,0.0,,,[],[],set(),[],[],[1129]
1104,KRAS Q22K,0.0,,,[],[],set(),[],[],[1130]
1105,NOTCH1 Q2459X,0.0,,,[],[],set(),[],[],[1131]
1106,NOTCH1 Q2409X,0.0,,,[],[],set(),[],[],[1132]
1107,NOTCH1 Q2391X,0.0,,,[],[],set(),[],[],[1133]
1108,NOTCH1 Q2315X,0.0,,,[],[],set(),[],[],[1134]
1109,NOTCH1 C1685F,0.0,,,[],[],set(),[],[],[1135]
1110,NOTCH1 V1676D,0.0,,,[],[],set(),[],[],[1136]
1111,NOTCH1 Y1619N,0.0,,,[],[],set(),[],[],[1137]
1112,NOTCH1 I1616N,0.0,,,[],[],set(),[],[],[1138]
1113,NOTCH1 Q1614K,0.0,,,[],[],set(),[],[],[1139]
1114,NOTCH1 L1600Q,0.0,,,['LEU1600GLN'],[2822],{<CIViC source 1630>},[],[],[1140]
1115,NOTCH1 R1586P,0.0,,,[],[],set(),[],[],[1141]
1116,NOTCH1 L1585R,0.0,,,['LEU1585ARG'],[2823],{<CIViC source 1630>},[],[],[1142]
1117,NOTCH1 V1577A,0.0,,,['VAL1577ALA'],[2824],{<CIViC source 1630>},[],[],[1143]
1118,NOTCH1 V1577E,0.0,,,['VAL1577GLU'],[2825],{<CIViC source 1630>},[],[],[1144]
1119,NOTCH1 L1574Q,0.0,,,['LEU1574GLN'],[2826],{<CIViC source 1630>},[],[],[1145]
1120,JAK3 V674A,0.0,,,[],[],set(),[],[],[1146]
1121,JAK3 A572V,0.0,,,[],[],set(),[],[],[1147]
1122,JAK3 E183G,0.0,,,[],[],set(),[],[],[1148]
1123,JAK3 R172Q,0.0,,,[],[],set(),[],[],[1149]
1124,JAK3 L156P,0.0,,,[],[],set(),[],[],[1150]
1125,PIK3CA H1047L,12.5,,,"['RS121913279', 'HIS1047LEU']","[12197, 2827, 2828, 4433, 4432, 9485, 2089, 8009, 8019]","{<CIViC source 1463>, <CIViC source 1435>, <CIViC source 76>, <CIViC source 3929>, <CIViC source 1479>, <CIViC source 4994>, <CIViC source 1464>}",[],[],[1151]
1127,ATM P292R,0.0,,,['PRO292ARG'],[],set(),[],[],[1153]
1128,ATM M1FS,0.0,,,[],[],set(),[],[],[1154]
1129,ATM K293*,3.0,,,"['K293X', 'LYS293TER', 'RS1057516442']",[2832],{<CIViC source 1541>},[],[],[1155]
1130,ATM R2459C,0.0,,,[],[2833],{<CIViC source 1541>},[],[],[1156]
1131,ATM Q984E,0.0,,,['GLN984GLU'],[2834],{<CIViC source 1541>},[],[],[1157]
1132,ATM F1025L,3.0,,,['PHE1025LEU'],[2835],{<CIViC source 1541>},[],[],[1158]
1133,ATM Q1084*,0.0,,,"['Q1084X', 'GLN1084TER']",[2836],{<CIViC source 1541>},[],[],[1159]
1134,ATM D1930V,2.0,,,"['M72L', 'ASP1930VAL', 'MET72LEU']",[2837],{<CIViC source 1541>},[],[],[1160]
1135,ATM R2034P,0.0,,,['ARG2034PRO'],[2838],{<CIViC source 1541>},[],[],[1161]
1136,ATM E2187*,3.0,,,"['E2187X', 'GLU2187TER']",[2839],{<CIViC source 1541>},[],[],[1162]
1137,ATM L2427P,3.0,,,['LEU2427PRO'],[2840],{<CIViC source 1541>},[],[],[1163]
1138,ATM F2732V,3.0,,,"['PHE2732VAL', 'RS876659619']",[2841],{<CIViC source 1541>},[],[],[1164]
1139,ATM R777FS,0.0,,,[],[2842],{<CIViC source 1541>},[],[],[1165]
1140,ATM K468FS,2.0,,,['LYS468GLUFS'],[2843],{<CIViC source 1541>},[],[],[1166]
1141,ATM V1268FS,0.0,,,[],[2844],{<CIViC source 1541>},[],[],[1167]
1142,ATM D1682H,3.0,,,"['RS121434217', 'ASP1682HIS']",[2845],{<CIViC source 1541>},[],[],[1168]
1143,ATM A2062V,3.0,,,['ALA2062VAL'],[2846],{<CIViC source 1541>},[],[],[1169]
1144,ATM R1575H,0.0,,,"['ARG1575HIS', 'RS550552791']",[2847],{<CIViC source 1541>},[],[],[1170]
1145,ATM A2274T,0.0,,,"['ALA2274THR', 'RS567060474']",[2848],{<CIViC source 1541>},[],[],[1171]
1146,ATM C2488Y,3.0,,,"['CYS2488TYR', 'RS774281788']",[2849],{<CIViC source 1541>},[],[],[1172]
1148,NOTCH1 F1592C,0.0,,,[],[2852],{<CIViC source 1630>},[],[],[1174]
1149,NRAS G12V,0.0,,,['RS121913237'],[4465],{<CIViC source 2007>},[],[],[1175]
1150,PIK3CA R38H,0.0,,,[],[],set(),[],[],[1176]
1151,PIK3CA E453K,0.0,,,[],[],set(),[],[],[1177]
1152,PIK3CA R93W,5.0,,,['ARG93TRP'],[4467],{<CIViC source 76>},[],[],[1178]
1153,PIK3CA G106V,0.0,,,[],[],set(),[],[],[1179]
1154,PIK3CA R108H,0.0,,,[],[],set(),[],[],[1180]
1155,EGFR R776C,0.0,,,"['R723C', 'R731C']","[4468, 5818]",{<CIViC source 1528>},[],[],[1181]
1156,EGFR S784F,0.0,,,['SER784PHE'],"[4469, 4235, 5822, 5823]","{<CIViC source 1503>, <CIViC source 1528>, <CIViC source 2065>}",[],[],[1182]
1157,ABL1 E292V,2.0,,,"['E311V', 'GLU311VAL', 'GLU292VAL']",[],set(),[],[],[1183]
1159,BRAF T599I,0.0,,,[],[],set(),[],[],[1185]
1160,BRAF N581S,5.0,,,"['N189S', 'N9S', 'RS121913370']",[5967],{<CIViC source 2414>},[],[],[1186]
1161,EGFR A864T,0.0,,,"['A811T', 'A819T', 'ALA864THR', 'RS1171287261']",[4495],{<CIViC source 1528>},[],[],[1187]
1162,EGFR N826S,0.0,,,"['N773S', 'N781S']",[4496],{<CIViC source 1528>},[],[],[1188]
1163,EGFR V851A,0.0,,,[],[],set(),[],[],[1189]
1164,AKT1 E49K,0.0,,,[],[],set(),[],[],[1190]
1165,AKT1 L52R,0.0,,,[],[10762],{<CIViC source 4398>},[],[],[1191]
1166,AKT1 D323H,0.0,,,[],[],set(),[],[],[1192]
1167,BRAF R462I,0.0,,,[],[],set(),[],[],[1193]
1168,BRAF I463S,0.0,,,[],[],set(),[],[],[1194]
1169,BRAF G464E,0.0,,,[],[],set(),[],[],[1195]
1170,BRAF G466A,0.0,,,"['G74A', 'RS121913351', 'GLY466ALA']",[4499],{<CIViC source 1946>},[],[],[1196]
1171,BRAF E586K,0.0,,,[],[],set(),[],[],[1197]
1172,BRAF A728V,2.0,,,['A336V'],[7614],{<CIViC source 1161>},[],[],[1198]
1173,BRAF V600G,0.0,,,[],[7618],{<CIViC source 3026>},[],[],[1199]
1174,PIK3CA R38C,0.0,,,[],[],set(),[],[],[1200]
1175,PIK3CA G106R,0.0,,,[],[],set(),[],[],[1201]
1176,PIK3CA K111E,0.0,,,[],[],set(),[],[],[1202]
1177,PIK3CA P124L,0.0,,,[],[],set(),[],[],[1203]
1178,PIK3CA E365K,0.0,,,[],[],set(),[],[],[1204]
1179,PIK3CA E453Q,0.0,,,[],[],set(),[],[],[1205]
1180,KIT S501_A502INSAY,0.0,,,[],"[2855, 2856, 2858, 2859, 4501, 4502, 4503, 4504, 4506, 4507]","{<CIViC source 2106>, <CIViC source 2049>, <CIViC source 1585>, <CIViC source 965>, <CIViC source 2105>, <CIViC source 1588>, <CIViC source 846>, <CIViC source 2042>, <CIViC source 844>, <CIViC source 2051>}",[],[],[1206]
1181,KRAS R164Q,3.0,,,"['ARG164GLN', 'RS758575947']",[7935],{<CIViC source 1544>},[],[],[1207]
1182,KRAS T74P,0.0,,,[],[],set(),[],[],[1208]
1183,PDGFRA V533E,0.0,,,[],[],set(),[],[],[1209]
1184,PDGFRA S566_E571>R,0.0,,,[],[],set(),[],[],[1210]
1185,PDGFRA N659S,0.0,,,[],[],set(),[],[],[1211]
1186,PDGFRA H650Q,0.0,,,[],[],set(),[],[],[1212]
1187,PDGFRA H845_N848>P,0.0,,,[],[],set(),[],[],[1213]
1188,EGFR E746_T751delinsVA,0.0,,,['E746_T751>VA'],[2860],{<CIViC source 1510>},[],[],[1214]
1189,ERBB2 S310Y,0.0,,,[],"[12232, 11489]","{<CIViC source 4879>, <CIViC source 1160>}",[],[],[1215]
1190,ERBB2 P707S,0.0,,,[],[],set(),[],[],[1216]
1191,ERBB3 A232V,0.0,,,[],"[9629, 9630, 9631]",{<CIViC source 1644>},[],[],[1217]
1192,ERBB3 P262H,0.0,,,['P203H'],"[9671, 9672, 9673]",{<CIViC source 1644>},[],[],[1218]
1193,ERBB3 T389K,0.0,,,[],[],set(),[],[],[1219]
1194,ERBB3 Q809R,0.0,,,[],[],set(),[],[],[1220]
1195,ERBB3 S846I,0.0,,,[],[],set(),[],[],[1221]
1196,ERBB3 E928G,0.0,,,[],[],set(),[],[],[1222]
1197,ERBB3 V104L,0.0,,,[],[],set(),[],[],[1223]
1198,ERBB3 R426W,0.0,,,[],[],set(),[],[],[1224]
1199,ERBB3 V1035D,0.0,,,[],[],set(),[],[],[1225]
1200,AKT2 D324H,0.0,,,[],[],set(),[],[],[1226]
1201,AKT3 E17K,3.0,,,"['RS397514606', 'GLU17LYS']",[4521],{<CIViC source 1941>},[],[],[1227]
1202,AKT3 L51R,0.0,,,[],[],set(),[],[],[1228]
1203,AKT3 D320H,0.0,,,[],[],set(),[],[],[1229]
1204,ABL1 L384M,5.5,,,"['L403M', 'LEU403MET', 'LEU384MET']",[6276],{<CIViC source 1622>},[],[],[1230]
1206,ABL1 L387F,7.0,,,"['L406F', 'LEU406PHE', 'LEU387PHE']",[],set(),[],[],[1232]
1207,ABL1 G398R,5.0,,,"['G417R', 'GLY398ARG', 'GLY417ARG']",[],set(),[],[],[1233]
1208,PIK3CA K111N,13.0,,,"['LYS111ASN', 'RS1057519934']","[2085, 2866, 8550, 8183, 8662, 8011, 8020]","{<CIViC source 1435>, <CIViC source 2486>, <CIViC source 1468>}",[],[],[1234]
1209,PIK3CA I391M,5.0,,,"['ILE391MET', 'RS2230461']","[2867, 8663]",{<CIViC source 1468>},[],[],[1235]
1210,BRCA1 M1V,0.0,,,"['MET1VAL', 'RS80357287']",[],set(),[],[],[1236]
1211,BRCA1 M1I,0.0,,,['MET1ILE'],[],set(),[],[],[1237]
1212,BRCA1 C61G,0.0,,,"['CYS61GLY', 'RS28897672']",[],set(),[],[],[1238]
1213,BRCA1 C64Y,0.0,,,"['CYS64TYR', 'RS55851803']",[],set(),[],[],[1239]
1214,BRCA1 R71G,0.0,,,"['ARG71GLY', 'RS80357382']",[],set(),[],[],[1240]
1215,BRCA1 R71K,0.0,,,"['ARG71LYS', 'RS80356913']",[],set(),[],[],[1241]
1216,BRCA1 R1495M,0.0,,,"['ARG1495MET', 'R1516M']",[],set(),[],[],[1242]
1217,BRCA1 E1559K,0.0,,,"['GLU1559LYS', 'RS80356988']",[],set(),[],[],[1243]
1218,BRCA1 D1692N,0.0,,,"['ASP1692ASN', 'RS80187739']",[],set(),[],[],[1244]
1219,BRCA1 R1443*,0.0,,,"['R1443X', 'ARG1443TER', 'RS41293455']",[],set(),[],[],[1245]
1220,BRCA1 Q1467*,0.0,,,"['Q1467X', 'GLN1467TER', 'RS397509171']",[2878],{<CIViC source 1328>},[],[],[1246]
1221,BRCA2 M1R,0.0,,,"['MET1ARG', 'RS80358547']",[2879],{<CIViC source 1328>},[],[],[1247]
1222,BRCA2 M1I,0.0,,,"['MET1ILE', 'RS80358650']",[2880],{<CIViC source 1328>},[],[],[1248]
1223,BRCA2 V159M,0.0,,,"['VAL159MET', 'RS80358702']",[2881],{<CIViC source 1328>},[],[],[1249]
1224,BRCA2 V211L,0.0,,,[],[2882],{<CIViC source 1328>},[],[],[1250]
1225,BRCA2 V211I,0.0,,,[],[2883],{<CIViC source 1328>},[],[],[1251]
1226,BRCA2 R2336P,0.0,,,"['ARG2336PRO', 'RS28897743']",[2884],{<CIViC source 1328>},[],[],[1252]
1227,BRCA2 R2336H,0.0,,,"['RS28897743', 'ARG2336HIS']",[],set(),[],[],[1253]
1228,TP53 V143A,0.0,,,['VAL143ALA'],"[2890, 2891, 7118]","{<CIViC source 1651>, <CIViC source 1650>, <CIViC source 2758>}",[],[],[1254]
1229,MGMT Underexpression,65.0,,,[],"[2899, 2901, 2903, 2902, 2904]","{<CIViC source 1667>, <CIViC source 1665>, <CIViC source 1666>, <CIViC source 1662>, <CIViC source 1664>}",[],[],[1255]
1230,TERT Overexpression,0.0,,,[],[2900],{<CIViC source 1663>},[],[],[1256]
1231,RRM1 Underexpression,100.0,,,[],"[2905, 5530, 6436, 5506, 5508, 5599, 6434, 10143, 12043, 12044, 6432, 8024]","{<CIViC source 2263>, <CIViC source 2287>, <CIViC source 4233>, <CIViC source 2539>, <CIViC source 2543>, <CIViC source 1009>, <CIViC source 2538>, <CIViC source 2257>, <CIViC source 2253>, <CIViC source 2541>, <CIViC source 1668>}",[],[],[1257]
1232,PTPRF EXPRESSION,0.0,,,[],"[2909, 2910]",{<CIViC source 1672>},[],[],[1258]
1233,AEBP1 Overexpression,0.0,,,[],[2911],{<CIViC source 1673>},[],[],[1259]
1234,RET C609Y,20.0,"There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.","There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.",['CYS609TYR'],"[2913, 2914]","{<CIViC source 1676>, <CIViC source 1675>}","[1676, 1677]","[<CIViC source 1676>, <CIViC source 1677>]",[1260]
1235,MDM2 Amplification,0.0,,,[],"[2916, 5518, 9023]","{<CIViC source 3811>, <CIViC source 1679>, <CIViC source 2259>}",[],[],[1261]
1236,MDM4 EXPRESSION,0.0,,,[],[2917],{<CIViC source 1679>},[],[],[1262]
1237,KIT N822K,29.5,,,"['ASN822LYS', 'RS121913514']","[2918, 4595, 4166, 4168, 7408, 7414, 4167, 4169, 6958, 7370, 7371, 2448, 7379]","{<CIViC source 2049>, <CIViC source 62>, <CIViC source 2045>, <CIViC source 2913>, <CIViC source 2682>, <CIViC source 2042>, <CIViC source 412>}",[],[],[1263]
1238,KIT C809G,7.5,,,['CYS809GLY'],[2920],{<CIViC source 62>},[],[],[1264]
1239,KIT D820A,7.5,,,['ASP820ALA'],"[2921, 4164, 7411]","{<CIViC source 62>, <CIViC source 2042>}",[],[],[1265]
1240,KIT D820G,7.5,,,"['ASP820GLY', 'RS121913682']","[2922, 4165, 7412]","{<CIViC source 62>, <CIViC source 2042>}",[],[],[1266]
1241,KIT T670I,21.5,,,"['THR670ILE', 'RS121913516']","[2924, 4509, 7416, 7417, 4510, 7399]","{<CIViC source 1735>, <CIViC source 62>, <CIViC source 2042>}",[],[],[1267]
1242,MDM4 Amplification,0.0,,,[],[2925],{<CIViC source 1679>},[],[],[1268]
1243,BRAF Amplification,17.5,,,[],[2929],{<CIViC source 1681>},[],[],[1269]
1244,MAP2K1 F53L,0.0,,,['PHE53LEU'],[2930],{<CIViC source 1681>},[],[],[1270]
1245,ROS1 G2032R,2.5,,,"['GLY2032ARG', 'RS1057519788', 'GLY2026ARG', 'GLY2028ARG', 'G2026R', 'G2028R']","[7684, 4614, 7687, 2934, 4615, 4616]","{<CIViC source 3049>, <CIViC source 866>, <CIViC source 3050>, <CIViC source 868>, <CIViC source 2113>, <CIViC source 381>}",[],[],[1271]
1246,MAP2K1 K57N,17.0,,,"['LYS57ASN', 'RS869025608']","[2935, 7709, 2936]","{<CIViC source 1685>, <CIViC source 1684>, <CIViC source 3060>}",[],[],[1272]
1247,CTAG1B Overexpression,15.0,,,[],[2940],{<CIViC source 1687>},[],[],[1273]
1248,CTAG2 Overexpression,15.0,,,[],[2941],{<CIViC source 1687>},[],[],[1274]
1249,ALK L1198F,0.0,,,"['LEU1198PHE', 'RS751306825']","[4782, 2942]",{<CIViC source 567>},[],[],[1275]
1250,SMO Amplification,0.0,,,[],"[2945, 2946]",{<CIViC source 1688>},[],[],[1276]
1251,v::NTRK3 Fusion,105.0,,,['Fusion (multiple partners)'],"[11125, 6568, 2949, 2954]","{<CIViC source 4345>, <CIViC source 1689>, <CIViC source 1690>, <CIViC source 2445>}",[],[],[1277]
1252,LMNA::NTRK1 Fusion,115.0,,,['LMNA-NTRK1'],"[6391, 8900, 2960, 6100, 8878, 8902, 8904, 9588, 11576, 11577, 11578, 11650, 2955, 8903, 10095, 11346, 11354, 11349, 8901]","{<CIViC source 4804>, <CIViC source 2978>, <CIViC source 1691>, <CIViC source 2528>, <CIViC source 3715>, <CIViC source 1693>, <CIViC source 4824>, <CIViC source 4803>, <CIViC source 3734>, <CIViC source 3736>, <CIViC source 1289>, <CIViC source 3735>, <CIViC source 2467>, <CIViC source 4361>}",[],[],[1278]
1253,BRD4 Overexpression,0.0,,,[],"[9315, 2957, 9316]","{<CIViC source 1692>, <CIViC source 3995>, <CIViC source 3996>}",[],[],[1279]
1254,NTRK1 Amplification,17.5,,,[],"[2958, 12120, 10170]","{<CIViC source 2978>, <CIViC source 1689>, <CIViC source 5084>}",[],[],[1280]
1255,NTRK3 Amplification,5.0,,,[],[2959],{<CIViC source 1689>},[],[],[1281]
1257,CDK2 CYTOPLASMIC EXPRESSION,0.0,,,[],[2969],{<CIViC source 1699>},[],[],[1283]
1258,DCC EXPRESSION,15.0,,,[],[2972],{<CIViC source 1701>},[],[],[1284]
1259,CTNNB1 T41A,55.0,,,"['THR41ALA', 'RS121913412']","[2973, 5070, 6078, 3044, 6050, 6048]","{<CIViC source 1702>, <CIViC source 2444>, <CIViC source 2443>, <CIViC source 2449>, <CIViC source 2195>}",[],[],[1285]
1260,CTNNB1 S45F,80.0,,,"['SER45PHE', 'RS121913409']","[6086, 2974, 5071, 6084, 6085, 9788, 2976, 6083, 11018, 6049, 6082]","{<CIViC source 2454>, <CIViC source 4504>, <CIViC source 1702>, <CIViC source 2444>, <CIViC source 4170>, <CIViC source 2453>, <CIViC source 2455>, <CIViC source 2456>, <CIViC source 2457>, <CIViC source 2195>}",[],[],[1286]
1261,CTNNB1 S45P,35.0,,,"['SER45PRO', 'RS121913407']","[2975, 5072, 3043]","{<CIViC source 2195>, <CIViC source 1702>}",[],[],[1287]
1262,JAK3 M511I,0.0,,,"['MET511I', 'RS752661478']",[2977],{<CIViC source 1703>},[],[],[1288]
1263,JAK3 V722I,0.0,,,"['VAL722ILE', 'RS3213409']",[2978],{<CIViC source 1704>},[],[],[1289]
1264,JAK3 S61C,0.0,,,['SER61CYS'],[2979],{<CIViC source 1704>},[],[],[1290]
1265,JAK1 P429S,0.0,,,['PRO429SER'],[2980],{<CIViC source 1705>},[],[],[1291]
1266,JAK1 W690*,0.0,,,"['W690X', 'TRP690TER']",[2981],{<CIViC source 1705>},[],[],[1292]
1267,ARID1A Loss,7.0,,,[],"[2983, 6399, 2982, 7328]","{<CIViC source 2533>, <CIViC source 1706>, <CIViC source 2895>, <CIViC source 1707>}",[],[],[1293]
1268,VHL W8* (c.24G>A),2.5,,,"['TRP8X', 'TRP8STOP', 'C.24G>A']",[2986],{<CIViC source 1371>},[],[],[1294]
1269,ALK F1245V,7.5,,,"['PHE1245VAL', 'RS281864720']","[3048, 2987]","{<CIViC source 1689>, <CIViC source 1752>}",[],[],[1295]
1270,CTNNB1 Activating Mutation,4.0,,,[],[2988],{<CIViC source 1709>},[],[],[1296]
1272,BRAF T599dup,0.0,,,['THR599DUP'],"[2990, 9789]","{<CIViC source 1711>, <CIViC source 4171>}",[],[],[1298]
1273,MERTK OVEREXPRESSION,3.0,,,[],[2991],{<CIViC source 1717>},[],[],[1299]
1274,TP53 CONSERVED DOMAIN MUT,15.0,"This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292.","This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292.",[],[2993],{<CIViC source 1423>},"[1423, 1743, 1744]","[<CIViC source 1423>, <CIViC source 1744>, <CIViC source 1743>]",[1300]
1275,AKT3 Overexpression,7.0,,,[],"[1922, 3001, 6261, 1923]","{<CIViC source 1941>, <CIViC source 1344>, <CIViC source 1345>}",[],[],[1301]
1276,FLT3 D835V,19.0,,,"['RS121909646', 'ASP835VAL']","[3011, 3002, 4022, 4023, 3012, 3007, 3008, 3031, 3032, 3034, 3009, 3010, 8518]","{<CIViC source 1729>, <CIViC source 1737>, <CIViC source 1738>, <CIViC source 2031>, <CIViC source 1731>, <CIViC source 1740>, <CIViC source 3336>, <CIViC source 367>, <CIViC source 2030>, <CIViC source 152>, <CIViC source 1732>}",[],[],[1302]
1277,MYC Overexpression,9.0,,,[],"[5505, 3003, 10151]","{<CIViC source 1730>, <CIViC source 4241>, <CIViC source 2252>}",[],[],[1303]
1278,ERBB2 L755P,2.0,,,['LEU755PRO'],"[11754, 12107, 3005]","{<CIViC source 4879>, <CIViC source 1396>, <CIViC source 4792>}",[],[],[1304]
1279,ERBB2 T798M,2.0,,,['THR798MET'],[3006],{<CIViC source 1396>},[],[],[1305]
1280,TP53 Overexpression,65.0,,,[],"[2799, 2697, 3013, 8945]","{<CIViC source 3772>, <CIViC source 1557>, <CIViC source 1423>}",[],[],[1306]
1281,TP53 ALTERATION,60.0,P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.,P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.,[],"[2771, 3014, 9594]","{<CIViC source 4077>, <CIViC source 1423>}",[1423],[<CIViC source 1423>],[1307]
1282,ERBB2 L768S,0.0,,,"['LEU768SER', 'RS56366519']",[3020],{<CIViC source 1297>},[],[],[1308]
1283,ERBB2 L638S,0.0,,,[],[3021],{<CIViC source 1297>},[],[],[1309]
1284,ERBB2 V773,0.0,,,[],[3022],{<CIViC source 1297>},[],[],[1310]
1285,ERBB2 V773L,0.0,,,['VAL773LEU'],[3023],{<CIViC source 1297>},[],[],[1311]
1286,ERBB2 K753E,0.0,,,['LYS753GLU'],[3024],{<CIViC source 1297>},[],[],[1312]
1287,ERBB2 L753E,0.0,,,[],[3025],{<CIViC source 1297>},[],[],[1313]
1288,ERBB2 K755S,0.0,,,[],[3026],{<CIViC source 1297>},[],[],[1314]
1290,KIT V559,0.0,,,[],[3030],{<CIViC source 1736>},[],[],[1316]
1291,NRAS G13V,0.0,,,[],[3035],{<CIViC source 1741>},[],[],[1317]
1292,TP53 L3 Domain Mutation,0.0,,,[],"[3036, 3041]","{<CIViC source 1746>, <CIViC source 1555>}",[],[],[1318]
1293,GNAS R201H,5.0,,,[],"[3045, 8676]","{<CIViC source 1749>, <CIViC source 3652>}",[],[],[1319]
1294,ERBB2 NON-AMPLIFICATION,0.0,,,[],[3052],{<CIViC source 1755>},[],[],[1320]
1295,HRAS G12D,0.0,,,[],"[3698, 3697]","{<CIViC source 1924>, <CIViC source 1923>}",[],[],[1387]
1296,BRAF V600A,0.0,,,[],[],set(),[],[],[1388]
1297,EGFR L747_E749DELLRE,0.0,,,[],[],set(),[],[],[1389]
1298,EGFR E884K,0.0,,,['GLU884LYS'],[3813],{<CIViC source 1995>},[],[],[1390]
1299,HRAS Q61R,0.0,,,[],[3849],{<CIViC source 1924>},[],[],[1391]
1300,HRAS Q61K,0.0,,,[],[3850],{<CIViC source 1924>},[],[],[1392]
1301,HRAS G13R,0.0,,,[],[3853],{<CIViC source 2004>},[],[],[1393]
1302,HRAS G12V,0.0,,,[],"[3854, 3855, 9087]","{<CIViC source 2007>, <CIViC source 1923>, <CIViC source 3838>}",[],[],[1394]
1303,KRAS G13R,0.0,,,"['RS121913535', 'GLY13ARG']","[3905, 3906, 3907]","{<CIViC source 122>, <CIViC source 1926>, <CIViC source 1479>}",[],[],[1395]
1304,KRAS G13S,0.0,,,"['RS121913535', 'GLY13SER']","[3908, 3909, 3910]","{<CIViC source 122>, <CIViC source 1926>, <CIViC source 1479>}",[],[],[1396]
1305,FLT3 D835E,0.0,,,[],[4021],{<CIViC source 2030>},[],[],[1397]
1306,MAP2K2 F57C,0.0,,,['RS121434497'],[4030],{<CIViC source 1951>},[],[],[1398]
1307,PIK3CA D549N,0.0,,,"['ASP549ASN', 'RS1057519699']",[4053],{<CIViC source 1479>},[],[],[1399]
1308,FGFR3 K650E,10.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['RS78311289', 'LYS650GLU', 'K652E', 'LYS652GLU', 'TDII']","[4055, 10365, 10370, 10086, 10355, 10393, 10407, 10493, 10653, 10391, 10376, 10381, 10383]","{<CIViC source 4344>, <CIViC source 4337>, <CIViC source 1491>, <CIViC source 4142>, <CIViC source 4333>, <CIViC source 4323>, <CIViC source 3456>, <CIViC source 4330>, <CIViC source 4322>, <CIViC source 4364>, <CIViC source 4326>}",[],[],[1400]
1309,KIT P577_D579DELPYD,0.0,,,[],[],set(),[],[],[1401]
1310,KIT D816G,0.0,,,['ASP816GLY'],"[4158, 4157, 7410]","{<CIViC source 2058>, <CIViC source 2042>}",[],[],[1402]
1311,KIT N822K,0.0,,,['RS121913514'],[],set(),[],[],[1403]
1312,BRAF V600L,0.0,,,[],[7619],{<CIViC source 3026>},[],[],[1404]
1313,BRAF V600M,0.0,,,['RS121913378'],[7631],{<CIViC source 3026>},[],[],[1405]
1314,EGFR V689M,0.0,,,[],[],set(),[],[],[1406]
1315,EGFR L692F,0.0,,,[],[],set(),[],[],[1407]
1316,EGFR P699S,0.0,,,[],[],set(),[],[],[1408]
1317,EGFR N700D,0.0,,,[],[],set(),[],[],[1409]
1318,EGFR Q701X,0.0,,,[],[],set(),[],[],[1410]
1319,EGFR L703V,0.0,,,[],[],set(),[],[],[1411]
1320,EGFR E709K,0.0,,,['GLU709LYS'],"[9642, 9650]",{<CIViC source 4099>},[],[],[1412]
1321,EGFR E709Q,0.0,,,[],[6037],{<CIViC source 2437>},[],[],[1413]
1322,EGFR E709A,0.0,,,[],[],set(),[],[],[1414]
1323,EGFR E709G,0.0,,,[],[],set(),[],[],[1415]
1324,EGFR E709D,0.0,,,[],[],set(),[],[],[1416]
1325,EGFR L718R,0.0,,,[],[],set(),[],[],[1417]
1326,EGFR L718FS,0.0,,,[],[],set(),[],[],[1418]
1327,EGFR G719R,0.0,,,[],[],set(),[],[],[1419]
1328,EGFR G719D,7.5,,,"['RS121913428', 'GLY719ASP']",[4210],{<CIViC source 1503>},[],[],[1420]
1329,EGFR G721D,0.0,,,[],[],set(),[],[],[1421]
1330,EGFR L730F,0.0,,,[],[],set(),[],[],[1422]
1331,EGFR W731R,0.0,,,[],[],set(),[],[],[1423]
1332,EGFR W731X,0.0,,,[],[],set(),[],[],[1424]
1333,EGFR P733L,0.0,,,[],[],set(),[],[],[1425]
1334,EGFR E734K,0.0,,,[],[],set(),[],[],[1426]
1335,EGFR G735S,0.0,,,[],[],set(),[],[],[1427]
1336,EGFR I744T,0.0,,,[],[],set(),[],[],[1428]
1337,EGFR I744M,0.0,,,[],[],set(),[],[],[1429]
1338,EGFR K745R,0.0,,,[],[],set(),[],[],[1430]
1339,EGFR E746K,0.0,,,[],[10038],{<CIViC source 1388>},[],[],[1431]
1340,EGFR E746_T751delELREAT,0.0,,,['RS121913426'],[],set(),[],[],[1432]
1341,EGFR E746_S752>A,0.0,,,[],[4227],{<CIViC source 1988>},[],[],[1433]
1342,EGFR L747X,0.0,,,[],[],set(),[],[],[1434]
1343,EGFR L747_T751>S,0.0,,,[],[],set(),[],[],[1435]
1344,EGFR L747FS,0.0,,,[],[],set(),[],[],[1436]
1345,EGFR A750P,0.0,,,[],[],set(),[],[],[1437]
1346,EGFR S752Y,0.0,,,[],[],set(),[],[],[1438]
1347,EGFR N756D,0.0,,,[],[],set(),[],[],[1439]
1348,EGFR E758G,0.0,,,[],[],set(),[],[],[1440]
1349,EGFR I759N,0.0,,,[],[],set(),[],[],[1441]
1350,EGFR V765M,0.0,,,[],[],set(),[],[],[1442]
1351,EGFR S768N,0.0,,,['RS121913465'],"[4271, 4272]","{<CIViC source 1993>, <CIViC source 2078>}",[],[],[1443]
1352,EGFR V769L,0.0,,,[],[],set(),[],[],[1444]
1353,EGFR D770_N771insSVD,0.0,,,"['S768_D770DUP', 'ASP770_ASN771INSSERVALASP']","[5941, 4275, 4640]","{<CIViC source 1991>, <CIViC source 1230>}",[],[],[1445]
1354,EGFR H773_V774insH,0.0,,,[],"[5940, 4276]",{<CIViC source 1230>},[],[],[1446]
1355,EGFR G810D,0.0,,,[],[],set(),[],[],[1447]
1356,EGFR N826K,0.0,,,[],[],set(),[],[],[1448]
1357,EGFR L828F,0.0,,,[],[],set(),[],[],[1449]
1358,EGFR D830N,0.0,,,[],[],set(),[],[],[1450]
1359,EGFR D830Y,0.0,,,[],[],set(),[],[],[1451]
1360,EGFR R832C,0.0,,,[],[],set(),[],[],[1452]
1361,EGFR R836C,0.0,,,[],[],set(),[],[],[1453]
1362,EGFR R836L,0.0,,,[],[],set(),[],[],[1454]
1363,EGFR D837N,0.0,,,[],[],set(),[],[],[1455]
1364,EGFR D837Y,0.0,,,[],[],set(),[],[],[1456]
1365,EGFR L838P,7.5,,,['LEU838PRO'],[4252],{<CIViC source 1503>},[],[],[1457]
1366,EGFR A839T,0.0,,,[],[],set(),[],[],[1458]
1367,EGFR A839S,0.0,,,[],[],set(),[],[],[1459]
1368,EGFR A840V,0.0,,,[],[],set(),[],[],[1460]
1369,EGFR R841M,0.0,,,[],[],set(),[],[],[1461]
1370,EGFR L844M,0.0,,,[],[],set(),[],[],[1462]
1371,EGFR T847I,5.0,,,[],[4260],{<CIViC source 1503>},[],[],[1463]
1372,EGFR P848Q,0.0,,,[],[],set(),[],[],[1464]
1373,EGFR P848L,0.0,,,['RS148934350'],[4281],{<CIViC source 1991>},[],[],[1465]
1374,EGFR V851I,5.0,,,[],[4264],{<CIViC source 1503>},[],[],[1466]
1375,EGFR T854A,0.0,,,['THR854ALA'],[4282],{<CIViC source 2084>},[],[],[1467]
1376,EGFR D855G,0.0,,,[],[],set(),[],[],[1468]
1377,EGFR G857R,0.0,,,[],[],set(),[],[],[1469]
1378,EGFR G857V,0.0,,,[],[],set(),[],[],[1470]
1379,EGFR L858M,0.0,,,[],[],set(),[],[],[1471]
1380,EGFR L858FS,0.0,,,[],[],set(),[],[],[1472]
1381,EGFR L858Q,0.0,,,"['RS121434568', 'LEU858GLN']",[10040],{<CIViC source 1388>},[],[],[1473]
1382,EGFR A859T,0.0,,,['ALA859THR'],"[4297, 4296]","{<CIViC source 1991>, <CIViC source 2087>}",[],[],[1474]
1383,EGFR A859V,0.0,,,[],[],set(),[],[],[1475]
1384,EGFR L861M,0.0,,,[],[],set(),[],[],[1476]
1385,EGFR L861R,7.5,,,['RS121913444'],"[4300, 4669, 10036]","{<CIViC source 1503>, <CIViC source 1388>, <CIViC source 2088>}",[],[],[1477]
1386,EGFR G863D,0.0,,,[],[],set(),[],[],[1478]
1387,EGFR A864V,0.0,,,[],[],set(),[],[],[1479]
1388,EGFR E865K,0.0,,,[],[],set(),[],[],[1480]
1389,EGFR E868K,0.0,,,[],[],set(),[],[],[1481]
1390,EGFR E868G,3.0,,,['GLU868GLY'],[4301],{<CIViC source 2081>},[],[],[1482]
1391,EGFR Y869X,0.0,,,[],[],set(),[],[],[1483]
1392,EGFR A871T,0.0,,,[],[],set(),[],[],[1484]
1393,EGFR A871G,0.0,,,[],[],set(),[],[],[1485]
1394,EGFR A871V,0.0,,,[],[],set(),[],[],[1486]
1396,ABL1 L387M,15.0,,,['LEU387MET'],[],set(),[],[],[1488]
1397,HRAS G13V,0.0,,,[],[4418],{<CIViC source 1924>},[],[],[1489]
1398,KIT V459A,0.0,,,[],[],set(),[],[],[1490]
1399,KRAS A59T,0.0,,,"['RS121913528', 'ALA59THR']",[],set(),[],[],[1491]
1400,ALK F1174C,0.0,,,['PHE1174CYS'],[4430],{<CIViC source 924>},[],[],[1492]
1401,ALK T1151M,0.0,,,"['T49M', 'RS113994091']",[4431],{<CIViC source 2040>},[],[],[1493]
1402,ABL1 T277A,0.0,,,['THR277ALA'],[],set(),[],[],[1494]
1403,ABL1 S438C,0.0,,,"['S457C', 'SER438CYS', 'SER457CYS']",[4435],{<CIViC source 1532>},[],[],[1495]
1404,ABL1 E450G,0.0,,,['GLU450GLY'],[4437],{<CIViC source 1532>},[],[],[1496]
1405,KIT P551_E554delPMYE,6.0,,,[],"[4454, 4453, 4456, 4125, 4455]","{<CIViC source 2042>, <CIViC source 965>, <CIViC source 2043>, <CIViC source 846>}",[],[],[1497]
1406,KIT W557_V559insC,0.0,,,[],"[4460, 4461]","{<CIViC source 965>, <CIViC source 2043>}",[],[],[1498]
1407,PIK3CA S158L,7.5,,,['SER158LEU'],[4463],{<CIViC source 76>},[],[],[1499]
1408,PIK3CA E81K,5.0,,,"['GLU81LYS', 'RS1057519929']","[9483, 4464]","{<CIViC source 76>, <CIViC source 3929>}",[],[],[1500]
1409,PIK3CA G1049A,0.0,,,['GLY1049ALA'],[4466],{<CIViC source 1479>},[],[],[1501]
1410,EGFR G666V,0.0,,,[],[],set(),[],[],[1502]
1411,FBXW7 R505C,0.0,,,[],[4470],{<CIViC source 2102>},[],[],[1503]
1412,FBXW7 R505H,0.0,,,[],[4471],{<CIViC source 2102>},[],[],[1504]
1413,ALK F1174V,0.0,,,"['PHE1174VAL', 'RS281864719']",[4473],{<CIViC source 2103>},[],[],[1505]
1414,ABL1 L298V,2.5,,,"['L317V', 'LEU298VAL']","[4476, 4475]","{<CIViC source 1996>, <CIViC source 1532>}",[],[],[1506]
1415,ABL1 F311I,0.0,,,"['F330I', 'RS137853304']",[6248],{<CIViC source 1622>},[],[],[1507]
1416,ABL1 L364I,0.0,,,"['L383I', 'LEU364ILE']",[],set(),[],[],[1508]
1417,ABL1 E453Q,5.0,,,"['E472Q', 'GLU453GLN']",[],set(),[],[],[1509]
1418,ARID1A Q456*,0.0,,,['Q73X'],[4487],{<CIViC source 1706>},[],[],[1510]
1419,EGFR S768_D770dup,7.5,,,[],"[4490, 9224]","{<CIViC source 3023>, <CIViC source 2067>}",[],[],[1511]
1420,EGFR D770_N771insG,7.5,,,['ASP770_ASN771INSGLY'],[9223],{<CIViC source 3023>},[],[],[1512]
1421,EGFR H773_V774insNPH,7.5,,,[],[4493],{<CIViC source 1230>},[],[],[1513]
1422,EGFR D770_N771insGL,10.0,,,['RS397517111'],[4494],{<CIViC source 1230>},[],[],[1514]
1423,EGFR A763_Y764insFQEA,5.0,,,['RS397517106'],"[5939, 4647, 4648, 9225, 11320, 4497, 5951]","{<CIViC source 2116>, <CIViC source 4656>, <CIViC source 472>, <CIViC source 1230>, <CIViC source 3023>}",[],[],[1515]
1424,EGFR EGFRVIII,0.0,,,[],[11116],{<CIViC source 4458>},[],[],[1516]
1425,KRAS G13V,5.0,,,"['RS397517040', 'GLY13VAL']","[4508, 6312, 6321]","{<CIViC source 2019>, <CIViC source 176>}",[],[],[1517]
1426,PDGFRA D842_M844del,0.0,,,"['ASP842_MET844DEL', 'DIM842-844DEL']",[4511],{<CIViC source 2041>},[],[],[1518]
1427,EGFR L747FS*10,0.0,,,[],[],set(),[],[],[1519]
1428,MTOR Q2223K,0.0,,,[],[4522],{<CIViC source 2107>},[],[],[1520]
1429,CDKN2A W110*,0.0,,,"['W59X', 'RS121913389', 'W110X']",[4523],{<CIViC source 932>},[],[],[1521]
1430,CDKN2A A20P,0.0,,,['ALA20PRO'],"[4524, 9323]","{<CIViC source 3872>, <CIViC source 932>}",[],[],[1522]
1432,ABL1 M343T,2.0,,,"['M362T', 'MET343THR', 'MET362THR']",[],set(),[],[],[1524]
1433,ABL1 F317V,0.0,,,"['F336V', 'RS1057519773']",[4536],{<CIViC source 2093>},[],[],[1525]
1434,ABL1 E279K,7.5,,,"['GLU279LYS', 'E298K']",[],set(),[],[],[1526]
1435,ABL1 Q300R,5.0,,,"['Q319R', 'GLN300ARG', 'GLN319ARG']",[],set(),[],[],[1527]
1436,ABL1 F311L,7.0,,,"['RS137853304', 'F330L', 'PHE311LEU']",[],set(),[],[],[1528]
1437,ABL1 N331S,2.5,,,"['N350S', 'RS144448357', 'ASN331SER', 'ASN350SER']",[],set(),[],[],[1529]
1438,ABL1 L364P,2.5,,,"['L383P', 'LEU364PRO', 'LEU383PRO']",[],set(),[],[],[1530]
1439,ABL1 H396P,18.0,,,"['HIS396PRO', 'H415P']",[],set(),[],[],[1531]
1441,ABL1 I432T,0.0,,,"['ILE432THR', 'I451T', 'ILE451THR']",[],set(),[],[],[1533]
1442,ABL1 E450V,5.0,,,"['E469V', 'GLU450VAL']",[],set(),[],[],[1534]
1443,ABL1 E453K,2.5,,,"['E472K', 'GLU453LYS']",[],set(),[],[],[1535]
1444,ABL1 E453A,5.0,,,"['E472A', 'GLU453ALA']",[],set(),[],[],[1536]
1445,ABL1 P480A,2.5,,,"['P499A', 'PRO480ALA', 'PRO499ALA']",[],set(),[],[],[1537]
1446,ABL1 F486Y,0.0,,,"['F505Y', 'PHE486TYR']","[4569, 4570, 4573]","{<CIViC source 1997>, <CIViC source 1529>, <CIViC source 2001>}",[],[],[1538]
1447,PDGFRA W559_R560DELWR,0.0,,,[],[4574],{<CIViC source 2108>},[],[],[1539]
1448,PDGFRA L579M,0.0,,,['L819M'],[4575],{<CIViC source 2051>},[],[],[1540]
1449,KIT Q556_I571DEL,0.0,,,[],[4576],{<CIViC source 2105>},[],[],[1541]
1450,KIT Y553_W557DELYEVQW,0.0,,,[],[4577],{<CIViC source 2105>},[],[],[1542]
1451,KIT V555_I571DEL,0.0,,,[],[4580],{<CIViC source 2105>},[],[],[1543]
1452,FLT3 E611_F612INS25,0.0,,,[],"[4581, 4582]","{<CIViC source 2109>, <CIViC source 2030>}",[],[],[1544]
1453,KIT K550_W557delKPMYEVQW,0.0,,,[],[],set(),[],[],[1545]
1454,KIT T417_D419DELTYDINSI,0.0,,,[],[4584],{<CIViC source 2049>},[],[],[1546]
1455,KIT D579_H580insIDPTQLPYD,0.0,,,[],[4585],{<CIViC source 2049>},[],[],[1547]
1456,KIT Y570_L576DEL,0.0,,,[],"[4586, 4587]","{<CIViC source 965>, <CIViC source 2043>}",[],[],[1548]
1457,KIT K558delinsNP,3.0,,,[],"[4591, 4594]","{<CIViC source 965>, <CIViC source 2042>}",[],[],[1549]
1458,KIT V560_L576DEL,6.0,,,[],"[4598, 7393, 4061]","{<CIViC source 2043>, <CIViC source 2042>}",[],[],[1550]
1459,KIT V569_L576DEL,0.0,,,[],[4602],{<CIViC source 965>},[],[],[1551]
1460,MAPK1 E278E,0.0,,,['E322E'],[4607],{<CIViC source 525>},[],[],[1552]
1461,ALK L1196Q,0.0,,,['LEU1196GLN'],[4609],{<CIViC source 2110>},[],[],[1553]
1462,ALK L1152P,0.0,,,"['L50P', 'LEU1152PRO']",[4613],{<CIViC source 924>},[],[],[1554]
1463,BRCA1 W1815X,2.0,,,"['W125X', 'W1519X', 'W1550X', 'W1576X', 'W1768X', 'W1836X', 'W306X', 'W48X', 'W632X', 'W664X', 'W673X', 'W711X']",[4623],{<CIViC source 2114>},[],[],[1555]
1464,ALK L1198P,0.0,,,['LEU1198PRO'],[4626],{<CIViC source 78>},[],[],[1556]
1465,ERBB2 G776INSV_G/C,0.0,,,[],[4627],{<CIViC source 1526>},[],[],[1557]
1466,KIT A502_Y503insAY,7.0,,,[],"[4630, 4100, 4505, 7392]","{<CIViC source 965>, <CIViC source 2042>}",[],[],[1558]
1467,KIT D816E,8.0,,,"['D812E', 'ASP816GLU']","[4631, 7401]",{<CIViC source 2042>},[],[],[1559]
1468,SMO D473G,0.0,,,[],[4634],{<CIViC source 493>},[],[],[1560]
1469,SMO D473Y,0.0,,,[],[4635],{<CIViC source 1179>},[],[],[1561]
1470,SMO S278I,0.0,,,[],[4636],{<CIViC source 493>},[],[],[1562]
1471,SMO W281C,0.0,,,[],"[4637, 4638]","{<CIViC source 1942>, <CIViC source 493>}",[],[],[1563]
1472,SMO Q477E,0.0,,,[],[4639],{<CIViC source 493>},[],[],[1564]
1473,EGFR L747_A750INSP,0.0,,,[],[],set(),[],[],[1565]
1474,EGFR D770_N771insGT,0.0,,,['ASP770_ASN771INSGLYTHR'],[4643],{<CIViC source 2116>},[],[],[1566]
1475,EGFR V774_C775insHV,0.0,,,"['VAL774_CYS775INSHISVAL', 'H773_V774DUP']","[4645, 5809]","{<CIViC source 2116>, <CIViC source 1991>}",[],[],[1567]
1476,EGFR V769_D770INSASV,0.0,,,[],[],set(),[],[],[1568]
1477,EGFR D770_N771insNPG,3.0,,,[],"[4491, 4492, 4651, 5947]","{<CIViC source 2064>, <CIViC source 1230>}",[],[],[1569]
1478,SMO L412F,0.0,,,[],"[4654, 4652, 4653]","{<CIViC source 1942>, <CIViC source 2117>, <CIViC source 493>}",[],[],[1570]
1479,EGFR W731L,3.0,,,"['W678L', 'W686L', 'RS397517089']",[4655],{<CIViC source 2081>},[],[],[1571]
1480,EGFR E734Q,3.0,,,"['RS121913420', 'E681Q', 'E689Q']",[4656],{<CIViC source 2081>},[],[],[1572]
1481,EGFR T785A,3.0,,,"['T732A', 'T740A']",[4657],{<CIViC source 2081>},[],[],[1573]
1482,EGFR C797Y,3.0,,,"['C744Y', 'C752Y', 'CYS797TYR']",[4658],{<CIViC source 2081>},[],[],[1574]
1483,EGFR Y801H,3.0,,,"['Y748H', 'Y756H']",[4659],{<CIViC source 2081>},[],[],[1575]
1484,SMO V321M,0.0,,,[],"[4660, 4661, 4662]","{<CIViC source 1942>, <CIViC source 2118>, <CIViC source 493>}",[],[],[1576]
1485,EGFR E709_T710>D,0.0,,,[],"[4663, 3793]","{<CIViC source 1503>, <CIViC source 2119>}",[],[],[1577]
1486,EGFR V769A,0.0,,,"['V716A', 'V724A']",[4664],{<CIViC source 2120>},[],[],[1578]
1487,EGFR A767_V769dupASV,7.5,,,[],"[4665, 9220, 4666, 5949, 5948]","{<CIViC source 3023>, <CIViC source 1993>, <CIViC source 1230>}",[],[],[1579]
1488,EGFR L747_S752delinsQ,7.5,,,"['DEL L747-S752INSQ', 'LEU747_SER752DELINSGLN']",[4667],{<CIViC source 1509>},[],[],[1580]
1489,EGFR N771>GY,0.0,,,[],[4671],{<CIViC source 1993>},[],[],[1581]
1490,EGFR P546S,0.0,,,"['P493S', 'P501S']",[4672],{<CIViC source 2121>},[],[],[1582]
1491,SMO W281L,0.0,,,[],[4674],{<CIViC source 2118>},[],[],[1583]
1492,SMO G497W,0.0,,,[],[4675],{<CIViC source 1179>},[],[],[1584]
1493,SMO I408V,0.0,,,[],[4676],{<CIViC source 1942>},[],[],[1585]
1494,SMO C469Y,0.0,,,[],[4677],{<CIViC source 1942>},[],[],[1586]
1495,SMO T241M,0.0,,,[],[4678],{<CIViC source 1942>},[],[],[1587]
1496,SMO A459V,0.0,,,[],[4679],{<CIViC source 1942>},[],[],[1588]
1497,SMO S533N,0.0,,,[],[4680],{<CIViC source 1942>},[],[],[1589]
1498,PTCH1 W170X,0.0,,,[],[4681],{<CIViC source 1477>},[],[],[1590]
1499,PTCH1 W712X,0.0,,,[],[4682],{<CIViC source 1477>},[],[],[1591]
1500,PTCH1 Q787X,0.0,,,[],[4683],{<CIViC source 1477>},[],[],[1592]
1501,PTCH1 Q17X,0.0,,,[],[4684],{<CIViC source 1179>},[],[],[1593]
1502,PIK3CA R1023Q,0.0,,,['ARG1023GLN'],[4685],{<CIViC source 1479>},[],[],[1594]
1503,ABL1 H201L,0.0,,,"['H220L', 'HIS201LEU']",[4687],{<CIViC source 1532>},[],[],[1595]
1504,ABL1 Y232S,0.0,,,"['Y251S', 'TYR232SER']",[4688],{<CIViC source 1532>},[],[],[1596]
1505,ABL1 M237V,0.0,,,"['M256V', 'RS376578298', 'MET237VAL']",[4689],{<CIViC source 1532>},[],[],[1597]
1506,ABL1 I242T,0.0,,,"['I261T', 'ILE242THR']",[4690],{<CIViC source 1532>},[],[],[1598]
1507,ABL1 G250V,0.0,,,[],[4691],{<CIViC source 1532>},[],[],[1599]
1508,ABL1 Q252R,0.0,,,"['Q271R', 'GLN252ARG', 'GLN271ARG']",[],set(),[],[],[1600]
1509,ABL1 E258D,0.0,,,"['E277D', 'GLU258ASP']",[4694],{<CIViC source 1532>},[],[],[1601]
1510,ABL1 L273M,0.0,,,"['L292M', 'LEU273MET']",[4695],{<CIViC source 1532>},[],[],[1602]
1511,ABL1 E281K,0.0,,,"['E300K', 'GLU281LYS']",[4696],{<CIViC source 1532>},[],[],[1603]
1512,ABL1 V289I,0.0,,,"['V308I', 'VAL289ILE']",[4697],{<CIViC source 1532>},[],[],[1604]
1513,ABL1 Y342H,0.0,,,"['Y361H', 'TYR342HIS']",[4698],{<CIViC source 1532>},[],[],[1605]
1514,ABL1 D363Y,0.0,,,"['D382Y', 'ASP363TYR']",[4699],{<CIViC source 1532>},[],[],[1606]
1515,ABL1 A365V,0.0,,,['ALA365VAL'],[],set(),[],[],[1607]
1516,ABL1 A366G,0.0,,,"['A385G', 'ALA366GLY']",[],set(),[],[],[1608]
1517,ABL1 V379I,19.5,,,"['V398I', 'VAL379ILE', 'VAL398ILE']",[4704],{<CIViC source 1998>},[],[],[1609]
1518,ABL1 M388L,0.0,,,"['M407L', 'MET388LEU']",[4707],{<CIViC source 1532>},[],[],[1610]
1519,ABL1 Y393C,0.0,,,"['Y412C', 'TYR393CYS']",[4708],{<CIViC source 1532>},[],[],[1611]
1521,ABL1 S417Y,5.0,,,['SER417TYR'],[8089],{<CIViC source 1530>},[],[],[1613]
1522,ABL1 I418V,0.0,,,"['I437V', 'ILE418VAL']",[4714],{<CIViC source 1532>},[],[],[1614]
1523,ABL1 I418S,0.0,,,"['I437S', 'ILE418SER']",[4715],{<CIViC source 1532>},[],[],[1615]
1524,ABL1 P441L,0.0,,,"['P460L', 'PRO441LEU', 'RS764105054']",[4716],{<CIViC source 1532>},[],[],[1616]
1525,ABL1 E450K,0.0,,,"['E469K', 'GLU450LYS']",[4717],{<CIViC source 1532>},[],[],[1617]
1526,ABL1 E450Q,0.0,,,"['E469Q', 'GLU450GLN']",[],set(),[],[],[1618]
1527,ABL1 E450A,0.0,,,"['E469A', 'GLU450ALA']",[4719],{<CIViC source 1532>},[],[],[1619]
1528,ABL1 E453V,0.0,,,"['E472V', 'GLU453VAL']",[4720],{<CIViC source 1532>},[],[],[1620]
1529,ABL1 E459G,0.0,,,"['E478G', 'GLU459GLY']","[4721, 4722]","{<CIViC source 1532>, <CIViC source 1999>}",[],[],[1621]
1530,ABL1 M472I,0.0,,,"['M491I', 'MET472ILE']",[4723],{<CIViC source 1532>},[],[],[1622]
1531,ABL1 P480L,0.0,,,"['P499L', 'PRO480LEU', 'RS780160146']",[4724],{<CIViC source 1532>},[],[],[1623]
1532,ABL1 G514S,0.0,,,"['G533S', 'GLY514SER']",[4725],{<CIViC source 1532>},[],[],[1624]
1533,ABL1 F317I,3.0,,,"['F336I', 'RS1057519773', 'PHE317ILE']",[],set(),[],[],[1625]
1534,MAP2K1 E203K,0.0,,,['E27K'],[4728],{<CIViC source 60>},[],[],[1626]
1535,BRAF G596R,6.0,,,"['RS121913361', 'G204R', 'G24R', 'GLY596ARG']","[5969, 7558, 4729]","{<CIViC source 3005>, <CIViC source 108>, <CIViC source 2414>}",[],[],[1627]
1536,NF1 R163X,0.0,,,[],[4730],{<CIViC source 986>},[],[],[1628]
1537,FLT3 G846S,0.0,,,[],[],set(),[],[],[1629]
1538,FLT3 Y591_V592INSVDFREYE,0.0,,,[],"[4731, 4732, 4733, 4734]","{<CIViC source 2031>, <CIViC source 2109>, <CIViC source 2033>, <CIViC source 2030>}",[],[],[1630]
1539,FLT3 E588_Y589INSKYFYVDFRE,0.0,,,[],"[4735, 4736, 4737, 4738]","{<CIViC source 2031>, <CIViC source 2109>, <CIViC source 2033>, <CIViC source 2030>}",[],[],[1631]
1540,FLT3 V592_D593INSDFREY,0.0,,,[],"[4739, 4740, 4741, 4742]","{<CIViC source 2031>, <CIViC source 2109>, <CIViC source 2033>, <CIViC source 2030>}",[],[],[1632]
1541,EGFR E746_S752>I,0.0,,,[],[],set(),[],[],[1633]
1542,EGFR E746_T751>V,0.0,,,[],[],set(),[],[],[1634]
1543,EGFR E746_A750>IP,0.0,,,[],[4754],{<CIViC source 1988>},[],[],[1635]
1544,EGFR E746_T751>IP,0.0,,,[],[],set(),[],[],[1636]
1545,EGFR E746_P753>VS,0.0,,,[],[],set(),[],[],[1637]
1546,EGFR K745_E749delKELRE,0.0,,,[],[4764],{<CIViC source 1989>},[],[],[1638]
1547,ABL1 C475V,5.0,,,['CYS475VAL'],"[4768, 6977]",{<CIViC source 1997>},[],[],[1639]
1548,ABL1 N336S,5.0,,,"['N355S', 'ASN336SER', 'ASN355SER']",[],set(),[],[],[1640]
1549,ROS1 D2033N,0.0,,,[],"[4770, 7685, 7691]","{<CIViC source 3049>, <CIViC source 2122>}",[],[],[1641]
1550,POLD1 Y956N,0.0,,,[],[4771],{<CIViC source 2123>},[],[],[1642]
1551,SCN8A Q225X,0.0,,,[],[4772],{<CIViC source 2123>},[],[],[1643]
1552,PXDNL P1460T,0.0,,,[],[4773],{<CIViC source 2123>},[],[],[1644]
1553,PAPPA2 Y1520X,0.0,,,[],[4774],{<CIViC source 2123>},[],[],[1645]
1554,POLE4 A59E,0.0,,,[],[4775],{<CIViC source 2123>},[],[],[1646]
1555,POLD1 C284Y,0.0,,,[],[4776],{<CIViC source 2123>},[],[],[1647]
1556,POLD1 E374K,0.0,,,[],[4777],{<CIViC source 2123>},[],[],[1648]
1557,MET D1010Y,0.0,,,[],[4778],{<CIViC source 2125>},[],[],[1649]
1558,BRAF G596V,0.0,,,"['G204V', 'G24V']",[4779],{<CIViC source 1979>},[],[],[1650]
1559,MET D1010N,0.0,,,['D1028N'],"[4780, 4781, 6055]","{<CIViC source 2124>, <CIViC source 2446>, <CIViC source 2126>}",[],[],[1651]
1560,PIK3R2 N561D,3.0,,,[],[4783],{<CIViC source 1941>},[],[],[1652]
1561,PIK3CA D350G,2.0,,,['ASP350GLY'],[4784],{<CIViC source 1941>},[],[],[1653]
1562,NRAS Q179X,0.0,,,[],[4785],{<CIViC source 1920>},[],[],[1654]
1564,ABL1 R351W,9.0,,,"['R332W', 'ARG351TRP', 'RS779478267']","[6376, 4787]",{<CIViC source 2128>},[],[],[1656]
1565,ABL1 G340L,3.0,,,['GLY340LEU'],[4788],{<CIViC source 2128>},[],[],[1657]
1566,BRAF V600_K601DELINSD,0.0,,,[],"[4789, 4790]","{<CIViC source 2130>, <CIViC source 2129>}",[],[],[1658]
1567,KIT S628N,9.5,,,['S624N'],"[7463, 7462, 4791]",{<CIViC source 2054>},[],[],[1659]
1568,MET D1010H,0.0,,,[],"[4792, 4793]","{<CIViC source 2131>, <CIViC source 2125>}",[],[],[1660]
1569,ALK R1192P,0.0,,,"['ARG1192PRO', 'RS113994089']","[7567, 7569, 4795]","{<CIViC source 1236>, <CIViC source 2040>}",[],[],[1661]
1570,EGFR N771delinsVH,0.0,,,[],[4796],{<CIViC source 2067>},[],[],[1662]
1571,BRAF DELNVTAP,0.0,,,[],[4798],{<CIViC source 2133>},[],[],[1663]
1572,EGFR M766_A767insAI,0.0,,,[],[4799],{<CIViC source 1230>},[],[],[1664]
1573,EGFR Y764_V765insHH,0.0,,,[],"[5937, 4800]",{<CIViC source 1230>},[],[],[1665]
1574,EGFR D770_N771insGY,0.0,,,[],[],set(),[],[],[1666]
1575,EGFR P772_H773insYNP,7.5,,,[],[4802],{<CIViC source 1230>},[],[],[1667]
1576,EGFR P772_V774insPHV,7.5,,,[],[4803],{<CIViC source 1230>},[],[],[1668]
1577,LYN Y508F,0.0,,,[],"[4804, 4805]",{<CIViC source 2092>},[],[],[1669]
1578,ROS1 S1986Y,0.0,,,[],[4806],{<CIViC source 2113>},[],[],[1670]
1579,ROS1 S1986F,0.0,,,[],"[7686, 4807]","{<CIViC source 3049>, <CIViC source 2113>}",[],[],[1671]
1580,EGFR Y69FS*11,0.0,,,[],[4808],{<CIViC source 2134>},[],[],[1672]
1581,ERBB4 G1109C,0.0,,,"['G1093C', 'G1099C']","[4809, 9676, 9677]",{<CIViC source 2134>},[],[],[1673]
1582,ESR1 E380Q,0.0,,,[],"[12224, 4810]","{<CIViC source 2135>, <CIViC source 4727>}",[],[],[1674]
1583,ESR1 L536R,0.0,,,[],"[12228, 4811]","{<CIViC source 2135>, <CIViC source 4727>}",[],[],[1675]
1584,FBXW7 S668FS*39,0.0,,,[],[4820],{<CIViC source 2102>},[],[],[1676]
1585,FBXW7 L403FS*34,0.0,,,[],[4821],{<CIViC source 2102>},[],[],[1677]
1586,FBXW7 G579W,0.0,,,[],[4822],{<CIViC source 2102>},[],[],[1678]
1587,FBXW7 R658Q,0.0,,,[],[4823],{<CIViC source 2102>},[],[],[1679]
1588,RAF1 R391W,3.0,,,"['R176W', 'R270W', 'R310W', 'R411W']","[4824, 11044]",{<CIViC source 2137>},[],[],[1680]
1589,JAK2 Splice Site (c.1641+2T>G),7.5,,,"['F547 SPLICE SITE MUTATION', '(C.1641+2T>G) F547 SPLICE SITE']",[4825],{<CIViC source 1036>},[],[],[1681]
1590,ARID1A P1175FS*5,2.0,,,[],[4826],{<CIViC source 1706>},[],[],[1682]
1591,ALK R214H,0.0,,,['ARG214HIS'],[4827],{<CIViC source 2138>},[],[],[1683]
1592,PSMD4 Amplification,0.0,,,[],[4834],{<CIViC source 2140>},[],[],[1684]
1593,CDK6 Amplification,0.0,,,[],[4843],{<CIViC source 2147>},[],[],[1685]
1594,ACVR1 G328V,35.0,,,"['GLY328VAL', 'RS387906589']","[4846, 6955, 10011, 6092, 8035]","{<CIViC source 2149>, <CIViC source 3226>, <CIViC source 2448>, <CIViC source 2680>}",[],[],[1686]
1595,v::RET Fusion,192.5,,,['RET Fusion'],"[8852, 11233, 11234, 11318, 7066, 7069, 8850, 4847, 4848, 4849, 11266, 12134, 12135, 4850, 6949]","{<CIViC source 2150>, <CIViC source 3693>, <CIViC source 3692>, <CIViC source 1206>, <CIViC source 2677>, <CIViC source 2151>, <CIViC source 4628>, <CIViC source 1207>, <CIViC source 2745>, <CIViC source 4030>, <CIViC source 4613>, <CIViC source 5095>, <CIViC source 5096>, <CIViC source 4654>}",[],[],[1687]
1596,RET V804L,0.0,,,['VAL804LEU'],[],set(),[],[],[1688]
1597,RET G810A,0.0,,,['Gly810Ala'],[],set(),[],[],[1689]
1598,RET Mutation,95.0,,,[],"[8851, 12157, 8984, 7070, 4854]","{<CIViC source 3693>, <CIViC source 2153>, <CIViC source 5115>, <CIViC source 3061>, <CIViC source 2745>}",[],[],[1690]
1599,FGFR3::v Fusion,7.5,,,['FGFR3 Fusion'],"[7262, 11258, 7424, 7224, 10405]","{<CIViC source 4325>, <CIViC source 2837>, <CIViC source 2927>, <CIViC source 2859>}",[],[],[1691]
1600,FGFR3 G691R,0.0,,,"['GLY691ARG', 'G693R']",[4870],{<CIViC source 2167>},[2167],[<CIViC source 2167>],[1692]
1601,CHEK1 Overexpression,4.0,,,[],[4874],{<CIViC source 1730>},[],[],[1693]
1602,VHL E12D (c.36G>C),0.0,,,"['GLU12ASP', 'C.36G>C', 'RS973493604']",[4878],{<CIViC source 2174>},[],[],[1694]
1603,TP53 R158H,9.0,,,['ARG158HIS'],"[4886, 10237, 10561]","{<CIViC source 4356>, <CIViC source 1696>, <CIViC source 4271>}",[],[],[1695]
1604,TP53 R249S,7.0,,,[],"[4888, 7110, 7116, 10540, 9461]","{<CIViC source 4356>, <CIViC source 4058>, <CIViC source 2757>, <CIViC source 1696>}",[],[],[1696]
1605,TP53 R280K,4.0,,,[],[4889],{<CIViC source 1696>},[],[],[1697]
1606,TP53 R280T,4.0,,,[],"[4890, 10063]",{<CIViC source 1696>},[],[],[1698]
1607,TP53 R158L,4.0,,,['ARG158LEU'],"[4891, 10065]",{<CIViC source 1696>},[],[],[1699]
1608,RET C634R,0.0,,,[],"[4894, 11874]","{<CIViC source 4953>, <CIViC source 2177>}",[],[],[1700]
1609,VHL E46* (c.136G>T),10.0,,,"['GLU46TER', 'E46X', 'C.136G>T']","[4895, 10424, 10631]","{<CIViC source 2179>, <CIViC source 2285>, <CIViC source 1278>}",[],[],[1733]
1610,VHL E52K (c.154G>A),15.0,,,"['GLU52LYS', 'C.154G>A', 'RS373068386']","[4896, 10425, 5272]","{<CIViC source 2179>, <CIViC source 2285>, <CIViC source 1278>}",[],[],[1734]
1611,VHL E52fs* (c.156G>T),0.0,,,[],"[4897, 6555]","{<CIViC source 2611>, <CIViC source 2174>}",[],[],[1735]
1612,VHL E55* (c.163G>T),7.5,,,['GLU55TER'],[4898],{<CIViC source 2180>},[],[],[1736]
1613,VHL G39fs (c.114del),0.0,,,"['G39FS', 'GLY39ALAFSTER28']",[4901],{<CIViC source 2183>},[],[],[1737]
1614,VHL L158P (c.473T>C),30.0,,,"['C.473T>C', 'LEU158PRO', 'RS121913346']","[4938, 4902, 4951, 5103, 5281, 6613, 6922, 8764, 9041, 9190, 9537, 10466]","{<CIViC source 2657>, <CIViC source 2179>, <CIViC source 3819>, <CIViC source 2187>, <CIViC source 3870>, <CIViC source 2184>, <CIViC source 1278>, <CIViC source 2186>, <CIViC source 2610>, <CIViC source 2192>, <CIViC source 2285>, <CIViC source 3670>}",[],[],[1738]
1615,VHL R167Q (c.500G>A),110.0,R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.,R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2 and suprressed tumorgenesis.,"['C.500G>A', 'ARG167GLN', 'RS5030821']","[5062, 8296, 9802, 4903, 4913, 4953, 4981, 5076, 5093, 5264, 5314, 5330, 5381, 5402, 5503, 5546, 5700, 5762, 5792, 6118, 6222, 6344, 6520, 6526, 6619, 6653, 6694, 6698, 6748, 6752, 6768, 6780, 6841, 6880, 7714, 7757, 8147, 8324, 8372, 8447, 8449, 8472, 8498, 8524, 8543, 8552, 8622, 8778, 8792, 8815, 8960, 8992, 9031, 9103, 9206, 9345, 9378, 9394, 9425, 9538, 9653, 10160, 10412, 10474, 10691, 10713, 10731, 10818, 10832, 10844, 10845, 10850, 10851, 10858, 10889, 10902, 10912, 10915, 10937, 5182, 5242, 5354, 5469, 5485, 5487, 5567, 5781, 6291, 6528, 6587, 8256, 8537, 8711, 8736, 8808, 8831, 9929, 5419, 8951]","{<CIViC source 2324>, <CIViC source 2269>, <CIViC source 2627>, <CIViC source 2187>, <CIViC source 3845>, <CIViC source 4376>, <CIViC source 2285>, <CIViC source 3665>, <CIViC source 3919>, <CIViC source 2242>, <CIViC source 3778>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 3671>, <CIViC source 2628>, <CIViC source 2229>, <CIViC source 3683>, <CIViC source 2616>, <CIViC source 2239>, <CIViC source 4456>, <CIViC source 2240>, <CIViC source 3543>, <CIViC source 1259>, <CIViC source 3576>, <CIViC source 4419>, <CIViC source 2646>, <CIViC source 3572>, <CIViC source 2645>, <CIViC source 2644>, <CIViC source 2341>, <CIViC source 2282>, <CIViC source 2605>, <CIViC source 1264>, <CIViC source 3522>, <CIViC source 4436>, <CIViC source 3577>, <CIViC source 1368>, <CIViC source 2212>, <CIViC source 3546>, <CIViC source 2216>, <CIViC source 3682>, <CIViC source 4378>, <CIViC source 2610>, <CIViC source 2611>, <CIViC source 4020>, <CIViC source 3784>, <CIViC source 4023>, <CIViC source 2608>, <CIViC source 2179>, <CIViC source 3094>, <CIViC source 3429>, <CIViC source 3870>, <CIViC source 2277>, <CIViC source 2246>, <CIViC source 3814>, <CIViC source 3351>, <CIViC source 2649>, <CIViC source 4417>, <CIViC source 3525>, <CIViC source 3065>, <CIViC source 4432>, <CIViC source 2622>, <CIViC source 4451>, <CIViC source 3677>, <CIViC source 3675>, <CIViC source 2654>, <CIViC source 2245>, <CIViC source 2650>, <CIViC source 4428>, <CIViC source 3526>, <CIViC source 3457>, <CIViC source 2317>, <CIViC source 4442>, <CIViC source 3539>, <CIViC source 3843>, <CIViC source 2334>, <CIViC source 2184>, <CIViC source 2241>, <CIViC source 2192>, <CIViC source 4429>, <CIViC source 3402>, <CIViC source 2251>, <CIViC source 1329>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 2489>, <CIViC source 2193>, <CIViC source 2606>, <CIViC source 3489>, <CIViC source 3580>, <CIViC source 3534>, <CIViC source 4469>, <CIViC source 4462>, <CIViC source 2655>, <CIViC source 2506>, <CIViC source 3657>, <CIViC source 4433>, <CIViC source 1372>}",[2255],[<CIViC source 2255>],[1739]
1616,VHL S183C (c.548delC),0.0,,,"['C.548DELC', 'SER183CYS']",[],set(),[],[],[1740]
1617,VHL Y98H (c.292T>C),67.5,,,"['C.292T>C', 'TYR98HIS', 'RS5030809']","[7645, 7876, 8293, 4906, 4967, 4990, 5256, 5418, 5707, 7750, 7751, 8197, 8355, 8403, 8444, 8490, 8698, 8715, 8717, 8955, 9126, 9181, 9198, 10175, 10687, 10711, 10775, 10783, 10831, 10848, 10990, 5372, 5451, 5474, 5519, 5601, 5807, 6554, 8254, 8703, 8728, 8757, 9909]","{<CIViC source 2324>, <CIViC source 3487>, <CIViC source 3382>, <CIViC source 2187>, <CIViC source 2241>, <CIViC source 4376>, <CIViC source 2219>, <CIViC source 3402>, <CIViC source 3665>, <CIViC source 1329>, <CIViC source 4373>, <CIViC source 3919>, <CIViC source 3167>, <CIViC source 4404>, <CIViC source 3859>, <CIViC source 2293>, <CIViC source 2186>, <CIViC source 4473>, <CIViC source 3714>, <CIViC source 2260>, <CIViC source 2610>, <CIViC source 2320>, <CIViC source 3655>, <CIViC source 2239>, <CIViC source 3092>, <CIViC source 3661>, <CIViC source 3662>, <CIViC source 4431>, <CIViC source 3669>, <CIViC source 2245>, <CIViC source 2349>, <CIViC source 3523>, <CIViC source 4419>, <CIViC source 3657>, <CIViC source 3034>, <CIViC source 3429>, <CIViC source 3544>, <CIViC source 3512>, <CIViC source 3870>, <CIViC source 2286>, <CIViC source 2246>, <CIViC source 4402>}",[],[],[1741]
1618,VHL H115Q (c.345C>A),5.0,,,"['C.345C>A', 'HIS115GLN', 'RS864622646']","[8530, 10200, 4907]","{<CIViC source 2655>, <CIViC source 3573>, <CIViC source 2186>}",[],[],[1742]
1619,VHL F119L (c.357C>G),22.5,,,"['C.357C>G', 'PHE119LEU', 'RS1559428077']","[5088, 5411, 9203, 4908, 5436, 5454]","{<CIViC source 1259>, <CIViC source 3919>, <CIViC source 2241>, <CIViC source 2186>, <CIViC source 2245>, <CIViC source 2243>}",[],[],[1743]
1620,VHL A149T (c.445G>A),5.0,,,"['C.445G>A', 'ALA149THR', 'RS587780077']","[6875, 8584, 4909]","{<CIViC source 2655>, <CIViC source 3607>, <CIViC source 2186>}",[],[],[1744]
1621,VHL T157I (c.470C>T),32.5,,,"['C.470C>T', 'THR157ILE', 'RS869025660']","[4910, 5254, 6612, 6878, 8368, 8468, 8777, 8988, 9194, 10496, 10623, 10869, 5214, 5232, 5294, 6581]","{<CIViC source 2218>, <CIViC source 3487>, <CIViC source 4350>, <CIViC source 2655>, <CIViC source 3916>, <CIViC source 3784>, <CIViC source 2211>, <CIViC source 2174>, <CIViC source 3535>, <CIViC source 4438>, <CIViC source 2610>, <CIViC source 2186>, <CIViC source 3671>, <CIViC source 2240>, <CIViC source 1278>, <CIViC source 2611>}",[],[],[1745]
1622,VHL R161Q (c.482G>A),72.5,,,"['C.482G>A', 'ARG161GLN', 'RS730882035']","[9125, 4911, 5061, 5125, 5179, 5262, 5311, 5400, 5584, 5673, 5681, 5706, 6501, 6691, 6754, 6774, 6776, 6836, 7141, 7720, 7891, 8412, 8438, 8450, 8458, 8475, 8493, 8709, 8769, 9030, 9040, 9110, 9253, 9437, 9991, 10468, 10671, 10728, 10756, 10777, 10820, 10868, 10900, 5466, 5481, 5526, 5669, 5699, 5795, 6338, 6496, 8255, 8718, 8733, 8805, 8874, 9925]","{<CIViC source 2324>, <CIViC source 2603>, <CIViC source 2304>, <CIViC source 2627>, <CIViC source 3546>, <CIViC source 3845>, <CIViC source 2216>, <CIViC source 2241>, <CIViC source 2649>, <CIViC source 2773>, <CIViC source 4417>, <CIViC source 2285>, <CIViC source 4371>, <CIViC source 3402>, <CIViC source 2598>, <CIViC source 3665>, <CIViC source 3516>, <CIViC source 3919>, <CIViC source 3167>, <CIViC source 3673>, <CIViC source 2174>, <CIViC source 2310>, <CIViC source 3818>, <CIViC source 4438>, <CIViC source 4451>, <CIViC source 4378>, <CIViC source 2343>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 3677>, <CIViC source 2319>, <CIViC source 2193>, <CIViC source 2511>, <CIViC source 3542>, <CIViC source 3793>, <CIViC source 3858>, <CIViC source 3067>, <CIViC source 3662>, <CIViC source 2245>, <CIViC source 2650>, <CIViC source 3527>, <CIViC source 4392>, <CIViC source 2179>, <CIViC source 2648>, <CIViC source 3657>, <CIViC source 2645>, <CIViC source 2261>, <CIViC source 2317>, <CIViC source 2282>, <CIViC source 2300>, <CIViC source 3712>, <CIViC source 1264>, <CIViC source 3529>, <CIViC source 2246>, <CIViC source 3522>, <CIViC source 4402>}",[],[],[1746]
1623,VHL R167W (c.499C>T),112.5,,,"['C.499C>T', 'ARG167TRP', 'R126W', 'RS5030820']","[5052, 5253, 5265, 5786, 6416, 8288, 8652, 4912, 4952, 4980, 5012, 5077, 5313, 5382, 5468, 5527, 5545, 5558, 5702, 5848, 6117, 6350, 6490, 6491, 6519, 6618, 6700, 6731, 6747, 6761, 6773, 6777, 6840, 6879, 6926, 7142, 7736, 8148, 8149, 8150, 8151, 8226, 8350, 8373, 8394, 8440, 8469, 8473, 8477, 8485, 8526, 8573, 8621, 8751, 8782, 8968, 8991, 9032, 9046, 9059, 9066, 9121, 9192, 9369, 9386, 9403, 9988, 10304, 10473, 10497, 10730, 10749, 10819, 10828, 10859, 10870, 10953, 4995, 5184, 5484, 5621, 5663, 5667, 5695, 5769, 5796, 6477, 6631, 6652, 6667, 6689, 8519, 8561, 8585, 8605, 8710, 8735, 8800, 8807, 8823, 9052, 9928, 6586]","{<CIViC source 2324>, <CIViC source 2269>, <CIViC source 2627>, <CIViC source 2187>, <CIViC source 3607>, <CIViC source 2285>, <CIViC source 3665>, <CIViC source 3919>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 2612>, <CIViC source 3671>, <CIViC source 3536>, <CIViC source 3683>, <CIViC source 2217>, <CIViC source 2647>, <CIViC source 3855>, <CIViC source 3542>, <CIViC source 2240>, <CIViC source 3543>, <CIViC source 3587>, <CIViC source 2640>, <CIViC source 1259>, <CIViC source 4419>, <CIViC source 3572>, <CIViC source 3974>, <CIViC source 2645>, <CIViC source 2261>, <CIViC source 2644>, <CIViC source 2625>, <CIViC source 2286>, <CIViC source 2282>, <CIViC source 2605>, <CIViC source 1264>, <CIViC source 3522>, <CIViC source 4436>, <CIViC source 1368>, <CIViC source 2216>, <CIViC source 2365>, <CIViC source 3783>, <CIViC source 3676>, <CIViC source 2296>, <CIViC source 4378>, <CIViC source 2610>, <CIViC source 2611>, <CIViC source 4020>, <CIViC source 2629>, <CIViC source 3668>, <CIViC source 3784>, <CIViC source 2179>, <CIViC source 3389>, <CIViC source 4350>, <CIViC source 3429>, <CIViC source 3870>, <CIViC source 2316>, <CIViC source 2300>, <CIViC source 2335>, <CIViC source 2246>, <CIViC source 3814>, <CIViC source 3567>, <CIViC source 3351>, <CIViC source 2649>, <CIViC source 4417>, <CIViC source 2328>, <CIViC source 2622>, <CIViC source 4384>, <CIViC source 4473>, <CIViC source 3677>, <CIViC source 2272>, <CIViC source 2657>, <CIViC source 2245>, <CIViC source 2650>, <CIViC source 3540>, <CIViC source 3601>, <CIViC source 3821>, <CIViC source 3482>, <CIViC source 2317>, <CIViC source 3084>, <CIViC source 3828>, <CIViC source 3511>, <CIViC source 3826>, <CIViC source 2241>, <CIViC source 2188>, <CIViC source 2580>, <CIViC source 1329>, <CIViC source 2343>, <CIViC source 4438>, <CIViC source 1278>, <CIViC source 2186>, <CIViC source 2193>, <CIViC source 3489>, <CIViC source 3823>, <CIViC source 3635>, <CIViC source 2655>, <CIViC source 3657>, <CIViC source 2592>, <CIViC source 2190>}",[],[],[1747]
1624,VHL L178P (c.533T>C),50.0,,,"['C.533T>C', 'LEU178PRO', 'RS5030822']","[5149, 4914, 4983, 5316, 8993, 10621, 5198, 5470, 7004, 8712, 8738, 8832, 9858, 9931, 6591]","{<CIViC source 2303>, <CIViC source 2324>, <CIViC source 3665>, <CIViC source 1329>, <CIViC source 3657>, <CIViC source 3784>, <CIViC source 2174>, <CIViC source 2216>, <CIViC source 2186>, <CIViC source 2245>, <CIViC source 2610>, <CIViC source 2240>, <CIViC source 1264>, <CIViC source 2611>, <CIViC source 3683>}",[],[],[1748]
1625,VHL F76I (c.226T>A),0.0,,,"['C.226T>A', 'PHE76ILE', 'RS1559425911']",[4915],{<CIViC source 2186>},[],[],[1749]
1626,VHL V62fs (c.180del),0.0,,,"['C.180DELG', 'VAL62CYSFS', 'NP_000542.1:P.VAL62CYSFS']",[],set(),[],[],[1750]
1628,VHL Q73* (c.217C>T),27.5,,,"['Q73X', 'C.217C>T', 'GLN73TER', 'RS869025619']","[4918, 5135, 5000, 5030, 5036, 5270, 5337, 5594, 6793, 6861, 8135, 8424, 8525, 8786, 9267, 9999, 10434, 10436, 10792, 8753]","{<CIViC source 2231>, <CIViC source 3351>, <CIViC source 2285>, <CIViC source 3571>, <CIViC source 1373>, <CIViC source 4404>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 2193>, <CIViC source 3669>, <CIViC source 3973>, <CIViC source 2650>, <CIViC source 2179>, <CIViC source 2655>, <CIViC source 2286>, <CIViC source 2190>, <CIViC source 1264>, <CIViC source 3522>}",[],[],[1752]
1630,VHL N78H (c.232A>C),32.5,,,"['C.232A>C', 'ASN78HIS']","[5130, 4920, 4962, 9346, 10544, 5341, 8754]","{<CIViC source 1329>, <CIViC source 2235>, <CIViC source 3784>, <CIViC source 3669>, <CIViC source 2186>, <CIViC source 2240>, <CIViC source 1264>}",[],[],[1754]
1631,VHL N78S (c.233A>G),72.5,,,"['C.233A>G', 'ASN78SER', 'RS5030804']","[5020, 4921, 5001, 5027, 5250, 5521, 5842, 6022, 6745, 6795, 6863, 7893, 8211, 8378, 8395, 8523, 8940, 8970, 9025, 9120, 9137, 9199, 9270, 9368, 9539, 10439, 10712, 10865, 10879, 10901, 10963, 5187, 5376, 5491, 5587, 5665, 5680, 6289, 6429, 6545, 6548, 6558, 6656, 8723, 8794, 9859, 9903]","{<CIViC source 3664>, <CIViC source 2324>, <CIViC source 4442>, <CIViC source 2624>, <CIViC source 2216>, <CIViC source 2365>, <CIViC source 4376>, <CIViC source 2192>, <CIViC source 2285>, <CIViC source 3571>, <CIViC source 3676>, <CIViC source 3919>, <CIViC source 3167>, <CIViC source 4451>, <CIViC source 2174>, <CIViC source 2310>, <CIViC source 2186>, <CIViC source 4473>, <CIViC source 3714>, <CIViC source 2610>, <CIViC source 2284>, <CIViC source 2611>, <CIViC source 2303>, <CIViC source 4020>, <CIViC source 3855>, <CIViC source 2431>, <CIViC source 3784>, <CIViC source 3793>, <CIViC source 3489>, <CIViC source 2239>, <CIViC source 3973>, <CIViC source 2650>, <CIViC source 2298>, <CIViC source 2504>, <CIViC source 2179>, <CIViC source 3389>, <CIViC source 2655>, <CIViC source 2261>, <CIViC source 2644>, <CIViC source 3870>, <CIViC source 3512>, <CIViC source 2190>, <CIViC source 1264>, <CIViC source 1372>, <CIViC source 4436>}",[],[],[1755]
1632,VHL N78T (c.233A>C),5.0,,,"['C.233A>C', 'ASN78THR', 'RS5030804']","[9814, 10545, 4922, 6332]","{<CIViC source 3973>, <CIViC source 2186>, <CIViC source 2509>, <CIViC source 2240>}",[],[],[1756]
1633,VHL S80I (c.239G>T),15.0,,,"['C.239G>T', 'SER80ILE', 'RS5030805']","[5683, 4923, 5236, 5800, 6796, 8327, 8467, 8529, 8535, 9271, 10961, 5213, 5428, 5522, 5597, 6559, 6663, 8725]","{<CIViC source 3571>, <CIViC source 2311>, <CIViC source 3576>, <CIViC source 3665>, <CIViC source 2212>, <CIViC source 3460>, <CIViC source 2174>, <CIViC source 2261>, <CIViC source 2625>, <CIViC source 2286>, <CIViC source 3973>, <CIViC source 2186>, <CIViC source 4473>, <CIViC source 2650>, <CIViC source 2243>, <CIViC source 2345>, <CIViC source 3534>, <CIViC source 2611>}",[],[],[1757]
1634,VHL P86fs (c.254_255insC),10.0,,,['P86AFS*46'],[4924],{<CIViC source 2186>},[],[],[1758]
1635,VHL P86A (c.256C>G),5.0,,,"['C.256C>G', 'PRO86ALA', 'RS398123481']","[6635, 8748, 10960, 4925, 5209, 6550, 6560]","{<CIViC source 2613>, <CIViC source 3667>, <CIViC source 2174>, <CIViC source 2186>, <CIViC source 4473>, <CIViC source 2610>, <CIViC source 2611>}",[],[],[1759]
1636,VHL P86L (c.257C>T),27.5,,,"['C.257C>T', 'PRO86LEU', 'RS730882034']","[4926, 5157, 5291, 6486, 6733, 6802, 8527, 8567, 8617, 8750, 8973, 9272, 9354, 9382, 10307, 10547, 10857, 5210, 5243, 6562]","{<CIViC source 2588>, <CIViC source 2213>, <CIViC source 2216>, <CIViC source 3592>, <CIViC source 3571>, <CIViC source 3621>, <CIViC source 2174>, <CIViC source 2186>, <CIViC source 2611>, <CIViC source 4020>, <CIViC source 4435>, <CIViC source 3668>, <CIViC source 3784>, <CIViC source 3973>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 2640>, <CIViC source 3974>, <CIViC source 1264>}",[],[],[1760]
1637,VHL W88R (c.262T>A),10.0,,,"['C.262T>A', 'TRP88ARG', 'RS1553619431']","[5060, 8407, 8432, 8956, 9135, 9179, 10942, 4927, 5168, 5598, 8756, 9906]","{<CIViC source 2324>, <CIViC source 3870>, <CIViC source 3512>, <CIViC source 2286>, <CIViC source 3669>, <CIViC source 4473>, <CIViC source 2186>, <CIViC source 3862>, <CIViC source 3714>, <CIViC source 1264>, <CIViC source 2193>, <CIViC source 3522>}",[],[],[1761]
1638,VHL S111FS (c.331delA),10.0,,,"['C.331DELA', 'SER111FS']",[4928],{<CIViC source 2186>},[],[],[1762]
1639,VHL S111N (c.332G>A),12.5,,,"['C.332G>A', 'SER111ASN', 'RS869025631']","[5021, 5003, 5585, 6601, 6771, 8532, 9184, 9275, 10863, 4929, 8872]","{<CIViC source 3571>, <CIViC source 3711>, <CIViC source 2646>, <CIViC source 3870>, <CIViC source 2190>, <CIViC source 2282>, <CIViC source 3973>, <CIViC source 2610>, <CIViC source 2186>, <CIViC source 1264>, <CIViC source 4436>}",[],[],[1763]
1640,VHL S111R (c.333C>G),15.0,,,"['C.333C>G', 'SER111ARG', 'RS765978945']","[4930, 5498]","{<CIViC source 1372>, <CIViC source 2186>}",[],[],[1764]
1641,EGFR Gain-of-function,20.0,,,['ACTIVATING MUTATION'],[4931],{<CIViC source 1610>},[],[],[1765]
1642,VHL Y112* (c.336C>A),10.0,,,"['C.336C>A', 'Y112X', 'TYR112TER']",[4932],{<CIViC source 2186>},[],[],[1766]
1643,VHL W117C (c.351G>T),22.5,,,"['C.351G>T', 'TRP117CYS', 'RS727504215']","[8697, 4933, 5090, 5295, 5395, 8768, 9186, 10004, 10453, 5044, 6330, 6682]","{<CIViC source 3654>, <CIViC source 1259>, <CIViC source 2179>, <CIViC source 2626>, <CIViC source 3870>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 2240>, <CIViC source 2509>, <CIViC source 2285>, <CIViC source 2193>}",[],[],[1767]
1644,VHL L129Q (c.386insAGA),10.0,,,[],[4934],{<CIViC source 2186>},[],[],[1768]
1645,VHL L135* (c.404T>A),17.5,,,"['C.404T>A', 'L135X', 'LEU135TER']","[4935, 4992, 6608, 6826, 8942, 5607]","{<CIViC source 2187>, <CIViC source 2286>, <CIViC source 2610>, <CIViC source 2186>, <CIViC source 3714>, <CIViC source 2650>}",[],[],[1769]
1646,VHL N150fs (c.449del),7.5,There are no similar variants in ClinVar with this exact genomic location.,There are no similar variants in ClinVar with this exact genomic location.,"['N150IFS*9', 'N150FS (C.448DELA)']",[4936],{<CIViC source 2186>},[],[],[1770]
1647,VHL P154fs (c.462delA),7.5,,,"['C.462DELA', 'PRO154FS']","[4937, 6467]","{<CIViC source 2573>, <CIViC source 2186>}",[],[],[1771]
1648,VHL C162R (c.484T>C),22.5,,,"['RS1553620313', 'C.484T>C', 'CYS162ARG']","[8459, 8989, 10204, 10618, 4939, 5175, 5349, 8574, 6161]","{<CIViC source 1370>, <CIViC source 1373>, <CIViC source 2235>, <CIViC source 2655>, <CIViC source 3784>, <CIViC source 3602>, <CIViC source 2186>, <CIViC source 2240>, <CIViC source 3529>}",[],[],[1772]
1649,VHL C162F (c.485G>T),22.5,,,"['C.485G>T', 'CYS162PHE', 'RS397516444']","[8593, 9205, 10829, 4940, 5050, 5189, 8245, 6584]","{<CIViC source 4419>, <CIViC source 3919>, <CIViC source 2174>, <CIViC source 2186>, <CIViC source 3398>, <CIViC source 2302>, <CIViC source 2611>, <CIViC source 2193>}",[],[],[1773]
1650,VHL C162W (c.486C>G),32.5,,,"['C.486C>G', 'CYS162TRP', 'RS869025662']","[5063, 6527, 6616, 6837, 7895, 8397, 8439, 8528, 8634, 9026, 9047, 9251, 9279, 9399, 9990, 10125, 10205, 10470, 10703, 10976, 4941, 5190, 5267, 5355, 6535, 9926, 6585]","{<CIViC source 2324>, <CIViC source 1368>, <CIViC source 4374>, <CIViC source 2285>, <CIViC source 3571>, <CIViC source 1373>, <CIViC source 3919>, <CIViC source 3167>, <CIViC source 2174>, <CIViC source 2607>, <CIViC source 2610>, <CIViC source 4473>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 2611>, <CIViC source 2193>, <CIViC source 2239>, <CIViC source 3793>, <CIViC source 2488>, <CIViC source 3973>, <CIViC source 2650>, <CIViC source 3821>, <CIViC source 2179>, <CIViC source 2655>, <CIViC source 3512>, <CIViC source 4029>, <CIViC source 3522>}",[],[],[1774]
1651,VHL V166D (c.497T>A),10.0,,,"['C.497T>A', 'VAL166ASP']",[4942],{<CIViC source 2186>},[],[],[1775]
1652,VHL L184P (c.551T>C),32.5,,,"['C.551T>C', 'LEU184PRO', 'RS1064793878']","[6119, 8491, 4943, 5055, 6167, 6027]","{<CIViC source 1370>, <CIViC source 2431>, <CIViC source 3546>, <CIViC source 2282>, <CIViC source 2186>, <CIViC source 2193>}",[],[],[1776]
1653,VHL E186* (c.556G>T),15.0,,,"['C.556G>T', 'E186X', 'GLU186TER', 'RS367545984']","[4944, 5057, 8761]","{<CIViC source 3669>, <CIViC source 2193>, <CIViC source 2186>}",[],[],[1777]
1654,VHL E186K (c.556G>A),5.0,,,"['C.556G>A', 'GLU186LYS', 'RS367545984']","[6881, 10735, 4945, 10651]","{<CIViC source 2655>, <CIViC source 4379>, <CIViC source 2193>, <CIViC source 2186>}",[],[],[1778]
1655,VHL R167fs (c.502insTTGTCCGT),0.0,,,[],[4946],{<CIViC source 2186>},[],[],[1779]
1656,VHL R176fs (c.526del),17.5,,,"['C.526DELA', 'ARG176FS', 'RS1559429711', 'R176GFS*26 (C.526DEL)']","[5166, 4947, 5652, 8496, 9252, 6655, 8760]","{<CIViC source 2624>, <CIViC source 3919>, <CIViC source 3546>, <CIViC source 3669>, <CIViC source 2186>, <CIViC source 1264>, <CIViC source 2193>}",[],[],[1780]
1657,VHL Q145H (c.435_436delGC),0.0,,,"['C.435_436DELGC', 'GLN145HISFS', 'RS869025652']",[4948],{<CIViC source 2187>},[],[],[1781]
1658,VHL P154L (c.461C>T),25.0,,,"['C.461C>T', 'PRO154LEU']","[5684, 4949, 4976, 6609, 8139, 8140, 9389, 10956, 5154, 5461, 5609]","{<CIViC source 4020>, <CIViC source 2311>, <CIViC source 1329>, <CIViC source 2187>, <CIViC source 2286>, <CIViC source 3351>, <CIViC source 2610>, <CIViC source 4473>, <CIViC source 2245>, <CIViC source 1264>}",[],[],[1782]
1659,VHL L158fs (c.471dupT),5.0,,,['C.685INST'],"[4950, 5646]","{<CIViC source 1259>, <CIViC source 2187>}",[],[],[1783]
1660,VHL S183* (c.548C>A),15.0,,,"['C.548C>A', 'S183X', 'SER183TER', 'RS5030823']","[4954, 5370, 5623, 8224, 8399, 8682, 8877, 10986, 5211, 5471, 6677, 9932, 6592]","{<CIViC source 2324>, <CIViC source 3389>, <CIViC source 2239>, <CIViC source 2187>, <CIViC source 2174>, <CIViC source 2625>, <CIViC source 2286>, <CIViC source 3512>, <CIViC source 4473>, <CIViC source 2245>, <CIViC source 3714>, <CIViC source 2192>, <CIViC source 2611>}",[],[],[1784]
1661,VHL A56fs (c.166_167insA),5.0,,,"['L15409.1:380INSA', '380INSA']",[4956],{<CIViC source 1329>},[],[],[1785]
1663,VHL S65W (c.194C>G),105.0,,,"['C.194C>G', 'SER65TRP', 'RS5030826']","[4917, 4958, 4998, 5026, 5034, 5161, 5328, 5693, 5765, 6352, 6468, 6661, 6789, 7746, 8208, 8954, 9136, 9265, 10702, 10774, 10786, 10926, 5212, 5592, 8229, 8974, 9786, 9897, 6556]","{<CIViC source 2324>, <CIViC source 2574>, <CIViC source 4374>, <CIViC source 2328>, <CIViC source 2192>, <CIViC source 1329>, <CIViC source 4404>, <CIViC source 2174>, <CIViC source 4463>, <CIViC source 2514>, <CIViC source 2186>, <CIViC source 3390>, <CIViC source 3714>, <CIViC source 4401>, <CIViC source 2229>, <CIViC source 2611>, <CIViC source 2193>, <CIViC source 2323>, <CIViC source 3092>, <CIViC source 3973>, <CIViC source 2650>, <CIViC source 2315>, <CIViC source 3389>, <CIViC source 2625>, <CIViC source 3870>, <CIViC source 2286>, <CIViC source 2190>, <CIViC source 1264>}",[],[],[1787]
1664,VHL S65L (c.194C>T),72.5,,,"['C.194C>T', 'SER65LEU', 'RS5030826']","[4959, 5104, 5582, 6710, 6791, 6859, 8569, 8875, 9038, 9127, 9482, 10430, 5159, 5287, 5499, 6644, 6662, 6728, 8795, 8975, 9896, 6131, 6890]","{<CIViC source 1370>, <CIViC source 2324>, <CIViC source 2617>, <CIViC source 3713>, <CIViC source 3816>, <CIViC source 3594>, <CIViC source 2192>, <CIViC source 2285>, <CIViC source 1329>, <CIViC source 3676>, <CIViC source 1278>, <CIViC source 3714>, <CIViC source 2323>, <CIViC source 2657>, <CIViC source 3860>, <CIViC source 2634>, <CIViC source 2650>, <CIViC source 275>, <CIViC source 2655>, <CIViC source 2625>, <CIViC source 2282>, <CIViC source 1264>, <CIViC source 1372>}",[],[],[1788]
1665,VHL V66* (c.196delG),0.0,,,"['V66X', 'C.196DELG', 'VAL66TER']","[4960, 8136]","{<CIViC source 3351>, <CIViC source 1329>}",[],[],[1789]
1667,VHL R79P (c.236G>C),7.5,,,"['C.236G>C', 'ARG79PRO']","[4963, 8146, 9262]","{<CIViC source 3351>, <CIViC source 1329>, <CIViC source 3972>}",[],[],[1791]
1668,VHL S80R (c.240T>G),12.5,,,"['C.240T>G', 'SER80ARG']","[4964, 5448]","{<CIViC source 1329>, <CIViC source 2245>}",[],[],[1792]
1669,VHL L89P (c.266T>C),27.5,,,"['C.266T>C', 'LEU89PRO', 'RS5030807']","[5321, 4965, 5086, 5753, 6807, 8398, 9093, 10891, 10989, 5150, 5368, 5449, 5600, 6552, 8249, 9054, 9907, 6140]","{<CIViC source 1370>, <CIViC source 3828>, <CIViC source 1259>, <CIViC source 4442>, <CIViC source 1329>, <CIViC source 2324>, <CIViC source 1368>, <CIViC source 2239>, <CIViC source 2226>, <CIViC source 3512>, <CIViC source 2286>, <CIViC source 4473>, <CIViC source 2245>, <CIViC source 2650>, <CIViC source 2610>, <CIViC source 1264>, <CIViC source 3398>, <CIViC source 3823>}",[],[],[1793]
1670,VHL E94* (c.280G>T),40.0,,,"['C.280G>T', 'E94X', 'GLU94TER', 'RS5030829']","[8286, 4966, 5137, 5405, 5433, 5550, 5561, 6810, 8214, 5771, 9908]","{<CIViC source 2324>, <CIViC source 3389>, <CIViC source 1329>, <CIViC source 2269>, <CIViC source 2275>, <CIViC source 3429>, <CIViC source 2241>, <CIViC source 2650>, <CIViC source 2328>, <CIViC source 1264>, <CIViC source 2243>}",[],[],[1794]
1671,VHL P103FS (c.309_310delTG),7.5,,,"['C.309_310DELTG', 'PRO103FS']","[4968, 5138]","{<CIViC source 1264>, <CIViC source 1329>}",[],[],[1795]
1672,VHL R113* (c.337C>T),52.5,,,"['C.337C>T', 'R113X', 'ARG113TER', 'RS5030810']","[4969, 5043, 5073, 5177, 5260, 5304, 5352, 5379, 5492, 6353, 6602, 7143, 9541, 10166, 10448, 10922, 5603, 5802, 6673, 6681, 9860, 6566]","{<CIViC source 2774>, <CIViC source 2216>, <CIViC source 2285>, <CIViC source 1329>, <CIViC source 2174>, <CIViC source 4463>, <CIViC source 2626>, <CIViC source 2514>, <CIViC source 1278>, <CIViC source 2610>, <CIViC source 2347>, <CIViC source 2611>, <CIViC source 2193>, <CIViC source 2303>, <CIViC source 2599>, <CIViC source 2239>, <CIViC source 2240>, <CIViC source 2249>, <CIViC source 1259>, <CIViC source 2179>, <CIViC source 2625>, <CIViC source 2286>}",[],[],[1796]
1673,VHL G114C (c.340G>T),12.5,,,"['C.340G>T', 'GLY114CYS']","[4970, 5139, 6145]","{<CIViC source 1264>, <CIViC source 1370>, <CIViC source 1329>}",[],[],[1797]
1674,VHL L118P (c.353T>C),45.0,,,"['C.353T>C', 'LEU118PRO', 'RS5030830']","[5143, 4971, 5083, 5276, 5846, 8998, 9976, 10454, 10614, 5435, 5477, 6905]","{<CIViC source 2657>, <CIViC source 1259>, <CIViC source 2179>, <CIViC source 1329>, <CIViC source 3784>, <CIViC source 2365>, <CIViC source 1278>, <CIViC source 2240>, <CIViC source 1264>, <CIViC source 2243>, <CIViC source 2285>, <CIViC source 2246>}",[],[],[1798]
1676,VHL N131fs (c.390_391del),15.0,,,"['C.390_391DELTA', 'ASN131PRO', 'N131PFS*3', 'ASN131PROFSTER3']","[4973, 5128]","{<CIViC source 1264>, <CIViC source 1329>}",[],[],[1800]
1677,VHL F136S (c.407T>C),47.5,,,"['C.407T>C', 'PHE136SER', 'RS5030833']","[5152, 4974, 5284, 5543, 5764, 6347, 6512, 8482, 8789, 9101, 9188, 9997, 10459, 10852, 10978, 5202, 5608, 5757, 9917, 6573]","{<CIViC source 2327>, <CIViC source 3828>, <CIViC source 2324>, <CIViC source 2269>, <CIViC source 1368>, <CIViC source 2285>, <CIViC source 1329>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 4473>, <CIViC source 2611>, <CIViC source 3543>, <CIViC source 2179>, <CIViC source 3870>, <CIViC source 2286>, <CIViC source 2605>, <CIViC source 4433>, <CIViC source 1264>}",[],[],[1801]
1678,VHL L153fs (c.457delC),17.5,There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.,There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.,"['C.457DELC', 'LEU153FS']","[5145, 4975]","{<CIViC source 1264>, <CIViC source 1329>}",[],[],[1802]
1679,VHL L158V (c.472C>G),22.5,,,"['C.472C>G', 'LEU158VAL']","[5146, 4977, 5239, 5389, 5580, 9001, 5464, 8804, 6160]","{<CIViC source 1370>, <CIViC source 1329>, <CIViC source 2212>, <CIViC source 3789>, <CIViC source 2282>, <CIViC source 2245>, <CIViC source 3677>, <CIViC source 2240>, <CIViC source 1264>}",[],[],[1803]
1680,VHL R161* (c.481C>T),85.0,,,"['C.481C>T', 'R161X', 'ARG161TER', 'RS5030818']","[5761, 8295, 8612, 4978, 5009, 5028, 5031, 5049, 5075, 5240, 5263, 5375, 5483, 5525, 5617, 5791, 5793, 6116, 6221, 6356, 6427, 6614, 6697, 6708, 6770, 6835, 7715, 7755, 8153, 8154, 8222, 8349, 8391, 8426, 8497, 8592, 8770, 8937, 9005, 9109, 9128, 9195, 9204, 9277, 9363, 9540, 10203, 10467, 10485, 10501, 10784, 10812, 10860, 10877, 10921, 10983, 5181, 5233, 6201, 6220, 6630, 6676, 8243, 8799, 9923, 5670, 6488, 6583]","{<CIViC source 2324>, <CIViC source 2487>, <CIViC source 1368>, <CIViC source 3916>, <CIViC source 2212>, <CIViC source 2211>, <CIViC source 3546>, <CIViC source 3845>, <CIViC source 3511>, <CIViC source 3351>, <CIViC source 2192>, <CIViC source 2285>, <CIViC source 3065>, <CIViC source 1329>, <CIViC source 1373>, <CIViC source 3919>, <CIViC source 3676>, <CIViC source 4404>, <CIViC source 2174>, <CIViC source 4463>, <CIViC source 2514>, <CIViC source 2612>, <CIViC source 1278>, <CIViC source 2610>, <CIViC source 3671>, <CIViC source 3714>, <CIViC source 2628>, <CIViC source 4473>, <CIViC source 2611>, <CIViC source 2340>, <CIViC source 2193>, <CIViC source 4020>, <CIViC source 2239>, <CIViC source 3793>, <CIViC source 3489>, <CIViC source 2488>, <CIViC source 2301>, <CIViC source 3973>, <CIViC source 2634>, <CIViC source 2650>, <CIViC source 2302>, <CIViC source 4441>, <CIViC source 4416>, <CIViC source 2590>, <CIViC source 1259>, <CIViC source 3389>, <CIViC source 3482>, <CIViC source 2179>, <CIViC source 4350>, <CIViC source 2646>, <CIViC source 2655>, <CIViC source 2261>, <CIViC source 3429>, <CIViC source 2625>, <CIViC source 2286>, <CIViC source 2190>, <CIViC source 2341>, <CIViC source 2282>, <CIViC source 3398>, <CIViC source 2485>, <CIViC source 1264>, <CIViC source 3861>, <CIViC source 1372>, <CIViC source 3093>, <CIViC source 3522>, <CIViC source 4436>}",[],[],[1804]
1681,VHL R167G (c.499C>G),0.0,,,"['C.499C>G', 'ARG167GLY', 'RS5030820']","[4979, 10758, 5241, 5566]","{<CIViC source 4393>, <CIViC source 2212>, <CIViC source 1329>, <CIViC source 2277>}",[],[],[1805]
1682,VHL V170F (c.508G>T),7.5,,,"['C.508G>T', 'VAL170PHE']","[4982, 8130]","{<CIViC source 3351>, <CIViC source 1329>}",[],[],[1806]
1683,VHL I180V (c.538A>G),7.5,,,"['C.538A>G', 'ILE180VAL', 'RS377715747']","[5142, 4984]","{<CIViC source 1264>, <CIViC source 1329>}",[],[],[1807]
1684,VHL L184R (c.551T>G),7.5,,,"['C.551T>G', 'LEU184ARG']","[4985, 5199, 6593]","{<CIViC source 2611>, <CIViC source 1329>, <CIViC source 2174>}",[],[],[1808]
1685,VHL Y185* (c.555C>G),15.0,,,"['C.555C>G', 'Y185X', 'TYR185TER', 'RS864622109']","[4986, 5056, 5170, 6015, 7735, 8429, 9055]","{<CIViC source 1329>, <CIViC source 2187>, <CIViC source 3084>, <CIViC source 1264>, <CIViC source 2193>, <CIViC source 3522>, <CIViC source 3823>}",[],[],[1809]
1686,VHL Q195* (c.583C>T),60.0,,,"['C.583C>T', 'Q195X', 'GLN195TER', 'RS5030825']","[5134, 4987, 5097, 5404, 5691, 6623, 8128, 8129, 8693, 9255, 10738, 10811, 5360, 5472, 6596]","{<CIViC source 1329>, <CIViC source 4381>, <CIViC source 2239>, <CIViC source 2174>, <CIViC source 3351>, <CIViC source 2241>, <CIViC source 2610>, <CIViC source 2192>, <CIViC source 2180>, <CIViC source 2245>, <CIViC source 1264>, <CIViC source 2611>, <CIViC source 4416>, <CIViC source 3967>}",[],[],[1810]
1687,VHL S65* (c.194C>A),15.0,,,"['C.194C>A', 'S65X', 'SER65TER', 'RS5030826']","[4988, 5033, 5422, 5591, 9898]","{<CIViC source 2324>, <CIViC source 2187>, <CIViC source 2286>, <CIViC source 2243>, <CIViC source 2193>}",[],[],[1811]
1688,VHL G93fs (c.278delG),0.0,,,"['GLY93ALA', 'C.277DELG', 'G93AFS', 'C.278DELG']",[4989],{<CIViC source 2187>},[],[],[1812]
1689,VHL D121G (c.362A>G),17.5,,,"['C.362A>G', 'ASP121GLY', 'RS5030832']","[4991, 5578, 7756, 9187, 5437, 5455, 8242]","{<CIViC source 2187>, <CIViC source 3870>, <CIViC source 2282>, <CIViC source 2245>, <CIViC source 3398>, <CIViC source 2243>, <CIViC source 3093>}",[],[],[1813]
1690,VHL F136C (c.407T>G),12.5,,,"['C.407T>G', 'PHE136CYS', 'RS5030833']","[4993, 5412, 6827, 10751, 10805, 5438, 5480, 9918]","{<CIViC source 2324>, <CIViC source 2187>, <CIViC source 4378>, <CIViC source 2241>, <CIViC source 2650>, <CIViC source 4414>, <CIViC source 2243>, <CIViC source 2246>}",[],[],[1814]
1691,VHL V84L (c.250G>T),10.0,,,"['C.250G>T', 'VAL84LEU', 'RS5030827']","[8455, 8539, 8587, 9372, 9385, 4994, 5230, 5430, 5801, 8802, 8203]","{<CIViC source 4020>, <CIViC source 3386>, <CIViC source 3974>, <CIViC source 2211>, <CIViC source 3607>, <CIViC source 3677>, <CIViC source 2243>, <CIViC source 2188>, <CIViC source 3529>, <CIViC source 3578>, <CIViC source 2346>}",[],[],[1815]
1692,VHL S72fs (c.214del),10.0,,,"['C.214DELT', 'SER72FS', 'S72FS (C.214DELT)']","[5163, 4999, 8976]","{<CIViC source 1264>, <CIViC source 2190>, <CIViC source 2323>}",[],[],[1816]
1694,VHL Q96P (c.287A>C),0.0,,,"['C.287A>C', 'GLN96PRO']","[5002, 9392, 10552]","{<CIViC source 2190>, <CIViC source 4020>, <CIViC source 2240>}",[],[],[1818]
1696,VHL L116V (c.346C>G),10.0,,,"['C.346C>G', 'LEU116VAL']","[5022, 5005, 5228]","{<CIViC source 1264>, <CIViC source 2190>, <CIViC source 2210>}",[],[],[1820]
1697,VHL W117* (c.351G>A),0.0,,,"['C.351G>A', 'W117X', 'TRP117TER', 'RS727504215']","[5006, 6904, 8611, 9276, 10773, 10833]","{<CIViC source 2657>, <CIViC source 4419>, <CIViC source 2190>, <CIViC source 3973>, <CIViC source 4400>, <CIViC source 1264>}",[],[],[1821]
1698,VHL L118R (c.353T>G),0.0,,,"['C.353T>G', 'LEU118ARG', 'RS5030830']","[5007, 7738]","{<CIViC source 2190>, <CIViC source 3084>}",[],[],[1822]
1699,VHL N141fs (c.422del),0.0,,,"['C.421DELA', 'ASN141FS', 'C.422DELA']","[5023, 5008]","{<CIViC source 1264>, <CIViC source 2190>}",[],[],[1823]
1700,VHL C162Y (c.485G>A),27.5,,,"['C.485G>A', 'CYS162TYR', 'RS397516444']","[5010, 5383, 5581, 6615, 6838, 6923, 8545, 8990, 9278, 10469, 10916, 5493, 5563]","{<CIViC source 2657>, <CIViC source 4462>, <CIViC source 3784>, <CIViC source 2190>, <CIViC source 2282>, <CIViC source 3973>, <CIViC source 2610>, <CIViC source 1372>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 2277>, <CIViC source 3580>, <CIViC source 2285>}",[],[],[1824]
1701,VHL V166F (c.496G>T),17.5,,,"['C.496G>T', 'VAL166PHE', 'RS104893825']","[5024, 5011, 5302, 6357, 8791, 9989, 10472, 10681, 10694, 10729, 10950, 5655, 6666, 8606, 8734, 8836]","{<CIViC source 2179>, <CIViC source 3487>, <CIViC source 3665>, <CIViC source 3674>, <CIViC source 1368>, <CIViC source 2625>, <CIViC source 4374>, <CIViC source 2190>, <CIViC source 2514>, <CIViC source 4378>, <CIViC source 1278>, <CIViC source 4480>, <CIViC source 1264>, <CIViC source 2291>, <CIViC source 2285>, <CIViC source 3683>}",[],[],[1825]
1702,VHL V170D (c.509T>A),40.0,,,"['C.509T>A', 'VAL170ASP']","[5863, 5013, 5029, 5092, 6522, 6843, 8446, 8959, 9042, 10161]","{<CIViC source 1259>, <CIViC source 3778>, <CIViC source 2190>, <CIViC source 2605>, <CIViC source 2650>, <CIViC source 2192>, <CIViC source 3525>, <CIViC source 3543>, <CIViC source 3820>, <CIViC source 2373>}",[],[],[1826]
1703,VHL R177* (c.529A>T),7.5,,,"['C.529A>T', 'R177X', 'ARG177TER', 'RS1559429717']","[5014, 5025, 5331, 6013]","{<CIViC source 1264>, <CIViC source 2190>, <CIViC source 2187>, <CIViC source 2229>}",[],[],[1827]
1704,VHL L188fs (c.563del),0.0,,,"['C.563DELT', 'LEU188ARGFS', 'L188RFS (C.563DELT)']",[5015],{<CIViC source 2190>},[],[],[1828]
1705,VHL E186del (c.558_560delAGA),0.0,,,"['C.558_560DELAGA', 'GLU186DEL', 'RS1559429813']",[5016],{<CIViC source 2190>},[],[],[1829]
1706,POLE P286R,15.0,,,[],[5017],{<CIViC source 2191>},[],[],[1830]
1707,POLE V411L,15.0,,,[],"[5018, 8631, 10626]","{<CIViC source 2191>, <CIViC source 3627>, <CIViC source 4358>}",[],[],[1831]
1708,POLE S459F,15.0,,,[],[5019],{<CIViC source 2191>},[],[],[1832]
1710,VHL E70* (c.208G>T),27.5,,,"['C.208G>T', 'E70X', 'GLU70TER', 'RS5030802']","[6059, 5035, 8209, 9266, 5361, 5445]","{<CIViC source 3389>, <CIViC source 2239>, <CIViC source 3973>, <CIViC source 2186>, <CIViC source 2245>, <CIViC source 2193>}",[],[],[1834]
1711,VHL F76S (c.227T>C),7.5,,,"['PHE76SER', 'C.277T>C', 'RS730882033']",[5037],{<CIViC source 2193>},[],[],[1835]
1712,VHL L188V (c.562C>G),15.0,,,"['C.562C>G', 'LEU188VAL', 'RS5030824']","[5038, 5409, 6719, 7889, 8442, 8492, 10846, 10952, 5367, 5571, 5657, 5854, 6495, 8534, 8720, 8205]","{<CIViC source 3167>, <CIViC source 2279>, <CIViC source 2597>, <CIViC source 4430>, <CIViC source 2239>, <CIViC source 3546>, <CIViC source 2292>, <CIViC source 3662>, <CIViC source 3575>, <CIViC source 2635>, <CIViC source 2241>, <CIViC source 4473>, <CIViC source 2366>, <CIViC source 3386>, <CIViC source 2193>, <CIViC source 3522>}",[],[],[1836]
1713,VHL P81S (c.241C>T),20.0,,,"['C.241C>T', 'PRO81SER', 'RS104893829']","[5039, 5390, 6505, 8413, 8441, 8971, 9428, 10157, 10657, 10796, 10849, 5369, 5537, 5806, 6703, 8826, 9905, 8521]","{<CIViC source 2324>, <CIViC source 3569>, <CIViC source 2376>, <CIViC source 2267>, <CIViC source 4404>, <CIViC source 3784>, <CIViC source 2239>, <CIViC source 2349>, <CIViC source 2632>, <CIViC source 4431>, <CIViC source 2605>, <CIViC source 3683>, <CIViC source 2240>, <CIViC source 3543>, <CIViC source 3517>, <CIViC source 2193>, <CIViC source 3522>, <CIViC source 4047>}",[],[],[1837]
1714,VHL L101G (c.301_302delinsGG),5.0,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.302T>C (p.Leu101Pro; L101P) (https://www.ncbi.nlm.nih.gov/clinvar/variation/480963/),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.302T>C (p.Leu101Pro; L101P) (https://www.ncbi.nlm.nih.gov/clinvar/variation/480963/),['C.301_302CT>GG'],[5040],{<CIViC source 2193>},[],[],[1838]
1715,VHL T105P (c.313A>C),12.5,,,"['C.313A>C', 'THR105PRO', 'RS1553619461']","[5293, 8325, 8363, 9105, 10003, 10445, 5041]","{<CIViC source 3487>, <CIViC source 2179>, <CIViC source 3458>, <CIViC source 3845>, <CIViC source 1278>, <CIViC source 2285>, <CIViC source 2193>}",[],[],[1839]
1716,VHL R107P (c.320G>C),7.5,,,"['C.320G>C', 'ARG107PRO', 'RS193922609']","[5042, 5552]","{<CIViC source 2193>, <CIViC source 2269>}",[],[],[1840]
1717,VHL L118fs (c.352_353insA),7.5,,,"['LEU118FS', 'RS869025641']",[5045],{<CIViC source 2193>},[],[],[1841]
1718,VHL N167T (c.392A>C),0.0,,,[],[],set(),[],[],[1842]
1719,VHL T133fs (c.397del),15.0,,,"['Q132FS (C.395DELA)', 'T133LFS*26']","[5047, 6056, 6607]","{<CIViC source 2610>, <CIViC source 2431>, <CIViC source 2193>}",[],[],[1843]
1720,VHL D143fs (c.430delG),7.5,,,[],"[5048, 10516]","{<CIViC source 2193>, <CIViC source 2187>}",[],[],[1844]
1721,VHL Q164* (c.490C>T),30.0,,,"['C.490C>T', 'Q164X', 'GLN164TER', 'RS5030819']","[5051, 5096, 5403, 7716, 8427, 9044, 10987, 5359, 6638, 9927, 6925]","{<CIViC source 2324>, <CIViC source 2657>, <CIViC source 2616>, <CIViC source 2239>, <CIViC source 2241>, <CIViC source 4473>, <CIViC source 2192>, <CIViC source 2193>, <CIViC source 3522>, <CIViC source 3821>, <CIViC source 3065>}",[],[],[1845]
1722,VHL Y175D (c.523T>G),7.5,,,"['C.523T>G', 'TYR175ASP']",[5053],{<CIViC source 2193>},[],[],[1846]
1723,VHL V181fs (c.540_543del),7.5,,,"['VAL181FS', 'C.540_543DELCGTC', 'RS869025664']","[5054, 8428]","{<CIViC source 2193>, <CIViC source 3522>}",[],[],[1847]
1724,VHL Q96* (c.286C>T),22.5,,,"['C.286C>T', 'Q96X', 'GLN96TER', 'RS1131690959']","[5058, 5271, 5583, 6811, 8531, 9273, 10001, 10444, 6327, 6143]","{<CIViC source 1370>, <CIViC source 3571>, <CIViC source 2179>, <CIViC source 2282>, <CIViC source 3973>, <CIViC source 1278>, <CIViC source 2509>, <CIViC source 2650>, <CIViC source 2285>, <CIViC source 2193>}",[],[],[1848]
1725,VHL P86R (c.257C>G),17.5,,,"['C.257C>G', 'PRO86ARG', 'RS730882034']","[5156, 5059, 6636, 6803, 6864, 8431, 9138, 6657]","{<CIViC source 2624>, <CIViC source 2655>, <CIViC source 3870>, <CIViC source 2614>, <CIViC source 2650>, <CIViC source 1264>, <CIViC source 2193>, <CIViC source 3522>}",[],[],[1849]
1726,VHL G144* (c.430G>T),7.5,,,"['C.430G>T', 'G144X', 'GLY144TER', 'RS869025650']","[5064, 8681, 6534, 8607]","{<CIViC source 2192>, <CIViC source 2193>, <CIViC source 1368>, <CIViC source 2488>}",[],[],[1850]
1727,VHL L128F (c.381_382delinsTT),0.0,,,['L128F (C.381_382GC>TT)'],"[5065, 5084, 9027, 10521]","{<CIViC source 1259>, <CIViC source 2193>, <CIViC source 3793>}",[],[],[1851]
1728,VHL L188P (c.563T>C),15.0,,,"['C.563T>C', 'LEU188PRO']","[5066, 5282, 8443, 9207, 9341, 9981, 10478]","{<CIViC source 2179>, <CIViC source 3919>, <CIViC source 1278>, <CIViC source 2285>, <CIViC source 2193>, <CIViC source 3522>, <CIViC source 4012>}",[],[],[1852]
1729,VHL S111C (c.330_331delinsTT),7.5,Note that there is a different variant reported at this amino acid position of VHL in ClinVar. Clinvar ID: 565557,Note that there is a different variant reported at this amino acid position of VHL in ClinVar. Clinvar ID: 565557,['S111C (C.330_331CA>TT)'],"[5067, 9200]","{<CIViC source 2193>, <CIViC source 3919>}",[],[],[1853]
1731,VHL R161P (c.482G>C),7.5,,,"['C.482G>C', 'ARG161PRO']","[5074, 5259, 5401, 10993, 5618, 9924]","{<CIViC source 2324>, <CIViC source 1259>, <CIViC source 4481>, <CIViC source 2222>, <CIViC source 2286>, <CIViC source 2241>}",[],[],[1855]
1732,VHL Q164R (c.491A>G),20.0,,,"['C.491A>G', 'GLN164ARG', 'RS267607170']","[5133, 5444, 5078, 8392, 8838, 8806, 10177]","{<CIViC source 1259>, <CIViC source 3510>, <CIViC source 2244>, <CIViC source 3684>, <CIViC source 2186>, <CIViC source 3677>, <CIViC source 1264>}",[],[],[1856]
1733,VHL G114R (c.340G>C),12.5,,,"['C.340G>C', 'GLY114ARG', 'RS869025636']","[5633, 5079, 5305, 8435, 9067, 9118, 9185, 9202, 9973, 10449, 10520, 10861, 5476, 8758]","{<CIViC source 1259>, <CIViC source 2179>, <CIViC source 2246>, <CIViC source 3919>, <CIViC source 3855>, <CIViC source 3870>, <CIViC source 2216>, <CIViC source 3669>, <CIViC source 2186>, <CIViC source 2285>, <CIViC source 2289>, <CIViC source 2193>, <CIViC source 3522>, <CIViC source 4436>}",[],[],[1857]
1734,VHL G93D (c.278G>A),0.0,,,"['C.278G>A', 'GLY93ASP', 'RS1553619440']","[5080, 6346, 6853, 8433, 8583, 8701, 10197, 10550, 6664]","{<CIViC source 3657>, <CIViC source 2655>, <CIViC source 2625>, <CIViC source 2514>, <CIViC source 3607>, <CIViC source 2186>, <CIViC source 2240>, <CIViC source 3522>, <CIViC source 2651>}",[],[],[1858]
1735,VHL G93S (c.277G>A),22.5,,,"['C.277G>A', 'GLY93SER', 'RS5030808']","[5081, 5100, 5407, 6493, 6507, 8699, 8716, 10158, 10813, 5362, 5562, 6072]","{<CIViC source 2276>, <CIViC source 1259>, <CIViC source 2595>, <CIViC source 2239>, <CIViC source 3661>, <CIViC source 2605>, <CIViC source 2241>, <CIViC source 2447>, <CIViC source 2192>, <CIViC source 3543>, <CIViC source 4416>, <CIViC source 3656>}",[],[],[1859]
1736,VHL L101R (c.302T>G),0.0,,,"['C.302T>G', 'LEU101ARG']","[5659, 5082, 5551, 6866, 5790]","{<CIViC source 1259>, <CIViC source 2269>, <CIViC source 2655>, <CIViC source 2294>, <CIViC source 2339>}",[],[],[1860]
1737,VHL L188Q (c.563T>A),10.0,,,"['C.563T>A', 'LEU188GLN']","[5085, 6061]","{<CIViC source 1259>, <CIViC source 2186>}",[],[],[1861]
1738,VHL K159E (c.475A>G),0.0,,,"['C.475A>G', 'LYS159GLU']","[5087, 10955]","{<CIViC source 1259>, <CIViC source 4473>}",[],[],[1862]
1739,EGFR Rare Exon 18-21 Mutation,30.0,"Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.","Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.",[],"[4755, 4762]",{<CIViC source 1503>},[],[],[1863]
1740,VHL P192fs (c.575delC),0.0,,,"['C.573DELC', 'PRO192GLN', 'C.575DELC', 'PRO192GLNFSTER10']",[5089],{<CIViC source 1259>},[],[],[1864]
1741,VHL Y112H (c.334T>C),10.0,,,"['C.334T>C', 'TYR112HIS', 'RS104893824']","[5091, 8775, 9029, 9090, 9096, 9201, 10190, 5475, 5520, 5658, 6428]","{<CIViC source 3828>, <CIViC source 1259>, <CIViC source 3919>, <CIViC source 4264>, <CIViC source 3793>, <CIViC source 3842>, <CIViC source 2293>, <CIViC source 2260>, <CIViC source 3671>, <CIViC source 2186>, <CIViC source 2246>}",[],[],[1865]
1742,EGFR L861,15.0,,,[],[4298],{<CIViC source 1503>},[],[],[1866]
1743,VHL R64P (c.191G>C),7.5,,,"['C.191G>C', 'ARG64PRO', 'RS104893826']","[5094, 5255, 6704, 6772, 8358, 8370, 9264, 10699, 10719, 10884, 10892, 10918, 5185, 5674, 6478, 6498, 8812, 8821, 8202]","{<CIViC source 3487>, <CIViC source 4442>, <CIViC source 4374>, <CIViC source 2600>, <CIViC source 3972>, <CIViC source 2192>, <CIViC source 2219>, <CIViC source 2175>, <CIViC source 2174>, <CIViC source 4378>, <CIViC source 3683>, <CIViC source 2647>, <CIViC source 3488>, <CIViC source 4462>, <CIViC source 3679>, <CIViC source 4443>, <CIViC source 2633>, <CIViC source 2581>, <CIViC source 3386>}",[],[],[1867]
1744,VHL N131fs (c.393_394delinsA),0.0,,,['N131FS (C.393_394CC>A)'],[5095],{<CIViC source 2192>},[],[],[1868]
1745,VHL E189fs (c.565del),15.0,,,"['E189FS (C.565DELG)', 'E189KFS*13 (C.565DEL)', 'GLU189LYSFS*13']","[5098, 6523, 8486, 8594]","{<CIViC source 2192>, <CIViC source 2605>, <CIViC source 3543>, <CIViC source 2302>}",[],[],[1869]
1747,VHL I151T (c.452T>C),25.0,,,"['C.452T>C', 'ILE151THR', 'RS869025655']","[5101, 6696, 7607, 8219, 8404, 10706, 5141, 5720]","{<CIViC source 2324>, <CIViC source 3389>, <CIViC source 2628>, <CIViC source 3512>, <CIViC source 4375>, <CIViC source 2192>, <CIViC source 1264>}",[],[],[1871]
1748,VHL K159fs (c.473dup),7.5,,,"['C.473INST', 'C.473DUPT']","[5102, 5280, 8683, 9986]","{<CIViC source 2192>, <CIViC source 2179>, <CIViC source 1278>}",[],[],[1872]
1749,VHL S68P (c.202T>C),7.5,,,"['C.202T>C', 'SER68PRO']","[5105, 8420, 9122, 10814]","{<CIViC source 2192>, <CIViC source 3855>, <CIViC source 4416>, <CIViC source 3521>}",[],[],[1873]
1750,VHL S80N (c.239G>A),25.0,,,"['C.239G>A', 'SER80ASN', 'RS5030805']","[5106, 5289, 5415, 8465, 9349, 9996, 10440, 5371, 5427, 8834, 9904]","{<CIViC source 2324>, <CIViC source 2179>, <CIViC source 3665>, <CIViC source 3533>, <CIViC source 2239>, <CIViC source 2241>, <CIViC source 1278>, <CIViC source 2192>, <CIViC source 2243>, <CIViC source 2285>, <CIViC source 3683>}",[],[],[1874]
1751,VHL V130F (c.388G>T),0.0,,,"['C.388G>T', 'VAL130PHE', 'RS104893830']","[5107, 5329, 5542, 8217, 5606]","{<CIViC source 3389>, <CIViC source 2269>, <CIViC source 2286>, <CIViC source 2192>, <CIViC source 2229>}",[],[],[1875]
1752,CIC Loss,0.0,,,[],"[5108, 5109, 5110, 5111, 5112, 5113, 5114, 5115, 5116]",{<CIViC source 2207>},[],[],[1876]
1753,ETV1 Overexpression,0.0,,,[],"[5117, 5118]",{<CIViC source 2207>},[],[],[1877]
1754,ETV5 Overexpression,0.0,,,[],"[5120, 5122]",{<CIViC source 2207>},[],[],[1878]
1755,ATXN1L Loss,0.0,,,[],"[5124, 5123]",{<CIViC source 2207>},[],[],[1879]
1756,ATM Loss,0.0,,,[],"[7461, 5126]","{<CIViC source 2958>, <CIViC source 2208>}",[],[],[1880]
1757,ATM F858L,0.0,,,[],[5127],{<CIViC source 2208>},[],[],[1881]
1759,VHL Q145* (c.433C>T),10.0,,,"['C.433C>T', 'Q145X', 'GLN145TER']","[5132, 5560, 6348, 5248, 5719, 5798, 6674]","{<CIViC source 2324>, <CIViC source 2344>, <CIViC source 2215>, <CIViC source 2625>, <CIViC source 2274>, <CIViC source 2514>, <CIViC source 1264>}",[],[],[1883]
1760,VHL E134* (c.400G>T),0.0,,,"['C.400G>T', 'E134X', 'GLU134TER']","[5136, 10830, 8248]","{<CIViC source 1264>, <CIViC source 3398>, <CIViC source 4419>}",[],[],[1884]
1761,VHL H115P (c.344A>C),7.5,,,"['C.344A>C', 'HIS115PRO', 'RS5030812']",[5140],{<CIViC source 1264>},[],[],[1885]
1762,VHL L128R (c.383T>G),17.5,,,"['C.383T>G', 'LEU128ARG']","[5144, 6114]","{<CIViC source 1264>, <CIViC source 2282>}",[],[],[1886]
1763,VHL L169P (c.506T>C),17.5,,,"['C.506T>C', 'LEU169PRO', 'RS1131690962']","[5147, 5197, 6164, 6589]","{<CIViC source 1264>, <CIViC source 1370>, <CIViC source 2611>, <CIViC source 2174>}",[],[],[1887]
1764,VHL L178R (c.533T>G),15.0,,,"['C.533T>G', 'LEU178ARG']","[5148, 8291, 5716, 6699, 6844, 5774]","{<CIViC source 2323>, <CIViC source 2628>, <CIViC source 3429>, <CIViC source 2650>, <CIViC source 2328>, <CIViC source 1264>}",[],[],[1888]
1765,VHL M54fs (c.161dup),17.5,,,"['M54IFS*78 (C.161DUP)', 'M54FS (C.161INST)', 'M54FS (C.161DUPT)']","[5151, 5283, 10427, 8700]","{<CIViC source 1264>, <CIViC source 2285>, <CIViC source 1278>, <CIViC source 3657>}",[],[],[1889]
1766,EGFR G719D,0.0,,,[],[],set(),[],[],[1890]
1767,EGFR L747P,5.0,,,['LEU747PRO'],[4220],{<CIViC source 1503>},[],[],[1891]
1768,EGFR V774A,7.5,,,['VAL774ALA'],[4226],{<CIViC source 1503>},[],[],[1892]
1769,VHL F91* (c.272_273delinsAA),10.0,,,['C.272TC>AA'],[5153],{<CIViC source 1264>},[],[],[1893]
1770,EGFR V774M,5.0,,,['VAL774MET'],[4231],{<CIViC source 1503>},[],[],[1894]
1771,EGFR K806E,5.0,,,"['LYS806GLU', 'RS754652044']",[4239],{<CIViC source 1503>},[],[],[1895]
1772,EGFR N826Y,5.0,,,['ASN826TYR'],[4244],{<CIViC source 1503>},[],[],[1896]
1773,EGFR V834I,7.5,,,[],[4248],{<CIViC source 1503>},[],[],[1897]
1774,EGFR L838P,0.0,,,[],[],set(),[],[],[1898]
1775,EGFR N842S,5.0,,,['ASN842SER'],[4256],{<CIViC source 1503>},[],[],[1899]
1776,EGFR T847I,0.0,,,[],[],set(),[],[],[1900]
1777,EGFR V851I,0.0,,,[],[],set(),[],[],[1901]
1778,VHL P86S (c.256C>T),42.5,,,"['C.256C>T', 'PRO86SER', 'RS398123481']","[5158, 5278, 5286, 5391, 5752, 6008, 6104, 6801, 7754, 8456, 8556, 8771, 8813, 8967, 8972, 9092, 9139, 9366, 10000, 10442, 11006, 5775, 5785, 6551, 6561, 8244, 8803]","{<CIViC source 3828>, <CIViC source 1368>, <CIViC source 2187>, <CIViC source 2334>, <CIViC source 2216>, <CIViC source 3783>, <CIViC source 2328>, <CIViC source 2285>, <CIViC source 4493>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 2610>, <CIViC source 3677>, <CIViC source 2611>, <CIViC source 4020>, <CIViC source 3784>, <CIViC source 3680>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 1259>, <CIViC source 2179>, <CIViC source 3870>, <CIViC source 3584>, <CIViC source 3398>, <CIViC source 1264>, <CIViC source 3529>, <CIViC source 3093>}",[],[],[1902]
1779,VHL S65P (c.193T>C),10.0,,,"['C.193T>C', 'SER65PRO', 'RS869025616']","[5160, 5509, 9370, 10429, 8793, 6130]","{<CIViC source 1370>, <CIViC source 2179>, <CIViC source 3676>, <CIViC source 3974>, <CIViC source 1264>, <CIViC source 2285>}",[],[],[1903]
1780,VHL S72P (c.214T>C),10.0,,,"['C.214T>C', 'SER72PRO', 'RS869025618']","[5162, 5841]","{<CIViC source 1264>, <CIViC source 2365>}",[],[],[1904]
1781,VHL T124fs (c.369del),0.0,,,"['C.367DELG', 'GLY123FS', 'C.369DELG', 'T124HFS*35']","[5164, 5715]","{<CIViC source 1264>, <CIViC source 2323>}",[],[],[1905]
1782,VHL L135fs (c.404del),7.5,,,"['C.404DELT', 'LEU135FS', 'L135Y*24']","[5165, 6912, 5195]","{<CIViC source 1264>, <CIViC source 2657>, <CIViC source 2174>}",[],[],[1906]
1783,VHL R177fs (c.528del),15.0,,,"['ARG176FS', 'C.528DELG', 'R177DFS*25 (C.528DELG)', 'R176FS (C.528DELG)', 'R176FS (C.528DEL)']","[5167, 5622, 5643, 8141, 8142]","{<CIViC source 1264>, <CIViC source 1329>, <CIViC source 3351>, <CIViC source 2286>}",[],[],[1907]
1784,VHL W88* (c.264G>A),7.5,,,"['C.264G>A', 'W88X', 'TRP88TER']","[5169, 5713, 8571, 6543]","{<CIViC source 1264>, <CIViC source 2323>, <CIViC source 3599>, <CIViC source 2488>}",[],[],[1908]
1785,VHL V155E (c.464T>A),10.0,,,"['C.464T>A', 'VAL155GLU']","[5171, 5686, 7739, 9053]","{<CIViC source 1264>, <CIViC source 3084>, <CIViC source 3823>, <CIViC source 2312>}",[],[],[1909]
1786,VHL V170A (c.509T>C),0.0,,,"['C.509T>C', 'VAL170ALA', 'RS864321642']","[6760, 6786]","{<CIViC source 2645>, <CIViC source 2649>}",[],[],[1910]
1788,VHL F76fs (c.223_224insT),7.5,,,"['ILE75FS', 'C.224DUPT', 'C.223_224INST']",[5174],{<CIViC source 1373>},[],[],[1912]
1789,VHL K196* (c.586A>T),5.0,,,"['C.586A>T', 'K196X', 'LYS196TER', 'RS281860296']","[10208, 5176, 8645]","{<CIViC source 2655>, <CIViC source 1373>, <CIViC source 3632>}",[],[],[1913]
1790,VHL R120G (c.358A>G),22.5,,,"['C.358A>G', 'ARG120GLY', 'RS869025642']","[5756, 5178, 6511, 6605, 8481, 6571]","{<CIViC source 1368>, <CIViC source 2174>, <CIViC source 2605>, <CIViC source 2610>, <CIViC source 3543>, <CIViC source 2611>}",[],[],[1914]
1791,VHL R161G (c.481C>G),7.5,,,"['C.481C>G', 'ARG161GLY', 'RS5030818']","[5258, 5310, 5180, 5353, 8572, 9922, 6582]","{<CIViC source 2324>, <CIViC source 2239>, <CIViC source 2174>, <CIViC source 2216>, <CIViC source 3600>, <CIViC source 2221>, <CIViC source 2611>}",[],[],[1915]
1792,VHL R167L (c.500G>T),7.5,,,"['RS5030821', 'C.500G>T', 'ARG167LEU']","[9191, 5183, 6588]","{<CIViC source 2611>, <CIViC source 2174>, <CIViC source 3870>}",[],[],[1916]
1793,VHL N141fs (c.422_440del),0.0,,,"['C.422_440DEL19', 'ASN141FS']","[8690, 5186, 6575]","{<CIViC source 2611>, <CIViC source 2174>}",[],[],[1917]
1794,VHL D126FS (c.375_376insC),5.0,,,"['C.375_376INSC', 'ASP126FS']","[4972, 5188, 6572]","{<CIViC source 2611>, <CIViC source 1329>, <CIViC source 2174>}",[],[],[1918]
1795,VHL E160fs (c.479_480delAG),10.0,,,"['GLU160FS', 'C.479_480DELAG', 'G160AFS*13', 'C.477_478DEL']","[5616, 5191, 5465]","{<CIViC source 2286>, <CIViC source 2245>, <CIViC source 2174>}",[],[],[1919]
1796,VHL G93R (c.277G>C),10.0,,,"['C.277G>C', 'GLY93ARG', 'RS5030808']","[8323, 10697, 10704, 5192, 5432, 5450, 8801]","{<CIViC source 3457>, <CIViC source 2174>, <CIViC source 4374>, <CIViC source 2245>, <CIViC source 3677>, <CIViC source 2243>}",[],[],[1920]
1797,VHL H115Y (c.343C>T),10.0,,,"['C.343C>T', 'HIS115TYR', 'RS5030811']","[9975, 10451, 5193, 5363, 6570]","{<CIViC source 2179>, <CIViC source 2239>, <CIViC source 2174>, <CIViC source 2285>, <CIViC source 2611>}",[],[],[1921]
1798,VHL I109FS (c.326delT),0.0,,,"['C.326DELT', 'ILE109FS']",[5194],{<CIViC source 2174>},[],[],[1922]
1799,VHL L153P (c.458T>C),7.5,,,"['C.458T>C', 'LEU153PRO']","[6920, 5196, 6576]","{<CIViC source 2657>, <CIViC source 2611>, <CIViC source 2174>}",[],[],[1923]
1800,VHL L188R (c.563T>G),7.5,,,"['C.563T>G', 'LEU188ARG']","[5200, 6595]","{<CIViC source 2611>, <CIViC source 2174>}",[],[],[1924]
1801,VHL L85fs (c.253_254ins38),0.0,,,[],[5201],{<CIViC source 2174>},[],[],[1925]
1803,VHL P103A (c.307C>G),0.0,,,"['C.307C>G', 'PRO103ALA', 'RS864622267']","[5204, 6565]","{<CIViC source 2611>, <CIViC source 2174>}",[],[],[1927]
1804,VHL P138T (c.412C>A),10.0,,,"['PRO138THR', 'C.412C>A']","[5205, 6574]","{<CIViC source 2611>, <CIViC source 2174>}",[],[],[1928]
1805,VHL P59fs (c.176delC),10.0,,,"['PRO59FS', 'C.176DELC', 'P59RFS*8 (C.176DELC)']","[5155, 4957, 8143, 5206]","{<CIViC source 1264>, <CIViC source 3351>, <CIViC source 1329>, <CIViC source 2174>}",[],[],[1929]
1806,VHL P59S (c.175C>T),0.0,,,"['C.175C>T', 'PRO59SER', 'RS876659041']","[10709, 5207]","{<CIViC source 2174>, <CIViC source 4375>}",[],[],[1930]
1807,VHL P61= (c.183C>G),0.0,,,"['C.183C>G', 'PRO61PRO', 'P61P (C.183C>G)']","[5555, 6021, 9534, 5208]","{<CIViC source 2431>, <CIViC source 2269>, <CIViC source 2174>, <CIViC source 2320>}",[],[],[1931]
1808,VHL Y175* (c.525C>A),5.0,"Note that there is a different variant reported at this amino acid position of VHL in ClinVar, which produces the same protein change. NM_000551.3(VHL):c.525C>G (p.Tyr175Ter), https://www-ncbi-nlm-nih-gov/clinvar/variation/182974/","Note that there is a different variant reported at this amino acid position of VHL in ClinVar, which produces the same protein change. NM_000551.3(VHL):c.525C>G (p.Tyr175Ter), https://www-ncbi-nlm-nih-gov/clinvar/variation/182974/","['Y175X', 'TYR175TER', 'C.525C>A']","[9545, 9980, 10475, 10799, 10917, 5216, 6621, 6166]","{<CIViC source 1370>, <CIViC source 2179>, <CIViC source 4462>, <CIViC source 4404>, <CIViC source 2174>, <CIViC source 2610>, <CIViC source 3671>, <CIViC source 2285>}",[],[],[1932]
1809,VHL Y98C  (c.293A>G),5.0,,,"['C.293A>G', 'TYR98CYS', 'RS864321643']","[5397, 5844, 6354, 8353, 8553, 9057, 9274, 5217, 6665, 8704, 6564]","{<CIViC source 3576>, <CIViC source 3657>, <CIViC source 2174>, <CIViC source 3485>, <CIViC source 2625>, <CIViC source 2514>, <CIViC source 3973>, <CIViC source 2365>, <CIViC source 2240>, <CIViC source 3824>, <CIViC source 2611>}",[],[],[1933]
1810,VHL V155G (c.464T>G),2.5,,,"['C.464T>G', 'VAL155GLY']","[5847, 5218, 6579]","{<CIViC source 2365>, <CIViC source 2174>, <CIViC source 2611>}",[],[],[1934]
1811,VHL V170G (c.509T>G),15.0,,,"['C.509T>G', 'VAL170GLY']","[5303, 7737, 8766, 8774, 9051, 9098, 10778, 10936, 10946, 5172, 5219, 8239, 6590]","{<CIViC source 3828>, <CIViC source 4476>, <CIViC source 3397>, <CIViC source 2174>, <CIViC source 4468>, <CIViC source 3084>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 1264>, <CIViC source 4402>, <CIViC source 2611>, <CIViC source 3823>}",[],[],[1935]
1812,VHL V66G (c.197T>G),0.0,,,"['C.197T>G', 'VAL66GLY']",[5220],{<CIViC source 2174>},[],[],[1936]
1813,VHL V84L (c.250G>C),0.0,,,"['VAL84LEU', 'C.250G>C', 'RS5030827']","[8419, 10196, 10488, 10499, 10722, 5221]","{<CIViC source 4350>, <CIViC source 2655>, <CIViC source 2174>, <CIViC source 3511>, <CIViC source 4378>, <CIViC source 3520>}",[],[],[1937]
1814,VHL Exon 2 Deletion,7.5,,,[],"[5754, 5528, 6625, 6714, 6850, 8745, 9107, 9352, 9390, 10173, 10214, 10302, 10787, 10881, 10969, 11001, 5223, 6286, 6633, 6671, 8259, 8825, 10009, 10163]","{<CIViC source 4442>, <CIViC source 1368>, <CIViC source 3845>, <CIViC source 3402>, <CIViC source 2502>, <CIViC source 4404>, <CIViC source 4493>, <CIViC source 3666>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 2612>, <CIViC source 2610>, <CIViC source 4473>, <CIViC source 3683>, <CIViC source 4020>, <CIViC source 2634>, <CIViC source 2650>, <CIViC source 3974>, <CIViC source 2585>, <CIViC source 2261>, <CIViC source 2625>, <CIViC source 2509>, <CIViC source 1372>}",[],[],[1938]
1815,VHL Exon 3 Deletion,25.0,,,['c.464-?_642+?del'],"[5308, 5850, 6290, 6360, 6626, 6715, 6852, 6854, 6857, 6886, 7132, 8122, 8123, 8638, 8742, 9108, 9119, 9261, 9282, 10106, 10167, 10174, 10788, 10968, 5224, 5759, 5767, 6223, 6423, 6476, 6521, 6542, 6634, 6641, 6672, 8740, 10006]","{<CIViC source 2617>, <CIViC source 1368>, <CIViC source 3845>, <CIViC source 2216>, <CIViC source 3351>, <CIViC source 2365>, <CIViC source 3972>, <CIViC source 2328>, <CIViC source 2192>, <CIViC source 2651>, <CIViC source 3665>, <CIViC source 1373>, <CIViC source 4404>, <CIViC source 3666>, <CIViC source 2174>, <CIViC source 2514>, <CIViC source 2612>, <CIViC source 2610>, <CIViC source 4473>, <CIViC source 1372>, <CIViC source 2490>, <CIViC source 2654>, <CIViC source 2599>, <CIViC source 3855>, <CIViC source 2488>, <CIViC source 3973>, <CIViC source 2634>, <CIViC source 2650>, <CIViC source 2505>, <CIViC source 2655>, <CIViC source 2625>, <CIViC source 3429>, <CIViC source 2576>, <CIViC source 2509>, <CIViC source 2585>}",[],[],[1939]
1816,VHL EXON 2-3 DELETION,7.5,,,[],"[6425, 6627, 6705, 6709, 6750, 6851, 6885, 8365, 10105, 10971, 5226, 6517, 6533, 10007]","{<CIViC source 3487>, <CIViC source 2655>, <CIViC source 2174>, <CIViC source 2644>, <CIViC source 3429>, <CIViC source 2488>, <CIViC source 1372>, <CIViC source 2634>, <CIViC source 2610>, <CIViC source 2633>, <CIViC source 2650>, <CIViC source 4473>, <CIViC source 2192>, <CIViC source 2585>}",[],[],[1940]
1817,VHL S168T (c.503G>C),0.0,,,"['C.503G>C', 'SER168THR']",[5229],{<CIViC source 2210>},[],[],[1941]
1818,VHL P86S (c.257C>T),0.0,,,[],[5231],{<CIViC source 2211>},[],[],[1942]
1819,VHL Q164H (c.492G>C),0.0,,,"['C.492G>C', 'GLN164HIS']","[8223, 8228, 10498, 5234, 5565]","{<CIViC source 3389>, <CIViC source 2211>, <CIViC source 2277>, <CIViC source 4350>}",[],[],[1943]
1820,VHL L63P (c.188T>C),0.0,,,"['C.188T>C', 'LEU63PRO', 'RS104893827']","[9034, 10710, 6126, 5235]","{<CIViC source 3815>, <CIViC source 2212>, <CIViC source 4375>, <CIViC source 2175>}",[],[],[1944]
1821,VHL F119fs (c.354_355del),0.0,,,"['PHE119GLNFSTER12', 'F119QFS*12']",[5237],{<CIViC source 2212>},[],[],[1945]
1822,VHL Y156C (c.467A>G),27.5,,,"['C.467A>G', 'TYR156CYS', 'RS397516441']","[5298, 5417, 5760, 6516, 8369, 8554, 8708, 9998, 10943, 5238, 5257, 5463, 6113, 8732, 8835]","{<CIViC source 3487>, <CIViC source 2179>, <CIViC source 4474>, <CIViC source 3665>, <CIViC source 1368>, <CIViC source 3657>, <CIViC source 2212>, <CIViC source 2605>, <CIViC source 2241>, <CIViC source 1278>, <CIViC source 3582>, <CIViC source 2220>, <CIViC source 2245>, <CIViC source 2277>, <CIViC source 3683>}",[],[],[1946]
1823,VHL Null (Partial deletion of 4.6 Kb),0.0,,,[],"[5244, 5879]","{<CIViC source 2214>, <CIViC source 2174>}",[],[],[1947]
1824,VHL R69fs (c.204insG),5.0,,,['C.204DUPG'],"[8957, 5245]","{<CIViC source 2215>, <CIViC source 3714>}",[],[],[1948]
1825,VHL G144fs (c.432insG),5.0,,,[],[5247],{<CIViC source 2215>},[],[],[1949]
1827,VHL Null (Partial deletion of Exon 2),0.0,,,[],"[5251, 5627, 9351, 10301]","{<CIViC source 2286>, <CIViC source 3974>, <CIViC source 2212>}",[],[],[1951]
1828,VHL Null (Partial deletion of Exon 3),0.0,,,[],"[5252, 5504, 5628]","{<CIViC source 2286>, <CIViC source 2251>, <CIViC source 2212>}",[],[],[1952]
1829,VHL N131K (c.393C>A),10.0,,,"['C.393C>A', 'ASN131LYS', 'RS1064794272']","[5529, 9095, 10457, 5266, 5457]","{<CIViC source 3828>, <CIViC source 1278>, <CIViC source 2245>, <CIViC source 2262>, <CIViC source 2285>}",[],[],[1953]
1830,VHL T105fs (c.315insAC),0.0,,,[],[5268],{<CIViC source 1278>},[],[],[1954]
1831,VHL P71fs (c.211insT),7.5,,,[],"[5269, 9969]","{<CIViC source 2179>, <CIViC source 1278>}",[],[],[1955]
1832,VHL E70K (c.208G>A),37.5,"The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.","The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.","['C.208G>A', 'GLU70LYS', 'RS5030802']","[5805, 6120, 6288, 6742, 6860, 7140, 8478, 8639, 8677, 10872, 5273, 5780, 6503, 8577]","{<CIViC source 1373>, <CIViC source 2655>, <CIViC source 2348>, <CIViC source 2334>, <CIViC source 2644>, <CIViC source 4438>, <CIViC source 2605>, <CIViC source 1278>, <CIViC source 2192>, <CIViC source 3604>, <CIViC source 3543>}",[],[],[1956]
1833,VHL H115Q (c.345C>G),22.5,,,"['HIS115GLN', 'C.345C>G', 'RS864622646']","[5515, 5494, 6604, 8780, 10452, 10736, 5274, 5755]","{<CIViC source 2249>, <CIViC source 2179>, <CIViC source 4380>, <CIViC source 1368>, <CIViC source 2610>, <CIViC source 3671>, <CIViC source 1278>, <CIViC source 2285>}",[],[],[1957]
1834,VHL H191FS (c.571delC),7.5,,,"['C.571DELC', 'HIS191FS']","[5275, 8152, 8784, 9102, 9983]","{<CIViC source 3828>, <CIViC source 2179>, <CIViC source 3351>, <CIViC source 1278>, <CIViC source 3671>}",[],[],[1958]
1835,VHL Null (c.1-?_463+?del),0.0,,,[],[],set(),[],[],[1959]
1836,VHL L140fs (c.417_418delTC),7.5,,,[],"[5279, 9972]","{<CIViC source 2179>, <CIViC source 1278>}",[],[],[1960]
1838,VHL P154= (c.462A>C),15.0,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/),"['C.462A>C', 'PRO154PRO', 'P154P (C.462A>C)']","[6513, 8451, 8483, 8691, 8788, 9196, 9979, 10690, 5285, 6577]","{<CIViC source 2179>, <CIViC source 3528>, <CIViC source 2616>, <CIViC source 2174>, <CIViC source 2605>, <CIViC source 3917>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 3543>, <CIViC source 2611>}",[],[],[1962]
1839,VHL S80R (c.238A>C),32.5,,,"['SER80ARG', 'C.238A>C', 'RS786202787']","[5510, 5288, 5547, 5548, 10962]","{<CIViC source 2179>, <CIViC source 1278>, <CIViC source 2269>, <CIViC source 4473>}",[],[],[1963]
1840,VHL R60FS (c.179delG),7.5,,,"['C.179DELG', 'ARG60FS']","[5290, 8422]","{<CIViC source 1278>, <CIViC source 3522>}",[],[],[1964]
1841,VHL I109TfsX50 (c.326delT),0.0,,,"['C.326DELT', 'ILE109THRFSX50', 'I109FS', 'ILE109THRFSTER50']",[5292],{<CIViC source 2216>},[],[],[1965]
1842,VHL W88S (c.263G>C),12.5,,,"['C.263G>C', 'TRP88SER', 'RS119103277']","[6805, 8212, 8985, 10443, 10548, 5296]","{<CIViC source 3389>, <CIViC source 3784>, <CIViC source 1278>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 2285>}",[],[],[1966]
1843,VHL Y156D (c.466T>G),17.5,,,"['C.466T>G', 'TYR156ASP']","[6112, 5297, 10462]","{<CIViC source 2179>, <CIViC source 2285>, <CIViC source 1278>}",[],[],[1967]
1844,VHL Y156* (c.468T>G),7.5,,,"['C.468T>G', 'Y156X', 'TYR156TER']","[5299, 6105, 9112, 9994, 10463, 6328]","{<CIViC source 1259>, <CIViC source 2179>, <CIViC source 3845>, <CIViC source 1278>, <CIViC source 2509>, <CIViC source 2285>}",[],[],[1968]
1845,VHL Y175* (c.525C>G),30.0,,,"['C.525C>G', 'Y175X', 'TYR175TER', 'RS5030835']","[9542, 5300, 5440, 8776, 9065, 10476, 6632, 7005, 8737]","{<CIViC source 3828>, <CIViC source 2179>, <CIViC source 3665>, <CIViC source 2612>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 2610>, <CIViC source 2243>, <CIViC source 2285>}",[],[],[1969]
1846,VHL V130L (c.388G>C),12.5,,,"['C.388G>C', 'VAL130LEU', 'RS104893830']","[6115, 6824, 6910, 9260, 10002, 10456, 10714, 10815, 5301, 6637, 10349, 5531]","{<CIViC source 2657>, <CIViC source 2179>, <CIViC source 2403>, <CIViC source 2615>, <CIViC source 2264>, <CIViC source 2282>, <CIViC source 4376>, <CIViC source 1278>, <CIViC source 2650>, <CIViC source 2285>, <CIViC source 3971>}",[],[],[1970]
1847,VHL Exon 2-3 Deletion,0.0,,,['NULL (C.341-?_642+?DEL)'],"[5306, 6349, 8633, 8741, 9106]","{<CIViC source 1373>, <CIViC source 3666>, <CIViC source 3845>, <CIViC source 2216>, <CIViC source 2514>}",[],[],[1971]
1848,VHL Splice Site (c.463+1G>A),0.0,,,['C.463+1G>A'],"[5307, 5398, 8389, 8660, 8783, 8986, 9097, 5895, 6540]","{<CIViC source 3828>, <CIViC source 2269>, <CIViC source 3784>, <CIViC source 2174>, <CIViC source 3489>, <CIViC source 2216>, <CIViC source 2488>, <CIViC source 3671>, <CIViC source 2240>}",[],[],[1972]
1850,VHL Splice Site (c.464-1G>A),5.0,,,"['C.464-1G>A', 'RS5030817']","[5309, 5387, 5612, 6831, 8460, 9364, 9398, 5357, 5898, 8201, 8575]","{<CIViC source 4020>, <CIViC source 2239>, <CIViC source 2174>, <CIViC source 3602>, <CIViC source 2216>, <CIViC source 2286>, <CIViC source 3385>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 3529>, <CIViC source 4028>}",[],[],[1974]
1851,VHL R167fsX4 (c.499_504delinsT),0.0,,,"['C.499_504DELINST', 'ARG167FSX4']",[5312],{<CIViC source 2216>},[],[],[1975]
1852,VHL E173* (c.517G>T),0.0,,,"['C.517G>T', 'E173X', 'GLU173TER']","[5315, 6735, 5672]","{<CIViC source 2303>, <CIViC source 2640>, <CIViC source 2216>}",[],[],[1976]
1853,VHL V194fs (c.581_582del),7.5,,,"['C.579_580DELTG', 'VAL194FSX39', 'C.581_582DELTG', 'V153FS', 'V194FS (C.581_582DELTG)']","[5317, 5441, 5624, 6065]","{<CIViC source 2286>, <CIViC source 2243>, <CIViC source 2187>, <CIViC source 2216>}",[],[],[1977]
1854,VHL Null (c.-678-?_340+?del),0.0,,,[],[5318],{<CIViC source 2216>},[],[],[1978]
1855,VHL Null (c.-678-?_642+?del),0.0,,,[],[5319],{<CIViC source 2216>},[],[],[1979]
1856,VHL R82P (c.245G>C),17.5,,,"['C.245G>C', 'ARG82PRO', 'RS794726890']","[5320, 5511, 5864, 6494, 6799, 6892, 8779, 9099, 10441, 8246]","{<CIViC source 2657>, <CIViC source 2179>, <CIViC source 3828>, <CIViC source 2596>, <CIViC source 2226>, <CIViC source 1278>, <CIViC source 3671>, <CIViC source 2650>, <CIViC source 3398>, <CIViC source 2285>}",[],[],[1980]
1857,VHL N100fsX131 (c.298_299InsA),0.0,,,[],[5322],{<CIViC source 2226>},[],[],[1981]
1858,SUFU Deletion,0.0,,,[],[5324],{<CIViC source 494>},[],[],[1982]
1859,PTCH1 Deletion,0.0,,,[],[5326],{<CIViC source 494>},[],[],[1983]
1860,VHL Splicing alteration (c.553+1G>A),0.0,,,[],[],set(),[],[],[1984]
1861,VHL Splicing alteration (c.553+5G>C),0.0,,,"['C.340+5G>C', 'IVS1+5G>C']",[],set(),[],[],[1985]
1862,VHL *214L (c.641G>T),10.0,,,"['X214L', '*214LEXT*15', 'RS869025668']",[5334],{<CIViC source 2230>},[],[],[1986]
1863,VHL *214W (c.642A>G),5.0,,,"['C.642A>G', 'TER214TRP', 'NM_000551:*214WEXT*14']",[5335],{<CIViC source 2230>},[],[],[1987]
1864,VHL *214C (c.642A>T),5.0,,,"['C.642A>T', 'X214C', 'TER214CYS', 'RS1559430011']",[5336],{<CIViC source 2230>},[],[],[1988]
1865,VHL G144fs (c.431delG),0.0,,,"['C.431DELG', 'GLY144FS', 'GLY144ASPFS', 'RS869025651']",[],set(),[],[],[1989]
1866,VHL Splice Site (c.464-1G>T),12.5,"There are three similar variants in ClinVar with this exact genomic position with ClinVar IDs: 223221, 223220, and 43603 of which only 223221 is an exact match (NM_000551.3:c.464-1G>T).","There are three similar variants in ClinVar with this exact genomic position with ClinVar IDs: 223221, 223220, and 43603 of which only 223221 is an exact match (NM_000551.3:c.464-1G>T).","['C.464-1G>T', 'RS5030817', 'IVS2-1G>T']","[5388, 5614, 5642, 6718, 6746, 8145, 8987, 5343, 6073, 6643, 6727]","{<CIViC source 2617>, <CIViC source 1329>, <CIViC source 2235>, <CIViC source 3784>, <CIViC source 2644>, <CIViC source 1710>, <CIViC source 2286>, <CIViC source 3351>, <CIViC source 2634>, <CIViC source 2240>, <CIViC source 275>}",[],[],[1990]
1868,VHL Splice Site (c.464-2A>T),5.0,,,"['C.464-2A>T', 'RS5030816']",[5351],{<CIViC source 2239>},[],[],[1992]
1870,VHL Q132* (c.394C>T),10.0,,,"['C.394C>T', 'Q132X', 'GLN132TER', 'RS5030813']","[5384, 5502, 10965, 5358, 5458, 8555, 9916]","{<CIViC source 2251>, <CIViC source 2324>, <CIViC source 2239>, <CIViC source 4473>, <CIViC source 2245>, <CIViC source 2240>, <CIViC source 3583>}",[],[],[1994]
1872,VHL L129fs (c.384delT),7.5,,,"['C.384DELT', 'LEU129FS']","[5365, 9915]","{<CIViC source 2324>, <CIViC source 2239>}",[],[],[1996]
1873,VHL L178Q (c.533T>A),12.5,,,"['C.533T>A', 'LEU178GLN', 'RS5030822']","[5867, 6764, 7749, 7890, 9060, 10781, 5366, 5696, 8257, 8719, 9930]","{<CIViC source 2324>, <CIViC source 3167>, <CIViC source 2375>, <CIViC source 4404>, <CIViC source 2239>, <CIViC source 2645>, <CIViC source 3092>, <CIViC source 2316>, <CIViC source 3662>, <CIViC source 3826>, <CIViC source 3402>}",[],[],[1997]
1874,VHL Splice Site (c.463+1G>C),5.0,,,"['C.463+1G>C', 'RS869025657']","[5373, 9919]","{<CIViC source 2324>, <CIViC source 2239>}",[],[],[1998]
1875,VHL V74G (c.221T>G),15.0,,,"['C.221T>G', 'VAL74GLY', 'RS5030803']","[9268, 5374, 5424, 5446, 5595, 9899]","{<CIViC source 2324>, <CIViC source 2239>, <CIViC source 2286>, <CIViC source 3973>, <CIViC source 2245>, <CIViC source 2243>}",[],[],[1999]
1876,VHL H115R (c.344A>G),10.0,,,"['C.344A>G', 'HIS115ARG', 'RS5030812']","[6819, 7748, 8216, 5377, 5605, 5772, 9913]","{<CIViC source 2324>, <CIViC source 3389>, <CIViC source 2239>, <CIViC source 3092>, <CIViC source 2286>, <CIViC source 2650>, <CIViC source 2328>}",[],[],[2000]
1877,VHL N131S (c.392A>G),7.5,,,[],"[5380, 6725]","{<CIViC source 2638>, <CIViC source 2240>}",[],[],[2001]
1878,VHL Q73FS (c.215delC),0.0,,,"['GLN73FS', 'C.215DELC']","[5385, 5860]","{<CIViC source 2370>, <CIViC source 2240>}",[],[],[2002]
1879,VHL S111R (c.333C>A),0.0,,,"['SER111ARG', 'C.333C>A']","[5392, 5714]","{<CIViC source 2323>, <CIViC source 2240>}",[],[],[2003]
1880,VHL S168FS (c.503delG),0.0,,,"['C.503DELG', 'SER168FS']",[5393],{<CIViC source 2240>},[],[],[2004]
1881,VHL P172fs  (c.516delT),0.0,,,"['C.516DELT', 'PRO172FS']",[5394],{<CIViC source 2240>},[],[],[2005]
1882,VHL Y112N (c.334T>A),0.0,,,"['C.334T>A', 'TYR112ASN', 'RS104893824']","[5866, 5396]","{<CIViC source 2374>, <CIViC source 2240>}",[],[],[2006]
1883,VHL R107G  (c.319C>G),7.5,,,"['C.319C>G', 'ARG107GLY', 'RS397516440']","[5399, 5523, 9353, 10303, 10991]","{<CIViC source 3974>, <CIViC source 2241>, <CIViC source 4473>, <CIViC source 2261>}",[],[],[2007]
1884,VHL G93C (c.277G>T),7.5,,,"['C.277G>T', 'GLY93CYS', 'RS5030808']","[5406, 8689, 8747, 9129, 6563]","{<CIViC source 3667>, <CIViC source 2174>, <CIViC source 2241>, <CIViC source 3862>, <CIViC source 2611>}",[],[],[2008]
1885,VHL G93V (c.278G>T),7.5,,,"['C.278G>T', 'GLY93VAL']","[5408, 8213, 9180]","{<CIViC source 2241>, <CIViC source 3870>, <CIViC source 3389>}",[],[],[2009]
1886,VHL L198Q  (c.593T>A),12.5,,,"['C.593T>A', 'LEU198GLN']","[5410, 8225, 5473]","{<CIViC source 2241>, <CIViC source 2245>, <CIViC source 3389>}",[],[],[2010]
1887,VHL S65A (c.193T>G),7.5,,,"['C.193T>G', 'SER65ALA', 'RS869025616']","[5413, 8471, 9284, 10262, 10299]","{<CIViC source 3974>, <CIViC source 2241>, <CIViC source 3915>, <CIViC source 3538>}",[],[],[2011]
1888,VHL S68W (c.203C>G),7.5,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 625222 C>T).,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 625222 C>T).,[],"[5414, 8402, 8454]","{<CIViC source 3529>, <CIViC source 2241>, <CIViC source 3513>}",[],[],[2012]
1889,VHL Y156N (c.466T>A),7.5,,,"['C.466T>A', 'TYR156ASN']",[5416],{<CIViC source 2241>},[],[],[2013]
1890,VHL P61fs (c.183insC),7.5,,,[],[5420],{<CIViC source 2243>},[],[],[2014]
1892,VHL Null (Complete deletion),0.0,,,[],"[10700, 10973, 10995]","{<CIViC source 4483>, <CIViC source 4473>, <CIViC source 4374>}",[],[],[2016]
1893,VHL Splice Site (c.341-1G>A),0.0,,,['IVS1-1G>A'],"[5425, 6530]","{<CIViC source 2231>, <CIViC source 2609>}",[],[],[2017]
1895,VHL Splicing alteration (c.464-1G>C),0.0,"There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.","There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.",['IVS2-1G>C'],[],set(),[],[],[2019]
1896,VHL L85P (c.254T>C),5.0,,,"['C.254T>C', 'LEU85PRO', 'RS5030828']","[6023, 6800, 10981, 5431, 6135, 8953]","{<CIViC source 1370>, <CIViC source 3088>, <CIViC source 2431>, <CIViC source 4473>, <CIViC source 2650>, <CIViC source 2243>}",[],[],[2020]
1897,VHL R108dup (c.322_324dup),5.0,,,"['R107DUP', 'R108INS (C.324INSCGC)']",[5434],{<CIViC source 2243>},[],[],[2021]
1899,VHL A149fs (c.449del14-nt),5.0,,,[],"[5442, 9283]","{<CIViC source 2243>, <CIViC source 3973>}",[],[],[2023]
1900,VHL 3'UTR alteration (c.639+10C>G),5.0,,,['C.639+10C>G'],[5443],{<CIViC source 2243>},[],[],[2024]
1902,VHL G114S (c.340G>A),5.0,,,"['C.340G>A', 'GLY114SER']","[6902, 8371, 8941, 10793, 5452, 5586, 8578]","{<CIViC source 2657>, <CIViC source 4404>, <CIViC source 3489>, <CIViC source 2283>, <CIViC source 2245>, <CIViC source 3714>, <CIViC source 3591>}",[],[],[2026]
1903,VHL W117fs (c.349dup),5.0,,,"['TRP117LEUFS', 'C.349DUPT']",[5453],{<CIViC source 2245>},[],[],[2027]
1904,VHL A122I (c.364_365GC>AT),12.5,,,"['C.364_365GC>AT', 'ALA122ILE']","[6417, 5456]","{<CIViC source 2241>, <CIViC source 2245>}",[],[],[2028]
1905,VHL N150fs (c.445_458del),5.0,,,"['C.445_458DEL', 'ASN150FS']",[5459],{<CIViC source 2245>},[],[],[2029]
1906,VHL I151M (c.453C>G),5.0,,,"['C.453C>G', 'ILE151MET']","[6011, 9123, 5460]","{<CIViC source 2245>, <CIViC source 2187>, <CIViC source 3856>}",[],[],[2030]
1907,VHL Splicing alteration (c.462-2A>G),0.0,,,[],[],set(),[],[],[2031]
1909,VHL L163H (c.488T>A),5.0,,,"['C.488T>A', 'LEU163HIS']","[8418, 5467, 5619]","{<CIViC source 2286>, <CIViC source 3519>, <CIViC source 2245>}",[],[],[2033]
1911,VHL C162fs (c.483del),5.0,,,"['C.483DELA', 'CYS162FS', 'C162AFS*8']",[5482],{<CIViC source 2246>},[],[],[2035]
1912,VHL Null (Partial deletion of Exons 2 & 3),7.5,,,[],"[5486, 5630, 8423]","{<CIViC source 2286>, <CIViC source 2246>, <CIViC source 3522>}",[],[],[2036]
1913,VHL N78I (c.233A>T),5.0,,,"['C.233A>T', 'ASN78ILE', 'RS5030804']","[5559, 6707, 10809, 5489]","{<CIViC source 2273>, <CIViC source 2634>, <CIViC source 1372>, <CIViC source 4415>}",[],[],[2037]
1914,VHL I147V (c.439A>G),0.0,,,"['C.439A>G', 'ILE147VAL', 'RS1057517560']",[5490],{<CIViC source 2248>},[],[],[2038]
1915,VHL W88FS (c.263_265delGGCinsTT),5.0,,,"['C.263_265DELGGCINSTT', 'TRP88FS']",[5495],{<CIViC source 1372>},[],[],[2039]
1916,VHL K159fs (c.477_478insCA),5.0,,,"['LYS159FS', 'C.477_478INSCA']","[5496, 8798]","{<CIViC source 1372>, <CIViC source 3676>}",[],[],[2040]
1917,VHL Q73FS (c.217delC),5.0,,,"['C.217DELC', 'GLN73FS']",[5500],{<CIViC source 1372>},[],[],[2041]
1918,VHL A149fs (c.445delG),5.0,,,"['C.445DELG', 'ALA149FS']",[5501],{<CIViC source 1372>},[],[],[2042]
1919,VHL G104A (c.311G>C),15.0,,,"['C.311G>C', 'GLY104ALA', 'RS869025630']","[5512, 6109]","{<CIViC source 2179>, <CIViC source 1278>}",[],[],[2043]
1920,VHL R107H (c.320G>A),10.0,,,"['C.320G>A', 'ARG107HIS', 'RS193922609']","[5513, 8359, 10992, 8818]","{<CIViC source 2179>, <CIViC source 4473>, <CIViC source 3683>, <CIViC source 3487>}",[],[],[2044]
1921,VHL S111C (c.331A>T),17.5,,,"['SER111CYS', 'RS1559426203', 'C.331A>T']","[5514, 6600, 5564]","{<CIViC source 2179>, <CIViC source 2610>, <CIViC source 2277>}",[],[],[2045]
1922,VHL V155L (c.463G>C),10.0,,,[],"[5516, 10461, 10977]","{<CIViC source 2179>, <CIViC source 2285>, <CIViC source 4473>}",[],[],[2046]
1923,CTNNB1 Exon 3 Deletion,0.0,,,[],"[5517, 9662]","{<CIViC source 3103>, <CIViC source 2258>}",[],[],[2047]
1924,VHL Splice Site (c.463+1G>T),0.0,Two similar variants at this exact genomic location are reported in ClinVar (ClinVar ID 526679 G>A and ClinVar ID 223217 G>C).,Two similar variants at this exact genomic location are reported in ClinVar (ClinVar ID 526679 G>A and ClinVar ID 223217 G>C).,['C.463+1G>T'],"[5524, 6877, 9423, 5896, 6675, 6578]","{<CIViC source 2269>, <CIViC source 2655>, <CIViC source 2625>, <CIViC source 2174>, <CIViC source 2261>, <CIViC source 2611>}",[],[],[2048]
1926,DICER1 E1705K,20.0,,,['GLU1705LYS'],"[5533, 5885, 11480]","{<CIViC source 2265>, <CIViC source 2266>}",[],[],[2050]
1927,DICER1 D1709N,37.5,,,[],"[5534, 5886, 5899]","{<CIViC source 2265>, <CIViC source 2266>}",[],[],[2051]
1928,DICER1 E1813Q,22.5,,,['GLU1813GLN'],"[5535, 5892]","{<CIViC source 2265>, <CIViC source 2266>}",[],[],[2052]
1929,VHL D126Y (c.376G>T),0.0,,,"['C.376G>T', 'ASP126TYR', 'RS104893831']",[5536],{<CIViC source 2264>},[],[],[2053]
1930,VHL T124I (c.371C>T),0.0,,,"['C.371C>T', 'THR124ILE', 'RS193922610']","[5541, 5803, 8388, 10725]","{<CIViC source 2347>, <CIViC source 4378>, <CIViC source 2269>, <CIViC source 3489>}",[],[],[2054]
1931,VHL P146fs (c.437del),7.5,,,"['C.436DELC', 'PRO146FS', 'C.437DELC', 'P146LFS*13']",[5544],{<CIViC source 2269>},[],[],[2055]
1932,VHL W88R (c.262T>C),7.5,,,"['TRP88ARG', 'C.262T>C', 'RS1553619431']","[5549, 6865, 8417, 10871]","{<CIViC source 2655>, <CIViC source 3518>, <CIViC source 2269>, <CIViC source 4438>}",[],[],[2056]
1933,VHL H115fs (c.344del),7.5,,,"['C.344DELA', 'HIS115FS', 'RS1553619937', 'HIS115PROFSTER44 (C.344DEL)', 'H115FS (C.344DELA)', 'H115PFS*44 (C.344DEL)']",[5553],{<CIViC source 2269>},[],[],[2057]
1934,VHL P102fs (c.305delC),7.5,,,"['C.305DELC', 'PRO102FS']",[5554],{<CIViC source 2269>},[],[],[2058]
1935,VHL G144R (c.430G>A),0.0,,,"['C.430G>A', 'GLY144ARG', 'RS869025650']","[5556, 5856]","{<CIViC source 2367>, <CIViC source 2270>}",[],[],[2059]
1936,VHL H125P (c.374A>C),0.0,,,"['C.374A>C', 'HIS125PRO', 'RS869025643']","[6737, 8377, 10772, 10855, 5557, 5808]","{<CIViC source 2271>, <CIViC source 3489>, <CIViC source 4433>, <CIViC source 4400>, <CIViC source 2642>, <CIViC source 2349>}",[],[],[2060]
1937,ACVR1 Gain-of-Function,15.0,,,[],[4845],{<CIViC source 2149>},[],[],[2061]
1938,VHL Q164H (c.491G>C),0.0,,,"['GLN164HIS', 'C.491G>C']",[],set(),[],[],[2062]
1939,STK11 F354L,0.0,,,"['PHE354LEU', 'RS59912467']",[5568],{<CIViC source 2278>},[],[],[2063]
1940,VHL P192S (c.574C>T),0.0,,,"['C.574C>T', 'PRO192SER', 'RS28940300']",[5570],{<CIViC source 2264>},[],[],[2064]
1941,VHL Splice Region (c.463+3A>G),0.0,There is an identical variant match in ClinVar at this exact genomic position with ClinVar ID: 428796 (A>G).,There is an identical variant match in ClinVar at this exact genomic position with ClinVar ID: 428796 (A>G).,['IVS2+3A>G'],"[5697, 8220, 9061, 5572]","{<CIViC source 2316>, <CIViC source 3826>, <CIViC source 3389>, <CIViC source 2280>}",[],[],[2065]
1942,VHL Y175N (c.523T>A),7.5,,,"['C.523T>A', 'TYR175ASN']","[5576, 5701, 8809]","{<CIViC source 2282>, <CIViC source 3677>, <CIViC source 2317>}",[],[],[2066]
1943,VHL Y175C (c.524A>G),7.5,,,"['C.524A>G', 'TYR175CYS', 'RS193922613']","[5577, 7133, 10732, 10927, 5747, 5853, 8810, 8264]","{<CIViC source 2326>, <CIViC source 2767>, <CIViC source 4463>, <CIViC source 2282>, <CIViC source 4378>, <CIViC source 3677>, <CIViC source 2366>}",[],[],[2067]
1944,VHL V87A (c.260T>C),0.0,,,"['C.260T>C', 'VAL87ALA']","[5588, 10199]","{<CIViC source 2655>, <CIViC source 2285>}",[],[],[2068]
1945,VHL P97L (c.290C>T),0.0,,,"['C.290C>T', 'PRO97LEU']","[5589, 8702, 8727]","{<CIViC source 3657>, <CIViC source 3665>, <CIViC source 2285>}",[],[],[2069]
1946,VHL L184H (c.551T>A),0.0,,,"['C.551T>A', 'LEU184HIS']","[5590, 8787, 8713]","{<CIViC source 3657>, <CIViC source 2285>, <CIViC source 3671>}",[],[],[2070]
1947,VHL R69fs (c.204insG),0.0,,,[],[],set(),[],[],[2071]
1949,VHL G106fs (c.316insA),0.0,,,[],[5602],{<CIViC source 2286>},[],[],[2073]
1950,VHL Splice Site (c.340+1G>T),0.0,"Two very similar variants are reported in ClinVar at this exact genomic position: (ClinVar ID 223190, G>A) and (ClinVar ID 182973 G>C).","Two very similar variants are reported in ClinVar at this exact genomic position: (ClinVar ID 223190, G>A) and (ClinVar ID 182973 G>C).","['C.340+1G>T', 'RS730882032', 'IVS1 1G>T']","[5604, 7734, 6487]","{<CIViC source 2286>, <CIViC source 2589>}",[],[],[2074]
1951,VHL Splice Site (c.463+2T>C),27.5,,,"['C.463+2T>C', 'RS5030814']","[5610, 6514, 6610, 8387, 8487, 8684, 9379, 10794, 10853, 5356, 9920]","{<CIViC source 2324>, <CIViC source 4020>, <CIViC source 4404>, <CIViC source 2239>, <CIViC source 3489>, <CIViC source 2286>, <CIViC source 2605>, <CIViC source 4433>, <CIViC source 2610>, <CIViC source 2192>, <CIViC source 3543>}",[],[],[2075]
1952,VHL V155M (c.463G>A),0.0,,,"['C.463G>A', 'VAL155MET', 'RS869025659']","[8457, 10617, 5611, 8797, 6157]","{<CIViC source 1370>, <CIViC source 3676>, <CIViC source 2286>, <CIViC source 2240>, <CIViC source 3529>}",[],[],[2076]
1953,VHL Splice Site (c.464-1G>C),5.0,"There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.","There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.","['C.464-1G>C', 'RS5030817', 'IVS2-1G>C']","[5429, 5613, 6830, 8221, 10795, 10874, 5745]","{<CIViC source 2231>, <CIViC source 3389>, <CIViC source 4439>, <CIViC source 4404>, <CIViC source 2286>, <CIViC source 2650>, <CIViC source 1264>}",[],[],[2077]
1954,VHL Splice Site (c.464-2A>G),15.0,,,"['C.464-2A>G', 'RS5030816']","[5615, 10875, 10967, 5462, 5724, 5851, 6685, 9921]","{<CIViC source 2324>, <CIViC source 4439>, <CIViC source 2239>, <CIViC source 2626>, <CIViC source 2286>, <CIViC source 4473>, <CIViC source 2245>, <CIViC source 1264>}",[],[],[2078]
1955,VHL Q164L (c.491A>T),7.5,,,"['C.491A>T', 'GLN164LEU']","[6617, 10954, 5620]","{<CIViC source 2286>, <CIViC source 2610>, <CIViC source 4473>}",[],[],[2079]
1958,VHL Null (Partial deletion of Exon 1),0.0,,,[],"[5626, 5685, 5698]","{<CIViC source 2286>, <CIViC source 2316>, <CIViC source 2311>}",[],[],[2082]
1959,VHL Null (Partial deletion of Exons 1 & 2),0.0,,,[],[5629],{<CIViC source 2286>},[],[],[2083]
1960,VHL P81L (c.242C>T),0.0,,,"['C.242C>T', 'PRO81LEU', 'RS193922608']","[8749, 9004, 5631, 8871]","{<CIViC source 3667>, <CIViC source 2288>, <CIViC source 3792>, <CIViC source 3711>}",[],[],[2084]
1961,VHL T152I (c.455C>T),0.0,,,"['C.455C>T', 'THR152ILE']","[8814, 10682, 5632]","{<CIViC source 3487>, <CIViC source 2288>, <CIViC source 3681>}",[],[],[2085]
1963,VHL L63fs (c.189_192delGCGC),0.0,,,[],[5635],{<CIViC source 2187>},[],[],[2087]
1964,VHL F76del (c.227_229del),120.0,Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).,Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).,"['PHE76DEL', 'C.224_226DELTCT', 'C.226_228DELTTC', 'C.227_229DELTCT', 'DELPHE76', 'F76DEL (C.227_229DELTCT)']","[4919, 5682, 7752, 5378, 5386, 5421, 5540, 5596, 5636, 5641, 5650, 5744, 5749, 5750, 5766, 6121, 6711, 6712, 6743, 6758, 6784, 6794, 6862, 8138, 8380, 8430, 8464, 8570, 8579, 8696, 8969, 9269, 9766, 9796, 9995, 10108, 10435, 10705, 10866, 10985, 5203, 5340, 5426, 5447, 5497, 5654, 6547, 8651, 9901, 6557]","{<CIViC source 2231>, <CIViC source 2324>, <CIViC source 2311>, <CIViC source 2269>, <CIViC source 1368>, <CIViC source 2187>, <CIViC source 3351>, <CIViC source 2328>, <CIViC source 2649>, <CIViC source 2192>, <CIViC source 4375>, <CIViC source 2285>, <CIViC source 3595>, <CIViC source 3653>, <CIViC source 1329>, <CIViC source 2622>, <CIViC source 2174>, <CIViC source 2186>, <CIViC source 3532>, <CIViC source 4473>, <CIViC source 1278>, <CIViC source 2610>, <CIViC source 2243>, <CIViC source 2611>, <CIViC source 2193>, <CIViC source 3784>, <CIViC source 3489>, <CIViC source 3973>, <CIViC source 2634>, <CIViC source 3606>, <CIViC source 2245>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 1259>, <CIViC source 2179>, <CIViC source 2235>, <CIViC source 2655>, <CIViC source 2645>, <CIViC source 2644>, <CIViC source 2286>, <CIViC source 2190>, <CIViC source 2282>, <CIViC source 1264>, <CIViC source 1372>, <CIViC source 3093>, <CIViC source 3522>, <CIViC source 4436>}",[],[],[2088]
1965,VHL R82_V84del (c.243_251del),17.5,,,"['P81DELRVV (C.243_251DELGCGCGTCGT)', 'ARG82_VAL84DEL']","[5726, 5637, 6722]","{<CIViC source 1264>, <CIViC source 1329>, <CIViC source 2636>}",[],[],[2089]
1966,VHL P40fs (c.118ins),7.5,,,[],[5638],{<CIViC source 1329>},[],[],[2090]
1967,VHL T152fs (c.455insA),15.0,,,[],"[5639, 5734, 10518]","{<CIViC source 1264>, <CIViC source 1329>, <CIViC source 2187>}",[],[],[2091]
1968,VHL T157fs (c.472ins),7.5,,,[],[5640],{<CIViC source 1329>},[],[],[2092]
1969,VHL Splice Site (c.464-2A>C),0.0,,,['C.464-2A>C'],[5644],{<CIViC source 1259>},[],[],[2093]
1970,VHL T157fs (c.472ins1-nt),0.0,,,[],[5645],{<CIViC source 1259>},[],[],[2094]
1971,VHL I151fs (c.452insA),0.0,,,[],[5647],{<CIViC source 1259>},[],[],[2095]
1972,VHL F158ins (c.472insTTT),0.0,,,[],[5648],{<CIViC source 1259>},[],[],[2096]
1973,VHL G93_Y98del (c.275_292del),7.5,,,['D92_Y98DEL'],[5649],{<CIViC source 2193>},[],[],[2097]
1974,VHL E160fs (c.477del),7.5,,,"['C.475DELA', 'LYS159FS', 'E160SFS*10']","[5651, 8425, 8462]","{<CIViC source 2193>, <CIViC source 3522>, <CIViC source 3530>}",[],[],[2098]
1975,VHL V66del (c.197_220del),5.0,,,['197DEL24'],[5653],{<CIViC source 1278>},[],[],[2099]
1976,VHL S183fs (c.548delC),0.0,,,"['C.548DELC', 'SER183FS']","[4904, 9256, 5656]","{<CIViC source 1710>, <CIViC source 2185>, <CIViC source 3968>}",[],[],[2100]
1977,VHL V84M (c.250G>A),5.0,,,"['C.250G>A', 'VAL84MET', 'RS5030827']","[9134, 10721, 10821, 5660]","{<CIViC source 4378>, <CIViC source 2295>, <CIViC source 3862>, <CIViC source 4417>}",[],[],[2101]
1979,VHL Null (Partial deletion),0.0,,,[],"[5804, 8405, 8411, 8421, 8494, 8647, 8714, 9028, 9045, 10194, 10929, 10945, 5662, 5870, 6598, 8869]","{<CIViC source 2269>, <CIViC source 2295>, <CIViC source 3515>, <CIViC source 3546>, <CIViC source 3793>, <CIViC source 2174>, <CIViC source 3512>, <CIViC source 2611>, <CIViC source 3710>, <CIViC source 2347>, <CIViC source 3660>, <CIViC source 4465>, <CIViC source 4475>, <CIViC source 3522>, <CIViC source 3821>, <CIViC source 3790>}",[],[],[2103]
1980,VHL Splice Region (c.340+5G>C),5.0,,,"['C.340+5G>C', 'C.533+5G>C', 'IVS1+5G>C']","[5004, 5333, 6818, 6869, 7721, 8613, 9937, 5246, 5661, 10658, 5664]","{<CIViC source 2376>, <CIViC source 2295>, <CIViC source 2215>, <CIViC source 2655>, <CIViC source 2297>, <CIViC source 2190>, <CIViC source 2621>, <CIViC source 2650>, <CIViC source 1264>, <CIViC source 2229>, <CIViC source 3068>}",[],[],[2104]
1981,VHL D197N (c.589G>A),0.0,,,"['C.589G>A', 'ASP197ASN']","[5666, 8588]","{<CIViC source 2299>, <CIViC source 3608>}",[],[],[2105]
1982,VHL S80G (c.238A>G),0.0,,,"['C.238A>G', 'SER80GLY', 'RS786202787']","[6502, 5668]","{<CIViC source 2604>, <CIViC source 2300>}",[],[],[2106]
1983,VHL F76L (c.228C>G),0.0,,,"['C.228C>G', 'PHE76LEU']",[5671],{<CIViC source 2302>},[],[],[2107]
1984,ARID1A Underexpression,34.0,,,[],"[5676, 5787, 5675]","{<CIViC source 2336>, <CIViC source 2306>, <CIViC source 2305>}",[],[],[2108]
1986,VHL R82L (c.245G>T),0.0,,,"['C.245G>T', 'ARG82LEU', 'RS794726890']","[5678, 5751, 9062, 10489, 10864, 5692, 5694]","{<CIViC source 1368>, <CIViC source 2308>, <CIViC source 3511>, <CIViC source 2316>, <CIViC source 3826>, <CIViC source 2314>, <CIViC source 4436>}",[],[],[2110]
1988,VHL N78D (c.232A>G),0.0,,,"['C.232A>G', 'ASN78ASP', 'RS869025621']","[5687, 6744, 8495]","{<CIViC source 2313>, <CIViC source 3546>, <CIViC source 2644>}",[],[],[2112]
1989,VHL N78Y (c.232A>T),0.0,,,"['C.232A>T', 'ASN78TYR', 'RS869025621']","[5688, 8328, 8538]","{<CIViC source 3576>, <CIViC source 3460>, <CIViC source 2180>}",[],[],[2113]
1990,VHL Splice Site (c.340+1G>A),50.0,,,"['C.340+1G>A', 'C.553+1G>A']","[5689, 5845, 7712, 5099, 5332, 5488, 6509, 8215, 8480, 8772, 9091, 9974, 8602, 8729, 8796, 9912]","{<CIViC source 3828>, <CIViC source 2179>, <CIViC source 3389>, <CIViC source 3665>, <CIViC source 3676>, <CIViC source 2324>, <CIViC source 2247>, <CIViC source 2605>, <CIViC source 2365>, <CIViC source 1278>, <CIViC source 2180>, <CIViC source 3671>, <CIViC source 2192>, <CIViC source 2229>, <CIViC source 3543>, <CIViC source 3063>}",[],[],[2114]
1991,VHL Y185* (c.555C>A),0.0,,,"['Y185X', 'TYR185TER', 'C.555C>A']","[5690, 10964]","{<CIViC source 4473>, <CIViC source 2180>}",[],[],[2115]
1993,VHL P95R (c.284C>G),0.0,,,"['C.284C>G', 'PRO95ARG']",[5703],{<CIViC source 2317>},[],[],[2117]
1994,VHL P103L (c.308C>T),0.0,,,"['C.308C>T', 'PRO103LEU']","[10873, 5704]","{<CIViC source 2318>, <CIViC source 4438>}",[],[],[2118]
1995,VHL F119S (c.356T>C),0.0,,,"['C.356T>C', 'PHE119SER']","[8566, 5705, 8204]","{<CIViC source 2318>, <CIViC source 3386>, <CIViC source 3591>}",[],[],[2119]
1996,VHL P138L (c.413C>T),0.0,,,"['C.413C>T', 'PRO138LEU', 'RS780178275']",[5708],{<CIViC source 2321>},[],[],[2120]
1997,VHL P61fs (c.181delCCGT),0.0,,,[],[5710],{<CIViC source 2323>},[],[],[2121]
1998,VHL S68* (c.203C>A),0.0,,,"['C.203C>A', 'S68X', 'SER68TER']","[5711, 6132]","{<CIViC source 1370>, <CIViC source 2323>}",[],[],[2122]
1999,VHL C77del (c.229_231delTGC),0.0,,,"['C.229_231DELTGC', 'CYS77DEL']",[5712],{<CIViC source 2323>},[],[],[2123]
2000,VHL W88C (c.264G>C),0.0,,,"['C.264G>C', 'TRP88CYS', 'RS869025622']","[9661, 5717]","{<CIViC source 2324>, <CIViC source 3389>}",[],[],[2124]
2001,VHL Q132P (c.395A>C),17.5,,,"['C.395A>C', 'GLN132PRO', 'RS1347416980']","[5131, 8218, 9977, 10458, 10979, 5718]","{<CIViC source 2324>, <CIViC source 2179>, <CIViC source 3389>, <CIViC source 4473>, <CIViC source 1264>, <CIViC source 2285>}",[],[],[2125]
2002,VHL D198fs (c.592_593delCT),0.0,,,"['C.592_593DELCT', 'ASP198FS']",[5721],{<CIViC source 2240>},[],[],[2126]
2003,VHL E94FS (c.279delC),5.0,,,"['C.279DELC', 'GLY93FS', 'GLU94FS']",[5722],{<CIViC source 2325>},[],[],[2127]
2004,VHL P97= (c.291C>G),0.0,,,"['C.291C>G', 'PRO97PRO', 'RS1805159']",[5723],{<CIViC source 2325>},[],[],[2128]
2005,VHL G114dup (c.342dupGGT),5.0,,,[],[5725],{<CIViC source 1264>},[],[],[2129]
2006,VHL S65FS (c.194delC),7.5,,,"['C.194DELC', 'SER65FS']","[5727, 9344]","{<CIViC source 1264>, <CIViC source 3711>}",[],[],[2130]
2007,VHL Q73fs (c.214insGCCC),7.5,,,[],[5728],{<CIViC source 1264>},[],[],[2131]
2008,VHL C77fs (c.228dup),17.5,,,"['440_441INSC', 'C.227_228INSC', 'F76FS', 'C.227INSC']","[5729, 4961, 8144, 8520]","{<CIViC source 1264>, <CIViC source 3351>, <CIViC source 3568>, <CIViC source 1329>}",[],[],[2132]
2009,VHL Splice Site (c.341-2A>C),12.5,,,['C.341-2A>C'],"[5748, 5730]","{<CIViC source 2192>, <CIViC source 1264>}",[],[],[2133]
2010,VHL Intronic deletion (c.341-13delCGTTTCCAACAATTTCTCGGTGT),5.0,,,[],[5731],{<CIViC source 1264>},[],[],[2134]
2011,VHL G123fs (c.369_375delGACACAC),2.5,,,"['GLY123FS', 'C.369_375DELGACACAC']","[8414, 5732]","{<CIViC source 1264>, <CIViC source 3517>}",[],[],[2135]
2012,VHL H125fs (c.374insA),7.5,,,[],[5733],{<CIViC source 1264>},[],[],[2136]
2013,VHL K159fs (c.474_476delGAAinsC),7.5,,,"['C.474_476DELGAAINSC', 'LEU158FS', 'LYS159FS', 'K159FS']",[5735],{<CIViC source 1264>},[],[],[2137]
2014,VHL Y175* (c.525delC),7.5,,,"['TYR175FS', 'C.525DELC']",[5736],{<CIViC source 1264>},[],[],[2138]
2015,VHL L188fs (c.562delC),10.0,,,"['C.562DELC', 'LEU188FS']",[5737],{<CIViC source 1264>},[],[],[2139]
2016,VHL K196fs (c.584_585delAG),10.0,,,"['C.584_585DELAG', 'GLN195FS']",[5738],{<CIViC source 1264>},[],[],[2140]
2017,VHL D197FS (c.589delG),7.5,,,"['C.589DELG', 'ASP197FS']",[5739],{<CIViC source 1264>},[],[],[2141]
2018,VHL T202fs (c.606insA),7.5,,,['T202FS (C.606DUPA)'],"[5740, 6678]","{<CIViC source 1264>, <CIViC source 2625>}",[],[],[2142]
2019,VHL R113FS (c.337delC),7.5,,,"['C.337DELC', 'ARG113FS']",[5741],{<CIViC source 1264>},[],[],[2143]
2020,VHL A56fs (c.166dup),7.5,,,"['C.165DUP', 'C.165_166DUPG', 'A56GFS*76 (C.166DUP)']",[5742],{<CIViC source 1264>},[],[],[2144]
2021,VHL P61FS (c.182_185delCCGT),10.0,,,"['C.182_185DELCCGT', 'PRO61FS']",[5743],{<CIViC source 1264>},[],[],[2145]
2022,VHL Splice Region (c.463+3A>T),0.0,One similar variant at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,One similar variant at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,['C.463+3A>T'],[5746],{<CIViC source 1264>},[],[],[2146]
2023,VHL K196E (c.586A>G),0.0,,,"['C.586A>G', 'LYS196GLU', 'RS281860296']",[5758],{<CIViC source 2326>},[],[],[2147]
2024,VHL R161= (c.481C>A),5.0,,,['R161R (C.481C>A)'],"[5768, 6687]","{<CIViC source 2626>, <CIViC source 2328>}",[],[],[2148]
2025,VHL N90I (c.269A>T),0.0,,,"['C.269A>T', 'ASN90ILE', 'RS143985153']","[8287, 8290, 6808, 6897, 8116, 8117, 8118, 10549, 10959, 5770, 6339]","{<CIViC source 2657>, <CIViC source 3429>, <CIViC source 3349>, <CIViC source 4473>, <CIViC source 2650>, <CIViC source 2240>, <CIViC source 2328>, <CIViC source 2512>}",[],[],[2149]
2026,VHL I151F (c.451A>T),5.0,,,"['C.451A>T', 'ILE151PHE']","[6832, 5773]","{<CIViC source 2650>, <CIViC source 2328>}",[],[],[2150]
2027,VHL W88* (c.263G>A),7.5,,,"['W88X', 'TRP88TER', 'C.263G>A', 'RS119103277']","[8292, 5776, 6806, 7606, 9374, 10695, 10911, 10948, 6538, 6138]","{<CIViC source 1370>, <CIViC source 4455>, <CIViC source 3974>, <CIViC source 3429>, <CIViC source 4374>, <CIViC source 4477>, <CIViC source 2488>, <CIViC source 2650>, <CIViC source 2328>, <CIViC source 2628>}",[],[],[2151]
2028,VHL 3'UTR alteration (c.*70C>A),5.0,,,"['C.*70C>A', '(C.642+70C>A)']","[6846, 5777]","{<CIViC source 2650>, <CIViC source 2328>}",[],[],[2152]
2029,VHL G114fs (c.326_339dupTCCACAGCTACCGA),0.0,,,[],[5778],{<CIViC source 2332>},[],[],[2153]
2030,VHL D121H (c.361G>C),0.0,,,"['C.361G>C', 'ASP121HIS']","[5779, 6479, 8870]","{<CIViC source 2333>, <CIViC source 2582>, <CIViC source 3711>}",[],[],[2154]
2031,VHL Q145Tfs* (c.432_433insA),0.0,,,"['C.432_433INSA', 'GLN145THRFS*']",[5782],{<CIViC source 2334>},[],[],[2155]
2032,VHL S111R (c.331A>C),0.0,,,"['SER111ARG', 'C.331A>C']","[5783, 9911]","{<CIViC source 2324>, <CIViC source 2334>}",[],[],[2156]
2033,VHL L128P (c.383T>C),0.0,,,"['C.383T>C', 'LEU128PRO']","[6873, 8470, 8632, 5784]","{<CIViC source 2655>, <CIViC source 3537>, <CIViC source 1373>, <CIViC source 2334>}",[],[],[2157]
2034,VHL F76fs (c.222_225dup),0.0,,,"['C.222_225DUPCATC', 'F76H*57']",[5788],{<CIViC source 2337>},[],[],[2158]
2035,AR V9 EXPRESSION,0.0,,,['AR-V9'],[5789],{<CIViC source 2338>},[],[],[2159]
2036,VHL Y98FS (c.291delC),10.0,,,"['TYR98FS', 'C.291DELC']",[5794],{<CIViC source 2342>},[],[],[2160]
2037,VHL S183L (c.548C>T),0.0,,,"['C.548C>T', 'SER183LEU', 'RS5030823']","[10733, 5797]","{<CIViC source 4378>, <CIViC source 2343>}",[],[],[2161]
2038,VHL N150S (c.449A>G),5.0,,,"['C.449A>G', 'ASN150SER', 'RS760184234']",[5799],{<CIViC source 2344>},[],[],[2162]
2039,CTLA4 EXPRESSION,0.0,,,[],[5810],{<CIViC source 2350>},[],[],[2163]
2040,CX3CL1 Underexpression,0.0,,,[],[5812],{<CIViC source 2350>},[],[],[2164]
2041,FANCA S1088F,0.0,,,['SER1088PHE'],[5813],{<CIViC source 2352>},[],[],[2165]
2042,SLC3A2::NRG1 Fusion,15.0,,,['SLC3A2-NRG1'],"[5814, 7489, 7491, 7495]","{<CIViC source 2975>, <CIViC source 2977>, <CIViC source 2353>}",[],[],[2166]
2043,FGFR4 Overexpression,0.0,,,[],"[7522, 5828, 7137, 7520, 7521]","{<CIViC source 2355>, <CIViC source 2988>, <CIViC source 2989>}",[],[],[2167]
2044,RAD50 L1237F,10.0,,,[],[5829],{<CIViC source 2356>},[],[],[2168]
2045,BTK MUTATION,20.0,,,[],"[5833, 11938]","{<CIViC source 4965>, <CIViC source 2360>}",[],[],[2169]
2046,PLCG2 MUTATION,25.0,,,[],[5834],{<CIViC source 259>},[],[],[2170]
2047,TSC2 Loss-of-function,0.0,,,[],"[7281, 5838]","{<CIViC source 2869>, <CIViC source 2363>}",[],[],[2171]
2048,MTOR Gain-of-Function,0.0,,,[],[5839],{<CIViC source 2363>},[],[],[2172]
2049,VHL E94K (c.280G>A),0.0,,,"['C.280G>A', 'GLU94LYS', 'RS5030829']","[5843, 8616]","{<CIViC source 2365>, <CIViC source 3620>}",[],[],[2173]
2050,EGFR Wildtype,20.0,,,[],"[2512, 6185, 12204]","{<CIViC source 2478>, <CIViC source 1502>, <CIViC source 5135>}",[],[],[2174]
2051,VHL R79C (c.235C>T),0.0,,,[],"[11024, 5852]","{<CIViC source 2605>, <CIViC source 2366>}",[],[],[2175]
2052,VHL Y175C (c.524A>G),0.0,,,"['C.524A>G', 'TYR175CYS', 'RS193922613']",[],set(),[],[],[2176]
2053,VHL M54I (c.162G>C),0.0,,,"['MET54ILE', 'C.162G>C']","[5857, 6701]","{<CIViC source 2630>, <CIViC source 2368>}",[],[],[2177]
2054,ATP1B1::NRG1 Fusion,15.0,,,['ATP1B1-NRG1'],"[5858, 7492]","{<CIViC source 2369>, <CIViC source 2959>}",[],[],[2178]
2055,SDC4::NRG1 Fusion,7.5,,,['SDC4-NRG1'],[5859],{<CIViC source 2369>},[],[],[2179]
2056,TSPYL1 P62S,0.0,,,"['PRO62SER', 'RS3828743']","[5861, 8947]",{<CIViC source 2372>},[],[],[2180]
2057,VHL R177ins (c.531insCTGAGAGTAAAGCCTGAA),5.0,,,[],[5865],{<CIViC source 1278>},[],[],[2181]
2058,VHL Null (Large deletion),20.0,,,[],"[5868, 8415, 8595, 8994, 10162, 10188, 10944, 6326, 9020, 9933]","{<CIViC source 2324>, <CIViC source 2376>, <CIViC source 3784>, <CIViC source 2239>, <CIViC source 2186>, <CIViC source 2509>, <CIViC source 2302>, <CIViC source 2245>, <CIViC source 3517>, <CIViC source 4475>}",[],[],[2182]
2059,ERRFI1 E384Ter,0.0,,,[],[],set(),[],[],[2183]
2060,VHL Partial deletion of 0.7 Kb,0.0,,,[],[5871],{<CIViC source 2174>},[],[],[2184]
2061,VHL Partial deletion of 1 Kb,0.0,,,[],[5872],{<CIViC source 2174>},[],[],[2185]
2062,VHL Partial deletion of 1.2 Kb,0.0,,,[],[5873],{<CIViC source 2174>},[],[],[2186]
2063,VHL Partial deletion of 1.5 Kb,0.0,,,[],[5874],{<CIViC source 2174>},[],[],[2187]
2064,VHL Partial deletion of 11 Kb,0.0,,,[],[5875],{<CIViC source 2174>},[],[],[2188]
2065,VHL Partial deletion of 12 Kb,0.0,,,[],[5876],{<CIViC source 2174>},[],[],[2189]
2066,VHL Partial deletion of 3.5 Kb,0.0,,,[],[5877],{<CIViC source 2174>},[],[],[2190]
2067,VHL Partial deletion of 3 Kb,0.0,,,[],"[6729, 5878]","{<CIViC source 2174>, <CIViC source 2640>}",[],[],[2191]
2068,VHL Partial deletion of 7.5 Kb,0.0,,,[],[5880],{<CIViC source 2174>},[],[],[2192]
2069,VHL Partial deletion of 7 Kb,0.0,,,[],[5881],{<CIViC source 2174>},[],[],[2193]
2070,VHL Partial deletion of 8.2 Kb,0.0,,,[],[5882],{<CIViC source 2174>},[],[],[2194]
2071,DICER1 D1709G,10.0,,,[],"[5887, 5897]",{<CIViC source 2266>},[],[],[2195]
2072,DICER1 D1709E,7.5,,,[],"[5888, 5900]",{<CIViC source 2266>},[],[],[2196]
2073,DICER1 D1810H,0.0,,,['ASP1810HIS'],[5889],{<CIViC source 2266>},[],[],[2197]
2074,DICER1 D1810Y,0.0,,,['ASP1810TYR'],"[5890, 5901, 6093]","{<CIViC source 2266>, <CIViC source 2463>}",[],[],[2198]
2075,DICER1 D1810N,0.0,,,['ASP1810ASN'],[5891],{<CIViC source 2266>},[],[],[2199]
2076,DICER1 E1813G,0.0,,,['GLU1813GLY'],[5893],{<CIViC source 2266>},[],[],[2200]
2077,DICER1 E1813K,0.0,,,['GLU1813LYS'],[5894],{<CIViC source 2266>},[],[],[2201]
2078,FGFR2::v Fusion,95.0,,,[],"[11257, 7423, 1918, 7322, 7969]","{<CIViC source 1341>, <CIViC source 2927>, <CIViC source 2893>, <CIViC source 3200>}",[],[],[2202]
2079,EGFR::RAD51 Fusion,30.0,,,['EGFR-RAD51'],"[11015, 5909, 11021, 7314, 11016, 11017, 11019]","{<CIViC source 2385>, <CIViC source 2086>, <CIViC source 2889>, <CIViC source 4508>}",[],[],[2203]
2080,KDR Overexpression,0.0,,,[],"[7854, 5910]","{<CIViC source 3142>, <CIViC source 2386>}",[],[],[2204]
2081,FLT4 Amplification,0.0,,,[],"[5911, 7539]","{<CIViC source 2999>, <CIViC source 2387>}",[],[],[2205]
2082,FGFR2 FGFR2 mutations,0.0,,,[],[],set(),[],[],[2206]
2083,PDCD1LG2 EXPRESSION,0.0,,,[],[5917],{<CIViC source 2390>},[],[],[2207]
2084,LAG3 EXPRESSION,0.0,,,[],[5918],{<CIViC source 2391>},[],[],[2208]
2085,DLL3 Expression,0.0,,,[],"[7764, 5919]","{<CIViC source 3098>, <CIViC source 2392>}",[],[],[2209]
2086,KMT2E::ASNS Fusion,0.0,,,['KMT2E-ASNS'],[5926],{<CIViC source 2398>},[],[],[2210]
2087,BAP1 ALTERNATIVE TRANSCRIPT (ATI),3.0,,,[],[5929],{<CIViC source 2402>},[],[],[2211]
2088,BAP1 Loss,0.0,,,[],"[5930, 12007, 8329]","{<CIViC source 2403>, <CIViC source 4984>, <CIViC source 3461>}",[],[],[2212]
2089,EGFR M766_A767insASV,7.5,,,[],[5938],{<CIViC source 1230>},[],[],[2213]
2090,EGFR D770delinsGY,10.0,,,[],"[4801, 5942]",{<CIViC source 1230>},[],[],[2214]
2091,EGFR delL747_P753insS,0.0,,,[],[],set(),[],[],[2215]
2092,EGFR E746_A750del,0.0,,,[],[],set(),[],[],[2216]
2093,EGFR P772_H773insH,0.0,,,[],[5950],{<CIViC source 1230>},[],[],[2217]
2094,STRN::ALK Fusion,7.5,,,['STRN-ALK'],[5952],{<CIViC source 2408>},[],[],[2218]
2095,BARD1 Loss-of-function,3.0,,,[],[5953],{<CIViC source 2409>},[],[],[2219]
2097,BRAF G496A,5.0,,,[],[5966],{<CIViC source 2414>},[],[],[2221]
2098,BRAF G466V,14.0,,,"['GLY466VAL', 'RS121913351']","[5968, 7552, 7553, 7554]","{<CIViC source 3005>, <CIViC source 2414>}",[],[],[2222]
2099,BRAF G606E,5.0,,,['GLY606GLU'],[5970],{<CIViC source 2414>},[],[],[2223]
2100,BRAF P731T,5.0,,,['PRO731THR'],[5972],{<CIViC source 2414>},[],[],[2224]
2101,BRAF intron 9 rearrangement,20.0,,,[],"[6401, 5973]","{<CIViC source 1941>, <CIViC source 2414>}",[],[],[2225]
2102,BRAF intron 10 rearrangement,20.0,,,[],"[6400, 5974]","{<CIViC source 1941>, <CIViC source 2414>}",[],[],[2226]
2103,MACF1::BRAF Fusion,5.0,,,['MACF1-BRAF'],[5975],{<CIViC source 2414>},[],[],[2227]
2105,CUX1::BRAF Fusion,5.0,,,['CUX1-BRAF'],[5977],{<CIViC source 2414>},[],[],[2229]
2106,ASS1 Loss,6.0,,,[],"[5988, 5989]","{<CIViC source 2415>, <CIViC source 2416>}",[],[],[2230]
2107,FLCN Mutation,0.0,,,[],[5990],{<CIViC source 2417>},[],[],[2231]
2108,FLCN Loss,0.0,,,[],[5991],{<CIViC source 2418>},[],[],[2232]
2109,BCL2 Mutation,15.0,,,[],[5992],{<CIViC source 2419>},[],[],[2233]
2110,KMT2D Loss,0.0,,,[],[5993],{<CIViC source 2420>},[],[],[2234]
2111,RASA1 Loss-of-function,3.0,,,[],[5994],{<CIViC source 2421>},[],[],[2235]
2112,ATM Loss-of-function,0.0,,,[],[5995],{<CIViC source 2422>},[],[],[2236]
2113,KDM5C Mutation,0.0,,,[],[5997],{<CIViC source 2234>},[],[],[2237]
2114,BARD1 ISOFORM EXPRESSION,0.0,,,[],[5998],{<CIViC source 2402>},[],[],[2238]
2115,TPT1 Overexpression,0.0,,,[],[5999],{<CIViC source 2423>},[],[],[2239]
2116,TLK2 Amplification,3.0,,,[],[6000],{<CIViC source 2424>},[],[],[2240]
2117,VHL R82C (c.244C>T),0.0,,,"['C.244C>T', 'ARG82CYS', 'RS1214305423']",[6007],{<CIViC source 2187>},[],[],[2241]
2118,VHL W88L (c.263G>T),0.0,,,"['C.263G>T', 'TRP88LEU']","[6009, 6646]","{<CIViC source 2619>, <CIViC source 2187>}",[],[],[2242]
2119,VHL S111G (c.331A>G),0.0,,,"['C.331A>G', 'SER111GLY', 'RS1559426203']","[6010, 8722, 9049]","{<CIViC source 3664>, <CIViC source 2187>, <CIViC source 3822>}",[],[],[2243]
2120,VHL I151M (c.453C>G),0.0,,,"['C.453C>G', 'ILE151MET']",[],set(),[],[],[2244]
2121,VHL E160* (c.478G>T),0.0,,,"['C.478G>T', 'GLU160TER', 'E160X']",[6012],{<CIViC source 2187>},[],[],[2245]
2122,VHL I180N (c.539T>A),0.0,,,"['C.539T>A', 'ILE180ASN']",[6014],{<CIViC source 2187>},[],[],[2246]
2123,VHL L198R (c.593T>G),0.0,,,"['C.593T>G', 'LEU198ARG']",[6016],{<CIViC source 2187>},[],[],[2247]
2124,VHL T100A (c.298A>G),0.0,,,['THR100ALA'],[6024],{<CIViC source 2431>},[],[],[2248]
2125,VHL W117* (c.350G>A),0.0,,,"['W117X', 'TRP117TER']",[6025],{<CIViC source 2431>},[],[],[2249]
2126,VHL I151S (c.452T>G),0.0,,,"['C.452T>G', 'ILE151SER', 'RS869025655']","[6026, 6833, 6876, 6919, 8409, 10890, 8604]","{<CIViC source 2657>, <CIViC source 4442>, <CIViC source 1368>, <CIViC source 2655>, <CIViC source 2431>, <CIViC source 2650>, <CIViC source 3514>}",[],[],[2250]
2127,VHL Q96fs (c.286insT),0.0,,,[],[8297],{<CIViC source 3429>},[],[],[2251]
2128,VHL G104fs (c.309delT),0.0,,,[],"[6028, 6029, 6900]","{<CIViC source 2657>, <CIViC source 2431>}",[],[],[2252]
2129,VHL N174fs (c.520delA),0.0,,,[],[6030],{<CIViC source 2431>},[],[],[2253]
2130,DBI PROMOTER DEMETHYLATION,0.0,,,[],[6033],{<CIViC source 104>},[],[],[2254]
2131,EGFR A702S,0.0,,,['ALA702SER'],[6035],{<CIViC source 2435>},[],[],[2255]
2133,EGFR Exon 18 deletion,0.0,,,[],[6038],{<CIViC source 2438>},[],[],[2257]
2135,EGFR I744_K745insKIPVAI,0.0,,,[],[6041],{<CIViC source 2065>},[],[],[2259]
2138,VHL L63fs (c.187delC),0.0,,,[],[6057],{<CIViC source 2431>},[],[],[2262]
2139,VHL P61fs (c.181delC),0.0,,,[],[6058],{<CIViC source 2431>},[],[],[2263]
2140,VHL R82_V84del (c.244_252del),10.0,,,"['C.244_252DEL', 'C.245_253DEL']",[6060],{<CIViC source 2186>},[],[],[2264]
2141,VHL A56_P59del (c.166_178del),7.5,,,[],[6062],{<CIViC source 2187>},[],[],[2265]
2142,VHL G104fs (c.310delG),0.0,,,[],[6063],{<CIViC source 2187>},[],[],[2266]
2143,VHL Q132fs (c.395_396delAA),0.0,,,[],[6064],{<CIViC source 2187>},[],[],[2267]
2145,VHL M54_A56del (c.159_168del),0.0,,,[],[6066],{<CIViC source 1710>},[],[],[2269]
2146,VHL V74fs (c.213_232del),0.0,,,[],[6067],{<CIViC source 1710>},[],[],[2270]
2147,VHL F76_N78del (c.226_232del),0.0,,,[],[6068],{<CIViC source 1710>},[],[],[2271]
2148,VHL N141fs (c.421_422delAA),0.0,,,[],[6069],{<CIViC source 1710>},[],[],[2272]
2149,VHL R161fs (c.481insC),0.0,,,[],[6070],{<CIViC source 1710>},[],[],[2273]
2150,VHL P172fs (c.514delC),0.0,,,[],[6071],{<CIViC source 1710>},[],[],[2274]
2151,ACVR1 R258G,0.0,,,['ARG258GLY'],[6077],{<CIViC source 2448>},[],[],[2275]
2152,AMER1 R358X,0.0,,,[],[6079],{<CIViC source 2450>},[],[],[2276]
2153,CRLF2 V2del,0.0,,,[],[6080],{<CIViC source 2451>},[],[],[2277]
2154,CTNNB1 p.S45F,0.0,,,[],[],set(),[],[],[2278]
2155,CRLF2 G24R,0.0,,,[],[6087],{<CIViC source 2458>},[],[],[2279]
2156,ACVR1 G328W,5.0,,,['GLY328TRP'],"[10013, 6088]","{<CIViC source 2448>, <CIViC source 2459>}",[],[],[2280]
2157,CTNNB1 S37C,0.0,,,[],[6089],{<CIViC source 2460>},[],[],[2281]
2158,DROSHA E518K,0.0,,,[],[6090],{<CIViC source 2461>},[],[],[2282]
2159,ACVR1 G328E,7.5,This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.,This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.,[],[6091],{<CIViC source 2448>},[2680],[<CIViC source 2680>],[2283]
2161,CRLF2 F232C,0.0,,,['PHE232CYS'],"[6094, 7210]",{<CIViC source 2464>},[],[],[2285]
2162,v::NRG1 Fusion,57.5,"NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.","NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.",['NRG1 Fusion'],"[12246, 12247, 6273, 6095, 6096, 7534]","{<CIViC source 2501>, <CIViC source 2465>, <CIViC source 5172>}",[],[],[2286]
2163,STRN::NTRK2 Fusion,7.5,,,['STRN-NTRK2'],[6098],{<CIViC source 2467>},[],[],[2287]
2165,PDE4DIP::NTRK1 Fusion,12.5,,,['PDE4DIP-NTRK1'],"[6102, 7420]","{<CIViC source 2467>, <CIViC source 2925>}",[],[],[2289]
2166,VHL G144E (c.431G>A),5.0,,,[],"[9036, 6106]","{<CIViC source 3815>, <CIViC source 2175>}",[],[],[2290]
2167,VHL I147T (c.440T>C),0.0,,,"['C.440T>C', 'ILE147THR', 'RS1060503555']","[9035, 6107]","{<CIViC source 3815>, <CIViC source 2175>}",[],[],[2291]
2168,VHL Splice Region (c.463+8C>T),5.0,,,[],"[9536, 5439, 6108]","{<CIViC source 2243>, <CIViC source 2175>, <CIViC source 2320>}",[],[],[2292]
2169,VHL G104= (c.312C>G),2.5,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.312C>T (p.Gly104=; G104=) https://www-ncbi-nlm-nih-gov/clinvar/variation/456582/,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.312C>T (p.Gly104=; G104=) https://www-ncbi-nlm-nih-gov/clinvar/variation/456582/,['G104G (C.312C>G)'],[6110],{<CIViC source 1278>},[],[],[2293]
2170,VHL F91L (c.273C>G),5.0,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.273C>A (p.Phe91Leu; F91L) (https://www-ncbi-nlm-nih-gov/clinvar/variation/411978/),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.273C>A (p.Phe91Leu; F91L) (https://www-ncbi-nlm-nih-gov/clinvar/variation/411978/),"['C.273C>G', 'PHE91LEU']",[6111],{<CIViC source 1278>},[],[],[2294]
2171,VHL L128fs (c.382del),0.0,,,['C.382DELC'],[],set(),[],[],[2298]
2172,VHL W88fs (c.261dup),7.5,,,"['C.261DUP', 'C.261INSA', 'TRP88METFSTER44', 'W88MFS*44']",[6122],{<CIViC source 2192>},[],[],[2299]
2174,VHL E55fs (c.162delG),0.0,,,[],[6127],{<CIViC source 1370>},[],[],[2301]
2175,VHL R60fs (c.178_179del),0.0,,,"['C.176_177DEL', 'R60AFS*71']",[6128],{<CIViC source 1370>},[],[],[2302]
2176,VHL P61_S65del (c.183_195del),0.0,,,[],[6129],{<CIViC source 1370>},[],[],[2303]
2177,VHL E70fs (c.209_210delAG),0.0,,,[],[6133],{<CIViC source 1370>},[],[],[2304]
2178,VHL L85fs (c.253delC),0.0,,,[],[6134],{<CIViC source 1370>},[],[],[2305]
2179,VHL P86fs (c.255_256delGC),0.0,,,[],[6136],{<CIViC source 1370>},[],[],[2306]
2180,VHL P86H (c.257C>A),0.0,,,"['C.257C>A', 'PRO86HIS']","[6894, 10988, 6137]","{<CIViC source 1370>, <CIViC source 2657>, <CIViC source 4473>}",[],[],[2307]
2181,VHL L89H (c.266T>A),0.0,,,"['RS5030807', 'C.266T>A', 'LEU89HIS']","[6895, 10755, 6139]","{<CIViC source 1370>, <CIViC source 2657>, <CIViC source 4390>}",[],[],[2308]
2182,VHL N90fs (c.269delA),0.0,,,[],[6141],{<CIViC source 1370>},[],[],[2309]
2183,VHL E94_P97del (c.281_291del),0.0,,,[],[6142],{<CIViC source 1370>},[],[],[2310]
2184,VHL K114fs (c.339_340delAG),0.0,,,[],[6144],{<CIViC source 1370>},[],[],[2311]
2185,VHL L116fs (c.347delT),0.0,,,"['C.347DELT', 'LEU116FS']",[6146],{<CIViC source 1370>},[],[],[2312]
2186,VHL L118fs (c.349_350insG),0.0,,,[],[6147],{<CIViC source 1370>},[],[],[2313]
2187,VHL T124fs (c.370_371insTGCAGGA),0.0,,,[],[6148],{<CIViC source 1370>},[],[],[2314]
2188,VHL N131fs (c.389delT),0.0,,,[],[6149],{<CIViC source 1370>},[],[],[2315]
2189,VHL S139fs (c.415insC),0.0,,,[],[6150],{<CIViC source 1370>},[],[],[2316]
2190,VHL N141fs (c.420delC),0.0,,,"['C.420DELC', 'LEU140FS', 'L140FS', 'ASN141METFSTER18', 'N141MFS*18']",[6151],{<CIViC source 1370>},[],[],[2317]
2191,VHL N141fs (c.422_428del),0.0,,,"['N141TFS*16', 'C.421_427DEL']",[6152],{<CIViC source 1370>},[],[],[2318]
2192,VHL G144fs (c.429_430insGGAC),0.0,,,[],[6153],{<CIViC source 1370>},[],[],[2319]
2193,VHL G144fs (c.430_433delGGAC),0.0,,,[],[6154],{<CIViC source 1370>},[],[],[2320]
2194,VHL Q145H (c.435G>T),0.0,,,[],[6155],{<CIViC source 1370>},[],[],[2321]
2196,VHL T157fs (c.469delA),0.0,,,"['C.469DELA', 'THR157FS']","[6921, 6158]","{<CIViC source 1370>, <CIViC source 2657>}",[],[],[2323]
2197,VHL L158_K159del (c.472_477del),0.0,,,[],[6159],{<CIViC source 1370>},[],[],[2324]
2198,VHL V166fs (c.498delC),0.0,,,[],[6162],{<CIViC source 1370>},[],[],[2325]
2199,VHL L169_V170del (c.505_510del),0.0,,,[],[6163],{<CIViC source 1370>},[],[],[2326]
2200,VHL K171fs (c.512_516delAGCCT),0.0,,,[],[6165],{<CIViC source 1370>},[],[],[2327]
2201,VHL H191fs (c.570_574delCCACC),0.0,,,[],[6168],{<CIViC source 1370>},[],[],[2328]
2202,VHL I206fs (c.615delinsAA),0.0,,,"['C.615DELC', 'ARG205FS', 'I206NFS*?', '614-615INSAA;615DELC']",[6169],{<CIViC source 1370>},[],[],[2329]
2203,ERBB2 L869R,0.0,,,"['LEU869ARG', 'RS1131692237']",[6173],{<CIViC source 2397>},[],[],[2330]
2204,ERBB2 T798I,3.0,,,['THR798ILE'],"[6175, 6174, 6176]",{<CIViC source 2397>},[],[],[2331]
2205,EGFR A750T,0.0,,,['ALA750THR'],[6177],{<CIViC source 2473>},[],[],[2332]
2206,EGFR R705K,5.0,,,['ARG705LYS'],[6182],{<CIViC source 2473>},[],[],[2333]
2207,EGFR Rare Mutation,5.0,This subset of EGFR mutations consists of mutations other than L858R and exon 19 deletion. Reports of responsiveness to tyrosine kinase inhibitors in this EGFR mutation subgroup do not differ widely from those reported for known common sensitizing EGFR mutations.,This subset of EGFR mutations consists of mutations other than L858R and exon 19 deletion. Reports of responsiveness to tyrosine kinase inhibitors in this EGFR mutation subgroup do not differ widely from those reported for known common sensitizing EGFR mutations.,[],[6186],{<CIViC source 2478>},[],[],[2334]
2213,ABL1 L248R,7.0,,,['LEU248ARG'],[],set(),[],[],[2340]
2216,ABL1 F317S,1.0,,,['PHE317SER'],[],set(),[],[],[2343]
2219,MLH1 Glu34Lys (c.100G>A),0.0,,,[],[6225],{<CIViC source 2493>},[],[],[2346]
2220,IL7R S185C,0.0,,,[],[6226],{<CIViC source 2494>},[],[],[2347]
2221,IL7R V253G,0.0,,,[],[6227],{<CIViC source 2495>},[],[],[2348]
2222,IL7R exon 6 mutations,0.0,,,[],[6228],{<CIViC source 2497>},[],[],[2349]
2223,P2RY8::CRLF2 Fusion,0.0,"The P2RY8-CRLF2 fusion has been associated with the BCR-ABL1-like (Philadelphia (Ph)-like) molecular subtype of B-ALL, but it has also been observed in other genetic subtypes including hyperdiploid, iAMP21 and B-ALL with dic(9;20). The fusion is generated by a ~320-kb interstitial deletion in Xp22 (in the so-called pseudo-autosomal (PAR) region) which fuses the exon 1 of P2RY8 with the exon 1 of CRLF2. The P2RY8-CRLF2 fusion has been shown to be enriched in Down syndrome B-ALL cases. CRLF2 rearrangements are also significantly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispanic/Latino ethnicity.","The P2RY8-CRLF2 fusion has been associated with the BCR-ABL1-like (Philadelphia (Ph)-like) molecular subtype of B-ALL, but it has also been observed in other genetic subtypes including hyperdiploid, iAMP21 and B-ALL with dic(9;20). The fusion is generated by a ~320-kb interstitial deletion in Xp22 (in the so-called pseudo-autosomal (PAR) region) which fuses the exon 1 of P2RY8 with the exon 1 of CRLF2. The P2RY8-CRLF2 fusion has been shown to be enriched in Down syndrome B-ALL cases. CRLF2 rearrangements are also significantly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispanic/Latino ethnicity.","['PAR DELETION', 'P2RY8-CRLF2']","[7065, 7211, 7213, 6231, 6229, 7239, 6230, 11622]","{<CIViC source 2499>, <CIViC source 2739>, <CIViC source 2495>, <CIViC source 2464>, <CIViC source 2498>}",[],[],[2350]
2232,ABL1 F317C,2.0,,,"['PHE317CYS', 'F336C', 'RS1057519774']",[],set(),[],[],[2359]
2233,AKT1 Overexpression,3.0,,,[],[6259],{<CIViC source 1941>},[],[],[2360]
2235,PIK3CA Overexpression,0.0,,,[],[6265],{<CIViC source 1941>},[],[],[2362]
2236,PIK3R2 Overexpression,2.0,,,[],[6266],{<CIViC source 1941>},[],[],[2363]
2237,PREX2 R172I,10.0,,,['ARG172ILE'],[6268],{<CIViC source 1941>},[],[],[2364]
2238,TF Loss,0.0,,,[],[6269],{<CIViC source 1941>},[],[],[2365]
2239,PTEN WILD TYPE,0.0,,,[],[6272],{<CIViC source 1941>},[],[],[2366]
2240,VHL 3p26.3-25.3 11Mb del,7.5,,,[],[6287],{<CIViC source 2503>},[],[],[2367]
2243,ABL1 E459K,25.0,,,"['RS1064156', 'GLU459LYS']",[],set(),[],[],[2370]
2244,ABL1 TKD Mutation,60.0,,,[],"[6311, 6335, 6342, 6996]","{<CIViC source 2484>, <CIViC source 1996>, <CIViC source 1997>, <CIViC source 1532>}",[],[],[2371]
2246,VHL c.128-?_250+?,5.0,,,[],[6329],{<CIViC source 2509>},[],[],[2373]
2247,VHL c.251-?_429+?,0.0,,,[],[6331],{<CIViC source 2509>},[],[],[2374]
2248,ABL1 P-Loop Mutation,30.0,,,[],"[6336, 6997, 8094]","{<CIViC source 1530>, <CIViC source 1996>, <CIViC source 1997>}",[],[],[2375]
2249,ABL1 Non-P-Loop Mutation,30.0,,,[],"[6337, 6998]","{<CIViC source 1996>, <CIViC source 1997>}",[],[],[2376]
2250,RHEB Y35N,0.0,,,[],[6340],{<CIViC source 2513>},[],[],[2377]
2251,BRCA1 COPY-NEUTRAL LOSS OF HETEROZYGOSITY,0.0,,,[],[],set(),[],[],[2378]
2252,BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY,0.0,,,[],[],set(),[],[],[2379]
2253,VHL V130I (c.388G>A),0.0,"Two clinvar entries at this same genomic location with 2 different nucleotide changes result in 2 different amino acid changes at aa130. (Clinvar ID: 496061 (V130F, c.388G>T); 2229 (V130L, c.388G>C)","Two clinvar entries at this same genomic location with 2 different nucleotide changes result in 2 different amino acid changes at aa130. (Clinvar ID: 496061 (V130F, c.388G>T); 2229 (V130L, c.388G>C)","['VAL130ILE', 'C.388G>A']","[6345, 10980]","{<CIViC source 2514>, <CIViC source 4473>}",[],[],[2380]
2254,VHL L118P (c.353T>C) and R107G  (c.319C>G),0.0,,,[],[6351],{<CIViC source 2514>},[],[],[2381]
2255,VHL Null (c.1-?_340+?del),0.0,,,[],[],set(),[],[],[2382]
2256,VHL Q203TfsX53 (c.606dupA),0.0,,,[],[6359],{<CIViC source 2514>},[],[],[2383]
2257,PBLD Underexpression,0.0,,,[],[6364],{<CIViC source 2331>},[],[],[2384]
2258,EWSR1::NR4A3 Fusion,0.0,,,['EWSR1-NR4A3'],"[6378, 9819]","{<CIViC source 2519>, <CIViC source 4188>}",[],[],[2385]
2259,ERRFI1 Underexpression,0.0,,,[],[6379],{<CIViC source 2520>},[],[],[2386]
2260,CSF3R T618I,14.0,,,['THR618ILE'],"[9072, 6381, 6380]","{<CIViC source 3833>, <CIViC source 2521>, <CIViC source 2522>}",[],[],[2387]
2261,CALR Mutation,50.0,,,[],[6382],{<CIViC source 966>},[],[],[2388]
2262,MPL MUTATION,0.0,,,[],[],set(),[],[],[2389]
2263,MAP2K1 56_61QKQKVG>R,0.0,,,[],[6384],{<CIViC source 2523>},[],[],[2390]
2265,PTPN6 Underexpression,0.0,,,[],[6390],{<CIViC source 2476>},[],[],[2392]
2266,TRIM63::NTRK1 Fusion,0.5,,,['NTRK1-TRIM63'],[6392],{<CIViC source 2529>},[],[],[2393]
2267,DDR2::NTRK1 Fusion,0.5,,,['NTRK1-DDR2'],[6393],{<CIViC source 2529>},[],[],[2394]
2268,GON4L::NTRK1 Fusion,0.5,,,['NTRK1-GON4L'],[6394],{<CIViC source 2529>},[],[],[2395]
2269,ETV6::NTRK2 Fusion,13.0,,,['ETV6-NTRK2'],"[6396, 10099]","{<CIViC source 2530>, <CIViC source 1289>}",[],[],[2396]
2270,CRKL Amplification,0.0,,,[],"[6397, 6398]","{<CIViC source 2532>, <CIViC source 2531>}",[],[],[2397]
2271,BRAF D594K,30.0,,,[],"[6402, 6403]",{<CIViC source 1479>},[],[],[2398]
2272,FGFR3 V555L,0.0,,,"['V443L', 'VAL555LEU', 'VAL443LEU']",[6405],{<CIViC source 2534>},[2534],[<CIViC source 2534>],[2399]
2273,FGFR3 V555M,2.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL443MET', 'V443M', 'VAL555MET', 'ENSP00000414914.2:P.VAL555MET ']","[6406, 6408]","{<CIViC source 2534>, <CIViC source 2535>}",[2534],[<CIViC source 2534>],[2400]
2274,FGFR3 L608V,0.0,,,"['LEU604VAL', 'L496V', 'LEU496VAL', 'L604V', 'L608V', 'LEU608VAL']",[6407],{<CIViC source 2534>},[],[],[2401]
2276,FGFR3 R248C,8.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['RS121913482', 'ARG248CYS']","[7305, 6410, 8281, 8318, 8319, 8946, 7940, 8320, 8321, 10413, 10387, 10511]","{<CIViC source 3773>, <CIViC source 4338>, <CIViC source 2534>, <CIViC source 3136>, <CIViC source 3454>, <CIViC source 4353>, <CIViC source 2859>, <CIViC source 3455>, <CIViC source 3456>, <CIViC source 1337>, <CIViC source 2927>}",[],[],[2403]
2277,FGFR3 Y373C,21.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['TYR375CYS', 'RS121913485', 'Y375C', 'TYR373CYS']","[7308, 8879, 477, 6411, 6412, 10366, 8880, 8881, 8882, 8883, 8884, 10354, 10385, 10408, 10510]","{<CIViC source 2534>, <CIViC source 3722>, <CIViC source 3696>, <CIViC source 2687>, <CIViC source 4337>, <CIViC source 4353>, <CIViC source 2859>, <CIViC source 3456>, <CIViC source 3723>, <CIViC source 2927>, <CIViC source 3694>, <CIViC source 291>}",[],[],[2404]
2278,FGFR3 G380R,2.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLY380ARG', 'G382R', 'GLY382ARG']","[6413, 10490, 10368, 10384, 10396, 10403, 10415, 10416]","{<CIViC source 4336>, <CIViC source 4338>, <CIViC source 2534>, <CIViC source 4333>, <CIViC source 4327>, <CIViC source 4334>, <CIViC source 4349>, <CIViC source 4321>}",[],[],[2405]
2279,FGFR3 G370C,3.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLY370CYS', 'G372C', 'GLY372CYS']","[7307, 6414, 10353, 10414]","{<CIViC source 4338>, <CIViC source 2534>, <CIViC source 3456>, <CIViC source 2859>}",[],[],[2406]
2281,BRAF Non-V600,45.0,,,[],"[3046, 7855, 11298, 11299]","{<CIViC source 1750>, <CIViC source 4646>, <CIViC source 3143>}",[],[],[2408]
2282,ERCC1 Underexpression,30.0,,,[],"[6431, 6430, 6433, 8025, 10142, 10146]","{<CIViC source 2540>, <CIViC source 4233>, <CIViC source 2537>, <CIViC source 2538>, <CIViC source 4235>}",[],[],[2409]
2283,ERCC1 Overexpression,0.0,,,[],[6435],{<CIViC source 2542>},[],[],[2410]
2284,SDHB p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC),5.0,ClinGen Canonical Allele Identifier: CA658820851,ClinGen Canonical Allele Identifier: CA658820851,['C.589_600DUP'],[6442],{<CIViC source 2549>},[],[],[2411]
2285,FGFR2 Underexpression,0.0,,,[],[6443],{<CIViC source 2550>},[],[],[2412]
2286,SMAD4 FRAMESHIFT MUTATION,0.0,,,[],[],set(),[],[],[2413]
2287,MAP2K1 E102_I103delEI,0.0,,,[],[6447],{<CIViC source 2554>},[],[],[2414]
2288,SMAD4 Loss-of-function,0.0,,,[],[6448],{<CIViC source 2555>},[],[],[2415]
2289,H3-3A K28M,65.0,"K28M is a highly recurrent mutation in this gene in multiple cancer types but particularly well known in brain cancers. In amino acid position 27 of H3F3A there is an arginine (R). The medically relevant Lysine (K) is in position 28. Also UNIPROT records the lysine in position 28. However, K27M is common in the literature so is included as a synonym.","K28M is a highly recurrent mutation in this gene in multiple cancer types but particularly well known in brain cancers. In amino acid position 27 of H3F3A there is an arginine (R). The medically relevant Lysine (K) is in position 28. Also UNIPROT records the lysine in position 28. However, K27M is common in the literature so is included as a synonym.",['K27M'],"[8626, 6449, 7601, 9414, 6450, 6453, 9794, 9800, 9801, 9816, 9824, 9850, 11038, 9840, 9841, 9842, 9792, 9795, 9848, 9849, 9798, 9799, 9797, 9837]","{<CIViC source 2556>, <CIViC source 4173>, <CIViC source 4174>, <CIViC source 2680>, <CIViC source 2560>, <CIViC source 3021>, <CIViC source 3965>, <CIViC source 2448>, <CIViC source 4176>, <CIViC source 4175>, <CIViC source 4178>, <CIViC source 2821>, <CIViC source 3625>, <CIViC source 2557>}","[3846, 3847, 3848]","[<CIViC source 3848>, <CIViC source 3846>, <CIViC source 3847>]",[2416]
2290,FGFR2 Overexpression,0.0,,,[],"[6454, 6456, 6459, 6460, 7830, 6466, 7832]","{<CIViC source 3133>, <CIViC source 2563>, <CIViC source 3135>, <CIViC source 2567>, <CIViC source 2566>, <CIViC source 2561>, <CIViC source 2572>}",[],[],[2417]
2291,SPRY2 UNDEREXPRESSION,0.0,,,[],[6455],{<CIViC source 2562>},[],[],[2418]
2292,NR2F2 OVEREXPRESSION,0.0,,,[],[6461],{<CIViC source 2568>},[],[],[2419]
2293,H3-3B K36M,20.0,,,[],[6463],{<CIViC source 2570>},[],[],[2420]
2294,H3-3A G34W,20.0,,,[],[6469],{<CIViC source 2570>},[],[],[2421]
2296,VHL F136fs (c.407delC),0.0,,,[],[6480],{<CIViC source 2582>},[],[],[2423]
2297,KMT2C Loss-of-function,0.0,,,[],[],set(),[],[],[2424]
2298,VHL H191D (c.571C>G),0.0,,,"['C.571C>G', 'HIS191ASP', 'RS28940301']","[6485, 6649, 8251]","{<CIViC source 2620>, <CIViC source 2587>, <CIViC source 3400>}",[],[],[2425]
2300,VHL P154S (c.460C>T),0.0,,,[],"[6489, 10826, 8730, 8833]","{<CIViC source 2591>, <CIViC source 3665>, <CIViC source 4417>, <CIViC source 3683>}",[],[],[2427]
2301,VHL G104V (c.311G>T),7.5,,,"['C.311G>T', 'GLY104VAL', 'RS869025630']","[7134, 10949, 6492]","{<CIViC source 4478>, <CIViC source 2594>, <CIViC source 2768>}",[],[],[2428]
2302,VHL t(1;3)(q32;q13.3),0.0,,,[],[6499],{<CIViC source 2601>},[],[],[2429]
2303,VHL P40R (c.119C>G),0.0,,,"['C.119C>G', 'PRO40ARG']",[6500],{<CIViC source 2602>},[],[],[2430]
2304,VHL c.213 ?_463 ?del,7.5,,,[],[6504],{<CIViC source 2605>},[],[],[2431]
2305,VHL V87fs (c.259_260insA),7.5,,,"['C.259_260INSA', 'VAL87FS', 'V87DFS*45']","[6506, 8479, 10688]","{<CIViC source 3543>, <CIViC source 2605>, <CIViC source 2616>}",[],[],[2432]
2306,VHL c.89c297 ,0.0,,,[],[6508],{<CIViC source 2605>},[],[],[2433]
2308,VHL c.341-59_341-14del,7.5,,,[],[6510],{<CIViC source 2605>},[],[],[2435]
2310,VHL V166A (c.497T>C),7.5,,,['VAL166ALA'],"[6518, 8484, 8680]","{<CIViC source 3543>, <CIViC source 2605>, <CIViC source 2192>}",[],[],[2437]
2311,VHL 235 (CAG-TAG),0.0,,,[],[6524],{<CIViC source 2605>},[],[],[2438]
2312,VHL Rearrangement,10.0,,,[],"[6525, 8767, 9094, 9208, 9987, 10482, 10523, 8649, 6599]","{<CIViC source 3828>, <CIViC source 2179>, <CIViC source 3919>, <CIViC source 2282>, <CIViC source 2605>, <CIViC source 3671>, <CIViC source 2285>, <CIViC source 2193>, <CIViC source 2611>}",[],[],[2439]
2313,VHL P138R (c.413C>G),2.5,,,"['C.413C>G', 'PRO138ARG']","[6529, 6915]","{<CIViC source 2657>, <CIViC source 2608>}",[],[],[2440]
2314,VHL Splicing alteration (c.341-1G>A),0.0,,,[],[],set(),[],[],[2441]
2315,VHL A50= (c.150C>G) and Splice Site (c.463-1G>T),0.0,,,[],[6531],{<CIViC source 2609>},[],[],[2442]
2316,VHL Q132Hfs*45 (c.343_395dup),0.0,,,[],[6536],{<CIViC source 2488>},[],[],[2443]
2317,VHL Q73Pfs*59 (c.217dupC),0.0,,,[],[6537],{<CIViC source 2488>},[],[],[2444]
2318,VHL V74Sfs*53 (c.219_232delGGTCATCTTCTGCA),0.0,,,[],[6539],{<CIViC source 2488>},[],[],[2445]
2319,VHL D121Mfs*38 (c.361delG),0.0,,,"['ASP121METFS*38', 'C.361DELG']","[10109, 6541]","{<CIViC source 2488>, <CIViC source 2190>}",[],[],[2446]
2320,VHL V66Gfs*89 (c.197_209del),5.0,,,[],[6546],{<CIViC source 2610>},[],[],[2447]
2321,VHL R79_S80del (c.236_241delGCAGTC),5.0,,,[],[6549],{<CIViC source 2610>},[],[],[2448]
2322,VHL D92G (c.275A>G),5.0,,,"['C.275A>G', 'ASP92GLY']","[8763, 6553]","{<CIViC source 2610>, <CIViC source 3670>}",[],[],[2449]
2323,VHL Y98C (c.293A>G),0.0,,,[],[10723],{<CIViC source 4378>},[],[],[2450]
2324,VHL N141fs (c.422_440del),0.0,,,[],[],set(),[],[],[2451]
2326,VHL Y156_T157del (c.465_470del),0.0,,,"['Y156_T157DEL (C.465_470DEL)', 'C.465_470DEL', 'C.465_470DELGTATAC']","[8695, 6580]","{<CIViC source 2611>, <CIViC source 2174>}","[2174, 2611]","[<CIViC source 2174>, <CIViC source 2611>]",[2453]
2327,VHL Splice Site (c.341-1G>T),0.0,There is a similar but non identical variant to this one in ClinVar (Clinvar ID: 823743; NM_000551.4(VHL):c.341-1G>A).,There is a similar but non identical variant to this one in ClinVar (Clinvar ID: 823743; NM_000551.4(VHL):c.341-1G>A).,['C.554-1G>T'],[6594],{<CIViC source 2611>},[],[],[2454]
2328,VHL G114Vfs*45 (c.339delA),7.5,,,[],[6603],{<CIViC source 2610>},[],[],[2455]
2330,VHL Splice Site (c.464-2G>A),0.0,,,[],[6611],{<CIViC source 2610>},[],[],[2457]
2331,VHL R167P (c.500G>C),7.5,,,"['RS5030821', 'C.500G>C', 'ARG167PRO']","[6620, 6766, 6842]","{<CIViC source 2506>, <CIViC source 2610>, <CIViC source 2650>}",[],[],[2458]
2332,VHL L178P (c.532C>T),7.5,,,[],[6622],{<CIViC source 2610>},[],[],[2459]
2333,VHL N131K (c.393C>G),0.0,,,"['ASN131LYS', 'C.393C>G']",[6629],{<CIViC source 2612>},[],[],[2460]
2334,VHL Splice Region (c.463+3A>C),0.0,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 428796 A>G).,[],[6639],{<CIViC source 2616>},[],[],[2461]
2335,VHL S72fs (c.216delC),0.0,,,"['SER72FS', 'C.216DELC']",[6640],{<CIViC source 2617>},[],[],[2462]
2336,VHL H110P (c.329A>C),0.0,,,"['C.329A>C', 'HIS110PRO']",[6642],{<CIViC source 2617>},[],[],[2463]
2337,VHL Splicing alteration (IVS2-1G>T),0.0,,,[],[],set(),[],[],[2464]
2338,VHL Exon 1 del (151nt),0.0,,,['NULL (PARTIAL DELETION OF EXON 1)'],[6645],{<CIViC source 2618>},[],[],[2465]
2339,VHL E52* (c.154G>T),0.0,,,"['C.154G>T', 'E52X', 'GLU52TER', 'RS373068386']","[10739, 10759, 10925, 6648]","{<CIViC source 2620>, <CIViC source 4382>, <CIViC source 4395>, <CIViC source 4463>}",[],[],[2466]
2340,VHL L158Q (c.473T>A),0.0,At same genomic location a clinvar entry with a different base change and amino acid substitution (Clinvar ID 182980; L158P c.473T>C),At same genomic location a clinvar entry with a different base change and amino acid substitution (Clinvar ID 182980; L158P c.473T>C),[],[6651],{<CIViC source 2621>},[],[],[2467]
2341,PRKCB D427N,3.0,,,[],[6654],{<CIViC source 2623>},[],[],[2468]
2342,VHL R176fs (c.526del),0.0,,,"['R176FS (C.526DELA)', 'R176GFS (C.526DEL)']",[],set(),[],[],[2469]
2343,VHL W117C (c.351G>X),0.0,,,[],[6658],{<CIViC source 2624>},[],[],[2470]
2344,VHL T104fs (c.313_315delC),0.0,,,[],[6659],{<CIViC source 2624>},[],[],[2471]
2345,VHL EXON 1-2 DELETION and BRK1 DELETION,0.0,,,[],[6670],{<CIViC source 2625>},[],[],[2472]
2346,VHL M54fs (c.160delA),0.0,,,[],[6679],{<CIViC source 2626>},[],[],[2473]
2347,VHL P59fs (c.176insAGCAdelTCCTGCGCT),0.0,,,[],[6680],{<CIViC source 2626>},[],[],[2474]
2348,VHL F119L (c.355T>C),0.0,,,"['PHE119LEU', 'C.355T>C', 'RS1553619948']","[6872, 8357, 8582, 10757, 6683]","{<CIViC source 3487>, <CIViC source 2655>, <CIViC source 2626>, <CIViC source 3607>, <CIViC source 4392>}",[],[],[2475]
2349,VHL I151N (c.452T>A),0.0,,,[],"[8559, 10525, 6684]","{<CIViC source 2626>, <CIViC source 2650>, <CIViC source 3586>}",[],[],[2476]
2350,VHL V155fs (c.464_468delTGTAT),0.0,,,[],"[10526, 6686]","{<CIViC source 2626>, <CIViC source 2650>}",[],[],[2477]
2351,VHL L163P (c.488T>C),0.0,,,"['C.488T>C', 'LEU163PRO', 'RS28940297']","[8636, 10206, 6688]","{<CIViC source 2655>, <CIViC source 1373>, <CIViC source 2626>}",[],[],[2478]
2352,VHL D197Rfs* (c.588_588dupA),0.0,,,[],"[6785, 9793, 6690]","{<CIViC source 2627>, <CIViC source 2645>, <CIViC source 2649>}",[],[],[2479]
2353,VHL Y98S (c.293A>C),0.0,,,"['C.293A>C', 'TYR98SER']","[9182, 6693, 6753, 6778, 6814, 8434, 10750]","{<CIViC source 2627>, <CIViC source 2645>, <CIViC source 3870>, <CIViC source 4384>, <CIViC source 2650>, <CIViC source 2649>, <CIViC source 3522>}",[],[],[2480]
2354,VHL I151T (c.452T>C),0.0,,,[],[],set(),[],[],[2481]
2355,VHL A149fs (c.446delG),0.0,,,[],[6706],{<CIViC source 2634>},[],[],[2482]
2357,VHL Y98N (c.292T>A),0.0,,,"['C.292T>A', 'TYR98ASN']","[8294, 6713, 6813, 6898]","{<CIViC source 2657>, <CIViC source 2650>, <CIViC source 2634>, <CIViC source 3429>}",[],[],[2484]
2359,VHL R167fs (c.501insTTGTCCGT),0.0,,,[],[6720],{<CIViC source 2636>},[],[],[2486]
2360,VHL I75del (c.221delTCA),0.0,,,[],[6721],{<CIViC source 2636>},[],[],[2487]
2361,VHL *214G (c.640T>G),5.0,,,"['X214G', 'TER214GLY', 'C.640T>G', 'X > GLY + 14AA']","[10779, 6723, 8258]","{<CIViC source 2637>, <CIViC source 3402>, <CIViC source 4402>}",[],[],[2488]
2362,VHL *214C (c.641_642insC),5.0,,,"['X214C', 'TER214CYS', 'C.641INSC']","[9347, 6724]","{<CIViC source 3815>, <CIViC source 2637>}",[],[],[2489]
2363,VHL N131S (c.392A>G),0.0,,,[],[],set(),[],[],[2490]
2364,VHL G114V (c.341G>T),0.0,Note that this variant occurs at the first base of the second exon of VHL. This exon is known to be skipped in some transcripts. RNA splicing effect should be considered in the interpretation.,Note that this variant occurs at the first base of the second exon of VHL. This exon is known to be skipped in some transcripts. RNA splicing effect should be considered in the interpretation.,[],[6730],{<CIViC source 2640>},[],[],[2491]
2365,VHL Partial deletion of 4 Kb,0.0,,,[],[6734],{<CIViC source 2640>},[],[],[2492]
2366,VHL V194G (c.581T>G),0.0,,,"['VAL194GLY', 'C.581T>G', 'RS1131690963']",[6736],{<CIViC source 2641>},[],[],[2493]
2367,VHL R120T (c.359G>C),0.0,,,[],[6738],{<CIViC source 2642>},[],[],[2494]
2368,VHL P138fs (c.410dup),0.0,,,['P138AFS*6'],[6739],{<CIViC source 2642>},[],[],[2495]
2370,VHL M54Gfs*77 (c.160_161delAT),0.0,,,[],[6741],{<CIViC source 2644>},[],[],[2497]
2371,VHL L198Wfs*4 (c.592delC),0.0,,,[],[],set(),[],[],[2498]
2372,VHL K196fs (c.588insA),0.0,,,[],[6751],{<CIViC source 2645>},[],[],[2499]
2373,VHL Y98S (c.293A>C),0.0,,,[],[],set(),[],[],[2500]
2374,VHL L198P (c.593T>C),0.0,,,"['C.593T>C', 'LEU198PRO', 'RS869025667']","[6755, 6779, 9263, 11014]","{<CIViC source 4502>, <CIViC source 3972>, <CIViC source 2645>, <CIViC source 2649>}",[],[],[2501]
2375,VHL E160V (c.479A>T),0.0,,,"['C.479A>T', 'GLU160VAL', 'RS864321641']","[6756, 6781]","{<CIViC source 2645>, <CIViC source 2649>}",[],[],[2502]
2376,VHL S183W (c.548C>G),0.0,,,"['C.548C>G', 'SER183TRP', 'RS5030823']","[6757, 6782]","{<CIViC source 2645>, <CIViC source 2649>}",[],[],[2503]
2377,VHL Splice Site (c.341-2A>G),0.0,,,[],"[6762, 9383]","{<CIViC source 4020>, <CIViC source 2645>}",[],[],[2504]
2378,VHL L163F (c.487C>T),0.0,,,"['C.487C>T', 'LEU163PHE', 'RS1553620318']","[6763, 6783, 8476, 10903]","{<CIViC source 4452>, <CIViC source 3542>, <CIViC source 2645>, <CIViC source 2649>}",[],[],[2505]
2379,VHL L85_E94del (c.254_283del30bp),0.0,,,[],[6767],{<CIViC source 2646>},[],[],[2506]
2380,VHL c.516_517dupGTCAAGCCT and c.532_542delCTGGACATCGTinsATTA,0.0,,,[],[6769],{<CIViC source 2646>},[],[],[2507]
2381,VHL L129P (c.386T>C),5.0,,,['L129P (C.386T>G)'],"[6775, 10957, 5479]","{<CIViC source 2246>, <CIViC source 2648>, <CIViC source 4473>}",[],[],[2508]
2382,VHL V62Efs*71 (c.185_193delTGCTGCGCTinsAGCA),0.0,,,[],[6790],{<CIViC source 2650>},[],[],[2509]
2383,VHL R69AFS*63 (c.204_205insG),0.0,,,"['C.204_205INSG', 'ARG69ALAFS*63']","[5593, 6792]","{<CIViC source 2286>, <CIViC source 2650>}",[],[],[2510]
2384,VHL S80fs (c.239del),7.5,,,"['C.239DELG', 'SER80ILEFS*79', 'S80IFS*79 (C.239DELG)']","[6797, 8996]","{<CIViC source 3784>, <CIViC source 2650>}",[],[],[2511]
2385,VHL S80fs (c.239_245del),0.0,,,"['C.239_245DELGTCCGCG', 'SER80FS', 'S80FS (C.239_245DELGTCCGCG)', 'SER80THRFS*77']",[6798],{<CIViC source 2650>},[],[],[2512]
2386,VHL V87E (c.260T>A),0.0,,,"['C.260T>A', 'VAL87GLU']","[6804, 10822]","{<CIViC source 2650>, <CIViC source 4417>}",[],[],[2513]
2387,VHL D92fs (c.275delinsCC),0.0,,,['C.275DELAINSCC'],[6809],{<CIViC source 2650>},[],[],[2514]
2388,VHL P97Afs*35 (c.287_288insA),0.0,,,[],"[8298, 6812]","{<CIViC source 2650>, <CIViC source 3429>}",[],[],[2515]
2389,VHL H110PFS*49 (c.329delA),0.0,,,"['C.329DELA', 'HIS110PROFS*49', 'RS1559426199']",[6815],{<CIViC source 2650>},[],[],[2516]
2390,VHL S111fs (c.332del),0.0,,,"['C.332DELG', 'SER111THRFS*48', 'S111TFS*48 (C.332DELG)']",[6816],{<CIViC source 2650>},[],[],[2517]
2391,VHL Splice Region (c.340 3_340 10delACGGGCCCinsCG),0.0,,,[],[6817],{<CIViC source 2650>},[],[],[2518]
2393,VHL H115FS (c.343delC),0.0,,,"['HIS115FS', 'C.343DELC', 'HIS115THRFS*44']",[6820],{<CIViC source 2650>},[],[],[2520]
2394,VHL W117G (c.349T>G),0.0,,,"['C.349T>G', 'TRP117GLY']","[8289, 6821]","{<CIViC source 2650>, <CIViC source 3429>}",[],[],[2521]
2395,VHL W117R (c.349T>A),0.0,,,"['C.349T>A', 'TRP117ARG']","[6822, 6903, 8533, 9058]","{<CIViC source 2657>, <CIViC source 3574>, <CIViC source 2650>, <CIViC source 3825>}",[],[],[2522]
2396,VHL W117S (c.350G>C),0.0,,,"['C.350G>C', 'TRP117SER']","[6823, 10486, 10494]","{<CIViC source 3511>, <CIViC source 4350>, <CIViC source 2650>}",[],[],[2523]
2397,VHL E134_V142del (c.402_428del),0.0,,,[],[6825],{<CIViC source 2650>},[],[],[2524]
2398,VHL Q145fs (c.433_437delCAGCC),0.0,,,[],[6828],{<CIViC source 2650>},[],[],[2525]
2399,VHL P146Gfs*14 (c.435_436insGG),0.0,,,[],[6829],{<CIViC source 2650>},[],[],[2526]
2400,VHL E160fs (c.480delG),0.0,,,"['GLU160FS', 'C.480DELG']",[6834],{<CIViC source 2650>},[],[],[2527]
2401,VHL C162* (c.486C>A),0.0,,,"['C.486C>A', 'C162X', 'CYS162TER', 'RS5030622']","[6839, 8384]","{<CIViC source 3489>, <CIViC source 2650>}",[],[],[2528]
2402,VHL E189_D190del (c.565_570delGAAGAC),0.0,,,[],[6845],{<CIViC source 2650>},[],[],[2529]
2404,"VHL c.(?_213)_(*3705_?)del (Exon1, 2, 3 deletion)",0.0,,,[],[],set(),[],[],[2531]
2405,VHL R82G (c.244C>G),0.0,"Note that while there is no exact match for this variant in ClinVar there are two close matches that affect the same amino acid position:

- NM_000551.3(VHL):c.245G>T (p.Arg82Leu). https://www.ncbi.nlm.nih.gov/clinvar/variation/526675/
- NM_000551.3(VHL):c.245G>C (p.Arg82Pro). https://www.ncbi.nlm.nih.gov/clinvar/variation/193118/","Note that while there is no exact match for this variant in ClinVar there are two close matches that affect the same amino acid position:

- NM_000551.3(VHL):c.245G>T (p.Arg82Leu). https://www.ncbi.nlm.nih.gov/clinvar/variation/526675/
- NM_000551.3(VHL):c.245G>C (p.Arg82Pro). https://www.ncbi.nlm.nih.gov/clinvar/variation/193118/",['ARG 82 GLY'],"[6855, 8726]","{<CIViC source 2652>, <CIViC source 3665>}",[],[],[2532]
2406,VHL D126N (c.376G>A),0.0,,,"['C.376G>A', 'ASP126ASN', 'RS104893831']","[6856, 9104, 10770, 8541]","{<CIViC source 3844>, <CIViC source 3579>, <CIViC source 4400>, <CIViC source 2653>}",[],[],[2533]
2407,VHL Splice Region (c.340+3_340+10delinsCG),0.0,"There are no identical variants in ClinVar with this exact genomic location. However, there are several variants in ClinVar involving disruption of this donor site by deletion or substitution of bases.","There are no identical variants in ClinVar with this exact genomic location. However, there are several variants in ClinVar involving disruption of this donor site by deletion or substitution of bases.","['IVSI 3INSCGDELACGGGCCC', 'IVSI + 3INSCGDELACGGGCCC']",[6858],{<CIViC source 2654>},[],[],[2534]
2408,VHL S65L (c.194C>T),0.0,,,[],[10782],{<CIViC source 4404>},[],[],[2535]
2409,VHL L101R (c.302T>G),0.0,,,[],[],set(),[],[],[2536]
2410,VHL R108fs (c.323delGC),0.0,,,[],[6867],{<CIViC source 2655>},[],[],[2537]
2412,VHL V114R (c.341T>C),0.0,,,[],[6870],{<CIViC source 2655>},[],[],[2539]
2413,VHL H115Q (c.346C>A),0.0,,,[],[6871],{<CIViC source 2655>},[],[],[2540]
2414,VHL S139F (c.416C>T),0.0,,,"['C.416C>T', 'SER139PHE', 'RS587780732']",[6874],{<CIViC source 2655>},[],[],[2541]
2415,VHL F190L (c.568T>C),0.0,,,[],[6882],{<CIViC source 2655>},[],[],[2542]
2416,VHL L198fs (c.592del),0.0,,,"['L198FS (C.592DELC)', 'L198WFS*4 (C.592DEL)', 'C.591DEL']","[6749, 6883]","{<CIViC source 2655>, <CIViC source 2644>}",[],[],[2543]
2418,VHL M54fs (c.160_175del),0.0,,,[],[6888],{<CIViC source 2656>},[],[],[2545]
2419,VHL P61fs Stop at 121(c.180_208del),0.0,,,[],[6889],{<CIViC source 2657>},[],[],[2546]
2420,VHL N67fs (c.197_213del),0.0,,,[],[6891],{<CIViC source 2657>},[],[],[2547]
2421,VHL V84fs (c.249_255del),0.0,,,[],[6893],{<CIViC source 2657>},[],[],[2548]
2422,VHL L89R (c.266T>G),0.0,,,"['C.266T>G', 'LEU89ARG']",[6896],{<CIViC source 2657>},[],[],[2549]
2423,NRAS Amplification,0.0,,,[],[6899],{<CIViC source 2658>},[],[],[2550]
2424,VHL G104fs*158 (c.311delC),0.0,,,[],[6901],{<CIViC source 2657>},[],[],[2551]
2425,VHL R120fs*158 (c.359delG),0.0,,,[],[6906],{<CIViC source 2657>},[],[],[2552]
2426,VHL D121_A122del (c.361_366del),2.5,,,[],[6907],{<CIViC source 2657>},[],[],[2553]
2427,VHL D126G (c.377A>G),0.0,,,"['C.377A>G', 'ASP126GLY', 'RS1354593943']",[6908],{<CIViC source 2657>},[],[],[2554]
2428,VHL G127fs (c.381delG),0.0,,,"['C.381DELG', 'GLY127FS', 'RS1559428107']",[6909],{<CIViC source 2657>},[],[],[2555]
2429,VHL T133fs*157 (c.397_400delACTG),0.0,,,"['C.397_400DELACTG', 'THR133FS*157']",[6911],{<CIViC source 2657>},[],[],[2556]
2430,VHL L135fs (c.405delA),0.0,,,[],[6913],{<CIViC source 2657>},[],[],[2557]
2431,VHL F137fs (c.408insT),0.0,,,[],[6914],{<CIViC source 2657>},[],[],[2558]
2432,VHL L140fs*158 (c.419delT),0.0,,,"['C.419DELT', 'LEU140FS*158']","[6916, 9388]","{<CIViC source 2657>, <CIViC source 4020>}",[],[],[2559]
2433,VHL G144fs (c.431del),0.0,,,"['C.431DELG', 'GLY144ASPFS', 'GLY144FS*158', 'RS869025651']","[6917, 5342]","{<CIViC source 2657>, <CIViC source 2235>}",[],[],[2560]
2434,VHL N150fs (c.447del),2.5,,,"['C.446DELC', 'N150IFS*9', 'A149FS']","[8665, 6918]","{<CIViC source 2657>, <CIViC source 3571>}",[],[],[2561]
2435,VHL T157fs*158 (c.469delA),0.0,,,"['C.469DELA', 'THR157FS*158']",[],set(),[],[],[2562]
2436,VHL L163fs*169 (c.488delT),0.0,,,"['C.488DELT', 'LEU163FS*169']",[6924],{<CIViC source 2657>},[],[],[2563]
2437,MYC Amplification,0.0,,,[],"[7048, 6928]","{<CIViC source 2726>, <CIViC source 2661>}",[],[],[2564]
2438,PTPN12 Loss-of-function,0.0,,,[],[6931],{<CIViC source 2664>},[],[],[2565]
2439,v::ABL1 Fusion,0.0,,,['ABL1 Fusion'],[6936],{<CIViC source 2495>},[],[],[2566]
2440,ETV6 Mutation,0.0,,,[],[6946],{<CIViC source 2675>},[],[],[2567]
2441,RET V804M,7.5,,,[],"[6951, 7068, 7516]","{<CIViC source 2677>, <CIViC source 1994>, <CIViC source 2745>}",[],[],[2568]
2443,HRAS Q61,10.0,,,[],[6960],{<CIViC source 2683>},[],[],[2570]
2444,v::ABL2 Fusion,3.0,,,['ABL2 Fusion'],"[6963, 7250]",{<CIViC source 2495>},[],[],[2571]
2445,v::JAK2 Fusion,20.0,,,['JAK2 Fusion'],"[6964, 12287, 12256]","{<CIViC source 2458>, <CIViC source 2495>, <CIViC source 3039>}",[],[],[2572]
2446,PTPN11 D61Y,0.0,,,['ASP61TYR'],[6967],{<CIViC source 2689>},[],[],[2573]
2447,SETBP1 D868N,0.0,,,[],[6968],{<CIViC source 2690>},[],[],[2574]
2448,ETV6::ABL1 Fusion,32.5,,,['ETV6-ABL1'],"[9073, 11326, 9171, 6969, 11614]","{<CIViC source 2495>, <CIViC source 4658>, <CIViC source 3896>, <CIViC source 3834>}",[],[],[2575]
2449,CTNNB1 G34V,0.0,,,[],"[9664, 6973]","{<CIViC source 3103>, <CIViC source 2692>}",[],[],[2576]
2450,AGGF1::PDGFRB Fusion,0.0,,,[],[],set(),[],[],[2577]
2451,NOTCH3 Overexpression,0.0,,,[],"[7001, 7002]","{<CIViC source 2698>, <CIViC source 2697>}",[],[],[2578]
2452,IKZF1 D186fs (c.556del),0.0,,,"['ASP186THRFSTER7', 'ASP186FS']",[7003],{<CIViC source 2699>},[],[],[2579]
2453,VHL N131T (c.392A>C),15.0,A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.,A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.,[],"[5129, 5046, 6606, 7006]","{<CIViC source 1264>, <CIViC source 2610>, <CIViC source 2193>}",[],[],[2580]
2454,HEY1::NCOA2 Fusion,70.0,HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).,HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).,['HEY1-NCOA2'],"[7008, 7025, 7026, 7124, 7125, 7017, 10798]","{<CIViC source 4407>, <CIViC source 2724>, <CIViC source 2725>, <CIViC source 2703>, <CIViC source 2716>}",[2704],[<CIViC source 2704>],[2581]
2455,PAX3::FOXO1 Fusion,38.0,,,['PAX3-FOXO1'],"[7009, 11684, 11687, 8885, 7011]","{<CIViC source 2706>, <CIViC source 2705>, <CIViC source 4843>, <CIViC source 4844>}",[],[],[2582]
2456,PAX7::FOXO1 Fusion,55.0,,,['PAX7-FOXO1'],"[7010, 11685, 11686, 8886]","{<CIViC source 2705>, <CIViC source 4843>, <CIViC source 4844>}",[],[],[2583]
2457,CDK9 Overexpression,0.0,,,[],"[9311, 7012, 9312]","{<CIViC source 2707>, <CIViC source 3993>, <CIViC source 3992>}",[],[],[2584]
2458,VEGFA Overexpression,0.0,,,[],"[7013, 9229, 7216, 7237]","{<CIViC source 3950>, <CIViC source 2848>, <CIViC source 2708>, <CIViC source 2830>}",[],[],[2585]
2459,PARP1 OVEREXPRESSION,3.0,,,[],"[7868, 7016, 7867]","{<CIViC source 3159>, <CIViC source 3158>, <CIViC source 2714>}",[],[],[2586]
2460,JAK2 F694L,5.0,,,[],[7021],{<CIViC source 2719>},[],[],[2587]
2461,EPOR Overexpression,0.0,,,[],"[7023, 7205, 7206]","{<CIViC source 2495>, <CIViC source 2824>, <CIViC source 3902>}",[],[],[2588]
2463,PIK3CA Wildtype,15.0,,,[],"[2038, 7047]",{<CIViC source 1463>},[],[],[2590]
2464,DICER1 E1813 mutations,0.0,,,[],[7049],{<CIViC source 2266>},[],[],[2591]
2465,KIT K642R,0.0,,,[],[7051],{<CIViC source 2727>},[],[],[2592]
2466,NUP98::NSD1 Fusion,20.0,,,['NUP98-NSD1'],"[9720, 7054]","{<CIViC source 4147>, <CIViC source 2729>}",[],[],[2593]
2467,ASCL1 EXPRESSION,0.0,,,[],[7055],{<CIViC source 2732>},[],[],[2594]
2468,HDAC2 Expression,0.0,,,[],[7057],{<CIViC source 2734>},[],[],[2595]
2469,LZTR1 LOSS-OF-FUNCTION,0.0,,,[],[7058],{<CIViC source 2735>},[],[],[2596]
2470,DICER1 R392fs and E1813D,0.0,,,[],[7059],{<CIViC source 2737>},[],[],[2597]
2471,IRS2 Amplification,0.0,,,[],"[10764, 7075]","{<CIViC source 2752>, <CIViC source 4398>}",[],[],[2598]
2472,EGFR I462K,0.0,,,['ILE462LYS'],[7079],{<CIViC source 2672>},[],[],[2599]
2473,EGFR I462R,0.0,,,['ILE462ARG'],[7080],{<CIViC source 2672>},[],[],[2600]
2474,EGFR S464L,0.0,,,['SER464LEU'],[7081],{<CIViC source 2672>},[],[],[2601]
2475,EGFR S464T,0.0,,,['SER464THR'],[7082],{<CIViC source 2672>},[],[],[2602]
2476,EGFR G465E,0.0,,,['GLY465GLU'],[7084],{<CIViC source 2672>},[],[],[2603]
2477,EGFR G465V,0.0,,,['GLY465VAL'],[7085],{<CIViC source 2672>},[],[],[2604]
2478,EGFR K467N,0.0,,,[],[7086],{<CIViC source 2672>},[],[],[2605]
2479,EGFR K489Q,0.0,,,['LYS489GLN'],[7088],{<CIViC source 2672>},[],[],[2606]
2480,EGFR K489E,0.0,,,['LYS489GLU'],[7089],{<CIViC source 2672>},[],[],[2607]
2481,EGFR I491K,0.0,,,['ILE491LYS'],[7090],{<CIViC source 2672>},[],[],[2608]
2482,EGFR I491R,0.0,,,['ILE491ARG'],[7091],{<CIViC source 2672>},[],[],[2609]
2483,EGFR S492C,0.0,,,['SER492CYS'],[7093],{<CIViC source 2672>},[],[],[2610]
2484,EGFR V441G,0.0,,,['VAL441GLY'],[7094],{<CIViC source 2672>},[],[],[2611]
2485,EGFR V441D,0.0,,,['VAL441ASP'],[7095],{<CIViC source 2672>},[],[],[2612]
2486,EGFR V441F,0.5,,,['VAL441PHE'],[7096],{<CIViC source 2672>},[],[],[2613]
2487,EGFR S442R,0.0,,,['SER442ARG'],[7097],{<CIViC source 2672>},[],[],[2614]
2488,EGFR S442I,0.0,,,['SER442ILE'],[7098],{<CIViC source 2672>},[],[],[2615]
2489,EGFR F404I,0.0,,,['PHE404ILE'],[7099],{<CIViC source 2672>},[],[],[2616]
2490,EGFR F404V,0.0,,,['PHE404VAL'],[7100],{<CIViC source 2672>},[],[],[2617]
2491,EGFR T415M,0.0,,,[],[7101],{<CIViC source 2672>},[],[],[2618]
2492,FLT3 Amplification,15.0,,,[],"[11667, 7102, 7103]","{<CIViC source 4830>, <CIViC source 2754>, <CIViC source 2755>}",[],[],[2619]
2493,KIT T417_D419delinsY,5.0,,,[],[2417],{<CIViC source 1586>},[],[],[2620]
2494,KIT F506_F508DUP,2.5,,,[],[2441],{<CIViC source 1586>},[],[],[2621]
2495,KIT K484_G487DEL,2.5,,,[],[2465],{<CIViC source 1586>},[],[],[2622]
2496,PDGFRA Exon 18 Mutation,2.5,,,[],"[7809, 2486]","{<CIViC source 3129>, <CIViC source 1586>}",[],[],[2623]
2497,TP53 V135A,0.0,,,[],[7123],{<CIViC source 2759>},[],[],[2624]
2499,CBFA2T3::GLIS2 Fusion,60.0,,,['CBFA2T3-GLIS2'],"[7126, 8503, 8551, 11884, 11885, 11886, 11887]","{<CIViC source 4960>, <CIViC source 2764>, <CIViC source 3553>, <CIViC source 4959>, <CIViC source 3581>}",[],[],[2630]
2501,ATF7IP::PDGFRB Fusion,0.0,,,['ATF7IP-PDGFRB'],"[7129, 7196]","{<CIViC source 2765>, <CIViC source 2818>}",[],[],[2632]
2502,VHL c.-77_-32del,0.0,,,[],"[7130, 9367]","{<CIViC source 4020>, <CIViC source 2766>}",[],[],[2633]
2503,VHL c.-61_-51dup11,0.0,,,[],[7131],{<CIViC source 2766>},[],[],[2634]
2504,ALK Overexpression,0.0,,,[],[7136],{<CIViC source 2770>},[],[],[2635]
2505,CDK4 Overexpression,0.0,,,[],"[7138, 8114]","{<CIViC source 2772>, <CIViC source 3123>}",[],[],[2636]
2506,KDR Amplification,0.0,,,[],[7139],{<CIViC source 2387>},[],[],[2637]
2507,CBL Y371H,7.5,,,[],"[7147, 7146]","{<CIViC source 2776>, <CIViC source 2777>}",[],[],[2638]
2508,v::BRAF Fusion,0.0,,,['BRAF Fusion'],[],set(),[],[],[2639]
2509,v::NTRK2 Fusion,30.0,,,[],"[10392, 11222, 7151]","{<CIViC source 4345>, <CIViC source 864>, <CIViC source 4332>}",[],[],[2640]
2510,FGFR1 Mutation,0.0,,,[],[7152],{<CIViC source 864>},[],[],[2641]
2511,PTPN11 Mutation,0.0,,,[],[7153],{<CIViC source 864>},[],[],[2642]
2512,KIT Exon 13 Mutation,5.0,,,[],[2475],{<CIViC source 412>},[],[],[2643]
2513,SMARCA4 Loss,4.0,,,[],"[8864, 7960, 7961, 7154, 7155]","{<CIViC source 2781>, <CIViC source 3625>, <CIViC source 1657>, <CIViC source 2782>}",[],[],[2644]
2514,KDM6A R1213*,0.0,,,[],[7163],{<CIViC source 2789>},[],[],[2645]
2515,BRCA1 R71M,0.0,,,[],[],set(),[],[],[2646]
2516,FBXW7 R465H,0.0,,,[],"[7174, 7170]","{<CIViC source 2799>, <CIViC source 2795>}",[],[],[2647]
2517,TP53 C238Y,2.75,,,['CYS238TYR'],"[7215, 7173]","{<CIViC source 2829>, <CIViC source 2798>}",[],[],[2648]
2518,KRAS Activating Mutation,0.0,,,[],"[7180, 7182, 7184]","{<CIViC source 2807>, <CIViC source 2811>, <CIViC source 2809>}",[],[],[2649]
2519,BRAF Exon 15 Mutation,7.5,,,[],"[4121, 4605]","{<CIViC source 2045>, <CIViC source 2046>}",[],[],[2650]
2520,KIT Wildtype,10.0,,,[],[4144],{<CIViC source 2046>},[],[],[2651]
2521,H3-3A MUTATION,20.0,,,[],"[7189, 9417]","{<CIViC source 2816>, <CIViC source 3965>}",[],[],[2652]
2522,ATRX DELETION,0.0,,,[],[],set(),[],[],[2653]
2523,CDKN2A Deletion,20.0,,,[],"[7192, 7311, 7985]","{<CIViC source 2816>, <CIViC source 3204>, <CIViC source 2887>}",[],[],[2654]
2524,MYB AMPLIFICATION,20.0,,,[],[7194],{<CIViC source 2816>},[],[],[2655]
2525,FAM131B::BRAF Fusion,0.0,,,['FAM131B-BRAF'],[7198],{<CIViC source 2819>},[3504],[<CIViC source 3504>],[2656]
2526,ERBB2 Activating Mutation,0.0,,,[],"[7201, 11676]","{<CIViC source 4837>, <CIViC source 2750>}",[],[],[2657]
2527,ERBB2 A775_G776insYVMA,0.0,,,[],"[7320, 7202]","{<CIViC source 2750>, <CIViC source 2891>}",[],[],[2658]
2528,FGFR1 Internal Duplication,20.0,,,[],[7203],{<CIViC source 2821>},[],[],[2659]
2529,NUP214::ABL1 Fusion,27.0,"The NUP214 -ABL1 fusion is composed of part of the NUP214 (Nucleoporin 214) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 34 of NUP214 to exon 2 of ABL1 (NUP214-ABL1 34-2). In T-ALL, the fusion is typically expressed from amplified extrachromosomal bodies (episomes) that arise when the genomic region from ABL1 to NUP214 circularizes to generate the NUP214-ABL1 fusion. In B-ALL, the fusion commonly results from an intrachromosomal duplication involving chromosome 9, with breakpoints within the NUP214 and ABL1 genes. The fusion has been identified in 6% of cases of T-lymphoblastic leukemia and rare cases of B-lymphoblastic leukemia by multiplex ligation-dependent probe amplification, single nucleotide polymorphism array, real-time polymerase chain reaction, and fluorescence in situ hybridization targeting the ABL1 gene. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the WD40 repeat and coiled-coil domains of NUP214 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and MAPK and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The case report that illustrates the clinical significance of the NUP214-ABL1 fusion describes a 6-year-old boy and a 15-year-old girl with BCR-ABL1-like B-lymphoblastic leukemia with normal karyotype. Both patients demonstrated minimal residual disease after induction chemotherapy, and later experienced relapse after either consolidation therapy or bone marrow transplant. Dasatinib was then prescribed and follow-up information is available for the older child, who successfully achieved a complete response for three months before succumbing to the disease. The clinical details of this case could predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).","The NUP214 -ABL1 fusion is composed of part of the NUP214 (Nucleoporin 214) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 34 of NUP214 to exon 2 of ABL1 (NUP214-ABL1 34-2). In T-ALL, the fusion is typically expressed from amplified extrachromosomal bodies (episomes) that arise when the genomic region from ABL1 to NUP214 circularizes to generate the NUP214-ABL1 fusion. In B-ALL, the fusion commonly results from an intrachromosomal duplication involving chromosome 9, with breakpoints within the NUP214 and ABL1 genes. The fusion has been identified in 6% of cases of T-lymphoblastic leukemia and rare cases of B-lymphoblastic leukemia by multiplex ligation-dependent probe amplification, single nucleotide polymorphism array, real-time polymerase chain reaction, and fluorescence in situ hybridization targeting the ABL1 gene. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the WD40 repeat and coiled-coil domains of NUP214 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and MAPK and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The case report that illustrates the clinical significance of the NUP214-ABL1 fusion describes a 6-year-old boy and a 15-year-old girl with BCR-ABL1-like B-lymphoblastic leukemia with normal karyotype. Both patients demonstrated minimal residual disease after induction chemotherapy, and later experienced relapse after either consolidation therapy or bone marrow transplant. Dasatinib was then prescribed and follow-up information is available for the older child, who successfully achieved a complete response for three months before succumbing to the disease. The clinical details of this case could predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",['NUP214-ABL1'],"[9148, 12218, 7208, 9074, 9150]","{<CIViC source 3876>, <CIViC source 2458>, <CIViC source 3877>, <CIViC source 2826>, <CIViC source 5145>}","[2458, 4257]","[<CIViC source 4257>, <CIViC source 2458>]",[2660]
2530,SSBP2::JAK2 Fusion,25.0,,,['T(5;9)(Q14.1;P24)'],"[8103, 7257, 8100, 7209, 11624]","{<CIViC source 3223>, <CIViC source 2495>, <CIViC source 2827>, <CIViC source 2498>}",[],[],[2661]
2531,CRLF2 F232C,0.0,,,[],[],set(),[],[],[2662]
2532,IGH::CRLF2 Fusion,20.0,,,['IGH-CRLF2'],"[7238, 11613, 7212, 8233, 7240, 11621, 7214, 8540]","{<CIViC source 2499>, <CIViC source 3032>, <CIViC source 2495>, <CIViC source 2464>, <CIViC source 2828>, <CIViC source 2498>}",[],[],[2663]
2533,BRAF EXON 15 MUTATION,0.0,,,[],[],set(),[],[],[2664]
2534,MYB::GATA1 Fusion,0.0,,,['MYB-GATA1'],[7217],{<CIViC source 2831>},[],[],[2665]
2535,EZH2 Y646S,3.0,,,"['Y641S', 'TYR641SER', 'TYR646SER']","[7218, 9522, 11051]","{<CIViC source 2832>, <CIViC source 4070>, <CIViC source 4540>}",[],[],[2666]
2536,MPL W515L,0.0,,,[],[7221],{<CIViC source 2835>},[],[],[2667]
2537,FOXO3 Mutation,0.0,,,[],"[7223, 7222]",{<CIViC source 2836>},[],[],[2668]
2538,TGFBR3 TGFBR3,0.0,,,[],[7225],{<CIViC source 2838>},[],[],[2669]
2539,EPHB2 EPHB2,0.0,,,[],[7226],{<CIViC source 2839>},[],[],[2670]
2540,CDKN1A rs1801270,15.0,,,[],[7227],{<CIViC source 2840>},[],[],[2671]
2542,EPHB2 D679N (c.2035G>A),0.0,,,[],[7230],{<CIViC source 2842>},[],[],[2673]
2543,"RB1 IVS20, A-G, -2",0.0,,,[],[7231],{<CIViC source 2843>},[],[],[2674]
2544,MSH2 L173P,0.0,,,[],[7233],{<CIViC source 2493>},[],[],[2675]
2545,EP300 G1506V,0.0,,,[],[7234],{<CIViC source 2845>},[],[],[2676]
2546,ERBB2 I654V,0.0,,,['ILE654VAL'],[7236],{<CIViC source 2847>},[],[],[2677]
2547,SNX2::ABL1 Fusion,30.5,"The SNX2-ABL1 fusion is composed of part of the SNX2 (Sorting Nexin 2) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 3 of SNX2 to exon 4 of ABL1 (SNX2-ABL1 3-4). The fusion is the result of a reciprocal translocation t(5;9)(p23.2;q34.12) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the sorting nexin, N-terminal domain of SNX2 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The SNX2-ABL1 fusion has been documented in six young men between the ages of 7 and 29 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (imatinib and dasatinib + imatinib) added to their chemotherapy regimens that, while producing initially encouraging results, ultimately did not prevent these individuals from succumbing to their disease. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).","The SNX2-ABL1 fusion is composed of part of the SNX2 (Sorting Nexin 2) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 3 of SNX2 to exon 4 of ABL1 (SNX2-ABL1 3-4). The fusion is the result of a reciprocal translocation t(5;9)(p23.2;q34.12) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the sorting nexin, N-terminal domain of SNX2 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The SNX2-ABL1 fusion has been documented in six young men between the ages of 7 and 29 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (imatinib and dasatinib + imatinib) added to their chemotherapy regimens that, while producing initially encouraging results, ultimately did not prevent these individuals from succumbing to their disease. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",['SNX2-ABL1'],"[9177, 9178, 7241, 7254, 7694, 7744, 7655]","{<CIViC source 3042>, <CIViC source 2857>, <CIViC source 2495>, <CIViC source 2849>, <CIViC source 3057>, <CIViC source 3323>}",[],[],[2678]
2548,WEE1 Overexpression,0.0,,,[],"[7242, 7243, 9232, 9231]","{<CIViC source 3953>, <CIViC source 3952>, <CIViC source 2851>, <CIViC source 2850>}",[],[],[2679]
2550,RCSD1::ABL1 Fusion,80.5,"The RCSD1-ABL1 fusion is composed of part of the RCSD1 (RCS Domain Containing 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 2 or, more frequently, exon 3 of RCSD1 to exon 4 of ABL1 (RCSD1-ABL1 3-4). The fusion is the result of a reciprocal translocation t(1;9)(q24.2;q34.12) and has been identified by FISH/karyotype, RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the ABL1 SH2, actin binding domain, and tyrosine kinase domain, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RCSD1-ABL1 fusion has been documented in greater than fifteen pediatric and adult patients with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. The majority that that were exposed to tyrosine kinase inhibitors (TKIs: imatinib, dasatinib, or ponatinib) experienced durable remissions until the TKIs were discontinued. The clinical details of these cases may predict response to treatment with TKIs and are the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).","The RCSD1-ABL1 fusion is composed of part of the RCSD1 (RCS Domain Containing 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 2 or, more frequently, exon 3 of RCSD1 to exon 4 of ABL1 (RCSD1-ABL1 3-4). The fusion is the result of a reciprocal translocation t(1;9)(q24.2;q34.12) and has been identified by FISH/karyotype, RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the ABL1 SH2, actin binding domain, and tyrosine kinase domain, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RCSD1-ABL1 fusion has been documented in greater than fifteen pediatric and adult patients with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. The majority that that were exposed to tyrosine kinase inhibitors (TKIs: imatinib, dasatinib, or ponatinib) experienced durable remissions until the TKIs were discontinued. The clinical details of these cases may predict response to treatment with TKIs and are the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",['RCSD1-ABL1'],"[7248, 7783, 9164, 9166, 9167, 9168, 9213, 9075, 9162, 9163, 9165, 9169, 11618, 7249, 9214]","{<CIViC source 3886>, <CIViC source 4017>, <CIViC source 2458>, <CIViC source 3888>, <CIViC source 2495>, <CIViC source 3890>, <CIViC source 3892>, <CIViC source 3891>, <CIViC source 2498>, <CIViC source 3101>, <CIViC source 3889>, <CIViC source 3921>}",[],[],[2681]
2551,FOXP1::ABL1 Fusion,10.0,"The FOXP1-ABL1 fusion is composed of part of the FOXP1 (Forkhead box P1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 27 of FOXP1to exon 4 of ABL1 (FOXP1-ABL1). The fusion is the result of a reciprocal translocation t(3;9)(p12;q34) and has been identified by RT-PCR, Sanger sequencing, and NGS. FOXP1 is critical for the transcriptional regulatory network of B lymphopoiesis; it may also act as a tumor suppressor gene. Absence or deficiency of FOXP1 during early B-cell development may block pro-B cell to pre-B cell development. The FOXP1-ABL1 fusion protein leads to activated tyrosine kinase and may further alter the critical cellular function of these 2 genes. Clinical significance: The FOXP1-ABL1 fusion has been documented in 3 young adult patients (2 male, 1 female) with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. One patient had tyrosine kinase inhibitors (dasatinib) added to the chemotherapy regimens, who had bone marrow tested negative for MRD at end of consolidation. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.","The FOXP1-ABL1 fusion is composed of part of the FOXP1 (Forkhead box P1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 27 of FOXP1to exon 4 of ABL1 (FOXP1-ABL1). The fusion is the result of a reciprocal translocation t(3;9)(p12;q34) and has been identified by RT-PCR, Sanger sequencing, and NGS. FOXP1 is critical for the transcriptional regulatory network of B lymphopoiesis; it may also act as a tumor suppressor gene. Absence or deficiency of FOXP1 during early B-cell development may block pro-B cell to pre-B cell development. The FOXP1-ABL1 fusion protein leads to activated tyrosine kinase and may further alter the critical cellular function of these 2 genes. Clinical significance: The FOXP1-ABL1 fusion has been documented in 3 young adult patients (2 male, 1 female) with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. One patient had tyrosine kinase inhibitors (dasatinib) added to the chemotherapy regimens, who had bone marrow tested negative for MRD at end of consolidation. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.",['FOXP1-ABL1'],"[9155, 7253, 7292, 7651, 11615, 9154]","{<CIViC source 3039>, <CIViC source 2857>, <CIViC source 2495>, <CIViC source 3881>, <CIViC source 3880>, <CIViC source 2877>}",[],[],[2682]
2552,PTK2B::KDM6A Fusion,0.0,,,['PTK2B-KDM6A'],[7255],{<CIViC source 2495>},[],[],[2683]
2553,PTK2B::STAG2 Fusion,0.0,,,['PTK2B-STAG2'],[7256],{<CIViC source 2495>},[],[],[2684]
2554,DGKH::ZFAND3 Fusion,0.0,,,['DGKH-ZFAND3'],[7258],{<CIViC source 2495>},[],[],[2685]
2555,IL2RB::MYH9 Fusion,0.0,,,['IL2RB-MYH9'],[7259],{<CIViC source 2495>},[],[],[2686]
2558,NF1 VARIANTS,0.0,,,[],[],set(),[],[],[2689]
2559,NTRK1 G595R,0.0,,,[],"[7267, 7269]",{<CIViC source 2863>},[],[],[2690]
2560,NTRK3 G623R,0.0,,,[],"[7268, 7270]",{<CIViC source 2863>},[],[],[2691]
2561,B2M Mutation,0.0,,,[],"[7271, 11930, 11891]","{<CIViC source 2864>, <CIViC source 258>, <CIViC source 4949>}",[],[],[2692]
2562,v::ROS1 Fusion,50.0,"ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement","ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement","['ROS1 Fusion', 'ROS1 Rearrangement']","[7282, 11123, 688, 7933, 12021, 1030, 2951, 8916, 11334, 11335, 12240, 1443, 1301]","{<CIViC source 3175>, <CIViC source 4558>, <CIViC source 5147>, <CIViC source 715>, <CIViC source 4995>, <CIViC source 3077>, <CIViC source 1689>, <CIViC source 894>, <CIViC source 2870>, <CIViC source 975>, <CIViC source 447>, <CIViC source 4660>, <CIViC source 3749>}","[447, 1307]","[<CIViC source 447>, <CIViC source 1307>]",[2693]
2564,KIT V555_V559DEL,5.0,,,[],[7288],{<CIViC source 965>},[],[],[2695]
2565,KIT K550_K559DEL,5.0,,,[],[7289],{<CIViC source 965>},[],[],[2696]
2566,PAX5 P80R,50.0,,,[],"[11519, 7290, 7291, 11522]","{<CIViC source 4774>, <CIViC source 2876>, <CIViC source 2875>}",[],[],[2697]
2568,CBL Mutation,0.0,,,[],[7294],{<CIViC source 2879>},[],[],[2699]
2569,CBL Q294E,0.0,,,[],[7295],{<CIViC source 2879>},[],[],[2700]
2570,CBL S80N,0.0,,,[],[],set(),[],[],[2701]
2571,CBL V391I,0.0,,,[],[7297],{<CIViC source 2879>},[],[],[2702]
2572,CBL W802*,0.0,,,[],[7298],{<CIViC source 2879>},[],[],[2703]
2573,CDKN2A Mutation,40.0,,,[],"[7299, 7300, 11815]","{<CIViC source 2880>, <CIViC source 4938>}",[],[],[2704]
2574,PBRM1 Loss-of-function,0.0,,,[],"[7584, 7301, 7536, 7537]","{<CIViC source 2855>, <CIViC source 3003>}",[],[],[2705]
2575,DEK::AFF2 Fusion,0.0,,,['DEK-AFF2'],[7304],{<CIViC source 2884>},[],[],[2706]
2576,KIF5B::MET Fusion,0.0,,,['KIF5B-MET'],[7309],{<CIViC source 2885>},[],[],[2707]
2578,PIK3CA E545X,0.0,,,[],[],set(),[],[],[2709]
2579,PIK3CA H1047X,50.0,,,[],[],set(),[],[],[2710]
2580,TP53 R213*,0.0,,,"['R213X', 'ARG213TER']",[7321],{<CIViC source 2892>},[],[],[2711]
2581,MTOR T1977K,0.0,,,[],"[7323, 9479]","{<CIViC source 2894>, <CIViC source 911>}",[],[],[2712]
2582,MTOR C1483F,0.0,,,[],[7324],{<CIViC source 2894>},[],[],[2713]
2583,MTOR F1888L,0.0,,,[],[7325],{<CIViC source 2894>},[],[],[2714]
2584,MTOR S2215F,0.0,,,[],[7326],{<CIViC source 2894>},[],[],[2715]
2585,MTOR L2230V,0.0,,,[],[7327],{<CIViC source 2894>},[],[],[2716]
2586,PSMD4 Overexpression,0.0,,,[],[7330],{<CIViC source 2897>},[],[],[2717]
2587,CCNE1 Underexpression,0.0,,,[],[7331],{<CIViC source 2898>},[],[],[2718]
2588,TP53 C135F,0.0,,,[],"[10588, 9440, 7334, 7335]","{<CIViC source 2902>, <CIViC source 4058>, <CIViC source 4356>, <CIViC source 2901>}",[],[],[2719]
2589,TP53 Y205,0.0,,,[],[7338],{<CIViC source 2904>},[],[],[2720]
2590,TP53 G245,0.0,,,[],[7339],{<CIViC source 2904>},[],[],[2721]
2591,TP53 K132,0.0,,,[],[7341],{<CIViC source 2904>},[],[],[2722]
2592,TP53 R248,0.0,,,[],[7342],{<CIViC source 2904>},[],[],[2723]
2593,TP53 G266,0.0,,,[],[7343],{<CIViC source 2904>},[],[],[2724]
2594,TP53 R273,0.0,,,[],[7344],{<CIViC source 2904>},[],[],[2725]
2595,TP53 P278,0.0,,,[],[7345],{<CIViC source 2904>},[],[],[2726]
2596,ERBB2 A129,0.0,,,[],[7346],{<CIViC source 2904>},[],[],[2727]
2597,TP53 W146,0.0,,,[],[7347],{<CIViC source 2904>},[],[],[2728]
2598,TP53 A129,0.0,,,[],[7348],{<CIViC source 2904>},[],[],[2729]
2599,TP53 E204,0.0,,,[],[7349],{<CIViC source 2904>},[],[],[2730]
2600,TP53 L114,0.0,,,[],[7350],{<CIViC source 2904>},[],[],[2731]
2601,TP53 P153,0.0,,,[],[7351],{<CIViC source 2904>},[],[],[2732]
2602,TP53 T170,0.0,,,[],[7352],{<CIViC source 2904>},[],[],[2733]
2603,TP53 D184,0.0,,,[],[7353],{<CIViC source 2904>},[],[],[2734]
2604,TP53 L206,0.0,,,[],[7354],{<CIViC source 2904>},[],[],[2735]
2605,KIT D820E,0.0,,,[],[7356],{<CIViC source 2906>},[],[],[2736]
2606,KIT Y553N,0.0,,,[],[7358],{<CIViC source 2907>},[],[],[2737]
2607,KIT P577_D579DEL,0.0,,,[],[7360],{<CIViC source 2055>},[],[],[2738]
2608,CRLF2 Overexpression,0.0,,,[],[7364],{<CIViC source 2910>},[],[],[2739]
2609,IKZF1 IKZF1 deletion,0.0,,,[],[],set(),[],[],[2740]
2610,EGFR R832L,0.0,,,['ARG832LEU'],"[7367, 7368]","{<CIViC source 2435>, <CIViC source 2912>}",[],[],[2741]
2611,FLT3 FLT3,0.0,,,[],[],set(),[],[],[2742]
2612,FGFR1OP2::FGFR1 Fusion,2.0,,,['FGFR1OP2-FGFR1'],[7380],{<CIViC source 2913>},[],[],[2743]
2613,IKZF1 Loss-of-function,20.0,,,[],[7383],{<CIViC source 2918>},[],[],[2744]
2614,EGFR M766Q,0.0,,,[],"[7388, 7389, 7390]",{<CIViC source 2917>},[],[],[2745]
2615,CCND2 Amplification,0.0,,,[],[7406],{<CIViC source 2924>},[],[],[2746]
2616,CCND3 Amplification,0.0,,,[],[7407],{<CIViC source 2924>},[],[],[2747]
2618,NFE2L2 Mutation,15.0,,,[],"[7425, 7446]","{<CIViC source 2928>, <CIViC source 2947>}",[],[],[2749]
2619,EML6::ALK Fusion,0.0,,,['EML6-ALK'],[],set(),[],[],[2750]
2620,TP53 V274S,0.0,,,[],[7431],{<CIViC source 2904>},[],[],[2751]
2621,ZNF217 AMPLIFICATION,0.0,,,[],[],set(),[],[],[2752]
2622,PRKN R275W,0.0,,,[],[7439],{<CIViC source 3165>},[],[],[2753]
2623,PRKN Loss,0.0,,,[],[7440],{<CIViC source 3164>},[],[],[2754]
2624,FUBP1 LOSS-OF-FUNCTION,0.0,,,[],[7441],{<CIViC source 3166>},[],[],[2755]
2626,STAG2 LOSS-OF-FUNCTION,0.0,,,[],[],set(),[],[],[2757]
2627,BRCA1 ATM,0.0,,,[],[7456],{<CIViC source 2956>},[],[],[2758]
2628,PALB2 Mutation,40.0,,,[],"[8504, 7460, 7474, 9294, 10835, 9550]","{<CIViC source 3554>, <CIViC source 2957>, <CIViC source 3983>, <CIViC source 2962>, <CIViC source 4413>, <CIViC source 1403>}",[],[],[2759]
2629,MPL Mutation,0.0,,,[],"[6383, 7464]","{<CIViC source 966>, <CIViC source 940>}",[],[],[2760]
2630,ZRSR2 MUTATION,0.0,,,[],[7466],{<CIViC source 2676>},[],[],[2761]
2631,NRG1 NRG1 FUSIONS,0.0,,,[],[7467],{<CIViC source 2959>},[],[],[2762]
2632,PIK3CA E545,40.0,,,[],[],set(),[],[],[2763]
2633,CDK12 Mutation,40.0,,,[],"[11204, 11735, 7473]","{<CIViC source 4881>, <CIViC source 2961>, <CIViC source 3554>}",[],[],[2764]
2634,BRAF K601,0.0,,,[],[7475],{<CIViC source 2967>},[],[],[2765]
2635,BRAF L597,0.0,,,[],"[7621, 7476, 7632, 7626]","{<CIViC source 3026>, <CIViC source 2967>}",[],[],[2766]
2636,BRAF D594,0.0,,,[],[7477],{<CIViC source 2967>},[],[],[2767]
2637,BRAF G596,0.0,,,[],[7478],{<CIViC source 2967>},[],[],[2768]
2638,CAD::ALK Fusion,7.5,,,['CAD-ALK'],[7481],{<CIViC source 2970>},[],[],[2769]
2639,GOPC::ROS1 Fusion,3.0,,,['GOPC-ROS1'],"[12140, 11849, 11855, 7483]","{<CIViC source 2972>, <CIViC source 4951>, <CIViC source 1689>}",[],[],[2770]
2640,CD74::NRG1 Fusion,0.0,,,['CD74-NRG1'],"[7490, 7494]","{<CIViC source 2975>, <CIViC source 2976>}",[],[],[2771]
2641,APP::NRG1 Fusion,7.5,,,['APP-NRG1'],[7493],{<CIViC source 2959>},[],[],[2772]
2642,RABL3 MUTATION,0.0,,,[],[7497],{<CIViC source 2979>},[],[],[2773]
2643,MET R1004G,7.5,,,['ARG1004GLY'],[7498],{<CIViC source 2980>},[],[],[2774]
2644,BRAF K439Q,0.0,,,[],[7499],{<CIViC source 2982>},[],[],[2775]
2645,BRAF K439T,0.0,,,[],[7500],{<CIViC source 2982>},[],[],[2776]
2646,TP53 S241F,3.0,,,[],"[10250, 7501]","{<CIViC source 2983>, <CIViC source 4271>}",[],[],[2777]
2647,MET Exon 14 Mutation,0.0,,,[],"[7840, 7503]","{<CIViC source 3139>, <CIViC source 2984>}",[],[],[2778]
2648,NAB2::STAT6 Fusion,0.0,,,[],[7504],{<CIViC source 2985>},[],[],[2779]
2649,FGFR2 N549H,0.0,,,[],"[7510, 7511]",{<CIViC source 1994>},[],[],[2780]
2650,FGFR1 V561M,0.0,,,[],"[7512, 7513]",{<CIViC source 1994>},[],[],[2781]
2651,TEK R849W,0.0,,,[],[7517],{<CIViC source 1994>},[],[],[2782]
2652,FGF19 EXPRESSION,0.0,,,[],[],set(),[],[],[2783]
2653,FGF19 Overexpression,20.0,,,[],"[7636, 7523, 7518, 7519]","{<CIViC source 3027>, <CIViC source 2987>, <CIViC source 2986>, <CIViC source 2989>}",[],[],[2784]
2654,FLT3 ITD N676K,0.0,,,[],"[7524, 9144]","{<CIViC source 2990>, <CIViC source 3741>}",[],[],[2785]
2655,TP53 R157H,0.0,,,[],[],set(),[],[],[2786]
2656,PRNCR1 rs1456315,0.0,,,[],[7545],{<CIViC source 3001>},[],[],[2787]
2657,PIK3CA G363A,0.0,,,['GLY363ALA'],"[7548, 10737]",{<CIViC source 927>},[],[],[2788]
2658,PIK3CA C971R,0.0,,,['CYS971ARG'],[7549],{<CIViC source 927>},[],[],[2789]
2659,PIK3CA R975S,0.0,,,[],[7550],{<CIViC source 927>},[],[],[2790]
2660,CDKN2A D108Y,0.0,,,[],[7551],{<CIViC source 3004>},[],[],[2791]
2661,BRAF G466E,0.0,,,[],[7555],{<CIViC source 3005>},[],[],[2792]
2662,BRAF L525R,0.0,,,[],"[7578, 7559, 7560]","{<CIViC source 3006>, <CIViC source 3010>}",[],[],[2793]
2663,BRAF N486_P490del,7.5,,,[],"[7730, 7561, 7562, 7563]","{<CIViC source 2133>, <CIViC source 3083>}",[],[],[2794]
2664,BRAF T488_P492del,0.0,,,[],[7564],{<CIViC source 2133>},[],[],[2795]
2665,BRAF P490_Q494del,0.0,,,[],[7565],{<CIViC source 2133>},[],[],[2796]
2667,ALK G1128A,0.0,,,[],"[7568, 7570]",{<CIViC source 1236>},[],[],[2798]
2668,BRAF D594E,0.0,,,[],[7573],{<CIViC source 3009>},[],[],[2799]
2669,BRAF Class 2 Mutations,0.0,,,[],[7574],{<CIViC source 3010>},[],[],[2800]
2670,BRAF Class 3 Mutations,0.0,,,[],[7575],{<CIViC source 3010>},[],[],[2801]
2671,BRAF F247L,0.0,,,[],[7576],{<CIViC source 3010>},[],[],[2802]
2672,BRAF R558Q,0.0,,,[],[7577],{<CIViC source 3010>},[],[],[2803]
2673,BRAF L485F,0.0,,,[],[7579],{<CIViC source 3010>},[],[],[2804]
2674,MAP2K1 V211D,0.0,,,[],"[7580, 7581]",{<CIViC source 3011>},[],[],[2805]
2675,KMT2A::v Fusion,0.0,,,"['MLL fusion', 'KMT2A Fusion']",[7582],{<CIViC source 2711>},[],[],[2806]
2676,BRCA1 gBRCAm,0.0,,,[],[7588],{<CIViC source 3015>},[],[],[2807]
2677,WNT11 Overexpression,0.0,,,[],[7589],{<CIViC source 3016>},[],[],[2808]
2681,MBD4 Frameshift,0.0,,,[],[7596],{<CIViC source 3018>},[],[],[2812]
2682,ALK G1202del,0.0,,,['G1202 Deletion'],[],set(),[],[],[2813]
2683,DRD5 low expression,0.0,,,[],[7600],{<CIViC source 3020>},[],[],[2814]
2684,H3C2 K27M,20.0,,,[],"[7602, 9546, 9844, 9843, 9845, 9583]","{<CIViC source 2448>, <CIViC source 2560>, <CIViC source 3021>}",[],[],[2815]
2686,FLT3 G697R,0.0,,,[],[7604],{<CIViC source 2991>},[],[],[2817]
2687,VHL Y112C (c.355A>G),0.0,,,"['C.355A>G', 'TYR112CYS', 'RS869025633']",[7608],{<CIViC source 3022>},[],[],[2818]
2689,BRAF V600_K601>E,7.5,,,[],"[7617, 7630]",{<CIViC source 3026>},[],[],[2820]
2690,BRAF V600_S602>DT,0.0,,,[],[7620],{<CIViC source 3026>},[],[],[2821]
2691,BRAF G469,15.0,,,[],"[7623, 7634]",{<CIViC source 3026>},[],[],[2822]
2692,BRAF G593D,0.0,,,[],[7624],{<CIViC source 3026>},[],[],[2823]
2693,BRAF T599_V600insT,0.0,,,[],[7625],{<CIViC source 3026>},[],[],[2824]
2694,BRAF V601E,0.0,,,[],"[7633, 7627]",{<CIViC source 3026>},[],[],[2825]
2695,BRAF A598V,7.5,,,['ALA598VAL'],[7635],{<CIViC source 3026>},[],[],[2826]
2696,FGF19 Expression,0.0,,,[],[],set(),[],[],[2827]
2697,IDH1 R132X,0.0,,,[],[],set(),[],[],[2828]
2698,JAK2 R683G,0.0,,,[],[],set(),[],[],[2829]
2699,TMPRSS2::ETV1 Fusion,0.0,,,[],[7644],{<CIViC source 290>},[],[],[2830]
2701,BRAF D594H,0.0,,,[],[7652],{<CIViC source 3005>},[],[],[2832]
2702,NECTIN4 D594H,0.0,,,[],[7656],{<CIViC source 3043>},[],[],[2833]
2703,MAP2K1 V60E,0.0,,,[],[7657],{<CIViC source 3044>},[],[],[2834]
2704,MAP2K1 G128V,0.0,,,[],[7658],{<CIViC source 3044>},[],[],[2835]
2705,MAP2K1 V154I,0.0,,,[],[7659],{<CIViC source 3044>},[],[],[2836]
2706,MAP2K1 P124L,0.0,,,[],[7661],{<CIViC source 3044>},[],[],[2837]
2707,MAP2K1 G276W,0.0,,,[],[7662],{<CIViC source 3044>},[],[],[2838]
2708,MAP2K1 F53Y,0.0,,,[],[7663],{<CIViC source 3044>},[],[],[2839]
2709,MAP2K2 C125S,0.0,,,[],"[7664, 7676]","{<CIViC source 3045>, <CIViC source 3044>}",[],[],[2840]
2710,MAP2K2 V35M,0.0,,,[],[7665],{<CIViC source 3044>},[],[],[2841]
2711,MAP2K2 L46F,0.0,,,[],[7666],{<CIViC source 3044>},[],[],[2842]
2712,MAP2K2 N126D,0.0,,,[],[7667],{<CIViC source 3044>},[],[],[2843]
2713,MITF Amplification,0.0,,,[],[7668],{<CIViC source 3044>},[],[],[2844]
2714,HOXD8 mutation,0.0,,,[],[7670],{<CIViC source 3044>},[],[],[2845]
2715,ATF7IP::JAK2 Fusion,15.0,"The ATF7IP-JAK2 fusion is composed of part of the ATF7IP (Activating Transcription Factor 7 Interacting Protein) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 10 of ATF7IP to exon 8 of JAK2 (ATF7IP-JAK2 10-8), exon 13 of ATF7IP to exon 16 of JAK2 (ATF7IP-JAK2 13-16), or exon 13 of ATF7IP to exon 17 of JAK2 (ATF7IP-JAK2 13-17). The fusion is predicted to result from a reciprocal translocation t(9;12) (p24;p13.1), and has been identified by RNA sequencing and Sanger sequencing in three adult patients with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil and MDN1 domains from ATF7IP and the JH2 pseudokinase and JH1 kinase domains from JAK2. The coiled coil domain is hypothesized to constitutively activate the JAK2 kinase domain, thereby upregulating the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel ATF7IP-JAK2 fusion has been documented in three cases for which specific clinical information is unavailable. A pre-clinical xenograft model containing the fusion was sensitive to exposure to the JAK2 inhibitor, ruxolitinib. Therefore, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The ATF7IP-JAK2 fusion is composed of part of the ATF7IP (Activating Transcription Factor 7 Interacting Protein) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 10 of ATF7IP to exon 8 of JAK2 (ATF7IP-JAK2 10-8), exon 13 of ATF7IP to exon 16 of JAK2 (ATF7IP-JAK2 13-16), or exon 13 of ATF7IP to exon 17 of JAK2 (ATF7IP-JAK2 13-17). The fusion is predicted to result from a reciprocal translocation t(9;12) (p24;p13.1), and has been identified by RNA sequencing and Sanger sequencing in three adult patients with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil and MDN1 domains from ATF7IP and the JH2 pseudokinase and JH1 kinase domains from JAK2. The coiled coil domain is hypothesized to constitutively activate the JAK2 kinase domain, thereby upregulating the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel ATF7IP-JAK2 fusion has been documented in three cases for which specific clinical information is unavailable. A pre-clinical xenograft model containing the fusion was sensitive to exposure to the JAK2 inhibitor, ruxolitinib. Therefore, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['ATF7IP-JAK2'],"[7671, 8095]","{<CIViC source 3223>, <CIViC source 2495>}",[],[],[2846]
2716,EBF1::JAK2 Fusion,7.5,"The EBF1-JAK2 fusion is composed of part of the EBF1 (Early B-Cell Factor Transcription Factor 1) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 14 of EBF1 to exon 17 of JAK2 (EBF1-JAK2 14-17). The fusion is predicted to result from a reciprocal translocation t(5;9) (q33.3;p24), and has been identified by RNA sequencing in one adolescent patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA binding, immunoglobulin-life fold, and helix-loop-helix domains from EBF1 and an intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the EBF1-JAK2 fusion protein has not been performed. Clinical significance: The novel EBF1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The EBF1-JAK2 fusion is composed of part of the EBF1 (Early B-Cell Factor Transcription Factor 1) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 14 of EBF1 to exon 17 of JAK2 (EBF1-JAK2 14-17). The fusion is predicted to result from a reciprocal translocation t(5;9) (q33.3;p24), and has been identified by RNA sequencing in one adolescent patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA binding, immunoglobulin-life fold, and helix-loop-helix domains from EBF1 and an intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the EBF1-JAK2 fusion protein has not been performed. Clinical significance: The novel EBF1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['EBF1-JAK2'],[7672],{<CIViC source 2495>},[],[],[2847]
2717,PPFIBP1::JAK2 Fusion,15.0,,,['PPFIBP1-JAK2'],"[7673, 8099]","{<CIViC source 3223>, <CIViC source 2495>}",[],[],[2848]
2718,STRN3::JAK2 Fusion,7.5,"The STRN3-JAK2 fusion is composed of part of the STRN3 (Striatin 3) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 9 of STRN3 to exon 17 of JAK2 (STRN3 -JAK2 9-17). The fusion is predicted to result from a reciprocal translocation t(9;14) (p24;q12), and has been identified by RNA sequencing in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the Striatin domain from STRN3 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the STRN3-JAK2 fusion protein has not been performed. Clinical significance: The novel STRN3-JAK2 fusion has been documented in a single case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The STRN3-JAK2 fusion is composed of part of the STRN3 (Striatin 3) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 9 of STRN3 to exon 17 of JAK2 (STRN3 -JAK2 9-17). The fusion is predicted to result from a reciprocal translocation t(9;14) (p24;q12), and has been identified by RNA sequencing in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the Striatin domain from STRN3 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the STRN3-JAK2 fusion protein has not been performed. Clinical significance: The novel STRN3-JAK2 fusion has been documented in a single case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['STRN3-JAK2'],[7674],{<CIViC source 2495>},[],[],[2849]
2719,TPR::JAK2 Fusion,7.5,"The TPR-JAK2 fusion is composed of part of the TPR (Translocated Promoter Region, Nuclear Basket Protein) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 39 of TPR to exon 17 of JAK2 (TPR -JAK2 39-17). The fusion stems from a reciprocal translocation t(1;9) (q31.1;p24), and has been identified by FISH and RNA sequencing in one young adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the TPR/MLP1/MLP2-like protein domain from TERF2 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the TPR-JAK2 fusion protein has not been performed. Clinical significance: The novel TPR-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The TPR-JAK2 fusion is composed of part of the TPR (Translocated Promoter Region, Nuclear Basket Protein) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 39 of TPR to exon 17 of JAK2 (TPR -JAK2 39-17). The fusion stems from a reciprocal translocation t(1;9) (q31.1;p24), and has been identified by FISH and RNA sequencing in one young adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the TPR/MLP1/MLP2-like protein domain from TERF2 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the TPR-JAK2 fusion protein has not been performed. Clinical significance: The novel TPR-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['TPR-JAK2'],[7675],{<CIViC source 2495>},[],[],[2850]
2720,SMAD4 R361C,2.5,,,[],"[6446, 7680, 9713]","{<CIViC source 2553>, <CIViC source 3047>, <CIViC source 3046>}",[],[],[2851]
2721,SMAD4 D351H,0.0,,,[],[7681],{<CIViC source 3046>},[],[],[2852]
2722,SMAD4 E330A,0.0,,,[],[7682],{<CIViC source 3047>},[],[],[2853]
2723,ERBB2 Exon 20 Insertion,25.0,,,[],"[11765, 10140, 7683, 12132, 12133]","{<CIViC source 4208>, <CIViC source 4879>, <CIViC source 4231>, <CIViC source 3048>, <CIViC source 5094>}",[],[],[2854]
2724,NTRK3 G623E,0.0,,,[],[7688],{<CIViC source 3050>},[],[],[2855]
2725,ROS1 S1986Y/F,0.0,,,[],[7689],{<CIViC source 2113>},[],[],[2856]
2726,ROS1 R2033N,0.0,,,[],[7690],{<CIViC source 2122>},[],[],[2857]
2727,SMAD4 D537Y,0.0,,,[],[7692],{<CIViC source 3052>},[],[],[2858]
2728,ETV6::JAK2 Fusion,25.0,"The ETV6-JAK2 fusion is composed of part of the ETV6 (ETS Variant Transcription Factor 6) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 4 of ETV6 to exon 17 of JAK2 (ETV6-JAK2 4-17), exon 5 of ETV6 to exon 12 of JAK2 (ETV6-JAK2 5-12), or exon 5 of ETV6 to exon 19 of JAK2 (ETV6-JAK2 5-19). The fusion results from the reciprocal translocation t(9;12)(p24;p13), cytogenetically cryptic, and has been identified by FISH and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the PNT domain from ETV6 and JH1 kinase domain from JAK2. The ETV6 PNT domain is hypothesized to result in dimerization, which leads to aberrant JAK2 kinase domain activation. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. The inclusion of the JH1 domain may affect functional effects and disease specificity of the abnormal fusion. Functionally, the fusion results in aberrant activation of JAK2 kinase, leading to activation of downstream signaling through the signal transducers and activators of transcription (STATs). The ETV6-JAK2 fusion is associated with hematologic malignancies and has been observed in B-lymphoblastic leukemia (~10%), T-lymphoblastic leukemia (isolated cases), and myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements (rare cases). Clinical significance: As a diagnostic biomarker, the ETV6-JAK2 fusion in B-lymphoblastic leukemia is associated with the BCR-ABL1-like subtype. As a prognostic marker, the ETV6-JAK2 fusion has been associated with high-risk disease. As a predictive marker, the ETV6-JAK2 fusion has been shown by limited pre-clinical data and case reports to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The ETV6-JAK2 fusion is composed of part of the ETV6 (ETS Variant Transcription Factor 6) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 4 of ETV6 to exon 17 of JAK2 (ETV6-JAK2 4-17), exon 5 of ETV6 to exon 12 of JAK2 (ETV6-JAK2 5-12), or exon 5 of ETV6 to exon 19 of JAK2 (ETV6-JAK2 5-19). The fusion results from the reciprocal translocation t(9;12)(p24;p13), cytogenetically cryptic, and has been identified by FISH and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the PNT domain from ETV6 and JH1 kinase domain from JAK2. The ETV6 PNT domain is hypothesized to result in dimerization, which leads to aberrant JAK2 kinase domain activation. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. The inclusion of the JH1 domain may affect functional effects and disease specificity of the abnormal fusion. Functionally, the fusion results in aberrant activation of JAK2 kinase, leading to activation of downstream signaling through the signal transducers and activators of transcription (STATs). The ETV6-JAK2 fusion is associated with hematologic malignancies and has been observed in B-lymphoblastic leukemia (~10%), T-lymphoblastic leukemia (isolated cases), and myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements (rare cases). Clinical significance: As a diagnostic biomarker, the ETV6-JAK2 fusion in B-lymphoblastic leukemia is associated with the BCR-ABL1-like subtype. As a prognostic marker, the ETV6-JAK2 fusion has been associated with high-risk disease. As a predictive marker, the ETV6-JAK2 fusion has been shown by limited pre-clinical data and case reports to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['ETV6-JAK2'],"[8102, 7696, 8097]","{<CIViC source 3223>, <CIViC source 2495>, <CIViC source 2498>}",[],[],[2859]
2729,BCR::JAK2 Fusion,35.0,"The BCR-JAK2 fusion is composed of part of the BCR (Breakpoint Cluster Region) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 14 of BCR to exon 17 of JAK2 (BCR-JAK2 4-17) and exon 1 of BCR to exons 15 (BCR-JAK2 1-15), 17 (BCR-JAK2 1-17), or 19 (BCR-JAK2 1-19). The fusion results from the reciprocal translocation t(9;22)(p24;p11.2), and has been identified by karyotype analysis, FISH, RT-PCR, targeted ligation amplification (TLA), and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from BCR and the JH1 kinase domain from JAK2. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. In pre-clinical studies, the coiled coil domain of BCR has been shown to mediate oligomeric activation of the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). The BCR-JAK2 fusion is associated with hematologic malignancies and has been observed in myeloproliferative neoplasms with eosinophilia (multiple cases), B-lymphoblastic leukemia (multiple cases), acute myeloid leukemia (a rare case), and B-cell lymphoma (rare case of Burkitt lymphoma). Clinical significance: As a diagnostic biomarker in B-lymphoblastic leukemia, the BCR-JAK2 fusion is frequently observed in the BCR-ABL1-like subtype. As a prognostic marker, the fusion appears to be associated with high-risk disease in pediatric and adult populations. As a predictive marker, patients whose diseases exhibit the BCR-JAK2 fusion have experienced partial responses or even complete remission with hydroxyurea and/or interferon alfa. Case reports have demonstrated the limited utility of tyrosine kinase inhibitors. One patient diagnosed with a myeloid neoplasm initially responded to the JAK2 inhibitor ruxolitinib, but relapsed after 18 months. Current research has suggested a survival advantage following allogeneic or autologous stem cell transplantation.","The BCR-JAK2 fusion is composed of part of the BCR (Breakpoint Cluster Region) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 14 of BCR to exon 17 of JAK2 (BCR-JAK2 4-17) and exon 1 of BCR to exons 15 (BCR-JAK2 1-15), 17 (BCR-JAK2 1-17), or 19 (BCR-JAK2 1-19). The fusion results from the reciprocal translocation t(9;22)(p24;p11.2), and has been identified by karyotype analysis, FISH, RT-PCR, targeted ligation amplification (TLA), and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from BCR and the JH1 kinase domain from JAK2. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. In pre-clinical studies, the coiled coil domain of BCR has been shown to mediate oligomeric activation of the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). The BCR-JAK2 fusion is associated with hematologic malignancies and has been observed in myeloproliferative neoplasms with eosinophilia (multiple cases), B-lymphoblastic leukemia (multiple cases), acute myeloid leukemia (a rare case), and B-cell lymphoma (rare case of Burkitt lymphoma). Clinical significance: As a diagnostic biomarker in B-lymphoblastic leukemia, the BCR-JAK2 fusion is frequently observed in the BCR-ABL1-like subtype. As a prognostic marker, the fusion appears to be associated with high-risk disease in pediatric and adult populations. As a predictive marker, patients whose diseases exhibit the BCR-JAK2 fusion have experienced partial responses or even complete remission with hydroxyurea and/or interferon alfa. Case reports have demonstrated the limited utility of tyrosine kinase inhibitors. One patient diagnosed with a myeloid neoplasm initially responded to the JAK2 inhibitor ruxolitinib, but relapsed after 18 months. Current research has suggested a survival advantage following allogeneic or autologous stem cell transplantation.",['BCR-JAK2'],"[7698, 8101, 7697, 8096]","{<CIViC source 3223>, <CIViC source 2495>, <CIViC source 3039>, <CIViC source 2498>}",[],[],[2860]
2730,PAX5::JAK2 Fusion,30.0,"The PAX5-JAK2 fusion is composed of part of the PAX5 (Paired Box 5) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 5 of PAX5 to exon 19 of JAK2 (PAX5-JAK2 5-19). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p13 and p24), and has been identified by RNA sequencing, RT-PCR, Sanger sequencing, and FISH in patients B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA-binding paired domain from PAX5 and the JH1 kinase domain from JAK2. A pre-clinical study has revealed that this fusion protein deregulates the PAX5 transcriptional pathway while also autophosphorylating the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). Clinical significance: As a diagnostic biomarker, the PAX5-JAK2 fusion in B-lymphoblastic leukemia is frequently associated with the BCR-ABL1-like subtype. As a prognostic marker, the fusion has been associated with intermediate to high-risk disease. As a predictive marker, the PAX5-JAK2 fusion has been shown in pre-clinical data to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The PAX5-JAK2 fusion is composed of part of the PAX5 (Paired Box 5) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 5 of PAX5 to exon 19 of JAK2 (PAX5-JAK2 5-19). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p13 and p24), and has been identified by RNA sequencing, RT-PCR, Sanger sequencing, and FISH in patients B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA-binding paired domain from PAX5 and the JH1 kinase domain from JAK2. A pre-clinical study has revealed that this fusion protein deregulates the PAX5 transcriptional pathway while also autophosphorylating the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). Clinical significance: As a diagnostic biomarker, the PAX5-JAK2 fusion in B-lymphoblastic leukemia is frequently associated with the BCR-ABL1-like subtype. As a prognostic marker, the fusion has been associated with intermediate to high-risk disease. As a predictive marker, the PAX5-JAK2 fusion has been shown in pre-clinical data to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['PAX5-JAK2'],"[7699, 7700, 7701, 8098, 8105, 11623]","{<CIViC source 3223>, <CIViC source 3058>, <CIViC source 2495>, <CIViC source 2498>, <CIViC source 3323>}",[],[],[2861]
2731,TERF2::JAK2 Fusion,7.5,,,['TERF2-JAK2'],"[7703, 7702]","{<CIViC source 2495>, <CIViC source 3039>}",[],[],[2862]
2732,USP25::JAK2 Fusion,7.5,,,['USP25-JAK2'],[7705],{<CIViC source 2498>},[],[],[2863]
2733,ZNF274::JAK2 Fusion,7.5,,,['ZNF274-JAK2'],[7706],{<CIViC source 2498>},[],[],[2864]
2734,RFX3::JAK2 Fusion,7.5,,,['RFX3-JAK2'],[7707],{<CIViC source 2498>},[],[],[2865]
2735,VHL P138= (c.414A>G),0.0,,,[],"[7713, 10727, 10747, 10753, 10824, 10904, 8828]","{<CIViC source 4453>, <CIViC source 3391>, <CIViC source 4378>, <CIViC source 4417>, <CIViC source 3064>, <CIViC source 3683>}",[],[],[2866]
2736,VHL M1? (c.3G>A),0.0,,,[],[],set(),[],[],[2867]
2737,VHL M211L (c.631A>C),0.0,,,[],"[7718, 10760]","{<CIViC source 4396>, <CIViC source 3066>}",[],[],[2868]
2739,VHL Exon 1 (Frameshift),0.0,,,[],[7722],{<CIViC source 3069>},[],[],[2870]
2740,BRCA2 K3326*,7.5,,,[],[7724],{<CIViC source 3071>},[],[],[2871]
2741,MAP2K2 H123Q,0.0,,,[],[7731],{<CIViC source 3083>},[],[],[2872]
2742,MAP2K2 G132D,0.0,,,[],[7732],{<CIViC source 3083>},[],[],[2873]
2743,MAP2K2 G132S,0.0,,,[],[7733],{<CIViC source 3083>},[],[],[2874]
2745,VHL t(2;3)(q35;q21),0.0,,,[],[7740],{<CIViC source 3085>},[],[],[2876]
2746,VHL R120* (c.358A>T),0.0,,,[],"[7741, 8560]","{<CIViC source 3086>, <CIViC source 3587>}",[],[],[2877]
2747,VHL N90H (c.268A>C),0.0,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 633017 A>T).,One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 633017 A>T).,[],[7742],{<CIViC source 3087>},[],[],[2878]
2748,VHL P154Rfs (c.461_462delCA),0.0,,,[],[7743],{<CIViC source 3088>},[],[],[2879]
2749,VHL Q164H (c.492G>T),0.0,,,[],"[7745, 7747]","{<CIViC source 3091>, <CIViC source 3092>}",[],[],[2880]
2750,VHL DelPhe76 (c.225del3bp),0.0,,,[],[],set(),[],[],[2881]
2751,"VHL c.298dupA, Frameshift",0.0,,,[],[],set(),[],[],[2882]
2752,NRF1::BRAF Fusion,7.5,,,['NRF1-BRAF'],[7763],{<CIViC source 3097>},[],[],[2883]
2753,CDKN2A c.151-1G>C,7.5,,,[],[7765],{<CIViC source 3099>},[],[],[2884]
2754,ABL1 T315V,2.0,,,['THR315VAL'],[],set(),[],[],[2885]
2756,ABL1 E292L,2.0,,,['GLY292LEU'],[],set(),[],[],[2887]
2757,ABL1 F317R,2.0,,,['PHE317ARG'],[],set(),[],[],[2888]
2761,CTNNB1 Exon 3 Mutation,55.0,,,[],"[7784, 7966, 7967, 9013, 12108, 12109, 12111, 12112, 12113, 12114, 12115, 7922, 7965, 12110, 9663]","{<CIViC source 5079>, <CIViC source 5078>, <CIViC source 5080>, <CIViC source 2692>, <CIViC source 5081>, <CIViC source 4266>, <CIViC source 3197>, <CIViC source 3195>, <CIViC source 3102>, <CIViC source 5077>, <CIViC source 3103>, <CIViC source 3196>, <CIViC source 5076>, <CIViC source 2195>}",[],[],[2892]
2762,DPYD EXON 11-19 DELETION,10.0,,,[],[7787],{<CIViC source 3114>},[],[],[2893]
2763,MET::ATXN7L1 Fusion,7.5,,,['MET-ATXN7L1'],[7793],{<CIViC source 3121>},[],[],[2894]
2764,NUDT15 Inactivating Mutation,0.0,,,[],[7794],{<CIViC source 3148>},[],[],[2895]
2765,NT5C2 R238W,13.0,,,[],"[7863, 7813, 7816, 8077]","{<CIViC source 3161>, <CIViC source 3131>}",[],[],[2896]
2766,NT5C2 S445F,13.0,,,[],"[7864, 7814, 7817]",{<CIViC source 3131>},[3131],[<CIViC source 3131>],[2897]
2767,NT5C2 Mutation,20.0,,,[],[7818],{<CIViC source 3131>},[],[],[2898]
2768,KMT2A KMT2A rearragements,0.0,,,[],[],set(),[],[],[2899]
2770,ABL1 E98G,10.0,,,['GLU98GLY'],[],set(),[],[],[2901]
2773,FGFR1 Overexpression,0.0,,,[],"[7831, 9582, 7952]","{<CIViC source 4098>, <CIViC source 3133>, <CIViC source 3183>}",[],[],[2904]
2774,FGFR2 P253R,7.5,,,[],[7833],{<CIViC source 3136>},[],[],[2905]
2775,FGFR3 Amplification,0.0,,,[],"[7955, 7835, 8061]","{<CIViC source 2999>, <CIViC source 3185>, <CIViC source 1233>}",[],[],[2906]
2776,FGFR4 Amplification,0.0,,,[],[7836],{<CIViC source 2999>},[],[],[2907]
2777,TACSTD2 Overexpression,0.0,,,[],[7837],{<CIViC source 3138>},[],[],[2908]
2780,IL6 Overexpression,2.0,,,[],"[7851, 7956]","{<CIViC source 3187>, <CIViC source 3140>}",[],[],[2911]
2781,EGFR G719X,0.0,,,[],[],set(),[],[],[2912]
2782,MET Y1003H,0.0,,,"['Y1021H', 'TYR1021HIS', 'TYR1003HIS']",[7860],{<CIViC source 3145>},[],[],[2913]
2783,ALK Expression,0.0,,,[],[7866],{<CIViC source 3157>},[],[],[2914]
2784,ABCB1 Overexpression,8.0,,,[],"[2681, 7869, 10016, 944]","{<CIViC source 3160>, <CIViC source 646>, <CIViC source 1621>}",[],[],[2915]
2785,PRPS1 PRPS1 MUTATION,20.0,,,[],[7871],{<CIViC source 3161>},[],[],[2916]
2786,LYN OVEREXPRESSION,4.0,,,[],"[7874, 9085, 7875]",{<CIViC source 1621>},[],[],[2917]
2787,PRPS1 T303S,7.0,,,[],"[7877, 7898, 7929]",{<CIViC source 3161>},[],[],[2918]
2788,PRPS1 L191F,9.0,,,[],"[7878, 7899, 7923, 7911]",{<CIViC source 3161>},[],[],[2919]
2789,PRPS1 D183E,7.0,,,[],"[7879, 7900, 7927]",{<CIViC source 3161>},[],[],[2920]
2790,PRPS1 K176N,7.0,,,[],"[7880, 7901, 7926]",{<CIViC source 3161>},[],[],[2921]
2791,PRPS1 G174E,0.0,,,[],"[7881, 7902]",{<CIViC source 3161>},[],[],[2922]
2792,PRPS1 N144S,9.0,,,[],"[7882, 7903, 7930, 7910]",{<CIViC source 3161>},[],[],[2923]
2793,PRPS1 N114D,0.0,,,[],"[7883, 7904]",{<CIViC source 3161>},[],[],[2924]
2794,PRPS1 S103I,4.0,,,[],"[7884, 7905]",{<CIViC source 3161>},[],[],[2925]
2795,PRPS1 S103N,7.0,,,[],"[7885, 7906, 7925]",{<CIViC source 3161>},[],[],[2926]
2796,PRPS1 S103T,8.0,,,[],"[7886, 7907, 7912, 7924]",{<CIViC source 3161>},[],[],[2927]
2797,PRPS1 A190V,0.0,,,[],"[7887, 7908]",{<CIViC source 3161>},[],[],[2928]
2798,PRPS1 A190T,26.0,,,[],"[7888, 7909, 7913, 7928]",{<CIViC source 3161>},[],[],[2929]
2799,VHL 106insR (c.316insGCC),7.5,,,[],"[7892, 8406]","{<CIViC source 3512>, <CIViC source 3167>}",[],[],[2930]
2801,VHL Deletion,5.0,,,[],"[7896, 5423, 5625, 5849, 6471, 6717, 8155, 8156, 8157, 8207, 8354, 8416, 8461, 8615, 8648, 8688, 8939, 9002, 9100, 9280, 9384, 10005, 10888, 10974, 6497, 6544, 6597, 6660, 8206, 8252, 8739, 8837, 8873, 9197, 10652]","{<CIViC source 2231>, <CIViC source 3828>, <CIViC source 4442>, <CIViC source 2624>, <CIViC source 2269>, <CIViC source 2365>, <CIViC source 3356>, <CIViC source 3790>, <CIViC source 3401>, <CIViC source 3665>, <CIViC source 3711>, <CIViC source 3167>, <CIViC source 3918>, <CIViC source 2174>, <CIViC source 4473>, <CIViC source 3714>, <CIViC source 3517>, <CIViC source 2611>, <CIViC source 2193>, <CIViC source 3683>, <CIViC source 4020>, <CIViC source 2599>, <CIViC source 3973>, <CIViC source 2634>, <CIViC source 2503>, <CIViC source 3389>, <CIViC source 2576>, <CIViC source 2286>, <CIViC source 3387>, <CIViC source 3620>, <CIViC source 3486>, <CIViC source 3529>, <CIViC source 1372>}",[],[],[2932]
2802,PRPS1 D183H,0.0,,,[],[7897],{<CIViC source 3161>},[],[],[2933]
2803,PRPS1 Y311C,0.0,,,[],[7914],{<CIViC source 3161>},[],[],[2934]
2804,PRPS1 D139G,3.0,,,[],[7915],{<CIViC source 3161>},[],[],[2935]
2805,PRPS1 C77S,3.0,,,[],[7916],{<CIViC source 3161>},[],[],[2936]
2806,PRPS1 I72V,3.0,,,[],[7917],{<CIViC source 3161>},[],[],[2937]
2807,PRPS1 V53A,3.0,,,[],[7918],{<CIViC source 3161>},[],[],[2938]
2808,PRPS1 A87T,4.0,,,[],[7919],{<CIViC source 3161>},[],[],[2939]
2809,PRPS1 M115T,4.0,,,[],[7920],{<CIViC source 3161>},[],[],[2940]
2810,EWSR1::WT1 Fusion,20.0,,,['EWSR1-WT1'],"[11405, 11406, 11407, 7921]","{<CIViC source 4693>, <CIViC source 4695>, <CIViC source 3107>, <CIViC source 4694>}",[],[],[2941]
2811,CTNNB1 exon 3 mutations,0.0,,,[],[],set(),[],[],[2942]
2813,PDGFRA Overexpression,3.0,,,[],"[7934, 7988]","{<CIViC source 1238>, <CIViC source 3176>}",[],[],[2944]
2814,FGFR2 W290C,0.0,,,[],"[11633, 7937]","{<CIViC source 4823>, <CIViC source 3136>}",[],[],[2945]
2815,FGFR2 S320C,0.0,,,[],[7938],{<CIViC source 3136>},[],[],[2946]
2816,FGFR2 K660E,0.0,,,[],[7939],{<CIViC source 3136>},[],[],[2947]
2820,ABL1 N146S,7.5,,,['ASN146SER'],[],set(),[],[],[2951]
2824,STAT1 Overexpression,0.0,,,[],[7951],{<CIViC source 3182>},[],[],[2955]
2825,JAK1 S646F,0.0,,,[],[7957],{<CIViC source 3032>},[],[],[2956]
2826,MET H1094L,0.0,,,"['H1112L', 'HIS1094LEU', 'HIS11122LEU']",[7958],{<CIViC source 3188>},[],[],[2957]
2827,SDHB Mutation,0.0,,,[],[7959],{<CIViC source 3189>},[],[],[2958]
2828,CHEK2 R474C c.1420C>T,7.5,,,[],"[7962, 10064]",{<CIViC source 1334>},[],[],[2959]
2829,BCL2 G101V,8.0,,,['GLY101VAL'],"[8174, 7970, 8305, 8303, 8185, 8334, 8841]","{<CIViC source 3201>, <CIViC source 3376>, <CIViC source 3445>, <CIViC source 3100>, <CIViC source 3500>, <CIViC source 3444>}",[],[],[2960]
2830,RUNX1 G336fs563X (c.1007_1013del),0.0,,,[],[7971],{<CIViC source 2204>},[],[],[2961]
2831,RUNX1 A28fsX109 (c.83insG),0.0,,,[],[7972],{<CIViC source 2204>},[],[],[2962]
2832,RUNX1 D96H (c.238G>C),0.0,,,[],[7973],{<CIViC source 2204>},[],[],[2963]
2833,RUNX1 K90fsX101,0.0,,,[],[7974],{<CIViC source 2204>},[],[],[2964]
2834,RUNX1 R292X (c.877C>T),0.0,,,[],[7975],{<CIViC source 2204>},[],[],[2965]
2835,MGMT Expression,0.0,,,[],[7977],{<CIViC source 3203>},[],[],[2966]
2837,LPP::HMGA2 Fusion,0.0,,,['LPP-HMGA2'],[],set(),[],[],[2968]
2838,HMGA2::LPP Fusion,0.0,,,['HMGA2-LPP'],[7984],{<CIViC source 1175>},[],[],[2969]
2839,VEGFC Overexpression,0.0,,,[],[7987],{<CIViC source 3211>},[],[],[2970]
2840,BCR::PDGFRA Fusion,7.5,,,['BCR-PDGFRA'],[7990],{<CIViC source 3214>},[],[],[2971]
2841,COL1A1::PDGFB Fusion,27.5,,,['COL1A1-PDGFB'],"[11271, 9787, 10336, 10314, 11729, 10332, 7991, 11730, 10334, 10335]","{<CIViC source 3215>, <CIViC source 4296>, <CIViC source 4298>, <CIViC source 4630>, <CIViC source 4300>, <CIViC source 4169>, <CIViC source 4878>, <CIViC source 4871>, <CIViC source 4299>, <CIViC source 4285>}",[],[],[2972]
2842,PDGFRB Overexpression,7.5,,,[],[7992],{<CIViC source 3215>},[],[],[2973]
2843,OFD1::JAK2 Fusion,10.0,"The OFD1-JAK2 fusion is composed of part of the OFD1 (Oral-Facial-Digital Syndrome 1) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. OFD1 is a centrosomal protein of primary cilia implicated in Oral-Facial-Digital Syndrome type 1, but it has not been previously described in hematologic malignancies. The published breakpoint joins exon 22 of OFD1 to exon 13 of JAK2 (OFD1-JAK2 22-13). This fusion is predicted to result from a reciprocal translocation t(X;9)(p22;p24), and has been identified in two patients by RNA sequencing, one of which demonstrated the abnormal karyotype 46,XY,-17+mar[11]/46,XY[9]. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the FERM and SH2 domains from OFD1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the OFD1-JAK2 fusion protein is reportedly underway. Clinical significance: The novel OFD1-JAK2 fusion has been documented in one 3-year-old and one 11-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia. Both children successfully maintained first complete remission following induction chemotherapy and allogeneic hematopoietic stem cell transplantation, with as long as 6 years of follow up. While neither patient was treated with a JAK2 inhibitor, the JH1 kinase domain present within the OFD1-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The OFD1-JAK2 fusion is composed of part of the OFD1 (Oral-Facial-Digital Syndrome 1) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. OFD1 is a centrosomal protein of primary cilia implicated in Oral-Facial-Digital Syndrome type 1, but it has not been previously described in hematologic malignancies. The published breakpoint joins exon 22 of OFD1 to exon 13 of JAK2 (OFD1-JAK2 22-13). This fusion is predicted to result from a reciprocal translocation t(X;9)(p22;p24), and has been identified in two patients by RNA sequencing, one of which demonstrated the abnormal karyotype 46,XY,-17+mar[11]/46,XY[9]. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the FERM and SH2 domains from OFD1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the OFD1-JAK2 fusion protein is reportedly underway. Clinical significance: The novel OFD1-JAK2 fusion has been documented in one 3-year-old and one 11-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia. Both children successfully maintained first complete remission following induction chemotherapy and allogeneic hematopoietic stem cell transplantation, with as long as 6 years of follow up. While neither patient was treated with a JAK2 inhibitor, the JH1 kinase domain present within the OFD1-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['OFD1-JAK2'],"[7997, 8104, 7995]","{<CIViC source 3222>, <CIViC source 3323>}",[],[],[2974]
2844,SMU1::JAK2 Fusion,7.5,"The SMU1-JAK2 fusion is composed of part of the SMU1 (SMU1 DNA Replication Regulator and Splicesomal Factor) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of SMU1 to exon 12 of JAK2 (SMU1-JAK2 18-12). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p21 and p24), and has been identified by RNA sequencing in an older adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the LisH, CTLH, HisP, and Wd40 domains from SMU1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. Pre-clinical data demonstrates increased JH1 kinase expression as a result of the SMU1-JAK2 fusion event, which is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel SMU1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The SMU1-JAK2 fusion is composed of part of the SMU1 (SMU1 DNA Replication Regulator and Splicesomal Factor) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of SMU1 to exon 12 of JAK2 (SMU1-JAK2 18-12). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p21 and p24), and has been identified by RNA sequencing in an older adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the LisH, CTLH, HisP, and Wd40 domains from SMU1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. Pre-clinical data demonstrates increased JH1 kinase expression as a result of the SMU1-JAK2 fusion event, which is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel SMU1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['SMU1-JAK2'],[7996],{<CIViC source 3223>},[],[],[2975]
2845,SNX29::JAK2 Fusion,7.5,"The SNX29-JAK2 fusion is composed of part of the SNX29 (Sorting Nexin 29) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 18 of SNX29 to exon 13 of JAK2 (SNX29 -JAK2 18-13). It is predicted to result from a reciprocal translocation t(9;16) (p24;q13.13), and has been identified by RNA sequencing in one normal-karyotype adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the RUN and PX_RUN domains from SNX29 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the SNX29-JAK2 fusion protein has not been performed. Clinical significance: The novel SNX29-JAK2 fusion has been documented in a single case that successfully maintained complete remission without relapse following induction chemotherapy. While the patient was not treated with a JAK2 inhibitor, the JH1 kinase domain present within the SNX29-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The SNX29-JAK2 fusion is composed of part of the SNX29 (Sorting Nexin 29) gene at the 5 end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 18 of SNX29 to exon 13 of JAK2 (SNX29 -JAK2 18-13). It is predicted to result from a reciprocal translocation t(9;16) (p24;q13.13), and has been identified by RNA sequencing in one normal-karyotype adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the RUN and PX_RUN domains from SNX29 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the SNX29-JAK2 fusion protein has not been performed. Clinical significance: The novel SNX29-JAK2 fusion has been documented in a single case that successfully maintained complete remission without relapse following induction chemotherapy. While the patient was not treated with a JAK2 inhibitor, the JH1 kinase domain present within the SNX29-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['SNX29-JAK2'],[7998],{<CIViC source 3224>},[],[],[2976]
2846,ZNF430::JAK2 Fusion,7.5,"The ZNF430-JAK2 fusion is composed of part of the ZNF430 (Zinc Finger Protein 430) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 4 of ZNF430 to exon 19 of JAK2 (ZNF430-JAK2 4-19). The fusion is predicted to result from a reciprocal translocation t(9;19)(p24;p12), and has been identified by RNA sequencing in one adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the KRAB_A-box domain from ZNF430 and the JH1 kinase domain from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the ZNF430-JAK2 fusion protein has not been performed. Clinical significance: The novel ZNF430-JAK2 fusion has been documented in one case for which clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The ZNF430-JAK2 fusion is composed of part of the ZNF430 (Zinc Finger Protein 430) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 4 of ZNF430 to exon 19 of JAK2 (ZNF430-JAK2 4-19). The fusion is predicted to result from a reciprocal translocation t(9;19)(p24;p12), and has been identified by RNA sequencing in one adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the KRAB_A-box domain from ZNF430 and the JH1 kinase domain from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the ZNF430-JAK2 fusion protein has not been performed. Clinical significance: The novel ZNF430-JAK2 fusion has been documented in one case for which clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['ZNF430-JAK2'],[7999],{<CIViC source 3223>},[],[],[2977]
2847,MIR21 Overexpression,0.0,,,[],"[8000, 8001, 8109, 8110]","{<CIViC source 3227>, <CIViC source 3228>, <CIViC source 3338>}",[],[],[2978]
2848,KRAS A146,15.0,,,[],"[3939, 10656]","{<CIViC source 76>, <CIViC source 4366>}",[],[],[2979]
2849,IL33 Overexpression,0.0,,,[],[8003],{<CIViC source 3232>},[],[],[2980]
2850,WDR12 OVEREXPRESSION,0.0,,,[],[8004],{<CIViC source 3244>},[],[],[2981]
2851,PLK1 OVEREXPRESSION,0.0,,,[],[8005],{<CIViC source 3244>},[],[],[2982]
2852,ACVR1 Mutation,15.0,,,[],"[8014, 10014, 10020, 10141]","{<CIViC source 2448>, <CIViC source 4232>, <CIViC source 2557>}",[],[],[2983]
2853,CXCL10 EXPRESSION,0.0,,,[],[8026],{<CIViC source 1291>},[],[],[2984]
2854,CCN2 Overexpression,0.0,,,[],[8027],{<CIViC source 3251>},[],[],[2985]
2855,STAT5B Y665F,0.0,,,[],[8029],{<CIViC source 3256>},[],[],[2986]
2856,MIGA1::BRAF Fusion,0.0,,,"['FAM73A-BRAF', 'FAM73A::BRAF', 'MIGA1-BRAF']",[8030],{<CIViC source 3257>},[],[],[2987]
2857,PCNA K164R LOSS-OF-MODIFICATION,0.0,,,[],[8032],{<CIViC source 3258>},[],[],[2988]
2858,EZH2 Y646F,14.0,"Y646F has been reported as one of the most recurrent alterations of EZH2 in DLBCL, FL and other malignancies. This mutation is thought to alter methyltransferase activity of EZH2 and confer sensitivity to EZH2 inhibitors such as tazemetostat.","Y646F has been reported as one of the most recurrent alterations of EZH2 in DLBCL, FL and other malignancies. This mutation is thought to alter methyltransferase activity of EZH2 and confer sensitivity to EZH2 inhibitors such as tazemetostat.","['Y641F', 'TYR641PHE', 'TYR646PHE']","[8036, 10394, 10999, 11000, 11083, 9516, 9517, 9519, 11012, 11025, 11048, 11106, 11010]","{<CIViC source 2307>, <CIViC source 364>, <CIViC source 4550>, <CIViC source 4532>, <CIViC source 4070>, <CIViC source 4492>, <CIViC source 4487>, <CIViC source 4509>}",[256],[<CIViC source 256>],[2989]
2859,BRCA2 P655R,0.0,,,[],[8037],{<CIViC source 1188>},[],[],[2990]
2860,KRAS V14I,0.0,,,[],[8041],{<CIViC source 3260>},[],[],[2991]
2861,TPM3::NTRK1 Fusion,77.0,,,['TPM3-NTRK1'],"[11703, 6101, 7419, 8042, 11692, 11743, 11861, 10094]","{<CIViC source 4951>, <CIViC source 2925>, <CIViC source 2445>, <CIViC source 4888>, <CIViC source 4801>, <CIViC source 3261>, <CIViC source 1289>, <CIViC source 2467>}",[],[],[2992]
2862,CDK5 Expression,0.0,,,[],[8043],{<CIViC source 3255>},[],[],[2993]
2863,MAEA E151INT,0.0,,,[],[8045],{<CIViC source 3262>},[],[],[2994]
2864,TP53BP1 D353E,0.0,,,[],[8046],{<CIViC source 3263>},[],[],[2995]
2865,ARID2 R1273* (c.3817C>T),0.0,,,[],[8051],{<CIViC source 3202>},[],[],[2996]
2867,EGFR L797S,0.0,,,[],[],set(),[],[],[2998]
2868,EGFR L718Q,0.0,,,[],"[8058, 8071, 8075, 8081]",{<CIViC source 3253>},[],[],[2999]
2869,EGFR L718V,0.0,,,[],"[8059, 8069, 8074]",{<CIViC source 3253>},[],[],[3000]
2870,PIK3CA V955I,10.0,,,['VAL955ILE'],[8063],{<CIViC source 2196>},[],[],[3001]
2871,NF2 c.1396C>T,5.0,,,[],"[8066, 8067]","{<CIViC source 3271>, <CIViC source 3270>}",[],[],[3002]
2872,EGFR C797G,0.0,,,['CYS797GLY'],[8078],{<CIViC source 3253>},[],[],[3003]
2873,EGFR L792H,0.0,,,['LEU792HIS'],[8079],{<CIViC source 3253>},[],[],[3004]
2874,TP53 P278A,0.0,,,['PRO278ALA'],"[8082, 8083, 9509]","{<CIViC source 3302>, <CIViC source 4058>}",[],[],[3005]
2875,FOXC2 Overexpression,0.0,,,[],[8084],{<CIViC source 3304>},[],[],[3006]
2876,ZEB1 Overexpression,0.0,,,[],[8085],{<CIViC source 3308>},[],[],[3007]
2877,CUL7 Overexpression,0.0,,,[],"[8087, 8088]",{<CIViC source 3317>},[],[],[3008]
2878,ABL1 Double Ph,10.0,,,['DOUBLE PHILADELPHIA CHROMOSOME'],[8093],{<CIViC source 1530>},[],[],[3009]
2879,ABL1 K356dup,0.0,,,[],"[8107, 10734]",{<CIViC source 3333>},[],[],[3010]
2880,FLT3 D835Y,6.0,,,"['ASP835TYR', 'RS121913488']","[8106, 11095, 11096, 8111, 11085, 11086, 8108]","{<CIViC source 3336>, <CIViC source 4167>, <CIViC source 3337>, <CIViC source 3332>}",[],[],[3011]
2881,VHL I180T (c.539T>C),0.0,"An entry at the same genomic location causing a different amino acid substitution (Clinvar ID: 625262; c.539T>G, I180S)","An entry at the same genomic location causing a different amino acid substitution (Clinvar ID: 625262; c.539T>G, I180S)",[],[8119],{<CIViC source 3350>},[],[],[3012]
2882,VHL R82_V84del (c.243delGCGCGTCGT),0.0,,,[],[8131],{<CIViC source 3351>},[],[],[3013]
2883,CSF1R Expression,0.0,,,[],"[8132, 8133, 8134]",{<CIViC source 3348>},[],[],[3014]
2884,VHL S72Afs*? (c.213_214insGCCC),0.0,,,[],"[8137, 9935]","{<CIViC source 1264>, <CIViC source 3351>}",[],[],[3015]
2885,VHL F26del (c.227delTCT),0.0,,,[],[],set(),[],[],[3016]
2886,VHL P154L (c.461C>T),0.0,,,[],[],set(),[],[],[3017]
2890,VHL c.-195G>A,0.0,,,[],"[8158, 8159, 8160, 8161, 8162, 8163, 8164]",{<CIViC source 3357>},[],[],[3021]
2891,VHL c.*294G>A,0.0,,,[],"[8165, 8166, 8167, 8168, 8169, 8170, 8171, 8172, 10768]","{<CIViC source 3357>, <CIViC source 4399>}",[],[],[3022]
2892,PML K227_T233del,0.0,,,[],[8175],{<CIViC source 3363>},[],[],[3023]
2893,PML S214L,0.0,,,['Ser214Leu'],[],set(),[],[],[3024]
2894,PML A216T,0.0,,,['ALA216THR'],[],set(),[],[],[3025]
2895,BCL2 G101A,0.0,,,[],[8184],{<CIViC source 3376>},[],[],[3026]
2896,BCL2 F104S,0.0,,,[],[8186],{<CIViC source 3376>},[],[],[3027]
2897,BCL2 F104L,0.0,,,[],[8187],{<CIViC source 3376>},[],[],[3028]
2898,BCL2 R107_R110dup,0.0,,,[],"[8309, 8188]","{<CIViC source 3445>, <CIViC source 3376>}",[],[],[3029]
2899,BCL2 A113G,0.0,,,[],"[8189, 8308]","{<CIViC source 3376>, <CIViC source 3445>}",[],[],[3030]
2900,BCL2 L119V,0.0,,,['LEU119VAL'],[8190],{<CIViC source 3376>},[],[],[3031]
2901,MYOD1 L122R,165.0,,,['LEU122ARG'],"[8193, 9532, 11582, 11583, 11584, 11585, 11586, 11587, 11588, 8313, 11564, 8194]","{<CIViC source 4799>, <CIViC source 4077>, <CIViC source 3378>, <CIViC source 3448>, <CIViC source 4806>, <CIViC source 4807>, <CIViC source 4800>}",[],[],[3032]
2902,RET G810,0.0,,,[],"[8195, 8196]",{<CIViC source 3381>},[],[],[3033]
2903,VHL c.-195G>A/C,0.0,,,[],[8199],{<CIViC source 3384>},[],[],[3034]
2904,VHL c.1149A>G,0.0,,,[],[8200],{<CIViC source 3384>},[],[],[3035]
2905,VHL E70Dfs(c.210delG),0.0,,,[],[8210],{<CIViC source 3389>},[],[],[3036]
2906,VHL I151T(c.452T>C),0.0,,,[],[],set(),[],[],[3037]
2908,VHL c.652T>A,0.0,,,[],[8227],{<CIViC source 3389>},[],[],[3039]
2909,VHL D143= (c.429C>T),0.0,,,[],[8230],{<CIViC source 3391>},[],[],[3040]
2910,VHL c.340+770T>C,0.0,,,[],[8231],{<CIViC source 3391>},[],[],[3041]
2911,CDK6 EXPRESSION,2.0,,,[],[7801],{<CIViC source 3123>},[],[],[3042]
2912,CDK4 EXPRESSION,0.0,,,[],[],set(),[],[],[3043]
2913,VHL R197_L198ins7(c.572_592dup),0.0,,,[],[8237],{<CIViC source 3395>},[],[],[3044]
2914,VHL p.F76del,0.0,,,[],[8240],{<CIViC source 3398>},[],[],[3045]
2915,VHL G34Rfs(c.99_100insA),0.0,,,[],[8241],{<CIViC source 3398>},[],[],[3046]
2916,VHL c.56_57DupInvCGGGAGGC,0.0,,,[],[8247],{<CIViC source 3398>},[],[],[3047]
2917,VHL S65T (c.193T>A),0.0,"Two clinvar entries at this same genomic location (Clinvar ID: 547829, 223160) with different base changes result in different amino acid changes (T>G = S65A) and T>C = S65P)","Two clinvar entries at this same genomic location (Clinvar ID: 547829, 223160) with different base changes result in different amino acid changes (T>G = S65A) and T>C = S65P)",[],[8253],{<CIViC source 3402>},[],[],[3048]
2918,ATM c.902-1G>T,3.0,,,[],[2224],{<CIViC source 1541>},[],[],[3049]
2919,ATM c.7089+1del,3.0,,,[],[2830],{<CIViC source 1541>},[],[],[3050]
2920,ATM c.7515+1_2del,3.0,,,[],[2831],{<CIViC source 1541>},[],[],[3051]
2921,CD79B MUTATION,0.0,,,[],"[8262, 11822]","{<CIViC source 3409>, <CIViC source 4940>}",[],[],[3052]
2922,FLT3 N676K,0.0,,,[],"[8263, 9530]","{<CIViC source 4075>, <CIViC source 3413>}",[],[],[3053]
2923,EWSR1::ATF1 Fusion,0.0,,,['EWSR1-ATF1'],"[8265, 7931, 12166]","{<CIViC source 3416>, <CIViC source 3169>, <CIViC source 5123>}",[],[],[3054]
2924,FLT3 Y693,0.0,,,[],[8285],{<CIViC source 3428>},[],[],[3055]
2925,VHL Y98N (c.292T>A),0.0,,,[],[],set(),[],[],[3056]
2926,GATA1 p.Ser51Alafs*86,0.0,,,[],[8302],{<CIViC source 3443>},[],[],[3057]
2927,BCL2 D103Y,0.0,,,[],"[8312, 8304]","{<CIViC source 3445>, <CIViC source 3201>}",[],[],[3058]
2928,BCL2 V156D,0.0,,,[],[8306],{<CIViC source 3445>},[],[],[3059]
2929,BCL2 R129L,0.0,,,['ARG129LEU'],[8307],{<CIViC source 3445>},[],[],[3060]
2930,BCL2 D103V,0.0,,,[],[8310],{<CIViC source 3445>},[],[],[3061]
2931,BCL2 D103E,0.0,,,[],"[8311, 8335]",{<CIViC source 3445>},[],[],[3062]
2934,FGFR2 Y376C,0.0,,,[],[8317],{<CIViC source 3447>},[],[],[3065]
2935,VHL L128F (c.382C>T),5.0,,,[],"[8322, 9250, 5478]","{<CIViC source 3919>, <CIViC source 2246>, <CIViC source 3457>}",[],[],[3066]
2937,VHL L128fs (c.381del),0.0,,,"['LEU128PHEFSTER30', 'L128FFS*30 (C.381DEL)']","[8326, 9393]","{<CIViC source 4020>, <CIViC source 3459>}",[],[],[3068]
2938,NTRK3 R248C,0.0,,,[],[8331],{<CIViC source 3463>},[],[],[3069]
2939,FLT3 Y842C,20.0,,,[],"[8337, 8339, 8336, 8338, 8340, 8654, 8934, 8935]","{<CIViC source 3472>, <CIViC source 3766>}",[],[],[3070]
2940,FLT3 F691L,6.0,,,[],"[8674, 9718, 9716, 9717, 8341, 8342, 8562, 8664, 8843, 8844, 8845, 8846, 9774]","{<CIViC source 3428>, <CIViC source 4145>, <CIViC source 3472>, <CIViC source 722>, <CIViC source 3643>, <CIViC source 4157>}",[],[],[3071]
2941,GATA2 Mutation,0.0,,,[],[8343],{<CIViC source 3475>},[],[],[3072]
2942,CARD11 MUTATION,0.0,,,[],"[8344, 11932, 11844]","{<CIViC source 3476>, <CIViC source 258>, <CIViC source 4950>}",[],[],[3073]
2943,TP53 Mutations,0.0,,,[],[],set(),[],[],[3074]
2944,FLT3 D835I,2.0,,,[],[8351],{<CIViC source 3336>},[],[],[3075]
2945,VHL P61_C77del (c.181_231del),0.0,,,[],[8352],{<CIViC source 3484>},[],[],[3076]
2946,VHL Y98C (c.293A>G),0.0,,,[],[],set(),[],[],[3077]
2947,VHL L135*,0.0,,,[],"[5579, 8356]","{<CIViC source 2282>, <CIViC source 3487>}",[],[],[3078]
2948,PIK3CA H1-47R,0.0,,,[],[],set(),[],[],[3079]
2949,VHL S139fs,0.0,,,[],[8366],{<CIViC source 3487>},[],[],[3080]
2951,BCL2 F104I,8.0,,,['PHE104ILE'],"[8375, 8376]",{<CIViC source 3502>},[],[],[3082]
2952,VHL 180fs*22 (c.540delC),0.0,,,[],[8379],{<CIViC source 3489>},[],[],[3083]
2954,VHL G104fs*23 (c.309_322del14),0.0,,,[],[8381],{<CIViC source 3489>},[],[],[3085]
2955,VHL V181fs (c.541delG),0.0,,,[],[8383],{<CIViC source 3489>},[],[],[3086]
2956,VHL P25L (c.74C>T) and P86T (c.256C>A),0.0,,,[],[8386],{<CIViC source 3489>},[],[],[3087]
2958,VHL V166Dfs*9 (c.480_481insCGATGCCTCCAGGT),0.0,,,[],"[8393, 10495]","{<CIViC source 3511>, <CIViC source 4350>}",[],[],[3089]
2959,VHL N78S (c.233A>G),0.0,,,[],[],set(),[],[],[3090]
2960,VHL L178P (c.533T>A),0.0,,,[],[8396],{<CIViC source 3512>},[],[],[3091]
2961,VHL C162W (c.486C>G),0.0,,,[],[],set(),[],[],[3092]
2962,VHL L89P (c.266T>C),0.0,,,[],[],set(),[],[],[3093]
2963,VHL S183* (c.548C>A),0.0,,,[],[],set(),[],[],[3094]
2964,VHL Partial deletion of 2 Kb,0.0,,,[],"[8400, 8408, 10322]","{<CIViC source 3512>, <CIViC source 3514>, <CIViC source 3714>}",[],[],[3095]
2965,VHL C77_N78insL (c.230_231insTCT),12.5,,,['77INSL'],"[7894, 8401, 5364, 9902]","{<CIViC source 3512>, <CIViC source 2324>, <CIViC source 2239>, <CIViC source 3167>}",[],[],[3096]
2966,VHL L169= (c.505C>T),0.0,"Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.507A>C (p.Leu169=, L169L)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238110/)","Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.507A>C (p.Leu169=, L169L)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238110/)",['L169L (C.505C>T)'],[8410],{<CIViC source 3514>},[],[],[3097]
2967,VHL V181fs (c.540_543delCGTC),0.0,,,[],[],set(),[],[],[3098]
2968,VHL G127_L128delinsGF (c.381_382delinsTT),0.0,,,[],[8436],{<CIViC source 3522>},[],[],[3099]
2969,VHL Exon Deletion,0.0,,,[],"[8445, 8623]","{<CIViC source 1264>, <CIViC source 3524>}",[],[],[3100]
2970,VHL c.65_55dup11,0.0,,,[],[8452],{<CIViC source 3528>},[],[],[3101]
2971,VHL 3' UTR alteration (c.*1149A>G),0.0,,,[],[8453],{<CIViC source 3528>},[],[],[3102]
2972,VHL R167G (c.500G>A),0.0,,,[],[8466],{<CIViC source 3534>},[],[],[3103]
2973,VHL S80I (c.239G>T),0.0,,,[],[],set(),[],[],[3104]
2974,VHL F?C (c.?T>G),0.0,,,[],[8474],{<CIViC source 3541>},[],[],[3105]
2975,VHL E189Kfs*? (c.565delG),0.0,,,[],[],set(),[],[],[3106]
2976,VHL Splice Region (c.464-3C>T),0.0,,,[],[8488],{<CIViC source 3543>},[],[],[3107]
2977,VHL Single Allele Deletion,0.0,,,[],"[8499, 8580]","{<CIViC source 3606>, <CIViC source 3522>}",[],[],[3108]
2980,NUP98::KDM5A Fusion,0.0,,,['NUP98-KDM5A'],[8502],{<CIViC source 3553>},[],[],[3111]
2981,PALB2 Oncogenic Mutations (loss of function alterations),0.0,,,[],[10856],{<CIViC source 4434>},[],[],[3112]
2982,ATM Oncogenic Mutations (loss of function alterations),0.0,,,[],[11842],{<CIViC source 4948>},[],[],[3113]
2983,MN1::CXXC5 Fusion,20.0,,,['MN1-CXXC5'],[],set(),[],[],[3114]
2984,GATA1 Mutation,0.0,,,[],[8511],{<CIViC source 966>},[],[],[3115]
2985,RBM15::MRTFA Fusion,20.0,,,"['RBM15-MKL1', 'RBM15-MRTFA', 'OTT-MAL']","[8513, 8512, 8514, 12260, 12261, 12262]","{<CIViC source 966>, <CIViC source 4960>, <CIViC source 5162>, <CIViC source 3553>, <CIViC source 3561>, <CIViC source 5163>}",[],[],[3116]
2987,FLT3 ITD & TKD MUTATIONS,0.0,,,[],"[8516, 8914]","{<CIViC source 2740>, <CIViC source 3305>}",[],[],[3118]
2988,VHL L140PfsX4 (c.418dup),0.0,,,[],[8522],{<CIViC source 3570>},[],[],[3119]
2989,VHL N78S (c.233A>G),0.0,,,[],[],set(),[],[],[3120]
2991,VHL H125Y (c.373C>T),0.0,,,[],[8542],{<CIViC source 3579>},[],[],[3122]
2992,VHL D179N (c.535G>A),0.0,,,[],[8546],{<CIViC source 3580>},[],[],[3123]
2993,VHL Y98C (c.293A>G ),0.0,,,[],[],set(),[],[],[3124]
2994,VHL Y98* (c.294C>G),0.0,,,['TYR98TER'],[8557],{<CIViC source 3585>},[],[],[3125]
2995,RUNX1::RUNX1T1 Fusion,120.0,,,['RUNX1-RUNX1T1'],"[8558, 11881, 11880, 11878, 11879, 11882]","{<CIViC source 4955>, <CIViC source 4957>, <CIViC source 1333>, <CIViC source 4956>, <CIViC source 4914>}",[],[],[3126]
2996,WT1 Mutations,0.0,,,[],[8563],{<CIViC source 3588>},[],[],[3127]
2997,TLX3::BCL11B Fusion,0.0,,,['TLX3-BCL11B'],[8564],{<CIViC source 3589>},[],[],[3128]
2998,VHL F148Lfs*11 (c.444del),0.0,,,[],[8565],{<CIViC source 3590>},[],[],[3129]
2999,VHL T152P (c.454A>C),0.0,,,[],"[8568, 8679]","{<CIViC source 2192>, <CIViC source 3593>}",[],[],[3130]
3001,VHL R108Hfs*23 (c.323_324del),0.0,,,[],"[8581, 10198]","{<CIViC source 2655>, <CIViC source 3607>}",[],[],[3132]
3002,VHL D121N (c.361G>A),0.0,,,[],"[8586, 10201]","{<CIViC source 2655>, <CIViC source 3607>}",[],[],[3133]
3003,SDHA R31* (c.91C>T),0.0,,,[],[8589],{<CIViC source 3608>},[],[],[3134]
3004,VHL S38P (c.112T>C),0.0,,,[],[8590],{<CIViC source 2302>},[],[],[3135]
3005,VHL I75Sfs*84 (c.223del),0.0,,,[],[8591],{<CIViC source 2302>},[],[],[3136]
3006,VHL E189fs (c.565del),0.0,,,[],[],set(),[],[],[3137]
3007,NPM1 MUTATION,0.0,,,[],[8596],{<CIViC source 966>},[],[],[3138]
3008,MECOM Overexpression,0.0,,,[],[8597],{<CIViC source 3612>},[],[],[3139]
3009,ETV6::RUNX1 Fusion,70.0,,,['ETV6-RUNX1'],"[8599, 8598, 12293]","{<CIViC source 5179>, <CIViC source 966>, <CIViC source 3613>}",[],[],[3140]
3010,KMT2A Rearrangement,0.0,,,[],"[8601, 8600, 7819]","{<CIViC source 966>, <CIViC source 3132>, <CIViC source 3614>}",[],[],[3141]
3011,VHL W117Cfs*42 (c.351del),0.0,,,[],[8603],{<CIViC source 1368>},[],[],[3142]
3012,VHL F148* (c.443_455delinsA),5.0,,,[],[8608],{<CIViC source 1368>},[],[],[3143]
3013,NTRK2 R458G,0.0,,,[],"[8609, 8610, 8625]",{<CIViC source 3615>},[],[],[3144]
3014,VHL Q96_P102del (c.287_307del),0.0,,,[],"[8614, 8643]","{<CIViC source 2365>, <CIViC source 3620>}",[],[],[3145]
3015,VHL I75S (c.224T>G),0.0,,,[],[8618],{<CIViC source 1264>},[],[],[3146]
3016,NTRK2 A203T,0.0,,,[],"[8619, 8620]",{<CIViC source 3615>},[],[],[3147]
3017,MEF2D MEF2D Rearrangement,0.0,,,[],[8624],{<CIViC source 3622>},[],[],[3148]
3019,VHL T100Nfs*32 (c.298dupA),0.0,,,[],"[7753, 8630]",{<CIViC source 3093>},[],[],[3150]
3020,VHL Null (c.1-?_642+?del),0.0,,,[],[],set(),[],[],[3151]
3021,GNA11 G209P,0.0,,,[],[8640],{<CIViC source 3628>},[],[],[3152]
3022,GNAQ G209P,0.0,,,[],[8641],{<CIViC source 3628>},[],[],[3153]
3023,VHL I75Yfs*57 (c.224dupT),0.0,,,[],[8644],{<CIViC source 3632>},[],[],[3154]
3024,VHL K196* (c.586AT),0.0,,,[],[],set(),[],[],[3155]
3025,VHL D126Efs* (c.377_378insG),0.0,,,[],[8650],{<CIViC source 2282>},[],[],[3156]
3027,KANK1::NTRK2 Fusion,30.0,,,['KANK1-NTRK2'],"[10360, 10361, 8653, 10362, 10896, 11854]","{<CIViC source 4951>, <CIViC source 4352>, <CIViC source 4316>, <CIViC source 4318>, <CIViC source 3636>, <CIViC source 4317>}",[],[],[3158]
3028,VHL c.463+43A>G,0.0,,,[],"[10399, 8655, 9857]","{<CIViC source 3637>, <CIViC source 4335>, <CIViC source 2320>}",[],[],[3159]
3029,FLT3 D839G,0.0,,,[],"[8908, 8927, 8656]","{<CIViC source 3759>, <CIViC source 3639>, <CIViC source 3731>}",[],[],[3160]
3030,VHL c.340+7G>A,0.0,,,[],[8659],{<CIViC source 2269>},[],[],[3161]
3031,VHL P154= (c.462A>G),0.0,,,[],[8661],{<CIViC source 2282>},[],[],[3162]
3032,VHL N150fs (c.447del),0.0,,,['N150IFS*'],[],set(),[],[],[3163]
3033,VHL L89S (c.265C>T),0.0,,,[],[8666],{<CIViC source 3571>},[],[],[3164]
3034,FLT3 M664I,0.0,,,[],[8667],{<CIViC source 3643>},[],[],[3165]
3035,FLT3 K663Q,0.0,,,[],[8670],{<CIViC source 3645>},[],[],[3166]
3036,FLT3 D839A,0.0,,,[],[8671],{<CIViC source 3643>},[],[],[3167]
3037,FLT3 D839N,0.0,,,[],[8672],{<CIViC source 3643>},[],[],[3168]
3038,FLT3 D839H,0.0,,,[],[8673],{<CIViC source 3643>},[],[],[3169]
3039,VHL C162Wfs*12(c.485dupG),0.0,,,[],[8678],{<CIViC source 2192>},[],[],[3170]
3040,VHL K159Efs*15(c.473dupT),0.0,,,[],[],set(),[],[],[3171]
3041,VHL L129Wfs*?(c.383delT),0.0,,,[],[8685],{<CIViC source 2286>},[],[],[3172]
3042,VHL A50= (c.150C>G),0.0,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.150C>A (p.Ala50=; A50=)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238101/),Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.150C>A (p.Ala50=; A50=)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238101/),['A50A (C.150C>G)'],"[8686, 10524]","{<CIViC source 2211>, <CIViC source 2174>}",[],[],[3173]
3043,VHL c.-65_-55dup11,0.0,,,[],[8687],{<CIViC source 2174>},[],[],[3174]
3044,VHL N141fs (c.422_440del),0.0,,,['N141IFS*12'],[],set(),[],[],[3175]
3045,VHL R107Pfs*25(c.314_315insC),0.0,,,[],[8694],{<CIViC source 2174>},[],[],[3176]
3047,VHL Null (Partial VHL deletion),0.0,,,[],[],set(),[],[],[3178]
3048,VHL D126N (c.376G>A) / S183L (c.548C>T),0.0,,,[],[],set(),[],[],[3179]
3049,VHL Null (deletion),0.0,,,[],"[8724, 9418, 10113]","{<CIViC source 3664>, <CIViC source 4041>, <CIViC source 2373>}",[],[],[3180]
3050,VHL P154S (c.460C>T),0.0,,,[],[],set(),[],[],[3181]
3051,VHL Y156H (c.466T>C),0.0,,,"['C.466T>C', 'TYR156HIS']","[8731, 8817]","{<CIViC source 3665>, <CIViC source 3683>}",[],[],[3182]
3052,VHL Null (c.341-?_463+?del),0.0,,,[],[],set(),[],[],[3183]
3053,VHL V62Cfs*5 (c.180del),10.0,,,[],"[4916, 5032, 10428, 8752, 10632]","{<CIViC source 3669>, <CIViC source 2186>, <CIViC source 1278>, <CIViC source 2285>, <CIViC source 2193>}",[],[],[3184]
3054,VHL P86Afs*46 (c.254_255insC),0.0,,,[],[8755],{<CIViC source 3669>},[],[],[3185]
3055,VHL N150Ifs*9 (c.449del),0.0,,,[],[8759],{<CIViC source 3669>},[],[],[3186]
3056,VHL R176Gfs*26 (c.526del),0.0,,,[],[10522],{<CIViC source 2193>},[],[],[3187]
3057,VHL Null (large 3' deletion),0.0,,,[],[8762],{<CIViC source 3669>},[],[],[3188]
3058,VHL V62Gfs*66 (c.185_195del),0.0,,,[],[8765],{<CIViC source 3670>},[],[],[3189]
3059,VHL P95Rfs*64 (c.284del),0.0,,,[],[8781],{<CIViC source 3671>},[],[],[3190]
3060,VHL R177_L178ins6 (c.531_532ins18),0.0,,,[],[8785],{<CIViC source 3671>},[],[],[3191]
3062,VHL Y156S (c.467A>C),0.0,Clinvar entry at same genomic location with different base and amino acid change (Clinvar ID 43600; Y156C c.467A>G),Clinvar entry at same genomic location with different base and amino acid change (Clinvar ID 43600; Y156C c.467A>G),"['C.467A>C', 'TYR156SER']",[8816],{<CIViC source 3683>},[],[],[3193]
3063,VHL A122V (c.365C>T),0.0,,,[],[8819],{<CIViC source 3683>},[],[],[3194]
3064,VHL A149fs (c.444dup),0.0,,,['A149CFS*25'],"[9982, 8822, 6156]","{<CIViC source 1370>, <CIViC source 2179>, <CIViC source 3683>}",[],[],[3195]
3065,VHL *214Gext*14 (c.640T>G),0.0,,,[],[8824],{<CIViC source 3683>},[],[],[3196]
3066,VHL G144R (c.430G>C),0.0,,,[],[8827],{<CIViC source 3683>},[],[],[3197]
3067,VHL L163I (c.487C>A),0.0,Clinvar entry at same genomic location with different amino acid change (Clinvar ID 480772; c.487C>T L163F),Clinvar entry at same genomic location with different amino acid change (Clinvar ID 480772; c.487C>T L163F),[],[8829],{<CIViC source 3683>},[],[],[3198]
3068,VHL P97L (c.290C>T) and L116P (c.347T>C),0.0,,,[],[8830],{<CIViC source 3683>},[],[],[3199]
3069,KRAS Wildtype,2.0,,,[],"[11262, 11264, 7052, 11057, 11655, 11659, 11661, 8840]","{<CIViC source 1935>, <CIViC source 2784>, <CIViC source 2721>, <CIViC source 1934>, <CIViC source 4826>}",[],[],[3200]
3070,FLT3 N841I,0.0,,,[],"[9235, 8858]","{<CIViC source 3699>, <CIViC source 1009>}",[],[],[3201]
3071,SMARCB1 Loss,50.0,,,[],"[8863, 8862, 9993, 11170, 11180, 11090, 11165, 11167, 11168, 11336, 11337, 11178, 11181, 11338, 11340]","{<CIViC source 4216>, <CIViC source 4573>, <CIViC source 4664>, <CIViC source 4662>, <CIViC source 3707>, <CIViC source 4572>, <CIViC source 4571>, <CIViC source 4661>, <CIViC source 4582>, <CIViC source 4576>, <CIViC source 3625>}",[],[],[3202]
3072,ATRX Mutation,15.0,,,[],"[8950, 8866, 8867, 8868]","{<CIViC source 3708>, <CIViC source 1085>}",[],[],[3203]
3073,EML4::ALK e6::e19,0.0,,,['EML4-ALK'],[],set(),[],[],[3204]
3074,PDGFRA V658A,0.0,,,[],"[8889, 8890]",{<CIViC source 1389>},[],[],[3205]
3075,EGFR G12V,0.0,,,[],[],set(),[],[],[3206]
3076,RBPMS::MET Fusion,0.0,,,['RBPMS-MET'],[8892],{<CIViC source 3729>},[],[],[3207]
3077,FLT3 ITD&F691(I/L),0.0,,,[],"[8893, 9779]","{<CIViC source 720>, <CIViC source 4165>}",[],[],[3208]
3078,FLT3 ITD & D835(V/Y/F/H),0.0,,,[],"[9141, 8894]","{<CIViC source 720>, <CIViC source 3741>}",[],[],[3209]
3079,FLT3 ITD & Y842C,0.0,,,[],"[8895, 8913, 9081, 9082]","{<CIViC source 3836>, <CIViC source 720>, <CIViC source 3337>, <CIViC source 3305>}",[],[],[3210]
3080,FLT3 ITD & D839G,0.0,,,[],"[9140, 8896, 8897, 8669]","{<CIViC source 720>, <CIViC source 3643>, <CIViC source 3741>}",[],[],[3211]
3081,FLT3 G697S,0.0,,,[],"[9022, 8898]",{<CIViC source 3428>},[],[],[3212]
3082,FLT3 N841K,0.0,,,[],"[9236, 8899]","{<CIViC source 3733>, <CIViC source 1009>}",[],[],[3213]
3083,GOLGA5::JAK2 Fusion,7.5,"The GOLGA5-JAK2 fusion is composed of part of the GOLGA5 (Golgin A5) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 10 of GOLGA5 to exon 12 of JAK2 (GOLGA5-JAK2 10-12). The fusion is predicted to result from a reciprocal translocation t(9;14)(p24;q32), and has been identified in one patient by RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from GOLGA5 and an aberrantly activated JH1 kinase domain from JAK2, which is thought to upregulate the pathway shared with signal transducers and activators of transcription (STATs). The inclusion of the JH1 domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The novel GOLGA5-JAK2 fusion has been documented in one 10-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia with complex karyotype. The clinical details of this case could predict response to treatment with JAK2 inhibitors. A xenograft model created from the patient's malignant cells demonstrated clearance of the leukemic clone in murine peripheral blood upon exposure to ruxolitinib. Moreover, this drug was added to the child's treatment regimen, resulting in nearly undetectable levels of the GOLGA5-JAK2 fusion measured after 64 days of therapy. The patient has reportedly remained in remission 20 months after CAR T-cell infusion and allogeneic hematopoietic stem cell transplantation. This child was included in the currently ongoing prospective clinical trial evaluating the efficacy of JAK2 inhibitors in treating pediatric B-lymphoblastic leukemia with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).","The GOLGA5-JAK2 fusion is composed of part of the GOLGA5 (Golgin A5) gene at the 5 end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3 end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 10 of GOLGA5 to exon 12 of JAK2 (GOLGA5-JAK2 10-12). The fusion is predicted to result from a reciprocal translocation t(9;14)(p24;q32), and has been identified in one patient by RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from GOLGA5 and an aberrantly activated JH1 kinase domain from JAK2, which is thought to upregulate the pathway shared with signal transducers and activators of transcription (STATs). The inclusion of the JH1 domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The novel GOLGA5-JAK2 fusion has been documented in one 10-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia with complex karyotype. The clinical details of this case could predict response to treatment with JAK2 inhibitors. A xenograft model created from the patient's malignant cells demonstrated clearance of the leukemic clone in murine peripheral blood upon exposure to ruxolitinib. Moreover, this drug was added to the child's treatment regimen, resulting in nearly undetectable levels of the GOLGA5-JAK2 fusion measured after 64 days of therapy. The patient has reportedly remained in remission 20 months after CAR T-cell infusion and allogeneic hematopoietic stem cell transplantation. This child was included in the currently ongoing prospective clinical trial evaluating the efficacy of JAK2 inhibitors in treating pediatric B-lymphoblastic leukemia with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).",['GOLGA5-JAK2'],[7007],{<CIViC source 2701>},[],[],[3214]
3084,FGFR4 G636C,0.0,,,[],"[10092, 8905]",{<CIViC source 3737>},[],[],[3215]
3085,FGFR4 N535K,0.0,,,[],[8906],{<CIViC source 3738>},[],[],[3216]
3086,FGFR4 V550E,0.0,,,[],[8907],{<CIViC source 3738>},[],[],[3217]
3087,FLT3 ITD and co-mutations,0.0,,,[],[8909],{<CIViC source 3741>},[],[],[3218]
3088,FLT3 ITD D651G,0.0,,,[],[8910],{<CIViC source 3305>},[],[],[3219]
3089,FLT3 ITD  N676D,0.0,,,[],[8911],{<CIViC source 3305>},[],[],[3220]
3090,FLT3 ITD I687F,0.0,,,[],[8912],{<CIViC source 3305>},[],[],[3221]
3091,PIK3CA Rare Mutation,10.0,,,[],"[2042, 8915]",{<CIViC source 1444>},[],[],[3222]
3092,LMNA::NTRK1 e2::e10,0.0,,,['LMNA-NTRK1 E2-E10'],[],set(),[],[],[3223]
3093,LMNA::NTRK1 e2::e11,0.0,,,['LMNA-NTRK1 E2-E11'],[],set(),[],[],[3224]
3094,LMNA::NTRK1 e11::e10,0.0,,,['LMNA-NTRK1 E11-E10'],[],set(),[],[],[3225]
3095,RET G810C,0.0,,,[],[8918],{<CIViC source 3755>},[],[],[3226]
3096,RET G810S,0.0,,,[],[8919],{<CIViC source 3755>},[],[],[3227]
3097,RET Y806C,0.0,,,[],[8920],{<CIViC source 3755>},[],[],[3228]
3098,RET Y806N,0.0,,,[],[8921],{<CIViC source 3755>},[],[],[3229]
3099,RET V738A,0.0,,,[],[8922],{<CIViC source 3755>},[],[],[3230]
3100,FLT3 D835 & I836,0.0,,,[],[8925],{<CIViC source 3757>},[],[],[3231]
3101,FLT3 I836,0.0,,,[],[8926],{<CIViC source 3758>},[],[],[3232]
3102,FLT3 Y589D,0.0,,,[],[8928],{<CIViC source 3759>},[],[],[3233]
3103,FLT3 Y842H,0.0,,,[],[8929],{<CIViC source 3759>},[],[],[3234]
3104,"PRKAR1A PRKAR1A LOH, allelic imbalance 17q",0.0,,,[],[8936],{<CIViC source 3767>},[],[],[3235]
3105,TSPYL1 R62S,0.0,,,[],[],set(),[],[],[3236]
3106,KIT N505I,0.0,,,[],[8962],{<CIViC source 3779>},[],[],[3237]
3107,KIT N505R,0.0,,,[],[8963],{<CIViC source 3780>},[],[],[3238]
3108,KIT Y503A,0.0,,,[],[8964],{<CIViC source 3780>},[],[],[3239]
3109,KIT F504A,0.0,,,[],[8965],{<CIViC source 3780>},[],[],[3240]
3110,BRAF V600_S605delinsDV,0.0,,,[],[8966],{<CIViC source 3781>},[],[],[3241]
3111,ATRX Underexpression,0.0,,,[],[],set(),[],[],[3242]
3112,ACTL6A Overexpression,0.0,,,[],"[8977, 8978, 8983]",{<CIViC source 3787>},[],[],[3243]
3113,VHL R120fs (c.358_359insAC),7.5,,,['R120NFS*40'],[8995],{<CIViC source 3784>},[],[],[3244]
3114,VHL C77fs (c.230del),7.5,,,[],[8997],{<CIViC source 3784>},[],[],[3245]
3115,VHL Q96_P97delinsH (c.288_290del),7.5,,,"['C.288DELGCC', 'C.288_290DELGCC']","[8999, 10553, 10612]","{<CIViC source 3784>, <CIViC source 2240>}",[],[],[3246]
3116,VHL G144fs (c.429_439del),7.5,,,"['G144FFS*26', 'C.428_438DEL']",[9000],{<CIViC source 3784>},[],[],[3247]
3117,VHL P103H (c.308C>A),0.0,,,[],"[9003, 10487]","{<CIViC source 3511>, <CIViC source 3791>}",[],[],[3248]
3118,MYCN Overexpression,0.0,,,[],[9006],{<CIViC source 3795>},[],[],[3249]
3119,VHL W88*,0.0,,,[],[6695],{<CIViC source 2628>},[],[],[3250]
3120,BCOR::CCNB3 Fusion,10.0,,,['BCOR-CCNB3'],"[10111, 9011, 12003, 12004, 12005]","{<CIViC source 4983>, <CIViC source 4982>, <CIViC source 3108>, <CIViC source 3110>, <CIViC source 4981>}",[],[],[3251]
3121,CIC::DUX4 Fusion,37.5,,,['CIC-DUX4'],"[9012, 11594, 11595, 10112]","{<CIViC source 3805>, <CIViC source 4813>, <CIViC source 4812>, <CIViC source 4227>}",[],[],[3252]
3122,CTNNB1 G34R,0.0,,,[],[9014],{<CIViC source 3195>},[],[],[3253]
3123,CTNNB1 S33F,0.0,,,[],[9015],{<CIViC source 3195>},[],[],[3254]
3124,CTNNB1 I35K,0.0,,,[],[9016],{<CIViC source 3195>},[],[],[3255]
3125,CTNNB1 D32Y,0.0,,,[],[9017],{<CIViC source 3195>},[],[],[3256]
3126,AKT1 S473 Phosphorylation,15.0,,,[],[4051],{<CIViC source 1474>},[],[],[3257]
3128,IGF1R Overexpression,20.0,,,[],"[10138, 9024]","{<CIViC source 4230>, <CIViC source 3812>}",[],[],[3259]
3129,VHL D213E (c.639T>G),0.0,,,[],[9037],{<CIViC source 3815>},[],[],[3260]
3130,VHL V62fs (c.180delG),0.0,,,[],"[9048, 9254, 9967]","{<CIViC source 3919>, <CIViC source 2179>, <CIViC source 3821>}",[],[],[3261]
3131,VHL Null (point mutation codon 238),0.0,,,[],[9050],{<CIViC source 3823>},[],[],[3262]
3132,VHL G93A (c.278G>C),0.0,,,[],[9056],{<CIViC source 3824>},[],[],[3263]
3133,VHL t(3;6)(p12.3;q24.3),0.0,,,[],[9063],{<CIViC source 3827>},[],[],[3264]
3134,VHL t(3;12)(q13.13;q24.23),0.0,,,[],[9064],{<CIViC source 3827>},[],[],[3265]
3135,KRAS P34R,0.0,,,[],[9068],{<CIViC source 3829>},[],[],[3266]
3136,CBL c.1477C>T,0.0,,,[],[9071],{<CIViC source 3832>},[],[],[3267]
3137,RANBP2::ABL1 Fusion,10.0,"The RANBP2-ABL1 fusion is composed of part of the RANBP2 (RAN Binding Protein 2) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of RANBP2 to exon 2 of ABL1 (RANBP2-ABL1 18-2). The fusion is the result of a reciprocal translocation t(2;9)(p12.3;q34.12) and has been identified by FISH/karyotype and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, includes the leucine zipper of RANBP2 and the tyrosine kinase of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RANBP2-ABL1 fusion has been documented in several juvenile and young adult patients with B-lymphoblastic leukemia, some of which were further classified as BCR-ABL1 (Ph)-like subtype. One 20-year-old female patient has been documented as being treated with dasatinib (140 mg daily) added to her clinical trial chemotherapy. While she experienced a brief response, her disease eventually relapsed and she expired. The use of tyrosine kinase inhibitors is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).","The RANBP2-ABL1 fusion is composed of part of the RANBP2 (RAN Binding Protein 2) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of RANBP2 to exon 2 of ABL1 (RANBP2-ABL1 18-2). The fusion is the result of a reciprocal translocation t(2;9)(p12.3;q34.12) and has been identified by FISH/karyotype and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, includes the leucine zipper of RANBP2 and the tyrosine kinase of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RANBP2-ABL1 fusion has been documented in several juvenile and young adult patients with B-lymphoblastic leukemia, some of which were further classified as BCR-ABL1 (Ph)-like subtype. One 20-year-old female patient has been documented as being treated with dasatinib (140 mg daily) added to her clinical trial chemotherapy. While she experienced a brief response, her disease eventually relapsed and she expired. The use of tyrosine kinase inhibitors is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).",['RANBP2-ABL1'],"[9076, 9211, 11617]","{<CIViC source 2495>, <CIViC source 3879>, <CIViC source 2498>}",[],[],[3268]
3138,ZMIZ1::ABL1 Fusion,32.5,"The ZMIZ1-ABL1 fusion is composed of part of the ZMIZ1 (Zinc Finger MIZ-Type Containing 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The most commonly published breakpoint joins exon 18 of ZMIZ1 to exon 2 of ABL1 (ZMIZ1-ABL1 18-2). The fusion is the result of a reciprocal translocation t(9;10)(q34.12;q22.3) and has been identified by FISH/karyotype, RT-PCR, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, which contains one of the proline-rich domains of ZMIZ1 and the ABL1 tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that upregulates the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Patients harboring the ZMIZ1-ABL1 fusion are hypothesized to be eligible for imatinib therapy.","The ZMIZ1-ABL1 fusion is composed of part of the ZMIZ1 (Zinc Finger MIZ-Type Containing 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The most commonly published breakpoint joins exon 18 of ZMIZ1 to exon 2 of ABL1 (ZMIZ1-ABL1 18-2). The fusion is the result of a reciprocal translocation t(9;10)(q34.12;q22.3) and has been identified by FISH/karyotype, RT-PCR, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, which contains one of the proline-rich domains of ZMIZ1 and the ABL1 tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that upregulates the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Patients harboring the ZMIZ1-ABL1 fusion are hypothesized to be eligible for imatinib therapy.",['ZMIZ1-ABL1'],"[9149, 11119, 9077, 9152, 11619, 9151, 11117, 11118, 11120]","{<CIViC source 3876>, <CIViC source 3039>, <CIViC source 2495>, <CIViC source 3878>, <CIViC source 2498>}",[],[],[3269]
3139,CENPC::ABL1 Fusion,5.0,"The CENPC-ABL1 fusion is composed of part of the CENPC (Centromere Protein C) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The CENPC-ABL1 fusion is in-frame and it has been documented in one pediatric patient with high risk BCR-ABL1-like B-lymphoblastic leukemia.","The CENPC-ABL1 fusion is composed of part of the CENPC (Centromere Protein C) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The CENPC-ABL1 fusion is in-frame and it has been documented in one pediatric patient with high risk BCR-ABL1-like B-lymphoblastic leukemia.",['CENPC-ABL1'],[9078],{<CIViC source 2498>},[],[],[3270]
3140,NUP153::ABL1 Fusion,5.0,"The NUP153-ABL1 fusion is composed of part of the NUP153 (Nucleoporin 153) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein, and the inclusion of the ABL1 tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. The NUP153-ABL1 has been documented in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia, as detected by RNA kinome capture and transcriptome sequencing.","The NUP153-ABL1 fusion is composed of part of the NUP153 (Nucleoporin 153) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein, and the inclusion of the ABL1 tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. The NUP153-ABL1 has been documented in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia, as detected by RNA kinome capture and transcriptome sequencing.",['NUP153-ABL1'],"[9079, 11616]","{<CIViC source 2495>, <CIViC source 2498>}",[],[],[3271]
3141,LSM14A::ABL1 Fusion,10.0,"The LSM14A-ABL1 fusion is composed of part of the LSM14A (LSM14A mRNA processing body assembly factor) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The fusion is in-frame and it has been documented in two patients with BCR-ABL1-like B-lymphoblastic leukemia (Ph-like ALL). The first patient was a child with high risk Ph-like ALL and the second patient was a 36 years old male who had a poor prednisone response and did not reach complete remission after vincristine-dexamethasone-rituximab or a combination of dasatinib and chemotherapy. The second patient died early of sepsis in a context of uncontrolled disease (survival 2 months).","The LSM14A-ABL1 fusion is composed of part of the LSM14A (LSM14A mRNA processing body assembly factor) gene at the 5 end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The fusion is in-frame and it has been documented in two patients with BCR-ABL1-like B-lymphoblastic leukemia (Ph-like ALL). The first patient was a child with high risk Ph-like ALL and the second patient was a 36 years old male who had a poor prednisone response and did not reach complete remission after vincristine-dexamethasone-rituximab or a combination of dasatinib and chemotherapy. The second patient died early of sepsis in a context of uncontrolled disease (survival 2 months).",['LSM14A-ABL1'],"[9080, 9153]","{<CIViC source 3879>, <CIViC source 2498>}",[],[],[3272]
3142,MSH3 K383fs,0.0,,,[],[9089],{<CIViC source 3841>},[],[],[3273]
3143,PDGFRA Mutation,7.5,,,[],"[11332, 11333, 11331, 2487]","{<CIViC source 1580>, <CIViC source 412>, <CIViC source 4638>, <CIViC source 2044>}",[],[],[3274]
3144,VHL Null (large rearrangement),0.0,,,[],[],set(),[],[],[3275]
3145,VHL Null (c.341-?_463+ ?del),0.0,,,[],[],set(),[],[],[3276]
3146,ZHX2 Overexpression,0.0,,,[],[9114],{<CIViC source 3852>},[],[],[3277]
3147,VHL L163R (c.488T>G),0.0,,,[],[9124],{<CIViC source 3857>},[],[],[3278]
3148,HDAC2 Overexpression,0.0,,,[],[9130],{<CIViC source 3864>},[],[],[3279]
3149,SPOP M117V,0.0,,,[],[9131],{<CIViC source 3866>},[],[],[3280]
3150,ERCC2 N238S,0.0,,,[],"[11505, 9132]","{<CIViC source 1143>, <CIViC source 3867>}",[],[],[3281]
3151,TP53 R110L,0.0,,,[],[9133],{<CIViC source 3868>},[],[],[3282]
3152,FLT3 ITD & Y597F,0.0,,,[],[9142],{<CIViC source 3741>},[],[],[3283]
3153,FLT3 ITD & L601F,0.0,,,[],[9143],{<CIViC source 3741>},[],[],[3284]
3154,CDKN2A D84N,0.0,,,[],[9145],{<CIViC source 3872>},[],[],[3285]
3155,PTEN G36R,0.0,,,[],[9147],{<CIViC source 3875>},[],[],[3286]
3156,SFPQ::ABL1 Fusion,32.5,"The SFPQ -ABL1 fusion is composed of part of the SFPQ (Splicing factor proline and glutamine rich) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 9 of SFPQ to exon 4 of ABL1 (SFPQ -ABL1). The fusion is the result of a reciprocal translocation t(1;9)(p34;q34) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The role of the partner gene SFPQ in this fusion remains to be investigated. SFPQ encodes for a protein belonging to a new functionally related group of fusion partners for tyrosine kinases involved in pre-mRNA processing. The presence of 2 coiled-coil domains in the 9 remaining exons of SFPQ could theoretically lead to SFPQABL1 oligomerization, thus leading to constitutive activation of the resulting tyrosine kinase, as reported with other partner genes. Though uncommon, this translocation might be targeted by tyrosine kinase inhibitors. Clinical significance: The SFPQ -ABL1 fusion has been documented in six patients (3 male, 3 female) between the ages of 10 and 34 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (dasatinib + imatinib) added to their chemotherapy regimens, who did not have relapse. One additional patient who did not have tyrosine kinase inhibitor also did not suffer from relapse. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.","The SFPQ -ABL1 fusion is composed of part of the SFPQ (Splicing factor proline and glutamine rich) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3 end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 9 of SFPQ to exon 4 of ABL1 (SFPQ -ABL1). The fusion is the result of a reciprocal translocation t(1;9)(p34;q34) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The role of the partner gene SFPQ in this fusion remains to be investigated. SFPQ encodes for a protein belonging to a new functionally related group of fusion partners for tyrosine kinases involved in pre-mRNA processing. The presence of 2 coiled-coil domains in the 9 remaining exons of SFPQ could theoretically lead to SFPQABL1 oligomerization, thus leading to constitutive activation of the resulting tyrosine kinase, as reported with other partner genes. Though uncommon, this translocation might be targeted by tyrosine kinase inhibitors. Clinical significance: The SFPQ -ABL1 fusion has been documented in six patients (3 male, 3 female) between the ages of 10 and 34 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (dasatinib + imatinib) added to their chemotherapy regimens, who did not have relapse. One additional patient who did not have tyrosine kinase inhibitor also did not suffer from relapse. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.",['SFPQ-ABL1'],"[9156, 9157, 9158, 9159, 9160, 9161, 9362]","{<CIViC source 3223>, <CIViC source 3883>, <CIViC source 2996>, <CIViC source 3882>, <CIViC source 3881>, <CIViC source 3884>, <CIViC source 3885>}",[],[],[3287]
3157,CDKN2A D108N,0.0,,,[],[9172],{<CIViC source 3897>},[],[],[3288]
3158,CTCF P378L,0.0,,,[],[9173],{<CIViC source 3898>},[],[],[3289]
3159,PIK3CB E1051K,0.0,,,[],[9174],{<CIViC source 3899>},[],[],[3290]
3160,NF1 R1276Q,0.0,,,[],[9175],{<CIViC source 3900>},[],[],[3292]
3161,PIK3CA D939G,0.0,,,[],[9176],{<CIViC source 3901>},[],[],[3293]
3162,VHL L101G (c.301_302delCTinsGG),0.0,,,[],[9183],{<CIViC source 3870>},[],[],[3294]
3163,VHL F136V (c.406T>G),0.0,,,[],[9193],{<CIViC source 3915>},[],[],[3295]
3164,VHL Null (rearrangement),0.0,,,[],[10696],{<CIViC source 4374>},[],[],[3296]
3165,VHL Null (11 kb 3' deletion),0.0,,,[],[9209],{<CIViC source 3919>},[],[],[3297]
3166,VHL P81S (c.241C>T) and L188V (c.562C>G),0.0,,,[],"[9210, 5538]","{<CIViC source 2267>, <CIViC source 3919>}",[],[],[3298]
3167,PPP2R1A P179R,4.0,,,[],[9212],{<CIViC source 3920>},[],[],[3299]
3168,SPOP R121Q,0.0,,,[],[9215],{<CIViC source 3866>},[],[],[3300]
3169,SPOP M117I,0.0,,,[],[9216],{<CIViC source 3866>},[],[],[3301]
3170,TYK2 Pro1104Ala,0.0,,,[],[9218],{<CIViC source 3943>},[],[],[3302]
3172,EGFR N771_P772insL,2.5,,,[],[9221],{<CIViC source 3023>},[],[],[3304]
3173,TNFRSF17 Gain,0.0,,,[],[9226],{<CIViC source 3948>},[],[],[3305]
3174,HDAC9 Overexpression,0.0,,,[],"[9230, 9855]","{<CIViC source 3951>, <CIViC source 4196>}",[],[],[3306]
3175,FOXF1 Overexpression,0.0,,,[],[9233],{<CIViC source 3954>},[],[],[3307]
3176,FLT3 N841T,0.0,,,[],[9237],{<CIViC source 1009>},[],[],[3308]
3177,ATRX Deletion,3.0,,,[],[9239],{<CIViC source 3957>},[],[],[3309]
3178,HDAC9 p.L33R,0.0,,,[],[9240],{<CIViC source 3958>},[],[],[3310]
3180,BAG4::FGFR1 Fusion,0.0,,,['BAG4-FGFR1'],[9243],{<CIViC source 3447>},[],[],[3312]
3181,CDKN1A rs1059234,15.0,,,[],[9244],{<CIViC source 2840>},[],[],[3313]
3182,CDKN1A rs1801270 and rs1059234,0.0,,,[],[9245],{<CIViC source 2840>},[],[],[3314]
3184,MEN1 Loss-of-function,0.0,,,[],[9249],{<CIViC source 3964>},[],[],[3316]
3185,VHL N174Lfs (c.520_521del),0.0,,,[],[9257],{<CIViC source 3968>},[],[],[3317]
3186,TP53 P250L,5.0,,,[],[9285],{<CIViC source 3868>},[],[],[3318]
3187,BTK Expression,0.0,,,[],[9287],{<CIViC source 3978>},[],[],[3319]
3188,BLK Expression,0.0,,,[],[9288],{<CIViC source 3978>},[],[],[3320]
3189,VEGFA VEGF165b Overexpression,0.0,,,[],[9289],{<CIViC source 3981>},[],[],[3321]
3190,VEGFA overexpression of VEGF-Axxxa,0.0,,,[],[9290],{<CIViC source 3982>},[],[],[3322]
3191,VEGFA low ratio of VEGF165b/VEGFtotal,0.0,,,[],"[9296, 9358]",{<CIViC source 3986>},[],[],[3323]
3192,VEGFA Overexpression of VEGF121,0.0,,,[],"[9490, 9297]","{<CIViC source 4068>, <CIViC source 3987>}",[],[],[3324]
3193,VEGFA Overexpression of VEGF121 and VEGF110,0.0,,,[],"[9300, 9298, 9299, 9301]","{<CIViC source 3989>, <CIViC source 3991>, <CIViC source 2830>, <CIViC source 3990>}",[],[],[3325]
3194,FLT3 Q575,0.0,,,[],"[9302, 9303, 9304]",{<CIViC source 3988>},[],[],[3326]
3195,FLT3 Y572,0.0,,,[],"[9305, 9306]",{<CIViC source 3988>},[],[],[3327]
3196,FLT3 E573,0.0,,,[],"[9307, 9309]",{<CIViC source 3988>},[],[],[3328]
3197,FLT3 S574,0.0,,,[],"[9308, 9310]",{<CIViC source 3988>},[],[],[3329]
3198,TCF19 EXPRESSION,0.0,,,[],[9314],{<CIViC source 3995>},[],[],[3330]
3199,LZTR1 G248R,0.0,,,[],[9317],{<CIViC source 3997>},[],[],[3331]
3200,CDKN2A E88K,0.0,,,[],[9318],{<CIViC source 3872>},[],[],[3332]
3201,CDKN2A D84Y,0.0,,,[],[9319],{<CIViC source 3872>},[],[],[3333]
3202,CDKN2A D84H,0.0,,,[],[9320],{<CIViC source 3872>},[],[],[3334]
3203,CDKN2A L16P,0.0,,,[],"[9321, 9322]",{<CIViC source 3872>},[],[],[3335]
3204,PIK3CA E39K,0.0,,,[],[9324],{<CIViC source 4006>},[],[],[3336]
3205,PIK3CA C604R,0.0,,,[],[9325],{<CIViC source 4006>},[],[],[3337]
3206,PIK3CA D350N,0.0,,,[],[9326],{<CIViC source 4006>},[],[],[3338]
3207,CTCF R377H,0.0,,,[],[9327],{<CIViC source 3898>},[],[],[3339]
3208,PTEN H93R,0.0,,,[],[9328],{<CIViC source 3875>},[],[],[3340]
3209,KRAS G10_A11insG,4.0,,,[],[9330],{<CIViC source 4009>},[],[],[3341]
3210,KRAS A11_G12insGA,4.0,,,[],[9331],{<CIViC source 4009>},[],[],[3342]
3211,SPOP E47K,0.0,,,[],[9332],{<CIViC source 3866>},[],[],[3343]
3212,EGFR R222C,2.0,,,['ARG222CYS'],"[9638, 9646, 9655, 9333]","{<CIViC source 4099>, <CIViC source 4006>}",[],[],[3344]
3213,SPOP E50K,0.0,,,[],[9334],{<CIViC source 3866>},[],[],[3345]
3214,SPOP G75R,0.0,,,[],[9335],{<CIViC source 3866>},[],[],[3346]
3215,SPOP S80R,0.0,,,[],[9336],{<CIViC source 3866>},[],[],[3347]
3216,SPOP P94A,0.0,,,[],[9337],{<CIViC source 3866>},[],[],[3348]
3217,SPOP D140G,0.0,,,[],[9338],{<CIViC source 3866>},[],[],[3349]
3218,KDR R1032Q,2.0,,,[],"[9339, 9957]",{<CIViC source 4010>},[],[],[3350]
3219,VHL t(3;8)(p13;q24.1),0.0,,,[],[9340],{<CIViC source 4011>},[],[],[3351]
3220,VHL Y98Afs(c.282_291dup),0.0,,,[],[9342],{<CIViC source 4013>},[],[],[3352]
3221,VHL P192R (c.575C>G),0.0,,,[],[9343],{<CIViC source 4014>},[],[],[3353]
3222,VHL K159* (c.474_475insT),0.0,,,[],[9348],{<CIViC source 4015>},[],[],[3354]
3223,VHL R177SFS*22 (c.531_542delinsTC),0.0,,,[],"[9350, 10300]",{<CIViC source 3974>},[],[],[3355]
3224,FGFR2 Y375C,0.0,,,[],"[11640, 9355]","{<CIViC source 4823>, <CIViC source 4016>}",[],[],[3356]
3225,FGFR2 C342R,0.0,,,[],[9356],{<CIViC source 4016>},[],[],[3357]
3226,FGFR2 C342Y,0.0,,,[],[9357],{<CIViC source 4016>},[],[],[3358]
3227,TBL1XR1::CSF1R Fusion,7.5,"The TBL1XR1-CSF1R fusion is composed of part of the TBL1XR1 (Transducin Beta Like 1 X-Linked Receptor 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (Colony Stimulating Factor 1 Receptor) gene at the 3 end (C-terminus of the fusion protein). CSF1R is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The breakpoint is not published, but is predicted to be the result of a reciprocal translocation t(3;5)(q26.32;q32) and has been identified by RNA sequencing in a single pediatric patient. The consequence of this fusion with respect to treatment response and disease outcome is unknown.","The TBL1XR1-CSF1R fusion is composed of part of the TBL1XR1 (Transducin Beta Like 1 X-Linked Receptor 1) gene at the 5 end (N-terminus of the fusion protein), and part of the ABL1 (Colony Stimulating Factor 1 Receptor) gene at the 3 end (C-terminus of the fusion protein). CSF1R is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The breakpoint is not published, but is predicted to be the result of a reciprocal translocation t(3;5)(q26.32;q32) and has been identified by RNA sequencing in a single pediatric patient. The consequence of this fusion with respect to treatment response and disease outcome is unknown.",['TBL1XR1-CSF1R'],[9361],{<CIViC source 2498>},[],[],[3359]
3228,VHL D92V (c.275A>T),0.0,,,[],[9365],{<CIViC source 4020>},[],[],[3360]
3229,VHL Null (del one VHL allele),0.0,,,[],[9371],{<CIViC source 3974>},[],[],[3361]
3230,VHL V166SFS*4 (c.496_506del),0.0,,,[],"[9387, 9373]","{<CIViC source 4020>, <CIViC source 3974>}",[],[],[3362]
3231,VHL F136LFS*23 (c.408del),0.0,,,[],"[9375, 10308, 10984, 9391]","{<CIViC source 4020>, <CIViC source 3974>, <CIViC source 4473>}",[],[],[3363]
3232,EZH2 Y646H,8.0,,,"['Y641H', 'TYR641HIS', 'TYR646HIS']","[9377, 9521]","{<CIViC source 2517>, <CIViC source 4070>}",[],[],[3364]
3233,VHL c.463+37_463+39del,0.0,,,[],[9380],{<CIViC source 4020>},[],[],[3365]
3234,VHL V130Wfs*30 (c.385_386dup),0.0,,,[],"[9381, 9971, 10455]","{<CIViC source 2285>, <CIViC source 4020>, <CIViC source 2179>}",[],[],[3366]
3235,CD44 CD4v8-v10 and CD44v3-v10,0.0,,,[],[9395],{<CIViC source 556>},[],[],[3367]
3236,CD44 CD44v9,0.0,,,[],[9396],{<CIViC source 4024>},[],[],[3368]
3237,CD44 CD44v8-10,0.0,,,[],"[9397, 9434]","{<CIViC source 4052>, <CIViC source 4025>}",[],[],[3369]
3238,VHL Splice site (c.463+2A>C),0.0,,,[],[9400],{<CIViC source 4029>},[],[],[3370]
3239,ALK I1171T,10.0,,,[],[9404],{<CIViC source 4032>},[],[],[3371]
3240,MET M1250T,0.0,,,"['MET1268THR', 'MET1250THR', 'M1268T']",[9405],{<CIViC source 4033>},[],[],[3372]
3241,CD44 CD44v6,20.0,,,[],"[9407, 9408, 9406, 9427, 9481, 9438, 9429, 9430]","{<CIViC source 4034>, <CIViC source 4054>, <CIViC source 4048>, <CIViC source 4046>, <CIViC source 4066>, <CIViC source 4035>, <CIViC source 4036>}",[],[],[3373]
3242,CDKN2A D84G,0.0,,,[],[9409],{<CIViC source 4038>},[],[],[3374]
3243,CDKN2A D84V,0.0,,,[],[9410],{<CIViC source 4038>},[],[],[3375]
3244,CDKN2A R87P,0.0,,,[],[9411],{<CIViC source 4038>},[],[],[3376]
3245,CDKN2A P48L,0.0,,,[],[9413],{<CIViC source 4038>},[],[],[3377]
3246,H3-3A G34V,0.0,,,[],"[9415, 9822, 9818, 9823]","{<CIViC source 4177>, <CIViC source 4176>, <CIViC source 3965>}",[],[],[3378]
3247,H3-3A G34R,15.0,,,[],"[9416, 9526, 9610, 9817, 9820, 9821, 9609, 9839]","{<CIViC source 4177>, <CIViC source 2560>, <CIViC source 3965>, <CIViC source 3966>, <CIViC source 4176>, <CIViC source 4178>}",[],[],[3379]
3248,CDKN2A D108H,0.0,,,[],[9419],{<CIViC source 3004>},[],[],[3380]
3249,PIK3R2 G373R,1.0,,,[],[9420],{<CIViC source 3927>},[],[],[3381]
3250,PTEN C136R,3.0,,,[],[9421],{<CIViC source 4043>},[],[],[3382]
3251,VHL E52*(c.156G>T),0.0,,,[],[9422],{<CIViC source 2174>},[],[],[3383]
3252,CDKN2A P81T,0.0,,,[],[9424],{<CIViC source 4044>},[],[],[3384]
3253,CD44 CD44s,0.0,,,[],[9426],{<CIViC source 4045>},[],[],[3385]
3254,CD44 CD44v5 and CD44v6,0.0,,,[],[9432],{<CIViC source 4050>},[],[],[3386]
3255,CD44 CD44v6+/CD44s-,0.0,,,[],[9433],{<CIViC source 4051>},[],[],[3387]
3256,CD44 CD44v6 and CD44v10,0.0,,,[],[9435],{<CIViC source 4053>},[],[],[3388]
3257,TP53 C176F,0.0,,,[],"[10567, 9443]","{<CIViC source 4058>, <CIViC source 4356>}",[],[],[3389]
3258,TP53 R181P,3.0,,,[],"[10531, 9445]","{<CIViC source 4058>, <CIViC source 4356>}",[],[],[3390]
3259,TP53 S183L,0.0,,,[],[9446],{<CIViC source 4058>},[],[],[3391]
3260,TP53 L194R,0.0,,,[],[9447],{<CIViC source 4058>},[],[],[3392]
3261,TP53 C238F,0.0,,,[],[9448],{<CIViC source 4058>},[],[],[3393]
3262,TP53 N239D,0.0,,,[],[9449],{<CIViC source 4058>},[],[],[3394]
3263,TP53 N239T,0.0,,,[],[9450],{<CIViC source 4058>},[],[],[3395]
3264,TP53 M243T,0.0,,,[],[9454],{<CIViC source 4058>},[],[],[3396]
3265,TP53 G244V,0.0,,,[],[9455],{<CIViC source 4058>},[],[],[3397]
3266,TP53 M246A,0.0,,,[],[9457],{<CIViC source 4058>},[],[],[3398]
3267,TP53 M246T,0.0,,,[],[9458],{<CIViC source 4058>},[],[],[3399]
3268,TP53 R249G,0.0,,,[],[9460],{<CIViC source 4058>},[],[],[3400]
3269,TP53 D259V,2.0,,,[],"[9462, 10269]","{<CIViC source 4058>, <CIViC source 4271>}",[],[],[3401]
3270,TP53 K305M,0.0,,,[],[9467],{<CIViC source 4058>},[],[],[3402]
3271,PTEN T277R,0.0,,,[],[9469],{<CIViC source 4062>},[],[],[3403]
3272,PTEN c.209+5G>A,0.0,,,[],[9470],{<CIViC source 4062>},[],[],[3404]
3273,PTEN Y336*,0.0,,,[],[9471],{<CIViC source 4062>},[],[],[3405]
3274,PTEN T277I,0.0,,,[],[9472],{<CIViC source 4061>},[],[],[3406]
3275,PTEN T277A,0.0,,,[],[9473],{<CIViC source 4060>},[],[],[3407]
3276,TEK Cis double mutants,0.0,,,[],[9474],{<CIViC source 3903>},[],[],[3408]
3277,TEK T1105N and T1106N,0.0,,,[],"[9475, 9478]",{<CIViC source 3903>},[],[],[3409]
3278,TEK Y897C and R915C,0.0,,,[],[9476],{<CIViC source 3903>},[],[],[3410]
3279,TEK R849W and R1108*,0.0,,,[],[9477],{<CIViC source 3903>},[],[],[3411]
3280,MTOR T1977R,0.0,,,[],[9480],{<CIViC source 911>},[],[],[3412]
3281,MTOR C1483R,0.0,,,[],[9487],{<CIViC source 4059>},[],[],[3413]
3282,MTOR L2427Q,0.0,,,[],[9488],{<CIViC source 4059>},[],[],[3414]
3283,AR Overexpression of AR-V9,0.0,,,[],[9491],{<CIViC source 2338>},[],[],[3415]
3284,TP53 A138V,0.0,,,[],[9492],{<CIViC source 4058>},[],[],[3416]
3285,TP53 T125R,0.0,,,[],[9498],{<CIViC source 4058>},[],[],[3417]
3286,TP53 P151A,0.0,,,[],[9501],{<CIViC source 4058>},[],[],[3418]
3287,TP53 G154S,0.0,,,[],[9502],{<CIViC source 4058>},[],[],[3419]
3288,TP53 R174K,0.0,,,[],[9503],{<CIViC source 4058>},[],[],[3420]
3289,TP53 R267Q,0.0,,,[],[9508],{<CIViC source 4058>},[],[],[3421]
3290,TP53 R283P,0.0,,,[],[9510],{<CIViC source 4058>},[],[],[3422]
3291,TP53 R337C,0.0,,,[],[9511],{<CIViC source 4058>},[],[],[3423]
3292,TP53 R337H,0.0,,,[],[9512],{<CIViC source 4058>},[],[],[3424]
3293,BRAF G469S,0.0,,,[],[9515],{<CIViC source 3009>},[],[],[3425]
3297,ARHGAP35 R997*,0.0,,,[],[9523],{<CIViC source 4071>},[],[],[3429]
3298,NFE2L2 E82D,0.0,,,[],[9524],{<CIViC source 4072>},[],[],[3430]
3299,CIC R215W,0.0,,,[],[9525],{<CIViC source 4073>},[],[],[3431]
3300,BRAF G463E,3.0,,,[],[9527],{<CIViC source 1161>},[],[],[3432]
3301,RRAS2 Q72L,0.0,,,[],[9528],{<CIViC source 4074>},[],[],[3433]
3302,PIK3CA R93Q,0.0,,,[],[9529],{<CIViC source 1476>},[],[],[3434]
3304,VHL Splice Site (c.341-6C>T),0.0,,,[],[9535],{<CIViC source 2320>},[],[],[3436]
3305,PIK3CA G1007R,0.0,,,[],[9543],{<CIViC source 4006>},[],[],[3437]
3306,PIK3CA N1044K,0.0,,,[],[9551],{<CIViC source 4006>},[],[],[3438]
3307,MTOR R2152C,0.0,,,[],[9556],{<CIViC source 911>},[],[],[3439]
3308,KLF4 K409Q,0.0,,,[],[9557],{<CIViC source 4089>},[],[],[3440]
3309,BRAF G468A,0.0,,,[],[9558],{<CIViC source 1161>},[],[],[3441]
3310,BRAF G463V,0.0,,,[],[9559],{<CIViC source 1161>},[],[],[3442]
3311,BRAF G465A,0.0,,,[],[9560],{<CIViC source 1161>},[],[],[3443]
3312,BRAF N580S,0.0,,,[],[9561],{<CIViC source 1161>},[],[],[3444]
3313,BRAF T598I,0.0,,,[],[9562],{<CIViC source 1161>},[],[],[3445]
3314,BRAF V599E,0.0,,,[],[9563],{<CIViC source 1161>},[],[],[3446]
3315,BRAF R461I,0.0,,,[],[9564],{<CIViC source 1161>},[],[],[3447]
3316,BRAF I462S,0.0,,,[],[9565],{<CIViC source 1161>},[],[],[3448]
3317,BRAF E585K,0.0,,,[],[9566],{<CIViC source 1161>},[],[],[3449]
3318,BRAF F594L,0.0,,,[],[9567],{<CIViC source 1161>},[],[],[3450]
3319,BRAF L596V,0.0,,,[],[9568],{<CIViC source 1161>},[],[],[3451]
3320,BRAF V600D,0.0,,,[],[9569],{<CIViC source 1161>},[],[],[3452]
3321,BRAF V599K,0.0,,,[],[9570],{<CIViC source 1161>},[],[],[3453]
3322,BRAF V599R,0.0,,,[],[9571],{<CIViC source 1161>},[],[],[3454]
3323,BRAF K600E,0.0,,,[],[9572],{<CIViC source 1161>},[],[],[3455]
3324,EP300 Y1414C,0.0,,,[],[9573],{<CIViC source 4090>},[],[],[3456]
3325,NFE2L2 G31A,3.0,,,[],[9574],{<CIViC source 4091>},[],[],[3457]
3326,PIK3CA P447_L455del,0.0,,,[],[9575],{<CIViC source 4092>},[],[],[3458]
3327,AR V1 expression,0.0,,,[],[9577],{<CIViC source 4094>},[],[],[3459]
3328,AR AR alternative transcripts,0.0,,,[],"[9578, 12258, 12259]","{<CIViC source 5161>, <CIViC source 5160>, <CIViC source 4095>}",[],[],[3460]
3329,AR V567es expression,0.0,,,[],[9579],{<CIViC source 4096>},[],[],[3461]
3330,TP53 E285V,0.0,,,[],[9580],{<CIViC source 4097>},[],[],[3462]
3331,PALB2 R414X,0.0,,,[],[9581],{<CIViC source 1403>},[],[],[3463]
3332,EGFR E114K,0.0,,,['GLU114LYS'],"[9587, 9585, 9586, 9584]","{<CIViC source 4099>, <CIViC source 4006>}",[],[],[3464]
3333,TPR::NTRK1 Fusion,17.5,,,['TPR-NTRK1'],"[11706, 11746, 11748, 9589, 11744, 11747, 11851, 11704, 11705]","{<CIViC source 2978>, <CIViC source 4360>, <CIViC source 4889>, <CIViC source 4951>, <CIViC source 2878>, <CIViC source 4853>, <CIViC source 4892>, <CIViC source 4891>, <CIViC source 4854>}",[],[],[3465]
3334,NTRK1 Point Mutations,0.0,,,[],[9590],{<CIViC source 2978>},[],[],[3466]
3335,NTRK3 Point Mutations,0.0,,,[],[9591],{<CIViC source 2978>},[],[],[3467]
3336,NTRK3 F617L,5.0,,,[],"[11571, 9592]",{<CIViC source 2978>},[],[],[3468]
3338,EGFR R165Q,0.0,,,['ARG165GLN'],"[9597, 9595, 9596]",{<CIViC source 4099>},[],[],[3470]
3339,KRAS KRAS4A underexpression,0.0,,,[],"[9598, 9599, 9600, 9602]","{<CIViC source 4102>, <CIViC source 4101>, <CIViC source 2500>, <CIViC source 4100>}",[],[],[3471]
3340,KRAS KRAS4A,0.0,,,[],[9601],{<CIViC source 4102>},[],[],[3472]
3341,TNC TNC-L,0.0,,,[],"[9604, 9603]","{<CIViC source 4104>, <CIViC source 4103>}",[],[],[3473]
3342,CEACAM1 CEACAM1-L,0.0,,,[],"[9605, 9606]","{<CIViC source 4106>, <CIViC source 4105>}",[],[],[3474]
3343,CEACAM1 CEACAM1-S,0.0,,,[],[9607],{<CIViC source 4107>},[],[],[3475]
3344,H3-3A K27,0.0,,,[],"[9608, 9812]","{<CIViC source 3966>, <CIViC source 4176>}",[],[],[3476]
3345,ESR2 beta-2 and beta-5,0.0,,,[],"[9611, 9617]","{<CIViC source 4111>, <CIViC source 4108>}",[],[],[3477]
3346,ESR2 underexpression beta-1,0.0,,,[],"[9612, 9613, 9618, 9619]","{<CIViC source 4109>, <CIViC source 4113>, <CIViC source 4110>, <CIViC source 4112>}",[],[],[3478]
3347,VHL T124del (c.369_371del),0.0,,,[],[9614],{<CIViC source 3517>},[],[],[3479]
3348,VHL L198P (c.593T>C) and P25L (c.74C>T),0.0,,,[],[9615],{<CIViC source 3972>},[],[],[3480]
3349,ESR2 alternative transcripts,0.0,,,[],[9620],{<CIViC source 4114>},[],[],[3481]
3350,LGR5 delta5,0.0,,,[],"[9621, 9622]","{<CIViC source 4115>, <CIViC source 4116>}",[],[],[3482]
3351,LGR5 LGR5FL,0.0,,,[],[9623],{<CIViC source 4117>},[],[],[3483]
3352,FN1 EDB,0.0,,,[],"[9624, 9625, 9626]","{<CIViC source 4120>, <CIViC source 4118>, <CIViC source 4119>}",[],[],[3484]
3353,DNMT3A R736H,0.0,,,[],[9628],{<CIViC source 4123>},[],[],[3485]
3354,TOP2A TOP2A/90,0.0,,,[],"[9634, 9635]","{<CIViC source 4128>, <CIViC source 4130>}",[],[],[3486]
3355,BRCA1 delta11q,0.0,,,[],[9636],{<CIViC source 4133>},[],[],[3487]
3356,EGFR G63R,0.0,,,['GLY63ARG'],"[9637, 9645]",{<CIViC source 4099>},[],[],[3488]
3357,EGFR P596L,0.0,,,['PRO596LEU'],"[9640, 9648, 9658]",{<CIViC source 4099>},[],[],[3489]
3358,EGFR K708R,0.0,,,['LYS708ARG'],"[9641, 9649, 9659]",{<CIViC source 4099>},[],[],[3490]
3359,VHL P2=(c.6C>G),0.0,,,[],"[9654, 10661]",{<CIViC source 2632>},[],[],[3491]
3360,CTNNB1 G34E,0.0,,,[],[9665],{<CIViC source 3103>},[],[],[3492]
3361,VHL N150fs (c.446delC),0.0,,,[],[9666],{<CIViC source 2634>},[],[],[3493]
3363,ERBB3 D297Y,0.0,,,[],[9675],{<CIViC source 2134>},[],[],[3495]
3364,ERBB4 E317K,0.0,,,[],[9678],{<CIViC source 2134>},[],[],[3496]
3365,ERBB2 S1050L,0.0,,,[],[9680],{<CIViC source 2134>},[],[],[3497]
3366,ERBB3 R1202W,0.0,,,[],[9681],{<CIViC source 2134>},[],[],[3498]
3367,ERCC2 Y72C,0.0,,,[],"[11504, 9685]","{<CIViC source 1143>, <CIViC source 3867>}",[],[],[3499]
3368,ERCC2 Y14C,0.0,,,[],[9686],{<CIViC source 3867>},[],[],[3500]
3369,ERCC2 Y24C,0.0,,,[],[9687],{<CIViC source 3867>},[],[],[3501]
3370,ERCC2 S44L,0.0,,,[],"[11502, 9688]","{<CIViC source 1143>, <CIViC source 3867>}",[],[],[3502]
3371,ERCC2 T46S,0.0,,,[],[9689],{<CIViC source 3867>},[],[],[3503]
3372,ERCC2 E79D,0.0,,,[],[9690],{<CIViC source 3867>},[],[],[3504]
3373,ERCC2 E86Q,0.0,,,[],"[11503, 9691, 9746, 9747]","{<CIViC source 4149>, <CIViC source 1143>, <CIViC source 4150>, <CIViC source 3867>}",[],[],[3505]
3374,ERCC2 Y209C,0.0,,,[],[9692],{<CIViC source 3867>},[],[],[3506]
3375,ERCC2 V242F,0.0,,,[],[9693],{<CIViC source 3867>},[],[],[3507]
3376,CD274 v242,0.0,,,[],[9695],{<CIViC source 4134>},[],[],[3508]
3377,AIMP2 DX2,0.0,,,[],[9696],{<CIViC source 4135>},[],[],[3509]
3378,BCL2L11 Alternative splicing,0.0,,,[],[9699],{<CIViC source 4138>},[],[],[3510]
3379,"CD19 delta-ex2, delta-ex5-6",0.0,,,[],[9700],{<CIViC source 4139>},[],[],[3511]
3380,BRAF p61BRAF(V600E),0.0,,,[],"[9703, 9702]",{<CIViC source 1950>},[],[],[3512]
3381,VHL L140fs*3 (c.419_420delTC),0.0,,,[],[9704],{<CIViC source 4020>},[],[],[3513]
3382,FGFR3 Y647C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['TYR647CYS '],[9705],{<CIViC source 4142>},[],[],[3514]
3383,FGFR3 M528I,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['MET528ILE'],"[9706, 9948]",{<CIViC source 4143>},[],[],[3515]
3384,FGFR3 F384L,0.0,"This variant was not activating and unable to transform NIH3T3 cells compared to activating mutations in FGFR3. 
This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.","This variant was not activating and unable to transform NIH3T3 cells compared to activating mutations in FGFR3. 
This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.","['PHE384LEU', 'F386L', 'PHE386LEU']","[6415, 9707, 10410]","{<CIViC source 2534>, <CIViC source 4143>, <CIViC source 4337>}",[],[],[3516]
3385,TAF15::ZNF384 Fusion,0.0,,,['TAF15-ZNF384'],[9708],{<CIViC source 4144>},[],[],[3517]
3387,SMAD4 R496H,0.0,,,[],[9710],{<CIViC source 3047>},[],[],[3519]
3388,SMAD4 G419V,0.0,,,[],[9711],{<CIViC source 3047>},[],[],[3520]
3389,SMAD4 E330K,0.0,,,[],[9712],{<CIViC source 3047>},[],[],[3521]
3390,SMAD4 G386D,0.0,,,[],[9714],{<CIViC source 3047>},[],[],[3522]
3391,SMAD4 G252*,0.0,,,[],[9715],{<CIViC source 3047>},[],[],[3523]
3392,MECOM t(3;21)(q26.2;q22),0.0,,,[],[9719],{<CIViC source 4146>},[],[],[3524]
3393,PAG1::ABL2 Fusion,0.0,,,['PAG1-ABL2'],[9721],{<CIViC source 2495>},[],[],[3525]
3394,RCSD1::ABL2 Fusion,0.0,,,['RCSD1-ABL2'],"[9722, 9768, 9769, 9770, 9772, 9771, 7251, 9773]","{<CIViC source 3039>, <CIViC source 2495>, <CIViC source 4158>, <CIViC source 4159>, <CIViC source 2498>, <CIViC source 3101>, <CIViC source 3622>}",[],[],[3526]
3396,PTEN A126D,0.0,,,[],[9724],{<CIViC source 3875>},[],[],[3528]
3397,PTEN H93D,0.0,,,[],[9725],{<CIViC source 3875>},[],[],[3529]
3398,PTEN H93Q,0.0,,,[],[9726],{<CIViC source 3875>},[],[],[3530]
3399,PTEN H93Y,0.0,,,[],[9727],{<CIViC source 3875>},[],[],[3531]
3400,PTEN N94I,0.0,,,[],[9728],{<CIViC source 3875>},[],[],[3532]
3401,PTEN P95L,0.0,,,[],[9729],{<CIViC source 3875>},[],[],[3533]
3402,PTEN P96Q,0.0,,,[],[9730],{<CIViC source 3875>},[],[],[3534]
3403,PTEN Y88C,0.0,,,[],[9731],{<CIViC source 3875>},[],[],[3535]
3404,PTEN F90L,0.0,,,[],[9732],{<CIViC source 3875>},[],[],[3536]
3405,PTEN E91A,0.0,,,[],[9733],{<CIViC source 3875>},[],[],[3537]
3406,PTEN D92A,0.0,,,[],[9734],{<CIViC source 3875>},[],[],[3538]
3407,PTEN D92E,0.0,,,[],[9735],{<CIViC source 3875>},[],[],[3539]
3408,PTEN D92G,0.0,,,[],[9736],{<CIViC source 3875>},[],[],[3540]
3409,PTEN D92H,0.0,,,[],[9737],{<CIViC source 3875>},[],[],[3541]
3410,PTEN D92V,0.0,,,[],[9738],{<CIViC source 3875>},[],[],[3542]
3411,PTEN R15K,0.0,,,[],[9739],{<CIViC source 4148>},[],[],[3543]
3412,PTEN A121E,0.0,,,[],[9740],{<CIViC source 3875>},[],[],[3544]
3413,PTEN I122S,0.0,,,[],[9741],{<CIViC source 3875>},[],[],[3545]
3414,PTEN H123D,0.0,,,[],[9742],{<CIViC source 3875>},[],[],[3546]
3415,PTEN C124S,0.0,,,[],[9743],{<CIViC source 3875>},[],[],[3547]
3416,PTEN K125E,0.0,,,[],[9744],{<CIViC source 3875>},[],[],[3548]
3417,PTEN G127E,0.0,,,[],[9745],{<CIViC source 3875>},[],[],[3549]
3418,KMT2A::AFDN Fusion,0.0,,,"['MLL-AF6', 'MLL::AF6', 'KMT2A-MLLT4', 'KMT2A-AFDN']","[9748, 8515]",{<CIViC source 3562>},[],[],[3550]
3419,KMT2A::MLLT10 Fusion,0.0,,,"['MLL-AF10', 'MLL::AF10', 'KMT2A-MLLT10', 'KMT2A-AF10', 'KMT2A::AF10']",[9749],{<CIViC source 3562>},[],[],[3551]
3420,KMT2A::ABI1 Fusion,0.0,,,"['MLL-ABI1', 'MLL::ABI1']",[9750],{<CIViC source 3562>},[],[],[3552]
3421,PTEN D162G,0.0,,,[],[9752],{<CIViC source 3875>},[],[],[3553]
3422,PTEN V166I,0.0,,,[],[9753],{<CIViC source 3875>},[],[],[3554]
3423,PTEN I168F,0.0,,,[],[9754],{<CIViC source 3875>},[],[],[3555]
3424,PTEN P169H,0.0,,,[],[9755],{<CIViC source 3875>},[],[],[3556]
3425,PTEN S170R,0.0,,,[],[9756],{<CIViC source 3875>},[],[],[3557]
3426,PTEN T160I,0.0,,,[],[9757],{<CIViC source 3875>},[],[],[3558]
3427,PTEN G165E,0.0,,,[],[9758],{<CIViC source 3875>},[],[],[3559]
3428,PTEN G165V,0.0,,,[],[9759],{<CIViC source 3875>},[],[],[3560]
3429,PTEN G129V,0.0,,,[],[9761],{<CIViC source 3875>},[],[],[3561]
3430,PTEN G129R,0.0,,,[],[9762],{<CIViC source 3875>},[],[],[3562]
3431,PTEN G129E,0.0,,,[],[9763],{<CIViC source 3875>},[],[],[3563]
3432,PTEN K128N,0.0,,,[],[9764],{<CIViC source 3875>},[],[],[3564]
3433,PTEN A126S,0.0,,,[],[9765],{<CIViC source 3875>},[],[],[3565]
3434,SSBP2::CSF1R Fusion,0.0,,,['SSBP2-CSF1R'],"[9767, 9803]","{<CIViC source 3945>, <CIViC source 2498>}",[],[],[3566]
3435,VHL D121Y(c.361G>T),0.0,,,[],[9775],{<CIViC source 3870>},[],[],[3567]
3436,JAK2 Overexpression,0.0,,,[],[9776],{<CIViC source 4161>},[],[],[3568]
3437,STAT5B Overexpression,0.0,,,[],[9777],{<CIViC source 4162>},[],[],[3569]
3438,CCND1 P287S,0.0,,,[],[9780],{<CIViC source 4166>},[],[],[3570]
3439,CCND1 P287T,0.0,,,[],[9781],{<CIViC source 4166>},[],[],[3571]
3440,FLT3 I836S,0.0,,,[],[9782],{<CIViC source 4167>},[],[],[3572]
3441,FLT3 I836T,0.0,,,[],[9783],{<CIViC source 4167>},[],[],[3573]
3442,TP53 V157D,0.0,,,[],[9784],{<CIViC source 4168>},[],[],[3574]
3443,PMS2 R20Q,0.0,,,[],[9785],{<CIViC source 4168>},[],[],[3575]
3444,ERBB2 Q709L,0.0,,,[],"[9790, 9791]",{<CIViC source 3075>},[],[],[3576]
3446,ZC3HAV1::ABL2 Fusion,0.0,,,['ZC3HAV1-ABL2'],"[9804, 11620]","{<CIViC source 4184>, <CIViC source 2495>}",[],[],[3578]
3447,TP53 R342P,3.0,,,[],[9805],{<CIViC source 4185>},[],[],[3579]
3448,TP53 L330P,3.0,,,[],[9806],{<CIViC source 4185>},[],[],[3580]
3449,TP53 L330R,3.0,,,[],[9807],{<CIViC source 4185>},[],[],[3581]
3450,TP53 R337P,3.0,,,[],"[9808, 10582]","{<CIViC source 4356>, <CIViC source 4185>}",[],[],[3582]
3451,TP53 L344P,3.0,,,[],[9809],{<CIViC source 4185>},[],[],[3583]
3452,TP53 K120E,0.0,,,[],[9810],{<CIViC source 4186>},[],[],[3584]
3453,TP53 E180K,0.0,,,[],[9811],{<CIViC source 4186>},[],[],[3585]
3455,H3-3A G34,0.0,,,[],[9815],{<CIViC source 4176>},[],[],[3587]
3456,RIT1 M90I,0.0,,,[],"[9825, 9826]",{<CIViC source 490>},[],[],[3588]
3457,RIT1 Q79L,0.0,,,[],"[9827, 9828]",{<CIViC source 490>},[],[],[3589]
3458,RIT1 Q40L,0.0,,,[],[9829],{<CIViC source 490>},[],[],[3590]
3459,RIT1 A77P,0.0,,,[],"[9830, 9832]",{<CIViC source 490>},[],[],[3591]
3460,RIT1 A77S,0.0,,,[],"[9831, 9833]",{<CIViC source 490>},[],[],[3592]
3461,RIT1 F82L,0.0,,,[],"[9834, 9835]",{<CIViC source 490>},[],[],[3593]
3462,H3-3A K27R,0.0,,,[],"[9836, 9838]",{<CIViC source 4178>},[],[],[3594]
3463,TP53 V197E,0.0,,,[],[9846],{<CIViC source 4191>},[],[],[3595]
3464,TP53 K120R,0.0,,,[],[9847],{<CIViC source 4192>},[],[],[3596]
3465,DDR2 High expression,0.0,,,[],[9853],{<CIViC source 4194>},[],[],[3597]
3466,DDR2 Overexpression,0.0,,,[],[9854],{<CIViC source 4195>},[],[],[3598]
3467,HDAC6 Overexpression,0.0,,,[],[9856],{<CIViC source 4197>},[],[],[3599]
3468,ATXN7 Q39P,0.0,,,[],[9861],{<CIViC source 4200>},[],[],[3600]
3469,ATXN7 Q30R,0.0,,,[],[9862],{<CIViC source 4200>},[],[],[3601]
3470,ATXN7 P40Q,0.0,,,[],[9863],{<CIViC source 4200>},[],[],[3602]
3471,ATXN7 P42_P43insP,0.0,,,[],[9864],{<CIViC source 4200>},[],[],[3603]
3472,EZH2 R690C,0.0,,,['ARG690CYS'],[9865],{<CIViC source 4201>},[],[],[3604]
3473,EZH2 C576W,0.0,,,['CYS576TRP'],[9866],{<CIViC source 4201>},[],[],[3605]
3474,EZH2 Y731D,0.0,,,['TYR731ASP'],[9867],{<CIViC source 4201>},[],[],[3606]
3475,EZH2 Y646C,2.0,,,"['TYR646CYS', 'Y641C', 'TYR641CYS']","[11052, 9868]","{<CIViC source 4201>, <CIViC source 4540>}",[],[],[3607]
3476,BRCA2 R2842C,0.0,,,[],[9869],{<CIViC source 4202>},[],[],[3608]
3477,BRCA2 Y2726C,0.0,,,[],[9870],{<CIViC source 4202>},[],[],[3609]
3478,BRCA2 D2611G,0.0,,,[],[9871],{<CIViC source 4202>},[],[],[3610]
3479,BRCA2 D3073G,0.0,,,[],[9872],{<CIViC source 4202>},[],[],[3611]
3480,BRCA2 L2654P,0.0,,,[],[9873],{<CIViC source 4202>},[],[],[3612]
3481,BRCA2 G2793E,0.0,,,[],[9874],{<CIViC source 4202>},[],[],[3613]
3482,BRCA2 Y2660D,0.0,,,[],[9875],{<CIViC source 4202>},[],[],[3614]
3483,BRCA2 G2585R,0.0,,,[],[9876],{<CIViC source 4202>},[],[],[3615]
3484,BRCA2 G2793R,0.0,,,[],[9877],{<CIViC source 4202>},[],[],[3616]
3485,BRCA2 L2792P,0.0,,,[],[9878],{<CIViC source 4202>},[],[],[3617]
3486,BRCA2 R2659G,0.0,,,[],[9879],{<CIViC source 4202>},[],[],[3618]
3487,BRCA2 R2784Q,0.0,,,[],[9880],{<CIViC source 4202>},[],[],[3619]
3488,BRCA2 G3076V,0.0,,,[],[9881],{<CIViC source 4202>},[],[],[3620]
3489,BRCA2 E3002K,0.0,,,[],[9882],{<CIViC source 4202>},[],[],[3621]
3490,ASPSCR1::TFE3 Fusion,59.0,,,['ASPSCR1-TFE3'],"[9978, 11530, 11529, 11531, 11532, 9883, 9884]","{<CIViC source 4203>, <CIViC source 4205>, <CIViC source 4782>, <CIViC source 4784>, <CIViC source 4214>, <CIViC source 4783>}",[],[],[3622]
3491,BRCA2 G3076E,0.0,,,[],[9887],{<CIViC source 4202>},[],[],[3623]
3492,BRCA2 L2510P,0.0,,,[],[9888],{<CIViC source 4202>},[],[],[3624]
3493,BRCA2 D2723A,0.0,,,[],[9889],{<CIViC source 4202>},[],[],[3625]
3494,BRCA2 R2784W,0.0,,,[],[9890],{<CIViC source 4202>},[],[],[3626]
3495,BRCA2 W2626C,0.0,,,[],[9891],{<CIViC source 4202>},[],[],[3627]
3496,BRCA2 G2609D,0.0,,,[],[9892],{<CIViC source 4202>},[],[],[3628]
3497,BRCA2 T2722R,0.0,,,[],[9893],{<CIViC source 4202>},[],[],[3629]
3498,BRCA2 I2627F,0.0,,,[],[9894],{<CIViC source 4202>},[],[],[3630]
3499,BRCA2 D2723G,0.0,,,[],[9895],{<CIViC source 4202>},[],[],[3631]
3500,VHL F76fs (c.224_225insA),0.0,,,[],[9900],{<CIViC source 2324>},[],[],[3632]
3501,VHL R108dup (c.322_324dupCGC),0.0,,,[],[9910],{<CIViC source 2324>},[],[],[3633]
3502,VHL W117fs (c.349dupT),0.0,,,[],[9914],{<CIViC source 2324>},[],[],[3634]
3503,VHL E55* (c.162_163insT),0.0,,,[],[9934],{<CIViC source 1264>},[],[],[3635]
3504,FLT3 ITD & N841K,0.0,,,[],[9936],{<CIViC source 3643>},[],[],[3636]
3505,VHL G104FS (c.309_310delTG),0.0,,,[],[9938],{<CIViC source 1264>},[],[],[3637]
3506,BRCA2 L2688P,0.0,,,[],[9940],{<CIViC source 4202>},[],[],[3638]
3507,BRCA2 D2723H,0.0,,,[],[9941],{<CIViC source 4202>},[],[],[3639]
3508,BRCA2 L2647P,0.0,,,[],[9942],{<CIViC source 4202>},[],[],[3640]
3509,BRCA2 N3124I,0.0,,,[],[9943],{<CIViC source 4202>},[],[],[3641]
3510,BRCA2 L2653P,0.0,,,[],[9944],{<CIViC source 4202>},[],[],[3642]
3511,PIM1 L2V,3.0,,,[],[9945],{<CIViC source 4212>},[],[],[3643]
3512,PIM1 P81S,3.0,,,[],[9946],{<CIViC source 4212>},[],[],[3644]
3513,PIM1 S97N,3.0,,,[],[9947],{<CIViC source 4212>},[],[],[3645]
3514,HOXC10 Overexpression,0.0,,,[],"[10147, 9949]",{<CIViC source 4213>},[],[],[3646]
3515,KDR S1100F,0.0,,,[],[9950],{<CIViC source 4010>},[],[],[3647]
3516,KDR L840F,0.0,,,[],[9951],{<CIViC source 4010>},[],[],[3648]
3517,KDR G800D,0.0,,,[],[9952],{<CIViC source 4010>},[],[],[3649]
3518,KDR G800R,0.0,,,[],[9953],{<CIViC source 4010>},[],[],[3650]
3519,KDR G843D,0.0,,,[],[9954],{<CIViC source 4010>},[],[],[3651]
3520,KDR S925F,0.0,,,[],[9955],{<CIViC source 4010>},[],[],[3652]
3521,KDR R1022Q,0.0,,,[],[9956],{<CIViC source 4010>},[],[],[3653]
3522,VHL E55fs (c.163dupG),0.0,,,[],"[9966, 10854]","{<CIViC source 2179>, <CIViC source 4433>}",[],[],[3654]
3523,VHL N67_V74del (c.197_220del),0.0,,,[],[9968],{<CIViC source 2179>},[],[],[3655]
3524,VHL R108fs (c.322_323insTG),0.0,,,[],[9970],{<CIViC source 2179>},[],[],[3656]
3525,VHL Q203fs (c.607_608delCA),0.0,,,[],[9984],{<CIViC source 2179>},[],[],[3657]
3526,VHL R205fs (c.614_615delGC),0.0,,,[],[9985],{<CIViC source 2179>},[],[],[3658]
3527,SMARCB1 LOSS OF NUCLEAR PROTEIN EXPRESSION,15.0,,,[],"[12332, 12327, 12328]","{<CIViC source 5191>, <CIViC source 5192>, <CIViC source 5193>}",[],[],[3659]
3528,CYSLTR2 L129Q,0.0,,,[],[10010],{<CIViC source 4217>},[],[],[3660]
3529,ACVR1 R206H,5.0,,,[],[10012],{<CIViC source 2448>},[],[],[3661]
3530,ACVR1 G356D,5.0,,,[],[10015],{<CIViC source 2448>},[],[],[3662]
3531,BRAF Q524L,0.0,,,[],[10017],{<CIViC source 3006>},[],[],[3663]
3532,ERBB2 I767M,0.0,,,[],[10029],{<CIViC source 170>},[],[],[3664]
3533,ERBB2 Y835F,0.0,,,[],[10030],{<CIViC source 170>},[],[],[3665]
3534,PIK3CA K944N,10.0,,,[],[10031],{<CIViC source 2196>},[],[],[3666]
3535,PIK3CA F930S,10.0,,,[],[10032],{<CIViC source 2196>},[],[],[3667]
3536,PIK3CA V955G,10.0,,,[],[10033],{<CIViC source 2196>},[],[],[3668]
3537,PIK3CA K966E,10.0,,,[],[10034],{<CIViC source 2196>},[],[],[3669]
3538,PIK3CA L938*,7.5,,,[],[10035],{<CIViC source 2196>},[],[],[3670]
3539,FBXW7 R465C,0.0,,,[],[10041],{<CIViC source 2799>},[],[],[3671]
3540,FBXW7 R479Q,0.0,,,[],[10042],{<CIViC source 2799>},[],[],[3672]
3541,FBXW7 R505L,0.0,,,[],[10043],{<CIViC source 2799>},[],[],[3673]
3542,NOTCH1 S2514A,0.0,,,[],[10044],{<CIViC source 2799>},[],[],[3674]
3543,NOTCH1 T2512A,0.0,,,[],[10045],{<CIViC source 2799>},[],[],[3675]
3544,NOTCH1 S2514E,0.0,,,[],[10046],{<CIViC source 2799>},[],[],[3676]
3545,NOTCH1 S2514P,0.0,,,[],[10047],{<CIViC source 2799>},[],[],[3677]
3546,ETV6 R418G,0.0,,,[],[10049],{<CIViC source 1316>},[],[],[3678]
3547,ETV6 N385_R418del,0.0,,,[],[10050],{<CIViC source 1316>},[],[],[3679]
3548,JAK1 S729C,0.0,,,[],[10052],{<CIViC source 1332>},[],[],[3680]
3549,JAK1 N451S,0.0,,,[],"[10053, 10056]",{<CIViC source 1332>},[],[],[3681]
3550,JAK1 E483D,0.0,,,[],"[10054, 10057]",{<CIViC source 1332>},[],[],[3682]
3551,JAK1 A1086S,0.0,,,[],"[10055, 10058]",{<CIViC source 1332>},[],[],[3683]
3552,TP53 T125T,4.0,,,[],[10059],{<CIViC source 1696>},[],[],[3684]
3553,PTPRD R995C,0.0,,,[],[10061],{<CIViC source 1276>},[],[],[3685]
3554,PTPRD T781A,0.0,,,[],[10062],{<CIViC source 1276>},[],[],[3686]
3555,KMT2A Amplification,0.0,,,[],[10071],{<CIViC source 4219>},[],[],[3687]
3556,ABL2 W469C,0.0,,,[],[10077],{<CIViC source 2128>},[],[],[3688]
3557,ABL2 Y399C,0.0,,,[],[10078],{<CIViC source 2128>},[],[],[3689]
3558,PTPRB Y309C,0.0,,,[],[10080],{<CIViC source 1324>},[],[],[3690]
3559,PTPRB W130R,0.0,,,[],[10081],{<CIViC source 1324>},[],[],[3691]
3560,FGFR3 E466K,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['GLU466LYS'],"[10083, 10390]","{<CIViC source 4330>, <CIViC source 4142>}",[],[],[3692]
3561,FGFR3 N540K,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['ASN540LYS'],"[10084, 10389]","{<CIViC source 4330>, <CIViC source 4142>}",[],[],[3693]
3562,FGFR3 N540S,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['ASN540SER'],[10085],{<CIViC source 4142>},[4142],[<CIViC source 4142>],[3694]
3563,FGFR3 K650N,2.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['LYS650ASN'],"[10087, 10377]","{<CIViC source 4326>, <CIViC source 4142>}",[],[],[3695]
3564,FGFR3 R669G,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['RS1490564667'],[10088],{<CIViC source 4142>},[],[],[3696]
3565,FGFR3 R669Q,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ARG669GLN', 'RS773089715']",[10089],{<CIViC source 4142>},[4142],[<CIViC source 4142>],[3697]
3566,FGFR3 D617G,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['ASP617GLY'],[10090],{<CIViC source 4142>},[],[],[3698]
3567,FGFR3 G637W,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['GLY637TRP'],[10091],{<CIViC source 4142>},[],[],[3699]
3568,ETV6::NTRK1 Fusion,3.0,,,['ETV6-NTRK1'],[10096],{<CIViC source 1289>},[],[],[3700]
3569,VCL::NTRK2 Fusion,3.0,,,['VCL-NTRK2'],[10097],{<CIViC source 1289>},[],[],[3701]
3570,AFAP1::NTRK2 Fusion,3.0,,,['AFAP1-NTRK2'],[10098],{<CIViC source 1289>},[],[],[3702]
3571,GALNT14 rs9679162,0.0,,,[],[10100],{<CIViC source 4220>},[],[],[3703]
3572,VHL S72fs (c.214_215insGCCC),0.0,,,[],[10101],{<CIViC source 2190>},[],[],[3704]
3573,AR L57Q,0.0,,,[],[10114],{<CIViC source 4229>},[],[],[3705]
3574,AR D221H,0.0,,,[],[10115],{<CIViC source 4229>},[],[],[3706]
3575,AR E198G,0.0,,,[],[10116],{<CIViC source 4229>},[],[],[3707]
3576,AR A234T,0.0,,,[],[10117],{<CIViC source 4229>},[],[],[3708]
3577,AR S296R,0.0,,,[],[10118],{<CIViC source 4229>},[],[],[3709]
3578,AR S334P,0.0,,,[],[10119],{<CIViC source 4229>},[],[],[3710]
3579,AR P340L,0.0,,,[],[10120],{<CIViC source 4229>},[],[],[3711]
3580,AR P504L,0.0,,,[],[10121],{<CIViC source 4229>},[],[],[3712]
3581,AR D528G,0.0,,,[],[10122],{<CIViC source 4229>},[],[],[3713]
3582,AR K720E,0.0,,,[],[10123],{<CIViC source 4229>},[],[],[3714]
3583,VHL W117R (c.349T>C),0.0,,,[],[10124],{<CIViC source 1368>},[],[],[3715]
3584,AR R726L,0.0,,,[],[10126],{<CIViC source 4229>},[],[],[3716]
3585,AR L744F,0.0,,,[],[10127],{<CIViC source 4229>},[],[],[3717]
3586,AR A748V,0.0,,,[],[10128],{<CIViC source 4229>},[],[],[3718]
3587,AR N756D,0.0,,,[],[10129],{<CIViC source 4229>},[],[],[3719]
3588,VHL M3I(c.3G>A) and M211L (c.631A>C),0.0,,,[],[10130],{<CIViC source 3066>},[],[],[3720]
3589,AR V757A,0.0,,,[],[10131],{<CIViC source 4229>},[],[],[3721]
3590,AR V757I,0.0,,,[],[10132],{<CIViC source 4229>},[],[],[3722]
3591,AR S759P,0.0,,,[],[10133],{<CIViC source 4229>},[],[],[3723]
3592,AR Y763C,0.0,,,[],[10134],{<CIViC source 4229>},[],[],[3724]
3593,AR A765T,0.0,,,[],[10135],{<CIViC source 4229>},[],[],[3725]
3594,AR Q798E,0.0,,,[],[10136],{<CIViC source 4229>},[],[],[3726]
3595,FLCN c.1285dupC,2.5,,,['HIS429FS'],[10137],{<CIViC source 2417>},[],[],[3727]
3596,SLC29A1 Overexpression,20.0,,,[],[10145],{<CIViC source 4234>},[],[],[3728]
3598,v::TFE3 Fusion,65.0,,,"['Xp11.2 translocation', 'Xp11 translocation', 'TFE3 Fusion']","[10150, 11533, 11701, 11606, 10164, 10149, 11683]","{<CIViC source 4786>, <CIViC source 4239>, <CIViC source 4785>, <CIViC source 4842>, <CIViC source 4240>}",[],[],[3730]
3599,KIT Overexpression,0.0,,,[],[10152],{<CIViC source 4243>},[],[],[3731]
3600,HSP90B1 Overexpression,0.0,,,[],[10153],{<CIViC source 4244>},[],[],[3732]
3601,KRAS Overexpression,0.0,,,[],[10154],{<CIViC source 4245>},[],[],[3733]
3602,COX2 Overexpression,0.0,,,[],[10155],{<CIViC source 4246>},[],[],[3734]
3603,BRAF Overexpression,0.0,,,[],[10156],{<CIViC source 4247>},[],[],[3735]
3604,VHL G30Dfs*32 (c.89_297del),0.0,,,[],[10159],{<CIViC source 3543>},[],[],[3736]
3605,EZH2 Activating Mutation,35.0,,,[],"[9709, 11107]","{<CIViC source 4551>, <CIViC source 3977>}",[],[],[3737]
3606,VHL T133Nfs*2 (c.397dup),0.0,,,[],[10165],{<CIViC source 2599>},[],[],[3738]
3607,VHL Y175Tfs*27 (c.523del),0.0,,,[],[10168],{<CIViC source 2599>},[],[],[3739]
3608,NTRK1 NTRK1 amplification,0.0,,,[],[10169],{<CIViC source 2978>},[],[],[3740]
3609,VHL V87fs (c.255_256insC),0.0,,,[],[10171],{<CIViC source 2186>},[],[],[3741]
3610,G3BP2::KIT Fusion,0.0,,,['G3BP2-KIT'],[10172],{<CIViC source 4253>},[],[],[3742]
3611,VHL N150fs (c.448delA),0.0,,,[],[10176],{<CIViC source 2186>},[],[],[3743]
3612,VHL E55fs (c.163delG),0.0,,,[],[10178],{<CIViC source 2186>},[],[],[3744]
3613,CTCF K365T,3.0,,,[],[10179],{<CIViC source 3898>},[],[],[3745]
3614,CCNE2 Overexpression,0.0,,,[],"[10184, 10185]",{<CIViC source 4261>},[],[],[3746]
3615,VHL S111I (c.332G>T),0.0,,,[],[10186],{<CIViC source 4262>},[],[],[3747]
3616,VHL V165G (c.494T>G),0.0,,,[],[10187],{<CIViC source 4263>},[],[],[3748]
3617,VHL Exon 3 Variant,0.0,,,[],[10189],{<CIViC source 2580>},[],[],[3749]
3618,ARHGAP35 S866F,0.0,,,[],[10191],{<CIViC source 4071>},[],[],[3750]
3619,ARHGAP35 A865_L870delinsV,0.0,,,[],[10192],{<CIViC source 4071>},[],[],[3751]
3620,SSTR5 expression,15.0,,,[],[10193],{<CIViC source 4265>},[],[],[3752]
3621,VHL L140Sfs*4 (c.417dup),0.0,,,[],[10202],{<CIViC source 2655>},[],[],[3753]
3622,BACH2 E788K,0.0,,,[],[10207],{<CIViC source 4267>},[],[],[3754]
3623,BACH2 L24P,0.0,,,[],[10209],{<CIViC source 4267>},[],[],[3755]
3624,BAP1 C91S,0.0,,,[],[10210],{<CIViC source 4268>},[],[],[3756]
3625,SMAD3 R373H,0.0,,,[],[10211],{<CIViC source 4269>},[],[],[3757]
3626,U2AF1 I24T,0.0,,,[],[10212],{<CIViC source 4270>},[],[],[3758]
3627,VHL N174FS*29 (c.519insAA),0.0,,,[],[10213],{<CIViC source 3968>},[],[],[3759]
3628,TP53 P98S,3.0,,,[],[10215],{<CIViC source 4271>},[],[],[3760]
3629,TP53 P98L,3.0,,,[],[10216],{<CIViC source 4271>},[],[],[3761]
3630,TP53 Y126D,3.0,,,[],[10217],{<CIViC source 4271>},[],[],[3762]
3631,TP53 Y126S,3.0,,,[],[10218],{<CIViC source 4271>},[],[],[3763]
3632,TP53 K139E,3.0,,,[],[10219],{<CIViC source 4271>},[],[],[3764]
3633,TP53 P151S,3.0,,,[],[10220],{<CIViC source 4271>},[],[],[3765]
3635,TP53 P152L,6.0,,,[],"[10223, 10559]","{<CIViC source 4356>, <CIViC source 4271>}",[],[],[3767]
3636,TP53 I162F,3.0,,,[],[10224],{<CIViC source 4271>},[],[],[3768]
3637,TP53 Y163H,3.0,,,[],[10225],{<CIViC source 4271>},[],[],[3769]
3638,TP53 Y236S,3.0,,,[],[10226],{<CIViC source 4271>},[],[],[3770]
3639,TP53 L252F,3.0,,,[],[10227],{<CIViC source 4271>},[],[],[3771]
3640,TP53 E258K,3.0,,,[],[10228],{<CIViC source 4271>},[],[],[3772]
3641,TP53 G262D,3.0,,,[],[10229],{<CIViC source 4271>},[],[],[3773]
3642,TP53 G266E,6.0,,,[],"[10231, 10575]","{<CIViC source 4356>, <CIViC source 4271>}",[],[],[3774]
3643,TP53 L308M,3.0,,,[],[10234],{<CIViC source 4271>},[],[],[3775]
3644,TP53 L323P,3.0,,,[],[10235],{<CIViC source 4271>},[],[],[3776]
3645,TP53 Q144P,3.0,,,[],[10236],{<CIViC source 4271>},[],[],[3777]
3646,TP53 P219H,3.0,,,[],[10238],{<CIViC source 4271>},[],[],[3778]
3647,TP53 Y220H,3.0,,,[],"[10239, 10572]","{<CIViC source 4356>, <CIViC source 4271>}",[],[],[3779]
3648,TP53 E224K,3.0,,,[],[10240],{<CIViC source 4271>},[],[],[3780]
3649,TP53 Y234H,3.0,,,[],[10241],{<CIViC source 4271>},[],[],[3781]
3650,TP53 T230S,3.0,,,[],[10242],{<CIViC source 4271>},[],[],[3782]
3651,TP53 H168Y,3.0,,,[],[10243],{<CIViC source 4271>},[],[],[3783]
3652,TP53 P177S,3.0,,,[],"[10244, 10539]","{<CIViC source 4356>, <CIViC source 4271>}",[],[],[3784]
3653,TP53 P177F,3.0,,,[],[10245],{<CIViC source 4271>},[],[],[3785]
3654,TP53 P177H,3.0,,,[],[10246],{<CIViC source 4271>},[],[],[3786]
3655,TP53 N239S,3.0,,,[],[10248],{<CIViC source 4271>},[],[],[3787]
3656,TP53 S241T,3.0,,,[],[10249],{<CIViC source 4271>},[],[],[3788]
3657,TP53 M246L,3.0,,,[],[10255],{<CIViC source 4271>},[],[],[3789]
3658,TP53 V274F,3.0,,,[],[10257],{<CIViC source 4271>},[],[],[3790]
3659,TP53 G279E,3.0,,,[],[10258],{<CIViC source 4271>},[],[],[3791]
3660,TP53 D281N,3.0,,,[],[10259],{<CIViC source 4271>},[],[],[3792]
3661,TP53 G177E,0.0,,,[],[10263],{<CIViC source 4271>},[],[],[3793]
3662,TP53 P152T,2.0,,,[],[10264],{<CIViC source 4271>},[],[],[3794]
3663,TP53 R156P,2.0,,,[],[10265],{<CIViC source 4271>},[],[],[3795]
3664,TP53 R181C,2.0,,,[],[10266],{<CIViC source 4271>},[],[],[3796]
3665,TP53 R181G,2.0,,,[],[10267],{<CIViC source 4271>},[],[],[3797]
3666,TP53 R181H,2.0,,,[],[10268],{<CIViC source 4271>},[],[],[3798]
3667,TP53 R283H,2.0,,,[],[10271],{<CIViC source 4271>},[],[],[3799]
3668,TP53 Y163N,2.0,,,[],[10272],{<CIViC source 4271>},[],[],[3800]
3669,TP53 L257P,2.0,,,[],[10273],{<CIViC source 4271>},[],[],[3801]
3670,TSC2 D1734E,0.0,,,[],[10274],{<CIViC source 4273>},[],[],[3802]
3671,SMAD4 H132Y,0.0,,,[],[10275],{<CIViC source 4274>},[],[],[3803]
3674,POLB MUTATION,0.0,,,[],[],set(),[],[],[3806]
3675,CDKN2B-AS1 EXPRESSION,0.0,,,[],[],set(),[],[],[3807]
3677,ERCC2 LOSS-OF-FUNCTION,0.0,,,[],[],set(),[],[],[3809]
3679,YAP1 EXPRESSION,0.0,,,[],[],set(),[],[],[3811]
3681,KIF3C EXPRESSION,0.0,,,[],[],set(),[],[],[3813]
3682,BAP1 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3814]
3683,ARID2 EXPRESSION,0.0,,,[],[],set(),[],[],[3815]
3684,NOS2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3816]
3685,TUBA1C OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3817]
3686,SPATS2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3818]
3687,MAGI2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3819]
3688,PIK3CD-AS2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3820]
3689,CARD9 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3821]
3690,WTAP OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3822]
3691,TFB2M OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3823]
3692,WNT2B OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3824]
3693,GPD1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3825]
3694,OTUD4 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3826]
3695,ABL2 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3827]
3696,GPX2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3828]
3697,SLC12A2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3829]
3698,MALAT1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3830]
3699,CHD1 LOSS,0.0,,,[],[],set(),[],[],[3831]
3700,SLC6A14 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3832]
3701,BCL11A OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3833]
3702,MYBL2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3834]
3703,MIR31 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3835]
3704,FAM83A OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3836]
3705,SQLE OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3837]
3706,NUSAP1 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3838]
3707,LGALS1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3839]
3708,USP10 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3840]
3709,ABCC11 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3841]
3710,ELFN1-AS1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3842]
3711,USP19 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3843]
3712,MAFB OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3844]
3713,LTF UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3845]
3714,GFOD3P UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3846]
3715,CD96 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3847]
3716,SST PROMOTER HYPERMETHYLATION,0.0,,,[],[],set(),[],[],[3848]
3717,ANXA2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3849]
3718,RGL4 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3850]
3719,SULT1B1 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3851]
3720,ABCG2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3852]
3721,GOT1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3853]
3722,GJB7 EXPRESSION,0.0,,,[],[],set(),[],[],[3854]
3723,HSD17B4 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3855]
3724,STEAP1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3856]
3725,KNL1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3857]
3726,MIR3174 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3858]
3727,CAVIN1 EXPRESSION,0.0,,,[],[],set(),[],[],[3859]
3728,TLR10 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3860]
3729,ANXA8 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3861]
3730,B4GALNT2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3862]
3731,INHBA OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3863]
3732,SPATA2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3864]
3733,FOXP3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3865]
3734,MIR185 EXPRESSION,0.0,,,[],[],set(),[],[],[3866]
3735,LAG3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3867]
3736,TNFSF14 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3868]
3737,FUCA1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3869]
3738,PORCN EXPRESSION,0.0,,,[],[],set(),[],[],[3870]
3739,ASS1 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3871]
3740,RGS16 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3872]
3741,MIR484 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3873]
3742,CEP55 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3874]
3743,CENPA OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3875]
3744,LRG1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3876]
3745,DGKA OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3877]
3746,AOC3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3878]
3747,HDAC5 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3879]
3748,YTHDF2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3880]
3749,TESC OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3881]
3750,MIR143 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3882]
3751,MACF1 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3883]
3752,OTUD3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3884]
3753,FLI1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3885]
3754,ACKR3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3886]
3755,NEK1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3887]
3756,SNHG4 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3888]
3758,HOXA13 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3890]
3759,UCP2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3891]
3760,LINC00520 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3892]
3761,MPC1 DELETION,0.0,,,[],[],set(),[],[],[3893]
3762,PALB2 DELETION,0.0,,,[],[],set(),[],[],[3894]
3763,RBM17 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3895]
3764,RAB18 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3896]
3765,HHLA2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3897]
3766,CDCA2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3898]
3767,EPS8L3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3899]
3768,EID3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3900]
3769,TGFB2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3901]
3770,PPP2R2A LOSS,0.0,,,[],[],set(),[],[],[3902]
3771,SPOP OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3903]
3772,HOTTIP OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3904]
3773,MIR28 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3905]
3774,GNA14 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3906]
3775,ERRFI1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3907]
3776,UPP1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3908]
3777,SERPINH1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3909]
3778,ESR1 Mutation,30.0,,,[],[11443],{<CIViC source 4727>},[],[],[3910]
3779,PDCD1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3911]
3780,TNNT2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3912]
3781,LINC00460 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3913]
3782,MMP14 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3914]
3783,LPAR1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3915]
3784,SNHG6 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3916]
3785,BRCA1 Wildtype,0.0,,,[],[],set(),[],[],[3917]
3786,PDXDC1 MUTATION,0.0,,,[],[],set(),[],[],[3918]
3787,SERINC2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3919]
3788,CEACAM6 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3920]
3789,NRG1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3921]
3790,STAT3 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3922]
3791,SMARCA4 ALTERATION,0.0,,,[],[],set(),[],[],[3923]
3792,LUZP2 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3924]
3793,MAN2A1 EXPRESSION,0.0,,,[],[],set(),[],[],[3925]
3794,TET1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3926]
3795,SPC25 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3927]
3796,MIR320A UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3928]
3797,SERPINE1 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3929]
3798,DRD1 EXPRESSION,0.0,,,[],[],set(),[],[],[3930]
3799,ZNF554 UNDEREXPRESSION,0.0,,,[],[],set(),[],[],[3931]
3800,CTBP2 OVEREXPRESSION,0.0,,,[],[],set(),[],[],[3932]
3804,AR EXPRESSION,0.0,,,[],[],set(),[],[],[3936]
3807,H3-3A K27M,0.0,,,[],"[10803, 10600, 10602, 10605]","{<CIViC source 4183>, <CIViC source 4173>}",[],[],[3939]
3809,BRCA1 L136P,0.0,,,[],[],set(),[],[],[3941]
3810,H3C7 K27M,0.0,,,[],[],set(),[],[],[3942]
3811,H3C3 k27m,0.0,,,[],[],set(),[],[],[3943]
3812,H3C14 K27M,0.0,,,[],[10611],{<CIViC source 4183>},[],[],[3944]
3813,XPO1 Overexpression,0.0,,,[],[],set(),[],[],[3945]
3814,ATXN7 Mutation,0.0,,,[],[],set(),[],[],[3946]
3815,FLT3 N841,0.0,,,[],[],set(),[],[],[3947]
3816,GALNT14 rs9679162: intron,0.0,,,[],[],set(),[],[],[3948]
3817,PALB2 Intronic mutations,0.0,,,[],[],set(),[],[],[3949]
3818,MLH1 mutation,0.0,,,[],[],set(),[],[],[3950]
3819,MSH2 mutation,0.0,,,[],[],set(),[],[],[3951]
3820,NFE2L2 G31R,0.0,,,[],[],set(),[],[],[3952]
3822,IGH::EPOR Fusion,0.0,,,['IGH-EPOR'],[],set(),[],[],[3954]
3824,AR T878A,0.0,,,[],[],set(),[],[],[3956]
3825,OCLN::RASGRF1 Fusion,0.0,,,['OCLN-RASGRF1'],[10716],{<CIViC source 4258>},[],[],[3957]
3826,KRAS fas,0.0,,,[],[],set(),[],[],[3958]
3827,SMAD4 D493H,0.0,,,[],[10276],{<CIViC source 4275>},[],[],[3959]
3828,NFE2L2 E79Q,0.0,,,[],[10277],{<CIViC source 4072>},[],[],[3960]
3829,EGFR R252C,0.0,,,[],[10278],{<CIViC source 4006>},[],[],[3961]
3830,BRCA1 H1686R,0.0,,,[],[10279],{<CIViC source 4276>},[],[],[3962]
3831,BRCA1 H1686Q,0.0,,,[],[10280],{<CIViC source 4276>},[],[],[3963]
3832,BRCA1 S1655F,0.0,,,[],[10281],{<CIViC source 4276>},[],[],[3964]
3833,BRCA1 M1652I,0.0,,,[],[10282],{<CIViC source 4276>},[],[],[3965]
3834,BRCA1 M1628T,0.0,,,[],[10283],{<CIViC source 4276>},[],[],[3966]
3835,BRCA1 R1589P,0.0,,,[],[10284],{<CIViC source 4276>},[],[],[3967]
3836,BRCA1 V1534M,0.0,,,[],[10285],{<CIViC source 4276>},[],[],[3968]
3837,BRCA1 S1486C,0.0,,,[],[10286],{<CIViC source 4276>},[],[],[3969]
3838,BRCA1 V1688del,0.0,,,[],[10287],{<CIViC source 4276>},[],[],[3970]
3839,BRCA1 R1699W,0.0,,,[],"[11130, 10288]","{<CIViC source 4276>, <CIViC source 4559>}",[],[],[3971]
3840,BRCA1 G1706E,0.0,,,[],[10289],{<CIViC source 4276>},[],[],[3972]
3841,BRCA1 G1706A,0.0,,,[],[10290],{<CIViC source 4276>},[],[],[3973]
3842,VHL L153Tfs,0.0,,,[],[],set(),[],[],[3974]
3843,VHL L153Tfs (c.456dup),0.0,,,[],[],set(),[],[],[3975]
3844,BRCA1 A1708E,0.0,,,[],[10291],{<CIViC source 4276>},[],[],[3976]
3845,TP53 N7777R,0.0,,,[],[],set(),[],[],[3977]
3846,BRCA1 W1718C,0.0,,,[],[10293],{<CIViC source 4276>},[],[],[3978]
3847,BRCA1 T1720A,0.0,,,[],[10294],{<CIViC source 4276>},[],[],[3979]
3848,BRCA1 D1739G,0.0,,,[],[10295],{<CIViC source 4276>},[],[],[3980]
3849,BRCA1 D1739V,0.0,,,[],[10296],{<CIViC source 4276>},[],[],[3981]
3850,BRCA1 L1764P,0.0,,,[],[10297],{<CIViC source 4276>},[],[],[3982]
3851,CRBN High expression,0.0,,,[],[],set(),[],[],[3983]
3852,VHL F136L (c.406T>C),0.0,,,[],[10305],{<CIViC source 3974>},[],[],[3984]
3853,VHL V155L (c.463G>T),0.0,,,[],[10306],{<CIViC source 3974>},[],[],[3985]
3854,SH3PXD2A::HTRA1 Fusion,0.0,,,['SH3PXD2A-HTRA1'],"[12201, 10309, 10311]","{<CIViC source 4875>, <CIViC source 4280>, <CIViC source 4282>}",[],[],[3986]
3855,CIC::LEUTX Fusion,0.0,,,['CIC-LEUTX'],[10310],{<CIViC source 4281>},[],[],[3987]
3856,MAP3K8::v Fusion,0.0,,,['MAP3K8 Fusion'],[10715],{<CIViC source 4283>},[],[],[3988]
3860,STAT1 Expression,0.0,,,[],[10316],{<CIViC source 4288>},[],[],[3992]
3861,BRCA1 G1770V,0.0,,,[],[10315],{<CIViC source 4276>},[],[],[3993]
3862,BRCA1 A1789T,0.0,,,[],[10317],{<CIViC source 4276>},[],[],[3994]
3863,BRCA1 W1837R,0.0,,,[],[10318],{<CIViC source 4276>},[],[],[3995]
3864,BRCA1 H1862L,0.0,,,[],[10319],{<CIViC source 4276>},[],[],[3996]
3865,BRCA1 P1812R,0.0,,,[],[10320],{<CIViC source 4276>},[],[],[3997]
3866,BRCA1 V1804D,0.0,,,[],[10321],{<CIViC source 4276>},[],[],[3998]
3867,VHL Partial deletion of 10 Kb,0.0,,,[],[10323],{<CIViC source 3714>},[],[],[3999]
3868,QKI::RAF1 Fusion,7.5,,,['QKI-RAF1'],[10326],{<CIViC source 4292>},[],[],[4000]
3869,KANK4::ALK Fusion,7.5,,,['KANK4-ALK'],[10327],{<CIViC source 4293>},[],[],[4001]
3871,PDGFB Rearrangement ,0.0,,,[],"[10312, 10330, 10333]","{<CIViC source 4284>, <CIViC source 4297>, <CIViC source 4295>}",[],[],[4003]
3872,TERT C250T,0.0,,,['-146C>T'],[10331],{<CIViC source 319>},[],[],[4004]
3874,DDX41 G320D,0.0,,,[],[],set(),[],[],[4006]
3875,DDX41 G530D,0.0,,,[],"[10345, 10346, 11435, 10339, 10344, 10646, 10340, 10341, 10347, 11433, 11434, 10342, 10343, 10348]","{<CIViC source 4308>, <CIViC source 4720>, <CIViC source 4311>, <CIViC source 1323>, <CIViC source 4363>, <CIViC source 4721>, <CIViC source 4722>, <CIViC source 4310>, <CIViC source 4306>, <CIViC source 4309>, <CIViC source 4305>, <CIViC source 4304>, <CIViC source 4303>, <CIViC source 4302>}",[],[],[4007]
3876,VHL t(3;6)(p13;q25.1),0.0,,,[],"[10357, 10350]","{<CIViC source 3827>, <CIViC source 4313>}",[],[],[4008]
3877,VHL t(3;12)(q13.2;q24.1),0.0,,,[],"[10356, 10351]","{<CIViC source 3827>, <CIViC source 4312>}",[],[],[4009]
3880,MS4A1 Y86C,0.0,,,[],[],set(),[],[],[4012]
3881,FGFR3 K650M,1.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['LYS650MET'],"[10491, 10369, 10380]","{<CIViC source 4349>, <CIViC source 4326>, <CIViC source 4322>}",[],[],[4013]
3882,PLCG2 N571S,0.0,,,[],[10371],{<CIViC source 3376>},[],[],[4014]
3883,PLCG2 D1140E,0.0,,,[],[10372],{<CIViC source 3376>},[],[],[4015]
3884,BTK C481Y,0.0,,,[],[10373],{<CIViC source 3376>},[],[],[4016]
3885,BTK C481R,0.0,,,[],[10374],{<CIViC source 3376>},[],[],[4017]
3886,MS4A1 Mutation,15.0,,,[],[10367],{<CIViC source 4320>},[],[],[4018]
3887,FGFR3 K650Q,4.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['LYS650GLN', 'LYS652GLN', 'LYS538GLN', 'LYS651GLN', 'K652Q', 'K538Q', 'K651Q']","[10378, 10401]","{<CIViC source 4333>, <CIViC source 4326>}",[],[],[4019]
3889,FGFR3 K650T,2.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['LYS650THR', 'LYS652THR', 'LYS538THR', 'LYS651THR', 'K652T', 'K538T', 'K651T']","[10492, 10382]","{<CIViC source 4349>, <CIViC source 4326>}",[],[],[4021]
3890,FGFR3 I538F,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ILE538PHE', 'ILE540PHE', 'ILE426PHE', 'ILE539PHE', 'I540F', 'I426F', 'I539F']",[10388],{<CIViC source 4330>},[],[],[4022]
3891,FGFR3 A391E,4.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ALA391GLU', 'ALA393GLU', 'A393E']","[8315, 10513, 10395, 10509, 10654]","{<CIViC source 4353>, <CIViC source 4365>, <CIViC source 4331>, <CIViC source 4334>, <CIViC source 3447>}",[],[],[4023]
3892,FGFR3 K650D,3.0,,,['LYS650ASP'],[10400],{<CIViC source 4333>},[],[],[4024]
3893,FGFR3 K650L,2.0,,,['LYS650LEU'],[10402],{<CIViC source 4333>},[],[],[4025]
3896,FGFR3 N540D,0.0,,,[],[10411],{<CIViC source 4337>},[],[],[4028]
3898,FGFR3 G697C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLY697CYS', 'GLY699CYS', 'G699C']","[10837, 10838, 10839]","{<CIViC source 4421>, <CIViC source 3455>, <CIViC source 4142>}",[],[],[4030]
3899,FGFR3 V50I,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['VAL50ILE'],[],set(),[],[],[4031]
3900,FGFR3 S84L,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['SER84LEU'],[],set(),[],[],[4032]
3901,FGFR3 R124W,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['ARG124TRP'],[],set(),[],[],[4033]
3902,FGFR3 S187Y,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['SER187TYR'],[],set(),[],[],[4034]
3903,FGFR3 R200C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['ARG200CYS'],[],set(),[],[],[4035]
3904,FGFR3 S217C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['SER217CYS'],[],set(),[],[],[4036]
3905,FGFR3 C228R,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['CYS228ARG'],[],set(),[],[],[4037]
3906,FGFR3 H274Y,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['HIS274TYR'],[],set(),[],[],[4038]
3907,FGFR3 Y278C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,['TYR278CYS'],[],set(),[],[],[4039]
3908,FGFR3 G346E,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,[],[],set(),[],[],[4040]
3909,FGFR3 S371C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['SER371CYS', 'SER373CYS', 'S373C']",[],set(),[],[],[4041]
3910,FGFR3 G375C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLY375CYS', 'GLY377CYS', 'G377C']",[],set(),[],[],[4042]
3911,FGFR3 V390M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL390MET', 'VAL392MET', 'V392M']",[],set(),[],[],[4043]
3912,FGFR3 A391V,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ALA391VAL', 'ALA393VAL', 'A393V']",[],set(),[],[],[4044]
3913,FGFR3 T394M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['THR394MET', 'T396M', 'THR396MET']",[],set(),[],[],[4045]
3914,FGFR3 R399C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['R401C', 'ARG399CYS', 'ARG401CYS']",[],set(),[],[],[4046]
3915,FGFR3 P402S,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['PRO402SER', 'P404S', 'PRO404SER']",[],set(),[],[],[4047]
3916,FGFR3 A452S,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['A454S', 'ALA452SER', 'ALA454SER']",[],set(),[],[],[4048]
3917,FGFR3 A500T,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ALA500THR', 'ALA502THR', 'A502T']",[],set(),[],[],[4049]
3918,FGFR3 K508M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['K510M', 'LYS508MET', 'LYS510MET']","[11796, 11797, 11798, 11799, 11800, 11802, 11803, 11804, 11805, 11806, 11807, 11801]","{<CIViC source 4928>, <CIViC source 4932>, <CIViC source 4935>, <CIViC source 4925>, <CIViC source 4926>, <CIViC source 4933>, <CIViC source 4898>, <CIViC source 4931>, <CIViC source 4930>, <CIViC source 4927>, <CIViC source 4934>, <CIViC source 4929>}",[],[],[4050]
3919,FGFR3 I538V,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ILE538VAL', 'ILE540VAL', 'I540V']",[],set(),[],[],[4051]
3920,FGFR3 P572A,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['PRO572ALA', 'PRO574ALA', 'P574A']",[],set(),[],[],[4052]
3921,FGFR3 C582F,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['CYS582PHE', 'CYS584PHE', 'C584F']",[],set(),[],[],[4053]
3922,FGFR3 E627D,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLU627ASP', 'E629D', 'GLU629ASP']",[],set(),[],[],[4054]
3923,FGFR3 V630M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL630MET', 'VAL632MET', 'V632M']",[],set(),[],[],[4055]
3924,FGFR3 D641N,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASP641ASN', 'ASP643ASN', 'D643N']",[],set(),[],[],[4056]
3925,FGFR3 D641G,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASP641GLY', 'ASP643GLY', 'D643G']",[],set(),[],[],[4057]
3926,FGFR3 V642M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL642MET', 'VAL644MET', 'V644M']",[],set(),[],[],[4058]
3927,FGFR3 H643D,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['HIS643ASP', 'H645D', 'HIS645ASP']",[],set(),[],[],[4059]
3928,FGFR3 D646Y,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['D648Y', 'ASP648TYR', 'ASP646TYR']",[],set(),[],[],[4060]
3929,FGFR3 K650R,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['LYS650ARG', 'LYS652ARG', 'K652R']",[],set(),[],[],[4061]
3930,FGFR3 N653H,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASN653HIS', 'ASN655HIS', 'N655H']",[],set(),[],[],[4062]
3931,FGFR3 V677I,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL677ILE', 'VAL679ILE', 'V679I']",[],set(),[],[],[4063]
3932,FGFR3 D762H,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASP762HIS', 'ASP764HIS', 'D764H']",[],set(),[],[],[4064]
3933,FGFR3 S780C,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['SER780CYS', 'SER782CYS', 'S782C']",[],set(),[],[],[4065]
3934,FGFR3 D785N,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASP785ASN', 'ASP787ASN', 'D787N']",[],set(),[],[],[4066]
3935,FGFR3 D786N,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ASP786ASN', 'ASP788ASN', 'D788N']",[],set(),[],[],[4067]
3936,FGFR3 V788M,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['VAL788MET', 'VAL790MET', 'V790M']",[],set(),[],[],[4068]
3937,FGFR3 R805Q,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['ARG805GLN', 'ARG807GLN', 'R807Q']",[],set(),[],[],[4069]
3938,FGFR3 G382D,0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['GLY382ASP', 'GLY384ASP', 'G384D']",[],set(),[],[],[4070]
3939,FGFR3 L8= (c.24C>G),0.0,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.,"['LEUCINE8=', 'LEUCINE8LEUCINE']",[],set(),[],[],[4071]
3940,TFEB t(6;11),0.0,,,[],[],set(),[],[],[4072]
3941,TFEB 6p21.1 amplification,0.0,,,[],[],set(),[],[],[4073]
3942,TFEB TFEB amplification,0.0,,,[],[],set(),[],[],[4074]
3943,EML6 EML6::NTRK3,0.0,,,[],[10418],{<CIViC source 4329>},[],[],[4075]
3944,VHL S43_E47del (c.123_137del),0.0,,,[],"[10423, 10806]","{<CIViC source 4414>, <CIViC source 2285>}",[],[],[4076]
3945,VHL E55Gfs*77 (c.163dup),0.0,,,[],[10426],{<CIViC source 2285>},[],[],[4077]
3946,VHL N67_V74del (c.197_221del),0.0,,,[],[10431],{<CIViC source 2285>},[],[],[4078]
3947,VHL R69Afs*63 (c.204dup),0.0,,,[],[10432],{<CIViC source 2285>},[],[],[4079]
3948,VHL P71Lfs*61 (c.211_212insT),0.0,,,[],[10433],{<CIViC source 2285>},[],[],[4080]
3950,VHL F76_C77del (c.226_231del),0.0,,,[],[10437],{<CIViC source 2285>},[],[],[4082]
3951,VHL F76* (c.227T>A; c.228C>A),0.0,,,[],[10438],{<CIViC source 2285>},[],[],[4083]
3952,VHL G106Tfs*54 (c.315_316insAC),0.0,,,[],"[10446, 10637]","{<CIViC source 2285>, <CIViC source 1278>}",[],[],[4084]
3953,VHL R108Lfs*52 (c.322_323insTG),0.0,,,[],[10447],{<CIViC source 2285>},[],[],[4085]
3954,VHL Splice Site (c.340+2_340+6del),0.0,,,[],[10450],{<CIViC source 2285>},[],[],[4086]
3955,VHL L140Qfs*3 (c.419_420del),0.0,,,[],[10460],{<CIViC source 2285>},[],[],[4087]
3956,VHL K159Efs*15 (c.473dup),0.0,,,[],[10464],{<CIViC source 2285>},[],[],[4088]
3957,VHL K159delinsI* (c.475_476insTTT),0.0,,,[],[10465],{<CIViC source 2285>},[],[],[4089]
3958,EZH2 Y646N,6.0,,,"['Y641N', 'TYR646ASN', 'TYR641ASN']","[11112, 11050, 9518, 9520, 11011, 11013, 11049, 11105]","{<CIViC source 4554>, <CIViC source 4539>, <CIViC source 4550>, <CIViC source 4070>, <CIViC source 4487>, <CIViC source 4540>}",[],[],[4090]
3959,VHL V165Lfs*5 (c.492del),0.0,,,[],[10471],{<CIViC source 2285>},[],[],[4091]
3960,VHL L178_D179insRVKPEL (c.531_532insCTGAGAGTAAAGCCTGAA),0.0,,,[],"[10477, 10630]","{<CIViC source 2285>, <CIViC source 1278>}",[],[],[4092]
3961,VHL H191Tfs*11 (c.571del),0.0,,,[],[10479],{<CIViC source 2285>},[],[],[4093]
3962,VHL Q203Gfs*52 (c.607_608del),0.0,,,[],[10480],{<CIViC source 2285>},[],[],[4094]
3963,VHL R205Hfs*50 (c.614_615del),0.0,,,[],[10481],{<CIViC source 2285>},[],[],[4095]
3964,VHL R161* (c.481C>T) AND R200fs (c.598del),0.0,,,[],[10500],{<CIViC source 4350>},[],[],[4096]
3965,VHL P76del (c.227_229del),0.0,,,[],"[10878, 10505]","{<CIViC source 4442>, <CIViC source 2174>}",[],[],[4097]
3966,CTRC::NTRK1 Fusion,0.0,,,['CTRC-NTRK1'],[],set(),[],[],[4098]
3967,VHL S65* (c.189_192del),0.0,,,[],"[10517, 10761]","{<CIViC source 4376>, <CIViC source 2187>}",[],[],[4099]
3968,VHL K159fs (c.472_473insT),0.0,,,[],[10519],{<CIViC source 2187>},[],[],[4100]
3969,TP53 R342STOP,0.0,,,[],[],set(),[],[],[4101]
3970,TP53 R156H,3.0,,,[],[10528],{<CIViC source 4356>},[],[],[4102]
3971,TP53 H178P,3.0,,,[],[10529],{<CIViC source 4356>},[],[],[4103]
3972,TP53 G245N,0.0,,,[],[],set(),[],[],[4104]
3973,TP53 M246R,0.0,,,[],[10534],{<CIViC source 4356>},[],[],[4105]
3974,TP53 E68G,3.0,,,[],[10541],{<CIViC source 4356>},[],[],[4106]
3975,SOS1 E846K,0.0,,,[],[10542],{<CIViC source 4357>},[],[],[4107]
3976,VHL C77Sfs*82 (c.230del),0.0,,,[],[10543],{<CIViC source 2240>},[],[],[4108]
3977,VHL S80Ifs*79 (c.239del),0.0,,,[],[10546],{<CIViC source 2240>},[],[],[4109]
3978,VHL Q96del (c.287_289del),0.0,,,[],[10551],{<CIViC source 2240>},[],[],[4110]
3979,TP53 L111R,3.0,,,[],[10554],{<CIViC source 4356>},[],[],[4111]
3980,TP53 H115Y,3.0,,,[],[10555],{<CIViC source 4356>},[],[],[4112]
3981,TP53 C124R,3.0,,,[],[10556],{<CIViC source 4356>},[],[],[4113]
3982,TP53 L139N,3.0,,,[],[10558],{<CIViC source 4356>},[],[],[4114]
3983,TP53 R158G,3.0,,,[],[10560],{<CIViC source 4356>},[],[],[4115]
3984,TP53 A161G,0.0,,,[],[10562],{<CIViC source 4356>},[],[],[4116]
3985,TP53 V173G,0.0,,,[],[10564],{<CIViC source 4356>},[],[],[4117]
3986,TP53 C176S,0.0,,,[],[10565],{<CIViC source 4356>},[],[],[4118]
3987,TP53 H193L,0.0,,,[],[10568],{<CIViC source 4356>},[],[],[4119]
3988,TP53 V197L,0.0,,,[],[10569],{<CIViC source 4356>},[],[],[4120]
3989,TP53 R213Q,0.0,,,[],[10570],{<CIViC source 4356>},[],[],[4121]
3990,TP53 G266V,3.0,,,[],[10574],{<CIViC source 4356>},[],[],[4122]
3991,TP53 V272G,3.0,,,[],[10577],{<CIViC source 4356>},[],[],[4123]
3992,TP53 C275F,0.0,,,[],[10579],{<CIViC source 4356>},[],[],[4124]
3993,TP53 L305M,0.0,,,[],[10581],{<CIViC source 4356>},[],[],[4125]
3994,TP53 A347G,0.0,,,[],[10583],{<CIViC source 4356>},[],[],[4126]
3995,TP53 A83E,0.0,,,[],[10584],{<CIViC source 4356>},[],[],[4127]
3996,TP53 A86T,0.0,,,[],[10585],{<CIViC source 4356>},[],[],[4128]
3997,TP53 A86E,0.0,,,[],[10586],{<CIViC source 4356>},[],[],[4129]
3998,TP53 S127Y,0.0,,,[],[10587],{<CIViC source 4356>},[],[],[4130]
3999,TP53 A138K,0.0,,,[],[10589],{<CIViC source 4356>},[],[],[4131]
4000,TP53 Q144Q,0.0,,,[],[10590],{<CIViC source 4356>},[],[],[4132]
4001,TP53 R158C,0.0,,,[],[10591],{<CIViC source 4356>},[],[],[4133]
4002,TP53 A161D,0.0,,,[],[10592],{<CIViC source 4356>},[],[],[4134]
4003,TP53 Q167R,0.0,,,[],[10593],{<CIViC source 4356>},[],[],[4135]
4004,TP53 A161V,0.0,,,[],[10594],{<CIViC source 4356>},[],[],[4136]
4005,TP53 H168R,0.0,,,[],[10595],{<CIViC source 4356>},[],[],[4137]
4006,TP53 H168Q,0.0,,,[],[10596],{<CIViC source 4356>},[],[],[4138]
4007,TP53 V173M,0.0,,,[],[10597],{<CIViC source 4356>},[],[],[4139]
4008,TP53 R181L,0.0,,,[],[10598],{<CIViC source 4356>},[],[],[4140]
4009,TP53 P190H,0.0,,,[],[10599],{<CIViC source 4356>},[],[],[4141]
4010,TP53 R196Q,0.0,,,[],[10601],{<CIViC source 4356>},[],[],[4142]
4011,TP53 S227C,0.0,,,[],[10603],{<CIViC source 4356>},[],[],[4143]
4012,TP53 G262C,0.0,,,[],[10604],{<CIViC source 4356>},[],[],[4144]
4013,TP53 C277Y,0.0,,,[],[10606],{<CIViC source 4356>},[],[],[4145]
4014,TP53 D281Y,0.0,,,[],[10607],{<CIViC source 4356>},[],[],[4146]
4015,TP53 K305N,0.0,,,[],[10608],{<CIViC source 4356>},[],[],[4147]
4016,TP53 R306E,0.0,,,[],[10609],{<CIViC source 4356>},[],[],[4148]
4017,TP53 R337S,0.0,,,[],[10610],{<CIViC source 4356>},[],[],[4149]
4019,VHL c.329ins2,0.0,,,[],[10613],{<CIViC source 2240>},[],[],[4151]
4020,VHL c.358ins2,0.0,,,[],[10615],{<CIViC source 2240>},[],[],[4152]
4021,VHL D143Efs*13 (c.429_438del),0.0,,,[],[10616],{<CIViC source 2240>},[],[],[4153]
4022,VHL S168Tfs*2 (c.503_513del),0.0,,,[],[10619],{<CIViC source 2240>},[],[],[4154]
4023,VHL E173Rfs*29 (c.516del),0.0,,,[],[10620],{<CIViC source 2240>},[],[],[4155]
4024,VHL L198Gfs*57 (c.592_593del),0.0,,,[],[10622],{<CIViC source 2240>},[],[],[4156]
4025,VHL c.563ins20,0.0,,,[],[10624],{<CIViC source 2240>},[],[],[4157]
4026,POLE L424V,0.0,,,[],[10627],{<CIViC source 4359>},[],[],[4158]
4027,VHL N67_V74del (c.198_221del),0.0,,,[],[10628],{<CIViC source 1278>},[],[],[4159]
4028,VHL L158dup (c.473_474insTTT),0.0,,,[],[10629],{<CIViC source 1278>},[],[],[4160]
4029,VHL E73* (c.217C>T),0.0,,,[],[10633],{<CIViC source 1278>},[],[],[4161]
4030,VHL Splice Region (c.340+1_340+5del),0.0,,,[],[10634],{<CIViC source 1278>},[],[],[4162]
4032,VHL p25l (C.74C>T) AND D126Rfs*6 (c.375_376insA) AND E55Rfs (c.163delG),0.0,,,[],[],set(),[],[],[4164]
4033,VHL P25L (c.74C>T) AND D126Rfs*6 (c.375_376insA) AND E55Rfs(c.163delG),0.0,,,[],"[10659, 10639]",{<CIViC source 2640>},[],[],[4165]
4035,VHL R167Q (c.500G>A) and I151N (c.452T>A),0.0,,,[],"[10641, 10642]",{<CIViC source 3586>},[],[],[4167]
4036,VHL Exon 1-3 Deletion and P81S (c.241C>T),0.0,,,[],[10643],{<CIViC source 2376>},[],[],[4168]
4037,VHL Exon 1-3 Deletion and Splice Region (c.340+5G>C),0.0,,,[],"[10644, 10645]",{<CIViC source 2376>},[],[],[4169]
4038,VHL  3'UTR alteration (c.*70C>T),0.0,,,[],[10647],{<CIViC source 2650>},[],[],[4170]
4039,VHL S111N (c.332G>A) ,0.0,,,[],[10648],{<CIViC source 2193>},[],[],[4171]
4040,VHL G144Dfs*15 (c.431del),0.0,,,[],[10649],{<CIViC source 2193>},[],[],[4172]
4041,VHL c.502ins8bp,0.0,,,[],[10650],{<CIViC source 2193>},[],[],[4173]
4042,VHL G114D (c.340+1G>A),0.0,,,[],[10655],{<CIViC source 2365>},[],[],[4174]
4043,VHL V155G (c.464T>G) and c.463+43A>G,0.0,,,[],[],set(),[],[],[4175]
4044,VHL P2=(c.6C>G) and P81S(c.241C>T),0.0,,,[],[10660],{<CIViC source 2632>},[],[],[4176]
4045,PDGFRA K385,0.0,,,[],"[10669, 10670]","{<CIViC source 4367>, <CIViC source 4370>}",[],[],[4177]
4046,VHL c.340+770T>C and R200W (c.598C>T),0.0,,,[],[10662],{<CIViC source 3391>},[],[],[4178]
4047,VHL V87Gfs*71(c.260_263del) and P81S(c.241C>T),0.0,,,[],"[10663, 10664]",{<CIViC source 3569>},[],[],[4179]
4049,VHL C162Y(c.486C>G) and L188V(c.562C>G) and P81S(c.241C>T) and F119L(c.357C>G),0.0,,,[],"[10667, 10668, 10672, 10673]",{<CIViC source 3569>},[],[],[4181]
4050,YES1 Overexpression,0.0,,,[],[],set(),[],[],[4182]
4051,PDGFRA V544ins,0.0,,,[],[],set(),[],[],[4183]
4052,VHL S80N (c.239G>A) and P25L (c.74C>T),0.0,,,[],[10674],{<CIViC source 3533>},[],[],[4184]
4053,VHL H115Pfs*44(c.344delA) and P61=(c.183C>G),0.0,,,[],[10675],{<CIViC source 2269>},[],[],[4185]
4054,VHL 2kb Deletion,0.0,,,[],"[10791, 10676]","{<CIViC source 4404>, <CIViC source 3389>}",[],[],[4186]
4055,VHL 5kb Deletion,0.0,,,[],"[10790, 10677]","{<CIViC source 4404>, <CIViC source 3389>}",[],[],[4187]
4056,VHL 10kb Deletion,0.0,,,[],[10678],{<CIViC source 3389>},[],[],[4188]
4057,VHL Partial Deletion and P61=( c.183C>G),0.0,,,[],[10679],{<CIViC source 2269>},[],[],[4189]
4058,VHL R200W (c.598C>T) and V130L (c.388G>C),0.0,,,[],[10680],{<CIViC source 2264>},[],[],[4190]
4059,VHL c.65_55dup11 AND  3' UTR alteration (c.*1149A>G),0.0,,,[],[10683],{<CIViC source 3528>},[],[],[4191]
4060,VHL Deletion AND I151S(c.452T>G),0.0,,,[],[10684],{<CIViC source 3401>},[],[],[4192]
4061,VHL Deletion AND R200W (c.598C>T),0.0,,,[],[10685],{<CIViC source 3401>},[],[],[4193]
4062,VHL Deletion AND R69C (c.205C>T),0.0,,,[],[10686],{<CIViC source 3401>},[],[],[4194]
4063,VHL S65L (c.194C>T) AND L89P (c.266T>A),0.0,,,[],[],set(),[],[],[4195]
4064,VHL Deletion AND R120_121S (c.360_362delAGA),0.0,,,[],[],set(),[],[],[4196]
4065,VHL c.341-59_341-14del AND F136fs (c.408delT),0.0,,,[],[10689],{<CIViC source 2616>},[],[],[4197]
4066,VHL V155= (c.465G>C),0.0,,,[],[10693],{<CIViC source 3389>},[],[],[4198]
4067,VHL L188del (c.562_564delCTG),0.0,,,[],[10698],{<CIViC source 4374>},[],[],[4199]
4068,VHL Partial deletion of 0.8 kb,0.0,,,[],[10701],{<CIViC source 4374>},[],[],[4200]
4069,VHL N90del (c.268_270del),0.0,,,[],[10707],{<CIViC source 4375>},[],[],[4201]
4070,VHL P59_R64del (c.174_191del),0.0,,,[],[10708],{<CIViC source 4375>},[],[],[4202]
4071,PIK3R1 R348*,0.0,,,[],[],set(),[],[],[4203]
4072,VHL R79G (c.235C>G),0.0,,,[],"[10720, 10982]","{<CIViC source 4378>, <CIViC source 4473>}",[],[],[4204]
4073,VHL T124P (c.370A>C),0.0,,,[],[10724],{<CIViC source 4378>},[],[],[4205]
4074,VHL F136C (c.407G>T),0.0,,,[],[10726],{<CIViC source 4378>},[],[],[4206]
4075,VHL D143= (c.429C>T) and c.340+770T>C,0.0,,,[],[10740],{<CIViC source 3391>},[],[],[4207]
4076,VHL R200W (c.598C>T) and c.340+694_340+711dup,0.0,,,[],[10741],{<CIViC source 3391>},[],[],[4208]
4077,VHL c.340+694_340+711dup,0.0,,,[],[10742],{<CIViC source 3391>},[],[],[4209]
4078,VHL R167Q(c.500G>A) and c.464-94T>A,0.0,,,[],[10743],{<CIViC source 2269>},[],[],[4210]
4079,VHL G144R (c.430G>A) and c.340+694_340+711dup,0.0,,,[],[10744],{<CIViC source 3391>},[],[],[4211]
4080,VHL Q164H (c.492G>T) and c.340+574A>T,0.0,,,[],[10745],{<CIViC source 3391>},[],[],[4212]
4081,VHL c.340+617C>G and c.340+648T>C,0.0,,,[],[10746],{<CIViC source 3391>},[],[],[4213]
4082,VHL  T124I (c.371C>T),0.0,,,[],[10752],{<CIViC source 4378>},[],[],[4214]
4083,VHL c.-195G>A AND c.*294G>A,0.0,,,[],[],set(),[],[],[4215]
4084,VHL  W8* (c.23G>A),0.0,,,[],[10754],{<CIViC source 4388>},[],[],[4216]
4085,VHL  L89P (c.266T>A),0.0,,,[],[],set(),[],[],[4217]
4086,ABL1 D276G,0.0,,,"['RS121913447', 'ASP276GLY', 'D295G']",[],set(),[],[],[4218]
4087,MS h,0.0,,,[],[],set(),[],[],[4219]
4088,F9 G555R,0.0,,,[],[],set(),[],[],[4220]
4089,AKT2 L78_Q79ins,0.0,,,[],[10763],{<CIViC source 4398>},[],[],[4221]
4090,AKT1 D323G,0.0,,,[],[10765],{<CIViC source 4398>},[],[],[4222]
4091,AKT1 F55Y,0.0,,,[],[10766],{<CIViC source 4398>},[],[],[4223]
4092,AKT1 P68-C77dup,0.0,,,[],[10767],{<CIViC source 4398>},[],[],[4224]
4093,VHL L201P (c.602T>C),0.0,,,[],[10769],{<CIViC source 4400>},[],[],[4225]
4094,VHL Splice Region (c.340+2T>C),0.0,,,[],[10771],{<CIViC source 4400>},[],[],[4226]
4095,VHL R107S (c.319C>A),0.0,,,[],[10776],{<CIViC source 4402>},[],[],[4227]
4096,VHL c.340+384G>C,0.0,,,[],[10780],{<CIViC source 4403>},[],[],[4228]
4098,VHL N193fs (c.576delA),0.0,,,[],[10807],{<CIViC source 4414>},[],[],[4230]
4099,VHL S43_E47dup (c.123_137dup),0.0,,,[],[10808],{<CIViC source 4414>},[],[],[4231]
4100,BRCA1  c.212+1G>T,0.0,,,[],[7164],{<CIViC source 2790>},[],[],[4232]
4101,VHL P45R (c.134C>G),0.0,,,[],[10816],{<CIViC source 2403>},[],[],[4233]
4102,VHL E21A (c.62A>C),0.0,,,[],[10817],{<CIViC source 2403>},[],[],[4234]
4103,VHL T105M (c.314C>T),0.0,,,[],[10823],{<CIViC source 4417>},[],[],[4235]
4104,VHL L153Q (c.458T>A),0.0,,,[],[10825],{<CIViC source 4417>},[],[],[4236]
4105,AURKB Overexpression,0.0,,,[],[10836],{<CIViC source 4418>},[],[],[4237]
4106,VHL L188V(c.562C>G),0.0,,,[],"[10827, 10847]","{<CIViC source 4431>, <CIViC source 4419>}",[],[],[4238]
4108,TYR GRCh37/hg19 11q14.3(chr11:88960991-88961138)x160,0.0,,,[],[10834],{<CIViC source 4420>},[],[],[4240]
4109,EGFR::SEPTIN14 Fusion,0.0,,,"['EGFR-SEPT14', 'EGFR::SEPTIN14', 'EGFR-SEPTIN14', 'EGFR::Septin-14']","[11153, 10914, 11003, 11005, 11004, 10843, 11002, 11155]","{<CIViC source 4460>, <CIViC source 4494>, <CIViC source 4566>, <CIViC source 4461>, <CIViC source 4425>, <CIViC source 4424>}",[],[],[4241]
4110,VOPP1::EGFR Fusion,0.0,,,['VOPP1-EGFR'],[10895],{<CIViC source 4426>},[],[],[4242]
4111,VHL Splice Site (c.341-3T>G),0.0,,,[],[10862],{<CIViC source 4436>},[],[],[4243]
4112,FLT3 Q575del,0.0,,,[],[],set(),[],[],[4244]
4114,VHL V130P (c.388G>T),0.0,,,[],[10882],{<CIViC source 4442>},[],[],[4246]
4115,VHL p.L159Es*15 (c.473dup),0.0,,,[],[10883],{<CIViC source 4442>},[],[],[4247]
4116,PTPN11 A461T,0.0,,,[],[10885],{<CIViC source 4444>},[],[],[4248]
4117,KAT6B Overexpression,0.0,,,[],[],set(),[],[],[4249]
4118,VHL Exon 3 deletion (c.464-11 T>A),0.0,,,[],[10893],{<CIViC source 4442>},[],[],[4250]
4119,SEC61G::EGFR Fusion,0.0,,,['SEC61G-EGFR'],"[10933, 10899, 10934, 10935]","{<CIViC source 4446>, <CIViC source 4466>, <CIViC source 4467>, <CIViC source 4450>}",[],[],[4251]
4120,NTRK3::SCAPER Fusion,2.5,,,['NTRK3-SCAPER'],[11526],{<CIViC source 4447>},[],[],[4252]
4121,SCP2::NTRK1 Fusion,10.0,,,['SCP2-NTRK1'],"[10897, 10898]","{<CIViC source 4449>, <CIViC source 4448>}",[],[],[4253]
4122,VHL Splice Site (c.340+563C>T),0.0,,,[],[10905],{<CIViC source 4454>},[],[],[4254]
4123,VHL Splice Site (c.340+578C>T),0.0,,,[],[10906],{<CIViC source 4454>},[],[],[4255]
4124,VHL Splice Site (c.340+617C>G),0.0,,,[],[10907],{<CIViC source 4454>},[],[],[4256]
4125,VHL Splice Site (c.340+682T>C),0.0,,,[],[10908],{<CIViC source 4454>},[],[],[4257]
4126,VHL Splice Site (c.340+725A>T),0.0,,,[],[10909],{<CIViC source 4454>},[],[],[4258]
4127,VHL Splice Site (c.340+866C>A),0.0,,,[],[10910],{<CIViC source 4454>},[],[],[4259]
4128,ETV6::RET Fusion,0.0,,,['ETV6-RET'],[],set(),[],[],[4260]
4129,VHL P154Qfs4*(c.461del),0.0,,,[],[],set(),[],[],[4261]
4130,VHL P154Qfs4*(c.461delC),0.0,,,[],[10919],{<CIViC source 4463>},[],[],[4262]
4131,VHL P192L (c.575C>T),0.0,,,[],[10920],{<CIViC source 4463>},[],[],[4263]
4132,VHL Null (c.341+1_3411),0.0,,,[],[10923],{<CIViC source 4463>},[],[],[4264]
4133,VHL P119L (c.355T>C),0.0,,,[],[10924],{<CIViC source 4463>},[],[],[4265]
4134,VHL R177Tfs*23 (c.530_536del),0.0,,,[],[10928],{<CIViC source 4464>},[],[],[4266]
4135,FGFR3 NM_001163213.1:c.2355_2356del,0.0,,,[],[],set(),[],[],[4267]
4137,ATRX Loss-of-function,0.0,,,[],"[10940, 10938, 10939]",{<CIViC source 4470>},[],[],[4269]
4138,EGFR EGFR ITD,0.0,,,[],[],set(),[],[],[4270]
4139,VHL N131*(c.390dupT),0.0,,,[],[10941],{<CIViC source 4472>},[],[],[4271]
4140,BRCA1 L1363P,0.0,,,[],[],set(),[],[],[4272]
4141,BRCA1 L1407P,0.0,,,[],[10947],{<CIViC source 4153>},[],[],[4273]
4142,VHL e,0.0,,,[],[],set(),[],[],[4274]
4143,VHL E31= (c.93G>A),0.0,,,[],[10951],{<CIViC source 4473>},[],[],[4275]
4144,VHL W112C (p.335A>G),0.0,,,[],[],set(),[],[],[4276]
4145,VHL W112C (c.335A>G),0.0,,,[],[],set(),[],[],[4277]
4146,VHL  Y112C (c.335A>G),0.0,,,[],[10958],{<CIViC source 4473>},[],[],[4278]
4147,VHL V165fs (c.493del),0.0,,,[],[10966],{<CIViC source 4473>},[],[],[4279]
4148,EGFR E746_S752insV,0.0,,,[],[4232],{<CIViC source 1991>},[],[],[4280]
4149,VHL V74fs (c.220del),0.0,,,[],[10975],{<CIViC source 4473>},[],[],[4281]
4150,EGFR::PURB Fusion,0.0,,,['EGFR-PURB'],[10996],{<CIViC source 2086>},[],[],[4282]
4151,EGFR::PPARGC1A Fusion,0.0,,,['EGFR-PPARGC1A'],"[11157, 10997]",{<CIViC source 4484>},[],[],[4283]
4152,VHL t(1;3)(p36.3;p25),0.0,,,[],[10998],{<CIViC source 4491>},[],[],[4284]
4154,EGFR::ZNF713 Fusion,0.0,,,['EGFR-ZNF713'],[11156],{<CIViC source 2889>},[],[],[4286]
4156,RRBP1::ALK Fusion,0.0,,,['RRBP1-ALK'],[],set(),[],[],[4288]
4157,EZHIP Overexpression,0.0,,,[],[],set(),[],[],[4289]
4158,MPL S204P,0.0,,,[],"[11008, 11009, 11007]","{<CIViC source 4501>, <CIViC source 4500>, <CIViC source 4499>}",[],[],[4290]
4159,BRCA1 b,0.0,,,[],[],set(),[],[],[4291]
4160,BRCA1 null variant,0.0,,,[],[],set(),[],[],[4292]
4161,KRAS R164G,0.0,,,[],[],set(),[],[],[4293]
4162,EGFR::BRAF Fusion,0.0,,,['EGFR-BRAF'],[11020],{<CIViC source 4505>},[],[],[4294]
4164,VHL Exon 1 Deletion and c.341-50G>A,0.0,,,[],[],set(),[],[],[4296]
4165,FGFR1 Overexpression,0.0,,,[],[11022],{<CIViC source 4503>},[],[],[4297]
4166,FGFR3 G802_X807del,0.0,,,['GLY802_TER807DEL'],[],set(),[],[],[4298]
4167,EML4::NTRK3 Fusion,69.5,,,['EML4-NTRK3'],"[11099, 10419, 10420, 11100, 11517, 10635, 10636, 11859, 10483, 10484, 10506, 10507, 10508, 10379, 10638]","{<CIViC source 4360>, <CIViC source 4951>, <CIViC source 4352>, <CIViC source 4347>, <CIViC source 4329>, <CIViC source 4346>, <CIViC source 4362>, <CIViC source 4328>, <CIViC source 4546>, <CIViC source 4361>, <CIViC source 4547>}",[],[],[4299]
4169,KIF5B::EGFR Fusion,7.5,,,['KIF5B-EGFR'],[11026],{<CIViC source 4522>},[],[],[4300]
4170,BRAF V600E AND BRAF V600M,2.5,,,[],[73],{<CIViC source 88>},[],[],"[12, 1405]"
4171,ALK Amplification,0.0,,,[],[],set(),[],[],[4301]
4172,EML4::ALK Fusion AND ALK Amplification,15.5,,,[],"[766, 767, 440]","{<CIViC source 508>, <CIViC source 262>, <CIViC source 507>}",[],[],"[4301, 5]"
4173,BRAF V600E AND BRAF Amplification,1.0,,,[],"[9885, 92]","{<CIViC source 4206>, <CIViC source 102>}",[],[],"[12, 1269]"
4174,BRAF Amplification AND ( BRAF V600E OR BRAF V600K ),10.0,,,[],[6262],{<CIViC source 1941>},[],[],"[12, 1269, 563]"
4175,EGFR Amplification AND EGFR::SEPTIN14 Fusion,5.0,,,[],"[11151, 10913]","{<CIViC source 4458>, <CIViC source 4466>}",[],[],"[4241, 190]"
4176,NTRK1 G667S,0.0,,,[],[],set(),[],[],[4302]
4177,NTRK1 G595R AND NTRK1 G667S,0.0,,,[],[9593],{<CIViC source 2978>},[],[],"[4302, 2690]"
4178,EML4::ALK Fusion AND EGFR L858R AND ALK Amplification,0.0,,,[],[],set(),[],[],"[4301, 5, 33]"
4179,SRSF2 P95L,3.0,,,['PRO95LEU'],[11027],{<CIViC source 4528>},[],[],[4303]
4180,SRSF2 P95H,3.0,,,['PRO95HIS'],[11028],{<CIViC source 4528>},[],[],[4304]
4181,CIC R201W,0.0,,,[],[11029],{<CIViC source 4529>},[],[],[4305]
4182,KLF5 E419K,2.0,,,[],[11030],{<CIViC source 4530>},[],[],[4306]
4183,KLF5 E419Q,2.0,,,[],[11031],{<CIViC source 4530>},[],[],[4307]
4184,ERC1::ALK Fusion,0.0,,,['ERC1-ALK'],[11032],{<CIViC source 4318>},[],[],[4308]
4185,IGHA1::FGFR3 Fusion,0.0,,,['IGHA1-FGFR3'],[],set(),[],[],[4309]
4186,FGFR3 G802_X807del AND IGHA1::FGFR3 Fusion,0.0,,,[],[11033],{<CIViC source 4542>},[],[],"[4309, 4298]"
4187,KDM6A Loss,0.0,,,[],"[11749, 11034, 11036, 11037, 11750]","{<CIViC source 4894>, <CIViC source 4893>, <CIViC source 4533>}",[],[],[4310]
4188,KDM6A Underexpression,0.0,,,[],[],set(),[],[],[4311]
4189,FLT3 ITD AND KDM6A Loss,0.0,,,[],[11035],{<CIViC source 4533>},[],[],"[4310, 55]"
4190,SMAD2 S276L,1.0,,,[],[11039],{<CIViC source 4535>},[],[],[4312]
4191,POLE L424I,0.0,,,[],[11040],{<CIViC source 4536>},[],[],[4313]
4192,CDKN2B Deletion,0.0,,,[],[],set(),[],[],[4314]
4193,POLE P286H,0.0,,,[],[11041],{<CIViC source 4536>},[],[],[4315]
4194,PAX5 Deletion,0.0,,,[],[],set(),[],[],[4316]
4195,ERG Deletion,0.0,,,[],[],set(),[],[],[4317]
4196,IKZF1 Deletion AND NOT ERG Deletion AND ( P2RY8::CRLF2 Fusion OR CDKN2A Deletion OR CDKN2B Deletion OR PAX5 Deletion ),0.0,,,['IKZF1 PLUS'],[7786],{<CIViC source 3113>},[],[],"[4316, 4314, 4317, 200, 2350, 2654]"
4197,SMARCA2 R1159Q,3.0,,,[],[11042],{<CIViC source 4537>},[],[],[4318]
4198,SMARCA2 K755R,3.0,,,[],[11043],{<CIViC source 4537>},[],[],[4319]
4199,NFE2L2 E79K,0.0,,,[],[11045],{<CIViC source 4538>},[],[],[4320]
4200,NFE2L2 T80K,0.0,,,[],[11046],{<CIViC source 4538>},[],[],[4321]
4201,NFE2L2 L30F,0.0,,,[],[11047],{<CIViC source 4538>},[],[],[4322]
4202,BRAF Mutation OR v::BRAF Fusion,0.0,,,[],[7149],{<CIViC source 864>},[],[],"[2639, 399]"
4203,CBL H94Y,0.0,,,[],[],set(),[],[],[4323]
4204,CBL S80N AND CBL H94Y,0.0,,,[],[7296],{<CIViC source 2879>},[],[],"[4323, 2701]"
4205,ALK L1196M,0.0,,,['LEU1196MET'],[],set(),[],[],[4324]
4206,EML4::ALK Fusion AND ALK L1198F AND ALK L1196M,0.0,,,[],[7594],{<CIViC source 3017>},[],[],"[4324, 5, 1275]"
4210,KRAS G12 OR KRAS G13 OR KRAS Q61,0.0,,,[],"[11055, 11056]",{<CIViC source 2784>},[],[],"[76, 80, 203]"
4211,EGFR Overexpression AND NOT KRAS Mutation,0.0,,,[],"[11058, 11062]",{<CIViC source 2784>},[],[],"[193, 336]"
4212,EGFR Overexpression AND KRAS Mutation,0.0,,,[],[11059],{<CIViC source 2784>},[],[],"[193, 336]"
4213,NOT KRAS Mutation AND ( BRAF V600E OR BRAF D594G ),0.0,,,[],[11060],{<CIViC source 2784>},[],[],"[611, 12, 336]"
4214,NRAS Mutation OR KRAS Mutation OR BRAF Mutation,0.0,,,[],[11061],{<CIViC source 2784>},[],[],"[336, 208, 399]"
4215,KMT2C Loss,0.0,,,[],[6484],{<CIViC source 2586>},[],[],[4326]
4216,PIK3CA E542K AND PTEN Loss,0.0,,,[],[11063],{<CIViC source 1004>},[],[],"[103, 214]"
4217,MYB::QKI Fusion,40.0,,,['MYB-QKI'],"[11065, 11773, 11769]","{<CIViC source 4906>, <CIViC source 4901>, <CIViC source 4543>}",[],[],[4327]
4218,MYB Rearrangement,42.5,,,[],"[11777, 11778, 11776, 11774, 11790]","{<CIViC source 4901>, <CIViC source 4907>, <CIViC source 4905>, <CIViC source 4906>, <CIViC source 4900>}",[],[],[4328]
4219,ALK E1210K,0.0,,,[],[],set(),[],[],[4329]
4220,EML4::ALK Fusion AND ALK E1210K,0.0,,,[],[11066],{<CIViC source 922>},[],[],"[5, 4329]"
4221,EML4::ALK Fusion AND ALK F1245C,14.5,,,[],"[1338, 1339, 11067, 1337]","{<CIViC source 922>, <CIViC source 923>}",[],[],"[5, 549]"
4222,ALK T1151K,0.0,,,[],[],set(),[],[],[4330]
4223,EML4::ALK Fusion AND ALK T1151K,0.0,,,[],[11068],{<CIViC source 922>},[],[],"[5, 4330]"
4224,ALK C1156Y,0.0,,,"['RS1057519859', 'CYS1156TYR']",[],set(),[],[],[4331]
4225,EML4::ALK Fusion AND ALK C1156Y,29.0,,,[],"[8860, 236, 841, 842, 4042, 4046, 1346, 7609, 11069, 7613, 11078, 4043, 4044]","{<CIViC source 3155>, <CIViC source 506>, <CIViC source 166>, <CIViC source 2035>, <CIViC source 2038>, <CIViC source 567>, <CIViC source 924>, <CIViC source 922>, <CIViC source 507>}",[],[],"[5, 4331]"
4226,ALK L1152V,0.0,,,[],[],set(),[],[],[4332]
4227,EML4::ALK Fusion AND ALK L1152V,0.0,,,[],[11070],{<CIViC source 922>},[],[],"[5, 4332]"
4228,EML4::ALK Fusion AND ALK I1171T,0.0,,,[],[11071],{<CIViC source 922>},[],[],"[5, 3371]"
4229,EML4::ALK Fusion AND ALK F1174C,0.0,,,[],"[11072, 11079]",{<CIViC source 922>},[],[],"[5, 1492]"
4230,EML4::ALK Fusion AND ALK L1196M,21.0,,,[],"[7865, 237, 4034, 4036, 4040, 442, 1341, 7597, 7598, 11073, 141, 11080, 4037, 4038, 4039]","{<CIViC source 2036>, <CIViC source 3155>, <CIViC source 2039>, <CIViC source 3017>, <CIViC source 78>, <CIViC source 166>, <CIViC source 262>, <CIViC source 924>, <CIViC source 508>, <CIViC source 922>, <CIViC source 507>, <CIViC source 2037>, <CIViC source 77>}",[],[],"[4324, 5]"
4231,ALK S1206R,0.0,,,[],[],set(),[],[],[4333]
4232,EML4::ALK Fusion AND ALK S1206R,0.0,,,[],"[11074, 11081]",{<CIViC source 922>},[],[],"[5, 4333]"
4233,ALK G1269S,0.0,,,[],[],set(),[],[],[4334]
4234,EML4::ALK Fusion AND ALK G1269S,0.0,,,[],"[11075, 11077]",{<CIViC source 922>},[],[],"[5, 4334]"
4235,EML4::ALK Fusion AND ALK R1275Q,0.0,,,[],[11076],{<CIViC source 922>},[],[],"[5, 9]"
4236,ALK G1202R AND v::ALK Fusion,7.5,"ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.","ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.",['ALK FUSION GLY1202ARG'],"[1357, 4624]","{<CIViC source 262>, <CIViC source 2034>}",[],[],"[171, 499]"
4237,EML4::ALK Fusion AND ALK G1202R,16.0,,,[],"[441, 1345, 1350, 1351, 7593, 1352, 4625]","{<CIViC source 925>, <CIViC source 924>, <CIViC source 262>, <CIViC source 3017>}",[],[],"[5, 171]"
4238,EML4::ALK Fusion AND ALK G1202R AND ALK L1198F,0.0,,,[],[7595],{<CIViC source 3017>},[],[],"[5, 171, 1275]"
4240,TP53 H214R,0.0,,,[],[11082],{<CIViC source 4058>},[],[],[4335]
4241,BRAF V600E AND EZH2 Y646F,0.0,,,[],[6952],{<CIViC source 2307>},[],[],"[2989, 12]"
4242,FLT3LG Expression,0.0,,,[],[],set(),[],[],[4336]
4243,FLT3 Overexpression AND FLT3LG Expression,0.0,,,[],"[11088, 11089]",{<CIViC source 4167>},[],[],"[4336, 603]"
4244,CHD7::BEND2 Fusion,2.5,,,"['CHD7-BEND2', 'Translocation (t(8;X)(q12.2;p22.13))']",[9219],{<CIViC source 3944>},[],[],[4337]
4245,EGFR Amplification AND EGFR EGFRVIII,0.0,,,[],[773],{<CIViC source 515>},[],[],"[190, 1516]"
4246,IGH::CRLF2 Fusion AND JAK2 R683G,0.0,,,[],[7641],{<CIViC source 3032>},[],[],"[2663, 2829]"
4247,CRLF2 Rearrangement ,0.0,,,[],[11097],{<CIViC source 3032>},[],[],[4338]
4248,FLT3 D835N,0.0,,,[],[11091],{<CIViC source 4167>},[],[],[4339]
4249,FLT3 D835G,0.0,,,[],[11092],{<CIViC source 4167>},[],[],[4340]
4250,FLT3 D593del,0.0,,,[],"[11093, 11094]",{<CIViC source 4167>},[],[],[4341]
4251,BRAF V600E AND EGFR L858R AND EGFR T790M,0.0,,,[],[11098],{<CIViC source 4545>},[],[],"[34, 33, 12]"
4253,EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y,20.0,EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.,EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.,[],"[843, 844, 7605]",{<CIViC source 567>},[],[],"[5, 4331, 1275]"
4254,EML4::ALK Fusion AND ALK G1202R AND ALK L1196M,0.0,,,[],"[7591, 7592]",{<CIViC source 3017>},[],[],"[4324, 5, 171]"
4255,EML4::ALK Fusion AND ALK L1152R,10.0,,,[],[763],{<CIViC source 506>},[],[],"[307, 5]"
4256,HMGA2::EGFR Fusion,0.0,,,['HMGA2-EGFR'],[],set(),[],[],[4342]
4257,EGFR::VSTM2A Fusion,0.0,,,['EGFR-VSTM2A'],"[11101, 11102, 11103]","{<CIViC source 4549>, <CIViC source 4425>, <CIViC source 4427>}",[],[],[4343]
4258,EGFR::WIF1 Fusion,0.0,,,['EGFR-WIF1'],[11104],{<CIViC source 4427>},[],[],[4344]
4280,MET Splice Site (c.2888-21_2888-1del),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4366]
4281,MET Splice Site (c.2888-35_2889delinsA),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4367]
4282,MET Splice Site (c.2888-17_2888-3del),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4368]
4283,MET Splice Site (c.2888-10_2911del),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4369]
4284,MET Splice Site (c.2888-37_2888-30del),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4370]
4285,MET Splice Site (c.2888-18_2888-5del),0.0,,,['EXON 14 SPLICE ACCEPTOR VARIANT'],[],set(),[],[],[4371]
4286,MET Splice Site (c.3024_3028+7del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4372]
4287,MET Splice Site (c.3028+1_3028+2insA),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4373]
4288,MET Splice Site (c.3028+1G>T),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[11221],{<CIViC source 4511>},[],[],[4374]
4289,MET Splice Site (c.3028+1G>A),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4375]
4290,MET Splice Site (c.3028+1G>C),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4376]
4291,MET Splice Site (c.3028+2T>C),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[11412],{<CIViC source 4700>},[],[],[4377]
4292,MET Splice Site (c.3028+2T>A),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4378]
4293,MET Splice Site (c.3028+2T>G),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4379]
4294,MET Splice Site (c.3005_3028+3delinsC),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4380]
4295,MET Splice Site (c.2999_3028+4del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4381]
4296,MET Splice Site (c.3017_3028+3del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4382]
4297,MET Splice Site (c.3028_3028+2del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4383]
4298,MET Splice Site (c.3028_3028+3del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4384]
4299,MET Splice Site (c.3028_3028+5del),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4385]
4300,MET Splice Site (c.3028G>A),0.0,,,['EXON 14 SPLICE DONOR VARIANT'],[],set(),[],[],[4386]
4304,v::ALK Fusion AND ALK L1196M,0.0,,,[],"[7611, 2343, 4035]","{<CIViC source 3024>, <CIViC source 2035>, <CIViC source 856>}",[],[],"[4324, 499]"
4305,EML4::ALK Fusion AND ALK L1198F,0.0,,,[],[7603],{<CIViC source 567>},[],[],"[5, 1275]"
4306,TYK2 P1104A,0.0,,,[],[],set(),[],[],[4388]
4307,ALK T1151dup,0.0,The ALK variant with duplication of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment.,The ALK variant with duplication of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment.,['T1151_L1152INST'],[],set(),[],[],[4389]
4308,EML4::ALK Fusion AND ALK T1151dup,18.0,"The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.","The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.",[],"[444, 1347, 1348, 1349, 4608]","{<CIViC source 924>, <CIViC source 262>}",[],[],"[5, 4389]"
4309,EML4::ALK Fusion AND ALK S1206Y,6.0,,,[],"[443, 1343, 4622]","{<CIViC source 924>, <CIViC source 262>}",[],[],"[172, 5]"
4310,ALK S1206Y AND v::ALK Fusion,0.0,,,[],[2865],{<CIViC source 856>},[],[],"[172, 499]"
4311,ALK G1269A AND v::ALK Fusion,10.0,,,[],"[8861, 4617, 4618, 1342, 1354, 1353, 1355]","{<CIViC source 3155>, <CIViC source 2034>, <CIViC source 2035>, <CIViC source 924>, <CIViC source 925>}",[],[],"[308, 499]"
4312,EML4::ALK Fusion AND ALK G1269A,17.5,The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.,The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.,"['EML4-ALK G1269A', 'EML4-ALK GLY1269ALA']","[764, 765, 4619, 4620, 4621]","{<CIViC source 2038>, <CIViC source 924>, <CIViC source 508>, <CIViC source 507>, <CIViC source 2040>}",[],[],"[5, 308]"
4313,ERBB4 E715K,0.0,,,[],[],set(),[],[],[4390]
4314,ERBB4 R687K,0.0,,,[],[],set(),[],[],[4391]
4315,ERBB4 K935I,0.0,,,[],[],set(),[],[],[4392]
4316,BRCA1 S1841N,0.0,,,[],[11126],{<CIViC source 4559>},[],[],[4393]
4317,BRCA1 S1841R,0.0,,,[],[11127],{<CIViC source 4559>},[],[],[4394]
4318,BRCA1 Y1853C,0.0,,,[],[11128],{<CIViC source 4559>},[],[],[4395]
4319,BRCA1 V1838E,0.0,,,[],[11129],{<CIViC source 4559>},[],[],[4396]
4320,BRCA1 R1699Q,0.0,,,[],[11131],{<CIViC source 4559>},[],[],[4397]
4321,BRCA1 T1700A,0.0,,,[],[11132],{<CIViC source 4559>},[],[],[4398]
4322,BRCA1 V1713A,0.0,,,[],[11133],{<CIViC source 4559>},[],[],[4399]
4323,BRCA1 M1775R,0.0,,,[],[11134],{<CIViC source 4559>},[],[],[4400]
4324,BRCA1 M1775K,0.0,,,[],[11135],{<CIViC source 4559>},[],[],[4401]
4325,CDH1 A298T,0.0,,,[],[11140],{<CIViC source 4562>},[],[],[4402]
4326,CDH1 W409R,0.0,,,[],[11141],{<CIViC source 4562>},[],[],[4403]
4327,CDH1 R732Q,0.0,,,[],[11142],{<CIViC source 4562>},[],[],[4404]
4328,EML4::ALK Fusion AND ALK I1171N AND ALK L1196M,17.5,,,[],"[11115, 11113]",{<CIViC source 3949>},[],[],"[4324, 5, 588]"
4329,EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M,7.5,,,[],[11114],{<CIViC source 3949>},[],[],"[4324, 5, 171, 588]"
4330,NPM1::ALK Fusion AND ALK I1171N,0.0,,,[],[4632],{<CIViC source 2110>},[],[],"[588, 513]"
4331,HIP1::ALK Fusion,0.0,,,['HIP1-ALK'],[],set(),[],[],[4405]
4332,ALK I1171N AND HIP1::ALK Fusion,5.0,,,[],[1483],{<CIViC source 995>},[],[],"[588, 4405]"
4333,v::ALK Fusion AND ALK I1171N,0.0,,,[],[4633],{<CIViC source 2115>},[],[],"[588, 499]"
4335,EGFR FGFR1,0.0,,,[],[],set(),[],[],[4407]
4336,EGFR S645C,3.0,,,[],[11144],{<CIViC source 2536>},[],[],[4408]
4337,EGFR K754E,3.0,,,[],[11145],{<CIViC source 2536>},[],[],[4409]
4338,ARAF S214F,3.0,,,[],[11146],{<CIViC source 2536>},[],[],[4410]
4339,ARAF V145L,3.0,,,[],[11148],{<CIViC source 2536>},[],[],[4411]
4340,GNA11 R183C,3.0,,,[],[11149],{<CIViC source 4564>},[],[],[4412]
4341,GNA11 Q209L,3.0,,,[],[11150],{<CIViC source 4564>},[],[],[4413]
4342,EZH2 A692V,0.0,,,"['A687V', 'ALA692VAL', 'ALA687VAL']","[11700, 11707]",{<CIViC source 4850>},[],[],[4414]
4343,EZH2 A682G,0.0,,,"['ALA682GLY', 'A677G', 'ALA677GLY']",[],set(),[],[],[4415]
4344,EZH2 Y646S OR EZH2 Y646F OR EZH2 Y646H OR EZH2 Y646C OR EZH2 Y646N OR EZH2 A692V OR EZH2 A682G,20.0,"The cobas EZH2 Mutation Test is an FDA-companion, qualitative real-time PCR test currently used to identify specific EZH2 mutations to help determine whether patients with follicular lymphoma should be considered for treatment with Tazverik (Tazemetostat). Those mutations can be any of five present in exon 16 (Y646N, Y646F, or Y646X = Y646H, Y646S, Y646C), or two located in exon 18 (A682G and A692V). The Y646X is reported in this manner due to the used master mix in the assay that contains one fluorescent dye to report any of the three variants in the X group.","The cobas EZH2 Mutation Test is an FDA-companion, qualitative real-time PCR test currently used to identify specific EZH2 mutations to help determine whether patients with follicular lymphoma should be considered for treatment with Tazverik (Tazemetostat). Those mutations can be any of five present in exon 16 (Y646N, Y646F, or Y646X = Y646H, Y646S, Y646C), or two located in exon 18 (A682G and A692V). The Y646X is reported in this manner due to the used master mix in the assay that contains one fluorescent dye to report any of the three variants in the X group.",['COBAS EZH2 MUTATION TEST'],"[11109, 11111, 11110]","{<CIViC source 4552>, <CIViC source 4553>}",[],[],"[2989, 4090, 2666, 3364, 3607, 4414, 4415]"
4345,EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion,0.0,,,[],[11152],{<CIViC source 4565>},[],[],"[4241, 1516]"
4346,EGFR Amplification AND EGFR EGFRVIII AND EGFR::SEPTIN14 Fusion,0.0,,,[],[11154],{<CIViC source 4424>},[],[],"[4241, 190, 1516]"
4347,EZH2 expression,5.0,,,[],[11108],{<CIViC source 4551>},[],[],[4416]
4348,ALK G1269A AND EML4::ALK e6::e19 AND ALK Amplification,0.0,,,[],[8887],{<CIViC source 507>},[],[],"[4301, 308, 3204]"
4349,FBXO11::ALK Fusion,0.0,,,['FBXO11-ALK'],[],set(),[],[],[4417]
4350,EML6::ALK Fusion AND FBXO11::ALK Fusion,0.0,,,[],[7428],{<CIViC source 2730>},[],[],"[4417, 2750]"
4351,EML4::ALK Fusion AND ALK V1180L,13.0,,,"['EML4-ALK VAL1180LEU', 'EML4-ALK V1180L']","[1286, 1289, 1290, 1288, 1291]",{<CIViC source 887>},[],[],"[5, 528]"
4352,EGFR::YAP1 Fusion,0.0,,,['EGFR-YAP1'],[11159],{<CIViC source 2889>},[],[],[4418]
4353,NOT KIT D816V,5.0,,,[],"[11158, 11367, 11164]","{<CIViC source 4567>, <CIViC source 4570>, <CIViC source 4675>}",[],[],[65]
4354,KIT D816F,0.0,,,[],[],set(),[],[],[4419]
4355,NOT KIT D816V AND ( KIT V560G OR KIT D816Y OR KIT D816F ),0.0,,,[],"[11163, 11162, 11161]","{<CIViC source 4569>, <CIViC source 4568>}",[],[],"[4419, 65, 984, 972]"
4356,EML4::ALK Fusion AND ALK G1202del,0.0,,,[],[7599],{<CIViC source 3019>},[],[],"[5, 2813]"
4357,EML4::ALK Fusion AND ALK I1171S,5.0,,,[],"[1484, 4794]","{<CIViC source 995>, <CIViC source 2040>}",[],[],"[5, 589]"
4358,HBB E6V,0.0,,,[],[11166],{<CIViC source 4571>},[],[],[4420]
4359,TBX2 Expression,0.0,,,[],[11171],{<CIViC source 4576>},[],[],[4421]
4360,TBXT Expression,0.0,,,[],"[11172, 12067]","{<CIViC source 4576>, <CIViC source 5035>}",[],[],[4422]
4361,TBXT Amplification,0.0,,,[],[11173],{<CIViC source 4578>},[],[],[4423]
4362,TBXT Gain,0.0,,,[],"[11174, 11175]",{<CIViC source 4579>},[],[],[4424]
4363,SMARCB1 Single nucleotide variant,0.0,,,[],[],set(),[],[],[4425]
4364,SMARCB1 Deletion AND SMARCB1 Single nucleotide variant,0.0,,,[],[11177],{<CIViC source 4580>},[],[],"[4425, 696]"
4365,KHDRBS1::NTRK3 Fusion,0.0,,,['KHDRBS1-NTRK3'],[],set(),[],[],[4426]
4366,MET Amplification AND MET Splice Site (c.3028G>A),7.5,,,[],[1095],{<CIViC source 754>},[],[],"[4386, 270]"
4367,MTOR E2419K,0.0,,,[],[],set(),[],[],[4427]
4368,MTOR E2014K AND MTOR E2419K,5.0,,,[],[1438],{<CIViC source 463>},[],[],"[4427, 572]"
4369,MYC Translocation,0.0,,,[],[11809],{<CIViC source 4937>},[],[],[4428]
4370,BCL2 Translocation,0.0,,,[],[11810],{<CIViC source 4937>},[],[],[4429]
4371,BCL6 Translocation,0.0,,,[],[],set(),[],[],[4430]
4372,MYC Translocation AND ( BCL2 Translocation OR BCL6 Translocation ),0.0,,,[],[9813],{<CIViC source 4187>},[],[],"[4428, 4429, 4430]"
4373,BCR::ABL1 Fusion AND ABL1 T315I,174.0,,,[],"[11236, 639, 234, 1390, 8044, 4365, 6197, 2672, 4369, 2668, 4373, 6990, 4362, 4364, 4366, 4368, 4374, 4375, 4376, 7038, 235, 2667, 2669, 2670, 6224, 2671, 4372, 6234, 6235, 6285, 7777, 7778, 7779, 7780, 2673, 4361, 4363, 4367, 4370, 4371, 4377, 4378, 6192, 6196]","{<CIViC source 1624>, <CIViC source 165>, <CIViC source 1621>, <CIViC source 2090>, <CIViC source 2482>, <CIViC source 2093>, <CIViC source 2491>, <CIViC source 1997>, <CIViC source 2091>, <CIViC source 2094>, <CIViC source 1530>, <CIViC source 2092>, <CIViC source 1532>, <CIViC source 1622>, <CIViC source 402>, <CIViC source 2001>, <CIViC source 1529>, <CIViC source 156>, <CIViC source 3249>, <CIViC source 1999>, <CIViC source 1629>, <CIViC source 942>, <CIViC source 2095>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1531>, <CIViC source 2480>, <CIViC source 1996>, <CIViC source 1994>, <CIViC source 2096>}",[],[],"[2, 1]"
4374,BCR::ABL1 Fusion AND ABL1 F311I,5.0,,,"['BCR-ABL PHE311ILE', 'BCR-ABL1 F311I', 'BCR-ABL1 PHE311ILE', 'BCR-ABL F311I']","[4478, 4479, 4477]","{<CIViC source 2090>, <CIViC source 1996>, <CIViC source 1532>}",[],[],"[1, 1507]"
4375,EGFR Mutation AND v::RET Fusion,0.0,,,[],[],set(),[],[],"[442, 1687]"
4376,BCR::ABL1 Fusion AND ABL1 F317L,96.5,"BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.","BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.",[],"[637, 6309, 4381, 6978, 2675, 4384, 4385, 8509, 4382, 7030, 7045, 638, 2677, 6215, 7839, 2674, 2676, 2680, 4380, 4383, 4390, 4391, 6252, 6270]","{<CIViC source 1530>, <CIViC source 2095>, <CIViC source 1621>, <CIViC source 2090>, <CIViC source 401>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 2091>, <CIViC source 1622>, <CIViC source 2480>, <CIViC source 1996>, <CIViC source 400>}",[],[],"[1028, 1]"
4380,BCR::ABL1 Fusion AND ( ABL1 F317L OR ABL1 F317V ),0.0,,,[],[4386],{<CIViC source 2093>},[],[],"[1028, 1, 1525]"
4381,BCR::ABL1 Fusion AND ABL1 F317V,13.0,,,[],"[6208, 7843, 7845, 4535, 6253]","{<CIViC source 1622>, <CIViC source 2480>, <CIViC source 2002>, <CIViC source 1621>}",[],[],"[1, 1525]"
4382,SNCAIP Tandem duplication,0.0,,,[],[11193],{<CIViC source 4588>},[],[],[4432]
4383,IDH1 R132Q,0.0,,,[],"[11195, 11196]",{<CIViC source 4590>},[],[],[4433]
4385,BAP1 Q267fs,0.0,,,[],[11199],{<CIViC source 4593>},[],[],[4435]
4386,CHEK2 mutation,30.0,,,[],"[11205, 11737]","{<CIViC source 4881>, <CIViC source 3554>}",[],[],[4436]
4387,PPP2R2A Mutation,10.0,,,[],[11206],{<CIViC source 3554>},[],[],[4437]
4388,RAD54L Mutation,30.0,,,[],[11207],{<CIViC source 3554>},[],[],[4438]
4389,BRIP1 Mutation,20.0,,,[],[11208],{<CIViC source 3554>},[],[],[4439]
4390,BARD1 Mutation,20.0,,,[],[11209],{<CIViC source 3554>},[],[],[4440]
4391,CHEK1 Mutation,20.0,,,[],[11210],{<CIViC source 3554>},[],[],[4441]
4392,FANCL Mutation,0.0,,,[],[11211],{<CIViC source 3554>},[],[],[4442]
4393,RAD51B Mutation,20.0,,,[],[11212],{<CIViC source 3554>},[],[],[4443]
4394,RAD51C Mutation,0.0,,,[],[11213],{<CIViC source 3554>},[],[],[4444]
4395,RAD51D Mutation,20.0,,,[],[11214],{<CIViC source 3554>},[],[],[4445]
4396,CDKN1A rs1801270 AND CDKN1A rs1059234,0.0,,,[],[],set(),[],[],"[3313, 2671]"
4397,NEAT1 Overexpression,0.0,,,[],[],set(),[],[],[4446]
4398,EGFR::ZNF880 Fusion,0.0,,,['EGFR-ZNF880'],[11215],{<CIViC source 4490>},[],[],[4447]
4399,EZH2 Y646S AND EZH2 Y646F AND EZH2 Y646H AND EZH2 Y646C AND EZH2 Y646N AND EZH2 A692V AND EZH2 A682G,0.0,,,[],[11220],{<CIViC source 2517>},[],[],"[2989, 4090, 2666, 3364, 3607, 4414, 4415]"
4401,EGFR S768I AND EGFR G719A AND EGFR L861Q,0.0,,,[],[],set(),[],[],"[562, 1020, 999]"
4402,ERBB2 L15F,0.0,,,[],"[11231, 11232]",{<CIViC source 3074>},[],[],[4449]
4404,MECP2 c.771_814del,0.0,,,[],[],set(),[],[],[4450]
4405,MECP2 c.21delC,0.0,,,[],[],set(),[],[],[4451]
4406,EGFR L858R AND EGFR Exon 19 Deletion,0.0,,,[],[],set(),[],[],"[33, 133]"
4407,TP53 Loss,3.0,,,[],[1146],{<CIViC source 792>},[],[],[4452]
4408,BRCA1 Mutation AND BRCA2 Mutation,0.0,,,[],[11245],{<CIViC source 3659>},[],[],"[186, 185]"
4409,BRCA1 Mutation OR BRCA2 Mutation,40.0,,,[],"[11243, 11246, 11304, 11305, 11738, 11666]","{<CIViC source 4622>, <CIViC source 4560>, <CIViC source 4882>, <CIViC source 4829>}",[],[],"[186, 185]"
4410,FGFR3 S249C AND FGFR3 R248C AND FGFR3 Y373C AND FGFR3 G370C,0.0,,,[],[11259],{<CIViC source 2927>},[],[],"[2406, 2403, 2404, 628]"
4411,FLT3 D385,0.0,,,[],[],set(),[],[],[4453]
4412,FLT3 internal tandem duplication,0.0,,,[],[],set(),[],[],[4454]
4413,FLT3 D835 AND FLT3 I836 AND FLT3 internal tandem duplication,0.0,,,[],[],set(),[],[],"[4454, 437, 3232]"
4414,FLT3 ITD AND FLT3 D835 AND FLT3 I836,0.0,,,[],"[11260, 11261]","{<CIViC source 2740>, <CIViC source 3080>}",[],[],"[55, 437, 3232]"
4415,IDH2 R140G,0.0,,,[],[],set(),[],[],[4455]
4416,IDH2 R140L,0.0,,,[],[],set(),[],[],[4456]
4417,IDH2 R140Q,0.0,,,[],[],set(),[],[],[4457]
4418,IDH2 R140W,0.0,,,[],[],set(),[],[],[4458]
4419,IDH2 R172G,0.0,,,[],[],set(),[],[],[4459]
4420,IDH2 R172M,0.0,,,[],[],set(),[],[],[4460]
4421,IDH2 R172S,0.0,,,[],[],set(),[],[],[4461]
4422,IDH2 R172W,0.0,,,[],[],set(),[],[],[4462]
4423,IDH2 R172K AND IDH2 R140G AND IDH2 R140L AND IDH2 R140Q AND IDH2 R140W AND IDH2 R172G AND IDH2 R172M AND IDH2 R172S AND IDH2 R172W,0.0,,,[],[],set(),[],[],"[63, 4455, 4458, 4456, 4459, 4461, 4457, 4460, 4462]"
4424,v::RET Fusion OR RET Mutation,0.0,,,[],"[11267, 11268, 12056]","{<CIViC source 5024>, <CIViC source 4613>, <CIViC source 3693>}",[],[],"[1690, 1687]"
4425,TSC1 mutation,0.0,,,[],[],set(),[],[],[4463]
4426,TSC2 mutation,0.0,,,[],[],set(),[],[],[4464]
4427,TSC1 mutation OR TSC2 mutation,0.0,,,[],[11269],{<CIViC source 2869>},[],[],"[4463, 4464]"
4428,NRAS Wildtype,0.0,,,[],"[11270, 11656, 11660, 11662]","{<CIViC source 4629>, <CIViC source 4826>}",[],[],[4465]
4429,PIK3CA E542K AND PIK3CA E545K AND PIK3CA H1047R AND PIK3CA E545A AND PIK3CA E545G AND PIK3CA Q546E AND PIK3CA Q546R AND PIK3CA C420R AND PIK3CA E545D AND PIK3CA H1047Y AND PIK3CA H1047L,0.0,,,[],[],set(),[],[],"[1151, 883, 888, 931, 938, 107, 103, 104, 886, 934, 882]"
4431,BCR::ABL1 Fusion AND ABL1 E255K,83.0,,,[],"[4350, 2660, 4353, 4718, 6232, 4347, 4348, 4351, 4352, 6991, 7039, 233, 2659, 2661, 6214, 2662, 4346, 4349, 4354, 4355, 6193, 6194, 6282]","{<CIViC source 2484>, <CIViC source 1530>, <CIViC source 165>, <CIViC source 2001>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 2480>, <CIViC source 1996>, <CIViC source 1999>, <CIViC source 2096>}",[],[],"[3, 1]"
4432,EGFR L858R OR EGFR Exon 19 Deletion,410.0,,,[],"[11219, 11239, 11240, 12015, 12144, 7363, 11241, 12131, 12156, 3791, 4759, 2156]","{<CIViC source 2909>, <CIViC source 4619>, <CIViC source 4600>, <CIViC source 5103>, <CIViC source 4990>, <CIViC source 1503>, <CIViC source 595>, <CIViC source 1514>, <CIViC source 4620>, <CIViC source 5093>, <CIViC source 5114>}",[],[],"[33, 133]"
4433,TERT c.-124C.T,0.0,,,[],[],set(),[],[],[4466]
4434,ETV6::NTRK2 Fusion AND TERT c.-124C.T,0.0,,,[],[11278],{<CIViC source 4635>},[],[],"[4466, 2396]"
4435,ERBB2 Amplification OR ERBB2 Overexpression,0.0,,,[],[11255],{<CIViC source 708>},[],[],"[306, 875]"
4438,FN1::ALK Fusion,0.0,,,['FN1-ALK'],[11292],{<CIViC source 4642>},[],[],[4468]
4439,TPM4::ALK Fusion,0.0,,,['TPM4-ALK'],[11293],{<CIViC source 4643>},[],[],[4469]
4440,ERBB2 G776V,0.0,,,[],[11295],{<CIViC source 4645>},[],[],[4470]
4441,ARAF Mutation,0.0,,,[],[11297],{<CIViC source 4646>},[],[],[4471]
4442,ARAF S225V,0.0,,,[],[],set(),[],[],[4472]
4443,ARAF P216A,0.0,,,[],[],set(),[],[],[4473]
4444,ARAF Mutation AND ARAF S225V AND ARAF P216A,0.0,,,[],[11296],{<CIViC source 4646>},[],[],"[4471, 4472, 4473]"
4445,BRAF N486_P490 ,0.0,,,[],[11300],{<CIViC source 4647>},[],[],[4474]
4446,MAP2K1 K57_G61del,0.0,,,[],[11301],{<CIViC source 4647>},[],[],[4475]
4447,RET M918T AND RET V804M,0.0,,,[],"[6950, 11307]",{<CIViC source 2677>},[],[],"[113, 2568]"
4448,BRAF V600R AND BRAF Non-V600,0.0,,,[],[11308],{<CIViC source 103>},[],[],"[16, 2408]"
4449,TET2 E796K,0.0,,,[],[],set(),[],[],[4476]
4450,BAX L76R,0.0,,,[],[],set(),[],[],[4477]
4451,AXIN2 P455K,0.0,,,[],[],set(),[],[],[4478]
4452,BRAF V600E AND CDKN2A Deletion AND CDKN2B Deletion AND TET2 E796K AND BAX L76R AND AXIN2 P455K,0.0,,,[],[11314],{<CIViC source 4653>},[],[],"[4314, 4476, 4477, 4478, 12, 2654]"
4453,BRAF V600E OR KIAA1549::BRAF Fusion,0.0,,,[],"[12016, 11316]","{<CIViC source 2973>, <CIViC source 4991>}",[],[],"[618, 12]"
4454,BRCA1 Mutation OR BRCA2 Mutation OR PALB2 Mutation,0.0,,,[],[11317],{<CIViC source 3983>},[],[],"[186, 185, 2759]"
4455,BRCA2 Deletion,0.0,,,[],[],set(),[],[],[4479]
4456,TP53 Deletion,0.0,,,[],[],set(),[],[],[4480]
4457,PTEN Deletion AND BRCA2 Deletion AND TP53 Deletion,0.0,,,[],[11319],{<CIViC source 4655>},[],[],"[4479, 4480, 213]"
4458,EGFR Exon 19 insertion,0.0,,,[],[],set(),[],[],[4481]
4459,EGFR A763_Y764insFQEA OR EGFR Exon 19 insertion,0.0,,,[],[],set(),[],[],"[4481, 1515]"
4460,ERBB2 A775_G776insYVMA,0.0,,,[],[],set(),[],[],[4482]
4461,ERBB2 A775_G776insYVMA,0.0,,,[],[],set(),[],[],[4483]
4462,ERBB2 A775_G776insIVMA,0.0,,,[],[],set(),[],[],[4484]
4463,ERBB2 A775_G776ins YVMA,0.0,,,[],"[11488, 11494]",{<CIViC source 1160>},[],[],[4485]
4464,ERBB2 G778_P780dup,0.0,,,[],"[11762, 1048, 1890, 1892, 285]","{<CIViC source 4879>, <CIViC source 170>, <CIViC source 729>, <CIViC source 661>}",[],[],[4486]
4465,ERBB2 G778-779 insCPG,0.0,,,[],[],set(),[],[],[4487]
4466,ERBB2 G776_V777>VCV,0.0,,,[],[],set(),[],[],[4488]
4467,ERBB2 G776delinsVC,0.0,,,[],[11761],{<CIViC source 4879>},[],[],[4489]
4468,ERBB2 L755P,0.0,,,[],[],set(),[],[],[4490]
4469,ERBB2 V659E,0.0,,,[],[],set(),[],[],[4491]
4470,ERBB2 S310F,5.0,,,[],"[11751, 11496, 11691, 11492, 11493, 11547, 11364, 11365]","{<CIViC source 4879>, <CIViC source 1143>, <CIViC source 4746>, <CIViC source 3074>, <CIViC source 1160>, <CIViC source 4837>}",[],[],[4492]
4471,ERBB2 S335C,0.0,,,[],[],set(),[],[],[4493]
4472,ERBB2 Amplification OR ERBB2 A775_G776insYVMA OR ERBB2 A775_G776insIVMA OR ERBB2 A775_G776ins YVMA OR ERBB2 G778_P780dup OR ERBB2 G778-779 insCPG OR ERBB2 G776_V777>VCV OR ERBB2 G776delinsVC OR ERBB2 L755P OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 S335C,0.0,,,[],[11323],{<CIViC source 3048>},[],[],"[4487, 4483, 4488, 4491, 4484, 4485, 4486, 4489, 4490, 4492, 4493, 306]"
4473,ERBB2 Mutation OR ERBB2 Exon 20 Insertion,0.0,,,[],[],set(),[],[],"[666, 2854]"
4474,ERBB2 G776S,0.0,,,[],[],set(),[],[],[4494]
4475,ERBB2 D769H OR ERBB2 L755S OR ERBB2 V777L OR ERBB2 S310Y OR ERBB2 L755P OR ERBB2 Exon 20 Insertion OR ERBB2 S310F OR ERBB2 G776S,0.0,,,[],[],set(),[],[],"[4494, 4492, 1304, 39, 44, 35, 1215, 2854]"
4476,DCTN1::ALK Fusion,0.0,,,['DCTN1-ALK'],"[10932, 11856]","{<CIViC source 3229>, <CIViC source 4951>}",[],[],[4495]
4477,ZMYM2::FGFR1 Fusion,0.0,,,['ZMYM2-FGFR1'],[1104],{<CIViC source 762>},[],[],[4496]
4478,BCR::FGFR1 Fusion,0.0,,,['BCR-FGFR1'],[11726],{<CIViC source 4873>},[],[],[4497]
4479,CEP43::FGFR1 Fusion,0.0,,,"['FGFR1OP-FGFR1', 'FGFR1OP::FGFR1', 'CEP43-FGFR1']",[],set(),[],[],[4498]
4480,TRIM24::FGFR1 Fusion,0.0,,,['TRIM24-FGFR1'],[],set(),[],[],[4499]
4481,FGFR1 Translocation,0.0,,,[],[],set(),[],[],[4500]
4482,ZMYM2::FGFR1 Fusion OR BCR::FGFR1 Fusion OR CEP43::FGFR1 Fusion OR TRIM24::FGFR1 Fusion OR FGFR1 Translocation,0.0,,,[],"[11324, 12241, 12242]",{<CIViC source 4657>},[],[],"[4497, 4498, 4496, 4499, 4500]"
4483,PCM1::JAK2 Fusion OR ETV6::ABL1 Fusion OR BCR::JAK2 Fusion,0.0,,,[],[],set(),[],[],"[2860, 571, 2575]"
4484,PCM1::JAK2 Fusion OR BCR::JAK2 Fusion,0.0,,,[],[11325],{<CIViC source 4658>},[],[],"[2860, 571]"
4485,KIT Exon 11 Mutation OR KIT Exon 9 Mutation OR PDGFRA Exon 18 Mutation,0.0,,,[],[11327],{<CIViC source 4659>},[],[],"[509, 66, 2623]"
4486,KIT Exon 11 577-582insPYD,0.0,,,[],[],set(),[],[],[4501]
4487,KIT Exon 11 557_560delWKVVE,0.0,,,[],[],set(),[],[],[4502]
4488,KIT L576P OR KIT Amplification OR KIT W557R OR KIT V559A OR KIT V560D OR KIT K642E OR KIT D820Y OR KIT Exon 11 577-582insPYD OR KIT Exon 11 557_560delWKVVE,0.0,,,[],[],set(),[],[],"[4501, 4502, 958, 971, 72, 586, 969, 978, 986]"
4489,RAF1 Mutation,0.0,,,[],[],set(),[],[],[4503]
4490,MAP2K1 Mutation,0.0,,,[],[],set(),[],[],[4504]
4491,MAP2K2 Mutation,0.0,,,[],[],set(),[],[],[4505]
4492,NRAS Mutation OR KRAS Mutation OR RAF1 Mutation OR MAP2K1 Mutation OR MAP2K2 Mutation,0.0,,,[],"[11328, 11329]",{<CIViC source 4646>},[],[],"[4503, 4504, 4505, 336, 208]"
4493,GATA3 Mutation,0.0,,,[],[],set(),[],[],[4506]
4494,GNAS Mutation,0.0,,,[],[],set(),[],[],[4507]
4495,KRAS G12R AND GATA3 Mutation AND GNAS Mutation,0.0,,,[],[11330],{<CIViC source 2886>},[],[],"[530, 4506, 4507]"
4496,ABL1 TKD Mutation OR ABL1 P-Loop Mutation OR ABL1 Non-P-Loop Mutation,0.0,,,[],[11339],{<CIViC source 4663>},[],[],"[2371, 2375, 2376]"
4499,EGFR S768I OR EGFR G719A OR EGFR L861Q,50.0,,,[],[11229],{<CIViC source 594>},[],[],"[562, 1020, 999]"
4500,GAB1::ABL1 Fusion,0.0,,,['GAB1-ABL1'],[],set(),[],[],[4509]
4501,ERBB2 V777L AND PIK3CA H1047R,0.0,,,[],[],set(),[],[],"[44, 107]"
4502,CCNE1 Amplification AND ERBB2 Overexpression,0.0,,,[],[],set(),[],[],"[187, 875]"
4503,LMNA::NTRK1 Fusion AND NTRK1 G595R,6.0,,,[],"[11347, 11350, 11356]",{<CIViC source 4361>},[],[],"[1278, 2690]"
4504,NTRK1 F589L,0.0,,,[],[],set(),[],[],[4510]
4505,LMNA::NTRK1 Fusion AND NTRK1 F589L,6.0,,,[],"[11348, 11351, 11355]",{<CIViC source 4361>},[],[],"[4510, 1278]"
4507,LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L,3.0,,,[],"[11352, 11353, 11358]",{<CIViC source 4361>},[],[],"[4510, 1278, 2690]"
4508,NTRK1 G667C ,0.0,,,[],[],set(),[],[],[4511]
4509,LMNA::NTRK1 Fusion AND NTRK1 G667C ,0.0,,,[],"[11357, 11359]",{<CIViC source 4361>},[],[],"[4511, 1278]"
4510,ERBB2 R143Q,0.0,,,[],"[11360, 11361]",{<CIViC source 3074>},[],[],[4512]
4511,ERBB2 D277H,0.0,,,[],"[11362, 11363]",{<CIViC source 3074>},[],[],[4513]
4512,NOT KIT D816V AND v::PDGFRB Fusion,0.0,,,[],[11368],{<CIViC source 4674>},[],[],"[65, 568]"
4513,KIT F522C,0.0,,,[],[],set(),[],[],[4514]
4514,NOT KIT D816V AND KIT F522C,0.0,,,[],[11366],{<CIViC source 4677>},[],[],"[4514, 65]"
4515,MET R988C,0.0,,,[],[],set(),[],[],[4515]
4516,MET T1010I,0.0,,,[],[],set(),[],[],[4516]
4517,MET R988C AND MET T1010I,0.0,,,[],[11370],{<CIViC source 4513>},[],[],"[4515, 4516]"
4518,MET Amplification OR ERBB2 Amplification,0.0,,,[],[11372],{<CIViC source 4517>},[],[],"[306, 270]"
4519,RIT1 Mutation OR NF1 Mutation,0.0,,,[],[11373],{<CIViC source 4517>},[],[],"[297, 587]"
4520,MDM2 Amplification AND MET D1010H,0.0,,,[],[11374],{<CIViC source 4523>},[],[],"[1261, 1660]"
4521,MET Amplification AND MET Exon 14 Skipping Mutation,0.0,,,[],[11375],{<CIViC source 4520>},[],[],"[324, 270]"
4522,PIK3CA E545K AND MET Exon 14 Skipping Mutation,0.0,,,[],[11376],{<CIViC source 4520>},[],[],"[324, 104]"
4523,NOT MET Amplification AND MET Exon 14 Skipping Mutation,0.0,,,[],"[11381, 11390]","{<CIViC source 4682>, <CIViC source 4518>}",[],[],"[324, 270]"
4524,MET Exon 14 Skipping Mutation AND MET Overexpression,0.0,,,[],[11382],{<CIViC source 4525>},[],[],"[324, 621]"
4526,ROS1 Amplification,0.0,,,[],[],set(),[],[],[4517]
4527,MET Amplification OR ALK Amplification OR ROS1 Amplification,0.0,,,[],[11386],{<CIViC source 2124>},[],[],"[4301, 4517, 270]"
4528,MET Amplification OR MET Exon 14 Skipping Mutation,0.0,,,[],"[11387, 11388, 11458]","{<CIViC source 4738>, <CIViC source 4519>}",[],[],"[324, 270]"
4529,HRAS Overexpression,0.0,,,[],[],set(),[],[],[4518]
4530,MET Y1230C,0.0,,,[],[],set(),[],[],[4519]
4531,MET Exon 14 Skipping Mutation AND MET Y1230C,0.0,,,[],[11389],{<CIViC source 4681>},[],[],"[4519, 324]"
4532,MET Y1230H,0.0,,,[],[],set(),[],[],[4520]
4533,MET Exon 14 Skipping Mutation AND MET Y1230H,0.0,,,[],[11392],{<CIViC source 4684>},[],[],"[4520, 324]"
4534,MET Splice Site (c.3025_3028+5del),0.0,,,[],[11393],{<CIViC source 4685>},[],[],[4521]
4535,EGFR Exon 19 Deletion AND MET Exon 14 Skipping Mutation,0.0,,,[],[11394],{<CIViC source 4686>},[],[],"[324, 133]"
4536,CD274 Overexpression,0.0,,,[],[],set(),[],[],[4522]
4537,MET Exon 14 Skipping Mutation AND CD274 Overexpression,0.0,,,[],"[11419, 11463, 11396, 11397, 11414, 11460, 11695, 11457]","{<CIViC source 4737>, <CIViC source 4742>, <CIViC source 4740>, <CIViC source 4688>, <CIViC source 4702>, <CIViC source 4848>, <CIViC source 4708>}",[],[],"[4522, 324]"
4538,MET Y1003S,0.0,,,[],[11402],{<CIViC source 4690>},[],[],[4523]
4539,MET Exon 14 Skipping Mutation AND MET D1228N,0.0,,,[],"[11403, 11413]","{<CIViC source 4691>, <CIViC source 4701>}",[],[],"[649, 324]"
4541,EGFR L858R AND MET Amplification,0.0,,,[],[11408],{<CIViC source 4696>},[],[],"[33, 270]"
4542,MET Y1003N,0.0,,,[],[],set(),[],[],[4525]
4543,EGFR Exon 19 Deletion AND MET Y1003N,0.0,,,[],[11418],{<CIViC source 4707>},[],[],"[4525, 133]"
4544,MET Amplification AND MYC Amplification,0.0,,,[],"[11420, 11421]",{<CIViC source 4709>},[],[],"[270, 2564]"
4545,MET Exon 14 Skipping Mutation OR MET Overexpression,0.0,,,[],[11422],{<CIViC source 4710>},[],[],"[324, 621]"
4546,EGFR ITD ,0.0,,,[],[11281],{<CIViC source 4471>},[],[],[4526]
4547,BCOR ITD ,165.0,,,['INTERNAL TANDEM DUPLICATION'],"[10801, 10800, 10802, 10804, 11423, 11524, 11525, 10887, 11424, 11581, 11589]","{<CIViC source 4808>, <CIViC source 4711>, <CIViC source 4411>, <CIViC source 4712>, <CIViC source 4805>, <CIViC source 4397>, <CIViC source 4778>, <CIViC source 4777>, <CIViC source 3559>}",[],[],[4527]
4548,ZFTA::RELA Fusion,103.0,,,"['RELA FUSION', 'C11ORF95::RELA', 'ZFTA-RELA']","[8627, 8628, 11432, 11439, 11440, 11448, 11441, 11442]","{<CIViC source 4732>, <CIViC source 4726>, <CIViC source 4719>, <CIViC source 3626>, <CIViC source 3625>}",[],[],[4528]
4549,ABL1 Y253H,0.0,,,"['RS121913461', 'Y272H', 'TYR272HIS']",[],set(),[],[],[4529]
4550,BCR::ABL1 Fusion AND ABL1 Y253H,82.0,,,[],"[4335, 7040, 4336, 4332, 6200, 6992, 7947, 7949, 4331, 4333, 4334, 2654, 4329, 4330, 4337, 4338, 6237]","{<CIViC source 2484>, <CIViC source 2001>, <CIViC source 2090>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 1999>, <CIViC source 2096>}",[],[],"[4529, 1]"
4551,ABL1 Mutation,0.0,,,[],[],set(),[],[],[4530]
4552,BCR::ABL1 Fusion AND ABL1 Mutation,0.0,,,[],[11341],{<CIViC source 4665>},[],[],"[4530, 1]"
4553,BCR::ABL1 Fusion AND ABL1 D276G,18.0,,,[],"[4359, 4357, 2663, 2666, 4356, 4358, 4360, 6246]","{<CIViC source 2002>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1622>, <CIViC source 1996>}",[],[],"[4218, 1]"
4554,RUNX1 R135T,0.0,,,[],[],set(),[],[],[4531]
4555,BCR::ABL1 Fusion AND ABL1 G250E,67.0,,,[],"[4316, 7041, 4319, 6993, 2646, 4313, 4314, 4317, 4318, 2645, 2649, 7853, 9083, 2647, 2648, 4312, 4315, 4320, 4321, 6244, 6267]","{<CIViC source 1530>, <CIViC source 1621>, <CIViC source 2090>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 1999>, <CIViC source 2096>}",[],[],"[1, 1023]"
4556,BCR::ABL1 Fusion AND ABL1 M351T,65.5,,,[],"[4396, 4393, 2683, 4398, 7827, 4394, 4397, 6989, 7037, 2682, 2685, 2686, 7841, 2684, 4392, 4395, 4399, 6254, 7505, 7769]","{<CIViC source 1530>, <CIViC source 1621>, <CIViC source 2090>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 1994>, <CIViC source 2096>}",[],[],"[1029, 1]"
4557,BCR::ABL1 Fusion AND ABL1 A365V,0.0,,,[],[4700],{<CIViC source 1532>},[],[],"[1607, 1]"
4558,BCR::ABL1 Fusion AND ABL1 A366G,0.0,,,[],[4701],{<CIViC source 1532>},[],[],"[1608, 1]"
4559,MET Exon 14 Skipping Mutation AND ( MET D1228N OR MET Y1230H ),0.0,,,[],[],set(),[],[],"[649, 4520, 324]"
4560,ZFTA::NCOA1 Fusion,5.0,,,['ZFTA-NCOA1'],[11428],{<CIViC source 4718>},[],[],[4532]
4561,ZFTA::NCOA2 Fusion,5.0,,,['ZFTA-NCOA2'],[11429],{<CIViC source 4718>},[],[],[4533]
4562,ZFTA::MAML2 Fusion,5.0,,,['ZFTA-MAML2'],[11430],{<CIViC source 4718>},[],[],[4534]
4563,MN1::ZFTA Fusion,2.5,,,['MN1-ZFTA'],[11431],{<CIViC source 4718>},[],[],[4535]
4564,QKI::NTRK2 Fusion,12.5,,,['QKI-NTRK2'],"[11437, 11438, 11449, 11450, 11451]","{<CIViC source 864>, <CIViC source 4733>, <CIViC source 4352>, <CIViC source 4723>}",[],[],[4536]
4565,CDKN2A Deletion AND ZFTA::RELA Fusion,0.0,,,[],[11446],{<CIViC source 4730>},[],[],"[4528, 2654]"
4566,ZFTA::v Fusion,0.0,,,"['ZFTA-v', 'ZFTA Fusion']",[],set(),[],[],[4537]
4567,EGFR Amplification OR MET Amplification,0.0,,,[],[11453],{<CIViC source 4734>},[],[],"[190, 270]"
4569,EGFR Mutation AND ( MET Amplification OR MET Overexpression ),0.0,,,[],[11456],{<CIViC source 4736>},[],[],"[270, 621, 442]"
4570,MET Splice Site (c.2888_3028del),0.0,,,[],[],set(),[],[],[4538]
4571,KRAS G12D AND MET Splice Site (c.2888_3028del),0.0,,,[],[11461],{<CIViC source 4741>},[],[],"[4538, 79]"
4572,MET Splice Site (c.2888_2919del),0.0,,,[],[],set(),[],[],[4539]
4573,MET Amplification AND MET Splice Site (c.2888_2919del),0.0,,,[],[11462],{<CIViC source 4741>},[],[],"[4539, 270]"
4574,MET Splice Site (c.2888-21_2888-20delinsGC),0.0,,,[],[],set(),[],[],[4540]
4575,EGFR G719A AND MET Splice Site (c.2888-21_2888-20delinsGC),0.0,,,[],[11466],{<CIViC source 4745>},[],[],"[4540, 999]"
4576,ERBB2 S653C,0.0,,,[],"[11467, 11468]",{<CIViC source 3074>},[],[],[4541]
4577,DICER1 RNase IIIb Mutation,0.0,,,[],"[11481, 11472]","{<CIViC source 4747>, <CIViC source 4753>}",[],[],[4542]
4578,DICER1 Loss-of-function,0.0,,,[],"[11479, 11473]","{<CIViC source 4747>, <CIViC source 4752>}",[],[],[4543]
4579,DICER1 RNase IIIb Mutation AND DICER1 Loss-of-function,0.0,,,[],"[11471, 11478, 11482, 11483]","{<CIViC source 4752>, <CIViC source 4754>, <CIViC source 4747>, <CIViC source 4755>}",[],[],"[4542, 4543]"
4580,MET Splice Site (c.3028+3A>G),0.0,,,[],[11475],{<CIViC source 4749>},[],[],[4544]
4581,EGFR L858R AND EGFR T790M AND MET Exon 14 Skipping Mutation,0.0,,,[],[11486],{<CIViC source 4758>},[],[],"[34, 324, 33]"
4584,NTRK1 ATRX,0.0,,,[],[],set(),[],[],[4547]
4585,PTEN A121E AND NTRK1 ATRX,0.0,,,[],[11495],{<CIViC source 4287>},[],[],"[4547, 3544]"
4586,ERBB2 T306M,0.0,,,[],[],set(),[],[],[4548]
4587,ERBB2 S310F AND NOT ERBB2 T306M,0.0,,,[],[11497],{<CIViC source 1143>},[],[],"[4492, 4548]"
4588,ERBB2 R678L,0.0,,,[],[11498],{<CIViC source 1143>},[],[],[4549]
4589,ERBB2 V777M,0.0,,,[],[11500],{<CIViC source 1143>},[],[],[4550]
4590,ERCC2 D257N,0.0,,,[],[11506],{<CIViC source 1143>},[],[],[4551]
4591,ERCC2 T484M,0.0,,,[],[11507],{<CIViC source 1143>},[],[],[4552]
4592,ETV6::NTRK3 Fusion AND NTRK3 G623E,0.0,,,[],[],set(),[],[],"[801, 2855]"
4593,ESR1::CCDC170 Fusion,0.0,,,['ESR1-CCDC170'],"[11510, 11511, 11512, 11513, 11514]",{<CIViC source 4764>},[],[],[4553]
4594,EGFR E14,0.0,,,[],[],set(),[],[],[4554]
4596,NTRK3 G623R AND EML4::NTRK3 Fusion,5.0,,,[],"[11515, 11516]",{<CIViC source 4361>},[],[],"[4299, 2691]"
4597,SETD2 Loss,0.0,,,[],[],set(),[],[],[4555]
4598,EPCAM c.556490_*8438del,0.0,,,[],[11518],{<CIViC source 4773>},[],[],[4556]
4600,FGFR3 P449S,0.0,,,['P451S'],[],set(),[],[],[4558]
4603,FGFR3 V57M,0.0,,,[],[],set(),[],[],[4561]
4604,FGFR3 G65R,0.0,,,[],[],set(),[],[],[4562]
4605,FGFR3 T450M,0.0,,,[],[],set(),[],[],[4563]
4606,FGFR3 A717T,0.0,,,[],[],set(),[],[],[4564]
4607,FGFR3 G52S,0.0,,,[],[],set(),[],[],[4565]
4608,FGFR3 R238Q,0.0,,,[],[],set(),[],[],[4566]
4609,FGFR3 G44S,0.0,,,[],[],set(),[],[],[4567]
4610,FGFR3 P799L,0.0,,,[],[],set(),[],[],[4568]
4611,FGFR3 L164V,0.0,,,[],[],set(),[],[],[4569]
4612,FGFR3 T242M,0.0,,,[],[],set(),[],[],[4570]
4613,FGFR3 D758N,0.0,,,[],[],set(),[],[],[4571]
4614,FGFR3 K517R,0.0,,,[],[],set(),[],[],[4572]
4615,FLT3 TKD MUTATION AND FLT3 D835Y,0.0,,,[],[],set(),[],[],"[56, 3011]"
4616,FLT3 ITD AND FLT3 D835Y,0.0,,,[],[247],{<CIViC source 172>},[],[],"[55, 3011]"
4617,FLT3 ITD AND FLT3 D835H,0.0,,,[],[],set(),[],[],"[55, 612]"
4618,JMJD1C::FOXR2 Fusion,0.0,,,['JMJD1C-FOXR2'],[],set(),[],[],[4573]
4620,FOXR2 Rearrangement,40.0,,,[],"[11527, 11528]","{<CIViC source 4781>, <CIViC source 3559>}",[],[],[4575]
4622,YAP1::TFE3 Fusion,40.0,,,['YAP1-TFE3'],"[11682, 11536, 11538, 11537]","{<CIViC source 4788>, <CIViC source 4789>, <CIViC source 4790>}",[],[],[4577]
4623,NM nm0,0.0,,,[],[],set(),[],[],[4578]
4624,v::NTRK1 Fusion AND NTRK1 G595R,0.0,,,[],[11540],{<CIViC source 2445>},[],[],"[419, 2690]"
4625,v::NTRK3 Fusion AND NTRK3 G623R,0.0,,,[],[11541],{<CIViC source 2445>},[],[],"[1277, 2691]"
4626,v::NTRK1 Fusion AND NTRK1 F589L,0.0,,,[],[11542],{<CIViC source 2445>},[],[],"[4510, 419]"
4627,v::NTRK1 Fusion AND NTRK1 G667S,0.0,,,[],[11543],{<CIViC source 2445>},[],[],"[4302, 419]"
4628,NTRK3 G696A,0.0,,,[],[],set(),[],[],[4579]
4629,v::NTRK3 Fusion AND NTRK3 G696A,0.0,,,[],[11544],{<CIViC source 2445>},[],[],"[4579, 1277]"
4630,ND1 p.Ile657Met,0.0,,,[],[],set(),[],[],[4580]
4631,ND1 c.1971T>G,0.0,,,[],[11546],{<CIViC source 4794>},[],[],[4581]
4632,KRAS G12D AND ERBB2 S310F,0.0,,,[],[11548],{<CIViC source 4746>},[],[],"[4492, 79]"
4633,ERBB2 S423R,0.0,,,[],[11549],{<CIViC source 4746>},[],[],[4582]
4634,KRAS G12D AND ERBB2 S423R,0.0,,,[],[11550],{<CIViC source 4746>},[],[],"[4582, 79]"
4635,ERBB2 R678Q AND KRAS G12D,0.0,,,[],[11552],{<CIViC source 4746>},[],[],"[42, 79]"
4637,ERBB2 Q679L,0.0,,,[],[11553],{<CIViC source 4746>},[],[],[4583]
4638,KRAS G12D AND ERBB2 Q679L,0.0,,,[],[11554],{<CIViC source 4746>},[],[],"[4583, 79]"
4639,ERBB2 E717D,0.0,,,[],[11555],{<CIViC source 4746>},[],[],[4584]
4640,KRAS G12D AND ERBB2 E717D,0.0,,,[],[11556],{<CIViC source 4746>},[],[],"[4584, 79]"
4641,ERBB2 L755S AND KRAS G12D,0.0,,,[],[11558],{<CIViC source 4746>},[],[],"[39, 79]"
4642,ERBB2 V777L AND KRAS G12D,0.0,,,[],[11560],{<CIViC source 4746>},[],[],"[44, 79]"
4643,ERBB2 V842I AND KRAS G12D,0.0,,,[],[11562],{<CIViC source 4746>},[],[],"[45, 79]"
4644,MTAP Deletion,0.0,,,[],[12158],{<CIViC source 5116>},[],[],[4585]
4645,VGLL2::v Fusion,0.0,,,['VGLL2 Fusion'],"[11565, 11568]",{<CIViC source 4800>},[],[],[4586]
4646,v::NCOA2 Fusion,0.0,,,['NCOA2 Fusion'],"[11566, 11567]",{<CIViC source 4800>},[],[],[4587]
4647,ERBB2 V842I ,0.0,,,[],[11570],{<CIViC source 4746>},[],[],[4588]
4648,ERBB2 V777L AND KRAS G12C,0.0,,,[],[11572],{<CIViC source 4746>},[],[],"[44, 78]"
4649,ERBB2 E401G,0.0,,,[],"[11579, 11580]",{<CIViC source 4673>},[],[],[4589]
4650,KRAS G12C AND ERBB2 V842I ,0.0,,,[],[11573],{<CIViC source 4746>},[],[],"[4588, 78]"
4651,ERBB2 E410G,0.0,,,[],[],set(),[],[],[4590]
4652,GK rs12069019 Gg,0.0,,,[],[],set(),[],[],[4591]
4653,MET Overexpression AND EWSR1::ATF1 Fusion,0.0,,,[],[11455],{<CIViC source 4735>},[],[],"[621, 3054]"
4655,CRTC1::MAML2 Fusion,0.0,,,['CRTC1-MAML2'],"[11591, 11592]","{<CIViC source 4810>, <CIViC source 4811>}",[],[],[4593]
4656,CRTC3::MAML2 Fusion,0.0,,,['CRTC3-MAML2'],[11593],{<CIViC source 4811>},[],[],[4594]
4657,FOS Rearrangement,0.0,,,[],"[11596, 11786]","{<CIViC source 4912>, <CIViC source 4814>}",[],[],[4595]
4658,FOSB Rearrangement,0.0,,,[],"[11597, 11787]","{<CIViC source 4814>, <CIViC source 4913>}",[],[],[4596]
4659,EGFR T790M AND EGFR Exon 19 Deletion,0.0,,,[],[11598],{<CIViC source 1286>},[],[],"[34, 133]"
4660,EGFR L858R AND EGFR T790M,0.0,,,[],[11599],{<CIViC source 1286>},[],[],"[34, 33]"
4661,ABL1 M244V,0.0,,,"['RS121913456', 'M263V', 'MET263VAL']",[],set(),[],[],[4597]
4662,BCR::ABL1 Fusion AND ABL1 M244V,0.0,,,[],"[4302, 2636, 2639, 4303, 4387, 4305, 4307, 4308, 6994, 4304, 7042, 7825, 2638, 2640, 7850, 4306, 6242, 7771]","{<CIViC source 1530>, <CIViC source 1621>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1620>, <CIViC source 1532>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 2096>, <CIViC source 1996>, <CIViC source 1999>}",[],[],"[4597, 1]"
4663,ABL1 F359V,0.0,,,['RS121913452'],[],set(),[],[],[4598]
4664,BCR::ABL1 Fusion AND ABL1 F359V,0.0,,,[],"[3819, 6970, 2168, 2169, 3815, 3818, 3820, 3816, 3817, 6995, 7043, 8002, 2170, 2167, 3814, 3821, 3822, 6256]","{<CIViC source 2484>, <CIViC source 1530>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1531>, <CIViC source 1997>, <CIViC source 1622>, <CIViC source 2096>, <CIViC source 1996>, <CIViC source 1999>}",[],[],"[4598, 1]"
4665,ERBB2 R34Q,0.0,,,[],[11600],{<CIViC source 4645>},[],[],[4599]
4666,FUS::ERG Fusion,40.0,,,['FUS-ERG'],"[12321, 12322, 11601, 12323]","{<CIViC source 5184>, <CIViC source 4816>, <CIViC source 5186>, <CIViC source 5185>}",[],[],[4600]
4667,FUS::FEV Fusion,0.0,,,['FUS-FEV'],[11602],{<CIViC source 4816>},[],[],[4601]
4668,EWSR1::ERG Fusion,32.5,,,['EWSR1-ERG'],"[475, 10338, 11603]","{<CIViC source 4816>, <CIViC source 4815>, <CIViC source 289>}",[],[],[4602]
4669,EWSR1::NFATC2 Fusion,0.0,,,['EWSR1-NFATC2'],[11604],{<CIViC source 4817>},[],[],[4603]
4670,FUS::NFATC2 Fusion,0.0,,,['FUS-NFATC2'],[11605],{<CIViC source 4817>},[],[],[4604]
4671,ARHGAP26 Overexpression,0.0,,,[],[],set(),[],[],[4605]
4672,ABL1 E255V,0.0,,,"['RS121913449', 'GLU255VAL']",[],set(),[],[],[4606]
4673,BCR::ABL1 Fusion AND ABL1 E255V,54.5,,,[],"[4447, 2656, 4448, 6971, 4443, 7245, 4444, 4446, 6986, 2850, 2851, 4441, 4442, 4445, 4449, 4450, 4451]","{<CIViC source 2484>, <CIViC source 1530>, <CIViC source 2001>, <CIViC source 2090>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 2096>}",[],[],"[4606, 1]"
4674,ABL1 F359I,0.0,,,"['RS121913452', 'F378I', 'PHE359ILE']",[],set(),[],[],[4607]
4675,BCR::ABL1 Fusion AND ABL1 F359I,0.0,,,[],"[4532, 4533, 4530, 4531, 6984, 4529]","{<CIViC source 2002>, <CIViC source 1532>, <CIViC source 1997>, <CIViC source 1996>, <CIViC source 2096>}",[],[],"[4607, 1]"
4676,PTCH1 Loss-of-function,0.0,,,[],"[11607, 11608]","{<CIViC source 4820>, <CIViC source 4819>}",[],[],[4608]
4677,ABL1 E355G,0.0,,,"['RS121913450', 'GLU355GLY']",[],set(),[],[],[4609]
4678,BCR::ABL1 Fusion AND ABL1 E355G,0.0,,,[],"[4403, 2664, 4404, 8090, 4401, 4400, 4402, 7036, 4405, 6255]","{<CIViC source 1530>, <CIViC source 2001>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1622>, <CIViC source 2096>, <CIViC source 1996>, <CIViC source 1999>}",[],[],"[4609, 1]"
4679,ABL1 F359C,0.0,,,"['RS1057519775', 'F378C', 'PHE359CYS']",[],set(),[],[],[4610]
4680,BCR::ABL1 Fusion AND ABL1 F359C,0.0,,,"['BCR-ABL1 F359C', 'BCR-ABL1 PHE359CYS', 'BCR-ABL F359C', 'BCR-ABL PHE359CYS', 'BCR::ABL1 F359C']","[4483, 4482, 6233, 4481, 4484, 4480, 6985, 7035, 2854, 6239]","{<CIViC source 2484>, <CIViC source 2104>, <CIViC source 1998>, <CIViC source 1532>, <CIViC source 1997>, <CIViC source 1622>, <CIViC source 2096>}",[],[],"[4610, 1]"
4681,BCR::ABL1 Fusion AND ARAF S214C,0.0,,,[],[],set(),[],[],"[10, 1]"
4682,ABL1 H396R,0.0,,,"['RS121913454', 'HIS396ARG']",[],set(),[],[],[4611]
4683,BCR::ABL1 Fusion AND ABL1 H396R,0.0,,,"['BCR-ABL1 H396R', 'BCR-ABL H396R', 'BCR::ABL H396R', 'BCR::ABL1 H396R']","[4413, 7823, 2688, 4414, 4415, 4410, 4411, 6988, 2687, 2689, 4409, 4412, 4416, 4417, 6258]","{<CIViC source 1530>, <CIViC source 2001>, <CIViC source 2002>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1997>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 1999>, <CIViC source 2096>}",[],[],"[4611, 1]"
4684,FGFR2::? Fusion,0.0,,,[],"[10406, 10404]",{<CIViC source 4325>},[],[],[4612]
4685,FGFR2::v Fusion OR FGFR2::? Fusion,75.0,,,['FGFR2 FUSION OR REARRANGEMENT'],"[8173, 11230, 11609, 5908, 7329, 11612, 11632, 1913]","{<CIViC source 2896>, <CIViC source 4612>, <CIViC source 1337>, <CIViC source 4823>, <CIViC source 2384>, <CIViC source 4821>, <CIViC source 3360>}",[],[],"[2202, 4612]"
4686,FGFR2::KIAA1217 Fusion,0.0,,,['FGFR2-KIAA1217'],"[11611, 11647]","{<CIViC source 4823>, <CIViC source 4821>}",[],[],[4613]
4687,TNIP1::PDGFRB Fusion,0.0,,,['TNIP1-PDGFRB'],[11626],{<CIViC source 2495>},[],[],[4614]
4688,FGFR2::POC1B Fusion,0.0,,,['FGFR2-POC1B'],[11627],{<CIViC source 4823>},[],[],[4615]
4689,FGFR2::DBP Fusion,0.0,,,['FGFR2-DBP'],[11628],{<CIViC source 4823>},[],[],[4616]
4690,FGFR2::FILIP1 Fusion,0.0,,,['FGFR2-FILIP1'],[11630],{<CIViC source 4823>},[],[],[4617]
4691,FGFR2 C383R,0.0,,,[],[11631],{<CIViC source 4823>},[],[],[4618]
4692,FGFR1::TACC1 Fusion,0.0,,,['FGFR1-TACC1'],[11634],{<CIViC source 4823>},[],[],[4619]
4693,FGFR1 M563T,0.0,,,[],[11636],{<CIViC source 4823>},[],[],[4620]
4694,FGFR1::PLAG1 Fusion,0.0,,,['FGFR1-PLAG1'],[11639],{<CIViC source 4823>},[],[],[4621]
4695,FGFR2::NRAP Fusion,0.0,,,['FGFR2-NRAP'],[11641],{<CIViC source 4823>},[],[],[4622]
4696,FGFR2 Amplification AND FGFR2::? Fusion,0.0,,,[],[11642],{<CIViC source 4823>},[],[],"[4612, 629]"
4697,FGFR2::WAC Fusion,0.0,,,['FGFR2-WAC'],[11643],{<CIViC source 4823>},[],[],[4623]
4698,FGFR2::TNS1 Fusion,0.0,,,['FGFR2-TNS1'],[11644],{<CIViC source 4823>},[],[],[4624]
4699,FGFR2::TTC28 Fusion,0.0,,,['FGFR2-TTC28'],[11645],{<CIViC source 4823>},[],[],[4625]
4700,FGFR2::CCDC6 Fusion,0.0,,,['FGFR2-CCDC6'],[11646],{<CIViC source 4823>},[],[],[4626]
4702,SLC4A4::ROS1 Fusion,0.0,,,['SLC4A4-ROS1'],[11651],{<CIViC source 4599>},[],[],[4628]
4703,RET D378_G685>E,0.0,,,[],[11658],{<CIViC source 4827>},[],[],[4629]
4704,ERBB3 Mutation,0.0,,,[],[],set(),[],[],[4630]
4705,ERBB2 Amplification OR ERBB2 Mutation OR ERBB3 Mutation,0.0,,,[],[],set(),[],[],"[306, 4630, 666]"
4706,ERBB2 Mutation OR ERBB3 Mutation,0.0,,,[],[11669],{<CIViC source 4831>},[],[],"[4630, 666]"
4707,BRAF V600E OR BRAF K601E,15.0,,,[],[11670],{<CIViC source 4832>},[],[],"[12, 584]"
4709,CCND1 Amplification OR CCND2 Amplification OR CCND3 Amplification,0.0,,,[],[11673],{<CIViC source 4835>},[],[],"[18, 2746, 2747]"
4710,FGFR1 K656E,0.0,,,[],[],set(),[],[],[4631]
4711,FGFR1 Amplification OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion OR FGFR2 FGFR2 mutations,0.0,,,[],[],set(),[],[],"[267, 1691, 629, 569, 2206, 827]"
4712,FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion,0.0,,,[],[11675],{<CIViC source 3447>},[],[],"[267, 511, 1691, 629, 569, 827]"
4713,ABL1 L248V,0.0,,,"['RS121913455', 'LEU248VAL', 'L267V']",[],set(),[],[],[4632]
4714,BCR::ABL1 Fusion AND ABL1 L248V,0.0,,,[],"[6308, 2642, 4310, 7029, 7044, 2641, 2644, 4309, 4311, 6236]","{<CIViC source 1530>, <CIViC source 2002>, <CIViC source 1998>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1622>, <CIViC source 1996>}",[],[],"[4632, 1]"
4715,BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Mutation,0.0,,,[],[11681],{<CIViC source 4841>},[],[],"[275, 12, 587, 336, 208]"
4716,CDKN2A Loss OR CDKN2A Mutation,15.0,,,[],"[11653, 11654]",{<CIViC source 4825>},[],[],"[554, 2704]"
4718,ABL1 Q252H,0.0,,,"['GLN252HIS', 'Q271H', 'RS121913458']",[],set(),[],[],[4634]
4719,BCR::ABL1 Fusion AND ABL1 Q252H,31.0,,,[],"[2651, 4327, 2652, 2650, 2653, 7849, 4322, 4323, 4324, 4325, 4326, 4328, 6245, 6274, 7506, 7507, 6219]","{<CIViC source 1530>, <CIViC source 1621>, <CIViC source 2090>, <CIViC source 2001>, <CIViC source 2002>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 2480>, <CIViC source 1994>}",[],[],"[4634, 1]"
4720,ABL1 F486S,0.0,,,"['PHE486SER', 'F505S']",[],set(),[],[],[4635]
4721,BCR::ABL1 Fusion AND ABL1 F486S,0.0,,,[],"[4571, 8091, 4440, 6987, 2829, 4438, 4439]","{<CIViC source 1530>, <CIViC source 2002>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1997>}",[],[],"[4635, 1]"
4722,ABL1 A397P,0.0,,,"['A416P', 'ALA397PRO']",[],set(),[],[],[4636]
4723,BCR::ABL1 Fusion AND ABL1 A397P,0.0,,,[],"[4709, 4710, 7034]","{<CIViC source 1998>, <CIViC source 1532>}",[],[],"[4636, 1]"
4724,ABL1 D363G,0.0,,,['Asp363Gly'],[],set(),[],[],[4637]
4725,BCR::ABL1 Fusion AND ABL1 D363G,0.0,,,[],"[4692, 7820]",{<CIViC source 2096>},[],[],"[4637, 1]"
4726,ABL1 D421G,0.0,,,['ASP421GLY'],[],set(),[],[],[4638]
4727,BCR::ABL1 Fusion AND ABL1 D421G,0.0,,,[],[4559],{<CIViC source 1996>},[],[],"[4638, 1]"
4728,ABL1 V299L,0.0,,,"['RS1057519771', 'VAL299LEU']",[],set(),[],[],[4639]
4729,BCR::ABL1 Fusion AND ABL1 E255K AND ABL1 V299L,0.0,,,[],[7781],{<CIViC source 2002>},[],[],"[4639, 3, 1]"
4730,BCR::ABL1 Fusion AND ABL1 V299L,22.0,,,[],"[6982, 4541, 4538, 4540, 2862, 6216, 4537, 4539, 6241, 6247, 7767]","{<CIViC source 2090>, <CIViC source 2002>, <CIViC source 2093>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1997>, <CIViC source 1622>, <CIViC source 2480>}",[],[],"[4639, 1]"
4731,MAP2K4 Amplification,0.0,,,[],[12081],{<CIViC source 4845>},[],[],[4640]
4732,MLH1 Loss,0.0,,,[],[],set(),[],[],[4641]
4733,MSH2 Loss OR MLH1 Loss,0.0,,,[],[11677],{<CIViC source 4838>},[],[],"[4641, 808]"
4734,EZH2 Mutation OR SMARCA4 Loss OR SMARCB1 Loss,0.0,,,[],[11694],{<CIViC source 4846>},[],[],"[163, 2644, 3202]"
4735,MET Splice Site (c.3027_3028+21delAGGTATATTTCAGTTTATTGTTC,0.0,,,[],[],set(),[],[],[4642]
4736,EGFR T790M AND EGFR Exon 19 Deletion AND MET Splice Site (c.3027_3028+21delAGGTATATTTCAGTTTATTGTTC,0.0,,,[],[11693],{<CIViC source 4847>},[],[],"[34, 4642, 133]"
4737,NF1 Inactivating Mutation,0.0,,,[],[],set(),[],[],[4643]
4738,BRAF Inactivating Mutation,0.0,,,[],[],set(),[],[],[4644]
4739,NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation OR BRAF Inactivating Mutation,0.0,,,[],[],set(),[],[],"[275, 4643, 4644, 336, 208]"
4740,NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR BRAF Mutation OR NF1 Inactivating Mutation,0.0,,,[],[],set(),[],[],"[275, 4643, 336, 208, 399]"
4741,ABL1 T315A,0.0,,,"['THR315ALA', 'T334A', 'RS1057519772']",[],set(),[],[],[4645]
4742,BCR::ABL1 Fusion AND ABL1 T315A,0.0,,,[],"[6190, 7842, 7844, 7768]","{<CIViC source 2480>, <CIViC source 2002>, <CIViC source 1621>}",[],[],"[4645, 1]"
4743,BCR::ABL1 Fusion AND ABL1 E279K,0.0,,,[],"[4543, 4542, 4544, 7772]","{<CIViC source 2002>, <CIViC source 1529>, <CIViC source 1532>}",[],[],"[1526, 1]"
4744,BCR::ABL1 Fusion AND ABL1 E292L,0.0,,,[],[7773],{<CIViC source 2002>},[],[],"[1, 2887]"
4745,BCR::ABL1 Fusion AND ABL1 E292V,0.0,,,[],"[4474, 2853]","{<CIViC source 1622>, <CIViC source 1532>}",[],[],"[1183, 1]"
4746,BCR::ABL1 Fusion AND ABL1 E450Q,0.0,,,[],[7942],{<CIViC source 2096>},[],[],"[1, 1618]"
4747,v::TFEB Fusion,20.0,,,"['TFEB Fusion', ' t(6;11)(p21;q12)']","[11534, 11535, 11539]","{<CIViC source 4786>, <CIViC source 4791>, <CIViC source 4787>}",[],[],[4646]
4748,BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation,0.0,,,[],[11696],{<CIViC source 4841>},[],[],"[275, 4643, 12, 336, 208]"
4749,RB1 Wildtype,0.0,,,[],[],set(),[],[],[4647]
4750,RB1 Wildtype AND ( CDKN2A Loss OR CDKN2A Mutation ),0.0,,,[],[11665],{<CIViC source 4828>},[],[],"[4647, 554, 2704]"
4751,TFEB Amplification,0.0,,,[],[10625],{<CIViC source 4339>},[],[],[4648]
4752,UFD1::NTRK2 Fusion,0.0,,,['UFD1-NTRK2'],[],set(),[],[],[4649]
4754,RALGPS2::NTRK3 Fusion,0.0,,,['RALGPS2-NTRK3'],[],set(),[],[],[4651]
4756,IDH2 Mutation OR IDH1 Mutation,0.0,,,[],[11708],{<CIViC source 4762>},[],[],"[645, 570]"
4757,KRAS Alteration,0.0,,,[],[],set(),[],[],[4653]
4758,CDKN2A alteration,0.0,,,[],[],set(),[],[],[4654]
4759,SMAD4 Alteration,0.0,,,[],[],set(),[],[],[4655]
4760,TP53 ALTERATION OR KRAS Alteration OR CDKN2A alteration OR SMAD4 Alteration,0.0,,,[],[],set(),[],[],"[4653, 4654, 4655, 1307]"
4761,TP53 R267W,0.0,,,[],[],set(),[],[],[4656]
4762,KRAS G12D AND KRAS G12R AND CDKN2A Loss AND CDKN2B Loss AND SMAD4 Deletion AND TP53 R267W,0.0,,,[],[11711],{<CIViC source 4855>},[],[],"[530, 4656, 79, 554, 555, 646]"
4763,KRAS G12D AND KRAS G12R AND CDKN2A Loss AND CDKN2B Loss AND TP53 R267W,0.0,,,[],[11710],{<CIViC source 4855>},[],[],"[530, 4656, 79, 554, 555]"
4764,TP53 V218E,0.0,,,[],[],set(),[],[],[4657]
4765,BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E,0.0,,,[],[11712],{<CIViC source 4855>},[],[],"[306, 4657, 12, 564]"
4766,ERBB2 E321G,0.0,,,[],[],set(),[],[],[4658]
4767,CDKN2A p16 R80*,0.0,,,[],[],set(),[],[],[4659]
4768,KRAS G12D AND CDKN2A p16 R80*,0.0,,,[],[11713],{<CIViC source 4855>},[],[],"[4659, 79]"
4769,ERBB2 E265K,0.0,,,[],[],set(),[],[],[4660]
4770,ERBB2 G279E,0.0,,,[],[],set(),[],[],[4661]
4771,ERBB2 G309E,0.0,,,[],[],set(),[],[],[4662]
4772,ERBB2 G292R,0.0,,,[],"[12119, 12116, 12117, 12118]","{<CIViC source 4645>, <CIViC source 1645>, <CIViC source 5075>, <CIViC source 5083>}",[],[],[4663]
4773,ERBB2 G660D,0.0,,,[],[],set(),[],[],[4664]
4774,NF1 D1976fs,0.0,,,[],[],set(),[],[],[4665]
4775,KRAS G12D AND GNAS R201C AND NF1 D1976fs,0.0,,,[],[11714],{<CIViC source 4855>},[],[],"[826, 4665, 79]"
4776,ERBB2 R678W,0.0,,,[],[],set(),[],[],[4666]
4777,ERBB2 L726F,0.0,,,[],[],set(),[],[],[4667]
4778,ERBB2 L726I,0.0,,,[],[],set(),[],[],[4668]
4779,ERBB2 T733I,0.0,,,[],[],set(),[],[],[4669]
4780,ERBB2 L755A,0.0,,,[],[11752],{<CIViC source 4879>},[],[],[4670]
4781,ERBB2 L755R,0.0,,,[],[],set(),[],[],[4671]
4782,ERBB2 L755F,0.0,,,[],[],set(),[],[],[4672]
4783,ERBB2 L755M,0.0,,,[],[11753],{<CIViC source 4879>},[],[],[4673]
4784,ERBB2 L755V,0.0,,,[],[],set(),[],[],[4674]
4785,ERBB2 D769V,0.0,,,[],[],set(),[],[],[4675]
4786,ERBB2 D769N,0.0,,,[],[],set(),[],[],[4676]
4787,ERBB2 L785P,0.0,,,[],[],set(),[],[],[4677]
4788,ERBB2 G776C,0.0,,,[],[],set(),[],[],[4678]
4789,ERBB2 G776D,0.0,,,[],[],set(),[],[],[4679]
4790,ERBB2 V777A,0.0,,,[],[],set(),[],[],[4680]
4791,ERBB2 P780L,0.0,,,[],[],set(),[],[],[4681]
4792,ERBB2 V794M,0.0,,,[],[],set(),[],[],[4682]
4793,ERBB2 D808N,0.0,,,[],[],set(),[],[],[4683]
4794,ERBB2 D821N,0.0,,,[],[],set(),[],[],[4684]
4795,ERBB2 T862I,0.0,,,[],[],set(),[],[],[4685]
4796,ERBB2 E914K,0.0,,,[],[],set(),[],[],[4686]
4797,ERBB2 R896H,0.0,,,[],[],set(),[],[],[4687]
4798,ERBB2 Y537N,0.0,,,[],[],set(),[],[],[4688]
4799,ERBB2 D538G,0.0,,,[],[],set(),[],[],[4689]
4800,TCF3::PBX1 Fusion,90.0,,,['TCF3-PBX1'],"[11771, 11715, 11717, 11718, 11720, 11772, 11724, 11719]","{<CIViC source 4903>, <CIViC source 4858>, <CIViC source 4869>, <CIViC source 4863>, <CIViC source 4864>, <CIViC source 4861>, <CIViC source 4899>, <CIViC source 4865>}",[],[],[4690]
4803,KRAS G13E,0.0,,,[],[],set(),[],[],[4693]
4804,XRCC3 Mutation,0.0,,,[],[],set(),[],[],[4694]
4805,ORC1 Mutation,0.0,,,[],[],set(),[],[],[4695]
4806,XRCC3 Mutation OR ORC1 Mutation,0.0,,,[],[11716],{<CIViC source 4866>},[],[],"[4694, 4695]"
4807,RET TKD Mutation,0.0,,,[],[11721],{<CIViC source 4870>},[],[],[4696]
4808,RET CLD1 Mutation,0.0,,,[],[11722],{<CIViC source 4870>},[],[],[4697]
4809,FGFR1 FUS,0.0,,,[],[],set(),[],[],[4698]
4810,KIF5B::FGFR1 e15::e11,0.0,,,['KIF5B-FGFR1'],[11725],{<CIViC source 4872>},[],[],[4699]
4811,TP53 ALTERATION AND VEGFA Overexpression,0.0,,,[],[],set(),[],[],"[1307, 2585]"
4812,TP53 Mutation AND VEGFA Overexpression,0.0,,,[],[11727],{<CIViC source 4874>},[],[],"[2585, 222]"
4813,MUS81 Mutation,0.0,,,[],[],set(),[],[],[4700]
4814,NBN Mutation,0.0,,,[],[],set(),[],[],[4701]
4815,ATM Mutation OR BRCA2 Mutation OR RAD51B Mutation OR MUS81 Mutation OR NBN Mutation,0.0,,,[],[],set(),[],[],"[186, 4443, 4700, 4701, 178]"
4816,MUS81 Loss,0.0,,,[],[],set(),[],[],[4702]
4817,RAD51B Loss,0.0,,,[],[],set(),[],[],[4703]
4818,BRCA2 Loss,0.0,,,[],[],set(),[],[],[4704]
4819,NBN Loss OR ATM Loss OR MUS81 Loss OR RAD51B Loss OR BRCA2 Loss,0.0,,,[],[11728],{<CIViC source 4876>},[],[],"[4703, 4704, 4702, 853, 1880]"
4820,BCR::ABL1 Fusion AND ( ABL1 T315I OR ABL1 E255K ),0.0,,,[],[],set(),[],[],"[3, 2, 1]"
4821,KRAS G12W,0.0,,,[],[],set(),[],[],[4705]
4822,KRAS G12F,0.0,,,[],[],set(),[],[],[4706]
4823,KRAS G12N,0.0,,,[],[],set(),[],[],[4707]
4824,KRAS A59G,0.0,,,[],[],set(),[],[],[4708]
4825,NRAS G13E,0.0,,,[],[],set(),[],[],[4709]
4826,NRAS G12W,0.0,,,[],[],set(),[],[],[4710]
4827,NRAS G12A,0.0,,,[],[],set(),[],[],[4711]
4828,BCR::ABL1 Fusion AND ABL1 E450V,0.0,,,[],"[4563, 4564]","{<CIViC source 1996>, <CIViC source 1532>}",[],[],"[1534, 1]"
4829,BCR::ABL1 Fusion AND ABL1 E453A,0.0,,,[],"[4567, 6980]",{<CIViC source 1997>},[],[],"[1536, 1]"
4830,BCR::ABL1 Fusion AND ABL1 E453K,0.0,,,[],"[4566, 4565]","{<CIViC source 1996>, <CIViC source 1532>}",[],[],"[1535, 1]"
4831,EMILIN2::PDGFD Fusion,0.0,,,[],[11732],{<CIViC source 4880>},[],[],[4712]
4832,BCR::ABL1 Fusion AND ABL1 E453Q,0.0,,,[],[4486],{<CIViC source 1996>},[],[],"[1509, 1]"
4833,BCR::ABL1 Fusion AND ABL1 E459K,0.0,,,[],"[6310, 8092, 7031, 7046]","{<CIViC source 1530>, <CIViC source 1998>, <CIViC source 1532>}",[],[],"[1, 2370]"
4834,BCR::ABL1 Fusion AND ABL1 E98G,0.0,,,[],"[4711, 7822]",{<CIViC source 2096>},[],[],"[1, 2901]"
4835,BCR::ABL1 Fusion AND ABL1 F311L,0.0,,,[],"[4546, 4547, 4548, 6238]","{<CIViC source 1622>, <CIViC source 1996>, <CIViC source 1531>, <CIViC source 1532>}",[],[],"[1528, 1]"
4836,BCR::ABL1 Fusion AND ABL1 F317C,0.0,,,[],[6250],{<CIViC source 1622>},[],[],"[1, 2359]"
4837,BCR::ABL1 Fusion AND ABL1 F317I,0.0,,,[],"[4726, 6251, 6217]","{<CIViC source 1622>, <CIViC source 2480>, <CIViC source 2095>}",[],[],"[1625, 1]"
4838,BCR::ABL1 Fusion AND ABL1 F317R,0.0,,,[],[7774],{<CIViC source 2002>},[],[],"[1, 2888]"
4839,BCR::ABL1 Fusion AND ABL1 F317S,0.0,,,[],[6218],{<CIViC source 2480>},[],[],"[1, 2343]"
4840,NRAS G12F,0.0,,,[],[],set(),[],[],[4713]
4841,NRAS G12N,0.0,,,[],[],set(),[],[],[4714]
4842,NRAS G12R,0.0,,,[],[],set(),[],[],[4715]
4843,NRAS Q61E,0.0,,,[],[],set(),[],[],[4716]
4844,NRAS A59G,0.0,,,[],[],set(),[],[],[4717]
4845,BAP1 Deficient,0.0,,,[],[],set(),[],[],[4718]
4846,BRCA1 Deficient,0.0,,,[],[],set(),[],[],[4719]
4847,BAP1 Deficient OR BRCA1 Deficient,0.0,,,[],[],set(),[],[],"[4718, 4719]"
4848,SETD2 Mutation,0.0,,,[],[],set(),[],[],[4720]
4849,BAP1 Mutation OR NF2 Mutation OR SETD2 Mutation,0.0,,,[],[11742],{<CIViC source 4885>},[],[],"[183, 4720, 659]"
4850,NTRK3 SPECC1L,0.0,,,[],[],set(),[],[],[4721]
4851,SPECC1L::NTRK3 Fusion,0.0,,,[],[11745],{<CIViC source 4890>},[],[],[4722]
4852,ERBB2 A775_G776insTVMA,0.0,,,[],[11755],{<CIViC source 4879>},[],[],[4723]
4853,ERBB2 A775_G776insV,0.0,,,[],[11756],{<CIViC source 4879>},[],[],[4724]
4854,ERBB2 A775_G776insVVMA,0.0,,,[],[11757],{<CIViC source 4879>},[],[],[4725]
4855,ERBB2 G776_V777delinsVCD,0.0,,,[],[11758],{<CIViC source 4879>},[],[],[4726]
4856,ERBB2 G776delinsCV,0.0,,,[],[11759],{<CIViC source 4879>},[],[],[4727]
4857,ERBB2 G776delinsLC,0.0,,,[],[11760],{<CIViC source 4879>},[],[],[4728]
4858,ERBB2 G778_S779insLPS,0.0,,,[],[11763],{<CIViC source 4879>},[],[],[4729]
4859,MCL1 Amplification,0.0,,,[],[11768],{<CIViC source 4897>},[],[],[4730]
4860,NRAS A59T,0.0,,,[],[],set(),[],[],[4731]
4861,NRAS A146V,0.0,,,[],[],set(),[],[],[4732]
4862,NRAS A146T,0.0,,,[],[],set(),[],[],[4733]
4863,NRAS A146P,0.0,,,[],[],set(),[],[],[4734]
4864,NRAS K117N,0.0,,,[],[],set(),[],[],[4735]
4865,RET C609S,0.0,,,[],[],set(),[],[],[4736]
4866,RET C609R,0.0,,,[],[],set(),[],[],[4737]
4867,RET C609G,0.0,,,[],[],set(),[],[],[4738]
4868,RET C609F,0.0,,,[],[],set(),[],[],[4739]
4869,RET C609W,0.0,,,[],[],set(),[],[],[4740]
4870,RET C611S,0.0,,,[],[],set(),[],[],[4741]
4871,RET C611R,0.0,,,[],[],set(),[],[],[4742]
4872,BCR::ABL1 Fusion AND ABL1 G398R,0.0,,,[],"[2864, 4560, 4561]",{<CIViC source 1529>},[],[],"[1233, 1]"
4873,BCR::ABL1 Fusion AND ABL1 H396P,0.0,,,[],"[4554, 4556, 7846, 7847, 9084, 4379, 4555, 4557, 4558, 6240, 7770]","{<CIViC source 1621>, <CIViC source 2002>, <CIViC source 1529>, <CIViC source 1532>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 1996>, <CIViC source 1994>}",[],[],"[1, 1531]"
4874,BCR::ABL1 Fusion AND ABL1 I432T,0.0,,,[],[4562],{<CIViC source 1996>},[],[],"[1533, 1]"
4875,BCR::ABL1 Fusion AND ABL1 L248R,0.0,,,[],"[6210, 6243, 7776]","{<CIViC source 1622>, <CIViC source 2480>, <CIViC source 2002>}",[],[],"[2340, 1]"
4876,BCR::ABL1 Fusion AND ABL1 L248R AND ABL1 F359I,0.0,,,[],[7775],{<CIViC source 2002>},[],[],"[2340, 4607, 1]"
4877,BCR::ABL1 Fusion AND ABL1 L364I,0.0,,,[],"[4434, 4485, 7826]","{<CIViC source 1532>, <CIViC source 2096>}",[],[],"[1508, 1]"
4878,MYBL1 Rearrangement,40.0,,,[],"[11780, 11781, 11779]","{<CIViC source 4907>, <CIViC source 4901>, <CIViC source 4905>}",[],[],[4743]
4880,SERPINE1::FOSB Fusion,0.0,,,[],[11785],{<CIViC source 4911>},[],[],[4745]
4881,ARID1A Wildtype,0.0,,,[],[],set(),[],[],[4746]
4882,ARID1A Loss OR ARID1A Wildtype,0.0,,,[],[11789],{<CIViC source 4917>},[],[],"[1293, 4746]"
4883,EGFR P753L,0.0,,,[],[],set(),[],[],[4747]
4884,BCR::ABL1 Fusion AND ABL1 L364P,0.0,,,[],[4551],{<CIViC source 1996>},[],[],"[1530, 1]"
4885,BCR::ABL1 Fusion AND ABL1 L384M,0.0,,,[],"[7824, 4527, 4525, 4526, 4528, 2861]","{<CIViC source 2002>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1622>, <CIViC source 2096>}",[],[],"[1, 1230]"
4886,BCR::ABL1 Fusion AND ABL1 L387F,0.0,,,[],"[4553, 4552, 6981, 2863]","{<CIViC source 1622>, <CIViC source 1996>, <CIViC source 1997>}",[],[],"[1232, 1]"
4887,BCR::ABL1 Fusion AND ABL1 L387M,0.0,,,[],"[4406, 4407, 4408]","{<CIViC source 2096>, <CIViC source 1531>, <CIViC source 1532>}",[],[],"[1488, 1]"
4888,BCR::ABL1 Fusion AND ABL1 L364I AND ABL1 M244V,0.0,,,[],[7943],{<CIViC source 2096>},[],[],"[1508, 4597, 1]"
4889,BCR::ABL1 Fusion AND ABL1 M343T,0.0,,,[],[4534],{<CIViC source 2002>},[],[],"[1524, 1]"
4890,BCR::ABL1 Fusion AND ABL1 M388L,0.0,,,[],[7950],{<CIViC source 2096>},[],[],"[1, 1610]"
4891,BCR::ABL1 Fusion AND ABL1 N146S,0.0,,,[],[7945],{<CIViC source 2096>},[],[],"[1, 2951]"
4892,PRKCB Mutation,0.0,,,[],"[11794, 11978]","{<CIViC source 4968>, <CIViC source 4923>}",[],[],[4748]
4893,PLCG1 S345F,0.0,,,[],[11795],{<CIViC source 4924>},[],[],[4749]
4894,RALGPS2::NTRK3 e1::e4,0.0,,,['RALGPS2-NTRK3'],[11699],{<CIViC source 4851>},[],[],[4750]
4895,TP53 Mutation AND TP53 Overexpression,0.0,,,[],[],set(),[],[],"[222, 1306]"
4896,GATAD2A::LYN Fusion,0.0,,,['GATAD2A-LYN'],[],set(),[],[],[4751]
4897,BCR::ABL1 Fusion AND ABL1 N331S,0.0,,,[],"[4550, 4549]","{<CIViC source 1996>, <CIViC source 1997>}",[],[],"[1, 1529]"
4898,BCR::ABL1 Fusion AND ABL1 N336S,0.0,,,[],"[4769, 6979]",{<CIViC source 1997>},[],[],"[1, 1640]"
4899,BCR::ABL1 Fusion AND ABL1 P480A,0.0,,,[],[4568],{<CIViC source 1996>},[],[],"[1, 1537]"
4900,BCR::ABL1 Fusion AND ABL1 Q252R,0.0,,,[],[4693],{<CIViC source 2001>},[],[],"[1600, 1]"
4901,BCR::ABL1 Fusion AND ABL1 Q300R,0.0,,,[],"[4545, 6983]",{<CIViC source 1997>},[],[],"[1527, 1]"
4902,BCR::ABL1 Fusion AND ABL1 S417Y,0.0,,,[],"[2679, 4712, 4713]","{<CIViC source 1530>, <CIViC source 1532>, <CIViC source 1999>}",[],[],"[1, 1613]"
4903,BCR::ABL1 Fusion AND ABL1 S438C,0.0,,,[],[7948],{<CIViC source 2096>},[],[],"[1495, 1]"
4904,MYC Translocation AND BCL2 Translocation,0.0,,,[],[11811],{<CIViC source 4937>},[],[],"[4428, 4429]"
4905,DDX3X D347G,0.0,,,[],[11812],{<CIViC source 4938>},[],[],[4752]
4906,ARID1A Q185*,0.0,,,[],[11813],{<CIViC source 4938>},[],[],[4753]
4907,CCND3 mutation,0.0,,,[],"[11926, 11814]","{<CIViC source 258>, <CIViC source 4938>}",[],[],[4754]
4908,BCL7A mutation,0.0,,,[],"[11936, 11816]","{<CIViC source 4965>, <CIViC source 4938>}",[],[],[4755]
4909,CHD8 mutation,0.0,,,[],[11817],{<CIViC source 4938>},[],[],[4756]
4910,FBXO11 mutation,0.0,,,[],[11818],{<CIViC source 4938>},[],[],[4757]
4911,FOXO1 mutation,0.0,,,[],"[11934, 11819]","{<CIViC source 258>, <CIViC source 4938>}",[],[],[4758]
4912,GNA13 mutation,0.0,,,[],"[11912, 11820, 11821]","{<CIViC source 258>, <CIViC source 4938>, <CIViC source 4939>}",[],[],[4759]
4913,WNK1 mutation,0.0,,,[],[11823],{<CIViC source 4941>},[],[],[4760]
4914,USP7 mutation,0.0,,,[],[11824],{<CIViC source 4938>},[],[],[4761]
4915,TFAP4 mutation,0.0,,,[],[11826],{<CIViC source 4938>},[],[],[4762]
4916,TCF3 mutation,0.0,,,[],[11827],{<CIViC source 4942>},[],[],[4763]
4917,SIN3A mutation,0.0,,,[],"[11984, 11829]","{<CIViC source 4968>, <CIViC source 4938>}",[],[],[4764]
4918,RFX7 mutation,0.0,,,[],[11831],{<CIViC source 4938>},[],[],[4765]
4919,PCBP1 mutation,0.0,,,[],[11833],{<CIViC source 4943>},[],[],[4766]
4920,P2RY8 mutation,0.0,,,[],"[11973, 11834]","{<CIViC source 4944>, <CIViC source 257>}",[],[],[4767]
4921,KMT2D mutation,0.0,,,[],"[11836, 11835, 11871, 11892, 11896]","{<CIViC source 258>, <CIViC source 4952>, <CIViC source 4949>, <CIViC source 4938>}",[],[],[4768]
4922,BMP7 mutation,0.0,,,[],[11837],{<CIViC source 4946>},[],[],[4769]
4923,EIF4A1 mutation,0.0,,,[],[11838],{<CIViC source 4946>},[],[],[4770]
4924,GNAI2 mutation,0.0,,,[],"[11943, 11839]","{<CIViC source 4971>, <CIViC source 4938>}",[],[],[4771]
4925,HNRNPU mutation,0.0,,,[],[11840],{<CIViC source 4946>},[],[],[4772]
4926,ID3 mutation,0.0,,,[],[11841],{<CIViC source 4947>},[],[],[4773]
4927,BIRC3 mutation,0.0,,,[],[11843],{<CIViC source 4949>},[],[],[4774]
4928,DAZAP1 mutation,0.0,,,[],[11845],{<CIViC source 4949>},[],[],[4775]
4929,EWSR1 mutation,0.0,,,[],[11846],{<CIViC source 4949>},[],[],[4776]
4930,HNRNPH1 non-coding mutations,0.0,,,[],"[11905, 11847]",{<CIViC source 4949>},[],[],[4777]
4931,EEF1G::ROS1 Fusion,0.0,,,[],[11850],{<CIViC source 4951>},[],[],[4778]
4932,EML1::NTRK2 Fusion,0.0,,,[],[11852],{<CIViC source 4951>},[],[],[4779]
4933,RET T930P,0.0,,,[],"[11863, 11868]",{<CIViC source 4870>},[],[],[4780]
4934,RET T930K,0.0,,,[],"[11864, 11869]",{<CIViC source 4870>},[],[],[4781]
4935,RET D898_E901del,0.0,,,[],"[11865, 11870]",{<CIViC source 4870>},[],[],[4782]
4936,RET T930M,0.0,,,[],[11866],{<CIViC source 4870>},[],[],[4783]
4937,MEF2B mutation,0.0,,,[],"[11919, 11872]","{<CIViC source 258>, <CIViC source 4952>}",[],[],[4784]
4938,RET E632_L633del,0.0,,,[],"[11875, 11873]","{<CIViC source 4954>, <CIViC source 4953>}",[],[],[4785]
4939,RET C618R,0.0,,,[],[11877],{<CIViC source 4954>},[],[],[4786]
4940,RET C611G,0.0,,,[],[],set(),[],[],[4787]
4941,RET C611Y,0.0,,,[],[],set(),[],[],[4788]
4942,RET C618S,0.0,,,[],[],set(),[],[],[4789]
4943,RET C618Y,0.0,,,[],[],set(),[],[],[4790]
4944,RET C618F,0.0,,,[],[],set(),[],[],[4791]
4945,RET C618W,0.0,,,[],[],set(),[],[],[4792]
4946,RET C620R,0.0,,,[],[],set(),[],[],[4793]
4947,FGFR1 Amplification OR FGFR2 Amplification,0.0,,,[],[],set(),[],[],"[267, 629]"
4948,FGFR1 Alteration,0.0,,,[],[],set(),[],[],[4794]
4949,FGFR2 Alteration,0.0,,,[],[],set(),[],[],[4795]
4950,FGFR1 Alteration OR FGFR2 Alteration,0.0,,,[],[11883],{<CIViC source 4958>},[],[],"[4794, 4795]"
4951,BCR::ABL1 Fusion AND ABL1 T315V,0.0,,,[],[7766],{<CIViC source 2002>},[],[],"[1, 2885]"
4952,YAP1::MAMLD1 Fusion,0.0,,,[],[11888],{<CIViC source 4961>},[],[],[4796]
4953,YAP1::FAM118B Fusion,0.0,,,[],[11889],{<CIViC source 4962>},[],[],[4797]
4954,YAP1::v Fusion,0.0,,,['YAP1 Fusion'],[11890],{<CIViC source 3626>},[],[],[4798]
4955,UBR5 Mutation,0.0,,,[],[11897],{<CIViC source 4949>},[],[],[4799]
4956,NSD2 Mutation,0.0,,,[],[11898],{<CIViC source 4949>},[],[],[4800]
4957,SP140 Mutation,0.0,,,[],[11901],{<CIViC source 4949>},[],[],[4801]
4958,NOTCH2 Mutation,0.0,,,[],"[11902, 11971]","{<CIViC source 3409>, <CIViC source 4949>}",[],[],[4802]
4959,S1PR1 Mutation,0.0,,,[],[11903],{<CIViC source 4949>},[],[],[4803]
4960,NFKBIE Mutation,0.0,,,[],"[11904, 11966]","{<CIViC source 3409>, <CIViC source 4949>}",[],[],[4804]
4961,ACTB Mutation,0.0,,,[],[11906],{<CIViC source 257>},[],[],[4805]
4962,ARID1A Mutation,0.0,,,[],[11907],{<CIViC source 4964>},[],[],[4806]
4963,TNFRSF14 Mutation,0.0,,,[],[11909],{<CIViC source 258>},[],[],[4807]
4964,SGK1 Mutation,0.0,,,[],[11910],{<CIViC source 258>},[],[],[4808]
4965,BCL10 Mutation,0.0,,,[],[11911],{<CIViC source 258>},[],[],[4809]
4966,BTG2 Mutation,0.0,,,[],[11914],{<CIViC source 258>},[],[],[4810]
4967,BCL6 Mutation,0.0,,,[],[11915],{<CIViC source 258>},[],[],[4811]
4968,CIITA Mutation,0.0,,,[],[11916],{<CIViC source 258>},[],[],[4812]
4969,FAS Mutation,0.0,,,[],[11917],{<CIViC source 258>},[],[],[4813]
4970,BTG1 Mutation,0.0,,,[],[11918],{<CIViC source 258>},[],[],[4814]
4971,IRF8 Mutation,0.0,,,[],[11920],{<CIViC source 258>},[],[],[4815]
4972,TMEM30A Mutation,0.0,,,[],[11921],{<CIViC source 258>},[],[],[4816]
4973,TMEM30A loss-of-function mutation,0.0,,,[],[11922],{<CIViC source 4966>},[],[],[4817]
4974,CD58 Mutation,0.0,,,[],[11923],{<CIViC source 258>},[],[],[4818]
4975,KLHL6 Mutation,0.0,,,[],[11924],{<CIViC source 258>},[],[],[4819]
4976,CD70 Mutation,0.0,,,[],[11925],{<CIViC source 258>},[],[],[4820]
4977,CREBBP Mutation,0.0,,,[],"[8501, 11927]","{<CIViC source 3552>, <CIViC source 4967>}",[],[],[4821]
4978,EP300 Mutation,0.0,,,[],[11928],{<CIViC source 4967>},[],[],[4822]
4979,H1-2 Mutation,0.0,,,[],[11929],{<CIViC source 258>},[],[],[4823]
4980,ETS1 Mutation,0.0,,,[],[11931],{<CIViC source 258>},[],[],[4824]
4981,IRF4 Mutation,0.0,,,[],[11933],{<CIViC source 258>},[],[],[4825]
4982,BCL11A Mutation,0.0,,,[],[11935],{<CIViC source 4968>},[],[],[4826]
4983,CXCR4 Mutation,0.0,,,[],[11939],{<CIViC source 4969>},[],[],[4827]
4984,DDX3X Mutation,0.0,,,[],[11940],{<CIViC source 3409>},[],[],[4828]
4985,DTX1 Mutation,0.0,,,[],[11941],{<CIViC source 3409>},[],[],[4829]
4986,DUSP2 Mutation,0.0,,,[],[11942],{<CIViC source 4965>},[],[],[4830]
4987,EBF1 Mutation,0.0,,,[],[11999],{<CIViC source 4965>},[],[],[4831]
4988,GRHPR Mutation,0.0,,,[],[11944],{<CIViC source 3409>},[],[],[4832]
4989,H1-5 Mutation,0.0,,,[],[11945],{<CIViC source 4968>},[],[],[4833]
4990,H1-3 Mutation,0.0,,,[],[11946],{<CIViC source 4968>},[],[],[4834]
4991,H2AC6 Mutation,0.0,,,[],[11947],{<CIViC source 4968>},[],[],[4835]
4992,H2AC17 Mutation,0.0,,,[],[11948],{<CIViC source 4968>},[],[],[4836]
4993,H2BC5 Mutation,0.0,,,[],[11949],{<CIViC source 4965>},[],[],[4837]
4994,H2BC12 Mutation,0.0,,,[],[11950],{<CIViC source 4968>},[],[],[4838]
4995,HLA-A Mutation,0.0,,,[],[11951],{<CIViC source 4968>},[],[],[4839]
4996,HLA-B Mutation,0.0,,,[],[11952],{<CIViC source 4968>},[],[],[4840]
4997,HLA-C Mutation,0.0,,,[],[11953],{<CIViC source 4968>},[],[],[4841]
4998,HVCN1 Mutation,0.0,,,[],[11954],{<CIViC source 4968>},[],[],[4842]
4999,IL4R Mutation,0.0,,,[],[11955],{<CIViC source 4972>},[],[],[4843]
5000,ITPKB Mutation,0.0,,,[],[11956],{<CIViC source 3409>},[],[],[4844]
5001,KLF2 Mutation,0.0,,,[],[11957],{<CIViC source 3409>},[],[],[4845]
5002,KLHL14 Mutation,0.0,,,[],[11958],{<CIViC source 4964>},[],[],[4846]
5003,LTB Mutation,0.0,,,[],[11961],{<CIViC source 4968>},[],[],[4847]
5004,LYN Mutation,0.0,,,[],[11962],{<CIViC source 4968>},[],[],[4848]
5005,MEF2C Mutation,0.0,,,[],[11963],{<CIViC source 4968>},[],[],[4849]
5006,MGA Mutation,0.0,,,[],[11964],{<CIViC source 4964>},[],[],[4850]
5007,MPEG1 Mutation,0.0,,,[],[11965],{<CIViC source 4939>},[],[],[4851]
5008,NFKBIA Mutation,0.0,,,[],[11967],{<CIViC source 3409>},[],[],[4852]
5009,NFKBIZ 3-prime UTR mutation,0.0,,,[],[11968],{<CIViC source 4939>},[],[],[4853]
5010,NOL9 Mutation,0.0,,,[],[11969],{<CIViC source 3409>},[],[],[4854]
5011,OSBPL10 Mutation,0.0,,,[],[11972],{<CIViC source 3409>},[],[],[4855]
5012,PIM1 Mutation,0.0,,,[],[11974],{<CIViC source 4973>},[],[],[4856]
5013,PIM2 Mutation,0.0,,,[],[11975],{<CIViC source 3409>},[],[],[4857]
5014,POU2AF1 Mutation,0.0,,,[],[11976],{<CIViC source 4974>},[],[],[4858]
5015,POU2F2 Mutation,0.0,,,[],[11977],{<CIViC source 4968>},[],[],[4859]
5016,PRKDC Mutation,0.0,,,[],[11979],{<CIViC source 3409>},[],[],[4860]
5017,S1PR2 Mutation,0.0,,,[],[11982],{<CIViC source 4965>},[],[],[4861]
5018,SETD1B Mutation,0.0,,,[],[11983],{<CIViC source 4965>},[],[],[4862]
5019,SOCS1 Mutation,0.0,,,[],[11986],{<CIViC source 4975>},[],[],[4863]
5020,SPEN Mutation,0.0,,,[],[11987],{<CIViC source 4965>},[],[],[4864]
5021,STAT3 Mutation,0.0,,,[],[11988],{<CIViC source 4976>},[],[],[4865]
5022,STAT5B Mutation,0.0,,,[],[],set(),[],[],[4866]
5023,STAT6 Mutation,0.0,,,[],[11989],{<CIViC source 4977>},[],[],[4867]
5024,TBL1XR1 Mutation,0.0,,,[],[11990],{<CIViC source 4978>},[],[],[4868]
5025,TNFAIP3 Mutation,0.0,,,[],[11991],{<CIViC source 4979>},[],[],[4869]
5026,TOX Mutation,0.0,,,[],[11993],{<CIViC source 4965>},[],[],[4870]
5027,UBE2A Mutation,0.0,,,[],[11994],{<CIViC source 4965>},[],[],[4871]
5028,WEE1 Mutation,0.0,,,[],[11995],{<CIViC source 3409>},[],[],[4872]
5029,XPO1 Mutation,0.0,,,[],[11996],{<CIViC source 4978>},[],[],[4873]
5030,ZFP36L1 Mutation,0.0,,,[],[11997],{<CIViC source 4968>},[],[],[4874]
5031,TMSB4X Mutation,0.0,,,[],[11998],{<CIViC source 4980>},[],[],[4875]
5032,BIRC6 Mutation,0.0,,,[],[12000],{<CIViC source 4965>},[],[],[4876]
5033,CD83 Mutation,0.0,,,[],[12001],{<CIViC source 4965>},[],[],[4877]
5034,ZNF292 Mutation,0.0,,,[],[12002],{<CIViC source 4965>},[],[],[4878]
5035,S100B Expression,0.0,,,[],[],set(),[],[],[4879]
5036,LMNA::NTRK1 Fusion AND NOT S100B Expression,0.0,,,[],[],set(),[],[],"[1278, 4879]"
5037,LMNA::NTRK1 Fusion AND S100B Expression,0.0,,,[],[12006],{<CIViC source 2878>},[],[],"[1278, 4879]"
5038,UFD1::NTRK2 e6::e7,0.0,,,[],[11697],{<CIViC source 4851>},[],[],[4880]
5039,VPS18::NTRK3 e4::e1,0.0,,,[],[11698],{<CIViC source 4851>},[],[],[4881]
5040,MYB Truncation,0.0,,,[],[11775],{<CIViC source 4900>},[],[],[4882]
5041,RET C620S,0.0,,,[],[],set(),[],[],[4883]
5042,RET C620G,0.0,,,[],[],set(),[],[],[4884]
5043,RET C620Y,0.0,,,[],[],set(),[],[],[4885]
5044,RET C620F,0.0,,,[],[],set(),[],[],[4886]
5045,RET P628_L633del,0.0,,,[],[],set(),[],[],[4887]
5046,RET C630S,0.0,,,[],[],set(),[],[],[4888]
5047,RET C630R,0.0,,,[],[],set(),[],[],[4889]
5048,RET C630G,0.0,,,[],[],set(),[],[],[4890]
5049,RET C630Y,0.0,,,[],[],set(),[],[],[4891]
5050,RET C630F,0.0,,,[],[],set(),[],[],[4892]
5051,RET D631del,0.0,,,[],[],set(),[],[],[4893]
5052,RET D631Y,0.0,,,[],[],set(),[],[],[4894]
5053,RET D631_L633delinsE,0.0,,,[],[],set(),[],[],[4895]
5054,RET E632_A639delinsHR,0.0,,,[],[],set(),[],[],[4896]
5055,BRAF Alteration,0.0,,,[],[],set(),[],[],[4897]
5056,RET E632_T636delinsSS,0.0,,,[],[],set(),[],[],[4898]
5057,RET E632_C634delinsG,0.0,,,[],[],set(),[],[],[4899]
5058,RET E632_L633delinsV,0.0,,,[],[],set(),[],[],[4900]
5059,RET C634S,0.0,,,[],[],set(),[],[],[4901]
5060,RET C634G,0.0,,,[],[],set(),[],[],[4902]
5061,RET C634Y,0.0,,,[],[],set(),[],[],[4903]
5062,RET C634F,0.0,,,[],[],set(),[],[],[4904]
5063,RET C634L,0.0,,,[],[],set(),[],[],[4905]
5064,AKT1 Mutation,0.0,,,[],[],set(),[],[],[4906]
5065,PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation,0.0,,,[],[12020],{<CIViC source 4994>},[],[],"[311, 510, 4906]"
5066,ROS1 G2032R AND v::ROS1 Fusion,0.0,,,[],"[12022, 12236, 1251]","{<CIViC source 4995>, <CIViC source 867>, <CIViC source 5147>}",[],[],"[1271, 2693]"
5067,FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification,0.0,,,[],[12024],{<CIViC source 4997>},[],[],"[267, 629, 2906, 2907]"
5068,APC Mutation OR CTNNB1 Activating Mutation,0.0,,,[],[12023],{<CIViC source 4996>},[],[],"[174, 1296]"
5069,ERBB2 T790M,0.0,,,[],[],set(),[],[],[4907]
5070,ERBB2 Activating Mutation OR ERBB2 T790M,0.0,,,[],[12026],{<CIViC source 4999>},[],[],"[2657, 4907]"
5071,NF1 Mutation OR GNA11 Q209L,0.0,,,[],[12027],{<CIViC source 5000>},[],[],"[587, 4413]"
5072,CD74::ROS1 Fusion,0.0,,,[],[],set(),[],[],[4908]
5073,ROS1 L2026M AND CD74::ROS1 Fusion,0.0,,,[],"[1253, 1252, 1257, 1258]","{<CIViC source 867>, <CIViC source 868>}",[],[],"[516, 4908]"
5074,FIP1L1::PDGFRA Fusion AND PDGFRA T674I,0.0,,,[],"[7020, 1446, 1779, 4420]","{<CIViC source 376>, <CIViC source 1241>, <CIViC source 2097>, <CIViC source 2720>}",[],[],"[574, 577]"
5075,ROS1 G2032R AND CD74::ROS1 Fusion,0.0,"The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.","The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.",[],"[1100, 1254, 1101, 1249, 1250, 1255]","{<CIViC source 866>, <CIViC source 759>, <CIViC source 381>, <CIViC source 868>}",[],[],"[1271, 4908]"
5076,ROS1 G2032R AND SLC4A4::ROS1 Fusion,0.0,,,[],[7538],{<CIViC source 2998>},[],[],"[1271, 4628]"
5077,BRAF V600 OR v::BRAF Fusion,0.0,,,[],[12028],{<CIViC source 4991>},[],[],"[17, 2639]"
5078,NR4A3 reg_e@[SCPP]::NR4A3,0.0,,,[],[12030],{<CIViC source 5004>},[],[],[4909]
5079,RET A640G,0.0,,,[],[],set(),[],[],[4910]
5080,RET V642I,0.0,,,[],[],set(),[],[],[4911]
5081,RET S649L,0.0,,,[],[],set(),[],[],[4912]
5082,RET E768Q,0.0,,,[],[],set(),[],[],[4913]
5083,RET E768G,0.0,,,[],[],set(),[],[],[4914]
5084,RET E768D,0.0,,,[],[],set(),[],[],[4915]
5085,RET R770Q,0.0,,,[],[],set(),[],[],[4916]
5086,RET N777S,0.0,,,[],[],set(),[],[],[4917]
5087,RET V778I,0.0,,,[],[],set(),[],[],[4918]
5088,RET Q781R,0.0,,,[],[],set(),[],[],[4919]
5089,RET L881V,0.0,,,[],[],set(),[],[],[4920]
5090,RET A883F,0.0,,,[],[],set(),[],[],[4921]
5091,RET A883S,0.0,,,[],[],set(),[],[],[4922]
5092,RET A883T,0.0,,,[],[],set(),[],[],[4923]
5093,RET A883V,0.0,,,[],[],set(),[],[],[4924]
5094,RET E884V,0.0,,,[],[],set(),[],[],[4925]
5095,RET R886W,0.0,,,[],[],set(),[],[],[4926]
5096,RET S891A,0.0,,,[],[],set(),[],[],[4927]
5097,RET S904C,0.0,,,[],[],set(),[],[],[4928]
5098,RET S904F,0.0,,,[],[],set(),[],[],[4929]
5099,RET G911D,0.0,,,[],[],set(),[],[],[4930]
5100,RET R912W,0.0,,,[],[],set(),[],[],[4931]
5101,RET R912P,0.0,,,[],[],set(),[],[],[4932]
5102,RET R912L,0.0,,,[],[],set(),[],[],[4933]
5103,RET M918V,0.0,,,[],[],set(),[],[],[4934]
5104,RET S922P,0.0,,,[],[],set(),[],[],[4935]
5105,KMT2A Mutation,0.0,,,[],[],set(),[],[],[4936]
5106,KMT2C Mutation OR KMT2A Mutation,0.0,,,[],[12031],{<CIViC source 5005>},[],[],"[668, 4936]"
5107,ERBB2 G746S,0.0,,,[],[],set(),[],[],[4937]
5108,AKT1 Alterations,0.0,,,[],[],set(),[],[],[4938]
5109,PTEN Inactivating alteration,0.0,,,[],[],set(),[],[],[4939]
5110,PIK3CA Mutation OR AKT1 Alterations OR PTEN Inactivating alteration,0.0,,,[],[],set(),[],[],"[311, 4938, 4939]"
5111,ROS1 G2101A AND CD74::ROS1 Fusion,0.0,,,[],"[1259, 1260]",{<CIViC source 868>},[],[],"[518, 4908]"
5113,BCR::NTRK2 Fusion,2.5,,,[],"[12053, 12035]","{<CIViC source 5009>, <CIViC source 4951>}",[],[],[4941]
5114,ABL1 Y253F,0.0,,,[],[],set(),[],[],[4942]
5115,BCR::ABL1 Fusion AND ABL1 Y253F,0.0,,,[],"[4343, 8508, 4340, 2657, 2658, 4339, 4341, 4342, 4344, 7848, 2655, 4345, 7508, 7509]","{<CIViC source 1530>, <CIViC source 1621>, <CIViC source 2001>, <CIViC source 2002>, <CIViC source 1532>, <CIViC source 1529>, <CIViC source 1531>, <CIViC source 1996>, <CIViC source 1994>}",[],[],"[1, 4942]"
5117,TMB High,0.0,Tumors with a high mutational burden (TMB-High) are reported to have increased sensitivity to immunotherapy. High Tumor Mutation Burden is defined as 10 or more mutations per MB of DNA in an FDA approved companion diagnostic test based on next generation sequencing.,Tumors with a high mutational burden (TMB-High) are reported to have increased sensitivity to immunotherapy. High Tumor Mutation Burden is defined as 10 or more mutations per MB of DNA in an FDA approved companion diagnostic test based on next generation sequencing.,"['High Tumor Mutational Burden', 'TMB-H']","[12082, 12042, 12083, 12086, 12036]","{<CIViC source 5015>, <CIViC source 5057>, <CIViC source 2123>, <CIViC source 5010>, <CIViC source 5061>}",[],[],[4943]
5118,MSI High,0.0,"High microsatellite instability will often arise in cases where mismatch repair is deficient (dMMR). In tumors with MSI, marker length at microsatellite sequences will differ from that in normal tissue. Determination of MSI-High will usually include criteria such as tumor DNA showing additional microsatellite alleles of different lengths in multiple microsatellite markers, or greater than one third of all microsatellite markers examined.  MSI-H has been associated to better prognosis in colorectal cancer, and also reported to be associated with sensitivity to checkpoint inhibition therapy in some instances.","High microsatellite instability will often arise in cases where mismatch repair is deficient (dMMR). In tumors with MSI, marker length at microsatellite sequences will differ from that in normal tissue. Determination of MSI-High will usually include criteria such as tumor DNA showing additional microsatellite alleles of different lengths in multiple microsatellite markers, or greater than one third of all microsatellite markers examined.  MSI-H has been associated to better prognosis in colorectal cancer, and also reported to be associated with sensitivity to checkpoint inhibition therapy in some instances.","['MSI-H', 'Microsatellite Instability High', 'deficient DNA mismatch repair', 'dMMR']","[12341, 12343, 12039]","{<CIViC source 5013>, <CIViC source 5201>, <CIViC source 5200>}","[5049, 5039]","[<CIViC source 5039>, <CIViC source 5049>]",[4944]
5119,Kataegis Positive,0.0,"Tumors postitive for kataegis show areas of the genome with increased rates of mutation including C>T and C>G, where average intermutation distances may be less than 1kb apart in the enriched areas.","Tumors postitive for kataegis show areas of the genome with increased rates of mutation including C>T and C>G, where average intermutation distances may be less than 1kb apart in the enriched areas.",[],[12037],{<CIViC source 5047>},[],[],[4945]
5120,CK High,0.0,High complex karyotype (CK) is defined as having greater than or equal to 5 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA),High complex karyotype (CK) is defined as having greater than or equal to 5 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA),[],[12038],{<CIViC source 5012>},[5012],[<CIViC source 5012>],[4946]
5121,Chromothripsis Positive,0.0,,,[],"[12040, 12041]",{<CIViC source 5014>},[],[],[4947]
5122,RB1 Mutation OR ESR1 Mutation,0.0,,,[],[],set(),[],[],"[799, 3910]"
5123,ERBB2 P780_Y791insGSP,0.0,,,[],[],set(),[],[],[4948]
5125,ROS1 L2155S AND CD74::ROS1 Fusion,0.0,,,[],[1256],{<CIViC source 868>},[],[],"[517, 4908]"
5126,ERBB2 V777_S779dup,0.0,,,[],[],set(),[],[],[4950]
5127,ERBB2 G776_V777insL,0.0,,,[],[],set(),[],[],[4951]
5128,ERBB2 V777_G778insCG,0.0,,,[],[],set(),[],[],[4952]
5129,ERBB2 G776_V777insVGC,0.0,,,[],[],set(),[],[],[4953]
5130,ERBB2 G778dup,0.0,,,[],[],set(),[],[],[4954]
5131,ERBB2 G778_S779insCPG,0.0,,,[],[],set(),[],[],[4955]
5132,ERBB2 S779_P780insVGS,0.0,,,[],[],set(),[],[],[4956]
5133,ERBB2 I767F,0.0,,,[],[],set(),[],[],[4957]
5134,RET C618T,0.0,,,[],[],set(),[],[],[4958]
5135,RET L629_E632del,0.0,,,[],[],set(),[],[],[4959]
5136,RET E632_C634delinsDVA,0.0,,,[],[],set(),[],[],[4960]
5137,RET D631_L633delinsV,0.0,,,[],[],set(),[],[],[4961]
5138,RET L629_I638delinsCD,0.0,,,[],[],set(),[],[],[4962]
5139,RET L629_A640delinsVRP,0.0,,,[],[],set(),[],[],[4963]
5140,RET A883Y,0.0,,,[],[],set(),[],[],[4964]
5141,RET D898_E902del,0.0,,,[],[],set(),[],[],[4965]
5142,RET D903_S904delinsEP,0.0,,,[],[],set(),[],[],[4966]
5144,EGFR Alteration,0.0,,,[],[12139],{<CIViC source 5098>},[],[],[4967]
5145,EGFR Amplification OR EGFR Alteration,0.0,,,[],[12052],{<CIViC source 5021>},[],[],"[190, 4967]"
5146,TP53 R72P,0.0,,,[],[1302],{<CIViC source 895>},[],[],[4968]
5147,ERBB2 G776_V777delinsCVCG,0.0,,,[],[],set(),[],[],[4969]
5148,ERBB2 G776_V777insVC,0.0,,,[],[],set(),[],[],[4970]
5149,PIK3CA Mutation OR RB1 Mutation OR ESR1 Mutation,0.0,,,[],[12045],{<CIViC source 4671>},[],[],"[311, 799, 3910]"
5150,CD274 Amplification,0.0,,,[],[12054],{<CIViC source 5022>},[],[],[4971]
5151,v::NUTM1 Fusion,85.0,,,['NUTM1 Fusion'],"[12050, 12051, 12237, 12238, 12239, 12055, 12009]","{<CIViC source 5149>, <CIViC source 5148>, <CIViC source 5023>, <CIViC source 5150>, <CIViC source 375>, <CIViC source 4985>, <CIViC source 5020>}",[],[],[4972]
5152,BRD4::NUTM1 Fusion,45.5,,,[],"[12049, 7019, 7018, 12100, 1781, 12099]","{<CIViC source 2718>, <CIViC source 5019>, <CIViC source 1246>, <CIViC source 2717>, <CIViC source 5072>}",[],[],[4973]
5153,U2AF1 Q157P/R OR U2AF1 S34Y/F,0.0,,,[],[],set(),[],[],"[127, 128]"
5154,EWSR1::CREB3L1 Fusion,22.5,,,[],"[12058, 12057, 12059]","{<CIViC source 5026>, <CIViC source 5027>, <CIViC source 5025>}",[],[],[4974]
5155,FUS::CREB3L2 Fusion,35.0,,,[],"[12061, 12062, 12060]","{<CIViC source 5025>, <CIViC source 5028>, <CIViC source 5029>}",[],[],[4975]
5156,MET Splice Site (c.2929_3028),0.0,,,[],[],set(),[],[],[4976]
5157,MET D963E,0.0,,,[],[],set(),[],[],[4977]
5158,MET Splice Site (c.2888-5_2890delinsA),0.0,,,[],[],set(),[],[],[4978]
5159,OVOL2 Overexpression,0.0,,,[],[12064],{<CIViC source 5032>},[],[],[4979]
5160,AXIN2 rs143348853,0.0,,,[],[12065],{<CIViC source 5033>},[],[],[4980]
5161,ETV6::NTRK3 Fusion AND NTRK3 G623R,10.0,,,[],"[1874, 10093]",{<CIViC source 1289>},[],[],"[801, 2691]"
5162,KRAS G12 OR KRAS G13,0.0,,,[],[],set(),[],[],"[76, 80]"
5163,v::NTRK1 Fusion OR v::NTRK3 Fusion OR v::NTRK2 Fusion,0.0,,,[],[12071],{<CIViC source 4951>},[],[],"[419, 1277, 2640]"
5164,MET Amplification AND MET Splice Site (c.3028+3A>G),0.0,,,[],[],set(),[],[],"[270, 4544]"
5165,MET H1094Y,0.0,,,[],[],set(),[],[],[4981]
5166,MET Splice Site (c.3028+2T>G) AND MET Splice Site (c.2888-5_2890delinsA) AND MET H1094Y,0.0,,,[],[],set(),[],[],"[4379, 4978, 4981]"
5167,PIK3CA E542K AND TP53 R337L AND MET Splice Site (c.3028+1G>A),0.0,,,[],[],set(),[],[],"[103, 1112, 4375]"
5168,MET D1010H AND MET Y1230C,0.0,,,[],[],set(),[],[],"[1660, 4519]"
5169,MET Splice Site (c.2929_3028+212del),0.0,,,[],[],set(),[],[],[4982]
5170,NOT MET Amplification AND MET Splice Site (c.2929_3028+212del),0.0,,,[],[],set(),[],[],"[270, 4982]"
5171,MET Splice Site (c.3020_3028+17del),0.0,,,[],[],set(),[],[],[4983]
5172,MET Y1230H AND MET Splice Site (c.3020_3028+17del),0.0,,,[],[],set(),[],[],"[4520, 4983]"
5173,MET Splice Site (c.3028+3_3028+6del),0.0,,,[],[],set(),[],[],[4984]
5174,MSI Low,0.0,Low grade microsatellite instability (MSI-L) is not generally distinguished from microsatellite stable (MSS) or mismatch repair (MMR) competent tumors. In some cases MSS tumors have been reported to lack response to immune checkpoint inhibition.,Low grade microsatellite instability (MSI-L) is not generally distinguished from microsatellite stable (MSS) or mismatch repair (MMR) competent tumors. In some cases MSS tumors have been reported to lack response to immune checkpoint inhibition.,"['MMR competent', 'MSS', 'MSI-L', 'microsatellite stable']",[],set(),"[5039, 5049]","[<CIViC source 5039>, <CIViC source 5049>]",[4985]
5175,BRAF V600E AND MSI Low,0.0,"in colon carcinoma, patients with BRAF V600E tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of BRAF V600E was not seen in MSI High tumors.","in colon carcinoma, patients with BRAF V600E tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of BRAF V600E was not seen in MSI High tumors.",[],[12072],{<CIViC source 5048>},[],[],"[12, 4985]"
5176,KRAS Exon 2 Mutation AND MSI Low,0.0,"In colon carcinoma, patients with KRAS Exon 2 mutant tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of KRAS Exon 2 mutation was not seen in MSI High tumors.","In colon carcinoma, patients with KRAS Exon 2 mutant tumors that are microsatellite stable (MSS) have shown worse prognosis than MSS tumors with no BRAF or KRAS mutation. This prognostic effect of KRAS Exon 2 mutation was not seen in MSI High tumors.",[],[12073],{<CIViC source 5048>},[],[],"[75, 4985]"
5177,Aneuploidy Hyperdiploid,0.0,A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.  Hyperdiploid B lymphoblastic leukemia/lymphoma is the largest genetic entity B-cell precursor acute lymphoblastic leukemia in children which contain more than 50 and usually less than 66 chromosomes and associated with a favorable clinical outcome.,A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.  Hyperdiploid B lymphoblastic leukemia/lymphoma is the largest genetic entity B-cell precursor acute lymphoblastic leukemia in children which contain more than 50 and usually less than 66 chromosomes and associated with a favorable clinical outcome.,['Hyperdiploidy'],[],set(),[5050],[<CIViC source 5050>],[4986]
5178,MTOR Alteration,0.0,,,[],[],set(),[],[],[4987]
5180,PTEN Alterations,0.0,,,[],[],set(),[],[],[4989]
5181,AKT2 Mutation,0.0,,,[],[],set(),[],[],[4990]
5183,MET D1010H AND CD274 Overexpression,0.0,,,[],[],set(),[],[],"[1660, 4522]"
5184,MET Splice Site (c.3027_3028+14del),0.0,,,[],[],set(),[],[],[4991]
5185,MET D1228N AND MET Splice Site (c.3027_3028+14del),0.0,,,[],[],set(),[],[],"[649, 4991]"
5186,MET Splice Site (c.2888-1G>C),0.0,,,[],[],set(),[],[],[4992]
5187,MN1 Rearrangement,40.0,,,[],"[12078, 12079, 12077]","{<CIViC source 5055>, <CIViC source 3560>}",[],[],[4993]
5188,BCR::ABL1 Fusion AND ABL1 TKD Mutation,0.0,,,[],"[11342, 11289]","{<CIViC source 1996>, <CIViC source 1532>}",[],[],"[1, 2371]"
5189,MALAT1::GLI1 Fusion,0.0,,,[],[12080],{<CIViC source 5056>},[],[],[4994]
5190,LPP::HMGA2 Fusion OR HMGA2::LPP Fusion,0.0,,,[],[7983],{<CIViC source 1175>},[],[],"[2968, 2969]"
5191,MN1::BEND2 Fusion,0.0,,,['MN1-BEND2'],[8510],{<CIViC source 3559>},[],[],[4995]
5192,Methylation signature CpG island hypermethylation,0.0,,,['CIMP'],[],set(),[],[],[4996]
5193,HPV Type 18,0.0,,,[],[12084],{<CIViC source 5059>},[],[],[4997]
5194,HPV Type 16,0.0,,,[],[12085],{<CIViC source 5060>},[],[],[4998]
5195,MNX1::ETV6 Fusion,30.0,,,['MNX1-ETV6'],"[12091, 12092, 12093]","{<CIViC source 5066>, <CIViC source 5067>, <CIViC source 5065>}",[],[],[4999]
5196,YES1 Amplification,0.0,,,[],[],set(),[],[],[5000]
5197,EGFR Mutation AND YES1 Amplification,0.0,,,[],[12094],{<CIViC source 5068>},[],[],"[442, 5000]"
5198,ERBB2 Amplification AND YES1 Amplification,0.0,,,[],"[12095, 12096]",{<CIViC source 5069>},[],[],"[306, 5000]"
5201,FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion,0.0,,,[],[7261],{<CIViC source 2859>},[],[],"[511, 2202, 4612]"
5202,CD274 Overexpression AND MET Splice Site (c.3028+3A>G),0.0,,,[],[],set(),[],[],"[4522, 4544]"
5203,MET Splice Site (c.3028+1_3028+3delinsTT),0.0,,,[],[],set(),[],[],[5002]
5204,MET D1228N AND MET Splice Site (c.3028+1_3028+3delinsTT),0.0,,,[],[],set(),[],[],"[649, 5002]"
5205,MET Splice Site (c.288847_2888-24del),0.0,,,[],[],set(),[],[],[5003]
5206,PML::RARA Fusion AND PML S214L,0.0,,,[],[8178],{<CIViC source 3369>},[],[],"[108, 3024]"
5207,PML::RARA Fusion AND PML A216T,0.0,,,[],[8179],{<CIViC source 3369>},[],[],"[108, 3025]"
5209,HLA-A *02:01P,0.0,,,[],[],set(),[],[],[5005]
5210,HLA-A *02:02P,0.0,,,[],[],set(),[],[],[5006]
5211,HLA-A *02:03P,0.0,,,[],[],set(),[],[],[5007]
5212,HLA-A *02:06P,0.0,,,[],[],set(),[],[],[5008]
5213,MAGEA4 Expression,0.0,,,[],[],set(),[],[],[5009]
5214,HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P OR MAGEA4 Expression,0.0,,,[],[],set(),[],[],"[5005, 5006, 5007, 5008, 5009]"
5215,MAGEA4 Expression AND ( HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P ),0.0,,,[],[12138],{<CIViC source 5086>},[],[],"[5005, 5006, 5007, 5008, 5009]"
5216,KIF5B::RET Fusion AND RET V804L,0.0,,,[],"[4851, 7515]","{<CIViC source 2152>, <CIViC source 1994>}",[],[],"[273, 1688]"
5217,DEK::NUP214 Fusion,0.0,,,['DEK-NUP214'],"[12123, 12124, 12125, 12126, 12127]","{<CIViC source 5090>, <CIViC source 5088>, <CIViC source 5089>}",[],[],[5010]
5218,NPM1::MLF1 Fusion,0.0,,,[],"[12130, 12129, 12128]","{<CIViC source 5018>, <CIViC source 5092>, <CIViC source 5091>}",[],[],[5011]
5219,KIF5B::RET Fusion AND RET G810A,0.0,,,[],"[4852, 4853]",{<CIViC source 2152>},[],[],"[273, 1689]"
5220,CD72::ROS1 Fusion,0.0,,,['CD72-ROS1'],[1248],{<CIViC source 865>},[],[],[5012]
5221,SDC4::ROS1 Fusion,0.0,,,['SDC4-ROS1'],[1690],{<CIViC source 1141>},[],[],[5013]
5222,v::ALK Fusion OR v::ROS1 Fusion,0.0,,,[],[11671],{<CIViC source 4833>},[],[],"[499, 2693]"
5223,MET Amplification OR MET Exon 14 Skipping Mutation OR v::ALK Fusion OR v::ROS1 Fusion,0.0,,,[],[11385],{<CIViC source 2124>},[],[],"[270, 324, 499, 2693]"
5224,MAP3K1 Mutation,0.0,,,[],[],set(),[],[],[5014]
5225,MAP2K4 loss-of-function Mutation,0.0,,,[],[],set(),[],[],[5015]
5226,MAP3K1 Loss-of-Function Mutation,0.0,,,[],[],set(),[],[],[5016]
5227,MAP2K4 loss-of-function Mutation OR MAP3K1 Loss-of-Function Mutation,0.0,,,[],[12141],{<CIViC source 5100>},[],[],"[5015, 5016]"
5228,IFNGR1 Knockdown,0.0,,,[],[],set(),[],[],[5017]
5229,NFASC::NTRK1 Fusion,0.0,,,['NFASC-NTRK1'],[10930],{<CIViC source 4076>},[],[],[5018]
5230,LMNA::NTRK1 Fusion OR TPM3::NTRK1 Fusion,0.0,,,[],[978],{<CIViC source 677>},[],[],"[1278, 2992]"
5231,ETV6::FGFR3 Fusion,0.0,,,['ETV6-FGFR3'],[10409],{<CIViC source 4337>},[],[],[5019]
5232,FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion,0.0,,,[],[4861],{<CIViC source 1341>},[],[],"[830, 4626]"
5233,IFNGR1 Loss,0.0,,,[],[12142],{<CIViC source 5101>},[],[],[5020]
5238,BCR::ABL1 Fusion AND ABL1 V379I,0.0,,,[],"[4702, 7033, 4703, 6257, 4705]","{<CIViC source 1998>, <CIViC source 1531>, <CIViC source 1622>, <CIViC source 2096>, <CIViC source 1999>}",[],[],"[1, 1609]"
5239,PML::RARA Fusion AND PML A216V,0.0,,,[],"[8177, 1093]","{<CIViC source 752>, <CIViC source 3369>}",[],[],"[108, 462]"
5240,PML::RARA Fusion AND PML L218P,0.0,,,[],[1094],{<CIViC source 752>},[],[],"[108, 463]"
5241,BCR::ABL1 Fusion AND ABL1 V289I,0.0,,,[],[7946],{<CIViC source 2096>},[],[],"[1, 1604]"
5242,PDGFRB C843G,0.0,,,"['Cys843Gly', 'Cys843Gly']",[],set(),[],[],[5025]
5243,AGGF1::PDGFRB Fusion AND PDGFRB C843G,0.0,,,[],[6999],{<CIViC source 2695>},[],[],"[2577, 5025]"
5244,LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 G667C ,0.0,,,[],[2961],{<CIViC source 1693>},[],[],"[1278, 2690, 4511]"
5245,EGFR::FGFR1 e24::e10,0.0,,,"['EGFR-FGFR1', 'EGFR-FGFR1 Fusion']",[11143],{<CIViC source 4563>},[],[],[5026]
5246,CLIP2::EGFR e10::e18,0.0,,,['CLIP2-EGFR Fusion'],[],set(),[],[],[5027]
5247,Chromothripsis Positive AND CLIP2::EGFR e10::e18,0.0,,,[],[11169],{<CIViC source 4574>},[],[],"[4947, 5027]"
5248,v::DUX4 Fusion,0.0,,,['DUX4 Fusion'],[],set(),[],[],[5028]
5249,DUX4::v Fusion OR v::DUX4 Fusion,0.0,,,[],[11523],{<CIViC source 2876>},[],[],"[524, 5028]"
5250,GOLGA4::RAF1 Fusion,0.0,,,[],[8374],{<CIViC source 3499>},[],[],[5029]
5251,ANO10::RAF1 Fusion,0.0,,,[],[9021],{<CIViC source 5105>},[],[],[5030]
5252,TP53 Rearrangement,0.0,,,[],"[9247, 9248]","{<CIViC source 3962>, <CIViC source 3963>}",[],[],[5031]
5253,SLC4A4::RASGRF1 Fusion,0.0,,,[],[12146],{<CIViC source 4258>},[],[],[5032]
5254,IQGAP1::RASGRF1 Fusion,0.0,,,[],[12147],{<CIViC source 4258>},[],[],[5033]
5255,BCOR::MAML3 Fusion,0.0,,,[],[],set(),[],[],[5034]
5256,BCOR::CCNB3 Fusion OR BCOR::MAML3 Fusion,0.0,,,[],[11590],{<CIViC source 4808>},[],[],"[3251, 5034]"
5257,v::MITF Fusion,0.0,,,['MITF Fusion'],[11702],{<CIViC source 4786>},[],[],[5035]
5258,EMSY Amplification,0.0,,,[],[12148],{<CIViC source 5106>},[],[],[5036]
5259,EMSY Overexpression,0.0,,,[],[12149],{<CIViC source 5107>},[],[],[5037]
5260,JAK1 Mutation,0.0,,,[],[],set(),[],[],[5038]
5261,JAK2 Mutation,0.0,,,[],[],set(),[],[],[5039]
5262,B2M Mutation AND MSI High AND ( JAK1 Mutation OR JAK2 Mutation ),0.0,,,[],[],set(),[],[],"[2692, 4944, 5038, 5039]"
5263,MSI High AND ( B2M Mutation OR JAK1 Mutation OR JAK2 Mutation ),0.0,,,[],[12150],{<CIViC source 5108>},[],[],"[2692, 4944, 5038, 5039]"
5264,B2M Mutation AND MSI High,0.0,,,[],[],set(),[],[],"[2692, 4944]"
5265,B2M High Expression,0.0,,,[],[12151],{<CIViC source 5109>},[],[],[5040]
5266,B2M Loss,0.0,,,[],[12152],{<CIViC source 5110>},[],[],[5041]
5267,KAT6A::CREBBP Fusion,35.0,,,[],"[12153, 12154, 12155]","{<CIViC source 5112>, <CIViC source 5113>, <CIViC source 5111>}",[],[],[5042]
5268,PIK3CA Q75E,0.0,,,[],[12159],{<CIViC source 5117>},[],[],[5043]
5269,PIK3CA N345K OR PIK3CA M1043V OR PIK3CA Q75E,0.0,,,[],[12160],{<CIViC source 5117>},[],[],"[930, 936, 5043]"
5270,VHL P86S (c.256C>T) AND VHL Splice Region (c.340+5G>C),0.0,,,[],[6740],{<CIViC source 2643>},[],[],"[1902, 2104]"
5271,VHL E70K (c.208G>A) AND VHL Splice Region (c.340+5G>C),0.0,,,[],[6868],{<CIViC source 2655>},[],[],"[1956, 2104]"
5272,VHL R200W (c.598C>T) AND VHL V130I (c.388G>A),0.0,,,[],[5634],{<CIViC source 2290>},[],[],"[631, 2380]"
5273,VHL R200W (c.598C>T) AND VHL R161Q (c.482G>A),0.0,,,[],[8790],{<CIViC source 3673>},[],[],"[631, 1746]"
5274,VHL S139C (c.416C>G),0.0,,,[],[],set(),[],[],[5044]
5275,VHL R167Q (c.500G>A) AND VHL T105M (c.314C>T),0.0,,,[],[10640],{<CIViC source 2506>},[],[],"[1739, 4235]"
5276,VHL R167Q (c.500G>A) AND VHL P81S (c.241C>T),0.0,,,[],"[10665, 10666]",{<CIViC source 3569>},[],[],"[1739, 1837]"
5277,VHL Exon 3 Deletion AND VHL S139C (c.416C>G),0.0,,,[],[10867],{<CIViC source 4437>},[],[],"[1939, 5044]"
5278,VHL S183L (c.548C>T) AND VHL D126N (c.376G>A),0.0,,,[],[8721],{<CIViC source 3663>},[],[],"[2161, 2533]"
5279,VCP::TFE3 Fusion,0.0,,,[],[],set(),[],[],[5045]
5280,YWHAE::NUTM2A Fusion,0.0,,,[],[],set(),[],[],[5046]
5281,YWHAE::NUTM2B Fusion,0.0,,,[],[],set(),[],[],[5047]
5282,YWHAE::NUTM2E Fusion,0.0,,,[],[],set(),[],[],[5048]
5283,YWHAE::NUTM2A Fusion OR YWHAE::NUTM2B Fusion OR YWHAE::NUTM2E Fusion,0.0,,,"['NUTM2 FUSION', 'YWHAE-NUTM2 FUSION', 'YWHAE::NUTM2', 'YWHAE-FAM22', 'YWHAE::FAM22', 'T(10;17)(Q23;P13)']","[11782, 11783, 11784]","{<CIViC source 4909>, <CIViC source 4908>, <CIViC source 4910>}",[],[],"[5046, 5047, 5048]"
5284,Methylation signature ST-EPN-ZFTA,0.0,"The Supratentorial Ependymoma ZFTA Fusion-Positive Methylation Signature (ST-EPN-ZFTA, formerly ST-EPN-RELA) methylation based signature (Heidelberg Brain Tumor Methylation Classifier; DKFZ Classifier) found almost exclusively among supratentorial ependymomas with ZFTA-RELA (or other ZFTA) fusions, used commonly as a diagnostic tool for identifying ""Supratentorial ependymoma, ZFTA fusion-positive"" subtype as defined by the WHO Classification of Tumors of the Central Nervous (2021) even in the absence of DNA or RNA testing or evidence for these fusions.","The Supratentorial Ependymoma ZFTA Fusion-Positive Methylation Signature (ST-EPN-ZFTA, formerly ST-EPN-RELA) methylation based signature (Heidelberg Brain Tumor Methylation Classifier; DKFZ Classifier) found almost exclusively among supratentorial ependymomas with ZFTA-RELA (or other ZFTA) fusions, used commonly as a diagnostic tool for identifying ""Supratentorial ependymoma, ZFTA fusion-positive"" subtype as defined by the WHO Classification of Tumors of the Central Nervous (2021) even in the absence of DNA or RNA testing or evidence for these fusions.","['EPN, RELA', 'EPN-RELA', 'ST-EPN-RELA', 'ST-ZFTA', 'ST-RELA']","[11445, 11447]","{<CIViC source 4729>, <CIViC source 4731>}","[5120, 3626]","[<CIViC source 3626>, <CIViC source 5120>]",[5049]
5285,ZEB1 Increased Expression,0.0,,,[],[12163],{<CIViC source 5121>},[],[],[5050]
5286,MYB::NFIB Fusion,0.0,,,[],"[12167, 12164, 12165]","{<CIViC source 3812>, <CIViC source 5122>}",[],[],[5051]
5287,MTOR Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation,0.0,,,[],[12075],{<CIViC source 5052>},[],[],"[277, 311, 510, 4906, 4990]"
5288,PIK3CA H1047R OR PIK3CA H1047Y OR PIK3CA H1047L,0.0,,,[],[7318],{<CIViC source 2888>},[],[],"[107, 938, 1151]"
5291,MEF2D::? Fusion,0.0,,,[],[],set(),[],[],[5054]
5292,MEF2D::v Fusion,35.0,,,[],"[12178, 12199, 12176]","{<CIViC source 5130>, <CIViC source 5131>, <CIViC source 3622>}",[],[],[5055]
5293,UBTF UBTF-TD,0.0,,,[],[12179],{<CIViC source 5132>},[],[],[5056]
5294,LINC01969::UFSP1 Fusion,0.0,,,[],[],set(),[],[],[5057]
5295,MEF2D::BCL9 Fusion,0.0,,,[],[12177],{<CIViC source 5130>},[],[],[5058]
5296,PIK3CA E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D,0.0,,,[],[7468],{<CIViC source 2888>},[],[],"[104, 882, 883, 934]"
5297,IDH2 R172K OR IDH2 R172G OR IDH2 R172W,0.0,,,[],[11509],{<CIViC source 4762>},[],[],"[63, 4459, 4462]"
5298,IDH1 R132C OR IDH1 R132H OR IDH1 R132L OR IDH1 R132G OR IDH1 R132S,0.0,,,[],[11508],{<CIViC source 4762>},[],[],"[59, 420, 880, 927, 928]"
5299,PIK3CA Q546E OR PIK3CA Q546R,0.0,,,[],[7316],{<CIViC source 2888>},[],[],"[886, 888]"
5300,SDHA Loss,0.0,,,[],[],set(),[],[],[5059]
5301,SDHB Loss,0.0,,,[],[],set(),[],[],[5060]
5302,SDHC Loss,0.0,,,[],[],set(),[],[],[5061]
5303,SDHD Loss,0.0,,,[],[],set(),[],[],[5062]
5304,SDHA Loss OR SDHB Loss OR SDHC Loss OR SDHD Loss,0.0,,,[],[],set(),[],[],"[5059, 5060, 5061, 5062]"
5305,VPS18::NTRK3 e4::e18,0.0,,,[],[12257],{<CIViC source 5146>},[],[],[5063]
5306,EGFR L858R OR EGFR T790M,0.0,,,[],[12206],{<CIViC source 5135>},[],[],"[33, 34]"
5307,ZNF217 Overexpression,0.0,,,[],"[12207, 12208, 12209, 12210]","{<CIViC source 5137>, <CIViC source 5138>, <CIViC source 5136>}",[],[],[5064]
5308,FAAP20 loss,0.0,,,[],"[12211, 12212]",{<CIViC source 5139>},[],[],[5065]
5309,KMT2A Translocation,0.0,,,[],[12214],{<CIViC source 5141>},[],[],[5066]
5310,CLDN18 positive,0.0,,,[],"[12216, 12215]","{<CIViC source 5143>, <CIViC source 5142>}",[],[],[5067]
5311,ATR Loss-of-function,0.0,,,[],[12217],{<CIViC source 5144>},[],[],[5068]
5312,ESR1 Y537D,0.0,,,[],[12223],{<CIViC source 4727>},[],[],[5069]
5313,ESR1 L469V,0.0,,,[],[12225],{<CIViC source 4727>},[],[],[5070]
5314,ESR1 L536H,0.0,,,[],[12226],{<CIViC source 4727>},[],[],[5071]
5315,ESR1 L536P,0.0,,,[],[12227],{<CIViC source 4727>},[],[],[5072]
5316,IDH2 R172M OR IDH2 R172S,0.0,,,[],[12235],{<CIViC source 4762>},[],[],"[4460, 4461]"
5317,PIK3CA Exon 21 Mutation AND PIK3CA Exon 10 Mutation,0.0,,,[],[5350],{<CIViC source 232>},[],[],"[105, 106]"
5318,PIK3CA Exon 21 Mutation OR PIK3CA Exon 10 Mutation,0.0,,,[],"[6191, 7220]","{<CIViC source 2481>, <CIViC source 1475>}",[],[],"[105, 106]"
5319,PIK3CA H1047R OR PIK3CA H1047L,0.0,,,[],[3047],{<CIViC source 1751>},[],[],"[107, 1151]"
5322,DUX4L1::IGH Fusion,0.0,,,[],"[12248, 12249, 12251]","{<CIViC source 2876>, <CIViC source 882>, <CIViC source 5154>}",[],[],[5075]
5323,DUX4L1::v Fusion,0.0,,,[],[12250],{<CIViC source 5155>},[],[],[5076]
5324,NRG1 Fusion,0.0,,,[],[],set(),[],[],[5077]
5325,LRP1B alterations,0.0,,,[],[],set(),[],[],[5078]
5326,v::IRF4 Fusion,35.0,,,[],"[12253, 12255, 12254]","{<CIViC source 5158>, <CIViC source 5157>, <CIViC source 5159>}",[],[],[5079]
5327,FAT1 Loss,0.0,,,[],[12263],{<CIViC source 5164>},[],[],[5080]
5328,LRP1B Loss-of-function,0.0,,,[],[12252],{<CIViC source 5156>},[],[],[5081]
5329,EGFR G719A AND EGFR E709K,0.0,,,[],[6036],{<CIViC source 2436>},[],[],"[999, 1412]"
5330,EGFR G719C AND EGFR E709A,0.0,,,[],[6039],{<CIViC source 2065>},[],[],"[998, 1414]"
5331,MAP2K1 G128D,0.0,,,[],[],set(),[],[],[5082]
5332,MAP2K1 C121S AND MAP2K1 G128D,0.0,,,[],[6385],{<CIViC source 2523>},[],[],"[627, 5082]"
5333,EGFR L718Q AND EGFR L718V,0.0,,,[],"[8052, 8054]",{<CIViC source 3253>},[],[],"[2999, 3000]"
5334,TCF3::HLF Fusion,0.0,,,[],"[12169, 12170, 12171]","{<CIViC source 5124>, <CIViC source 2875>, <CIViC source 5125>}",[],[],[5083]
5335,IGH::IL3 Fusion,0.0,,,[],"[12243, 12244, 12245]","{<CIViC source 5153>, <CIViC source 5152>, <CIViC source 5151>}",[],[],[5084]
5336,TACSTD2 T256R,0.0,,,[],[12265],{<CIViC source 5169>},[],[],[5085]
5337,TOP1 E418K,0.0,,,[],[],set(),[],[],[5086]
5338,TOP1 -122fs,0.0,,,[],[],set(),[],[],[5087]
5339,TOP1 E418K OR TOP1 -122fs,0.0,,,[],[],set(),[],[],"[5086, 5087]"
5340,TOP1 E418K AND TOP1 -122fs,0.0,,,[],[12266],{<CIViC source 5169>},[],[],"[5086, 5087]"
5341,Methylation signature PA. ,0.0,,,[],[],set(),[],[],[5088]
5342,Methylation signature PA-NF1,0.0,,,[],[],set(),[],[],[5089]
5343,NF1 Mutation AND Methylation signature PA-NF1,0.0,,,[],"[12267, 12268, 12269, 12270]",{<CIViC source 5168>},[],[],"[587, 5089]"
5344,NF1 Splice Site (c.205-1G>C),0.0,,,[],[12273],{<CIViC source 5168>},[],[],[5090]
5345,NF1 Splice Site (c.1845+1G>A),0.0,,,[],[12274],{<CIViC source 5168>},[],[],[5091]
5346,NF1 D1644H,0.0,,,[],[12275],{<CIViC source 5168>},[],[],[5092]
5347,NF1 Y489C,0.0,,,[],[12276],{<CIViC source 5168>},[],[],[5093]
5348,NF1 Splice Site (c.654+2T>A),0.0,,,[],[12277],{<CIViC source 5168>},[],[],[5094]
5349,NF1 Y794fs*27,0.0,,,[],[12278],{<CIViC source 5168>},[],[],[5095]
5350,NF1 Q514fs*43,0.0,,,[],[12279],{<CIViC source 5168>},[],[],[5096]
5351,NF1 p.H2393fs*3,0.0,,,[],[12280],{<CIViC source 5168>},[],[],[5097]
5352,NF1 Y1783*,0.0,,,[],[12281],{<CIViC source 5168>},[],[],[5098]
5353,NF1 Y333*,0.0,,,[],[12282],{<CIViC source 5168>},[],[],[5099]
5354,NF1 R1276*,0.0,,,[],"[12283, 12349]",{<CIViC source 5168>},[],[],[5100]
5355,NF1 G1219E,0.0,,,[],[12284],{<CIViC source 5168>},[],[],[5101]
5356,NF1 p.W426*,0.0,,,[],[12285],{<CIViC source 5168>},[],[],[5102]
5357,NF1 p.R1276*,0.0,,,[],[12286],{<CIViC source 5168>},[],[],[5103]
5358,CREBBP HAT mutation,0.0,,,[],[12290],{<CIViC source 5173>},[],[],[5104]
5359,CREBBP R1446C,0.0,,,[],[12291],{<CIViC source 5174>},[],[],[5105]
5360,IGH::DUX4 Fusion,0.0,,,[],[7027],{<CIViC source 882>},[],[],[5106]
5361,EGFR D770_P772dup,0.0,,,[],"[12299, 12301, 12300, 12298, 12302, 12303]",{<CIViC source 5182>},[],[],[5107]
5362,ATP7B Expression,0.0,,,[],"[12304, 12305, 12306, 12307]",{<CIViC source 5183>},[],[],[5108]
5363,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 G250E,0.0,,,[],[12308],{<CIViC source 2090>},[],[],"[1, 2, 1023]"
5364,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 Q252H,0.0,,,[],[],set(),[],[],"[1, 2, 4634]"
5365,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 Y253H,0.0,,,[],[12309],{<CIViC source 2090>},[],[],"[1, 2, 4529]"
5366,ABL1 T315L,0.0,,,[],[],set(),[],[],[5109]
5367,BCR::ABL1 Fusion AND ABL1 T315L,0.0,,,[],[12310],{<CIViC source 2090>},[],[],"[1, 5109]"
5368,ABL1 T315M,0.0,,,[],[],set(),[],[],[5110]
5369,BCR::ABL1 Fusion AND ABL1 T315M,0.0,,,[],[12311],{<CIViC source 2090>},[],[],"[1, 5110]"
5370,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 E255V,0.0,,,[],[12312],{<CIViC source 2090>},[],[],"[1, 2, 4606]"
5371,BCR::ABL1 Fusion AND ABL1 Y253H AND ABL1 E255V,0.0,,,[],[12313],{<CIViC source 2090>},[],[],"[1, 4529, 4606]"
5372,BCR::ABL1 Fusion AND ABL1 E255V AND ABL1 V299L,0.0,,,[],[12314],{<CIViC source 2090>},[],[],"[1, 4606, 4639]"
5373,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 M244V,0.0,,,[],[12315],{<CIViC source 2090>},[],[],"[1, 2, 4597]"
5374,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 F359V,0.0,,,[],[12316],{<CIViC source 2090>},[],[],"[1, 2, 4598]"
5375,BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 H396R,0.0,,,[],[12317],{<CIViC source 2090>},[],[],"[1, 2, 4611]"
5376,BCR::ABL1 Fusion AND ABL1 M351T AND ABL1 V299L,0.0,,,[],[12318],{<CIViC source 2090>},[],[],"[1, 1029, 4639]"
5377,BCR::ABL1 Fusion AND ABL1 F359V AND ABL1 V299L,0.0,,,[],[12319],{<CIViC source 2090>},[],[],"[1, 4598, 4639]"
5378,BCR::ABL1 Fusion AND ABL1 F317L AND ABL1 F359V,0.0,,,[],[12320],{<CIViC source 2090>},[],[],"[1, 1028, 4598]"
5379,BRAF V600E AND NF1 Loss,0.0,,,[],[90],{<CIViC source 98>},[],[],"[12, 698]"
5380,DICER1 G1809R,0.0,,,[],[12324],{<CIViC source 2265>},[],[],[5111]
5381,TFCP2 EWSR1::TFCP2,0.0,,,[],[],set(),[],[],[5112]
5382,v::TFCP2 Fusion,15.0,,,[],"[12335, 12325]","{<CIViC source 5180>, <CIViC source 5196>}",[],[],[5113]
5383,FUS::TFCP2 Fusion,10.0,,,[],[12326],{<CIViC source 5190>},[],[],[5114]
5384,v::NR4A3 Fusion,15.0,,,[],"[12336, 12337]","{<CIViC source 5198>, <CIViC source 5197>}",[],[],[5115]
5385,FLT3 ITD AND FLT3 F691L,0.0,,,[],[],set(),[],[],"[55, 3071]"
5386,KEAP1 Mutation,0.0,,,[],[12339],{<CIViC source 5199>},[],[],[5116]
5387,STK11 Mutation AND KEAP1 Mutation,0.0,,,[],[12340],{<CIViC source 5199>},[],[],"[715, 5116]"
5388,EGFR A123B,0.0,,,[],[],set(),[],[],[5117]
5389,BAP1 Loss-of-function,0.0,,,[],[],set(),[],[],[5118]
5390,BRCA1 Loss-of-function OR BAP1 Loss-of-function,15.0,,,[],[11739],{<CIViC source 4883>},[],[],"[131, 5118]"
5391,ERCC6 Overexpression,0.0,,,[],[12121],{<CIViC source 5085>},[],[],[5119]
5392,NF1 Q1189*,0.0,,,[],[],set(),[],[],[5120]
5393,NF1 D1644H AND NF1 Q1189*,0.0,,,[],[12342],{<CIViC source 5168>},[],[],"[5092, 5120]"
5394,NF1 L1221R,0.0,,,[],[12344],{<CIViC source 5168>},[],[],[5121]
5395,NF1 L2118fs*33,0.0,,,[],[12345],{<CIViC source 5168>},[],[],[5122]
5396,NF1 Splice Site (c.2850+1G>A),0.0,,,[],[12346],{<CIViC source 5168>},[],[],[5123]
5397,NF1 spliceSplice Site (c.3871-1G>C),0.0,,,[],[],set(),[],[],[5124]
5398,NF1 Splice Site (c.3871-1G>C),0.0,,,[],[12347],{<CIViC source 5168>},[],[],[5125]
5399,NF1 Splice Site (c.4110+1G>T),0.0,,,[],[12348],{<CIViC source 5168>},[],[],[5126]
5400,NF1 I1445R,0.0,,,[],[12350],{<CIViC source 5168>},[],[],[5127]
5401,NF1 W9*,0.0,,,[],[12351],{<CIViC source 5168>},[],[],[5128]
5402,NF1 R1509H,0.0,,,[],[12352],{<CIViC source 5168>},[],[],[5129]
5403,NF1 L1243R,0.0,,,[],[12353],{<CIViC source 5168>},[],[],[5130]
5404,NF1 N412S,0.0,,,[],[12354],{<CIViC source 5168>},[],[],[5131]
5405,NF1 Splice Site (c.3113+1G>A),0.0,,,[],[12355],{<CIViC source 5168>},[],[],[5132]
5406,NF1 R1306*,0.0,,,[],[12356],{<CIViC source 5168>},[],[],[5133]
5407,NF1 R304*,0.0,,,[],[12357],{<CIViC source 5168>},[],[],[5134]
5408,NF1 6818A>T,0.0,,,[],[12358],{<CIViC source 5168>},[],[],[5135]
5409,NF1 G629R,0.0,,,[],[],set(),[],[],[5136]
5410,NF1 Splice Site (c.205-1G>C) AND NF1 G629R,0.0,,,[],"[12271, 12359]",{<CIViC source 5168>},[],[],"[5090, 5136]"
5411,BRAF V600 AND BRAF Amplification,0.0,,,[],[7677],{<CIViC source 3045>},[],[],"[17, 1269]"
5412,EGFR::RAD1 Fusion,0.0,,,[],[12360],{<CIViC source 2385>},[],[],[5137]
5413,EGFR::SHC1 Fusion,0.0,,,[],[12361],{<CIViC source 4797>},[],[],[5138]
